ID   CO4A5_HUMAN             Reviewed;        1685 AA.
AC   P29400; Q16006; Q16126; Q6LD84; Q7Z700; Q9NUB7;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 2.
DT   17-FEB-2016, entry version 186.
DE   RecName: Full=Collagen alpha-5(IV) chain;
DE   Flags: Precursor;
GN   Name=COL4A5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8120014;
RA   Zhou J., Leinonen A., Tryggvason K.;
RT   "Structure of the human type IV collagen COL4A5 gene.";
RL   J. Biol. Chem. 269:6608-6614(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE OF 1-910, AND VARIANT APSX CYS-521.
RC   TISSUE=Kidney;
RX   PubMed=1352287;
RA   Zhou J., Hertz J.M., Leinonen A., Tryggvason K.;
RT   "Complete amino acid sequence of the human alpha 5 (IV) collagen chain
RT   and identification of a single-base mutation in exon 23 converting
RT   glycine 521 in the collagenous domain to cysteine in an Alport
RT   syndrome patient.";
RL   J. Biol. Chem. 267:12475-12481(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 85-1685.
RC   TISSUE=Placenta;
RX   PubMed=2380186;
RA   Pihlajaniemi T., Pohjolainen E.R., Myers J.C.;
RT   "Complete primary structure of the triple-helical region and the
RT   carboxyl-terminal domain of a new type IV collagen chain, alpha
RT   5(IV).";
RL   J. Biol. Chem. 265:13758-13766(1990).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 924-1685.
RX   PubMed=2004755; DOI=10.1016/0888-7543(91)90214-Y;
RA   Zhou J., Hostikka S.L., Chow L.T., Tryggvason K.;
RT   "Characterization of the 3' half of the human type IV collagen alpha 5
RT   gene that is affected in the Alport syndrome.";
RL   Genomics 9:1-9(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 914-1685.
RX   PubMed=1689491; DOI=10.1073/pnas.87.4.1606;
RA   Hostikka S.L., Eddy R.L., Byers M.G., Hoeyhtyae M., Shows T.B.,
RA   Tryggvason K.;
RT   "Identification of a distinct type IV collagen alpha chain with
RT   restricted kidney distribution and assignment of its gene to the locus
RT   of X chromosome-linked Alport syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:1606-1610(1990).
RN   [8]
RP   NUCLEOTIDE SEQUENCE OF 1442-1471.
RX   PubMed=2339699;
RA   Myers J.C., Jones T.A., Pohjolainen E.R., Kadri A.S., Goddard A.D.,
RA   Sheer D., Solomon E., Pihlajaniemi T.;
RT   "Molecular cloning of alpha 5(IV) collagen and assignment of the gene
RT   to the region of the X chromosome containing the Alport syndrome
RT   locus.";
RL   Am. J. Hum. Genet. 46:1024-1033(1990).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 1-20.
RA   Guo C., van Damme B., Vanrenterghem Y., Devriendt K., Cassiman J.-J.,
RA   Marynen P.;
RL   Submitted (SEP-1994) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 1258-1270 (ISOFORM 2).
RX   PubMed=8301933; DOI=10.1038/ki.1993.384;
RA   Guo C., van Damme B., van Damme-Lombaerts R., van den Berghe H.,
RA   Cassiman J.-J., Marynen P.;
RT   "Differential splicing of COL4A5 mRNA in kidney and white blood cells:
RT   a complex mutation in the COL4A5 gene of an Alport patient deletes the
RT   NC1 domain.";
RL   Kidney Int. 44:1316-1321(1993).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1589-1598 AND 1677-1685, AND
RP   VARIANTS APSX 1597-TYR--THR-1685 DEL AND 1679-GLQ--THR-1685 DEL.
RX   PubMed=7853788; DOI=10.1038/ki.1994.399;
RA   Nakazato H., Hattori S., Ushijima T., Matsuura T., Koitabashi Y.,
RA   Takada T., Yoshioka K., Endo F., Matsuda I.;
RT   "Mutations in the COL4A5 gene in Alport syndrome: a possible mutation
RT   in primordial germ cells.";
RL   Kidney Int. 46:1307-1314(1994).
RN   [12]
RP   REVIEW ON VARIANTS.
RX   PubMed=9195222;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:6<477::AID-HUMU1>3.3.CO;2-H;
RA   Lemmink H.H., Schroeder C.H., Monnens L.A.H., Smeets H.J.M.;
RT   "The clinical spectrum of type IV collagen mutations.";
RL   Hum. Mutat. 9:477-499(1997).
RN   [13]
RP   VARIANT APSX SER-1564.
RX   PubMed=1672282; DOI=10.1016/0888-7543(91)90215-Z;
RA   Zhou J., Barker D.F., Hostikka S.L., Gregory M.C., Atkin C.L.,
RA   Tryggvason K.;
RT   "Single base mutation in alpha 5(IV) collagen chain gene converting a
RT   conserved cysteine to serine in Alport syndrome.";
RL   Genomics 9:10-18(1991).
RN   [14]
RP   VARIANT APSX ARG-325.
RX   PubMed=1376965;
RA   Knebelmann B., Deschenes G., Gros F., Hors M.-C., Gruenfeld J.-P.,
RA   Tryggvason K., Gubler M.-C., Antignac C.;
RT   "Substitution of arginine for glycine 325 in the collagen alpha 5 (IV)
RT   chain associated with X-linked Alport syndrome: characterization of
RT   the mutation by direct sequencing of PCR-amplified lymphoblast cDNA
RT   fragments.";
RL   Am. J. Hum. Genet. 51:135-142(1992).
RN   [15]
RP   VARIANT APSX GLU-325.
RX   PubMed=1363780; DOI=10.1093/hmg/1.2.127;
RA   Renieri A., Seri M., Myers J.C., Pihlajaniemi T., Massella L.,
RA   Rizzoni G.F., de Marchi M.;
RT   "De novo mutation in the COL4A5 gene converting glycine 325 to
RT   glutamic acid in Alport syndrome.";
RL   Hum. Mol. Genet. 1:127-129(1992).
RN   [16]
RP   VARIANTS APSX THR-1517; SER-1538 AND GLN-1563.
RX   PubMed=8406498; DOI=10.1006/geno.1993.1351;
RA   Lemmink H.L., Schroeder C.H., Brunner H.G., Nelen M.R., Zhou J.,
RA   Tryggvason K., Haggsma-Schouten W.A.G., Roodvoets A.P., Rascher W.,
RA   van Oost B.A., Smeets H.J.M.;
RT   "Identification of four novel mutations in the COL4A5 gene of patients
RT   with Alport syndrome.";
RL   Genomics 17:485-489(1993).
RN   [17]
RP   INVOLVEMENT IN DL-ATS.
RX   PubMed=8356449; DOI=10.1126/science.8356449;
RA   Zhou J., Mochizuki T., Smeets H., Antignac C., Laurila P.,
RA   de Paepe A., Tryggvason K., Reeders S.T.;
RT   "Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in
RT   inherited smooth muscle tumors.";
RL   Science 261:1167-1169(1993).
RN   [18]
RP   VARIANTS APSX GLU-400; VAL-406; VAL-638; ALA-638; ARG-653; ARG-796;
RP   ARG-869; ARG-872 AND CYS-1241.
RX   PubMed=7599631; DOI=10.1002/humu.1380050303;
RA   Boye E., Flinter F., Zhou J., Tryggvason K., Bobrow M., Harris A.;
RT   "Detection of 12 novel mutations in the collagenous domain of the
RT   COL4A5 gene in Alport syndrome patients.";
RL   Hum. Mutat. 5:197-204(1995).
RN   [19]
RP   VARIANT APSX ARG-1649.
RX   PubMed=8651292;
RA   Barker D.F., Pruchno C.J., Jiang X., Atkin C.L., Stone E.M.,
RA   Denison J.C., Fain P.R., Gregory M.C.;
RT   "A mutation causing Alport syndrome with tardive hearing loss is
RT   common in the western United States.";
RL   Am. J. Hum. Genet. 58:1157-1165(1996).
RN   [20]
RP   VARIANTS APSX.
RX   PubMed=8651296;
RA   Renieri A., Bruttini M., Galli L., Zanelli P., Neri T.M., Rossetti S.,
RA   Turco A.E., Heiskari N., Zhou J., Gusmano R., Massella L., Banfi G.,
RA   Scolari F., Sessa A., Rizzoni G.F., Tryggvason K., Pignatti P.F.,
RA   Savi M., Ballabio A., de Marchi M.;
RT   "X-linked Alport syndrome: an SSCP-based mutation survey over all 51
RT   exons of the COL4A5 gene.";
RL   Am. J. Hum. Genet. 58:1192-1204(1996).
RN   [21]
RP   VARIANTS APSX, AND VARIANTS ASP-430; SER-444; SER-619; ASN-664 AND
RP   MET-1428.
RX   PubMed=8940267;
RA   Knebelmann B., Breillat C., Forestier L., Arrondel C., Jacassier D.,
RA   Giatras I., Drouot L., Deschenes G., Gruenfeld J.-P., Broyer M.,
RA   Gubler M.-C., Antignac C.;
RT   "Spectrum of mutations in the COL4A5 collagen gene in X-linked Alport
RT   syndrome.";
RL   Am. J. Hum. Genet. 59:1221-1232(1996).
RN   [22]
RP   VARIANT APSX ASP-1498.
RX   PubMed=8829632;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:2<149::AID-HUMU9>3.3.CO;2-A;
RA   Tverskaya S., Bobrynina V., Tsalykova F., Ignatova M.,
RA   Krasnopolskaya X., Evgrafov O.;
RT   "Substitution of A1498D in noncollagen domain of a5(IV) collagen chain
RT   associated with adult-onset X-linked Alport syndrome.";
RL   Hum. Mutat. 7:149-150(1996).
RN   [23]
RP   VARIANT APSX GLN-1677.
RX   PubMed=9150741; DOI=10.1007/s004390050429;
RA   Barker D.F., Denison J.C., Atkin C.L., Gregory M.C.;
RT   "Common ancestry of three Ashkenazi-American families with Alport
RT   syndrome and COL4A5 R1677Q.";
RL   Hum. Genet. 99:681-684(1997).
RN   [24]
RP   VARIANTS APSX ARG-174; ARG-177; ARG-325; CYS-1410; TRP-1421; THR-1517
RP   AND ASP-1596.
RX   PubMed=9452056;
RA   Neri T.M., Zanelli P., de Palma G., Savi M., Rossetti S., Turco A.E.,
RA   Pignatti G.F., Galli L., Bruttini M., Renieri A., Mingarelli R.,
RA   Trivelli A., Pinciaroli A.R., Ragaiolo M., Rizzoni G.F., de Marchi M.;
RT   "Missense mutations in the COL4A5 gene in patients with X-linked
RT   Alport syndrome.";
RL   Hum. Mutat. Suppl. 1:S106-S109(1998).
RN   [25]
RP   VARIANTS APSX VAL-420; 456-PRO--PRO-458 DEL; ASP-573; ASP-624;
RP   ASP-635; 802-GLY--PRO-807 DEL; ARG-869; CYS-941; SER-1030; SER-1066;
RP   ASP-1143; ARG-1196; GLU-1261; SER-1357 AND ARG-1649.
RX   PubMed=9848783;
RA   Martin P., Heiskari N., Zhou J., Leinonen A., Tumelius T., Hertz J.M.,
RA   Barker D.F., Gregory M.C., Atkin C.L., Styrkarsdottir U., Neumann H.,
RA   Springate J., Shows T.B., Pettersson E., Tryggvason K.;
RT   "High mutation detection rate in the COL4A5 collagen gene in suspected
RT   Alport syndrome using PCR and direct DNA sequencing.";
RL   J. Am. Soc. Nephrol. 9:2291-2301(1998).
RN   [26]
RP   VARIANTS APSX GLU-579; LYS-633; ASP-947; VAL-953; ARG-1107; ARG-1158;
RP   SER-1170 AND TRP-1678, AND VARIANTS SER-444 AND ALA-739.
RX   PubMed=10561141; DOI=10.1016/S0272-6386(99)70042-9;
RA   Inoue Y., Nishio H., Shirakawa T., Nakanishi K., Nakamura H.,
RA   Sumino K., Nishiyama K., Iijima K., Yoshikawa N.;
RT   "Detection of mutations in the COL4A5 gene in over 90% of male
RT   patients with X-linked Alport's syndrome by RT-PCR and direct
RT   sequencing.";
RL   Am. J. Kidney Dis. 34:854-862(1999).
RN   [27]
RP   VARIANT APSX ARG-822.
RX   PubMed=10563487; DOI=10.1034/j.1399-0004.1999.560312.x;
RA   Cruz-Robles D., Garcia-Torres R., Antignac C., Forestier L.,
RA   Garcia de la Puente S., Correa-Rotter R., Garcia-Lopez E., Orozco L.;
RT   "Three novel mutations in the COL4A5 gene in Mexican Alport syndrome
RT   patients.";
RL   Clin. Genet. 56:242-243(1999).
RN   [28]
RP   VARIANTS APSX, AND VARIANTS.
RX   PubMed=10094548;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:2<124::AID-HUMU4>3.0.CO;2-Z;
RA   Plant K.E., Green P.M., Vetrie D., Flinter F.A.;
RT   "Detection of mutations in COL4A5 in patients with Alport syndrome.";
RL   Hum. Mutat. 13:124-132(1999).
RN   [29]
RP   VARIANT APSX CYS-177.
RX   PubMed=11004279; DOI=10.1016/S0002-9394(00)00466-9;
RA   Blasi M.A., Rinaldi R., Renieri A., Petrucci R., De Bernardo C.,
RA   Bruttini M., Grammatico P.;
RT   "Dot-and-fleck retinopathy in Alport syndrome caused by a novel
RT   mutation in the COL4A5 gene.";
RL   Am. J. Ophthalmol. 130:130-131(2000).
RN   [30]
RP   VARIANTS APSX ARG-216; ARG-415; GLU-1045; ASP-1086; SER-1167 AND
RP   864-SER--GLY-875 DEL.
RX   PubMed=10862091;
RX   DOI=10.1002/1098-1004(200006)15:6<579::AID-HUMU13>3.3.CO;2-B;
RA   Martin P., Heiskari N., Pajari H., Groenhagen-Riska C.,
RA   Kaeaeriaeinen H., Koskimies O., Tryggvason K.;
RT   "Spectrum of COL4A5 mutations in Finnish Alport syndrome patients.";
RL   Hum. Mutat. 15:579-579(2000).
RN   [31]
RP   VARIANTS APSX ARG-319; SER-739; VAL-902; GLU-911; ASP-1229 AND
RP   HIS-1511.
RX   PubMed=10684360; DOI=10.1007/s004670050025;
RA   Cheong H.I., Park H.W., Ha I.S., Choi Y.;
RT   "Mutational analysis of COL4A5 gene in Korean Alport syndrome.";
RL   Pediatr. Nephrol. 14:117-121(2000).
RN   [32]
RP   VARIANTS APSX ARG-192; ARG-292; ASP-295; ARG-325; ARG-558; VAL-603;
RP   ASP-624; ASP-629; GLU-722; VAL-898; ALA-1006; VAL-1006; ASP-1244;
RP   ARG-1649 AND PRO-1677, AND VARIANT SER-444.
RX   PubMed=11223851;
RX   DOI=10.1002/1096-8628(20010115)98:2<148::AID-AJMG1024>3.0.CO;2-W;
RA   Barker D.F., Denison J.C., Atkin C.L., Gregory M.C.;
RT   "Efficient detection of Alport syndrome COL4A5 mutations with
RT   multiplex genomic PCR-SSCP.";
RL   Am. J. Med. Genet. 98:148-160(2001).
RN   [33]
RP   INVOLVEMENT IN DL-ATS.
RX   PubMed=12784310; DOI=10.1002/ajmg.a.20019;
RA   Anker M.C., Arnemann J., Neumann K., Ahrens P., Schmidt H., Koenig R.;
RT   "Alport syndrome with diffuse leiomyomatosis.";
RL   Am. J. Med. Genet. A 119:381-385(2003).
RN   [34]
RP   VARIANT APSX GLU-123.
RX   PubMed=24522658; DOI=10.1007/s11033-014-3227-1;
RA   Guo Y., Yuan J., Liang H., Xiao J., Xu H., Yuan L., Gao K., Wu B.,
RA   Tang Y., Li X., Deng H.;
RT   "Identification of a novel COL4A5 mutation in a Chinese family with X-
RT   linked Alport syndrome using exome sequencing.";
RL   Mol. Biol. Rep. 41:3631-3635(2014).
CC   -!- FUNCTION: Type IV collagen is the major structural component of
CC       glomerular basement membranes (GBM), forming a 'chicken-wire'
CC       meshwork together with laminins, proteoglycans and
CC       entactin/nidogen.
CC   -!- SUBUNIT: There are six type IV collagen isoforms, alpha 1(IV)-
CC       alpha 6(IV), each of which can form a triple helix structure with
CC       2 other chains to generate type IV collagen network.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix, basement membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P29400-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29400-2; Sequence=VSP_001173;
CC         Note=Contains 2 extra G-X-X repeats into the triple-helix
CC         domain.;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is found in kidney.
CC   -!- DOMAIN: Alpha chains of type IV collagen have a non-collagenous
CC       domain (NC1) at their C-terminus, frequent interruptions of the G-
CC       X-Y repeats in the long central triple-helical domain (which may
CC       cause flexibility in the triple helix), and a short N-terminal
CC       triple-helical 7S domain.
CC   -!- PTM: Prolines at the third position of the tripeptide repeating
CC       unit (G-X-Y) are hydroxylated in some or all of the chains.
CC   -!- PTM: Type IV collagens contain numerous cysteine residues which
CC       are involved in inter- and intramolecular disulfide bonding. 12 of
CC       these, located in the NC1 domain, are conserved in all known type
CC       IV collagens.
CC   -!- PTM: The trimeric structure of the NC1 domains is stabilized by
CC       covalent bonds between Lys and Met residues. {ECO:0000250}.
CC   -!- DISEASE: Alport syndrome, X-linked (APSX) [MIM:301050]: A syndrome
CC       that is characterized by progressive glomerulonephritis, renal
CC       failure, sensorineural deafness, specific eye abnormalities
CC       (lenticonous and macular flecks), and glomerular basement membrane
CC       defects. The disorder shows considerable heterogeneity in that
CC       families differ in the age of end-stage renal disease and the
CC       occurrence of deafness. {ECO:0000269|PubMed:10094548,
CC       ECO:0000269|PubMed:10561141, ECO:0000269|PubMed:10563487,
CC       ECO:0000269|PubMed:10684360, ECO:0000269|PubMed:10862091,
CC       ECO:0000269|PubMed:11004279, ECO:0000269|PubMed:11223851,
CC       ECO:0000269|PubMed:1352287, ECO:0000269|PubMed:1363780,
CC       ECO:0000269|PubMed:1376965, ECO:0000269|PubMed:1672282,
CC       ECO:0000269|PubMed:24522658, ECO:0000269|PubMed:7599631,
CC       ECO:0000269|PubMed:7853788, ECO:0000269|PubMed:8406498,
CC       ECO:0000269|PubMed:8651292, ECO:0000269|PubMed:8651296,
CC       ECO:0000269|PubMed:8829632, ECO:0000269|PubMed:8940267,
CC       ECO:0000269|PubMed:9150741, ECO:0000269|PubMed:9452056,
CC       ECO:0000269|PubMed:9848783}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Deletions covering the N-terminal regions of COL4A5
CC       and COL4A6, which are localized in a head-to-head manner, are
CC       found in the chromosome Xq22.3 centromeric deletion syndrome. This
CC       results in a phenotype with features of diffuse leiomyomatosis and
CC       Alport syndrome (DL-ATS).
CC   -!- SIMILARITY: Belongs to the type IV collagen family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00736}.
CC   -!- SIMILARITY: Contains 1 collagen IV NC1 (C-terminal non-
CC       collagenous) domain. {ECO:0000255|PROSITE-ProRule:PRU00736}.
CC   -!- WEB RESOURCE: Name= Alport syndrome and COL4A5;
CC       URL="http://www.arup.utah.edu/database/ALPORT/ALPORT_welcome.php";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M58526; AAA99480.1; -; mRNA.
DR   EMBL; AL034369; CAA22267.2; -; Genomic_DNA.
DR   EMBL; AL031622; CAA22267.2; JOINED; Genomic_DNA.
DR   EMBL; AL035425; CAA22267.2; JOINED; Genomic_DNA.
DR   EMBL; AL035425; CAB90289.2; -; Genomic_DNA.
DR   EMBL; AL031622; CAB90289.2; JOINED; Genomic_DNA.
DR   EMBL; AL034369; CAB90289.2; JOINED; Genomic_DNA.
DR   EMBL; AL031622; CAI43038.1; -; Genomic_DNA.
DR   EMBL; AL034369; CAI43038.1; JOINED; Genomic_DNA.
DR   EMBL; AL035425; CAI43038.1; JOINED; Genomic_DNA.
DR   EMBL; AL136364; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471120; EAX02683.1; -; Genomic_DNA.
DR   EMBL; M90464; AAA52046.1; -; mRNA.
DR   EMBL; U04520; AAC27816.1; -; Genomic_DNA.
DR   EMBL; U04470; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04471; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04472; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04473; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04474; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04476; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04477; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04478; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04479; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04480; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04483; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04485; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04486; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04487; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04488; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04489; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04490; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04491; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04492; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04493; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04494; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04495; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04496; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04497; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04498; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04499; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04500; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04501; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04502; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04503; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04504; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04505; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04506; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04507; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04508; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04509; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04510; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04511; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04512; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04514; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04515; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04516; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04517; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04518; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04519; AAC27816.1; JOINED; Genomic_DNA.
DR   EMBL; U04520; AAF66217.2; -; Genomic_DNA.
DR   EMBL; U04470; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04471; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04472; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04473; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04474; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04476; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04477; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04478; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04479; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04480; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04483; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04485; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04486; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04487; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04488; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04489; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04490; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04491; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04492; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04493; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04494; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04495; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04496; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04497; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04498; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04499; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04500; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04501; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04502; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04503; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04504; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04505; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04506; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04507; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04508; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04509; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04510; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; AF199451; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; AF199452; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04511; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04512; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04514; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04515; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04516; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04517; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04518; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; U04519; AAF66217.2; JOINED; Genomic_DNA.
DR   EMBL; M63473; AAA51558.1; -; Genomic_DNA.
DR   EMBL; M63455; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63456; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63457; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63458; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63459; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63460; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63461; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63462; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63463; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63464; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63465; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63466; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63467; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63468; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63470; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63471; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M63472; AAA51558.1; JOINED; Genomic_DNA.
DR   EMBL; M31115; AAA52045.1; -; mRNA.
DR   EMBL; Z37153; CAA85512.1; -; Genomic_DNA.
DR   EMBL; S69168; AAC60612.1; -; mRNA.
DR   EMBL; S59334; AAD13909.1; -; mRNA.
DR   EMBL; S75903; AAB33374.1; -; Genomic_DNA.
DR   CCDS; CCDS14543.1; -. [P29400-1]
DR   CCDS; CCDS35366.1; -. [P29400-2]
DR   PIR; S22917; S22917.
DR   RefSeq; NP_000486.1; NM_000495.4. [P29400-1]
DR   RefSeq; NP_203699.1; NM_033380.2. [P29400-2]
DR   RefSeq; XP_006724679.1; XM_006724616.2. [P29400-2]
DR   UniGene; Hs.369089; -.
DR   ProteinModelPortal; P29400; -.
DR   SMR; P29400; 1460-1685.
DR   BioGrid; 107684; 13.
DR   IntAct; P29400; 18.
DR   MINT; MINT-1388512; -.
DR   ChEMBL; CHEMBL2364188; -.
DR   iPTMnet; P29400; -.
DR   PhosphoSite; P29400; -.
DR   BioMuta; COL4A5; -.
DR   DMDM; 461675; -.
DR   MaxQB; P29400; -.
DR   PRIDE; P29400; -.
DR   Ensembl; ENST00000328300; ENSP00000331902; ENSG00000188153. [P29400-2]
DR   Ensembl; ENST00000361603; ENSP00000354505; ENSG00000188153. [P29400-1]
DR   GeneID; 1287; -.
DR   KEGG; hsa:1287; -.
DR   UCSC; uc004enz.2; human. [P29400-2]
DR   CTD; 1287; -.
DR   GeneCards; COL4A5; -.
DR   GeneReviews; COL4A5; -.
DR   H-InvDB; HIX0028371; -.
DR   HGNC; HGNC:2207; COL4A5.
DR   MalaCards; COL4A5; -.
DR   MIM; 301050; phenotype.
DR   MIM; 303630; gene.
DR   neXtProt; NX_P29400; -.
DR   Orphanet; 88917; X-linked Alport syndrome.
DR   Orphanet; 1018; X-linked diffuse leiomyomatosis - Alport syndrome.
DR   PharmGKB; PA26722; -.
DR   GeneTree; ENSGT00830000128235; -.
DR   HOGENOM; HOG000085652; -.
DR   HOVERGEN; HBG004933; -.
DR   InParanoid; P29400; -.
DR   KO; K06237; -.
DR   OMA; MSMQPLK; -.
DR   OrthoDB; EOG7RZ5P3; -.
DR   TreeFam; TF344135; -.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474244; Extracellular matrix organization.
DR   Reactome; R-HSA-1650814; Collagen biosynthesis and modifying enzymes.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-2214320; Anchoring fibril formation.
DR   Reactome; R-HSA-3000157; Laminin interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   GeneWiki; COL4A5; -.
DR   GenomeRNAi; 1287; -.
DR   NextBio; 5205; -.
DR   PRO; PR:P29400; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; P29400; -.
DR   CleanEx; HS_COL4A5; -.
DR   ExpressionAtlas; P29400; baseline and differential.
DR   Genevisible; P29400; HS.
DR   GO; GO:0005605; C:basal lamina; IEA:Ensembl.
DR   GO; GO:0005587; C:collagen type IV trimer; TAS:ProtInc.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; IEA:InterPro.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl.
DR   Gene3D; 2.170.240.10; -; 1.
DR   InterPro; IPR016187; C-type_lectin_fold.
DR   InterPro; IPR008160; Collagen.
DR   InterPro; IPR001442; Collagen_VI_NC.
DR   Pfam; PF01413; C4; 2.
DR   Pfam; PF01391; Collagen; 20.
DR   SMART; SM00111; C4; 2.
DR   SUPFAM; SSF56436; SSF56436; 2.
DR   PROSITE; PS51403; NC1_IV; 1.
PE   1: Evidence at protein level;
KW   Alport syndrome; Alternative splicing; Basement membrane;
KW   Chromosomal rearrangement; Collagen; Complete proteome; Deafness;
KW   Disease mutation; Disulfide bond; Extracellular matrix; Glycoprotein;
KW   Hydroxylation; Polymorphism; Reference proteome; Repeat; Secreted;
KW   Signal.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27   1685       Collagen alpha-5(IV) chain.
FT                                /FTId=PRO_0000005852.
FT   DOMAIN     1461   1685       Collagen IV NC1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00736}.
FT   REGION       27     41       Nonhelical region (NC2).
FT   REGION       42   1456       Triple-helical region.
FT   CARBOHYD    125    125       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    451    451       Interchain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00736}.
FT   DISULFID    481    481       Interchain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00736}.
FT   DISULFID    484    484       Interchain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00736}.
FT   DISULFID   1476   1567       Or C-1476 with C-1564.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00736}.
FT   DISULFID   1509   1564       Or C-1509 with C-1567.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00736}.
FT   DISULFID   1521   1527       {ECO:0000255|PROSITE-ProRule:PRU00736}.
FT   DISULFID   1586   1681       Or C-1586 with C-1678.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00736}.
FT   DISULFID   1620   1678       Or C-1620 with C-1681.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00736}.
FT   DISULFID   1632   1638       {ECO:0000255|PROSITE-ProRule:PRU00736}.
FT   CROSSLNK   1549   1549       S-Lysyl-methionine sulfilimine (Met-Lys)
FT                                (interchain with K-1667). {ECO:0000250}.
FT   CROSSLNK   1667   1667       S-Lysyl-methionine sulfilimine (Lys-Met)
FT                                (interchain with M-1549). {ECO:0000250}.
FT   VAR_SEQ    1264   1264       G -> GPTGFQG (in isoform 2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_001173.
FT   VARIANT      54     54       G -> D (in APSX; adult type).
FT                                /FTId=VAR_001914.
FT   VARIANT     114    114       G -> S (in APSX).
FT                                /FTId=VAR_007991.
FT   VARIANT     123    123       G -> E (in APSX).
FT                                {ECO:0000269|PubMed:24522658}.
FT                                /FTId=VAR_071932.
FT   VARIANT     129    129       G -> E (in APSX; juvenile type).
FT                                /FTId=VAR_001915.
FT   VARIANT     129    129       G -> V (in APSX; juvenile type).
FT                                /FTId=VAR_001916.
FT   VARIANT     174    174       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:9452056}.
FT                                /FTId=VAR_001917.
FT   VARIANT     177    177       G -> C (in APSX; presenting with dot-and-
FT                                fleck retinopathy).
FT                                {ECO:0000269|PubMed:11004279}.
FT                                /FTId=VAR_011220.
FT   VARIANT     177    177       G -> R (in APSX; adult type).
FT                                {ECO:0000269|PubMed:9452056}.
FT                                /FTId=VAR_001918.
FT   VARIANT     192    192       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011221.
FT   VARIANT     204    204       G -> V (in APSX; juvenile type).
FT                                /FTId=VAR_011222.
FT   VARIANT     216    216       G -> R (in APSX; juvenile type).
FT                                {ECO:0000269|PubMed:10862091}.
FT                                /FTId=VAR_001919.
FT   VARIANT     219    219       G -> S (in APSX).
FT                                /FTId=VAR_001920.
FT   VARIANT     230    230       G -> R (in APSX; juvenile type).
FT                                /FTId=VAR_011223.
FT   VARIANT     239    239       G -> E (in APSX).
FT                                /FTId=VAR_011224.
FT   VARIANT     264    264       G -> R (in APSX; adult type).
FT                                /FTId=VAR_011225.
FT   VARIANT     289    289       G -> V (in APSX; juvenile type).
FT                                /FTId=VAR_001921.
FT   VARIANT     292    292       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011226.
FT   VARIANT     292    292       G -> V (in APSX; juvenile type).
FT                                /FTId=VAR_001922.
FT   VARIANT     295    295       G -> D (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011227.
FT   VARIANT     298    298       G -> S (in APSX).
FT                                /FTId=VAR_011228.
FT   VARIANT     319    319       G -> R (in APSX; juvenile type).
FT                                {ECO:0000269|PubMed:10684360}.
FT                                /FTId=VAR_011229.
FT   VARIANT     325    325       G -> E (in APSX).
FT                                {ECO:0000269|PubMed:1363780}.
FT                                /FTId=VAR_001923.
FT   VARIANT     325    325       G -> R (in APSX; juvenile and adult
FT                                types). {ECO:0000269|PubMed:11223851,
FT                                ECO:0000269|PubMed:1376965,
FT                                ECO:0000269|PubMed:9452056}.
FT                                /FTId=VAR_001924.
FT   VARIANT     331    331       G -> V (in APSX).
FT                                /FTId=VAR_007992.
FT   VARIANT     365    367       Missing (in APSX; juvenile type).
FT                                /FTId=VAR_001926.
FT   VARIANT     365    365       G -> E (in APSX; juvenile type).
FT                                /FTId=VAR_001925.
FT   VARIANT     371    371       G -> E (in APSX; juvenile type).
FT                                /FTId=VAR_001927.
FT   VARIANT     374    374       G -> A (in APSX).
FT                                /FTId=VAR_001928.
FT   VARIANT     383    383       G -> D (in APSX; juvenile type).
FT                                /FTId=VAR_001929.
FT   VARIANT     400    400       G -> E (in APSX; adult type).
FT                                {ECO:0000269|PubMed:7599631}.
FT                                /FTId=VAR_001930.
FT   VARIANT     406    406       G -> V (in APSX; adult type).
FT                                {ECO:0000269|PubMed:7599631}.
FT                                /FTId=VAR_001931.
FT   VARIANT     409    409       G -> D (in APSX).
FT                                /FTId=VAR_001932.
FT   VARIANT     412    412       G -> V (in APSX; adult type).
FT                                /FTId=VAR_011230.
FT   VARIANT     415    415       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:10862091}.
FT                                /FTId=VAR_011231.
FT   VARIANT     420    420       G -> E (in APSX; juvenile type).
FT                                /FTId=VAR_011232.
FT   VARIANT     420    420       G -> V (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_011233.
FT   VARIANT     423    423       G -> E (in APSX).
FT                                /FTId=VAR_011234.
FT   VARIANT     430    430       A -> D (in dbSNP:rs142883891).
FT                                {ECO:0000269|PubMed:8940267}.
FT                                /FTId=VAR_001933.
FT   VARIANT     444    444       I -> S (in dbSNP:rs2272946).
FT                                {ECO:0000269|PubMed:10561141,
FT                                ECO:0000269|PubMed:11223851,
FT                                ECO:0000269|PubMed:8940267}.
FT                                /FTId=VAR_001934.
FT   VARIANT     456    458       Missing (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_001935.
FT   VARIANT     466    466       G -> E (in APSX).
FT                                /FTId=VAR_001936.
FT   VARIANT     472    472       G -> R (in APSX).
FT                                /FTId=VAR_007993.
FT   VARIANT     491    491       G -> E (in APSX; juvenile type).
FT                                /FTId=VAR_011235.
FT   VARIANT     494    494       G -> D (in APSX; adult type).
FT                                /FTId=VAR_001937.
FT   VARIANT     496    507       Missing (in APSX; juvenile type).
FT                                /FTId=VAR_001938.
FT   VARIANT     497    497       G -> C (in APSX; adult type).
FT                                /FTId=VAR_011236.
FT   VARIANT     521    521       G -> C (in APSX).
FT                                {ECO:0000269|PubMed:1352287}.
FT                                /FTId=VAR_001939.
FT   VARIANT     521    521       G -> S (in APSX).
FT                                /FTId=VAR_001940.
FT   VARIANT     524    524       G -> D (in APSX; adult type).
FT                                /FTId=VAR_011237.
FT   VARIANT     545    545       G -> R (in APSX).
FT                                /FTId=VAR_007994.
FT   VARIANT     545    545       G -> V (in APSX).
FT                                /FTId=VAR_007995.
FT   VARIANT     558    558       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011238.
FT   VARIANT     561    561       G -> R (in APSX).
FT                                /FTId=VAR_007996.
FT   VARIANT     567    567       G -> A (in APSX; juvenile type).
FT                                /FTId=VAR_001941.
FT   VARIANT     573    573       G -> D (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_011239.
FT   VARIANT     579    579       G -> E (in APSX).
FT                                {ECO:0000269|PubMed:10561141}.
FT                                /FTId=VAR_011240.
FT   VARIANT     579    579       G -> R (in APSX; adult type).
FT                                /FTId=VAR_007997.
FT   VARIANT     603    603       G -> V (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011241.
FT   VARIANT     609    609       G -> R (in APSX; juvenile type).
FT                                /FTId=VAR_011242.
FT   VARIANT     609    609       G -> V (in APSX; juvenile type).
FT                                /FTId=VAR_001942.
FT   VARIANT     619    619       P -> S. {ECO:0000269|PubMed:8940267}.
FT                                /FTId=VAR_011243.
FT   VARIANT     621    621       G -> C (in APSX).
FT                                /FTId=VAR_011244.
FT   VARIANT     624    624       G -> D (in APSX).
FT                                {ECO:0000269|PubMed:11223851,
FT                                ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_011245.
FT   VARIANT     629    629       G -> D (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011246.
FT   VARIANT     632    632       G -> D (in APSX).
FT                                /FTId=VAR_011247.
FT   VARIANT     633    633       E -> K (in APSX).
FT                                {ECO:0000269|PubMed:10561141}.
FT                                /FTId=VAR_011248.
FT   VARIANT     635    635       G -> D (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_007998.
FT   VARIANT     638    638       G -> A (in APSX).
FT                                {ECO:0000269|PubMed:7599631}.
FT                                /FTId=VAR_001944.
FT   VARIANT     638    638       G -> S (in APSX; juvenile type).
FT                                /FTId=VAR_007999.
FT   VARIANT     638    638       G -> V (in APSX).
FT                                {ECO:0000269|PubMed:7599631}.
FT                                /FTId=VAR_001943.
FT   VARIANT     653    653       G -> R (in APSX; juvenile type).
FT                                {ECO:0000269|PubMed:7599631}.
FT                                /FTId=VAR_001945.
FT   VARIANT     664    664       K -> N (in dbSNP:rs34077552).
FT                                {ECO:0000269|PubMed:8940267}.
FT                                /FTId=VAR_001946.
FT   VARIANT     669    669       G -> A (in APSX; juvenile type).
FT                                /FTId=VAR_008000.
FT   VARIANT     681    681       G -> D (in APSX).
FT                                /FTId=VAR_011249.
FT   VARIANT     684    684       G -> V (in APSX; adult type).
FT                                /FTId=VAR_001947.
FT   VARIANT     687    687       G -> E (in APSX).
FT                                /FTId=VAR_008001.
FT   VARIANT     722    722       G -> E (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011250.
FT   VARIANT     739    739       P -> A (in dbSNP:rs104886164).
FT                                {ECO:0000269|PubMed:10561141}.
FT                                /FTId=VAR_011251.
FT   VARIANT     739    739       P -> S (in APSX; juvenile type;
FT                                dbSNP:rs104886164).
FT                                {ECO:0000269|PubMed:10684360}.
FT                                /FTId=VAR_011252.
FT   VARIANT     740    740       G -> E (in APSX; juvenile type).
FT                                /FTId=VAR_001948.
FT   VARIANT     743    743       G -> D (in APSX).
FT                                /FTId=VAR_008002.
FT   VARIANT     772    772       G -> D (in APSX; juvenile type).
FT                                /FTId=VAR_001949.
FT   VARIANT     796    796       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:7599631}.
FT                                /FTId=VAR_001950.
FT   VARIANT     802    807       Missing (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_011254.
FT   VARIANT     802    802       G -> R (in APSX).
FT                                /FTId=VAR_011253.
FT   VARIANT     808    808       G -> E (in APSX; adult type).
FT                                /FTId=VAR_008003.
FT   VARIANT     811    811       G -> V (in APSX; juvenile type).
FT                                /FTId=VAR_011255.
FT   VARIANT     822    824       Missing (in APSX).
FT                                /FTId=VAR_008004.
FT   VARIANT     822    822       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:10563487}.
FT                                /FTId=VAR_011256.
FT   VARIANT     852    852       G -> E (in APSX; juvenile type).
FT                                /FTId=VAR_008005.
FT   VARIANT     852    852       G -> R (in APSX).
FT                                /FTId=VAR_001951.
FT   VARIANT     864    875       Missing (in APSX).
FT                                {ECO:0000269|PubMed:10862091}.
FT                                /FTId=VAR_011257.
FT   VARIANT     866    866       G -> E (in APSX; adult type).
FT                                /FTId=VAR_001952.
FT   VARIANT     869    869       G -> R (in APSX; juvenile type).
FT                                {ECO:0000269|PubMed:7599631,
FT                                ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_001953.
FT   VARIANT     872    872       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:7599631}.
FT                                /FTId=VAR_001954.
FT   VARIANT     878    878       G -> R (in APSX).
FT                                /FTId=VAR_008006.
FT   VARIANT     898    898       M -> V (in APSX; mild phenotype).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011258.
FT   VARIANT     902    902       G -> V (in APSX; juvenile type).
FT                                {ECO:0000269|PubMed:10684360}.
FT                                /FTId=VAR_011259.
FT   VARIANT     911    911       G -> E (in APSX).
FT                                {ECO:0000269|PubMed:10684360}.
FT                                /FTId=VAR_011260.
FT   VARIANT     941    941       G -> C (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_011261.
FT   VARIANT     942    942       Missing (in APSX).
FT                                /FTId=VAR_001955.
FT   VARIANT     947    947       G -> D (in APSX).
FT                                {ECO:0000269|PubMed:10561141}.
FT                                /FTId=VAR_011262.
FT   VARIANT     953    953       G -> V (in APSX; found on the same allele
FT                                as variant Glu-1211; dbSNP:rs78972735).
FT                                {ECO:0000269|PubMed:10561141}.
FT                                /FTId=VAR_011263.
FT   VARIANT     988    992       Missing (in APSX; adult type).
FT                                /FTId=VAR_008007.
FT   VARIANT    1006   1006       G -> A (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011264.
FT   VARIANT    1006   1006       G -> V (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011265.
FT   VARIANT    1015   1015       G -> E (in APSX).
FT                                /FTId=VAR_011266.
FT   VARIANT    1015   1015       G -> V (in APSX).
FT                                /FTId=VAR_011267.
FT   VARIANT    1030   1030       G -> S (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_011268.
FT   VARIANT    1036   1036       G -> V (in APSX).
FT                                /FTId=VAR_011269.
FT   VARIANT    1039   1039       G -> S (in APSX; juvenile type).
FT                                /FTId=VAR_011270.
FT   VARIANT    1045   1045       G -> E (in APSX).
FT                                {ECO:0000269|PubMed:10862091}.
FT                                /FTId=VAR_011271.
FT   VARIANT    1066   1066       G -> R (in APSX).
FT                                /FTId=VAR_011272.
FT   VARIANT    1066   1066       G -> S (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_011273.
FT   VARIANT    1086   1086       G -> D (in APSX).
FT                                {ECO:0000269|PubMed:10862091}.
FT                                /FTId=VAR_011274.
FT   VARIANT    1104   1104       G -> V (in APSX).
FT                                /FTId=VAR_001956.
FT   VARIANT    1107   1107       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:10561141}.
FT                                /FTId=VAR_008008.
FT   VARIANT    1143   1143       G -> D (in APSX; juvenile type).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_001957.
FT   VARIANT    1143   1143       G -> S (in APSX; adult type).
FT                                /FTId=VAR_001958.
FT   VARIANT    1158   1158       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:10561141}.
FT                                /FTId=VAR_011275.
FT   VARIANT    1161   1161       G -> R (in APSX).
FT                                /FTId=VAR_008009.
FT   VARIANT    1167   1167       G -> S (in APSX).
FT                                {ECO:0000269|PubMed:10862091}.
FT                                /FTId=VAR_011276.
FT   VARIANT    1170   1170       G -> S (in APSX).
FT                                {ECO:0000269|PubMed:10561141}.
FT                                /FTId=VAR_011277.
FT   VARIANT    1182   1182       G -> R (in APSX; juvenile type).
FT                                /FTId=VAR_001959.
FT   VARIANT    1196   1196       G -> R (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_011278.
FT   VARIANT    1205   1205       G -> C (in APSX; juvenile type).
FT                                /FTId=VAR_011279.
FT   VARIANT    1211   1211       G -> E (in APSX; found on the same allele
FT                                as variant Val-953).
FT                                /FTId=VAR_011280.
FT   VARIANT    1211   1211       G -> R (in APSX).
FT                                /FTId=VAR_008010.
FT   VARIANT    1220   1220       G -> D (in APSX).
FT                                /FTId=VAR_008011.
FT   VARIANT    1229   1229       G -> D (in APSX; adult type).
FT                                {ECO:0000269|PubMed:10684360}.
FT                                /FTId=VAR_011281.
FT   VARIANT    1241   1241       G -> C (in APSX).
FT                                {ECO:0000269|PubMed:7599631}.
FT                                /FTId=VAR_001960.
FT   VARIANT    1244   1244       G -> D (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011282.
FT   VARIANT    1252   1252       G -> S (in APSX; adult type).
FT                                /FTId=VAR_011283.
FT   VARIANT    1261   1261       G -> E (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_011284.
FT   VARIANT    1270   1270       G -> S (in APSX).
FT                                /FTId=VAR_001961.
FT   VARIANT    1333   1333       G -> S (in APSX).
FT                                /FTId=VAR_008012.
FT   VARIANT    1357   1357       G -> S (in APSX).
FT                                {ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_011285.
FT   VARIANT    1379   1379       G -> V (in APSX; adult type).
FT                                /FTId=VAR_001962.
FT   VARIANT    1410   1410       R -> C (in APSX; adult and juvenile
FT                                types). {ECO:0000269|PubMed:9452056}.
FT                                /FTId=VAR_001963.
FT   VARIANT    1421   1421       G -> W (in APSX; adult type).
FT                                {ECO:0000269|PubMed:9452056}.
FT                                /FTId=VAR_001964.
FT   VARIANT    1422   1422       R -> C (in APSX; juvenile type).
FT                                /FTId=VAR_001965.
FT   VARIANT    1427   1427       G -> V (in APSX; adult type).
FT                                /FTId=VAR_008013.
FT   VARIANT    1428   1428       L -> M. {ECO:0000269|PubMed:8940267}.
FT                                /FTId=VAR_011286.
FT   VARIANT    1442   1442       G -> D (in APSX).
FT                                /FTId=VAR_008014.
FT   VARIANT    1451   1451       G -> S (in APSX).
FT                                /FTId=VAR_001966.
FT   VARIANT    1486   1486       G -> A (in APSX; adult type).
FT                                /FTId=VAR_008015.
FT   VARIANT    1488   1488       S -> F (in APSX).
FT                                /FTId=VAR_011287.
FT   VARIANT    1498   1498       A -> D (in APSX).
FT                                {ECO:0000269|PubMed:8829632}.
FT                                /FTId=VAR_001967.
FT   VARIANT    1511   1511       R -> H (in APSX; juvenile type; could be
FT                                a non pathogenic variant).
FT                                {ECO:0000269|PubMed:10684360}.
FT                                /FTId=VAR_011288.
FT   VARIANT    1517   1517       P -> T (in APSX; juvenile type).
FT                                {ECO:0000269|PubMed:8406498,
FT                                ECO:0000269|PubMed:9452056}.
FT                                /FTId=VAR_001968.
FT   VARIANT    1538   1538       W -> S (in APSX; adult type).
FT                                {ECO:0000269|PubMed:8406498}.
FT                                /FTId=VAR_001969.
FT   VARIANT    1559   1559       P -> A.
FT                                /FTId=VAR_008016.
FT   VARIANT    1563   1563       R -> Q (in APSX).
FT                                {ECO:0000269|PubMed:8406498}.
FT                                /FTId=VAR_001970.
FT   VARIANT    1564   1564       C -> S (in APSX; adult type).
FT                                {ECO:0000269|PubMed:1672282}.
FT                                /FTId=VAR_001971.
FT   VARIANT    1567   1567       C -> R (in APSX; juvenile type).
FT                                /FTId=VAR_011289.
FT   VARIANT    1596   1596       G -> D (in APSX).
FT                                {ECO:0000269|PubMed:9452056}.
FT                                /FTId=VAR_001972.
FT   VARIANT    1597   1685       Missing (in APSX).
FT                                {ECO:0000269|PubMed:7853788}.
FT                                /FTId=VAR_019594.
FT   VARIANT    1649   1649       L -> R (in APSX; adult type).
FT                                {ECO:0000269|PubMed:11223851,
FT                                ECO:0000269|PubMed:8651292,
FT                                ECO:0000269|PubMed:9848783}.
FT                                /FTId=VAR_001973.
FT   VARIANT    1677   1677       R -> P (in APSX).
FT                                {ECO:0000269|PubMed:11223851}.
FT                                /FTId=VAR_011290.
FT   VARIANT    1677   1677       R -> Q (in APSX).
FT                                {ECO:0000269|PubMed:9150741}.
FT                                /FTId=VAR_001974.
FT   VARIANT    1678   1678       C -> W (in APSX).
FT                                {ECO:0000269|PubMed:10561141}.
FT                                /FTId=VAR_011291.
FT   VARIANT    1679   1685       Missing (in APSX).
FT                                /FTId=VAR_019595.
FT   CONFLICT    440    441       AG -> GS (in Ref. 5; AAA99480).
FT                                {ECO:0000305}.
FT   CONFLICT    625    628       FGPP -> LALQ (in Ref. 5; AAA99480).
FT                                {ECO:0000305}.
FT   CONFLICT    667    668       LP -> FR (in Ref. 5; AAA99480).
FT                                {ECO:0000305}.
FT   CONFLICT    888    888       A -> R (in Ref. 5; AAA99480).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1685 AA;  161044 MW;  4450A6762F12A626 CRC64;
     MKLRGVSLAA GLFLLALSLW GQPAEAAACY GCSPGSKCDC SGIKGEKGER GFPGLEGHPG
     LPGFPGPEGP PGPRGQKGDD GIPGPPGPKG IRGPPGLPGF PGTPGLPGMP GHDGAPGPQG
     IPGCNGTKGE RGFPGSPGFP GLQGPPGPPG IPGMKGEPGS IIMSSLPGPK GNPGYPGPPG
     IQGLPGPTGI PGPIGPPGPP GLMGPPGPPG LPGPKGNMGL NFQGPKGEKG EQGLQGPPGP
     PGQISEQKRP IDVEFQKGDQ GLPGDRGPPG PPGIRGPPGP PGGEKGEKGE QGEPGKRGKP
     GKDGENGQPG IPGLPGDPGY PGEPGRDGEK GQKGDTGPPG PPGLVIPRPG TGITIGEKGN
     IGLPGLPGEK GERGFPGIQG PPGLPGPPGA AVMGPPGPPG FPGERGQKGD EGPPGISIPG
     PPGLDGQPGA PGLPGPPGPA GPHIPPSDEI CEPGPPGPPG SPGDKGLQGE QGVKGDKGDT
     CFNCIGTGIS GPPGQPGLPG LPGPPGSLGF PGQKGEKGQA GATGPKGLPG IPGAPGAPGF
     PGSKGEPGDI LTFPGMKGDK GELGSPGAPG LPGLPGTPGQ DGLPGLPGPK GEPGGITFKG
     ERGPPGNPGL PGLPGNIGPM GPPGFGPPGP VGEKGIQGVA GNPGQPGIPG PKGDPGQTIT
     QPGKPGLPGN PGRDGDVGLP GDPGLPGQPG LPGIPGSKGE PGIPGIGLPG PPGPKGFPGI
     PGPPGAPGTP GRIGLEGPPG PPGFPGPKGE PGFALPGPPG PPGLPGFKGA LGPKGDRGFP
     GPPGPPGRTG LDGLPGPKGD VGPNGQPGPM GPPGLPGIGV QGPPGPPGIP GPIGQPGLHG
     IPGEKGDPGP PGLDVPGPPG ERGSPGIPGA PGPIGPPGSP GLPGKAGASG FPGTKGEMGM
     MGPPGPPGPL GIPGRSGVPG LKGDDGLQGQ PGLPGPTGEK GSKGEPGLPG PPGPMDPNLL
     GSKGEKGEPG LPGIPGVSGP KGYQGLPGDP GQPGLSGQPG LPGPPGPKGN PGLPGQPGLI
     GPPGLKGTIG DMGFPGPQGV EGPPGPSGVP GQPGSPGLPG QKGDKGDPGI SSIGLPGLPG
     PKGEPGLPGY PGNPGIKGSV GDPGLPGLPG TPGAKGQPGL PGFPGTPGPP GPKGISGPPG
     NPGLPGEPGP VGGGGHPGQP GPPGEKGKPG QDGIPGPAGQ KGEPGQPGFG NPGPPGLPGL
     SGQKGDGGLP GIPGNPGLPG PKGEPGFHGF PGVQGPPGPP GSPGPALEGP KGNPGPQGPP
     GRPGLPGPEG PPGLPGNGGI KGEKGNPGQP GLPGLPGLKG DQGPPGLQGN PGRPGLNGMK
     GDPGLPGVPG FPGMKGPSGV PGSAGPEGEP GLIGPPGPPG LPGPSGQSII IKGDAGPPGI
     PGQPGLKGLP GPQGPQGLPG PTGPPGDPGR NGLPGFDGAG GRKGDPGLPG QPGTRGLDGP
     PGPDGLQGPP GPPGTSSVAH GFLITRHSQT TDAPQCPQGT LQVYEGFSLL YVQGNKRAHG
     QDLGTAGSCL RRFSTMPFMF CNINNVCNFA SRNDYSYWLS TPEPMPMSMQ PLKGQSIQPF
     ISRCAVCEAP AVVIAVHSQT IQIPHCPQGW DSLWIGYSFM MHTSAGAEGS GQALASPGSC
     LEEFRSAPFI ECHGRGTCNY YANSYSFWLA TVDVSDMFSK PQSETLKAGD LRTRISRCQV
     CMKRT
//
ID   SMO_MOUSE               Reviewed;         793 AA.
AC   P56726;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 2.
DT   09-DEC-2015, entry version 126.
DE   RecName: Full=Smoothened homolog;
DE            Short=SMO;
DE   Flags: Precursor;
GN   Name=Smo; Synonyms=Smoh;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9196051; DOI=10.1006/bbrc.1997.6750;
RA   Akiyama H., Shigeno C., Hiraki Y., Shukunami C., Kohno H., Akagi M.,
RA   Konishi J., Nakamura T.;
RT   "Cloning of a mouse Smoothened cDNA and expression patterns of
RT   hedgehog signalling molecules during chondrogenesis and cartilage
RT   differentiation in clonal mouse EC cells, ATDC5.";
RL   Biochem. Biophys. Res. Commun. 235:142-147(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   INTERACTION WITH ARRB2.
RX   PubMed=15618519; DOI=10.1126/science.1104135;
RA   Chen W., Ren X.R., Nelson C.D., Barak L.S., Chen J.K., Beachy P.A.,
RA   de Sauvage F., Lefkowitz R.J.;
RT   "Activity-dependent internalization of smoothened mediated by beta-
RT   arrestin 2 and GRK2.";
RL   Science 306:2257-2260(2004).
RN   [4]
RP   ASSOCIATION WITH THE BBSOME COMPLEX, AND INTERACTION WITH BBS5 AND
RP   BBS7.
RX   PubMed=22072986; DOI=10.1371/journal.pgen.1002358;
RA   Seo S., Zhang Q., Bugge K., Breslow D.K., Searby C.C., Nachury M.V.,
RA   Sheffield V.C.;
RT   "A novel protein LZTFL1 regulates ciliary trafficking of the BBSome
RT   and Smoothened.";
RL   PLoS Genet. 7:E1002358-E1002358(2011).
CC   -!- FUNCTION: G protein-coupled receptor that probably associates with
CC       the patched protein (PTCH) to transduce the hedgehog's proteins
CC       signal. Binding of sonic hedgehog (SHH) to its receptor patched is
CC       thought to prevent normal inhibition by patched of smoothened
CC       (SMO). Required for the accumulation of KIF7 and GLI3 in the cilia
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with ARRB2.
CC       Interacts with KIF7. Interacts with BBS5 and BBS7; the
CC       interactions are indicative for the association of SMO with the
CC       BBsome complex to facilitate ciliary localization of SMO.
CC       {ECO:0000250, ECO:0000269|PubMed:15618519,
CC       ECO:0000269|PubMed:22072986}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein. Cell
CC       projection, cilium {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor Fz/Smo
CC       family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 FZ (frizzled) domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00090}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC069469; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS19965.1; -.
DR   PIR; JC5539; JC5539.
DR   RefSeq; NP_795970.3; NM_176996.4.
DR   UniGene; Mm.29279; -.
DR   ProteinModelPortal; P56726; -.
DR   SMR; P56726; 63-179, 194-557.
DR   BioGrid; 235504; 1.
DR   IntAct; P56726; 17.
DR   STRING; 10090.ENSMUSP00000001812; -.
DR   BindingDB; P56726; -.
DR   ChEMBL; CHEMBL6080; -.
DR   GuidetoPHARMACOLOGY; 239; -.
DR   PhosphoSite; P56726; -.
DR   PaxDb; P56726; -.
DR   PRIDE; P56726; -.
DR   Ensembl; ENSMUST00000001812; ENSMUSP00000001812; ENSMUSG00000001761.
DR   GeneID; 319757; -.
DR   KEGG; mmu:319757; -.
DR   UCSC; uc009bef.2; mouse.
DR   CTD; 6608; -.
DR   MGI; MGI:108075; Smo.
DR   eggNOG; KOG3577; Eukaryota.
DR   eggNOG; ENOG410XRC8; LUCA.
DR   HOGENOM; HOG000252964; -.
DR   HOVERGEN; HBG000352; -.
DR   InParanoid; P56726; -.
DR   KO; K06226; -.
DR   OMA; KNSNRYP; -.
DR   OrthoDB; EOG74J972; -.
DR   TreeFam; TF106460; -.
DR   Reactome; R-MMU-5610787; Hedgehog 'off' state.
DR   Reactome; R-MMU-5635838; Activation of SMO.
DR   ChiTaRS; Smo; mouse.
DR   NextBio; 395350; -.
DR   PRO; PR:P56726; -.
DR   Proteomes; UP000000589; Chromosome 6.
DR   Bgee; P56726; -.
DR   CleanEx; MM_SMO; -.
DR   ExpressionAtlas; P56726; baseline and differential.
DR   Genevisible; P56726; MM.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0060170; C:ciliary membrane; IDA:MGI.
DR   GO; GO:0005929; C:cilium; IDA:CACAO.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0072372; C:primary cilium; IDA:BHF-UCL.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0004930; F:G-protein coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0005113; F:patched binding; ISO:MGI.
DR   GO; GO:0017147; F:Wnt-protein binding; IBA:GO_Central.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IMP:MGI.
DR   GO; GO:0048143; P:astrocyte activation; IMP:MGI.
DR   GO; GO:0060413; P:atrial septum morphogenesis; IGI:MGI.
DR   GO; GO:0048468; P:cell development; IMP:MGI.
DR   GO; GO:0001708; P:cell fate specification; IMP:MGI.
DR   GO; GO:0071397; P:cellular response to cholesterol; IEP:BHF-UCL.
DR   GO; GO:0007417; P:central nervous system development; IGI:MGI.
DR   GO; GO:0021953; P:central nervous system neuron differentiation; IMP:MGI.
DR   GO; GO:0021696; P:cerebellar cortex morphogenesis; IMP:MGI.
DR   GO; GO:0021987; P:cerebral cortex development; IMP:MGI.
DR   GO; GO:0021542; P:dentate gyrus development; IMP:MGI.
DR   GO; GO:0060248; P:detection of cell density by contact stimulus involved in contact inhibition; ISS:UniProtKB.
DR   GO; GO:0003140; P:determination of left/right asymmetry in lateral mesoderm; IMP:BHF-UCL.
DR   GO; GO:0007368; P:determination of left/right symmetry; IMP:MGI.
DR   GO; GO:0048589; P:developmental growth; IMP:MGI.
DR   GO; GO:0048565; P:digestive tract development; IMP:MGI.
DR   GO; GO:0021904; P:dorsal/ventral neural tube patterning; IMP:MGI.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IMP:MGI.
DR   GO; GO:0048568; P:embryonic organ development; IGI:MGI.
DR   GO; GO:0060684; P:epithelial-mesenchymal cell signaling; IMP:MGI.
DR   GO; GO:0048853; P:forebrain morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IMP:MGI.
DR   GO; GO:0001947; P:heart looping; IMP:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; IGI:MGI.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IDA:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0070986; P:left/right axis specification; IMP:MGI.
DR   GO; GO:0060644; P:mammary gland epithelial cell differentiation; IMP:MGI.
DR   GO; GO:0072285; P:mesenchymal to epithelial transition involved in metanephric renal vesicle formation; IMP:UniProtKB.
DR   GO; GO:0007494; P:midgut development; IMP:BHF-UCL.
DR   GO; GO:0035264; P:multicellular organism growth; IMP:MGI.
DR   GO; GO:0051451; P:myoblast migration; IGI:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0043392; P:negative regulation of DNA binding; IMP:UniProtKB.
DR   GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IMP:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0051799; P:negative regulation of hair follicle development; IMP:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:CACAO.
DR   GO; GO:0001755; P:neural crest cell migration; IGI:MGI.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IMP:MGI.
DR   GO; GO:0001503; P:ossification; IMP:MGI.
DR   GO; GO:0001649; P:osteoblast differentiation; IMP:MGI.
DR   GO; GO:0061113; P:pancreas morphogenesis; IMP:MGI.
DR   GO; GO:0007389; P:pattern specification process; IMP:MGI.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:MGI.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0007228; P:positive regulation of hh target transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IMP:MGI.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IMP:CACAO.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IGI:MGI.
DR   GO; GO:0046622; P:positive regulation of organ growth; IMP:CACAO.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IGI:MGI.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IMP:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:CACAO.
DR   GO; GO:0034504; P:protein localization to nucleus; IMP:MGI.
DR   GO; GO:0050821; P:protein stabilization; IDA:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IGI:MGI.
DR   GO; GO:2000826; P:regulation of heart morphogenesis; IMP:BHF-UCL.
DR   GO; GO:2000036; P:regulation of stem cell population maintenance; IMP:MGI.
DR   GO; GO:0048741; P:skeletal muscle fiber development; IMP:MGI.
DR   GO; GO:0007224; P:smoothened signaling pathway; IMP:UniProtKB.
DR   GO; GO:0021938; P:smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation; IMP:MGI.
DR   GO; GO:0021910; P:smoothened signaling pathway involved in ventral spinal cord patterning; IMP:BHF-UCL.
DR   GO; GO:0061053; P:somite development; IMP:BHF-UCL.
DR   GO; GO:0021794; P:thalamus development; IMP:MGI.
DR   GO; GO:0003323; P:type B pancreatic cell development; IMP:MGI.
DR   GO; GO:0001570; P:vasculogenesis; IMP:MGI.
DR   GO; GO:0007371; P:ventral midline determination; IMP:BHF-UCL.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   InterPro; IPR000539; Frizzled.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR026544; SMO.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   PANTHER; PTHR11309:SF35; PTHR11309:SF35; 1.
DR   Pfam; PF01534; Frizzled; 1.
DR   Pfam; PF01392; Fz; 1.
DR   PRINTS; PR00489; FRIZZLED.
DR   SMART; SM00063; FRI; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   Cell projection; Complete proteome; Developmental protein;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Receptor; Reference proteome; Signal; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     32       {ECO:0000255}.
FT   CHAIN        33    793       Smoothened homolog.
FT                                /FTId=PRO_0000013016.
FT   TOPO_DOM     33    237       Extracellular. {ECO:0000255}.
FT   TRANSMEM    238    258       Helical; Name=1. {ECO:0000255}.
FT   TOPO_DOM    259    265       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    266    286       Helical; Name=2. {ECO:0000255}.
FT   TOPO_DOM    287    318       Extracellular. {ECO:0000255}.
FT   TRANSMEM    319    339       Helical; Name=3. {ECO:0000255}.
FT   TOPO_DOM    340    362       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    363    383       Helical; Name=4. {ECO:0000255}.
FT   TOPO_DOM    384    406       Extracellular. {ECO:0000255}.
FT   TRANSMEM    407    427       Helical; Name=5. {ECO:0000255}.
FT   TOPO_DOM    428    455       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    456    476       Helical; Name=6. {ECO:0000255}.
FT   TOPO_DOM    477    528       Extracellular. {ECO:0000255}.
FT   TRANSMEM    529    549       Helical; Name=7. {ECO:0000255}.
FT   TOPO_DOM    550    793       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       69    185       FZ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00090}.
FT   REGION      542    573       Interaction with BBS5 and BBS7.
FT   CARBOHYD     38     38       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    192    192       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    497    497       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     74    138       {ECO:0000255|PROSITE-ProRule:PRU00090}.
FT   DISULFID     82    131       {ECO:0000255|PROSITE-ProRule:PRU00090}.
FT   DISULFID    122    158       {ECO:0000255|PROSITE-ProRule:PRU00090}.
FT   DISULFID    151    173       {ECO:0000255|PROSITE-ProRule:PRU00090}.
FT   DISULFID    197    217       {ECO:0000255|PROSITE-ProRule:PRU00090}.
FT   DISULFID    221    299       {ECO:0000255|PROSITE-ProRule:PRU00090}.
FT   DISULFID    318    394       {ECO:0000255|PROSITE-ProRule:PRU00090}.
FT   DISULFID    494    511       {ECO:0000255|PROSITE-ProRule:PRU00090}.
FT   CONFLICT     54     54       D -> N (in Ref. 1; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    266    266       Y -> L (in Ref. 1; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    690    690       R -> G (in Ref. 1; no nucleotide entry).
FT                                {ECO:0000305}.
SQ   SEQUENCE   793 AA;  87450 MW;  DEAD556A45F7C960 CRC64;
     MAAGRPVRGP ELAPRRLLQL LLLVLLGGPG RGAALSGNVT GPGPHSASGS SRRDVPVTSP
     PPPLLSHCGR AAHCEPLRYN VCLGSALPYG ATTTLLAGDS DSQEEAHGKL VLWSGLRNAP
     RCWAVIQPLL CAVYMPKCEN DRVELPSRTL CQATRGPCAI VERERGWPDF LRCTPDHFPE
     GCPNEVQNIK FNSSGQCEAP LVRTDNPKSW YEDVEGCGIQ CQNPLFTEAE HQDMHSYIAA
     FGAVTGLCTL FTLATFVADW RNSNRYPAVI LFYVNACFFV GSIGWLAQFM DGARREIVCR
     ADGTMRFGEP TSSETLSCVI IFVIVYYALM AGVVWFVVLT YAWHTSFKAL GTTYQPLSGK
     TSYFHLLTWS LPFVLTVAIL AVAQVDGDSV SGICFVGYKN YRYRAGFVLA PIGLVLIVGG
     YFLIRGVMTL FSIKSNHPGL LSEKAASKIN ETMLRLGIFG FLAFGFVLIT FSCHFYDFFN
     QAEWERSFRD YVLCQANVTI GLPTKKPIPD CEIKNRPSLL VEKINLFAMF GTGIAMSTWV
     WTKATLLIWR RTWCRLTGHS DDEPKRIKKS KMIAKAFSKR RELLQNPGQE LSFSMHTVSH
     DGPVAGLAFD LNEPSADVSS AWAQHVTKMV ARRGAILPQD VSVTPVATPV PPEEQANMWL
     VEAEISPELE KRLGRKKKRR KRKKEVCPLR PAPELHHSAP VPATSAVPRL PQLPRQKCLV
     AANAWGTGES CRQGAWTLVS NPFCPEPSPH QDPFLPGASA PRVWAQGRLQ GLGSIHSRTN
     LMEAEILDAD SDF
//
ID   CALR_HUMAN              Reviewed;         417 AA.
AC   P27797; Q6IAT4; Q9UDG2;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 1.
DT   17-FEB-2016, entry version 194.
DE   RecName: Full=Calreticulin;
DE   AltName: Full=CRP55;
DE   AltName: Full=Calregulin;
DE   AltName: Full=Endoplasmic reticulum resident protein 60;
DE            Short=ERp60;
DE   AltName: Full=HACBP;
DE   AltName: Full=grp60;
DE   Flags: Precursor;
GN   Name=CALR; Synonyms=CRTC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2332496; DOI=10.1172/JCI114582;
RA   McCauliffe D.P., Lux F.A., Lieu T.S., Sanz I., Hanke J., Newkirk M.M.,
RA   Bachinski L.L., Itoh Y., Siciliano M.J., Reichlin M., Sontheimer R.D.,
RA   Capra J.D.;
RT   "Molecular cloning, expression, and chromosome 19 localization of a
RT   human Ro/SS-A autoantigen.";
RL   J. Clin. Invest. 85:1379-1391(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1919005;
RA   Rokeach L.A., Haselby J.A., Meilof J.F., Smeenk R.J., Unnasch T.R.,
RA   Greene B.M., Hoch S.O.;
RT   "Characterization of the autoantigen calreticulin.";
RL   J. Immunol. 147:3031-3039(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1733953;
RA   McCauliffe D.P., Yang Y.S., Wilson J., Sontheimer R.D., Capra J.D.;
RT   "The 5'-flanking region of the human calreticulin gene shares homology
RT   with the human GRP78, GRP94, and protein disulfide isomerase
RT   promoters.";
RL   J. Biol. Chem. 267:2557-2562(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Liu J., Peng X., Yuan J., Qiang B.;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye, Pancreas, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 18-48; 65-92; 96-114; 168-205 AND 257-354.
RC   TISSUE=Placenta;
RX   PubMed=7841019;
RA   Houen G., Koch C.;
RT   "Human placental calreticulin: purification, characterization and
RT   association with other proteins.";
RL   Acta Chem. Scand. 48:905-911(1994).
RN   [12]
RP   PROTEIN SEQUENCE OF 18-41.
RX   PubMed=3260607; DOI=10.1172/JCI113607;
RA   Lieu T.-S., Newkirk M.M., Capra J.D., Sontheimer R.D.;
RT   "Molecular characterization of human Ro/SS-A antigen. Amino terminal
RT   sequence of the protein moiety of human Ro/SS-A antigen and
RT   immunological activity of a corresponding synthetic peptide.";
RL   J. Clin. Invest. 82:96-101(1988).
RN   [13]
RP   PROTEIN SEQUENCE OF 18-36.
RX   PubMed=1911778; DOI=10.1021/bi00105a008;
RA   Rojiani M.V., Finlay B.B., Gray V., Dedhar S.;
RT   "In vitro interaction of a polypeptide homologous to human Ro/SS-A
RT   antigen (calreticulin) with a highly conserved amino acid sequence in
RT   the cytoplasmic domain of integrin alpha subunits.";
RL   Biochemistry 30:9859-9866(1991).
RN   [14]
RP   PROTEIN SEQUENCE OF 18-32.
RX   PubMed=2400400;
RA   Krause K.-H., Simmerman H.K.B., Jones L.R., Campbell K.P.;
RT   "Sequence similarity of calreticulin with a Ca2(+)-binding protein
RT   that co-purifies with an Ins(1,4,5)P3-sensitive Ca2+ store in HL-60
RT   cells.";
RL   Biochem. J. 270:545-548(1990).
RN   [15]
RP   PROTEIN SEQUENCE OF 18-28.
RC   TISSUE=Liver;
RX   PubMed=1286669; DOI=10.1002/elps.11501301201;
RA   Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R.,
RA   Appel R.D., Hughes G.J.;
RT   "Human liver protein map: a reference database established by
RT   microsequencing and gel comparison.";
RL   Electrophoresis 13:992-1001(1992).
RN   [16]
RP   PROTEIN SEQUENCE OF 25-36; 74-111 AND 208-222, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [17]
RP   PROTEIN SEQUENCE OF 25-34; 56-62; 208-221 AND 273-278.
RC   TISSUE=Keratinocyte;
RX   PubMed=1286667; DOI=10.1002/elps.11501301199;
RA   Rasmussen H.H., van Damme J., Puype M., Gesser B., Celis J.E.,
RA   Vandekerckhove J.;
RT   "Microsequences of 145 proteins recorded in the two-dimensional gel
RT   protein database of normal human epidermal keratinocytes.";
RL   Electrophoresis 13:960-969(1992).
RN   [18]
RP   PROTEIN SEQUENCE OF 18-27, AND SUBCELLULAR LOCATION.
RX   PubMed=8418194; DOI=10.1084/jem.177.1.1;
RA   Dupuis M., Schaerer E., Krause K.-H., Tschopp J.;
RT   "The calcium-binding protein calreticulin is a major constituent of
RT   lytic granules in cytolytic T lymphocytes.";
RL   J. Exp. Med. 177:1-7(1993).
RN   [19]
RP   PROTEIN SEQUENCE OF 18-26.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [20]
RP   FUNCTION.
RX   PubMed=7876246; DOI=10.1074/jbc.270.9.4741;
RA   Nauseef W.M., McCormick S.J., Clark R.A.;
RT   "Calreticulin functions as a molecular chaperone in the biosynthesis
RT   of myeloperoxidase.";
RL   J. Biol. Chem. 270:4741-4747(1995).
RN   [21]
RP   INTERACTION WITH TRIM21.
RX   PubMed=8666824;
RA   Cheng S.T., Nguyen T.Q., Yang Y.S., Capra J.D., Sontheimer R.D.;
RT   "Calreticulin binds hYRNA and the 52-kDa polypeptide component of the
RT   Ro/SS-A ribonucleoprotein autoantigen.";
RL   J. Immunol. 156:4484-4491(1996).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10358038; DOI=10.1074/jbc.274.24.16917;
RA   Arosa F.A., de Jesus O., Porto G., Carmo A.M., de Sousa M.;
RT   "Calreticulin is expressed on the cell surface of activated human
RT   peripheral blood T lymphocytes in association with major
RT   histocompatibility complex class I molecules.";
RL   J. Biol. Chem. 274:16917-16922(1999).
RN   [23]
RP   FUNCTION, INTERACTION WITH NR3C1, SUBCELLULAR LOCATION, AND MASS
RP   SPECTROMETRY.
RX   PubMed=11149926; DOI=10.1083/jcb.152.1.127;
RA   Holaska J.M., Black B.E., Love D.C., Hanover J.A., Leszyk J.,
RA   Paschal B.M.;
RT   "Calreticulin is a receptor for nuclear export.";
RL   J. Cell Biol. 152:127-140(2001).
RN   [24]
RP   PARTIAL PROTEIN SEQUENCE, DISULFIDE BOND, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Placenta;
RX   PubMed=11322874; DOI=10.1046/j.1432-1327.2001.02138.x;
RA   Hoejrup P., Roepstorff P., Houen G.;
RT   "Human placental calreticulin characterization of domain structure and
RT   post-translational modifications.";
RL   Eur. J. Biochem. 268:2558-2565(2001).
RN   [25]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-344.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-48; LYS-159 AND LYS-209, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [27]
RP   INTERACTION WITH PPIB.
RX   PubMed=20801878; DOI=10.1074/jbc.M110.160101;
RA   Kozlov G., Bastos-Aristizabal S., Maattanen P., Rosenauer A.,
RA   Zheng F., Killikelly A., Trempe J.F., Thomas D.Y., Gehring K.;
RT   "Structural basis of cyclophilin B binding by the
RT   calnexin/calreticulin P-domain.";
RL   J. Biol. Chem. 285:35551-35557(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   CLEAVAGE OF SIGNAL PEPTIDE [LARGE SCALE ANALYSIS] AFTER ALA-17, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 195-205 IN COMPLEX WITH
RP   GABARAP, AND INTERACTION WITH GABARAP.
RX   PubMed=19154346; DOI=10.1111/j.1742-4658.2008.06857.x;
RA   Thielmann Y., Weiergraber O.H., Mohrluder J., Willbold D.;
RT   "Structural framework of the GABARAP-calreticulin interface --
RT   implications for substrate binding to endoplasmic reticulum
RT   chaperones.";
RL   FEBS J. 276:1140-1152(2009).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 18-368 IN COMPLEX WITH
RP   CALCIUM IONS, AND DISULFIDE BOND.
RX   PubMed=21423620; DOI=10.1371/journal.pone.0017886;
RA   Chouquet A., Paidassi H., Ling W.L., Frachet P., Houen G.,
RA   Arlaud G.J., Gaboriaud C.;
RT   "X-ray structure of the human calreticulin globular domain reveals a
RT   peptide-binding area and suggests a multi-molecular mechanism.";
RL   PLoS ONE 6:E17886-E17886(2011).
CC   -!- FUNCTION: Calcium-binding chaperone that promotes folding,
CC       oligomeric assembly and quality control in the endoplasmic
CC       reticulum (ER) via the calreticulin/calnexin cycle. This lectin
CC       interacts transiently with almost all of the monoglucosylated
CC       glycoproteins that are synthesized in the ER. Interacts with the
CC       DNA-binding domain of NR3C1 and mediates its nuclear export.
CC       Involved in maternal gene expression regulation. May participate
CC       in oocyte maturation via the regulation of calcium homeostasis (By
CC       similarity). {ECO:0000250, ECO:0000269|PubMed:11149926,
CC       ECO:0000269|PubMed:7876246}.
CC   -!- SUBUNIT: Monomer. Component of an EIF2 complex at least composed
CC       of CELF1/CUGBP1, CALR, CALR3, EIF2S1, EIF2S2, HSP90B1 and HSPA5.
CC       Interacts with PDIA3/ERp57 and C9orf9 (By similarity). Interacts
CC       with NR3C1 and TRIM21. Interacts with GABARAP. Interacts with
CC       PPIB. {ECO:0000250|UniProtKB:P14211, ECO:0000250|UniProtKB:P18418,
CC       ECO:0000269|PubMed:11149926, ECO:0000269|PubMed:19154346,
CC       ECO:0000269|PubMed:20801878, ECO:0000269|PubMed:21423620,
CC       ECO:0000269|PubMed:8666824}.
CC   -!- INTERACTION:
CC       P05067:APP; NbExp=2; IntAct=EBI-1049597, EBI-77613;
CC       O95166:GABARAP; NbExp=4; IntAct=EBI-1049597, EBI-712001;
CC       P04792:HSPB1; NbExp=2; IntAct=EBI-1049597, EBI-352682;
CC       Q03518:TAP1; NbExp=2; IntAct=EBI-1049597, EBI-747259;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum lumen
CC       {ECO:0000269|PubMed:10358038, ECO:0000269|PubMed:11149926}.
CC       Cytoplasm, cytosol {ECO:0000269|PubMed:11149926}. Secreted,
CC       extracellular space, extracellular matrix {ECO:0000305}. Cell
CC       surface {ECO:0000269|PubMed:10358038}. Sarcoplasmic reticulum
CC       lumen {ECO:0000250|UniProtKB:P28491}. Note=Also found in cell
CC       surface (T cells), cytosol and extracellular matrix
CC       (PubMed:10358038). Associated with the lytic granules in the
CC       cytolytic T-lymphocytes. {ECO:0000269|PubMed:10358038,
CC       ECO:0000269|PubMed:8418194}.
CC   -!- DOMAIN: Can be divided into a N-terminal globular domain, a
CC       proline-rich P-domain forming an elongated arm-like structure and
CC       a C-terminal acidic domain. The P-domain binds one molecule of
CC       calcium with high affinity, whereas the acidic C-domain binds
CC       multiple calcium ions with low affinity.
CC   -!- DOMAIN: The interaction with glycans occurs through a binding site
CC       in the globular lectin domain.
CC   -!- DOMAIN: The zinc binding sites are localized to the N-domain.
CC   -!- DOMAIN: Associates with PDIA3 through the tip of the extended arm
CC       formed by the P-domain.
CC   -!- MASS SPECTROMETRY: Mass=46879; Method=MALDI; Range=18-417;
CC       Evidence={ECO:0000269|PubMed:11149926};
CC   -!- SIMILARITY: Belongs to the calreticulin family. {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to be the 52 kDa Ro autoantigen.
CC       {ECO:0000305|PubMed:2332496}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Calreticulin entry;
CC       URL="https://en.wikipedia.org/wiki/Calreticulin";
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Calreticulin;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_other_405";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M32294; AAA36582.1; -; mRNA.
DR   EMBL; M84739; AAA51916.1; -; mRNA.
DR   EMBL; AY047586; AAL13126.1; -; mRNA.
DR   EMBL; AB451408; BAG70222.1; -; mRNA.
DR   EMBL; BT007448; AAP36116.1; -; mRNA.
DR   EMBL; CR457070; CAG33351.1; -; mRNA.
DR   EMBL; AD000092; AAB51176.1; -; Genomic_DNA.
DR   EMBL; CH471106; EAW84331.1; -; Genomic_DNA.
DR   EMBL; BC002500; AAH02500.1; -; mRNA.
DR   EMBL; BC007911; AAH07911.1; -; mRNA.
DR   EMBL; BC020493; AAH20493.1; -; mRNA.
DR   CCDS; CCDS12288.1; -.
DR   PIR; A42330; A37047.
DR   RefSeq; NP_004334.1; NM_004343.3.
DR   UniGene; Hs.515162; -.
DR   PDB; 2CLR; X-ray; 2.00 A; C/F=1-10.
DR   PDB; 3DOW; X-ray; 2.30 A; B=195-205.
DR   PDB; 3POS; X-ray; 1.65 A; A/B/C=18-204, A/B/C=302-368.
DR   PDB; 3POW; X-ray; 1.55 A; A=18-204, A=302-368.
DR   PDBsum; 2CLR; -.
DR   PDBsum; 3DOW; -.
DR   PDBsum; 3POS; -.
DR   PDBsum; 3POW; -.
DR   DisProt; DP00333; -.
DR   ProteinModelPortal; P27797; -.
DR   SMR; P27797; 18-367.
DR   BioGrid; 107262; 114.
DR   DIP; DIP-104N; -.
DR   IntAct; P27797; 33.
DR   MINT; MINT-101756; -.
DR   STRING; 9606.ENSP00000320866; -.
DR   DrugBank; DB00025; Antihemophilic Factor (Recombinant).
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB00031; Tenecteplase.
DR   iPTMnet; P27797; -.
DR   PhosphoSite; P27797; -.
DR   SwissPalm; P27797; -.
DR   BioMuta; CALR; -.
DR   DMDM; 117501; -.
DR   DOSAC-COBS-2DPAGE; P27797; -.
DR   OGP; P27797; -.
DR   REPRODUCTION-2DPAGE; IPI00020599; -.
DR   SWISS-2DPAGE; P27797; -.
DR   UCD-2DPAGE; P27797; -.
DR   PaxDb; P27797; -.
DR   PRIDE; P27797; -.
DR   DNASU; 811; -.
DR   Ensembl; ENST00000316448; ENSP00000320866; ENSG00000179218.
DR   GeneID; 811; -.
DR   KEGG; hsa:811; -.
DR   UCSC; uc002mvu.2; human.
DR   CTD; 811; -.
DR   GeneCards; CALR; -.
DR   HGNC; HGNC:1455; CALR.
DR   HPA; CAB001513; -.
DR   HPA; CAB019952; -.
DR   HPA; HPA002242; -.
DR   MalaCards; CALR; -.
DR   MIM; 109091; gene.
DR   neXtProt; NX_P27797; -.
DR   Orphanet; 3318; Essential thrombocythemia.
DR   Orphanet; 824; Myelofibrosis with myeloid metaplasia.
DR   PharmGKB; PA26046; -.
DR   eggNOG; KOG0674; Eukaryota.
DR   eggNOG; ENOG410XRR7; LUCA.
DR   HOGENOM; HOG000192435; -.
DR   HOVERGEN; HBG005407; -.
DR   InParanoid; P27797; -.
DR   KO; K08057; -.
DR   OMA; IANPEYV; -.
DR   OrthoDB; EOG77126Z; -.
DR   PhylomeDB; P27797; -.
DR   TreeFam; TF338438; -.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-168316; Assembly of Viral Components at the Budding Site.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-3000484; Scavenging by Class F Receptors.
DR   Reactome; R-HSA-381183; ATF6-alpha activates chaperone genes.
DR   Reactome; R-HSA-901042; Calnexin/calreticulin cycle.
DR   Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR   ChiTaRS; CALR; human.
DR   EvolutionaryTrace; P27797; -.
DR   GeneWiki; Calreticulin; -.
DR   GenomeRNAi; 811; -.
DR   NextBio; 3292; -.
DR   PRO; PR:P27797; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P27797; -.
DR   CleanEx; HS_CALR; -.
DR   ExpressionAtlas; P27797; baseline and differential.
DR   Genevisible; P27797; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; TAS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0071682; C:endocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; TAS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005622; C:intracellular; TAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0042824; C:MHC class I peptide loading complex; ISS:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005844; C:polysome; ISS:BHF-UCL.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0033018; C:sarcoplasmic reticulum lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0050681; F:androgen receptor binding; IDA:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0030246; F:carbohydrate binding; TAS:BHF-UCL.
DR   GO; GO:0051087; F:chaperone binding; TAS:BHF-UCL.
DR   GO; GO:0001849; F:complement component C1q binding; TAS:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:UniProtKB.
DR   GO; GO:0042562; F:hormone binding; IEA:Ensembl.
DR   GO; GO:0005178; F:integrin binding; IPI:BHF-UCL.
DR   GO; GO:0005506; F:iron ion binding; IEA:Ensembl.
DR   GO; GO:0003729; F:mRNA binding; IDA:BHF-UCL.
DR   GO; GO:0042277; F:peptide binding; IEA:Ensembl.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0044183; F:protein binding involved in protein folding; TAS:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; TAS:BHF-UCL.
DR   GO; GO:0042590; P:antigen processing and presentation of exogenous peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0002479; P:antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; TAS:Reactome.
DR   GO; GO:0002474; P:antigen processing and presentation of peptide antigen via MHC class I; TAS:Reactome.
DR   GO; GO:0036500; P:ATF6-mediated unfolded protein response; TAS:Reactome.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IGI:BHF-UCL.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; TAS:UniProtKB.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0071285; P:cellular response to lithium ion; IEA:Ensembl.
DR   GO; GO:0090398; P:cellular senescence; IGI:BHF-UCL.
DR   GO; GO:0061077; P:chaperone-mediated protein folding; IEA:Ensembl.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; TAS:Reactome.
DR   GO; GO:0042921; P:glucocorticoid receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0033144; P:negative regulation of intracellular steroid hormone receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IDA:BHF-UCL.
DR   GO; GO:0048387; P:negative regulation of retinoic acid receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0017148; P:negative regulation of translation; ISS:BHF-UCL.
DR   GO; GO:0002502; P:peptide antigen assembly with MHC class I protein complex; ISS:BHF-UCL.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IGI:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IGI:BHF-UCL.
DR   GO; GO:2000510; P:positive regulation of dendritic cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IGI:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; ISS:BHF-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0006611; P:protein export from nucleus; IDA:UniProtKB.
DR   GO; GO:0006457; P:protein folding; TAS:BHF-UCL.
DR   GO; GO:0034975; P:protein folding in endoplasmic reticulum; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0034504; P:protein localization to nucleus; IDA:UniProtKB.
DR   GO; GO:0022417; P:protein maturation by protein folding; TAS:BHF-UCL.
DR   GO; GO:0018279; P:protein N-linked glycosylation via asparagine; TAS:Reactome.
DR   GO; GO:0050821; P:protein stabilization; ISS:UniProtKB.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0040020; P:regulation of meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0051208; P:sequestering of calcium ion; TAS:BHF-UCL.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   Gene3D; 2.60.120.200; -; 2.
DR   InterPro; IPR001580; Calret/calnex.
DR   InterPro; IPR018124; Calret/calnex_CS.
DR   InterPro; IPR009169; Calreticulin.
DR   InterPro; IPR009033; Calreticulin/calnexin_P_dom.
DR   InterPro; IPR013320; ConA-like_dom.
DR   PANTHER; PTHR11073; PTHR11073; 1.
DR   Pfam; PF00262; Calreticulin; 2.
DR   PIRSF; PIRSF002356; Calreticulin; 1.
DR   PRINTS; PR00626; CALRETICULIN.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   SUPFAM; SSF63887; SSF63887; 1.
DR   PROSITE; PS00803; CALRETICULIN_1; 1.
DR   PROSITE; PS00804; CALRETICULIN_2; 1.
DR   PROSITE; PS00805; CALRETICULIN_REPEAT; 3.
DR   PROSITE; PS00014; ER_TARGET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Calcium; Chaperone; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disulfide bond;
KW   Endoplasmic reticulum; Extracellular matrix; Glycoprotein; Lectin;
KW   Metal-binding; Reference proteome; Repeat; Sarcoplasmic reticulum;
KW   Secreted; Signal; Zinc.
FT   SIGNAL        1     17       {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|PubMed:1286669,
FT                                ECO:0000269|PubMed:1911778,
FT                                ECO:0000269|PubMed:2400400,
FT                                ECO:0000269|PubMed:3260607,
FT                                ECO:0000269|PubMed:7841019,
FT                                ECO:0000269|PubMed:8418194,
FT                                ECO:0000269|PubMed:9150948}.
FT   CHAIN        18    417       Calreticulin.
FT                                /FTId=PRO_0000004173.
FT   REPEAT      191    202       1-1.
FT   REPEAT      210    221       1-2.
FT   REPEAT      227    238       1-3.
FT   REPEAT      244    255       1-4.
FT   REPEAT      259    269       2-1.
FT   REPEAT      273    283       2-2.
FT   REPEAT      287    297       2-3.
FT   REGION       18    197       N-domain.
FT   REGION      191    255       4 X approximate repeats.
FT   REGION      198    308       P-domain.
FT   REGION      237    270       Interaction with PPIB. {ECO:0000250}.
FT   REGION      259    297       3 X approximate repeats.
FT   REGION      309    417       C-domain.
FT   MOTIF       414    417       Prevents secretion from ER.
FT   COMPBIAS    351    408       Asp/Glu/Lys-rich.
FT   METAL        26     26       Calcium; via carbonyl oxygen.
FT   METAL        62     62       Calcium; via carbonyl oxygen.
FT   METAL        64     64       Calcium; via carbonyl oxygen.
FT   METAL       328    328       Calcium.
FT   BINDING     109    109       Carbohydrate. {ECO:0000250}.
FT   BINDING     111    111       Carbohydrate. {ECO:0000250}.
FT   BINDING     128    128       Carbohydrate. {ECO:0000250}.
FT   BINDING     135    135       Carbohydrate. {ECO:0000250}.
FT   BINDING     317    317       Carbohydrate. {ECO:0000250}.
FT   MOD_RES      48     48       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     159    159       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     209    209       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   CARBOHYD    344    344       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   DISULFID    105    137       {ECO:0000269|PubMed:11322874,
FT                                ECO:0000269|PubMed:21423620}.
FT   STRAND       20     25       {ECO:0000244|PDB:3POW}.
FT   HELIX        30     35       {ECO:0000244|PDB:3POW}.
FT   STRAND       37     39       {ECO:0000244|PDB:3POW}.
FT   STRAND       42     44       {ECO:0000244|PDB:3POW}.
FT   STRAND       49     52       {ECO:0000244|PDB:3POW}.
FT   TURN         60     63       {ECO:0000244|PDB:3POW}.
FT   STRAND       65     68       {ECO:0000244|PDB:3POW}.
FT   STRAND       70     84       {ECO:0000244|PDB:3POW}.
FT   STRAND       91     98       {ECO:0000244|PDB:3POW}.
FT   STRAND      104    107       {ECO:0000244|PDB:3POW}.
FT   STRAND      110    113       {ECO:0000244|PDB:3POW}.
FT   HELIX       119    121       {ECO:0000244|PDB:3POW}.
FT   STRAND      129    138       {ECO:0000244|PDB:3POW}.
FT   STRAND      142    150       {ECO:0000244|PDB:3POW}.
FT   STRAND      153    156       {ECO:0000244|PDB:3POW}.
FT   STRAND      166    176       {ECO:0000244|PDB:3POW}.
FT   STRAND      180    186       {ECO:0000244|PDB:3POW}.
FT   STRAND      189    195       {ECO:0000244|PDB:3POW}.
FT   HELIX       196    199       {ECO:0000244|PDB:3POW}.
FT   STRAND      201    203       {ECO:0000244|PDB:3DOW}.
FT   STRAND      311    322       {ECO:0000244|PDB:3POW}.
FT   STRAND      326    334       {ECO:0000244|PDB:3POW}.
FT   HELIX       336    345       {ECO:0000244|PDB:3POW}.
FT   HELIX       347    366       {ECO:0000244|PDB:3POW}.
SQ   SEQUENCE   417 AA;  48142 MW;  BC37C3C0F1054FB2 CRC64;
     MLLSVPLLLG LLGLAVAEPA VYFKEQFLDG DGWTSRWIES KHKSDFGKFV LSSGKFYGDE
     EKDKGLQTSQ DARFYALSAS FEPFSNKGQT LVVQFTVKHE QNIDCGGGYV KLFPNSLDQT
     DMHGDSEYNI MFGPDICGPG TKKVHVIFNY KGKNVLINKD IRCKDDEFTH LYTLIVRPDN
     TYEVKIDNSQ VESGSLEDDW DFLPPKKIKD PDASKPEDWD ERAKIDDPTD SKPEDWDKPE
     HIPDPDAKKP EDWDEEMDGE WEPPVIQNPE YKGEWKPRQI DNPDYKGTWI HPEIDNPEYS
     PDPSIYAYDN FGVLGLDLWQ VKSGTIFDNF LITNDEAYAE EFGNETWGVT KAAEKQMKDK
     QDEEQRLKEE EEDKKRKEEE EAEDKEDDED KDEDEEDEED KEEDEEEDVP GQAKDEL
//
ID   LRP5_HUMAN              Reviewed;        1615 AA.
AC   O75197; Q96TD6; Q9UES7; Q9UP66;
DT   10-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   12-APR-2005, sequence version 2.
DT   17-FEB-2016, entry version 158.
DE   RecName: Full=Low-density lipoprotein receptor-related protein 5;
DE            Short=LRP-5;
DE   Flags: Precursor;
GN   Name=LRP5; Synonyms=LR3, LRP7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Osteoblast;
RX   PubMed=9790987; DOI=10.1006/bbrc.1998.9545;
RA   Dong Y., Lathrop W., Weaver D., Qiu Q., Cini J., Bertolini D.,
RA   Chen D.;
RT   "Molecular cloning and characterization of LR3, a novel LDL receptor
RT   family protein with mitogenic activity.";
RL   Biochem. Biophys. Res. Commun. 251:784-790(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-1525.
RC   TISSUE=Osteoblast;
RX   PubMed=9714764; DOI=10.1016/S0378-1119(98)00311-4;
RA   Hey P.J., Twells R.C.J., Phillips M.S., Nakagawa Y., Brown S.D.,
RA   Kawaguchi Y., Cox R., Xie G., Dugan V., Hammond H., Metzker M.L.,
RA   Todd J.A., Hess J.F.;
RT   "Cloning of a novel member of the low-density lipoprotein receptor
RT   family.";
RL   Gene 216:103-111(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11401438; DOI=10.1006/geno.2000.6492;
RA   Twells R.C.J., Metzker M.L., Brown S.D., Cox R., Garey C., Hammond H.,
RA   Hey P.J., Levy E., Nakagawa Y., Philips M.S., Todd J.A., Hess J.F.;
RT   "The sequence and gene characterization of a 400-kb candidate region
RT   for IDDM4 on chromosome 11q13.";
RL   Genomics 72:231-242(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-1330.
RX   PubMed=12509515; DOI=10.1073/pnas.0133792100;
RA   Fujino T., Asaba H., Kang M.J., Ikeda Y., Sone H., Takada S.,
RA   Kim D.H., Ioka R.X., Ono M., Tomoyori H., Okubo M., Murase T.,
RA   Kamataki A., Yamamoto J., Magoori K., Takahashi S., Miyamoto Y.,
RA   Oishi H., Nose M., Okazaki M., Usui S., Imaizumi K., Yanagisawa M.,
RA   Sakai J., Yamamoto T.T.;
RT   "Low-density lipoprotein receptor-related protein 5 (LRP5) is
RT   essential for normal cholesterol metabolism and glucose-induced
RT   insulin secretion.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:229-234(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH FZD8 IN WNT-FZD-LRP5-LRP6 COMPLEX, INTERACTION WITH
RP   DKK1, AND FUNCTION.
RX   PubMed=11448771; DOI=10.1016/S0960-9822(01)00290-1;
RA   Semenov M.V., Tamai K., Brott B.K., Kuhl M., Sokol S., He X.;
RT   "Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6.";
RL   Curr. Biol. 11:951-961(2001).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH AXIN1.
RX   PubMed=11336703; DOI=10.1016/S1097-2765(01)00224-6;
RA   Mao J., Wang J., Liu B., Pan W., Farr G.H. III, Flynn C., Yuan H.,
RA   Takada S., Kimelman D., Li L., Wu D.;
RT   "Low-density lipoprotein receptor-related protein-5 binds to Axin and
RT   regulates the canonical Wnt signaling pathway.";
RL   Mol. Cell 7:801-809(2001).
RN   [10]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH AXIN1.
RX   PubMed=14731402; DOI=10.1016/S1097-2765(03)00484-2;
RA   Tamai K., Zeng X., Liu C., Zhang X., Harada Y., Chang Z., He X.;
RT   "A mechanism for Wnt coreceptor activation.";
RL   Mol. Cell 13:149-156(2004).
RN   [11]
RP   INTERACTION WITH MESD, AND CHARACTERIZATION OF VARIANT HBM VAL-171.
RX   PubMed=15143163; DOI=10.1128/MCB.24.11.4677-4684.2004;
RA   Zhang Y., Wang Y., Li X., Zhang J., Mao J., Li Z., Zheng J., Li L.,
RA   Harris S., Wu D.;
RT   "The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with
RT   Mesd.";
RL   Mol. Cell. Biol. 24:4677-4684(2004).
RN   [12]
RP   INTERACTION WITH DKK1 AND SOST, AND FUNCTION.
RX   PubMed=15778503; DOI=10.1074/jbc.M413274200;
RA   Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., Harris S.E.,
RA   Wu D.;
RT   "Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.";
RL   J. Biol. Chem. 280:19883-19887(2005).
RN   [13]
RP   INTERACTION WITH WNT1 IN THE WNT-FZD-LRP5-LRP6 COMPLEX, AND
RP   INTERACTION WITH SOST.
RX   PubMed=15908424; DOI=10.1074/jbc.M504308200;
RA   Semenov M., Tamai K., He X.;
RT   "SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.";
RL   J. Biol. Chem. 280:26770-26775(2005).
RN   [14]
RP   INTERACTION WITH CSNK1E.
RX   PubMed=16513652; DOI=10.1074/jbc.M510580200;
RA   Swiatek W., Kang H., Garcia B.A., Shabanowitz J., Coombs G.S.,
RA   Hunt D.F., Virshup D.M.;
RT   "Negative regulation of LRP6 function by casein kinase I epsilon
RT   phosphorylation.";
RL   J. Biol. Chem. 281:12233-12241(2006).
RN   [15]
RP   INTERACTION WITH MESD.
RX   PubMed=17488095; DOI=10.1021/bi700049g;
RA   Koduri V., Blacklow S.C.;
RT   "Requirement for natively unstructured regions of mesoderm development
RT   candidate 2 in promoting low-density lipoprotein receptor-related
RT   protein 6 maturation.";
RL   Biochemistry 46:6570-6577(2007).
RN   [16]
RP   INTERACTION WITH DKK1 AND MESD, AND CHARACTERIZATION OF VARIANT
RP   VAL-171.
RX   PubMed=19746449; DOI=10.1002/jcb.22335;
RA   Murrills R.J., Matteo J.J., Bhat B.M., Coleburn V.E., Allen K.M.,
RA   Chen W., Damagnez V., Bhat R.A., Bex F.J., Bodine P.V.;
RT   "A cell-based Dkk1 binding assay reveals roles for extracellular
RT   domains of LRP5 in Dkk1 interaction and highlights differences between
RT   wild-type and the high bone mass mutant LRP5(G171V).";
RL   J. Cell. Biochem. 108:1066-1075(2009).
RN   [17]
RP   INTERACTION WITH APCDD1.
RX   PubMed=20393562; DOI=10.1038/nature08875;
RA   Shimomura Y., Agalliu D., Vonica A., Luria V., Wajid M., Baumer A.,
RA   Belli S., Petukhova L., Schinzel A., Brivanlou A.H., Barres B.A.,
RA   Christiano A.M.;
RT   "APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis
RT   simplex.";
RL   Nature 464:1043-1047(2010).
RN   [18]
RP   VARIANTS OPPG GLN-494 AND TRP-570, AND VARIANT MET-667.
RX   PubMed=11719191; DOI=10.1016/S0092-8674(01)00571-2;
RA   Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S.,
RA   Reginato A.M., Wang H., Cundy T., Glorieux F.H., Lev D., Zacharin M.,
RA   Oexle K., Marcelino J., Suwairi W., Heeger S., Sabatakos G., Apte S.,
RA   Adkins W.N., Allgrove J., Arslan-Kirchner M., Batch J.A., Beighton P.,
RA   Black G.C., Boles R.G., Boon L.M., Borrone C., Brunner H.G.,
RA   Carle G.F., Dallapiccola B., De Paepe A., Floege B., Halfhide M.L.,
RA   Hall B., Hennekam R.C.M., Hirose T., Jans A., Jueppner H., Kim C.A.,
RA   Keppler-Noreuil K., Kohlschuetter A., LaCombe D., Lambert M.,
RA   Lemyre E., Letteboer T., Peltonen L., Ramesar R.S., Romanengo M.,
RA   Somer H., Steichen-Gersdorf E., Steinmann B., Sullivan B.,
RA   Superti-Furga A., Swoboda W., van den Boogaard M.-J., Van Hul W.,
RA   Vikkula M., Votruba M., Zabel B., Garcia T., Baron R., Olsen B.R.,
RA   Warman M.L.;
RT   "LDL receptor-related protein 5 (LRP5) affects bone accrual and eye
RT   development.";
RL   Cell 107:513-523(2001).
RN   [19]
RP   VARIANT HBM VAL-171, AND POLYMORPHISM.
RX   PubMed=11741193; DOI=10.1086/338450;
RA   Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M.,
RA   Folz C., Manning S.P., Swain P.M., Zhao S.-C., Eustace B., Lappe M.M.,
RA   Spitzer L., Zweier S., Braunschweiger K., Benchekroun Y., Hu X.,
RA   Adair R., Chee L., FitzGerald M.G., Tulig C., Caruso A., Tzellas N.,
RA   Bawa A., Franklin B., McGuire S., Nogues X., Gong G., Allen K.M.,
RA   Anisowicz A., Morales A.J., Lomedico P.T., Recker S.M.,
RA   Van Eerdewegh P., Recker R.R., Johnson M.L.;
RT   "A mutation in the LDL receptor-related protein 5 gene results in the
RT   autosomal dominant high-bone-mass trait.";
RL   Am. J. Hum. Genet. 70:11-19(2002).
RN   [20]
RP   VARIANT HBM VAL-171, AND CHARACTERIZATION OF VARIANT HBM VAL-171.
RX   PubMed=12015390; DOI=10.1056/NEJMoa013444;
RA   Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A.,
RA   Wu D., Insogna K., Lifton R.P.;
RT   "High bone density due to a mutation in LDL-receptor-related protein
RT   5.";
RL   N. Engl. J. Med. 346:1513-1521(2002).
RN   [21]
RP   VARIANTS OPTA1 TYR-111; ARG-171; THR-242 AND ILE-253, VARIANTS WENHY
RP   THR-214; VAL-214 AND THR-242, VARIANT VBCH2 THR-242, AND VARIANTS
RP   18-LEU--LEU-20 DEL; LEU-20 INS; ARG-89; MET-667 AND VAL-1330.
RX   PubMed=12579474; DOI=10.1086/368277;
RA   Van Wesenbeeck L., Cleiren E., Gram J., Beals R.K., Benichou O.,
RA   Scopelliti D., Key L., Renton T., Bartels C., Gong Y., Warman M.L.,
RA   de Vernejoul M.-C., Bollerslev J., Van Hul W.;
RT   "Six novel missense mutations in the LDL receptor-related protein 5
RT   (LRP5) gene in different conditions with an increased bone density.";
RL   Am. J. Hum. Genet. 72:763-771(2003).
RN   [22]
RP   VARIANTS EVR4 MET-173; HIS-1168 AND GLY-1361, AND VARIANT VAL-1525.
RX   PubMed=15024691; DOI=10.1086/383202;
RA   Toomes C., Bottomley H.M., Jackson R.M., Towns K.V., Scott S.,
RA   Mackey D.A., Craig J.E., Jiang L., Yang Z., Trembath R., Woodruff G.,
RA   Gregory-Evans C.Y., Gregory-Evans K., Parker M.J., Black G.C.M.,
RA   Downey L.M., Zhang K., Inglehearn C.F.;
RT   "Mutations in LRP5 or FZD4 underlie the common familial exudative
RT   vitreoretinopathy locus on chromosome 11q.";
RL   Am. J. Hum. Genet. 74:721-730(2004).
RN   [23]
RP   VARIANTS MET-667 AND VAL-1330.
RX   PubMed=15077203; DOI=10.1086/420771;
RA   Ferrari S.L., Deutsch S., Choudhury U., Chevalley T., Bonjour J.-P.,
RA   Dermitzakis E.T., Rizzoli R., Antonarakis S.E.;
RT   "Polymorphisms in the low-density lipoprotein receptor-related protein
RT   5 (LRP5) gene are associated with variation in vertebral bone mass,
RT   vertebral bone size, and stature in whites.";
RL   Am. J. Hum. Genet. 74:866-875(2004).
RN   [24]
RP   VARIANTS EVR4 GLN-570; GLY-752 AND LYS-1367.
RX   PubMed=15346351; DOI=10.1086/425080;
RA   Jiao X., Ventruto V., Trese M.T., Shastry B.S., Hejtmancik J.F.;
RT   "Autosomal recessive familial exudative vitreoretinopathy is
RT   associated with mutations in LRP5.";
RL   Am. J. Hum. Genet. 75:878-884(2004).
RN   [25]
RP   VARIANTS ARG-89 AND VAL-1330, FUNCTION, AND INVOLVEMENT IN
RP   OSTEOPOROSIS.
RX   PubMed=14727154; DOI=10.1007/s10038-003-0111-6;
RA   Mizuguchi T., Furuta I., Watanabe Y., Tsukamoto K., Tomita H.,
RA   Tsujihata M., Ohta T., Kishino T., Matsumoto N., Minakami H.,
RA   Niikawa N., Yoshiura K.;
RT   "LRP5, low-density-lipoprotein-receptor-related protein 5, is a
RT   determinant for bone mineral density.";
RL   J. Hum. Genet. 49:80-86(2004).
RN   [26]
RP   VARIANTS OPPG ASN-203; MET-244; PHE-307; TRP-348; GLN-353; LEU-356;
RP   LYS-390; GLU-400; ARG-404; ASN-434; LYS-460; GLN-494; VAL-520;
RP   TRP-570; ARG-610; ASN-683; HIS-733; TYR-1099; CYS-1113 AND ASP-1401,
RP   CHARACTERIZATION OF VARIANTS OPPG MET-244; LEU-356; LYS-390; ARG-404;
RP   ASN-434; VAL-520 AND ARG-610, AND CHARACTERIZATION OF VARIANTS EVR4
RP   MET-173; GLN-570; HIS-1168; GLY-1361 AND LYS-1367.
RX   PubMed=16252235; DOI=10.1086/497706;
RG   Osteoporosis-Pseudoglioma collaborative group;
RA   Ai M., Heeger S., Bartels C.F., Schelling D.K.;
RT   "Clinical and molecular findings in osteoporosis-pseudoglioma
RT   syndrome.";
RL   Am. J. Hum. Genet. 77:741-753(2005).
RN   [27]
RP   VARIANTS EVR4 PHE-145; CYS-444; THR-522; MET-535; ARG-610; CYS-617;
RP   ALA-798 AND ASP-1121, AND VARIANTS VAL-97 AND MET-1540.
RX   PubMed=15981244; DOI=10.1002/humu.20191;
RA   Qin M., Hayashi H., Oshima K., Tahira T., Hayashi K., Kondo H.;
RT   "Complexity of the genotype-phenotype correlation in familial
RT   exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4
RT   genes.";
RL   Hum. Mutat. 26:104-112(2005).
RN   [28]
RP   VARIANTS PRIMARY OSTEOPOROSIS THR-29 AND GLN-1036.
RX   PubMed=15824851; DOI=10.1359/JBMR.050101;
RA   Hartikka H., Makitie O., Mannikko M., Doria A.S., Daneman A.,
RA   Cole W.G., Ala-Kokko L., Sochett E.B.;
RT   "Heterozygous mutations in the LDL receptor-related protein 5 (LRP5)
RT   gene are associated with primary osteoporosis in children.";
RL   J. Bone Miner. Res. 20:783-789(2005).
RN   [29]
RP   VARIANT HBM MET-154.
RX   PubMed=15824861; DOI=10.1359/JBMR.041223;
RA   Rickels M.R., Zhang X., Mumm S., Whyte M.P.;
RT   "Oropharyngeal skeletal disease accompanying high bone mass and novel
RT   LRP5 mutation.";
RL   J. Bone Miner. Res. 20:878-885(2005).
RN   [30]
RP   VARIANTS IDIOPATHIC OSTEOPOROSIS LEU-356 AND LEU-455, VARIANT
RP   THR-1537, CHARACTERIZATION OF VARIANTS IDIOPATHIC OSTEOPOROSIS LEU-356
RP   AND LEU-455, AND CHARACTERIZATION OF VARIANT THR-1537.
RX   PubMed=16234968; DOI=10.1359/JBMR.050705;
RA   Crabbe P., Balemans W., Willaert A., van Pottelbergh I., Cleiren E.,
RA   Coucke P.J., Ai M., Goemaere S., van Hul W., de Paepe A.,
RA   Kaufman J.-M.;
RT   "Missense mutations in LRP5 are not a common cause of idiopathic
RT   osteoporosis in adult men.";
RL   J. Bone Miner. Res. 20:1951-1959(2005).
RN   [31]
RP   VARIANTS OPPG ARG-478 AND CYS-504.
RX   PubMed=16679074; DOI=10.1016/j.bone.2006.02.069;
RA   Cheung W.M.W., Jin L.Y., Smith D.K., Cheung P.T., Kwan E.Y.W., Low L.,
RA   Kung A.W.C.;
RT   "A family with osteoporosis pseudoglioma syndrome due to compound
RT   heterozygosity of two novel mutations in the LRP5 gene.";
RL   Bone 39:470-476(2006).
RN   [32]
RP   VARIANT EVR4 ARG-550.
RX   PubMed=16929062; DOI=10.1136/bjo.2006.092114;
RA   Downey L.M., Bottomley H.M., Sheridan E., Ahmed M., Gilmour D.F.,
RA   Inglehearn C.F., Reddy A., Agrawal A., Bradbury J., Toomes C.;
RT   "Reduced bone mineral density and hyaloid vasculature remnants in a
RT   consanguineous recessive FEVR family with a mutation in LRP5.";
RL   Br. J. Ophthalmol. 90:1163-1167(2006).
RN   [33]
RP   VARIANT HBM VAL-282, AND CHARACTERIZATION OF VARIANT HBM VAL-282.
RX   PubMed=17295608; DOI=10.1359/jbmr.070211;
RA   Balemans W., Devogelaer J.P., Cleiren E., Piters E., Caussin E.,
RA   Van Hul W.;
RT   "Novel LRP5 missense mutation in a patient with a high bone mass
RT   phenotype results in decreased DKK1-mediated inhibition of Wnt
RT   signaling.";
RL   J. Bone Miner. Res. 22:708-716(2007).
RN   [34]
RP   VARIANT OPPG ILE-531.
RX   PubMed=17437160; DOI=10.1007/s00198-007-0360-x;
RA   Barros E.R., Dias da Silva M.R., Kunii I.S., Hauache O.M.,
RA   Lazaretti-Castro M.;
RT   "A novel mutation in the LRP5 gene is associated with osteoporosis-
RT   pseudoglioma syndrome.";
RL   Osteoporos. Int. 18:1017-1018(2007).
RN   [35]
RP   VARIANT OPPG ALA-409.
RX   PubMed=18602879; DOI=10.1016/j.bone.2008.04.020;
RA   Streeten E.A., McBride D., Puffenberger E., Hoffman M.E., Pollin T.I.,
RA   Donnelly P., Sack P., Morton H.;
RT   "Osteoporosis-pseudoglioma syndrome: description of 9 new cases and
RT   beneficial response to bisphosphonates.";
RL   Bone 43:584-590(2008).
RN   [36]
RP   VARIANT 15-LEU--LEU-20 DEL.
RX   PubMed=19177549; DOI=10.1002/humu.20916;
RA   Chung B.D., Kayserili H., Ai M., Freudenberg J., Uzumcu A.,
RA   Uyguner O., Bartels C.F., Honing S., Ramirez A., Hanisch F.G.,
RA   Nurnberg G., Nurnberg P., Warman M.L., Wollnik B., Kubisch C.,
RA   Netzer C.;
RT   "A mutation in the signal sequence of LRP5 in a family with an
RT   osteoporosis-pseudoglioma syndrome (OPPG)-like phenotype indicates a
RT   novel disease mechanism for trinucleotide repeats.";
RL   Hum. Mutat. 30:641-648(2009).
RN   [37]
RP   VARIANTS EVR4 ALA-511 AND TRP-805.
RX   PubMed=19324841; DOI=10.1167/iovs.08-3320;
RA   Boonstra F.N., van Nouhuys C.E., Schuil J., de Wijs I.J.,
RA   van der Donk K.P., Nikopoulos K., Mukhopadhyay A., Scheffer H.,
RA   Tilanus M.A.D., Cremers F.P.M., Hoefsloot L.H.;
RT   "Clinical and molecular evaluation of probands and family members with
RT   familial exudative vitreoretinopathy.";
RL   Invest. Ophthalmol. Vis. Sci. 50:4379-4385(2009).
RN   [38]
RP   VARIANTS EVR4 LYS-441 AND PHE-1253.
RX   PubMed=20340138; DOI=10.1002/humu.21250;
RA   Nikopoulos K., Venselaar H., Collin R.W.J., Riveiro-Alvarez R.,
RA   Boonstra F.N., Hooymans J.M., Mukhopadhyay A., Shears D., van Bers M.,
RA   de Wijs I.J., van Essen A.J., Sijmons R.H., Tilanus M.A.D.,
RA   van Nouhuys C.E., Ayuso C., Hoefsloot L.H., Cremers F.P.M.;
RT   "Overview of the mutation spectrum in familial exudative
RT   vitreoretinopathy and Norrie disease with identification of 21 novel
RT   variants in FZD4, LRP5, and NDP.";
RL   Hum. Mutat. 31:656-666(2010).
RN   [39]
RP   VARIANT PRO-816, VARIANTS EVR4 THR-422; PRO-540 AND MET-852,
RP   CHARACTERIZATION OF VARIANTS EVR4 THR-422; PRO-540 AND MET-852, AND
RP   CHARACTERIZATION OF VARIANT PRO-816.
RX   PubMed=24715757;
RA   Fei P., Zhang Q., Huang L., Xu Y., Zhu X., Tai Z., Gong B., Ma S.,
RA   Yao Q., Li J., Zhao P., Yang Z.;
RT   "Identification of two novel LRP5 mutations in families with familial
RT   exudative vitreoretinopathy.";
RL   Mol. Vis. 20:395-409(2014).
CC   -!- FUNCTION: Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers
CC       beta-catenin signaling through inducing aggregation of receptor-
CC       ligand complexes into ribosome-sized signalsomes. Cell-surface
CC       coreceptor of Wnt/beta-catenin signaling, which plays a pivotal
CC       role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor
CC       complex recruits DVL1 polymers to the plasma membrane which, in
CC       turn, recruits the AXIN1/GSK3B-complex to the cell surface
CC       promoting the formation of signalsomes and inhibiting AXIN1/GSK3-
CC       mediated phosphorylation and destruction of beta-catenin. Appears
CC       be required for postnatal control of vascular regression in the
CC       eye. Required for posterior patterning of the epiblast during
CC       gastrulation. {ECO:0000269|PubMed:11336703,
CC       ECO:0000269|PubMed:11448771, ECO:0000269|PubMed:14727154,
CC       ECO:0000269|PubMed:14731402, ECO:0000269|PubMed:15778503}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Forms phosphorylated
CC       oligomer aggregates on Wnt-signaling (By similarity). Component of
CC       a Wnt-signaling complex that contains a WNT protein, a FZD protein
CC       and LRP5 or LRP6. Interacts with FZD8; the interaction is formed
CC       on WNT-binding and signaling. Interacts (via the phosphorylated
CC       PPPSP motif domains) with AXIN1; the interaction prevents
CC       inhibition of beta-catenin phosphorylation and signaling and is
CC       enhanced in the presence of GSK3B and WNT1 or WNT3A. Interacts
CC       (via beta-propeller regions 3 and 4) with DKK1; the interaction,
CC       enhanced by MESD and/or KREMEN, inhibits beta-catenin signaling by
CC       preventing GSK3-mediated phosphorylation of the PPPSP motifs and
CC       subsequent, AXIN1 binding. Interacts with MESD; the interaction
CC       prevents the formation of LRP5 aggregates, targets LRP5 to the
CC       plasma membrane and, when complexed with KREMEN2, increases DKK1
CC       binding. Interacts with CSNK1E. Interacts with SOST; the
CC       interaction antagonizes canonical Wnt signaling. Interacts with
CC       APCDD1. {ECO:0000250, ECO:0000269|PubMed:11336703,
CC       ECO:0000269|PubMed:11448771, ECO:0000269|PubMed:14731402,
CC       ECO:0000269|PubMed:15143163, ECO:0000269|PubMed:15778503,
CC       ECO:0000269|PubMed:15908424, ECO:0000269|PubMed:16513652,
CC       ECO:0000269|PubMed:17488095, ECO:0000269|PubMed:19746449,
CC       ECO:0000269|PubMed:20393562}.
CC   -!- INTERACTION:
CC       Q6IMN6:CAPRIN2; NbExp=3; IntAct=EBI-2466421, EBI-6918449;
CC       Q9BQB4:SOST; NbExp=2; IntAct=EBI-2466421, EBI-5746563;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum {ECO:0000250}. Note=Chaperoned to
CC       the plasma membrane by MESD. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with the highest level of
CC       expression in the liver and in aorta.
CC       {ECO:0000269|PubMed:9790987}.
CC   -!- PTM: Phosphorylation of cytoplasmic PPPSP motifs regulates the
CC       signal transduction of the Wnt signaling pathway through acting as
CC       a docking site for AXIN1. {ECO:0000250}.
CC   -!- POLYMORPHISM: Genetic variations in LRP5 define the bone mineral
CC       density quantitative trait locus 1 (BMND1) [MIM:601884]. Variance
CC       in bone mineral density influences bone mass and contributes to
CC       size determination in the general population.
CC       {ECO:0000269|PubMed:11741193}.
CC   -!- DISEASE: Vitreoretinopathy, exudative 4 (EVR4) [MIM:601813]: A
CC       disorder of the retinal vasculature characterized by an abrupt
CC       cessation of growth of peripheral capillaries, leading to an
CC       avascular peripheral retina. This may lead to compensatory retinal
CC       neovascularization, which is thought to be induced by hypoxia from
CC       the initial avascular insult. New vessels are prone to leakage and
CC       rupture causing exudates and bleeding, followed by scarring,
CC       retinal detachment and blindness. Clinical features can be highly
CC       variable, even within the same family. Patients with mild forms of
CC       the disease are asymptomatic, and their only disease related
CC       abnormality is an arc of avascular retina in the extreme temporal
CC       periphery. {ECO:0000269|PubMed:15024691,
CC       ECO:0000269|PubMed:15346351, ECO:0000269|PubMed:15981244,
CC       ECO:0000269|PubMed:16929062, ECO:0000269|PubMed:19324841,
CC       ECO:0000269|PubMed:20340138, ECO:0000269|PubMed:24715757}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Osteoporosis (OSTEOP) [MIM:166710]: A systemic skeletal
CC       disorder characterized by decreased bone mass and deterioration of
CC       bone microarchitecture without alteration in the composition of
CC       bone. The result is fragile bones and an increased risk of
CC       fractures, even after minimal trauma. Osteoporosis is a chronic
CC       condition of multifactorial etiology and is usually clinically
CC       silent until a fracture occurs. {ECO:0000269|PubMed:14727154,
CC       ECO:0000269|PubMed:15824851, ECO:0000269|PubMed:16234968}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Osteoporosis-pseudoglioma syndrome (OPPG) [MIM:259770]: A
CC       disease characterized by congenital or infancy-onset blindness and
CC       severe juvenile-onset osteoporosis and spontaneous fractures.
CC       Additional clinical manifestations may include microphthalmos,
CC       abnormalities of the iris, lens or vitreous, cataracts, short
CC       stature, microcephaly, ligamental laxity, mental retardation and
CC       hypotonia. {ECO:0000269|PubMed:11719191,
CC       ECO:0000269|PubMed:16252235, ECO:0000269|PubMed:16679074,
CC       ECO:0000269|PubMed:17437160, ECO:0000269|PubMed:18602879}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: High bone mass trait (HBM) [MIM:601884]: Rare phenotype
CC       characterized by exceptionally dense bones. HBM individuals show
CC       otherwise a completely normal skeletal structure and no other
CC       unusual clinical findings. {ECO:0000269|PubMed:11741193,
CC       ECO:0000269|PubMed:12015390, ECO:0000269|PubMed:15824861,
CC       ECO:0000269|PubMed:17295608}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Endosteal hyperostosis, Worth type (WENHY) [MIM:144750]:
CC       An autosomal dominant sclerosing bone dysplasia clinically
CC       characterized by elongation of the mandible, increased gonial
CC       angle, flattened forehead, and the presence of a slowly enlarging
CC       osseous prominence of the hard palate (torus palatinus). Serum
CC       calcium, phosphorus and alkaline phosphatase levels are normal.
CC       Radiologically, it is characterized by early thickening of the
CC       endosteum of long bones, the skull and of the mandible. With
CC       advancing age, the trabeculae of the metaphysis become thickened.
CC       WENHY becomes clinically and radiologically evident by
CC       adolescence, does not cause deformity except in the skull and
CC       mandible, and is not associated with bone pain or fracture.
CC       Affected patients have normal height, proportion, intelligence and
CC       longevity. {ECO:0000269|PubMed:12579474}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Osteopetrosis, autosomal dominant 1 (OPTA1) [MIM:607634]:
CC       A rare genetic disease characterized by abnormally dense bone, due
CC       to defective resorption of immature bone. Osteopetrosis occurs in
CC       two forms: a severe autosomal recessive form occurring in utero,
CC       infancy, or childhood, and a benign autosomal dominant form
CC       occurring in adolescence or adulthood. OPTA1 is an autosomal
CC       dominant form characterized by generalized osteosclerosis most
CC       pronounced in the cranial vault. Patients are often asymptomatic,
CC       but some suffer from pain and hearing loss. It appears to be the
CC       only type of osteopetrosis not associated with an increased
CC       fracture rate. {ECO:0000269|PubMed:12579474}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Van Buchem disease 2 (VBCH2) [MIM:607636]: VBCH2 is an
CC       autosomal dominant sclerosing bone dysplasia characterized by
CC       cranial osteosclerosis, thickened calvaria and cortices of long
CC       bones, enlarged mandible and normal serum alkaline phosphatase
CC       levels. {ECO:0000269|PubMed:12579474}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the LDLR family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 EGF-like domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 3 LDL-receptor class A domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00124}.
CC   -!- SIMILARITY: Contains 20 LDL-receptor class B repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00461}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LRP5ID44282ch11q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF077820; AAC72791.1; -; mRNA.
DR   EMBL; AF064548; AAC36467.1; -; mRNA.
DR   EMBL; AF283321; AAK52433.1; -; Genomic_DNA.
DR   EMBL; AF283320; AAK52433.1; JOINED; Genomic_DNA.
DR   EMBL; AB017498; BAA33051.1; -; mRNA.
DR   EMBL; AP000807; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471076; EAW74705.1; -; Genomic_DNA.
DR   EMBL; BC150595; AAI50596.1; -; mRNA.
DR   CCDS; CCDS8181.1; -.
DR   PIR; JE0372; JE0372.
DR   RefSeq; NP_001278831.1; NM_001291902.1.
DR   RefSeq; NP_002326.2; NM_002335.3.
DR   UniGene; Hs.6347; -.
DR   ProteinModelPortal; O75197; -.
DR   SMR; O75197; 32-1256.
DR   BioGrid; 110220; 35.
DR   DIP; DIP-47265N; -.
DR   IntAct; O75197; 9.
DR   MINT; MINT-1189744; -.
DR   STRING; 9606.ENSP00000294304; -.
DR   iPTMnet; O75197; -.
DR   PhosphoSite; O75197; -.
DR   BioMuta; LRP5; -.
DR   MaxQB; O75197; -.
DR   PaxDb; O75197; -.
DR   PRIDE; O75197; -.
DR   Ensembl; ENST00000294304; ENSP00000294304; ENSG00000162337.
DR   GeneID; 4041; -.
DR   KEGG; hsa:4041; -.
DR   UCSC; uc001ont.3; human.
DR   CTD; 4041; -.
DR   GeneCards; LRP5; -.
DR   GeneReviews; LRP5; -.
DR   HGNC; HGNC:6697; LRP5.
DR   HPA; CAB013001; -.
DR   HPA; HPA030505; -.
DR   HPA; HPA030506; -.
DR   MalaCards; LRP5; -.
DR   MIM; 144750; phenotype.
DR   MIM; 166710; phenotype.
DR   MIM; 259770; phenotype.
DR   MIM; 601813; phenotype.
DR   MIM; 601884; phenotype.
DR   MIM; 603506; gene.
DR   MIM; 607634; phenotype.
DR   MIM; 607636; phenotype.
DR   neXtProt; NX_O75197; -.
DR   Orphanet; 2783; Autosomal dominant osteopetrosis type 1.
DR   Orphanet; 2790; Autosomal dominant osteosclerosis, Worth type.
DR   Orphanet; 891; Familial exudative vitreoretinopathy.
DR   Orphanet; 3416; Hyperostosis corticalis generalisata.
DR   Orphanet; 85193; Idiopathic juvenile osteoporosis.
DR   Orphanet; 2924; Isolated polycystic liver disease.
DR   Orphanet; 2788; Osteoporosis - pseudoglioma.
DR   Orphanet; 178377; Osteosclerosis-developmental delay-craniosynostosis syndrome.
DR   Orphanet; 90050; Retinopathy of prematurity.
DR   PharmGKB; PA30455; -.
DR   eggNOG; ENOG410IPT4; Eukaryota.
DR   eggNOG; ENOG410XSY5; LUCA.
DR   GeneTree; ENSGT00760000118968; -.
DR   HOGENOM; HOG000230697; -.
DR   HOVERGEN; HBG049167; -.
DR   InParanoid; O75197; -.
DR   KO; K03068; -.
DR   OMA; LFWTCEA; -.
DR   OrthoDB; EOG75XGK3; -.
DR   PhylomeDB; O75197; -.
DR   TreeFam; TF315253; -.
DR   Reactome; R-HSA-201681; TCF dependent signaling in response to WNT.
DR   Reactome; R-HSA-3772470; Negative regulation of TCF-dependent signaling by WNT ligand antagonists.
DR   Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; R-HSA-4641263; Regulation of FZD by ubiquitination.
DR   Reactome; R-HSA-5339717; Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling.
DR   Reactome; R-HSA-5340588; RNF mutants show enhanced WNT signaling and proliferation.
DR   SignaLink; O75197; -.
DR   ChiTaRS; LRP5; human.
DR   GeneWiki; LRP5; -.
DR   GenomeRNAi; 4041; -.
DR   NextBio; 15826; -.
DR   PRO; PR:O75197; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; O75197; -.
DR   CleanEx; HS_LRP5; -.
DR   ExpressionAtlas; O75197; baseline and differential.
DR   Genevisible; O75197; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0017147; F:Wnt-protein binding; IBA:GO_Central.
DR   GO; GO:0060612; P:adipose tissue development; IMP:BHF-UCL.
DR   GO; GO:0060033; P:anatomical structure regression; IEA:Ensembl.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:1902262; P:apoptotic process involved in patterning of blood vessels; IEA:Ensembl.
DR   GO; GO:0048539; P:bone marrow development; IMP:BHF-UCL.
DR   GO; GO:0060349; P:bone morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0046849; P:bone remodeling; IEA:Ensembl.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042074; P:cell migration involved in gastrulation; IEA:Ensembl.
DR   GO; GO:0060764; P:cell-cell signaling involved in mammary gland development; IEA:Ensembl.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0035426; P:extracellular matrix-cell signaling; IEA:Ensembl.
DR   GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl.
DR   GO; GO:0006007; P:glucose catabolic process; IMP:BHF-UCL.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0071901; P:negative regulation of protein serine/threonine kinase activity; IMP:BHF-UCL.
DR   GO; GO:0002076; P:osteoblast development; IBA:GO_Central.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; TAS:Reactome.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IDA:BHF-UCL.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:BHF-UCL.
DR   GO; GO:0046850; P:regulation of bone remodeling; IEA:Ensembl.
DR   GO; GO:0060828; P:regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0061178; P:regulation of insulin secretion involved in cellular response to glucose stimulus; IBA:GO_Central.
DR   GO; GO:0060042; P:retina morphogenesis in camera-type eye; IMP:BHF-UCL.
DR   GO; GO:0061304; P:retinal blood vessel morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0016055; P:Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0044332; P:Wnt signaling pathway involved in dorsal/ventral axis specification; IDA:BHF-UCL.
DR   Gene3D; 2.120.10.30; -; 4.
DR   Gene3D; 4.10.400.10; -; 3.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR000033; LDLR_classB_rpt.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR017049; LRP5/6.
DR   Pfam; PF00057; Ldl_recept_a; 3.
DR   Pfam; PF00058; Ldl_recept_b; 13.
DR   PIRSF; PIRSF036314; LDL_recpt-rel_p5/6; 1.
DR   PRINTS; PR00261; LDLRECEPTOR.
DR   SMART; SM00181; EGF; 4.
DR   SMART; SM00192; LDLa; 3.
DR   SMART; SM00135; LY; 20.
DR   SUPFAM; SSF57424; SSF57424; 3.
DR   PROSITE; PS01209; LDLRA_1; 3.
DR   PROSITE; PS50068; LDLRA_2; 3.
DR   PROSITE; PS51120; LDLRB; 20.
PE   1: Evidence at protein level;
KW   Complete proteome; Developmental protein; Disease mutation;
KW   Disulfide bond; EGF-like domain; Endocytosis; Endoplasmic reticulum;
KW   Glycoprotein; Membrane; Osteogenesis imperfecta; Osteopetrosis;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transmembrane; Transmembrane helix; Wnt signaling pathway.
FT   SIGNAL        1     31       {ECO:0000255}.
FT   CHAIN        32   1615       Low-density lipoprotein receptor-related
FT                                protein 5.
FT                                /FTId=PRO_0000017328.
FT   TOPO_DOM     32   1384       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1385   1407       Helical. {ECO:0000255}.
FT   TOPO_DOM   1408   1615       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       75    119       LDL-receptor class B 1.
FT   REPEAT       78     81       YWTD 1.
FT   REPEAT      120    162       LDL-receptor class B 2.
FT   REPEAT      123    126       YWTD 2.
FT   REPEAT      163    206       LDL-receptor class B 3.
FT   REPEAT      166    169       YWTD 3.
FT   REPEAT      207    247       LDL-receptor class B 4.
FT   REPEAT      248    290       LDL-receptor class B 5.
FT   REPEAT      251    254       YWTD 4.
FT   DOMAIN      295    337       EGF-like 1.
FT   REPEAT      385    427       LDL-receptor class B 6.
FT   REPEAT      388    391       YWTD 5.
FT   REPEAT      428    470       LDL-receptor class B 7.
FT   REPEAT      431    434       YWTD 6.
FT   REPEAT      471    514       LDL-receptor class B 8.
FT   REPEAT      474    477       YWTD 7.
FT   REPEAT      515    557       LDL-receptor class B 9.
FT   REPEAT      558    600       LDL-receptor class B 10.
FT   REPEAT      559    562       YWTD 8.
FT   DOMAIN      601    641       EGF-like 2.
FT   REPEAT      687    729       LDL-receptor class B 11.
FT   REPEAT      690    693       YWTD 9.
FT   REPEAT      730    772       LDL-receptor class B 12.
FT   REPEAT      773    815       LDL-receptor class B 13.
FT   REPEAT      816    855       LDL-receptor class B 14.
FT   REPEAT      819    822       YWTD 10.
FT   REPEAT      856    898       LDL-receptor class B 15.
FT   REPEAT      859    862       YWTD 11.
FT   DOMAIN      902    942       EGF-like 3.
FT   REPEAT      989   1035       LDL-receptor class B 16.
FT   REPEAT     1036   1078       LDL-receptor class B 17.
FT   REPEAT     1079   1123       LDL-receptor class B 18.
FT   REPEAT     1124   1164       LDL-receptor class B 19.
FT   REPEAT     1165   1207       LDL-receptor class B 20.
FT   DOMAIN     1213   1254       EGF-like 4.
FT   DOMAIN     1258   1296       LDL-receptor class A 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1297   1333       LDL-receptor class A 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1335   1371       LDL-receptor class A 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   REGION       32    288       Beta-propeller 1.
FT   REGION      341    602       Beta-propeller 2.
FT   REGION      644    903       Beta-propeller 3.
FT   REGION      945   1212       Beta-propeller 4.
FT   MOTIF      1500   1506       PPPSP motif A.
FT   MOTIF      1538   1545       PPPSP motif B.
FT   MOTIF      1574   1581       PPPSP motif C.
FT   MOTIF      1591   1596       PPPSP motif D.
FT   MOTIF      1605   1612       PPPSP motif E.
FT   COMPBIAS   1495   1610       Pro-rich.
FT   CARBOHYD     93     93       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    138    138       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    446    446       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    499    499       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    705    705       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    878    878       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    299    310       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    306    321       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    323    336       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    605    616       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    612    625       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    627    640       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    906    917       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    913    926       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID    928    941       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1217   1228       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1224   1238       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1240   1253       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1259   1273       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1266   1286       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1280   1295       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1298   1310       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1305   1323       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1317   1332       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1336   1348       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1343   1361       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1355   1370       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   VARIANT      15     20       Missing (found in a family with
FT                                osteoporosis pseudoglioma syndrome;
FT                                impairs protein trafficking to the
FT                                endoplasmic reticulum and cell membrane).
FT                                {ECO:0000269|PubMed:19177549}.
FT                                /FTId=VAR_058582.
FT   VARIANT      18     20       Missing. {ECO:0000269|PubMed:12579474}.
FT                                /FTId=VAR_021804.
FT   VARIANT      20     20       L -> LL. {ECO:0000269|PubMed:12579474}.
FT                                /FTId=VAR_021805.
FT   VARIANT      29     29       A -> T (in primary osteoporosis).
FT                                {ECO:0000269|PubMed:15824851}.
FT                                /FTId=VAR_063941.
FT   VARIANT      89     89       Q -> R (in dbSNP:rs41494349).
FT                                {ECO:0000269|PubMed:12579474,
FT                                ECO:0000269|PubMed:14727154}.
FT                                /FTId=VAR_021806.
FT   VARIANT      97     97       A -> V (in dbSNP:rs143433231).
FT                                {ECO:0000269|PubMed:15981244}.
FT                                /FTId=VAR_063942.
FT   VARIANT     111    111       D -> Y (in OPTA1).
FT                                {ECO:0000269|PubMed:12579474}.
FT                                /FTId=VAR_021807.
FT   VARIANT     145    145       L -> F (in EVR4).
FT                                {ECO:0000269|PubMed:15981244}.
FT                                /FTId=VAR_063943.
FT   VARIANT     154    154       R -> M (in HBM).
FT                                {ECO:0000269|PubMed:15824861}.
FT                                /FTId=VAR_063944.
FT   VARIANT     171    171       G -> R (in OPTA1).
FT                                {ECO:0000269|PubMed:12579474}.
FT                                /FTId=VAR_021808.
FT   VARIANT     171    171       G -> V (in HBM; also in HBM individuals
FT                                with enlarged mandible and torus
FT                                palatinus; abolishes interaction with
FT                                MESD; impairs transport to cell surface;
FT                                no enhancement of DKK1 binding by MESD
FT                                resulting in impaired inhibition of Wnt
FT                                signaling by DKK1).
FT                                {ECO:0000269|PubMed:11741193,
FT                                ECO:0000269|PubMed:12015390,
FT                                ECO:0000269|PubMed:15143163,
FT                                ECO:0000269|PubMed:19746449}.
FT                                /FTId=VAR_021809.
FT   VARIANT     173    173       T -> M (in EVR4; an individual with
FT                                abnormal retinal vasculature and retinal
FT                                folds; dbSNP:rs80358306).
FT                                {ECO:0000269|PubMed:15024691,
FT                                ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_018465.
FT   VARIANT     203    203       D -> N (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063945.
FT   VARIANT     214    214       A -> T (in WENHY).
FT                                {ECO:0000269|PubMed:12579474}.
FT                                /FTId=VAR_021810.
FT   VARIANT     214    214       A -> V (in WENHY).
FT                                {ECO:0000269|PubMed:12579474}.
FT                                /FTId=VAR_021811.
FT   VARIANT     242    242       A -> T (in OPTA1, VBCH2 and WENHY).
FT                                {ECO:0000269|PubMed:12579474}.
FT                                /FTId=VAR_021812.
FT   VARIANT     244    244       T -> M (in OPPG; appears to traffic less
FT                                well than does the wild-type protein;
FT                                appears to be post-translationally
FT                                modified similar to wild-type protein; is
FT                                unable to transduce Wnt signal; has a
FT                                significantly reduced ability to
FT                                transduce Norrin signal).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063946.
FT   VARIANT     253    253       T -> I (in OPTA1).
FT                                {ECO:0000269|PubMed:12579474}.
FT                                /FTId=VAR_021813.
FT   VARIANT     282    282       M -> V (in HBM; unknown pathological
FT                                significance; lowered LRP5-mediated Wnt
FT                                signaling; no effect on DKK1 binding).
FT                                {ECO:0000269|PubMed:17295608}.
FT                                /FTId=VAR_063412.
FT   VARIANT     307    307       S -> F (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063947.
FT   VARIANT     348    348       R -> W (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063948.
FT   VARIANT     353    353       R -> Q (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063949.
FT   VARIANT     356    356       S -> L (in idiopathic osteoporosis and
FT                                OPPG; appears to traffic comparably than
FT                                does the wild-type protein; appears to be
FT                                post-translationally modified similar to
FT                                wild-type protein; is unable to transduce
FT                                Wnt signal; has a significantly reduced
FT                                ability to transduce Norrin signal).
FT                                {ECO:0000269|PubMed:16234968,
FT                                ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063950.
FT   VARIANT     390    390       T -> K (in OPPG; is unable to traffic
FT                                normally; appears to be post-
FT                                translationally modified similar to wild-
FT                                type protein; is unable to transduce Wnt
FT                                signal; has a significantly reduced
FT                                ability to transduce Norrin signal).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063951.
FT   VARIANT     400    400       A -> E (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063952.
FT   VARIANT     404    404       G -> R (in OPPG; appears to traffic less
FT                                well than does the wild-type protein;
FT                                appears to be post-translationally
FT                                modified similar to wild-type protein;
FT                                has 50% of wild-type activity to
FT                                transduce Wnt signal; has a significantly
FT                                reduced ability to transduce Norrin
FT                                signal). {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063953.
FT   VARIANT     409    409       T -> A (in OPPG).
FT                                {ECO:0000269|PubMed:18602879}.
FT                                /FTId=VAR_063954.
FT   VARIANT     422    422       A -> T (in EVR4; the mutation results in
FT                                significantly reduced Norrin signal
FT                                transduction).
FT                                {ECO:0000269|PubMed:24715757}.
FT                                /FTId=VAR_071012.
FT   VARIANT     434    434       D -> N (in OPPG; appears to traffic less
FT                                well than does the wild-type protein;
FT                                appears to be post-translationally
FT                                modified similar to wild-type protein;
FT                                has 50% of wild-type activity to
FT                                transduce Wnt signal; has a significantly
FT                                reduced ability to transduce Norrin
FT                                signal). {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063955.
FT   VARIANT     441    441       E -> K (in EVR4).
FT                                {ECO:0000269|PubMed:20340138}.
FT                                /FTId=VAR_063956.
FT   VARIANT     444    444       R -> C (in EVR4; associated in a EVR1
FT                                patient with mutation GLN-417 in FZD4).
FT                                {ECO:0000269|PubMed:15981244}.
FT                                /FTId=VAR_063957.
FT   VARIANT     455    455       S -> L (in idiopathic osteoporosis; shows
FT                                an inhibitory effect on Wnt signal
FT                                transduction).
FT                                {ECO:0000269|PubMed:16234968}.
FT                                /FTId=VAR_063958.
FT   VARIANT     460    460       E -> K (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063959.
FT   VARIANT     478    478       W -> R (in OPPG).
FT                                {ECO:0000269|PubMed:16679074}.
FT                                /FTId=VAR_063960.
FT   VARIANT     494    494       R -> Q (in OPPG).
FT                                {ECO:0000269|PubMed:11719191,
FT                                ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_021814.
FT   VARIANT     504    504       W -> C (in OPPG).
FT                                {ECO:0000269|PubMed:16679074}.
FT                                /FTId=VAR_063961.
FT   VARIANT     511    511       D -> A (in EVR4).
FT                                {ECO:0000269|PubMed:19324841}.
FT                                /FTId=VAR_063962.
FT   VARIANT     520    520       G -> V (in OPPG; appears to traffic
FT                                comparably than does the wild-type
FT                                protein; appears to be post-
FT                                translationally modified similar to wild-
FT                                type protein; is unable to transduce Wnt
FT                                signal; has a significantly reduced
FT                                ability to transduce Norrin signal).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063963.
FT   VARIANT     522    522       A -> T (in EVR4).
FT                                {ECO:0000269|PubMed:15981244}.
FT                                /FTId=VAR_063964.
FT   VARIANT     531    531       N -> I (in OPPG).
FT                                {ECO:0000269|PubMed:17437160}.
FT                                /FTId=VAR_063965.
FT   VARIANT     535    535       T -> M (in EVR4; autosomal recessive).
FT                                {ECO:0000269|PubMed:15981244}.
FT                                /FTId=VAR_063966.
FT   VARIANT     540    540       L -> P (in EVR4; the mutation results in
FT                                significantly reduced Norrin signal
FT                                transduction).
FT                                {ECO:0000269|PubMed:24715757}.
FT                                /FTId=VAR_071013.
FT   VARIANT     550    550       G -> R (in EVR4; autosomal recessive).
FT                                {ECO:0000269|PubMed:16929062}.
FT                                /FTId=VAR_063967.
FT   VARIANT     570    570       R -> Q (in EVR4; autosomal recessive; has
FT                                significantly reduced Wnt or Norrin
FT                                signal transduction).
FT                                {ECO:0000269|PubMed:15346351,
FT                                ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_021222.
FT   VARIANT     570    570       R -> W (in OPPG).
FT                                {ECO:0000269|PubMed:11719191,
FT                                ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_021815.
FT   VARIANT     610    610       G -> R (in EVR4 and OPPG; appears to
FT                                traffic less well than does the wild-type
FT                                protein; appears to be post-
FT                                translationally modified similar to wild-
FT                                type protein; has 60% of wild-type
FT                                activity to transduce Wnt signal; has a
FT                                significantly reduced ability to
FT                                transduce Norrin signal).
FT                                {ECO:0000269|PubMed:15981244,
FT                                ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063968.
FT   VARIANT     617    617       F -> C (in EVR4; autosomal recessive).
FT                                {ECO:0000269|PubMed:15981244}.
FT                                /FTId=VAR_063969.
FT   VARIANT     667    667       V -> M (in dbSNP:rs4988321).
FT                                {ECO:0000269|PubMed:11719191,
FT                                ECO:0000269|PubMed:12579474,
FT                                ECO:0000269|PubMed:15077203}.
FT                                /FTId=VAR_021816.
FT   VARIANT     683    683       D -> N (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063970.
FT   VARIANT     733    733       Y -> H (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063971.
FT   VARIANT     752    752       R -> G (in EVR4; autosomal recessive).
FT                                {ECO:0000269|PubMed:15346351}.
FT                                /FTId=VAR_021223.
FT   VARIANT     798    798       T -> A (in EVR4; dbSNP:rs80358316).
FT                                {ECO:0000269|PubMed:15981244}.
FT                                /FTId=VAR_063972.
FT   VARIANT     805    805       R -> W (in EVR4).
FT                                {ECO:0000269|PubMed:19324841}.
FT                                /FTId=VAR_063973.
FT   VARIANT     816    816       Q -> P (rare polymorphism; no effect on
FT                                Norrin signal transduction).
FT                                {ECO:0000269|PubMed:24715757}.
FT                                /FTId=VAR_071014.
FT   VARIANT     852    852       T -> M (in EVR4; de novo mutation found
FT                                in a patient also carrying mutation P-
FT                                540; unknown pathological significance;
FT                                the mutation results in significantly
FT                                reduced Norrin signal transduction).
FT                                {ECO:0000269|PubMed:24715757}.
FT                                /FTId=VAR_071015.
FT   VARIANT    1036   1036       R -> Q (in primary osteoporosis;
FT                                dbSNP:rs61889560).
FT                                {ECO:0000269|PubMed:15824851}.
FT                                /FTId=VAR_063974.
FT   VARIANT    1099   1099       D -> Y (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063975.
FT   VARIANT    1113   1113       R -> C (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063976.
FT   VARIANT    1121   1121       N -> D (in EVR4; dbSNP:rs80358317).
FT                                {ECO:0000269|PubMed:15981244}.
FT                                /FTId=VAR_063977.
FT   VARIANT    1168   1168       Y -> H (in EVR4; an individual with total
FT                                retinal detachment and retinoschisis; is
FT                                unable to transduce Wnt or Norrin signal
FT                                transduction).
FT                                {ECO:0000269|PubMed:15024691,
FT                                ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_018466.
FT   VARIANT    1204   1204       V -> L (in dbSNP:rs11607268).
FT                                /FTId=VAR_035208.
FT   VARIANT    1253   1253       C -> F (in EVR4).
FT                                {ECO:0000269|PubMed:20340138}.
FT                                /FTId=VAR_063978.
FT   VARIANT    1330   1330       A -> V (in dbSNP:rs3736228).
FT                                {ECO:0000269|PubMed:12509515,
FT                                ECO:0000269|PubMed:12579474,
FT                                ECO:0000269|PubMed:14727154,
FT                                ECO:0000269|PubMed:15077203}.
FT                                /FTId=VAR_021817.
FT   VARIANT    1361   1361       C -> G (in EVR4; autosomal dominant; has
FT                                mildly reduced Wnt or Norrin signal
FT                                transduction).
FT                                {ECO:0000269|PubMed:15024691,
FT                                ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_018467.
FT   VARIANT    1367   1367       E -> K (in EVR4; autosomal recessive;
FT                                dbSNP:rs28939709).
FT                                {ECO:0000269|PubMed:15346351,
FT                                ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_021224.
FT   VARIANT    1401   1401       G -> D (in OPPG).
FT                                {ECO:0000269|PubMed:16252235}.
FT                                /FTId=VAR_063979.
FT   VARIANT    1525   1525       A -> V (in dbSNP:rs1127291).
FT                                {ECO:0000269|PubMed:15024691,
FT                                ECO:0000269|PubMed:9714764}.
FT                                /FTId=VAR_021225.
FT   VARIANT    1537   1537       A -> T (could be associated with
FT                                idiopathic osteoporosis; does not result
FT                                in a significant alteration of Wnt signal
FT                                transduction).
FT                                {ECO:0000269|PubMed:16234968}.
FT                                /FTId=VAR_063980.
FT   VARIANT    1540   1540       T -> M (in dbSNP:rs141407040).
FT                                {ECO:0000269|PubMed:15981244}.
FT                                /FTId=VAR_063981.
FT   CONFLICT   1525   1528       Missing (in Ref. 3; AAK52433).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1615 AA;  179145 MW;  8BA25D07F51E02CA CRC64;
     MEAAPPGPPW PLLLLLLLLL ALCGCPAPAA ASPLLLFANR RDVRLVDAGG VKLESTIVVS
     GLEDAAAVDF QFSKGAVYWT DVSEEAIKQT YLNQTGAAVQ NVVISGLVSP DGLACDWVGK
     KLYWTDSETN RIEVANLNGT SRKVLFWQDL DQPRAIALDP AHGYMYWTDW GETPRIERAG
     MDGSTRKIIV DSDIYWPNGL TIDLEEQKLY WADAKLSFIH RANLDGSFRQ KVVEGSLTHP
     FALTLSGDTL YWTDWQTRSI HACNKRTGGK RKEILSALYS PMDIQVLSQE RQPFFHTRCE
     EDNGGCSHLC LLSPSEPFYT CACPTGVQLQ DNGRTCKAGA EEVLLLARRT DLRRISLDTP
     DFTDIVLQVD DIRHAIAIDY DPLEGYVYWT DDEVRAIRRA YLDGSGAQTL VNTEINDPDG
     IAVDWVARNL YWTDTGTDRI EVTRLNGTSR KILVSEDLDE PRAIALHPVM GLMYWTDWGE
     NPKIECANLD GQERRVLVNA SLGWPNGLAL DLQEGKLYWG DAKTDKIEVI NVDGTKRRTL
     LEDKLPHIFG FTLLGDFIYW TDWQRRSIER VHKVKASRDV IIDQLPDLMG LKAVNVAKVV
     GTNPCADRNG GCSHLCFFTP HATRCGCPIG LELLSDMKTC IVPEAFLVFT SRAAIHRISL
     ETNNNDVAIP LTGVKEASAL DFDVSNNHIY WTDVSLKTIS RAFMNGSSVE HVVEFGLDYP
     EGMAVDWMGK NLYWADTGTN RIEVARLDGQ FRQVLVWRDL DNPRSLALDP TKGYIYWTEW
     GGKPRIVRAF MDGTNCMTLV DKVGRANDLT IDYADQRLYW TDLDTNMIES SNMLGQERVV
     IADDLPHPFG LTQYSDYIYW TDWNLHSIER ADKTSGRNRT LIQGHLDFVM DILVFHSSRQ
     DGLNDCMHNN GQCGQLCLAI PGGHRCGCAS HYTLDPSSRN CSPPTTFLLF SQKSAISRMI
     PDDQHSPDLI LPLHGLRNVK AIDYDPLDKF IYWVDGRQNI KRAKDDGTQP FVLTSLSQGQ
     NPDRQPHDLS IDIYSRTLFW TCEATNTINV HRLSGEAMGV VLRGDRDKPR AIVVNAERGY
     LYFTNMQDRA AKIERAALDG TEREVLFTTG LIRPVALVVD NTLGKLFWVD ADLKRIESCD
     LSGANRLTLE DANIVQPLGL TILGKHLYWI DRQQQMIERV EKTTGDKRTR IQGRVAHLTG
     IHAVEEVSLE EFSAHPCARD NGGCSHICIA KGDGTPRCSC PVHLVLLQNL LTCGEPPTCS
     PDQFACATGE IDCIPGAWRC DGFPECDDQS DEEGCPVCSA AQFPCARGQC VDLRLRCDGE
     ADCQDRSDEA DCDAICLPNQ FRCASGQCVL IKQQCDSFPD CIDGSDELMC EITKPPSDDS
     PAHSSAIGPV IGIILSLFVM GGVYFVCQRV VCQRYAGANG PFPHEYVSGT PHVPLNFIAP
     GGSQHGPFTG IACGKSMMSS VSLMGGRGGV PLYDRNHVTG ASSSSSSSTK ATLYPPILNP
     PPSPATDPSL YNMDMFYSSN IPATARPYRP YIIRGMAPPT TPCSTDVCDS DYSASRWKAS
     KYYLDLNSDS DPYPPPPTPH SQYLSAEDSC PPSPATERSY FHLFPPPPSP CTDSS
//
ID   MUC1_HUMAN              Reviewed;        1255 AA.
AC   P15941; A5YRV1; A6ZID9; A6ZIE0; B1AVQ8; B1AVR0; B6ECA1; E7ESE5;
AC   E7EUG9; P13931; P15942; P17626; Q0VAP5; Q0VAP6; Q14128; Q14876;
AC   Q16437; Q16442; Q16615; Q6S4Y3; Q7Z547; Q7Z548; Q7Z550; Q7Z552;
AC   Q9BXA4; Q9UE75; Q9UE76; Q9UQL1; Q9Y4J2;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   17-FEB-2016, entry version 182.
DE   RecName: Full=Mucin-1;
DE            Short=MUC-1;
DE   AltName: Full=Breast carcinoma-associated antigen DF3;
DE   AltName: Full=Cancer antigen 15-3;
DE            Short=CA 15-3;
DE   AltName: Full=Carcinoma-associated mucin;
DE   AltName: Full=Episialin;
DE   AltName: Full=H23AG;
DE   AltName: Full=Krebs von den Lungen-6;
DE            Short=KL-6;
DE   AltName: Full=PEMT;
DE   AltName: Full=Peanut-reactive urinary mucin;
DE            Short=PUM;
DE   AltName: Full=Polymorphic epithelial mucin;
DE            Short=PEM;
DE   AltName: Full=Tumor-associated epithelial membrane antigen;
DE            Short=EMA;
DE   AltName: Full=Tumor-associated mucin;
DE   AltName: CD_antigen=CD227;
DE   Contains:
DE     RecName: Full=Mucin-1 subunit alpha;
DE              Short=MUC1-NT;
DE              Short=MUC1-alpha;
DE   Contains:
DE     RecName: Full=Mucin-1 subunit beta;
DE              Short=MUC1-beta;
DE     AltName: Full=MUC1-CT;
DE   Flags: Precursor;
GN   Name=MUC1; Synonyms=PUM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Pancreatic carcinoma;
RX   PubMed=2394722;
RA   Lan M.S., Batra S.K., Qi W.-N., Metzgar R.S., Hollingsworth M.A.;
RT   "Cloning and sequencing of a human pancreatic tumor mucin cDNA.";
RL   J. Biol. Chem. 265:15294-15299(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=2318825;
RA   Ligtenberg M.J.L., Vos H.L., Gennissen A.M.C., Hilkens J.;
RT   "Episialin, a carcinoma-associated mucin, is generated by a
RT   polymorphic gene encoding splice variants with alternative amino
RT   termini.";
RL   J. Biol. Chem. 265:5573-5578(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary carcinoma;
RX   PubMed=1697589;
RA   Gendler S.J., Lancaster C.A., Taylor-Papadimitriou J., Duhig T.,
RA   Peat N., Burchell J., Pemberton L., Lalani E.-N., Wilson D.;
RT   "Molecular cloning and expression of human tumor-associated
RT   polymorphic epithelial mucin.";
RL   J. Biol. Chem. 265:15286-15293(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=2268309; DOI=10.1016/S0006-291X(05)80888-5;
RA   Lancaster C.A., Peat N., Duhig T., Wilson D., Taylor-Papadimitriou J.,
RA   Gendler S.J.;
RT   "Structure and expression of the human polymorphic epithelial mucin
RT   gene: an expressed VNTR unit.";
RL   Biochem. Biophys. Res. Commun. 173:1019-1029(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Mammary carcinoma;
RX   PubMed=2351132; DOI=10.1111/j.1432-1033.1990.tb15511.x;
RA   Wreschner D.H., Hareuveni M., Tsarfaty I., Smorodinsky N., Horev J.,
RA   Zaretsky J., Kotkes P., Weiss M., Lathe R., Dion A., Keydar I.;
RT   "Human epithelial tumor antigen cDNA sequences. Differential splicing
RT   may generate multiple protein forms.";
RL   Eur. J. Biochem. 189:463-473(1990).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary carcinoma;
RX   PubMed=2112460; DOI=10.1111/j.1432-1033.1990.tb15512.x;
RA   Hareuveni M., Tsarfaty I., Zaretsky J., Kotkes P., Horev J.,
RA   Zrihan S., Weiss M., Green S., Lathe R., Keydar I., Wreschner D.H.;
RT   "A transcribed gene, containing a variable number of tandem repeats,
RT   codes for a human epithelial tumor antigen. cDNA cloning, expression
RT   of the transfected gene and over-expression in breast cancer tissue.";
RL   Eur. J. Biochem. 189:475-486(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=1688329; DOI=10.1016/0378-1119(90)90242-J;
RA   Tsarfaty I., Hareuveni M., Horev J., Zaretsky J., Weiss M.,
RA   Jeltsch J.-M., Garnier J.-M., Lathe R., Keydar I., Wreschner D.H.;
RT   "Isolation and characterization of an expressed hypervariable gene
RT   coding for a breast-cancer-associated antigen.";
RL   Gene 93:313-318(1990).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM Y).
RX   PubMed=7925397; DOI=10.1111/j.1432-1033.1994.00787.x;
RA   Zrihan-Licht S., Vos H.L., Baruch A., Elroy-Stein O., Sagiv D.,
RA   Keydar I., Hilkens J., Wreschner D.H.;
RT   "Characterization and molecular cloning of a novel MUC1 protein,
RT   devoid of tandem repeats, expressed in human breast cancer tissue.";
RL   Eur. J. Biochem. 224:787-795(1994).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; Y AND 8), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=9212228;
RX   DOI=10.1002/(SICI)1097-0215(19970703)72:1<87::AID-IJC13>3.0.CO;2-7;
RA   Oosterkamp H.M., Scheiner L., Stefanova M.C., Lloyd K.O.,
RA   Finstad C.L.;
RT   "Comparison of MUC-1 mucin expression in epithelial and non-epithelial
RT   cancer cell lines and demonstration of a new short variant form (MUC-
RT   1/Z).";
RL   Int. J. Cancer 72:87-94(1997).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ZD).
RX   PubMed=15623537; DOI=10.1074/jbc.M406943200;
RA   Levitin F., Baruch A., Weiss M., Stiegman K., Hartmann M.L.,
RA   Yoeli-Lerner M., Ziv R., Zrihan-Licht S., Shina S., Gat A.,
RA   Lifschitz B., Simha M., Stadler Y., Cholostoy A., Gil B., Greaves D.,
RA   Keydar I., Zaretsky J., Smorodinsky N., Wreschner D.H.;
RT   "A novel protein derived from the MUC1 gene by alternative splicing
RT   and frameshifting.";
RL   J. Biol. Chem. 280:10655-10663(2005).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; E2; J13; M6; S2; T10; Y-LSP
RP   AND ZD), ALTERNATIVE SPLICING, AND VARIANT MET-1117.
RX   PubMed=22941036; DOI=10.1007/s00262-012-1325-2;
RA   Zhang L., Vlad A., Milcarek C., Finn O.J.;
RT   "Human mucin MUC1 RNA undergoes different types of alternative
RT   splicing resulting in multiple isoforms.";
RL   Cancer Immunol. Immunother. 62:423-435(2013).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 9).
RC   TISSUE=Carcinoma;
RA   Zhang L.X., Li C.H., Sun L.Y., Yue W.;
RT   "Cloning of a new potential secreted short variant form of MUC1 mucin
RT   in epithelial cancer cell line.";
RL   Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM Y), AND VARIANT MET-1117.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15969018;
RA   Zhang L.X., Li C.H., Sun L.Y., Wang M., Lu H.J.;
RT   "Soluble expression of peptide containing MUC1/Y-specific epitope in
RT   Escherichia coli and preparation of the antibody.";
RL   Sheng Wu Gong Cheng Xue Bao 19:337-342(2003).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM F).
RA   Zhang L.X., Lu H.J.;
RT   "Cloning of a new MUC1 short variant mRNA F from HeLa cells.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM S2).
RA   Zhang L.X., Lu H.J.;
RT   "Cloning of a new MUC1 short variant mRNA S2 from HeLa cells.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM M6).
RA   Zhang L., Finn O.J.;
RT   "Isolation of MUC1 isoforms from MCF7 cells.";
RL   Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-1117 AND ASN-1142.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS Y AND Y-LSP).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [21]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3417635;
RA   Gendler S.J., Taylor-Papadimitriou J., Duhig T., Rothbard J.,
RA   Burchell J.;
RT   "A highly immunogenic region of a human polymorphic epithelial mucin
RT   expressed by carcinomas is made up of tandem repeats.";
RL   J. Biol. Chem. 263:12820-12823(1988).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-160 (ISOFORM 2).
RX   PubMed=2597151; DOI=10.1016/S0006-291X(89)80014-2;
RA   Abe M., Siddiqui J., Kufe D.;
RT   "Sequence analysis of the 5' region of the human DF3 breast carcinoma-
RT   associated antigen gene.";
RL   Biochem. Biophys. Res. Commun. 165:644-649(1989).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-109 (ISOFORM 2).
RC   TISSUE=Thyroid;
RX   PubMed=8608966;
RX   DOI=10.1002/(SICI)1097-0215(19960328)66:1<55::AID-IJC10>3.0.CO;2-A;
RA   Weiss M., Baruch A., Keydar I., Wreschner D.H.;
RT   "Preoperative diagnosis of thyroid papillary carcinoma by reverse
RT   transcriptase polymerase chain reaction of the MUC1 gene.";
RL   Int. J. Cancer 66:55-59(1996).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-89.
RC   TISSUE=Lung;
RX   PubMed=8604237;
RA   Yu C.J., Yang P.C., Shew J.Y., Hong T.M., Yang S.C., Lee Y.C.,
RA   Lee L.N., Luh K.T., Wu C.W.;
RT   "Mucin mRNA expression in lung adenocarcinoma cell lines and
RT   tissues.";
RL   Oncology 53:118-126(1996).
RN   [25]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-46 (ISOFORMS 3 AND 4).
RC   TISSUE=Mammary carcinoma;
RA   Buluwela L., Liu Q., Luqmani Y.A., Gomm J.J., Coombes R.C.;
RL   Submitted (OCT-1992) to the EMBL/GenBank/DDBJ databases.
RN   [26]
RP   PROTEIN SEQUENCE OF 24-33; 28-37 AND 1098-1107, AND PROTEOLYTIC
RP   PROCESSING.
RX   PubMed=11341784; DOI=10.1006/bbrc.2001.4775;
RA   Parry S., Silverman H.S., McDermott K., Willis A., Hollingsworth M.A.,
RA   Harris A.;
RT   "Identification of MUC1 proteolytic cleavage sites in vivo.";
RL   Biochem. Biophys. Res. Commun. 283:715-720(2001).
RN   [27]
RP   PROTEIN SEQUENCE OF 1098-1111, PROTEOLYTIC CLEAVAGE, AND MUTAGENESIS
RP   OF SER-1098.
RX   PubMed=15987679; DOI=10.1074/jbc.M506047200;
RA   Levitin F., Stern O., Weiss M., Gil-Henn C., Ziv R., Prokocimer Z.,
RA   Smorodinsky N.I., Rubinstein D.B., Wreschner D.H.;
RT   "The MUC1 SEA module is a self-cleaving domain.";
RL   J. Biol. Chem. 280:33374-33386(2005).
RN   [28]
RP   PROTEIN SEQUENCE OF TANDEM REPEAT, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND GLYCOSYLATION.
RX   PubMed=10373415; DOI=10.1074/jbc.274.26.18165;
RA   Mueller S., Alving K., Peter-Katalinic J., Zachara N., Gooley A.A.,
RA   Hanisch F.-G.;
RT   "High density O-glycosylation on tandem repeat peptide from secretory
RT   MUC1 of T47D breast cancer cells.";
RL   J. Biol. Chem. 274:18165-18172(1999).
RN   [29]
RP   PHOSPHORYLATION.
RX   PubMed=7988707; DOI=10.1016/0014-5793(94)01251-2;
RA   Zrihan-Licht S., Baruch A., Elroy-Stein O., Keydar I., Wreschner D.H.;
RT   "Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins.
RT   Cytokine receptor-like molecules.";
RL   FEBS Lett. 356:130-136(1994).
RN   [30]
RP   IDENTIFICATION IN A COMPLEX WITH SOS1 AND GRB2, INTERACTION WITH GRB2
RP   AND SOS1, AND PHOSPHORYLATION.
RX   PubMed=7664271;
RA   Pandey P., Kharbanda S., Kufe D.;
RT   "Association of the DF3/MUC1 breast cancer antigen with Grb2 and the
RT   Sos/Ras exchange protein.";
RL   Cancer Res. 55:4000-4003(1995).
RN   [31]
RP   GLYCOSYLATION AT THR-131 AND THR-139, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=7744025; DOI=10.1111/j.1432-1033.1995.0140l.x;
RA   Stadie T.R., Chai W., Lawson A.M., Byfield P.G., Hanisch F.G.;
RT   "Studies on the order and site specificity of GalNAc transfer to MUC1
RT   tandem repeats by UDP-GalNAc: polypeptide N-
RT   acetylgalactosaminyltransferase from milk or mammary carcinoma
RT   cells.";
RL   Eur. J. Biochem. 229:140-147(1995).
RN   [32]
RP   INTERACTION WITH CTNNB1 AND JUP, AND FUNCTION.
RX   PubMed=9139698; DOI=10.1074/jbc.272.19.12492;
RA   Yamamoto M., Bharti A., Li Y., Kufe D.;
RT   "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and
RT   beta-catenin in cell adhesion.";
RL   J. Biol. Chem. 272:12492-12494(1997).
RN   [33]
RP   GLYCOSYLATION WITHIN TANDEM REPEAT.
RX   PubMed=9312074; DOI=10.1074/jbc.272.40.24780;
RA   Mueller S., Goletz S., Packer N.H., Gooley A.A., Lawson A.M.,
RA   Hanisch F.-G.;
RT   "Localization of O-glycosylation sites on glycopeptide fragments from
RT   lactation-associated MUC1. All putative sites within the tandem repeat
RT   are glycosylation targets in vivo.";
RL   J. Biol. Chem. 272:24780-24793(1997).
RN   [34]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=9536947; DOI=10.1136/gut.42.2.220;
RA   Reid C.J., Harris A.;
RT   "Developmental expression of mucin genes in the human gastrointestinal
RT   system.";
RL   Gut 42:220-226(1998).
RN   [35]
RP   GLYCOSYLATION AT THR-131 AND THR-139, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=9597769;
RX   DOI=10.1002/(SICI)1096-9888(199804)33:4<358::AID-JMS642>3.3.CO;2-V;
RA   Hanisch F.G., Green B.N., Bateman R., Peter-Katalinic J.;
RT   "Localization of O-glycosylation sites of MUC1 tandem repeats by QTOF
RT   ESI mass spectrometry.";
RL   J. Mass Spectrom. 33:358-362(1998).
RN   [36]
RP   INTERACTION WITH GSK3B AND CTNNB1, PHOSPHORYLATION AT SER-1227, AND
RP   MUTAGENESIS OF SER-1223 AND SER-1227.
RX   PubMed=9819408;
RA   Li Y., Bharti A., Chen D., Gong J., Kufe D.;
RT   "Interaction of glycogen synthase kinase 3beta with the DF3/MUC1
RT   carcinoma-associated antigen and beta-catenin.";
RL   Mol. Cell. Biol. 18:7216-7224(1998).
RN   [37]
RP   CHARACTERIZATION (ISOFORM Y), AND MUTAGENESIS OF ASP-1116.
RX   PubMed=10197628;
RA   Baruch A., Hartmann M.-L., Yoeli M., Adereth Y., Greenstein S.,
RA   Stadler Y., Skornik Y., Zaretsky J., Smorodinsky N.I., Keydar I.,
RA   Wreschner D.H.;
RT   "The breast cancer-associated MUC1 gene generates both a receptor and
RT   its cognate binding protein.";
RL   Cancer Res. 59:1552-1561(1999).
RN   [38]
RP   INTERACTION WITH ICAM1.
RX   PubMed=11173916; DOI=10.1159/000051917;
RA   Hayashi T., Takahashi T., Motoya S., Ishida T., Itoh F., Adachi M.,
RA   Hinoda Y., Imai K.;
RT   "MUC1 mucin core protein binds to the domain 1 of ICAM-1.";
RL   Digestion 63 Suppl. 1:87-92(2001).
RN   [39]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11118479; DOI=10.1177/002215540104900107;
RA   Bennett R. Jr., Jaervelae T., Engelhardt P., Kostamovaara L.,
RA   Sparks P., Carpen O., Turunen O., Vaheri A.;
RT   "Mucin MUC1 is seen in cell surface protrusions together with ezrin in
RT   immunoelectron tomography and is concentrated at tips of filopodial
RT   protrusions in MCF-7 breast carcinoma cells.";
RL   J. Histochem. Cytochem. 49:67-77(2001).
RN   [40]
RP   INTERACTION WITH SRC; GSK3B AND CTNNB1, PHOSPHORYLATION AT TYR-1229,
RP   AND MUTAGENESIS OF TYR-1229.
RX   PubMed=11152665; DOI=10.1074/jbc.C000754200;
RA   Li Y., Kuwahara H., Ren J., Wen G., Kufe D.;
RT   "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1
RT   carcinoma-associated antigen with GSK3 beta and beta-catenin.";
RL   J. Biol. Chem. 276:6061-6064(2001).
RN   [41]
RP   POLYMORPHISM WITHIN THE REPEAT.
RX   PubMed=11350974; DOI=10.1074/jbc.M103187200;
RA   Engelmann K., Baldus S.E., Hanisch F.-G.;
RT   "Identification and topology of variant sequences within individual
RT   repeat domains of the human epithelial tumor mucin MUC1.";
RL   J. Biol. Chem. 276:27764-27769(2001).
RN   [42]
RP   INTERACTION WITH EGFR, PHOSPHORYLATION AT TYR-1229 BY EGFR, AND
RP   MUTAGENESIS OF TYR-1191; TYR-1203; TYR-1209; TYR-1218 AND TYR-1229.
RX   PubMed=11483589; DOI=10.1074/jbc.C100359200;
RA   Li Y., Ren J., Yu W., Li Q., Kuwahara H., Yin L., Carraway K.L. III,
RA   Kufe D.;
RT   "The epidermal growth factor receptor regulates interaction of the
RT   human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.";
RL   J. Biol. Chem. 276:35239-35242(2001).
RN   [43]
RP   PHOSPHORYLATION AT THR-1224, INTERACTION WITH PRKCD, FUNCTION, AND
RP   MUTAGENESIS OF SER-1223; THR-1224 AND SER-1227.
RX   PubMed=11877440; DOI=10.1074/jbc.M200436200;
RA   Ren J., Li Y., Kufe D.;
RT   "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma
RT   antigen in beta-catenin signaling.";
RL   J. Biol. Chem. 277:17616-17622(2002).
RN   [44]
RP   PHOSPHORYLATION AT TYR-1203; TYR-1212; TYR-1229 AND TYR-1243.
RX   PubMed=14521915; DOI=10.1016/j.bbrc.2003.09.030;
RA   Wang H., Lillehoj E.P., Kim K.C.;
RT   "Identification of four sites of stimulated tyrosine phosphorylation
RT   in the MUC1 cytoplasmic tail.";
RL   Biochem. Biophys. Res. Commun. 310:341-346(2003).
RN   [45]
RP   INTERACTION WITH LYN, AND PHOSPHORYLATION.
RX   PubMed=12750561;
RA   Li Y., Chen W., Ren J., Yu W.H., Li Q., Yoshida K., Kufe D.;
RT   "DF3/MUC1 signaling in multiple myeloma cells is regulated by
RT   interleukin-7.";
RL   Cancer Biol. Ther. 2:187-193(2003).
RN   [46]
RP   INTERACTION WITH CTNNB1, FUNCTION, AND MUTAGENESIS OF TYR-1229.
RX   PubMed=14688481;
RA   Huang L., Ren J., Chen D., Li Y., Kharbanda S., Kufe D.;
RT   "MUC1 cytoplasmic domain coactivates Wnt target gene transcription and
RT   confers transformation.";
RL   Cancer Biol. Ther. 2:702-706(2003).
RN   [47]
RP   INTERACTION WITH ADAM17, AND CLEAVAGE.
RX   PubMed=12441351; DOI=10.1074/jbc.M208326200;
RA   Thathiah A., Blobel C.P., Carson D.D.;
RT   "Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1
RT   shedding.";
RL   J. Biol. Chem. 278:3386-3394(2003).
RN   [48]
RP   INTERACTION WITH CTNNB1, AND SUBCELLULAR LOCATION.
RX   PubMed=12832415; DOI=10.1074/jbc.M304333200;
RA   Wen Y., Caffrey T.C., Wheelock M.J., Johnson K.R., Hollingsworth M.A.;
RT   "Nuclear association of the cytoplasmic tail of MUC1 and beta-
RT   catenin.";
RL   J. Biol. Chem. 278:38029-38039(2003).
RN   [49]
RP   INTERACTION WITH ERBB2; ERBB3 AND ERBB4, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF 1187-ARG--LYS-1189.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M.,
RA   Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism
RT   dependent on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [50]
RP   INTERACTION WITH AP1S2 AND GRB2, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF TYR-1191; TYR-1203; TYR-1229 AND TYR-1243.
RX   PubMed=15471854; DOI=10.1074/jbc.M409360200;
RA   Kinlough C.L., Poland P.A., Bruns J.B., Harkleroad K.L., Hughey R.P.;
RT   "MUC1 membrane trafficking is modulated by multiple interactions.";
RL   J. Biol. Chem. 279:53071-53077(2004).
RN   [51]
RP   INTERACTION WITH TP53, AND FUNCTION.
RX   PubMed=15710329; DOI=10.1016/j.ccr.2005.01.008;
RA   Wei X., Xu H., Kufe D.;
RT   "Human MUC1 oncoprotein regulates p53-responsive gene transcription in
RT   the genotoxic stress response.";
RL   Cancer Cell 7:167-178(2005).
RN   [52]
RP   INTERACTION WITH GSK3B, PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=16288032; DOI=10.1158/0008-5472.CAN-05-2474;
RA   Huang L., Chen D., Liu D., Yin L., Kharbanda S., Kufe D.;
RT   "MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated
RT   phosphorylation and degradation of beta-catenin.";
RL   Cancer Res. 65:10413-10422(2005).
RN   [53]
RP   ERRATUM.
RA   Kinlough C.L., Poland P.A., Bruns J.B., Harkleroad K.L., Hughey R.P.;
RL   J. Biol. Chem. 280:28827-28827(2005).
RN   [54]
RP   STRUCTURE OF CARBOHYDRATES, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15972891; DOI=10.1093/glycob/cwi099;
RA   Engelmann K., Kinlough C.L., Muller S., Razawi H., Baldus S.E.,
RA   Hughey R.P., Hanisch F.-G.;
RT   "Transmembrane and secreted MUC1 probes show trafficking-dependent
RT   changes in O-glycan core profiles.";
RL   Glycobiology 15:1111-1124(2005).
RN   [55]
RP   INTERACTION WITH LCK, PHOSPHORYLATION, FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=15513966; DOI=10.1189/jlb.0604333;
RA   Mukherjee P., Tinder T.L., Basu G.D., Gendler S.J.;
RT   "MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma
RT   cells and normal T cells.";
RL   J. Leukoc. Biol. 77:90-99(2005).
RN   [56]
RP   PALMITOYLATION AT CYS-1184 AND CYS-1186, SUBCELLULAR LOCATION,
RP   INTERACTION WITH AP1S1 AND AP1S2, AND MUTAGENESIS OF CYS-1184;
RP   CYS-1186; TYR-1203 AND 1187-ARG--LYS-1189.
RX   PubMed=16507569; DOI=10.1074/jbc.M512996200;
RA   Kinlough C.L., McMahan R.J., Poland P.A., Bruns J.B., Harkleroad K.L.,
RA   Stremple R.J., Kashlan O.B., Weixel K.M., Weisz O.A., Hughey R.P.;
RT   "Recycling of MUC1 is dependent on its palmitoylation.";
RL   J. Biol. Chem. 281:12112-12122(2006).
RN   [57]
RP   INTERACTION WITH ESR1.
RX   PubMed=16427018; DOI=10.1016/j.molcel.2005.11.030;
RA   Wei X., Xu H., Kufe D.;
RT   "MUC1 oncoprotein stabilizes and activates estrogen receptor alpha.";
RL   Mol. Cell 21:295-305(2006).
RN   [58]
RP   INTERACTION WITH CTNNB1, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=17524503; DOI=10.1016/j.bbamcr.2007.04.009;
RA   Lillehoj E.P., Lu W., Kiser T., Goldblum S.E., Kim K.C.;
RT   "MUC1 inhibits cell proliferation by a beta-catenin-dependent
RT   mechanism.";
RL   Biochim. Biophys. Acta 1773:1028-1038(2007).
RN   [59]
RP   INTERACTION WITH KLF4, AND FUNCTION.
RX   PubMed=17308127; DOI=10.1158/0008-5472.CAN-06-3063;
RA   Wei X., Xu H., Kufe D.;
RT   "Human mucin 1 oncoprotein represses transcription of the p53 tumor
RT   suppressor gene.";
RL   Cancer Res. 67:1853-1858(2007).
RN   [60]
RP   PHOSPHORYLATION AT TYR-1203; TYR-1218 AND TYR-1229, MUTAGENESIS OF
RP   TYR-1203 AND TYR-1218, SUBCELLULAR LOCATION, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=17545600; DOI=10.1158/0008-5472.CAN-06-4647;
RA   Singh P.K., Wen Y., Swanson B.J., Shanmugam K., Kazlauskas A.,
RA   Cerny R.L., Gendler S.J., Hollingsworth M.A.;
RT   "Platelet-derived growth factor receptor beta-mediated phosphorylation
RT   of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells.";
RL   Cancer Res. 67:5201-5210(2007).
RN   [61]
RP   INTERACTION WITH EGFR, AND FUNCTION.
RX   PubMed=16983337; DOI=10.1038/sj.onc.1209976;
RA   Pochampalli M.R., el Bejjani R.M., Schroeder J.A.;
RT   "MUC1 is a novel regulator of ErbB1 receptor trafficking.";
RL   Oncogene 26:1693-1701(2007).
RN   [62]
RP   MARKER IN BREAST CANCER.
RX   PubMed=20816948; DOI=10.1016/j.cca.2010.08.039;
RA   Duffy M.J., Evoy D., McDermott E.W.;
RT   "CA 15-3: uses and limitation as a biomarker for breast cancer.";
RL   Clin. Chim. Acta 411:1869-1874(2010).
RN   [63]
RP   INVOLVEMENT IN MCKD1.
RX   PubMed=23396133; DOI=10.1038/ng.2543;
RA   Kirby A., Gnirke A., Jaffe D.B., Baresova V., Pochet N.,
RA   Blumenstiel B., Ye C., Aird D., Stevens C., Robinson J.T.,
RA   Cabili M.N., Gat-Viks I., Kelliher E., Daza R., DeFelice M.,
RA   Hulkova H., Sovova J., Vylet'al P., Antignac C., Guttman M.,
RA   Handsaker R.E., Perrin D., Steelman S., Sigurdsson S., Scheinman S.J.,
RA   Sougnez C., Cibulskis K., Parkin M., Green T., Rossin E., Zody M.C.,
RA   Xavier R.J., Pollak M.R., Alper S.L., Lindblad-Toh K., Gabriel S.,
RA   Hart P.S., Regev A., Nusbaum C., Kmoch S., Bleyer A.J., Lander E.S.,
RA   Daly M.J.;
RT   "Mutations causing medullary cystic kidney disease type 1 lie in a
RT   large VNTR in MUC1 missed by massively parallel sequencing.";
RL   Nat. Genet. 45:299-303(2013).
RN   [64]
RP   STRUCTURE BY NMR OF 1041-1097 AND 1098-1152 OF WILD TYPE AND MUTANT
RP   ALA-1098, IDENTIFICATION BY MASS SPECTROMETRY, STRUCTURE OF
RP   CARBOHYDRATES, AND AUTOCATALYTIC CLEAVAGE.
RX   PubMed=16585136; DOI=10.1093/glycob/cwj110;
RA   Parry S., Hanisch F.G., Leir S.H., Sutton-Smith M., Morris H.R.,
RA   Dell A., Harris A.;
RT   "N-glycosylation of the MUC1 mucin in epithelial cells and
RT   secretions.";
RL   Glycobiology 16:623-634(2006).
CC   -!- FUNCTION: The alpha subunit has cell adhesive properties. Can act
CC       both as an adhesion and an anti-adhesion protein. May provide a
CC       protective layer on epithelial cells against bacterial and enzyme
CC       attack.
CC   -!- FUNCTION: The beta subunit contains a C-terminal domain which is
CC       involved in cell signaling, through phosphorylations and protein-
CC       protein interactions. Modulates signaling in ERK, SRC and NF-
CC       kappa-B pathways. In activated T-cells, influences directly or
CC       indirectly the Ras/MAPK pathway. Promotes tumor progression.
CC       Regulates TP53-mediated transcription and determines cell fate in
CC       the genotoxic stress response. Binds, together with KLF4, the PE21
CC       promoter element of TP53 and represses TP53 activity.
CC   -!- SUBUNIT: The alpha subunit forms a tight, non-covalent
CC       heterodimeric complex with the proteolytically-released beta-
CC       subunit. Interaction, via the tandem repeat region, with domain 1
CC       of ICAM1 is implicated in cell migration and metastases. Isoform 1
CC       binds directly the SH2 domain of GRB2, and forms a MUC1/GRB2/SOS1
CC       complex involved in RAS signaling. The cytoplasmic tail (MUC1CT)
CC       interacts with several proteins such as SRC, CTNNB1 and ERBs.
CC       Interaction with the SH2 domain of CSK decreases interaction with
CC       GSK3B. Interacts with CTNNB1/beta-catenin and JUP/gamma-catenin
CC       and promotes cell adhesion. Interaction with JUP/gamma-catenin is
CC       induced by heregulin. Binds PRKCD, ERBB2, ERBB3 and ERBB4.
CC       Heregulin (HRG) stimulates the interaction with ERBB2 and, to a
CC       much lesser extent, the interaction with ERBB3 and ERBB4.
CC       Interacts with P53 in response to DNA damage. Interacts with KLF4.
CC       Interacts with estrogen receptor alpha/ESR1, through its DNA-
CC       binding domain, and stimulates its transcription activity. Binds
CC       ADAM17. Isoform ZD forms disulfide-linked oligomers.
CC       {ECO:0000269|PubMed:11152665, ECO:0000269|PubMed:11173916,
CC       ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11877440,
CC       ECO:0000269|PubMed:12441351, ECO:0000269|PubMed:12750561,
CC       ECO:0000269|PubMed:12832415, ECO:0000269|PubMed:12939402,
CC       ECO:0000269|PubMed:14688481, ECO:0000269|PubMed:15471854,
CC       ECO:0000269|PubMed:15513966, ECO:0000269|PubMed:15710329,
CC       ECO:0000269|PubMed:16288032, ECO:0000269|PubMed:16427018,
CC       ECO:0000269|PubMed:16507569, ECO:0000269|PubMed:16983337,
CC       ECO:0000269|PubMed:17308127, ECO:0000269|PubMed:17524503,
CC       ECO:0000269|PubMed:7664271, ECO:0000269|PubMed:9139698,
CC       ECO:0000269|PubMed:9819408}.
CC   -!- INTERACTION:
CC       P00519:ABL1; NbExp=8; IntAct=EBI-2804728, EBI-375543;
CC       P17676:CEBPB; NbExp=8; IntAct=EBI-10053698, EBI-969696;
CC       P00533:EGFR; NbExp=3; IntAct=EBI-2804728, EBI-297353;
CC       P08581:MET; NbExp=2; IntAct=EBI-2804728, EBI-1039152;
CC       P15941-7:MUC1; NbExp=2; IntAct=EBI-2804728, EBI-4396776;
CC       P26368:U2AF2; NbExp=2; IntAct=EBI-2804728, EBI-742339;
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000269|PubMed:11118479, ECO:0000269|PubMed:12832415,
CC       ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15471854,
CC       ECO:0000269|PubMed:15972891, ECO:0000269|PubMed:16507569,
CC       ECO:0000269|PubMed:17524503, ECO:0000269|PubMed:17545600}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:11118479,
CC       ECO:0000269|PubMed:12832415, ECO:0000269|PubMed:12939402,
CC       ECO:0000269|PubMed:15471854, ECO:0000269|PubMed:15972891,
CC       ECO:0000269|PubMed:16507569, ECO:0000269|PubMed:17524503,
CC       ECO:0000269|PubMed:17545600}. Note=Exclusively located in the
CC       apical domain of the plasma membrane of highly polarized
CC       epithelial cells. After endocytosis, internalized and recycled to
CC       the cell membrane. Located to microvilli and to the tips of long
CC       filopodial protusions.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform Y: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 9: Secreted.
CC   -!- SUBCELLULAR LOCATION: Mucin-1 subunit beta: Cell membrane.
CC       Cytoplasm. Nucleus. Note=On EGF and PDGFRB stimulation,
CC       transported to the nucleus through interaction with CTNNB1, a
CC       process which is stimulated by phosphorylation. On HRG
CC       stimulation, colocalizes with JUP/gamma-catenin at the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=17;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=A;
CC         IsoId=P15941-1; Sequence=Displayed;
CC       Name=2; Synonyms=B;
CC         IsoId=P15941-2; Sequence=VSP_003280;
CC       Name=3; Synonyms=C;
CC         IsoId=P15941-3; Sequence=VSP_003281;
CC       Name=4; Synonyms=D;
CC         IsoId=P15941-4; Sequence=VSP_003282;
CC       Name=5; Synonyms=SEC;
CC         IsoId=P15941-5; Sequence=VSP_003288, VSP_003289;
CC       Name=6; Synonyms=X;
CC         IsoId=P15941-6; Sequence=VSP_003283, VSP_003284;
CC       Name=Y; Synonyms=MUC1/Y;
CC         IsoId=P15941-7; Sequence=VSP_003285;
CC       Name=8; Synonyms=Z;
CC         IsoId=P15941-8; Sequence=VSP_003286;
CC       Name=9; Synonyms=S;
CC         IsoId=P15941-9; Sequence=VSP_003286, VSP_003287;
CC       Name=F;
CC         IsoId=P15941-10; Sequence=VSP_035046, VSP_035047;
CC       Name=Y-LSP;
CC         IsoId=P15941-11; Sequence=VSP_003280, VSP_003285;
CC         Note=Lacks the mucin repeats.;
CC       Name=S2;
CC         IsoId=P15941-12; Sequence=VSP_003280, VSP_003285, VSP_003287;
CC       Name=M6;
CC         IsoId=P15941-13; Sequence=VSP_003286, VSP_046962, VSP_046963;
CC       Name=ZD; Synonyms=J19;
CC         IsoId=P15941-14; Sequence=VSP_047575, VSP_047576;
CC         Note=Lacks the mucin repeats. Exists as a disulfide-linked
CC         oligomer.;
CC       Name=T10;
CC         IsoId=P15941-15; Sequence=VSP_003280, VSP_047873;
CC       Name=E2;
CC         IsoId=P15941-16; Sequence=VSP_003280, VSP_047872;
CC       Name=J13;
CC         IsoId=P15941-17; Sequence=VSP_003280, VSP_003285, VSP_047874;
CC   -!- TISSUE SPECIFICITY: Expressed on the apical surface of epithelial
CC       cells, especially of airway passages, breast and uterus. Also
CC       expressed in activated and unactivated T-cells. Overexpressed in
CC       epithelial tumors, such as breast or ovarian cancer and also in
CC       non-epithelial tumor cells. Isoform 7 is expressed in tumor cells
CC       only. {ECO:0000269|PubMed:15513966, ECO:0000269|PubMed:9212228}.
CC   -!- DEVELOPMENTAL STAGE: During fetal development, expressed at low
CC       levels in the colonic epithelium from 13 weeks of gestation.
CC       {ECO:0000269|PubMed:9536947}.
CC   -!- PTM: Highly glycosylated (N- and O-linked carbohydrates and sialic
CC       acid). O-glycosylated to a varying degree on serine and threonine
CC       residues within each tandem repeat, ranging from mono- to penta-
CC       glycosylation. The average density ranges from about 50% in human
CC       milk to over 90% in T47D breast cancer cells. Further sialylation
CC       occurs during recycling. Membrane-shed glycoproteins from kidney
CC       and breast cancer cells have preferentially sialyated core 1
CC       structures, while secreted forms from the same tissues display
CC       mainly core 2 structures. The O-glycosylated content is
CC       overlapping in both these tissues with terminal fucose and
CC       galactose, 2- and 3-linked galactose, 3- and 3,6-linked GalNAc-ol
CC       and 4-linked GlcNAc predominating. Differentially O-glycosylated
CC       in breast carcinomas with 3,4-linked GlcNAc. N-glycosylation
CC       consists of high-mannose, acidic complex-type and hybrid glycans
CC       in the secreted form MUC1/SEC, and neutral complex-type in the
CC       transmembrane form, MUC1/TM. {ECO:0000269|PubMed:10373415,
CC       ECO:0000269|PubMed:7744025, ECO:0000269|PubMed:9312074,
CC       ECO:0000269|PubMed:9597769}.
CC   -!- PTM: Proteolytic cleavage in the SEA domain occurs in the
CC       endoplasmic reticulum by an autoproteolytic mechanism and requires
CC       the full-length SEA domain as well as requiring a Ser, Thr or Cys
CC       residue at the P + 1 site. Cleavage at this site also occurs on
CC       isoform MUC1/X but not on isoform MUC1/Y. Ectodomain shedding is
CC       mediated by ADAM17. {ECO:0000269|PubMed:11341784,
CC       ECO:0000269|PubMed:12441351, ECO:0000269|PubMed:15987679}.
CC   -!- PTM: Dual palmitoylation on cysteine residues in the CQC motif is
CC       required for recycling from endosomes back to the plasma membrane.
CC       {ECO:0000269|PubMed:16507569}.
CC   -!- PTM: Phosphorylated on tyrosines and serine residues in the C-
CC       terminal. Phosphorylation on tyrosines in the C-terminal increases
CC       the nuclear location of MUC1 and beta-catenin. Phosphorylation by
CC       PKC delta induces binding of MUC1 to beta-catenin/CTNNB1 and thus
CC       decreases the formation of the beta-catenin/E-cadherin complex.
CC       Src-mediated phosphorylation inhibits interaction with GSK3B. Src-
CC       and EGFR-mediated phosphorylation on Tyr-1229 increases binding to
CC       beta-catenin/CTNNB1. GSK3B-mediated phosphorylation on Ser-1227
CC       decreases this interaction but restores the formation of the beta-
CC       cadherin/E-cadherin complex. On T-cell receptor activation,
CC       phosphorylated by LCK. PDGFR-mediated phosphorylation increases
CC       nuclear colocalization of MUC1CT and CTNNB1.
CC       {ECO:0000269|PubMed:11152665, ECO:0000269|PubMed:11483589,
CC       ECO:0000269|PubMed:11877440, ECO:0000269|PubMed:12750561,
CC       ECO:0000269|PubMed:14521915, ECO:0000269|PubMed:15513966,
CC       ECO:0000269|PubMed:16288032, ECO:0000269|PubMed:17545600,
CC       ECO:0000269|PubMed:7664271, ECO:0000269|PubMed:7988707,
CC       ECO:0000269|PubMed:9819408}.
CC   -!- PTM: The N-terminal sequence has been shown to begin at position
CC       24 or 28. {ECO:0000269|PubMed:11341784}.
CC   -!- POLYMORPHISM: The number of repeats is highly polymorphic. It
CC       varies from 21 to 125 in the northern European population. The
CC       most frequent alleles contains 41 and 85 repeats. The tandemly
CC       repeated icosapeptide underlies polymorphism at three positions:
CC       PAPGSTAP[PAQT]AHGVTSAP[DT/ES]R, DT -> ES and the single
CC       replacements P -> A, P -> Q and P-> T. The most frequent
CC       replacement DT -> ES occurs in up to 50% of the repeats.
CC   -!- DISEASE: Note=MUC1/CA 15-3 is used as a serological clinical
CC       marker of breast cancer to monitor response to breast cancer
CC       treatment and disease recurrence (PubMed:20816948). Decreased
CC       levels over time may be indicative of a positive response to
CC       treatment. Conversely, increased levels may indicate disease
CC       progression. At an early stage disease, only 21% of patients
CC       exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a
CC       useful screening test. Most antibodies target the highly
CC       immunodominant core peptide domain of 20 amino acid
CC       (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize
CC       glycosylated epitopes. {ECO:0000269|PubMed:20816948}.
CC   -!- DISEASE: Medullary cystic kidney disease 1 (MCKD1) [MIM:174000]: A
CC       form of tubulointerstitial nephropathy characterized by formation
CC       of renal cysts at the corticomedullary junction. It is
CC       characterized by adult onset of impaired renal function and salt
CC       wasting resulting in end-stage renal failure by the sixth decade.
CC       {ECO:0000269|PubMed:23396133}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The name KL-6 was originally that of a murine
CC       monoclonal antibody reacting with pulmonary adenocarcinoma cell
CC       lines and pulmonary epithelial cells. This antibody recognizes a
CC       sialylated carbohydrate chain on MUC1.
CC   -!- SIMILARITY: Contains 1 SEA domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00188}.
CC   -!- CAUTION: O-glycosylation sites are annotated in first sequence
CC       repeat only. Residues at similar position are probably
CC       glycosylated in all repeats. Experimental sites were determined in
CC       a synthetic peptide glycosylated in vitro (PubMed:7744025,
CC       PubMed:9597769). {ECO:0000305|PubMed:7744025,
CC       ECO:0000305|PubMed:9597769}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD14369.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAD14376.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Mucin database;
CC       URL="http://www.medkem.gu.se/mucinbiology/databases/";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/muc1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05582; AAA60019.1; -; mRNA.
DR   EMBL; M32738; AAA35804.1; -; mRNA.
DR   EMBL; M32739; AAA35806.1; -; mRNA.
DR   EMBL; M34089; AAA35807.1; -; mRNA.
DR   EMBL; M34088; AAA35805.1; -; mRNA.
DR   EMBL; J05581; AAA59876.1; -; mRNA.
DR   EMBL; M61170; AAB53150.1; -; Genomic_DNA.
DR   EMBL; X52229; CAA36478.1; ALT_SEQ; mRNA.
DR   EMBL; X52228; CAA36477.1; ALT_SEQ; mRNA.
DR   EMBL; M35093; AAB59612.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X80761; CAA56734.1; -; mRNA.
DR   EMBL; U60259; AAD10856.1; -; mRNA.
DR   EMBL; U60260; AAD10857.1; -; mRNA.
DR   EMBL; U60261; AAD10858.1; -; mRNA.
DR   EMBL; AF125525; AAD27842.1; -; mRNA.
DR   EMBL; AY466157; AAR28764.1; -; mRNA.
DR   EMBL; AY327582; AAP97013.1; -; mRNA.
DR   EMBL; AY327584; AAP97015.1; -; mRNA.
DR   EMBL; AY327586; AAP97017.1; -; mRNA.
DR   EMBL; AY327587; AAP97018.1; -; mRNA.
DR   EMBL; EF583653; ABQ59628.1; -; mRNA.
DR   EMBL; EF670711; ABS01298.1; -; mRNA.
DR   EMBL; EF670712; ABS01299.1; -; mRNA.
DR   EMBL; FJ226040; ACI25172.1; -; mRNA.
DR   EMBL; FJ226047; ACI25179.1; -; mRNA.
DR   EMBL; AF348143; AAK30142.1; -; mRNA.
DR   EMBL; AY463543; AAR18816.1; -; Genomic_DNA.
DR   EMBL; AL713999; CAI95071.1; -; Genomic_DNA.
DR   EMBL; AL713999; CAI95073.1; -; Genomic_DNA.
DR   EMBL; AL713999; CAI95074.1; -; Genomic_DNA.
DR   EMBL; AL713999; CAI95080.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53116.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53117.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53118.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53119.1; -; Genomic_DNA.
DR   EMBL; BC120974; AAI20975.1; -; mRNA.
DR   EMBL; BC120975; AAI20976.1; -; mRNA.
DR   EMBL; Z17324; CAA78972.1; -; mRNA.
DR   EMBL; Z17325; CAA78973.1; -; mRNA.
DR   EMBL; M31823; AAA35757.1; -; mRNA.
DR   EMBL; S81781; AAD14376.1; ALT_INIT; mRNA.
DR   EMBL; S81736; AAD14369.1; ALT_INIT; mRNA.
DR   EMBL; M21868; AAA59874.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS1098.1; -. [P15941-8]
DR   CCDS; CCDS30882.1; -. [P15941-11]
DR   CCDS; CCDS30883.1; -. [P15941-7]
DR   CCDS; CCDS41408.1; -. [P15941-12]
DR   CCDS; CCDS41409.1; -. [P15941-10]
DR   CCDS; CCDS55641.1; -. [P15941-6]
DR   CCDS; CCDS55642.1; -. [P15941-13]
DR   PIR; A35175; A35175.
DR   RefSeq; NP_001018016.1; NM_001018016.2. [P15941-11]
DR   RefSeq; NP_001018017.1; NM_001018017.2. [P15941-7]
DR   RefSeq; NP_001037855.1; NM_001044390.2. [P15941-10]
DR   RefSeq; NP_001037856.1; NM_001044391.2.
DR   RefSeq; NP_001037857.1; NM_001044392.2. [P15941-12]
DR   RefSeq; NP_001037858.1; NM_001044393.2.
DR   RefSeq; NP_001191214.1; NM_001204285.1.
DR   RefSeq; NP_001191215.1; NM_001204286.1.
DR   RefSeq; NP_001191216.1; NM_001204287.1.
DR   RefSeq; NP_001191217.1; NM_001204288.1.
DR   RefSeq; NP_001191218.1; NM_001204289.1.
DR   RefSeq; NP_001191219.1; NM_001204290.1.
DR   RefSeq; NP_001191220.1; NM_001204291.1.
DR   RefSeq; NP_001191221.1; NM_001204292.1.
DR   RefSeq; NP_001191222.1; NM_001204293.1. [P15941-13]
DR   RefSeq; NP_001191223.1; NM_001204294.1. [P15941-6]
DR   RefSeq; NP_001191224.1; NM_001204295.1.
DR   RefSeq; NP_001191225.1; NM_001204296.1.
DR   RefSeq; NP_001191226.1; NM_001204297.1.
DR   RefSeq; NP_002447.4; NM_002456.5. [P15941-8]
DR   UniGene; Hs.89603; -.
DR   PDB; 1SM3; X-ray; 1.95 A; P=919-931.
DR   PDB; 2ACM; NMR; -; A=1042-1097, B=1098-1152.
DR   PDB; 2FO4; X-ray; 2.70 A; P=140-146.
DR   PDBsum; 1SM3; -.
DR   PDBsum; 2ACM; -.
DR   PDBsum; 2FO4; -.
DR   ProteinModelPortal; P15941; -.
DR   SMR; P15941; 1041-1144.
DR   BioGrid; 110669; 42.
DR   DIP; DIP-41890N; -.
DR   IntAct; P15941; 9.
DR   MINT; MINT-156679; -.
DR   STRING; 9606.ENSP00000357380; -.
DR   MEROPS; S71.001; -.
DR   iPTMnet; P15941; -.
DR   PhosphoSite; P15941; -.
DR   SwissPalm; P15941; -.
DR   UniCarbKB; P15941; -.
DR   BioMuta; MUC1; -.
DR   DMDM; 296439295; -.
DR   MaxQB; P15941; -.
DR   PaxDb; P15941; -.
DR   PRIDE; P15941; -.
DR   DNASU; 4582; -.
DR   Ensembl; ENST00000337604; ENSP00000338983; ENSG00000185499. [P15941-8]
DR   Ensembl; ENST00000342482; ENSP00000342814; ENSG00000185499. [P15941-16]
DR   Ensembl; ENST00000343256; ENSP00000339690; ENSG00000185499. [P15941-10]
DR   Ensembl; ENST00000368389; ENSP00000357374; ENSG00000185499. [P15941-9]
DR   Ensembl; ENST00000368390; ENSP00000357375; ENSG00000185499. [P15941-7]
DR   Ensembl; ENST00000368392; ENSP00000357377; ENSG00000185499. [P15941-11]
DR   Ensembl; ENST00000368393; ENSP00000357378; ENSG00000185499. [P15941-13]
DR   Ensembl; ENST00000368396; ENSP00000357381; ENSG00000185499. [P15941-12]
DR   Ensembl; ENST00000368398; ENSP00000357383; ENSG00000185499. [P15941-6]
DR   GeneID; 4582; -.
DR   KEGG; hsa:4582; -.
DR   UCSC; uc001fia.3; human. [P15941-7]
DR   UCSC; uc001fib.3; human. [P15941-10]
DR   UCSC; uc001fid.3; human.
DR   UCSC; uc001fie.3; human. [P15941-9]
DR   UCSC; uc001fig.3; human.
DR   UCSC; uc001fij.3; human.
DR   UCSC; uc001fik.3; human. [P15941-8]
DR   UCSC; uc001fin.3; human.
DR   UCSC; uc009wpm.3; human.
DR   CTD; 4582; -.
DR   GeneCards; MUC1; -.
DR   GeneReviews; MUC1; -.
DR   HGNC; HGNC:7508; MUC1.
DR   HPA; CAB000036; -.
DR   HPA; CAB001986; -.
DR   HPA; HPA004179; -.
DR   HPA; HPA007235; -.
DR   HPA; HPA008855; -.
DR   MalaCards; MUC1; -.
DR   MIM; 113720; gene.
DR   MIM; 158340; gene.
DR   MIM; 174000; phenotype.
DR   neXtProt; NX_P15941; -.
DR   Orphanet; 34149; Autosomal dominant medullary cystic kidney disease with or without hyperuricemia.
DR   PharmGKB; PA31309; -.
DR   eggNOG; ENOG410IX6R; Eukaryota.
DR   eggNOG; ENOG410ZQ7Z; LUCA.
DR   GeneTree; ENSGT00710000106874; -.
DR   HOGENOM; HOG000290201; -.
DR   HOVERGEN; HBG003075; -.
DR   InParanoid; P15941; -.
DR   KO; K06568; -.
DR   PhylomeDB; P15941; -.
DR   Reactome; R-HSA-913709; O-linked glycosylation of mucins.
DR   Reactome; R-HSA-977068; Termination of O-glycan biosynthesis.
DR   ChiTaRS; MUC1; human.
DR   EvolutionaryTrace; P15941; -.
DR   GeneWiki; MUC1; -.
DR   GenomeRNAi; 4582; -.
DR   NextBio; 13635564; -.
DR   PRO; PR:P15941; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P15941; -.
DR   ExpressionAtlas; P15941; baseline and differential.
DR   Genevisible; P15941; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0003712; F:transcription cofactor activity; IDA:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IDA:BHF-UCL.
DR   GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IDA:CACAO.
DR   GO; GO:1902166; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0010944; P:negative regulation of transcription by competitive promoter binding; IDA:BHF-UCL.
DR   GO; GO:0016266; P:O-glycan processing; TAS:Reactome.
DR   GO; GO:0090240; P:positive regulation of histone H4 acetylation; IDA:BHF-UCL.
DR   GO; GO:0036003; P:positive regulation of transcription from RNA polymerase II promoter in response to stress; IDA:BHF-UCL.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0006493; P:protein O-linked glycosylation; TAS:Reactome.
DR   GO; GO:0043618; P:regulation of transcription from RNA polymerase II promoter in response to stress; IDA:BHF-UCL.
DR   Gene3D; 3.30.70.960; -; 1.
DR   InterPro; IPR023217; Mucin-1.
DR   InterPro; IPR000082; SEA_dom.
DR   PANTHER; PTHR10006:SF8; PTHR10006:SF8; 1.
DR   Pfam; PF01390; SEA; 1.
DR   SMART; SM00200; SEA; 1.
DR   SUPFAM; SSF82671; SSF82671; 1.
DR   PROSITE; PS50024; SEA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autocatalytic cleavage;
KW   Cell membrane; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Lipoprotein;
KW   Membrane; Nucleus; Palmitate; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Secreted; Signal; Transmembrane;
KW   Transmembrane helix; Tumor suppressor.
FT   SIGNAL        1     23       {ECO:0000269|PubMed:10373415,
FT                                ECO:0000269|PubMed:11341784}.
FT   CHAIN        24   1255       Mucin-1.
FT                                /FTId=PRO_0000019277.
FT   CHAIN        24   1097       Mucin-1 subunit alpha.
FT                                /FTId=PRO_0000317446.
FT   CHAIN      1098   1255       Mucin-1 subunit beta.
FT                                /FTId=PRO_0000317447.
FT   TOPO_DOM     24   1158       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1159   1181       Helical. {ECO:0000255}.
FT   TOPO_DOM   1182   1255       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       61     80       1; approximate.
FT                                {ECO:0000269|PubMed:11350974}.
FT   REPEAT       81    100       2; approximate.
FT                                {ECO:0000269|PubMed:11350974}.
FT   REPEAT      101    120       3. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      121    140       4. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      141    160       5. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      161    180       6. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      181    200       7. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      201    220       8. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      221    240       9. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      241    260       10. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      261    280       11. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      281    300       12. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      301    320       13. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      321    340       14. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      341    360       15. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      361    380       16. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      381    400       17. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      401    420       18. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      421    440       19. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      441    460       20. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      461    480       21. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      481    500       22. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      501    520       23. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      521    540       24. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      541    560       25. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      561    580       26. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      581    600       27. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      601    620       28. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      621    640       29. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      641    660       30. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      661    680       31. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      681    700       32. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      701    720       33. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      721    740       34. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      741    760       35. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      761    780       36. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      781    800       37. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      801    820       38. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      821    840       39. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      841    860       40. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      861    880       41. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      881    900       42. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      901    920       43. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      921    940       44. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      941    960       45. {ECO:0000269|PubMed:11350974}.
FT   REPEAT      961    980       46; approximate.
FT                                {ECO:0000269|PubMed:11350974}.
FT   REPEAT      981   1000       47; approximate.
FT                                {ECO:0000269|PubMed:11350974}.
FT   REPEAT     1001   1020       48; approximate.
FT                                {ECO:0000269|PubMed:11350974}.
FT   DOMAIN     1039   1148       SEA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00188}.
FT   REGION      126    965       42 X 20 AA approximate tandem repeats of
FT                                P-A-P-G-S-T-A-P-P-A-H-G-V-T-S-A-P-D-T-R.
FT   REGION     1192   1228       Interaction with P53.
FT   REGION     1223   1230       Required for interaction with GSK3B.
FT   REGION     1233   1241       Required for interaction with beta- and
FT                                gamma-catenins.
FT   MOTIF      1203   1206       Interaction with GRB2.
FT   MOTIF      1229   1232       Interaction with SRC and ESR1.
FT   MOTIF      1243   1246       Required for interaction with AP1S2.
FT   SITE       1097   1098       Cleavage; by autolysis.
FT   MOD_RES    1203   1203       Phosphotyrosine; by PDGFR.
FT                                {ECO:0000269|PubMed:14521915,
FT                                ECO:0000269|PubMed:17545600}.
FT   MOD_RES    1212   1212       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:14521915}.
FT   MOD_RES    1218   1218       Phosphotyrosine; by PDGFR.
FT                                {ECO:0000269|PubMed:17545600}.
FT   MOD_RES    1224   1224       Phosphothreonine; by PKC/PRKCD.
FT                                {ECO:0000269|PubMed:11877440}.
FT   MOD_RES    1227   1227       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000269|PubMed:9819408}.
FT   MOD_RES    1229   1229       Phosphotyrosine; by CSK, EGFR and SRC.
FT                                {ECO:0000269|PubMed:11152665,
FT                                ECO:0000269|PubMed:11483589,
FT                                ECO:0000269|PubMed:14521915,
FT                                ECO:0000269|PubMed:17545600}.
FT   MOD_RES    1243   1243       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:14521915}.
FT   LIPID      1184   1184       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:16507569}.
FT   LIPID      1186   1186       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:16507569}.
FT   CARBOHYD    131    131       O-linked (GalNAc...).
FT                                {ECO:0000305|PubMed:7744025,
FT                                ECO:0000305|PubMed:9597769}.
FT   CARBOHYD    139    139       O-linked (GalNAc...).
FT                                {ECO:0000305|PubMed:7744025,
FT                                ECO:0000305|PubMed:9597769}.
FT   CARBOHYD    140    140       O-linked (GalNAc...). {ECO:0000255}.
FT   CARBOHYD    144    144       O-linked (GalNAc...). {ECO:0000255}.
FT   CARBOHYD    957    957       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    975    975       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1029   1029       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1055   1055       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1133   1133       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ      19     21       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.25}.
FT                                /FTId=VSP_003281.
FT   VAR_SEQ      19     19       T -> TATTAPKPAT (in isoform 2, isoform Y-
FT                                LSP, isoform E2, isoform J13, isoform S2
FT                                and isoform T10).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:22941036,
FT                                ECO:0000303|PubMed:2318825,
FT                                ECO:0000303|PubMed:2597151,
FT                                ECO:0000303|PubMed:8608966,
FT                                ECO:0000303|Ref.15}.
FT                                /FTId=VSP_003280.
FT   VAR_SEQ      20     31       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.25}.
FT                                /FTId=VSP_003282.
FT   VAR_SEQ      54   1151       Missing (in isoform E2).
FT                                {ECO:0000303|PubMed:22941036}.
FT                                /FTId=VSP_047872.
FT   VAR_SEQ      54   1093       Missing (in isoform T10).
FT                                {ECO:0000303|PubMed:22941036}.
FT                                /FTId=VSP_047873.
FT   VAR_SEQ      54   1053       Missing (in isoform J13, isoform Y,
FT                                isoform Y-LSP and isoform S2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:15969018,
FT                                ECO:0000303|PubMed:22941036,
FT                                ECO:0000303|PubMed:7925397,
FT                                ECO:0000303|PubMed:9212228,
FT                                ECO:0000303|Ref.15}.
FT                                /FTId=VSP_003285.
FT   VAR_SEQ      54   1035       Missing (in isoform 8, isoform 9 and
FT                                isoform M6).
FT                                {ECO:0000303|PubMed:22941036,
FT                                ECO:0000303|PubMed:9212228,
FT                                ECO:0000303|Ref.12, ECO:0000303|Ref.16}.
FT                                /FTId=VSP_003286.
FT   VAR_SEQ      54     96       VSMTSSVLSSHSPGSGSSTTQGQDVTLAPATEPASGSAATW
FT                                GQ -> IPAPTTTKSCRETFLKCFCRFINKGVFWASPILSS
FT                                GQDLWWYN (in isoform ZD).
FT                                {ECO:0000303|PubMed:15623537,
FT                                ECO:0000303|PubMed:22941036}.
FT                                /FTId=VSP_047575.
FT   VAR_SEQ      54     87       VSMTSSVLSSHSPGSGSSTTQGQDVTLAPATEPA -> IPA
FT                                PTTTKSCRETFLKCFCRFINKGVFWASPILS (in
FT                                isoform F). {ECO:0000303|Ref.14}.
FT                                /FTId=VSP_035046.
FT   VAR_SEQ      54     70       VSMTSSVLSSHSPGSGS -> IPAPTTTKSCRETFLKW
FT                                (in isoform 6).
FT                                {ECO:0000303|PubMed:22941036,
FT                                ECO:0000303|PubMed:9212228}.
FT                                /FTId=VSP_003283.
FT   VAR_SEQ      71   1095       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:22941036,
FT                                ECO:0000303|PubMed:9212228}.
FT                                /FTId=VSP_003284.
FT   VAR_SEQ      88   1139       Missing (in isoform F).
FT                                {ECO:0000303|Ref.14}.
FT                                /FTId=VSP_035047.
FT   VAR_SEQ      97   1255       Missing (in isoform ZD).
FT                                {ECO:0000303|PubMed:15623537,
FT                                ECO:0000303|PubMed:22941036}.
FT                                /FTId=VSP_047576.
FT   VAR_SEQ    1077   1181       Missing (in isoform 9 and isoform S2).
FT                                {ECO:0000303|PubMed:22941036,
FT                                ECO:0000303|Ref.12, ECO:0000303|Ref.15}.
FT                                /FTId=VSP_003287.
FT   VAR_SEQ    1077   1087       FLQIYKQGGFL -> VSIGLSFPMLP (in isoform
FT                                5). {ECO:0000303|PubMed:2351132}.
FT                                /FTId=VSP_003288.
FT   VAR_SEQ    1088   1255       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:2351132}.
FT                                /FTId=VSP_003289.
FT   VAR_SEQ    1141   1180       VSDVPFPFSAQSGAGVPGWGIALLVLVCVLVALAIVYLIA
FT                                -> GCLSVPPKELRAAGHLSSPGYLPSYERVPHLPHPWALC
FT                                AP (in isoform M6).
FT                                {ECO:0000303|PubMed:22941036,
FT                                ECO:0000303|Ref.16}.
FT                                /FTId=VSP_046962.
FT   VAR_SEQ    1181   1255       Missing (in isoform M6).
FT                                {ECO:0000303|PubMed:22941036,
FT                                ECO:0000303|Ref.16}.
FT                                /FTId=VSP_046963.
FT   VAR_SEQ    1232   1255       VSAGNGGSSLSYTNPAVAATSANL -> RQNGWSTMPRGAL
FT                                PEESQG (in isoform J13).
FT                                {ECO:0000303|PubMed:22941036}.
FT                                /FTId=VSP_047874.
FT   VARIANT    1117   1117       V -> M (in dbSNP:rs1611770).
FT                                {ECO:0000269|PubMed:15969018,
FT                                ECO:0000269|PubMed:22941036,
FT                                ECO:0000269|Ref.17}.
FT                                /FTId=VAR_019390.
FT   VARIANT    1142   1142       S -> N (in dbSNP:rs11465207).
FT                                {ECO:0000269|Ref.17}.
FT                                /FTId=VAR_019391.
FT   MUTAGEN    1098   1098       S->A,D,E,F,G,H,I,K,L,M,N,P,Q,R,V,W,Y:
FT                                Completely abrogates cleavage.
FT                                {ECO:0000269|PubMed:15987679}.
FT   MUTAGEN    1098   1098       S->C,T: Almost complete cleavage.
FT                                {ECO:0000269|PubMed:15987679}.
FT   MUTAGEN    1116   1116       D->A: Greatly reduced formation of
FT                                isoform 5/isoform Y complex.
FT                                {ECO:0000269|PubMed:10197628}.
FT   MUTAGEN    1116   1116       D->E: No effect on formation of isoform
FT                                5/isoform Y complex.
FT                                {ECO:0000269|PubMed:10197628}.
FT   MUTAGEN    1184   1184       C->A: S-palmitoylation reduced by 50%.
FT                                Complete loss of palmitoylation, no
FT                                effect on endocytosis, recycling
FT                                inhibited and AP1S1 binding reduced by
FT                                30%; when associated with C-1186.
FT                                Accumulates in intracellular
FT                                compartments; when associated with C-1186
FT                                and N-1203.
FT                                {ECO:0000269|PubMed:16507569}.
FT   MUTAGEN    1186   1186       C->A: S-palmitoylation reduced by 50%.
FT                                Complete loss of palmitoylation, no
FT                                effect on endocytosis, recycling
FT                                inhibited, and AP1S1 binding reduced by
FT                                30%; when associated with C-1184.
FT                                Accumulates in intracellular
FT                                compartments; when associated with C-1184
FT                                and N-1203.
FT                                {ECO:0000269|PubMed:16507569}.
FT   MUTAGEN    1187   1189       RRK->AAA: No nuclear targeting of HRG-
FT                                stimulated MUC1 C-terminal nor JUP/gamma-
FT                                catenin. No effect on interaction with
FT                                JUP/gamma-catenin.
FT                                {ECO:0000269|PubMed:12939402,
FT                                ECO:0000269|PubMed:16507569}.
FT   MUTAGEN    1187   1189       RRK->QQQ: No effect on palmitoylation.
FT                                {ECO:0000269|PubMed:12939402,
FT                                ECO:0000269|PubMed:16507569}.
FT   MUTAGEN    1191   1191       Y->F: No effect on EGFR-mediated
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:11483589,
FT                                ECO:0000269|PubMed:15471854}.
FT   MUTAGEN    1191   1191       Y->N: No effect on endocytosis.
FT                                {ECO:0000269|PubMed:11483589,
FT                                ECO:0000269|PubMed:15471854}.
FT   MUTAGEN    1203   1203       Y->E: No effect on nuclear colocalization
FT                                of MUC1CT and CTNNB1. No effect on in
FT                                vitro PDFGR-induced cell invasiveness.
FT                                {ECO:0000269|PubMed:11483589,
FT                                ECO:0000269|PubMed:15471854,
FT                                ECO:0000269|PubMed:16507569,
FT                                ECO:0000269|PubMed:17545600}.
FT   MUTAGEN    1203   1203       Y->F: No effect on EGFR-mediated
FT                                phosphorylation. No nuclear localization
FT                                of MUC1CT. Reduced in vitro PDGFR-induced
FT                                cell invasiveness.
FT                                {ECO:0000269|PubMed:11483589,
FT                                ECO:0000269|PubMed:15471854,
FT                                ECO:0000269|PubMed:16507569,
FT                                ECO:0000269|PubMed:17545600}.
FT   MUTAGEN    1203   1203       Y->N: Reduced endocytosis by 30%. Greatly
FT                                reduced binding to AP1S2 and GRB2.
FT                                Binding AP1S1 reduced by 25%. Reduced
FT                                endocytosis by 77%; when associated with
FT                                N-1243. Accumulates in intracellular
FT                                compartments; when associated with C-1184
FT                                and C-1186. {ECO:0000269|PubMed:11483589,
FT                                ECO:0000269|PubMed:15471854,
FT                                ECO:0000269|PubMed:16507569,
FT                                ECO:0000269|PubMed:17545600}.
FT   MUTAGEN    1209   1209       Y->F: Some reduction in EGFR-mediated
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:11483589}.
FT   MUTAGEN    1218   1218       Y->F: No effect on EGFR-mediated
FT                                phosphorylation. No nuclear
FT                                colocalization of MUC1CT and CTNNB1.
FT                                {ECO:0000269|PubMed:11483589,
FT                                ECO:0000269|PubMed:17545600}.
FT   MUTAGEN    1223   1223       S->A: No change in PRKCD- nor GSK3B-
FT                                mediated phosphorylation.
FT                                {ECO:0000269|PubMed:11877440,
FT                                ECO:0000269|PubMed:9819408}.
FT   MUTAGEN    1224   1224       T->A: Loss of PRKCD-mediated
FT                                phosphorylation. Decreased PRKCD binding.
FT                                No increased binding to CTNNB1 in the
FT                                presence of autophosphorylated PRKCD.
FT                                Increases formation of E-cadherin/beta-
FT                                catenin complex.
FT                                {ECO:0000269|PubMed:11877440}.
FT   MUTAGEN    1227   1227       S->A: No change in PRKCD-mediated
FT                                phosphorylation. Loss of GSK3B-mediated
FT                                phosphorylation. CTNNB1.
FT                                {ECO:0000269|PubMed:11877440,
FT                                ECO:0000269|PubMed:9819408}.
FT   MUTAGEN    1229   1229       Y->F: Greatly reduced EGFR- and Src-
FT                                mediated phosphorylation. No nuclear
FT                                localization of MUC1CT. Reduced in vitro
FT                                PDGFR-mediated phosphorylation. Decreased
FT                                Src-binding.
FT                                {ECO:0000269|PubMed:11152665,
FT                                ECO:0000269|PubMed:11483589,
FT                                ECO:0000269|PubMed:14688481,
FT                                ECO:0000269|PubMed:15471854}.
FT   MUTAGEN    1229   1229       Y->N: No effect on endocytosis.
FT                                {ECO:0000269|PubMed:11152665,
FT                                ECO:0000269|PubMed:11483589,
FT                                ECO:0000269|PubMed:14688481,
FT                                ECO:0000269|PubMed:15471854}.
FT   MUTAGEN    1243   1243       Y->N: Reduces binding to AP1S2 by 33%.
FT                                Greatly reduced binding to GRB2. Reduced
FT                                endocytosis by 50%. Reduced endocytosis
FT                                by 77%; when associated with N-1203.
FT                                {ECO:0000269|PubMed:15471854}.
FT   CONFLICT      2      2       T -> A (in Ref. 24; AAD14369).
FT                                {ECO:0000305}.
FT   CONFLICT    134    134       P -> Q (in Ref. 22; AAA35757).
FT                                {ECO:0000305}.
FT   CONFLICT    154    154       P -> Q (in Ref. 22; AAA35757).
FT                                {ECO:0000305}.
FT   CONFLICT   1021   1021       S -> T (in Ref. 2; AAA35805/AAA35807 and
FT                                3; AAA59876). {ECO:0000305}.
FT   CONFLICT   1143   1143       D -> G (in Ref. 11; AAP97018).
FT                                {ECO:0000305}.
FT   CONFLICT   1193   1193       Q -> L (in Ref. 13; AAK30142).
FT                                {ECO:0000305}.
FT   CONFLICT   1231   1231       K -> T (in Ref. 9; AAD10858).
FT                                {ECO:0000305}.
FT   CONFLICT   1251   1251       T -> A (in Ref. 1; AAA60019).
FT                                {ECO:0000305}.
FT   STRAND     1042   1052       {ECO:0000244|PDB:2ACM}.
FT   HELIX      1056   1059       {ECO:0000244|PDB:2ACM}.
FT   HELIX      1064   1080       {ECO:0000244|PDB:2ACM}.
FT   TURN       1082   1085       {ECO:0000244|PDB:2ACM}.
FT   STRAND     1086   1096       {ECO:0000244|PDB:2ACM}.
FT   STRAND     1099   1107       {ECO:0000244|PDB:2ACM}.
FT   TURN       1109   1111       {ECO:0000244|PDB:2ACM}.
FT   HELIX      1114   1132       {ECO:0000244|PDB:2ACM}.
FT   STRAND     1136   1142       {ECO:0000244|PDB:2ACM}.
SQ   SEQUENCE   1255 AA;  122102 MW;  5E28DFC4C20D9A82 CRC64;
     MTPGTQSPFF LLLLLTVLTV VTGSGHASST PGGEKETSAT QRSSVPSSTE KNAVSMTSSV
     LSSHSPGSGS STTQGQDVTL APATEPASGS AATWGQDVTS VPVTRPALGS TTPPAHDVTS
     APDNKPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS
     APDTRPAPGS TAPPAHGVTS APDTRPAPGS TAPPAHGVTS APDNRPALGS TAPPVHNVTS
     ASGSASGSAS TLVHNGTSAR ATTTPASKST PFSIPSHHSD TPTTLASHST KTDASSTHHS
     SVPPLTSSNH STSPQLSTGV SFFFLSFHIS NLQFNSSLED PSTDYYQELQ RDISEMFLQI
     YKQGGFLGLS NIKFRPGSVV VQLTLAFREG TINVHDVETQ FNQYKTEAAS RYNLTISDVS
     VSDVPFPFSA QSGAGVPGWG IALLVLVCVL VALAIVYLIA LAVCQCRRKN YGQLDIFPAR
     DTYHPMSEYP TYHTHGRYVP PSSTDRSPYE KVSAGNGGSS LSYTNPAVAA TSANL
//
ID   ELNE_HUMAN              Reviewed;         267 AA.
AC   P08246; P09649; Q6B0D9; Q6LDP5;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   09-DEC-2015, entry version 176.
DE   RecName: Full=Neutrophil elastase;
DE            EC=3.4.21.37;
DE   AltName: Full=Bone marrow serine protease;
DE   AltName: Full=Elastase-2;
DE   AltName: Full=Human leukocyte elastase;
DE            Short=HLE;
DE   AltName: Full=Medullasin;
DE   AltName: Full=PMN elastase;
DE   Flags: Precursor;
GN   Name=ELANE; Synonyms=ELA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3479752; DOI=10.1093/nar/15.22.9601;
RA   Nakamura H., Okano K., Aoki Y., Shimizu H., Naruto M.;
RT   "Nucleotide sequence of human bone marrow serine protease (medullasin)
RT   gene.";
RL   Nucleic Acids Res. 15:9601-9601(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2902087;
RA   Takahashi H., Nukiwa T., Yoshimura K., Quick C.D., States D.J.,
RA   Holmes M.D., Whang-Peng J., Knutsen T., Crystal R.G.;
RT   "Structure of the human neutrophil elastase gene.";
RL   J. Biol. Chem. 263:14739-14747(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2775493;
RA   Farley D., Travis J., Salvesen G.;
RT   "The human neutrophil elastase gene. Analysis of the nucleotide
RT   sequence reveals three distinct classes of repetitive DNA.";
RL   Biol. Chem. Hoppe-Seyler 370:737-744(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2322278; DOI=10.1016/0006-291X(90)90668-D;
RA   Okano K., Aoki Y., Shimizu H., Naruto M.;
RT   "Functional expression of human leukocyte elastase (HLE)/medullasin in
RT   eukaryotic cells.";
RL   Biochem. Biophys. Res. Commun. 167:1326-1332(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-219; LEU-257 AND
RP   LEU-262.
RG   NIEHS SNPs program;
RL   Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-267.
RX   PubMed=2822677;
RA   Okano K., Aoki Y., Sakurai T., Kajitani M., Kanai S., Shimazu T.,
RA   Shimizu H., Naruto M.;
RT   "Molecular cloning of complementary DNA for human medullasin: an
RT   inflammatory serine protease in bone marrow cells.";
RL   J. Biochem. 102:13-16(1987).
RN   [8]
RP   PROTEIN SEQUENCE OF 30-247.
RX   PubMed=3550808; DOI=10.1073/pnas.84.8.2228;
RA   Sinha S., Watorek W., Karr S., Giles J., Bode W., Travis J.;
RT   "Primary structure of human neutrophil elastase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:2228-2232(1987).
RN   [9]
RP   PRELIMINARY PROTEIN SEQUENCE OF 30-103.
RA   Travis J., Giles P.J., Porcelli L., Reilly C.F., Baugh R., Powers J.;
RL   (In) Protein degradation in health and disease,
RL   Ciba Foundation Symposium, pp.75:51-68, Excerpta Medica,
RL   Amsterdam and Oxford (1980).
RN   [10]
RP   PROTEIN SEQUENCE OF 30-49.
RX   PubMed=2501794; DOI=10.1073/pnas.86.14.5610;
RA   Gabay J.E., Scott R.W., Campanelli D., Griffith J., Wilde C.,
RA   Marra M.N., Seeger M., Nathan C.F.;
RT   "Antibiotic proteins of human polymorphonuclear leukocytes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:5610-5614(1989).
RN   [11]
RP   PROTEIN SEQUENCE OF 30-49.
RC   TISSUE=Neutrophil;
RX   PubMed=7897245; DOI=10.1016/0022-1759(94)00295-8;
RA   Gaskin G., Kendal H., Coulthart A., Turner N., Pusey C.D.;
RT   "Use of proteinase 3 purified by reverse phase HPLC to detect
RT   autoantibodies in systemic vasculitis.";
RL   J. Immunol. Methods 180:25-33(1995).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 75-267.
RX   PubMed=3422232;
RA   Takahashi H., Nukiwa T., Basset P., Cystal R.G.;
RT   "Myelomonocytic cell lineage expression of the neutrophil elastase
RT   gene.";
RL   J. Biol. Chem. 263:2543-2547(1988).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 123-267.
RX   PubMed=2462434;
RA   Farley D., Salvesen G.S., Travis J.;
RT   "Molecular cloning of human neutrophil elastase.";
RL   Biol. Chem. Hoppe-Seyler 369:3-7(1988).
RN   [14]
RP   PROTEIN SEQUENCE OF 262-267.
RX   PubMed=1859409; DOI=10.1016/0006-291X(91)90135-T;
RA   Aoki Y., Hase T.;
RT   "The primary structure and elastinolytic activity of medullasin (a
RT   serine protease of bone marrow).";
RL   Biochem. Biophys. Res. Commun. 178:501-506(1991).
RN   [15]
RP   FUNCTION.
RX   PubMed=15140022; DOI=10.1111/j.0906-6705.2004.00145.x;
RA   Tralau T., Meyer-Hoffert U., Schroder J.M., Wiedow O.;
RT   "Human leukocyte elastase and cathepsin G are specific inhibitors of
RT   C5a-dependent neutrophil enzyme release and chemotaxis.";
RL   Exp. Dermatol. 13:316-325(2004).
RN   [16]
RP   INTERACTION WITH NOTCH2NL, AND CHARACTERIZATION OF VARIANT CH GLN-220.
RX   PubMed=14673143; DOI=10.1128/MCB.24.1.58-70.2004;
RA   Duan Z., Li F.-Q., Wechsler J., Meade-White K., Williams K.,
RA   Benson K.F., Horwitz M.;
RT   "A novel notch protein, N2N, targeted by neutrophil elastase and
RT   implicated in hereditary neutropenia.";
RL   Mol. Cell. Biol. 24:58-70(2004).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-88 AND ASN-173.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS).
RX   PubMed=2911584; DOI=10.1073/pnas.86.1.7;
RA   Navia M.A., McKeever B.M., Springer J.P., Lin T.-Y., Williams H.R.,
RA   Fluder E.M., Dorn C.P., Hoogsteen K.;
RT   "Structure of human neutrophil elastase in complex with a peptide
RT   chloromethyl ketone inhibitor at 1.84-A resolution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:7-11(1989).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=3391280; DOI=10.1016/0014-5793(88)80118-2;
RA   Wei A.-Z., Mayr I., Bode W.;
RT   "The refined 2.3-A crystal structure of human leukocyte elastase in a
RT   complex with a valine chloromethyl ketone inhibitor.";
RL   FEBS Lett. 234:367-373(1988).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS).
RX   PubMed=3640709;
RA   Bode W., Wei A.-Z., Huber R., Meyer E., Travis J., Neumann S.;
RT   "X-ray crystal structure of the complex of human leukocyte elastase
RT   (PMN elastase) and the third domain of the turkey ovomucoid
RT   inhibitor.";
RL   EMBO J. 5:2453-2458(1986).
RN   [23]
RP   VARIANTS CH VAL-61; PHE-206 AND GLN-220.
RX   PubMed=10581030; DOI=10.1038/70544;
RA   Horwitz M., Benson K.F., Person R.E., Aprikyan A.G., Dale D.C.;
RT   "Mutations in ELA2, encoding neutrophil elastase, define a 21-day
RT   biological clock in cyclic haematopoiesis.";
RL   Nat. Genet. 23:433-436(1999).
RN   [24]
RP   VARIANTS SCN1 THR-57; THR-60; SER-71; MET-101; LEU-126; LEU-139;
RP   VAL-210 AND ARG-214, AND VARIANT CH LEU-139.
RX   PubMed=11001877;
RA   Dale D.C., Person R.E., Bolyard A.A., Aprikyan A.G., Bos C.,
RA   Bonilla M.A., Boxer L.A., Kannourakis G., Zeidler C., Welte K.,
RA   Benson K.F., Horwitz M.;
RT   "Mutations in the gene encoding neutrophil elastase in congenital and
RT   cyclic neutropenia.";
RL   Blood 96:2317-2322(2000).
RN   [25]
RP   VARIANTS SCN1 TYR-55; GLU-85; PRO-GLN-LEU-123 INS; LEU-126; SER-151;
RP   190-VAL--PHE-199 DEL AND ARG-205.
RX   PubMed=11675333; DOI=10.1182/blood.V98.9.2645;
RA   Ancliff P.J., Gale R.E., Liesner R., Hann I.M., Linch D.C.;
RT   "Mutations in the ELA2 gene encoding neutrophil elastase are present
RT   in most patients with sporadic severe congenital neutropenia but only
RT   in some patients with the familial form of the disease.";
RL   Blood 98:2645-2650(2001).
RN   [26]
RP   VARIANT SCN1 ARG-71.
RX   PubMed=12091371; DOI=10.1182/blood-2002-01-0060;
RA   Ancliff P.J., Gale R.E., Watts M.J., Liesner R., Hann I.M.,
RA   Strobel S., Linch D.C.;
RT   "Paternal mosaicism proves the pathogenic nature of mutations in
RT   neutrophil elastase in severe congenital neutropenia.";
RL   Blood 100:707-709(2002).
RN   [27]
RP   VARIANTS SCN1 LEU-42; PRO-47; LEU-53; PRO-81; PRO-84; PRO-121;
RP   PRO-127; LEU-139; PRO-152 AND 190-VAL--199-PHE DEL, VARIANTS CH
RP   LEU-43; PHE-46; MET-82; LEU-126; LEU-139; 190-VAL--199-PHE DEL;
RP   ILE-219 AND GLN-220, AND VARIANT LEU-262.
RX   PubMed=14962902; DOI=10.1182/blood-2003-10-3518;
RA   Bellanne-Chantelot C., Clauin S., Leblanc T., Cassinat B.,
RA   Rodrigues-Lima F., Beaufils S., Vaury C., Barkaoui M., Fenneteau O.,
RA   Maier-Redelsperger M., Chomienne C., Donadieu J.;
RT   "Mutations in the ELA2 gene correlate with more severe expression of
RT   neutropenia: a study of 81 patients from the French Neutropenia
RT   Register.";
RL   Blood 103:4119-4125(2004).
RN   [28]
RP   VARIANTS SCN1 LEU-98 AND LEU-101, AND CHARACTERIZATION OF VARIANTS
RP   SCN1 LEU-98 AND LEU-101.
RX   PubMed=17436313; DOI=10.1002/humu.20529;
RA   Salipante S.J., Benson K.F., Luty J., Hadavi V., Kariminejad R.,
RA   Kariminejad M.H., Rezaei N., Horwitz M.S.;
RT   "Double de novo mutations of ELA2 in cyclic and severe congenital
RT   neutropenia.";
RL   Hum. Mutat. 28:874-881(2007).
RN   [29]
RP   VARIANT SCN1 VAL-57.
RX   PubMed=18946670; DOI=10.1007/s00277-008-0629-y;
RA   Lee S.T., Yoon H.S., Kim H.J., Lee J.H., Park J.H., Kim S.H.,
RA   Seo J.J., Im H.J.;
RT   "A novel mutation Ala57Val of the ELA2 gene in a Korean boy with
RT   severe congenital neutropenia.";
RL   Ann. Hematol. 88:593-595(2009).
RN   [30]
RP   VARIANTS SCN1 ARG-44; CYS-46; TYR-53; ARG-85; ARG-203 AND CYS-203.
RX   PubMed=19036076; DOI=10.1111/j.1365-2141.2008.07493.x;
RA   Smith B.N., Ancliff P.J., Pizzey A., Khwaja A., Linch D.C., Gale R.E.;
RT   "Homozygous HAX1 mutations in severe congenital neutropenia patients
RT   with sporadic disease: a novel mutation in two unrelated British
RT   kindreds.";
RL   Br. J. Haematol. 144:762-770(2009).
RN   [31]
RP   VARIANTS SCN1 LEU-42; PRO-81; MET-101 AND LEU-126.
RX   PubMed=19415009; DOI=10.1097/MPH.0b013e3181984dbe;
RA   Shiohara M., Shigemura T., Saito S., Tanaka M., Yanagisawa R.,
RA   Sakashita K., Asada H., Ishii E., Koike K., Chin M., Kobayashi M.,
RA   Koike K.;
RT   "Ela2 mutations and clinical manifestations in familial congenital
RT   neutropenia.";
RL   J. Pediatr. Hematol. Oncol. 31:319-324(2009).
RN   [32]
RP   VARIANTS SCN1 VAL-25 AND THR-166.
RX   PubMed=20220065; DOI=10.3324/haematol.2009.017665;
RA   Germeshausen M., Zeidler C., Stuhrmann M., Lanciotti M., Ballmaier M.,
RA   Welte K.;
RT   "Digenic mutations in severe congenital neutropenia.";
RL   Haematologica 95:1207-1210(2010).
RN   [33]
RP   VARIANTS SCN1 PRO-59 AND GLU-235.
RX   PubMed=19927291; DOI=10.1002/pbc.22350;
RA   Fioredda F., Calvillo M., Lanciotti M., Lanza T., Giunti L.,
RA   Castagnola E., Lorenzi I., Tonelli R., Ghezzi P., Dufour C.;
RT   "Pegfilgrastim in children with severe congenital neutropenia.";
RL   Pediatr. Blood Cancer 54:465-467(2010).
RN   [34]
RP   VARIANT SCN1 SER-57.
RX   PubMed=20803142; DOI=10.1007/s00277-010-1056-4;
RA   van de Vosse E., Verhard E.M., Tool A.J., de Visser A.W.,
RA   Kuijpers T.W., Hiemstra P.S., van Dissel J.T.;
RT   "Severe congenital neutropenia in a multigenerational family with a
RT   novel neutrophil elastase (ELANE) mutation.";
RL   Ann. Hematol. 90:151-158(2011).
RN   [35]
RP   VARIANTS SCN1 THR-131; PRO-152; GLY-235 AND 190-VAL--199-PHE DEL.
RX   PubMed=21425445; DOI=10.1002/pbc.23104;
RA   Kurnikova M., Maschan M., Dinova E., Shagina I., Finogenova N.,
RA   Mamedova E., Polovtseva T., Shagin D., Shcherbina A.;
RT   "Four novel ELANE mutations in patients with congenital neutropenia.";
RL   Pediatr. Blood Cancer 57:332-335(2011).
RN   [36]
RP   VARIANTS SCN1 VAL-25; LEU-42; LEU-43; GLU-45; PHE-46; ARG-47; PRO-49;
RP   SER-55; ARG-56; SER-57; THR-57; VAL-57; PRO-59; 60-ILE-ALA-61 DELINS
RP   ARG; THR-60; VAL-61; VAL-65 DEL; 66-MET--HIS-70 DEL; TRP-67; ARG-71;
RP   PHE-71; TYR-71; GLY-72; GLY-80; PRO-81; MET-82; PRO-84; GLU-85;
RP   LEU-98; MET-98; LEU-101; MET-101; LEU-103; PRO-103; ASN-120; PHE-120;
RP   SER-120; PRO-121; HIS-123; ILE-124; LEU-126; ASP-127; THR-131;
RP   ASP-136; ARG-139; LEU-139; PHE-151; TRP-151; TYR-151; PRO-152;
RP   ASP-153; PRO-153; ARG-156; CYS-156; THR-166; ARG-203; ARG-205;
RP   SER-206; GLY-208; ARG-214; GLU-214; ILE-219; GLN-220; PRO-233; GLU-235
RP   AND GLY-235, VARIANTS CH LEU-45; VAL-61; PRO-81; LEU-97; ASN-104;
RP   PHE-120; LEU-126; LEU-139; HIS-143; 190-VAL--199-PHE DEL; CYS-203;
RP   ILE-209; TRP-210; ILE-219 AND GLN-220, AND VARIANTS VAL-118; ARG-125;
RP   MET-135 AND LEU-257.
RX   PubMed=23463630; DOI=10.1002/humu.22308;
RA   Germeshausen M., Deerberg S., Peter Y., Reimer C., Kratz C.P.,
RA   Ballmaier M.;
RT   "The spectrum of ELANE mutations and their implications in severe
RT   congenital and cyclic neutropenia.";
RL   Hum. Mutat. 34:905-914(2013).
CC   -!- FUNCTION: Modifies the functions of natural killer cells,
CC       monocytes and granulocytes. Inhibits C5a-dependent neutrophil
CC       enzyme release and chemotaxis. {ECO:0000269|PubMed:15140022}.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of proteins, including elastin.
CC       Preferential cleavage: Val-|-Xaa > Ala-|-Xaa.
CC   -!- SUBUNIT: Interacts with NOTCH2NL. {ECO:0000269|PubMed:14673143}.
CC   -!- INTERACTION:
CC       Q07563:Col17a1 (xeno); NbExp=2; IntAct=EBI-986345, EBI-6251005;
CC   -!- TISSUE SPECIFICITY: Bone marrow cells.
CC   -!- DISEASE: Cyclic haematopoiesis (CH) [MIM:162800]: Autosomal
CC       dominant disease in which blood-cell production from the bone
CC       marrow oscillates with 21-day periodicity. Circulating neutrophils
CC       vary between almost normal numbers and zero. During intervals of
CC       neutropenia, affected individuals are at risk for opportunistic
CC       infection. Monocytes, platelets, lymphocytes and reticulocytes
CC       also cycle with the same frequency. {ECO:0000269|PubMed:10581030,
CC       ECO:0000269|PubMed:11001877, ECO:0000269|PubMed:14962902,
CC       ECO:0000269|PubMed:23463630}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Neutropenia, severe congenital 1, autosomal dominant
CC       (SCN1) [MIM:202700]: A disorder of hematopoiesis characterized by
CC       maturation arrest of granulopoiesis at the level of promyelocytes
CC       with peripheral blood absolute neutrophil counts below 0.5 x
CC       10(9)/l and early onset of severe bacterial infections.
CC       {ECO:0000269|PubMed:11001877, ECO:0000269|PubMed:11675333,
CC       ECO:0000269|PubMed:12091371, ECO:0000269|PubMed:14962902,
CC       ECO:0000269|PubMed:17436313, ECO:0000269|PubMed:18946670,
CC       ECO:0000269|PubMed:19036076, ECO:0000269|PubMed:19415009,
CC       ECO:0000269|PubMed:19927291, ECO:0000269|PubMed:20220065,
CC       ECO:0000269|PubMed:20803142, ECO:0000269|PubMed:21425445,
CC       ECO:0000269|PubMed:23463630}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family. Elastase
CC       subfamily. {ECO:0000255|PROSITE-ProRule:PRU00274}.
CC   -!- SIMILARITY: Contains 1 peptidase S1 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00274}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA29300.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=CCHMC molecular genetics laboratory mutation
CC       database; Note=ELA2 elastase, neutrophil expressed (ELANE);
CC       URL="http://lovd.nl/ELANE";
CC   -!- WEB RESOURCE: Name=ELA2base; Note=ELA2 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/ELA2base/";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ela2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Elastase entry;
CC       URL="https://en.wikipedia.org/wiki/Elastase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00477; CAA68537.1; -; Genomic_DNA.
DR   EMBL; M20203; AAA36359.1; -; Genomic_DNA.
DR   EMBL; M20199; AAA36359.1; JOINED; Genomic_DNA.
DR   EMBL; M20200; AAA36359.1; JOINED; Genomic_DNA.
DR   EMBL; M20201; AAA36359.1; JOINED; Genomic_DNA.
DR   EMBL; M34379; AAA36173.1; -; mRNA.
DR   EMBL; AY596461; AAS89303.1; -; Genomic_DNA.
DR   EMBL; BC074816; AAH74816.1; -; mRNA.
DR   EMBL; BC074817; AAH74817.1; -; mRNA.
DR   EMBL; D00187; BAA00128.1; -; mRNA.
DR   EMBL; X05875; CAA29299.1; -; mRNA.
DR   EMBL; X05875; CAA29300.1; ALT_INIT; mRNA.
DR   EMBL; J03545; AAA52378.1; -; mRNA.
DR   EMBL; M27783; AAA35792.1; -; mRNA.
DR   CCDS; CCDS12045.1; -.
DR   PIR; A31976; ELHUL.
DR   RefSeq; NP_001963.1; NM_001972.2.
DR   RefSeq; XP_011526077.1; XM_011527775.1.
DR   RefSeq; XP_011526078.1; XM_011527776.1.
DR   RefSeq; XP_011545190.1; XM_011546888.1.
DR   UniGene; Hs.99863; -.
DR   PDB; 1B0F; X-ray; 3.00 A; A=30-247.
DR   PDB; 1H1B; X-ray; 2.00 A; A/B=30-247.
DR   PDB; 1HNE; X-ray; 1.84 A; E=30-247.
DR   PDB; 1PPF; X-ray; 1.80 A; E=30-247.
DR   PDB; 1PPG; X-ray; 2.30 A; E=30-247.
DR   PDB; 2RG3; X-ray; 1.80 A; A=30-247.
DR   PDB; 2Z7F; X-ray; 1.70 A; E=30-247.
DR   PDB; 3Q76; X-ray; 1.86 A; A/B=30-247.
DR   PDB; 3Q77; X-ray; 2.00 A; A=30-247.
DR   PDB; 4NZL; X-ray; 1.85 A; A=30-247.
DR   PDB; 4WVP; X-ray; 1.63 A; E=30-247.
DR   PDB; 5A09; X-ray; 1.81 A; A=30-247.
DR   PDB; 5A0A; X-ray; 1.78 A; E=30-247.
DR   PDB; 5A0B; X-ray; 2.23 A; A=30-247.
DR   PDB; 5A0C; X-ray; 2.10 A; A/B=30-247.
DR   PDB; 5ABW; X-ray; 1.60 A; A=30-247.
DR   PDBsum; 1B0F; -.
DR   PDBsum; 1H1B; -.
DR   PDBsum; 1HNE; -.
DR   PDBsum; 1PPF; -.
DR   PDBsum; 1PPG; -.
DR   PDBsum; 2RG3; -.
DR   PDBsum; 2Z7F; -.
DR   PDBsum; 3Q76; -.
DR   PDBsum; 3Q77; -.
DR   PDBsum; 4NZL; -.
DR   PDBsum; 4WVP; -.
DR   PDBsum; 5A09; -.
DR   PDBsum; 5A0A; -.
DR   PDBsum; 5A0B; -.
DR   PDBsum; 5A0C; -.
DR   PDBsum; 5ABW; -.
DR   ProteinModelPortal; P08246; -.
DR   SMR; P08246; 30-247.
DR   BioGrid; 108306; 9.
DR   IntAct; P08246; 5.
DR   MINT; MINT-1505052; -.
DR   STRING; 9606.ENSP00000263621; -.
DR   BindingDB; P08246; -.
DR   ChEMBL; CHEMBL248; -.
DR   DrugBank; DB00058; Alpha-1-proteinase inhibitor.
DR   DrugBank; DB00099; Filgrastim.
DR   DrugBank; DB00019; Pegfilgrastim.
DR   GuidetoPHARMACOLOGY; 2358; -.
DR   MEROPS; S01.131; -.
DR   BioMuta; ELANE; -.
DR   DMDM; 119292; -.
DR   PaxDb; P08246; -.
DR   PeptideAtlas; P08246; -.
DR   PRIDE; P08246; -.
DR   Ensembl; ENST00000263621; ENSP00000263621; ENSG00000197561.
DR   Ensembl; ENST00000590230; ENSP00000466090; ENSG00000197561.
DR   Ensembl; ENST00000615489; ENSP00000480128; ENSG00000277571.
DR   Ensembl; ENST00000632488; ENSP00000488075; ENSG00000277571.
DR   GeneID; 1991; -.
DR   KEGG; hsa:1991; -.
DR   UCSC; uc002lqb.3; human.
DR   CTD; 1991; -.
DR   GeneCards; ELANE; -.
DR   GeneReviews; ELANE; -.
DR   HGNC; HGNC:3309; ELANE.
DR   HPA; CAB015409; -.
DR   MalaCards; ELANE; -.
DR   MIM; 130130; gene.
DR   MIM; 162800; phenotype.
DR   MIM; 202700; phenotype.
DR   neXtProt; NX_P08246; -.
DR   Orphanet; 486; Autosomal dominant severe congenital neutropenia.
DR   Orphanet; 2686; Cyclic neutropenia.
DR   PharmGKB; PA27735; -.
DR   eggNOG; KOG3627; Eukaryota.
DR   eggNOG; COG5640; LUCA.
DR   GeneTree; ENSGT00760000118895; -.
DR   HOGENOM; HOG000251820; -.
DR   HOVERGEN; HBG013304; -.
DR   InParanoid; P08246; -.
DR   KO; K01327; -.
DR   OMA; QVFAVQR; -.
DR   OrthoDB; EOG7MKW6Q; -.
DR   PhylomeDB; P08246; -.
DR   BRENDA; 3.4.21.37; 2681.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-1592389; Activation of Matrix Metalloproteinases.
DR   SABIO-RK; P08246; -.
DR   EvolutionaryTrace; P08246; -.
DR   GeneWiki; Neutrophil_elastase; -.
DR   GenomeRNAi; 1991; -.
DR   NextBio; 8051; -.
DR   PRO; PR:P08246; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P08246; -.
DR   CleanEx; HS_ELA2; -.
DR   Genevisible; P08246; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0030141; C:secretory granule; IDA:MGI.
DR   GO; GO:0017053; C:transcriptional repressor complex; IDA:UniProtKB.
DR   GO; GO:0019955; F:cytokine binding; IPI:UniProtKB.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:MGI.
DR   GO; GO:0008233; F:peptidase activity; IDA:MGI.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0001106; F:RNA polymerase II transcription corepressor activity; IMP:UniProtKB.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IBA:GO_Central.
DR   GO; GO:0002438; P:acute inflammatory response to antigenic stimulus; IBA:GO_Central.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; NAS:UniProtKB.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0042742; P:defense response to bacterium; IDA:UniProtKB.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; IEA:Ensembl.
DR   GO; GO:0045079; P:negative regulation of chemokine biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0050922; P:negative regulation of chemotaxis; NAS:UniProtKB.
DR   GO; GO:0044130; P:negative regulation of growth of symbiont in host; IEA:Ensembl.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; NAS:UniProtKB.
DR   GO; GO:0045415; P:negative regulation of interleukin-8 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0070947; P:neutrophil mediated killing of fungus; IEA:Ensembl.
DR   GO; GO:0006909; P:phagocytosis; IBA:GO_Central.
DR   GO; GO:0050778; P:positive regulation of immune response; IEA:Ensembl.
DR   GO; GO:0045416; P:positive regulation of interleukin-8 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; NAS:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:UniProtKB.
DR   GO; GO:0030163; P:protein catabolic process; NAS:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IDA:MGI.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0009411; P:response to UV; IDA:UniProtKB.
DR   GO; GO:0001878; P:response to yeast; IEA:Ensembl.
DR   InterPro; IPR018114; Peptidase_S1_AS.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR001254; Trypsin_dom.
DR   Pfam; PF00089; Trypsin; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   SMART; SM00020; Tryp_SPc; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Hydrolase;
KW   Polymorphism; Protease; Reference proteome; Serine protease; Signal;
KW   Zymogen.
FT   SIGNAL        1     27       {ECO:0000255}.
FT   PROPEP       28     29       {ECO:0000269|PubMed:2501794,
FT                                ECO:0000269|PubMed:3550808,
FT                                ECO:0000269|PubMed:7897245}.
FT                                /FTId=PRO_0000027703.
FT   CHAIN        30    267       Neutrophil elastase.
FT                                /FTId=PRO_0000027704.
FT   DOMAIN       30    247       Peptidase S1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00274}.
FT   ACT_SITE     70     70       Charge relay system.
FT   ACT_SITE    117    117       Charge relay system.
FT   ACT_SITE    202    202       Charge relay system.
FT   CARBOHYD     88     88       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    124    124       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:3550808}.
FT   CARBOHYD    173    173       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:3550808}.
FT   DISULFID     55     71       {ECO:0000255|PROSITE-ProRule:PRU00274,
FT                                ECO:0000269|PubMed:3550808}.
FT   DISULFID    151    208       {ECO:0000255|PROSITE-ProRule:PRU00274,
FT                                ECO:0000269|PubMed:3550808}.
FT   DISULFID    181    187       {ECO:0000255|PROSITE-ProRule:PRU00274,
FT                                ECO:0000269|PubMed:3550808}.
FT   DISULFID    198    223       {ECO:0000255|PROSITE-ProRule:PRU00274,
FT                                ECO:0000269|PubMed:3550808}.
FT   VARIANT      25     25       A -> V (in SCN1).
FT                                {ECO:0000269|PubMed:20220065,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_064512.
FT   VARIANT      42     42       P -> L (in SCN1).
FT                                {ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:19415009,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070696.
FT   VARIANT      43     43       F -> L (in SCN1 and CH).
FT                                {ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070697.
FT   VARIANT      44     44       M -> R (in SCN1).
FT                                {ECO:0000269|PubMed:19036076}.
FT                                /FTId=VAR_070698.
FT   VARIANT      45     45       V -> E (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070699.
FT   VARIANT      45     45       V -> L (in CH).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070700.
FT   VARIANT      46     46       S -> C (in SCN1).
FT                                {ECO:0000269|PubMed:19036076}.
FT                                /FTId=VAR_070701.
FT   VARIANT      46     46       S -> F (in CH and SCN1).
FT                                {ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070702.
FT   VARIANT      47     47       L -> P (in SCN1).
FT                                {ECO:0000269|PubMed:14962902}.
FT                                /FTId=VAR_070703.
FT   VARIANT      47     47       L -> R (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070704.
FT   VARIANT      49     49       L -> P (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070705.
FT   VARIANT      53     53       H -> L (in SCN1).
FT                                {ECO:0000269|PubMed:14962902}.
FT                                /FTId=VAR_070706.
FT   VARIANT      53     53       H -> Q (in CH).
FT                                /FTId=VAR_070707.
FT   VARIANT      53     53       H -> Y (in SCN1).
FT                                {ECO:0000269|PubMed:19036076}.
FT                                /FTId=VAR_070708.
FT   VARIANT      55     55       C -> S (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070709.
FT   VARIANT      55     55       C -> Y (in SCN1).
FT                                {ECO:0000269|PubMed:11675333}.
FT                                /FTId=VAR_038609.
FT   VARIANT      56     56       G -> R (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070710.
FT   VARIANT      57     57       A -> S (in SCN1).
FT                                {ECO:0000269|PubMed:20803142,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070711.
FT   VARIANT      57     57       A -> T (in SCN1).
FT                                {ECO:0000269|PubMed:11001877,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038610.
FT   VARIANT      57     57       A -> V (in SCN1).
FT                                {ECO:0000269|PubMed:18946670,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070712.
FT   VARIANT      59     59       L -> P (in SCN1).
FT                                {ECO:0000269|PubMed:19927291,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070713.
FT   VARIANT      60     61       IA -> R. {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070714.
FT   VARIANT      60     60       I -> T (in SCN1).
FT                                {ECO:0000269|PubMed:11001877,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038611.
FT   VARIANT      61     61       A -> V (in SCN1 and CH).
FT                                {ECO:0000269|PubMed:10581030,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070715.
FT   VARIANT      65     65       Missing (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070716.
FT   VARIANT      66     70       Missing (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070717.
FT   VARIANT      67     67       S -> W (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070718.
FT   VARIANT      71     71       C -> F (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070719.
FT   VARIANT      71     71       C -> R (in SCN1; dbSNP:rs28931611).
FT                                {ECO:0000269|PubMed:12091371,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038612.
FT   VARIANT      71     71       C -> S (in SCN1).
FT                                {ECO:0000269|PubMed:11001877}.
FT                                /FTId=VAR_038613.
FT   VARIANT      71     71       C -> Y (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070720.
FT   VARIANT      72     72       V -> G (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070721.
FT   VARIANT      80     80       V -> G (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070722.
FT   VARIANT      81     81       R -> P (in SCN1 and CH).
FT                                {ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:19415009,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070723.
FT   VARIANT      82     82       V -> M (in SCN1 and CH).
FT                                {ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070724.
FT   VARIANT      84     84       L -> P (in SCN1).
FT                                {ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070725.
FT   VARIANT      85     85       G -> E (in SCN1).
FT                                {ECO:0000269|PubMed:11675333,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038614.
FT   VARIANT      85     85       G -> R (in SCN1).
FT                                {ECO:0000269|PubMed:19036076}.
FT                                /FTId=VAR_070726.
FT   VARIANT      97     97       Q -> L (in CH).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070727.
FT   VARIANT      98     98       V -> L (in SCN1; located on the same
FT                                allele as L-101; reduces proteolytic
FT                                enzyme activity by slightly less than
FT                                half; together with L-101 shows an
FT                                additive effect with minimal remaining
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:17436313,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038615.
FT   VARIANT      98     98       V -> M (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070728.
FT   VARIANT     101    101       V -> L (in SCN1; located on the same
FT                                allele as L-98; reduces proteolytic
FT                                enzyme activity by slightly less than
FT                                half; together with L-98 shows an
FT                                additive effect with minimal remaining
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:17436313,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038616.
FT   VARIANT     101    101       V -> M (in SCN1; dbSNP:rs28929494).
FT                                {ECO:0000269|PubMed:11001877,
FT                                ECO:0000269|PubMed:19415009,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038617.
FT   VARIANT     103    103       R -> L (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070729.
FT   VARIANT     103    103       R -> P (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070730.
FT   VARIANT     104    104       I -> N (in CH).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070731.
FT   VARIANT     118    118       I -> V. {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070732.
FT   VARIANT     120    120       I -> F (in SCN1 and CH).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070733.
FT   VARIANT     120    120       I -> N (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070734.
FT   VARIANT     120    120       I -> S (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070735.
FT   VARIANT     121    121       L -> P (in SCN1).
FT                                {ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070736.
FT   VARIANT     123    123       L -> H (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070737.
FT   VARIANT     123    123       L -> PQL (in SCN1).
FT                                /FTId=VAR_038618.
FT   VARIANT     124    124       N -> I (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070738.
FT   VARIANT     125    125       G -> R. {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070739.
FT   VARIANT     126    126       S -> L (in SCN1 and CH;
FT                                dbSNP:rs137854450).
FT                                {ECO:0000269|PubMed:11001877,
FT                                ECO:0000269|PubMed:11675333,
FT                                ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:19415009,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038619.
FT   VARIANT     127    127       A -> D (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070740.
FT   VARIANT     127    127       A -> P (in SCN1).
FT                                {ECO:0000269|PubMed:14962902}.
FT                                /FTId=VAR_070741.
FT   VARIANT     131    131       A -> T (in SCN1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21425445,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070742.
FT   VARIANT     135    135       V -> M. {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070743.
FT   VARIANT     136    136       A -> D (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070744.
FT   VARIANT     139    139       P -> L (in SCN1 and CH;
FT                                dbSNP:rs28929493).
FT                                {ECO:0000269|PubMed:11001877,
FT                                ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038620.
FT   VARIANT     139    139       P -> R (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070745.
FT   VARIANT     143    143       R -> H (in CH; unknown pathological
FT                                significance; dbSNP:rs200993994).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070746.
FT   VARIANT     151    151       C -> F (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070747.
FT   VARIANT     151    151       C -> S (in SCN1).
FT                                {ECO:0000269|PubMed:11675333}.
FT                                /FTId=VAR_038621.
FT   VARIANT     151    151       C -> W (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070748.
FT   VARIANT     151    151       C -> Y (in SCN1; unknown pathological
FT                                significance; dbSNP:rs57246956).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070749.
FT   VARIANT     152    152       L -> P (in SCN1).
FT                                {ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:21425445,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070750.
FT   VARIANT     153    153       A -> D (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070751.
FT   VARIANT     153    153       A -> P (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070752.
FT   VARIANT     156    156       W -> C (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070753.
FT   VARIANT     156    156       W -> R (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070754.
FT   VARIANT     166    166       A -> T (in SCN1; the patient also carries
FT                                mutation Lys-116 in G6PC3;
FT                                dbSNP:rs201788817).
FT                                {ECO:0000269|PubMed:20220065,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_064513.
FT   VARIANT     190    199       Missing (in SCN1 and CH).
FT                                {ECO:0000269|PubMed:11675333}.
FT                                /FTId=VAR_038622.
FT   VARIANT     203    203       G -> C (in SCN1 and CH).
FT                                {ECO:0000269|PubMed:19036076,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070755.
FT   VARIANT     203    203       G -> R (in SCN1).
FT                                {ECO:0000269|PubMed:19036076,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070756.
FT   VARIANT     205    205       P -> R (in SCN1).
FT                                {ECO:0000269|PubMed:11675333,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038623.
FT   VARIANT     206    206       L -> F (in CH).
FT                                {ECO:0000269|PubMed:10581030}.
FT                                /FTId=VAR_070757.
FT   VARIANT     206    206       L -> S (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070758.
FT   VARIANT     208    208       C -> G (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070759.
FT   VARIANT     209    209       N -> I (in CH).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070760.
FT   VARIANT     210    210       G -> V (in SCN1).
FT                                {ECO:0000269|PubMed:11001877}.
FT                                /FTId=VAR_038624.
FT   VARIANT     210    210       G -> W (in CH).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070761.
FT   VARIANT     214    214       G -> E (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070762.
FT   VARIANT     214    214       G -> R (in SCN1).
FT                                {ECO:0000269|PubMed:11001877,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_038625.
FT   VARIANT     219    219       V -> I (in CH and SCN1; unknown
FT                                pathological significance;
FT                                dbSNP:rs17216656).
FT                                {ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:23463630,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019237.
FT   VARIANT     220    220       R -> Q (in CH and SCN1; loss of
FT                                interaction with NOTCH2NL and loss of
FT                                NOTCH2NL and NOTCH2 proteolytic
FT                                cleavage). {ECO:0000269|PubMed:10581030,
FT                                ECO:0000269|PubMed:14673143,
FT                                ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070763.
FT   VARIANT     233    233       A -> P (in SCN1).
FT                                {ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070764.
FT   VARIANT     235    235       V -> E (in SCN1).
FT                                {ECO:0000269|PubMed:19927291,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070765.
FT   VARIANT     235    235       V -> G (in SCN1).
FT                                {ECO:0000269|PubMed:21425445,
FT                                ECO:0000269|PubMed:23463630}.
FT                                /FTId=VAR_070766.
FT   VARIANT     257    257       P -> L (in dbSNP:rs17216663).
FT                                {ECO:0000269|PubMed:23463630,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019238.
FT   VARIANT     262    262       P -> L (found in patients with severe
FT                                congenital or cyclic neutropenia;
FT                                dbSNP:rs17216670).
FT                                {ECO:0000269|PubMed:14962902,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019239.
FT   STRAND       44     49       {ECO:0000244|PDB:5ABW}.
FT   STRAND       52     61       {ECO:0000244|PDB:5ABW}.
FT   STRAND       64     67       {ECO:0000244|PDB:5ABW}.
FT   HELIX        69     72       {ECO:0000244|PDB:5ABW}.
FT   HELIX        77     79       {ECO:0000244|PDB:5ABW}.
FT   STRAND       81     85       {ECO:0000244|PDB:5ABW}.
FT   STRAND       97    106       {ECO:0000244|PDB:5ABW}.
FT   TURN        111    114       {ECO:0000244|PDB:5ABW}.
FT   STRAND      119    125       {ECO:0000244|PDB:5ABW}.
FT   STRAND      130    132       {ECO:0000244|PDB:2Z7F}.
FT   STRAND      150    158       {ECO:0000244|PDB:5ABW}.
FT   STRAND      161    163       {ECO:0000244|PDB:4WVP}.
FT   STRAND      170    177       {ECO:0000244|PDB:5ABW}.
FT   STRAND      185    189       {ECO:0000244|PDB:5ABW}.
FT   STRAND      191    193       {ECO:0000244|PDB:5ABW}.
FT   STRAND      205    208       {ECO:0000244|PDB:5ABW}.
FT   STRAND      211    218       {ECO:0000244|PDB:5ABW}.
FT   STRAND      220    222       {ECO:0000244|PDB:5ABW}.
FT   STRAND      226    228       {ECO:0000244|PDB:5ABW}.
FT   STRAND      230    234       {ECO:0000244|PDB:5ABW}.
FT   HELIX       235    238       {ECO:0000244|PDB:5ABW}.
FT   HELIX       239    246       {ECO:0000244|PDB:5ABW}.
SQ   SEQUENCE   267 AA;  28518 MW;  3F7610DC33CAA4B9 CRC64;
     MTLGRRLACL FLACVLPALL LGGTALASEI VGGRRARPHA WPFMVSLQLR GGHFCGATLI
     APNFVMSAAH CVANVNVRAV RVVLGAHNLS RREPTRQVFA VQRIFENGYD PVNLLNDIVI
     LQLNGSATIN ANVQVAQLPA QGRRLGNGVQ CLAMGWGLLG RNRGIASVLQ ELNVTVVTSL
     CRRSNVCTLV RGRQAGVCFG DSGSPLVCNG LIHGIASFVR GGCASGLYPD AFAPVAQFVN
     WIDSIIQRSE DNPCPHPRDP DPASRTH
//
ID   NRP1_MOUSE              Reviewed;         923 AA.
AC   P97333; Q6PAR3;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 2.
DT   17-FEB-2016, entry version 155.
DE   RecName: Full=Neuropilin-1;
DE   AltName: Full=A5 protein;
DE   AltName: CD_antigen=CD304;
DE   Flags: Precursor;
GN   Name=Nrp1; Synonyms=Nrp;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ; TISSUE=Embryonic brain;
RX   PubMed=8748368;
RX   DOI=10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F;
RA   Kawakami A., Kitsukawa T., Takagi S., Fujisawa H.;
RT   "Developmentally regulated expression of a cell surface protein,
RT   neuropilin, in the mouse nervous system.";
RL   J. Neurobiol. 29:1-17(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-261 AND ASN-522.
RC   TISSUE=Myoblast;
RX   PubMed=19656770; DOI=10.1074/mcp.M900195-MCP200;
RA   Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I.,
RA   Bausch-Fluck D., Elliott S.T., Boheler K.R., Van Eyk J.E.,
RA   Wollscheid B.;
RT   "The mouse C2C12 myoblast cell surface N-linked glycoproteome:
RT   identification, glycosite occupancy, and membrane orientation.";
RL   Mol. Cell. Proteomics 8:2555-2569(2009).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-894, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung,
RC   Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [6]
RP   INTERACTION WITH FER.
RX   PubMed=20133938; DOI=10.1074/jbc.M109.080689;
RA   Jiang S.X., Whitehead S., Aylsworth A., Slinn J., Zurakowski B.,
RA   Chan K., Li J., Hou S.T.;
RT   "Neuropilin 1 directly interacts with Fer kinase to mediate semaphorin
RT   3A-induced death of cortical neurons.";
RL   J. Biol. Chem. 285:9908-9918(2010).
CC   -!- FUNCTION: Receptor involved in the development of the
CC       cardiovascular system, in angiogenesis, in the formation of
CC       certain neuronal circuits and in organogenesis outside the nervous
CC       system. It mediates the chemorepulsant activity of semaphorins. It
CC       binds to semaphorin 3A, the PLGF-2 isoform of PGF, the VEGF-165
CC       isoform of VEGF and VEGF-B. Coexpression with KDR results in
CC       increased VEGF-165 binding to KDR as well as increased chemotaxis.
CC       It may regulate VEGF-induced angiogenesis (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer, and heterodimer with NRP2. Binds PLXNB1 (By
CC       similarity). Interacts with FER. {ECO:0000250,
CC       ECO:0000269|PubMed:20133938}.
CC   -!- INTERACTION:
CC       P34152:Ptk2; NbExp=2; IntAct=EBI-1555129, EBI-77070;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Nervous system.
CC   -!- DOMAIN: The tandem CUB domains mediate binding to semaphorin,
CC       while the tandem F5/8 domains are responsible for heparin and VEGF
CC       binding. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the neuropilin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 2 CUB domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00059}.
CC   -!- SIMILARITY: Contains 2 F5/8 type C domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00081}.
CC   -!- SIMILARITY: Contains 1 MAM domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00128}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D50086; BAA08789.1; -; mRNA.
DR   EMBL; CH466525; EDL11828.1; -; Genomic_DNA.
DR   EMBL; BC060129; AAH60129.1; -; mRNA.
DR   CCDS; CCDS22790.1; -.
DR   RefSeq; NP_032763.2; NM_008737.2.
DR   RefSeq; XP_006530829.1; XM_006530766.2.
DR   UniGene; Mm.271745; -.
DR   PDB; 4GZ9; X-ray; 2.70 A; A=22-586.
DR   PDB; 4GZA; X-ray; 7.00 A; H=22-586.
DR   PDBsum; 4GZ9; -.
DR   PDBsum; 4GZA; -.
DR   ProteinModelPortal; P97333; -.
DR   SMR; P97333; 25-586, 681-801.
DR   BioGrid; 201848; 5.
DR   DIP; DIP-39360N; -.
DR   IntAct; P97333; 12.
DR   MINT; MINT-99860; -.
DR   STRING; 10090.ENSMUSP00000026917; -.
DR   iPTMnet; P97333; -.
DR   PhosphoSite; P97333; -.
DR   SwissPalm; P97333; -.
DR   MaxQB; P97333; -.
DR   PaxDb; P97333; -.
DR   PRIDE; P97333; -.
DR   Ensembl; ENSMUST00000026917; ENSMUSP00000026917; ENSMUSG00000025810.
DR   GeneID; 18186; -.
DR   KEGG; mmu:18186; -.
DR   UCSC; uc009nzr.2; mouse.
DR   CTD; 8829; -.
DR   MGI; MGI:106206; Nrp1.
DR   eggNOG; ENOG410IE8T; Eukaryota.
DR   eggNOG; ENOG410YRBE; LUCA.
DR   GeneTree; ENSGT00760000119073; -.
DR   HOGENOM; HOG000039978; -.
DR   HOVERGEN; HBG000502; -.
DR   InParanoid; P97333; -.
DR   KO; K06724; -.
DR   OMA; CWHNGMS; -.
DR   OrthoDB; EOG7ZWD1D; -.
DR   TreeFam; TF316506; -.
DR   Reactome; R-MMU-194306; Neurophilin interactions with VEGF and VEGFR.
DR   Reactome; R-MMU-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-MMU-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion.
DR   Reactome; R-MMU-399956; CRMPs in Sema3A signaling.
DR   Reactome; R-MMU-445144; Signal transduction by L1.
DR   ChiTaRS; Nrp1; mouse.
DR   NextBio; 293506; -.
DR   PRO; PR:P97333; -.
DR   Proteomes; UP000000589; Chromosome 8.
DR   Bgee; P97333; -.
DR   CleanEx; MM_NRP1; -.
DR   Genevisible; P97333; MM.
DR   GO; GO:0030424; C:axon; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; ISO:MGI.
DR   GO; GO:0005769; C:early endosome; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; ISO:MGI.
DR   GO; GO:0005925; C:focal adhesion; ISO:MGI.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005883; C:neurofilament; IDA:MGI.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0097443; C:sorting endosome; IDA:BHF-UCL.
DR   GO; GO:0019838; F:growth factor binding; IPI:MGI.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0017154; F:semaphorin receptor activity; IDA:MGI.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; IMP:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0060978; P:angiogenesis involved in coronary vascular morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0048844; P:artery morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0048846; P:axon extension involved in axon guidance; IMP:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; IDA:MGI.
DR   GO; GO:0007413; P:axonal fasciculation; IMP:MGI.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; IMP:BHF-UCL.
DR   GO; GO:0021785; P:branchiomotor neuron axon guidance; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0016477; P:cell migration; IMP:MGI.
DR   GO; GO:0060980; P:cell migration involved in coronary vasculogenesis; IC:BHF-UCL.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; ISO:MGI.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IMP:BHF-UCL.
DR   GO; GO:0071679; P:commissural neuron axon guidance; IMP:BHF-UCL.
DR   GO; GO:0060982; P:coronary artery morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0016358; P:dendrite development; IMP:MGI.
DR   GO; GO:0060666; P:dichotomous subdivision of terminal units involved in salivary gland branching; IMP:MGI.
DR   GO; GO:1904835; P:dorsal root ganglion morphogenesis; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0035767; P:endothelial cell chemotaxis; ISO:MGI.
DR   GO; GO:0021612; P:facial nerve structural organization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1903375; P:facioacoustic ganglion development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0021828; P:gonadotrophin-releasing hormone neuronal migration to the hypothalamus; IMP:BHF-UCL.
DR   GO; GO:0007507; P:heart development; IGI:MGI.
DR   GO; GO:0048012; P:hepatocyte growth factor receptor signaling pathway; ISO:MGI.
DR   GO; GO:0008045; P:motor neuron axon guidance; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0030517; P:negative regulation of axon extension; IGI:MGI.
DR   GO; GO:0048843; P:negative regulation of axon extension involved in axon guidance; IDA:MGI.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0021675; P:nerve development; IMP:BHF-UCL.
DR   GO; GO:1901166; P:neural crest cell migration involved in autonomic nervous system development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0048666; P:neuron development; IMP:BHF-UCL.
DR   GO; GO:0001764; P:neuron migration; IMP:BHF-UCL.
DR   GO; GO:0043049; P:otic placode formation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0001569; P:patterning of blood vessels; IMP:BHF-UCL.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; ISO:MGI.
DR   GO; GO:0050918; P:positive chemotaxis; IMP:BHF-UCL.
DR   GO; GO:0048842; P:positive regulation of axon extension involved in axon guidance; IMP:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:1902336; P:positive regulation of retinal ganglion cell axon guidance; IMP:BHF-UCL.
DR   GO; GO:1902946; P:protein localization to early endosome; IMP:BHF-UCL.
DR   GO; GO:0048841; P:regulation of axon extension involved in axon guidance; IDA:MGI.
DR   GO; GO:0090259; P:regulation of retinal ganglion cell axon guidance; IMP:BHF-UCL.
DR   GO; GO:0061441; P:renal artery morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0061299; P:retina vasculature morphogenesis in camera-type eye; IMP:BHF-UCL.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; IMP:BHF-UCL.
DR   GO; GO:0071526; P:semaphorin-plexin signaling pathway; IDA:MGI.
DR   GO; GO:1902287; P:semaphorin-plexin signaling pathway involved in axon guidance; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1902285; P:semaphorin-plexin signaling pathway involved in neuron projection guidance; IMP:BHF-UCL.
DR   GO; GO:0097374; P:sensory neuron axon guidance; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0002040; P:sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0061549; P:sympathetic ganglion development; IMP:BHF-UCL.
DR   GO; GO:0048485; P:sympathetic nervous system development; IMP:MGI.
DR   GO; GO:0097490; P:sympathetic neuron projection extension; IMP:BHF-UCL.
DR   GO; GO:0097491; P:sympathetic neuron projection guidance; IMP:BHF-UCL.
DR   GO; GO:1901998; P:toxin transport; IMP:MGI.
DR   GO; GO:0061551; P:trigeminal ganglion development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0021636; P:trigeminal nerve morphogenesis; IMP:MGI.
DR   GO; GO:0021637; P:trigeminal nerve structural organization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0038190; P:VEGF-activated neuropilin signaling pathway; IMP:BHF-UCL.
DR   GO; GO:1902378; P:VEGF-activated neuropilin signaling pathway involved in axon guidance; IMP:BHF-UCL.
DR   GO; GO:0036486; P:ventral trunk neural crest cell migration; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0021649; P:vestibulocochlear nerve structural organization; IMP:ParkinsonsUK-UCL.
DR   Gene3D; 2.60.120.260; -; 2.
DR   Gene3D; 2.60.120.290; -; 2.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR000859; CUB_dom.
DR   InterPro; IPR000421; FA58C.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR000998; MAM_dom.
DR   InterPro; IPR014648; Neuropilin.
DR   InterPro; IPR022579; Neuropilin1_C.
DR   InterPro; IPR027146; NRP1.
DR   PANTHER; PTHR10127:SF654; PTHR10127:SF654; 1.
DR   Pfam; PF00431; CUB; 2.
DR   Pfam; PF11980; DUF3481; 1.
DR   Pfam; PF00754; F5_F8_type_C; 2.
DR   Pfam; PF00629; MAM; 1.
DR   PIRSF; PIRSF036960; Neuropilin; 1.
DR   PRINTS; PR00020; MAMDOMAIN.
DR   SMART; SM00042; CUB; 2.
DR   SMART; SM00231; FA58C; 2.
DR   SMART; SM00137; MAM; 1.
DR   SUPFAM; SSF49785; SSF49785; 2.
DR   SUPFAM; SSF49854; SSF49854; 2.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   PROSITE; PS01180; CUB; 2.
DR   PROSITE; PS01285; FA58C_1; 2.
DR   PROSITE; PS01286; FA58C_2; 2.
DR   PROSITE; PS50022; FA58C_3; 2.
DR   PROSITE; PS00740; MAM_1; 1.
DR   PROSITE; PS50060; MAM_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; Calcium; Complete proteome;
KW   Developmental protein; Differentiation; Disulfide bond; Glycoprotein;
KW   Heparan sulfate; Heparin-binding; Membrane; Metal-binding;
KW   Neurogenesis; Phosphoprotein; Proteoglycan; Receptor;
KW   Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22    923       Neuropilin-1.
FT                                /FTId=PRO_0000021860.
FT   TOPO_DOM     22    856       Extracellular. {ECO:0000255}.
FT   TRANSMEM    857    879       Helical. {ECO:0000255}.
FT   TOPO_DOM    880    923       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       27    141       CUB 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00059}.
FT   DOMAIN      147    265       CUB 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00059}.
FT   DOMAIN      275    424       F5/8 type C 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00081}.
FT   DOMAIN      431    583       F5/8 type C 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00081}.
FT   DOMAIN      645    811       MAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00128}.
FT   METAL       195    195       Calcium. {ECO:0000250|UniProtKB:O14786}.
FT   METAL       209    209       Calcium. {ECO:0000250|UniProtKB:O14786}.
FT   METAL       250    250       Calcium. {ECO:0000250|UniProtKB:O14786}.
FT   MOD_RES     894    894       Phosphoserine.
FT                                {ECO:0000244|PubMed:21183079}.
FT   CARBOHYD    150    150       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    261    261       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    300    300       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    522    522       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    612    612       O-linked (Xyl...) (chondroitin sulfate);
FT                                alternate.
FT                                {ECO:0000250|UniProtKB:O14786}.
FT   CARBOHYD    612    612       O-linked (Xyl...) (heparan sulfate);
FT                                alternate.
FT                                {ECO:0000250|UniProtKB:O14786}.
FT   CARBOHYD    842    842       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     27     54       {ECO:0000250|UniProtKB:O14786}.
FT   DISULFID     82    104       {ECO:0000250|UniProtKB:O14786}.
FT   DISULFID    147    173       {ECO:0000250|UniProtKB:O14786}.
FT   DISULFID    206    228       {ECO:0000250|UniProtKB:O14786}.
FT   DISULFID    275    424       {ECO:0000250|UniProtKB:O14786}.
FT   DISULFID    431    583       {ECO:0000250|UniProtKB:O14786}.
FT   CONFLICT     68     68       M -> I (in Ref. 1; BAA08789).
FT                                {ECO:0000305}.
FT   CONFLICT    170    170       S -> C (in Ref. 1; BAA08789).
FT                                {ECO:0000305}.
FT   CONFLICT    601    601       D -> H (in Ref. 1; BAA08789).
FT                                {ECO:0000305}.
FT   STRAND       27     32       {ECO:0000244|PDB:4GZ9}.
FT   STRAND       37     40       {ECO:0000244|PDB:4GZ9}.
FT   TURN         42     46       {ECO:0000244|PDB:4GZ9}.
FT   STRAND       53     59       {ECO:0000244|PDB:4GZ9}.
FT   STRAND       67     71       {ECO:0000244|PDB:4GZ9}.
FT   HELIX        80     82       {ECO:0000244|PDB:4GZ9}.
FT   STRAND       84     94       {ECO:0000244|PDB:4GZ9}.
FT   STRAND       97    103       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      105    107       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      115    124       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      135    140       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      146    151       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      153    159       {ECO:0000244|PDB:4GZ9}.
FT   TURN        161    164       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      172    178       {ECO:0000244|PDB:4GZ9}.
FT   HELIX       180    182       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      185    193       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      208    217       {ECO:0000244|PDB:4GZ9}.
FT   TURN        218    220       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      223    227       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      229    231       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      236    238       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      240    248       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      257    264       {ECO:0000244|PDB:4GZ9}.
FT   TURN        281    283       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      284    286       {ECO:0000244|PDB:4GZ9}.
FT   HELIX       288    290       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      291    294       {ECO:0000244|PDB:4GZ9}.
FT   HELIX       299    301       {ECO:0000244|PDB:4GZ9}.
FT   HELIX       303    305       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      326    342       {ECO:0000244|PDB:4GZ9}.
FT   TURN        347    349       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      352    368       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      373    378       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      385    389       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      391    414       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      417    424       {ECO:0000244|PDB:4GZ9}.
FT   HELIX       426    428       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      429    431       {ECO:0000244|PDB:4GZ9}.
FT   TURN        437    439       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      440    442       {ECO:0000244|PDB:4GZ9}.
FT   HELIX       444    446       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      447    449       {ECO:0000244|PDB:4GZ9}.
FT   TURN        450    453       {ECO:0000244|PDB:4GZ9}.
FT   HELIX       459    462       {ECO:0000244|PDB:4GZ9}.
FT   TURN        464    466       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      471    473       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      485    501       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      503    507       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      512    525       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      534    537       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      544    547       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      550    570       {ECO:0000244|PDB:4GZ9}.
FT   STRAND      573    583       {ECO:0000244|PDB:4GZ9}.
SQ   SEQUENCE   923 AA;  103000 MW;  23209818C5C42137 CRC64;
     MERGLPLLCA TLALALALAG AFRSDKCGGT IKIENPGYLT SPGYPHSYHP SEKCEWLIQA
     PEPYQRIMIN FNPHFDLEDR DCKYDYVEVI DGENEGGRLW GKFCGKIAPS PVVSSGPFLF
     IKFVSDYETH GAGFSIRYEI FKRGPECSQN YTAPTGVIKS PGFPEKYPNS LECTYIIFAP
     KMSEIILEFE SFDLEQDSNP PGGMFCRYDR LEIWDGFPEV GPHIGRYCGQ KTPGRIRSSS
     GVLSMVFYTD SAIAKEGFSA NYSVLQSSIS EDFKCMEALG MESGEIHSDQ ITASSQYGTN
     WSVERSRLNY PENGWTPGED SYKEWIQVDL GLLRFVTAVG TQGAISKETK KKYYVKTYRV
     DISSNGEDWI SLKEGNKAII FQGNTNPTDV VLGVFSKPLI TRFVRIKPVS WETGISMRFE
     VYGCKITDYP CSGMLGMVSG LISDSQITAS NQADRNWMPE NIRLVTSRTG WALPPSPHPY
     TNEWLQVDLG DEKIVRGVII QGGKHRENKV FMRKFKIAYS NNGSDWKTIM DDSKRKAKSF
     EGNNNYDTPE LRTFSPLSTR FIRIYPERAT HSGLGLRMEL LGCEVEAPTA GPTTPNGNPV
     DECDDDQANC HSGTGDDFQL TGGTTVLATE KPTIIDSTIQ SEFPTYGFNC EFGWGSHKTF
     CHWEHDSHAQ LRWSVLTSKT GPIQDHTGDG NFIYSQADEN QKGKVARLVS PVVYSQSSAH
     CMTFWYHMSG SHVGTLRVKL RYQKPEEYDQ LVWMVVGHQG DHWKEGRVLL HKSLKLYQVI
     FEGEIGKGNL GGIAVDDISI NNHISQEDCA KPTDLDKKNT EIKIDETGST PGYEGEGEGD
     KNISRKPGNV LKTLDPILIT IIAMSALGVL LGAVCGVVLY CACWHNGMSE RNLSALENYN
     FELVDGVKLK KDKLNPQSNY SEA
//
ID   VGFR1_HUMAN             Reviewed;        1338 AA.
AC   P17948; A3E342; A3E344; A8KA71; B0LPF1; B2BF46; B2BF47; B2BF48;
AC   B3FR89; B5A923; F5H5L6; O60722; P16057; Q12954;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   17-FEB-2016, entry version 194.
DE   RecName: Full=Vascular endothelial growth factor receptor 1;
DE            Short=VEGFR-1;
DE            EC=2.7.10.1;
DE   AltName: Full=Fms-like tyrosine kinase 1;
DE            Short=FLT-1;
DE   AltName: Full=Tyrosine-protein kinase FRT;
DE   AltName: Full=Tyrosine-protein kinase receptor FLT;
DE            Short=FLT;
DE   AltName: Full=Vascular permeability factor receptor;
DE   Flags: Precursor;
GN   Name=FLT1; Synonyms=FLT, FRT, VEGFR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2158038;
RA   Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H.,
RA   Sato M.;
RT   "Nucleotide sequence and expression of a novel human receptor-type
RT   tyrosine kinase gene (flt) closely related to the fms family.";
RL   Oncogene 5:519-524(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PROTEIN SEQUENCE OF
RP   N-TERMINUS, SUBCELLULAR LOCATION (ISOFORM 2), INTERACTION WITH VEGFA,
RP   AND FUNCTION.
RC   TISSUE=Umbilical vein;
RX   PubMed=8248162; DOI=10.1073/pnas.90.22.10705;
RA   Kendall R.L., Thomas K.A.;
RT   "Inhibition of vascular endothelial cell growth factor activity by an
RT   endogenously encoded soluble receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10705-10709(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH VEGFA, AND
RP   GLYCOSYLATION.
RC   TISSUE=Umbilical vein;
RX   PubMed=10471394; DOI=10.1006/bbrc.1999.1282;
RA   Herley M.T., Yu Y., Whitney R.G., Sato J.D.;
RT   "Characterization of the VEGF binding site on the Flt-1 receptor.";
RL   Biochem. Biophys. Res. Commun. 262:731-738(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION IN LIGAND BINDING,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, ROLE IN PREECLAMPSIA, AND INDUCTION.
RX   PubMed=18515749; DOI=10.1161/CIRCRESAHA.108.171504;
RA   Sela S., Itin A., Natanson-Yaron S., Greenfield C., Goldman-Wohl D.,
RA   Yagel S., Keshet E.;
RT   "A novel human-specific soluble vascular endothelial growth factor
RT   receptor 1: cell-type-specific splicing and implications to vascular
RT   endothelial growth factor homeostasis and preeclampsia.";
RL   Circ. Res. 102:1566-1574(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 6; 7 AND 8), ALTERNATIVE
RP   SPLICING, FUNCTION IN PHOSPHORYLATION OF SRC AND CANCER CELL
RP   INVASIVENESS, AND TISSUE SPECIFICITY.
RX   PubMed=20512933; DOI=10.1002/jcb.22584;
RA   Mezquita B., Mezquita J., Pau M., Mezquita C.;
RT   "A novel intracellular isoform of VEGFR-1 activates Src and promotes
RT   cell invasion in MDA-MB-231 breast cancer cells.";
RL   J. Cell. Biochem. 110:732-742(2010).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Mezquita J., Mezquita B., Pau M., Mezquita C.;
RT   "A new VEGFR1 receptor transcript coding for the extracellular domains
RT   of the protein followed by a C-terminal polyserine tail.";
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Placenta, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1018-1058, AND ALTERNATIVE
RP   SPLICING (ISOFORM 1).
RX   PubMed=3040650;
RA   Matsushime H., Yoshida M.C., Sasaki M., Shibuya M.;
RT   "A possible new member of tyrosine kinase family, human frt sequence,
RT   is highly conserved in vertebrates and located on human chromosome
RT   13.";
RL   Jpn. J. Cancer Res. 78:655-661(1987).
RN   [14]
RP   PARTIAL PROTEIN SEQUENCE, CATALYTIC ACTIVITY, PHOSPHORYLATION AT
RP   TYR-914; TYR-1213; TYR-1242; TYR-1327 AND TYR-1333, MUTAGENESIS OF
RP   TYR-914; TYR-1213; TYR-1242; TYR-1327 AND TYR-1333, AND INTERACTION
RP   WITH PLCG; GRB2; CRK; NCK1 AND PTPN11.
RX   PubMed=9722576; DOI=10.1074/jbc.273.36.23410;
RA   Ito N., Wernstedt C., Engstrom U., Claesson-Welsh L.;
RT   "Identification of vascular endothelial growth factor receptor-1
RT   tyrosine phosphorylation sites and binding of SH2 domain-containing
RT   molecules.";
RL   J. Biol. Chem. 273:23410-23418(1998).
RN   [15]
RP   INTERACTION WITH VEGFA, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY,
RP   FUNCTION IN PHOSPHORYLATION OF PLCG, AND ABSENCE OF MITOGENIC FUNCTION
RP   IN CULTURED FIBROBLASTS.
RX   PubMed=7824266;
RA   Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M.;
RT   "A unique signal transduction from FLT tyrosine kinase, a receptor for
RT   vascular endothelial growth factor VEGF.";
RL   Oncogene 10:135-147(1995).
RN   [16]
RP   FUNCTION IN CELL MIGRATION, FUNCTION IN VEGFA AND PGF SIGNALING, AND
RP   INDUCTION.
RX   PubMed=8605350;
RA   Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D.;
RT   "Migration of human monocytes in response to vascular endothelial
RT   growth factor (VEGF) is mediated via the VEGF receptor flt-1.";
RL   Blood 87:3336-3343(1996).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG AND ACTIVATION OF MAP KINASES,
RP   INTERACTION WITH PLCG, CATALYTIC ACTIVITY, MUTAGENESIS OF LYS-861 AND
RP   TYR-1169, AND PHOSPHORYLATION AT TYR-1169 AND TYR-1213.
RX   PubMed=9299537; DOI=10.1006/bbrc.1997.7327;
RA   Sawano A., Takahashi T., Yamaguchi S., Shibuya M.;
RT   "The phosphorylated 1169-tyrosine containing region of flt-1 kinase
RT   (VEGFR-1) is a major binding site for PLCgamma.";
RL   Biochem. Biophys. Res. Commun. 238:487-491(1997).
RN   [18]
RP   INTERACTION WITH PIK3R1; PTPN11 AND NCK1, AND PHOSPHORYLATION AT
RP   TYR-1213.
RX   PubMed=9600074; DOI=10.1006/bbrc.1998.8578;
RA   Igarashi K., Isohara T., Kato T., Shigeta K., Yamano T., Uno I.;
RT   "Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2.";
RL   Biochem. Biophys. Res. Commun. 246:95-99(1998).
RN   [19]
RP   FUNCTION AS NEGATIVE REGULATOR OF KDR-MEDIATED CELL PROLIFERATION.
RX   PubMed=11141500; DOI=10.1016/S0002-9440(10)63965-X;
RA   Dunk C., Ahmed A.;
RT   "Vascular endothelial growth factor receptor-2-mediated mitogenesis is
RT   negatively regulated by vascular endothelial growth factor receptor-1
RT   in tumor epithelial cells.";
RL   Am. J. Pathol. 158:265-273(2001).
RN   [20]
RP   INTERACTION WITH PIK3R1 AND VEGFA, AUTOPHOSPHORYLATION,
RP   PHOSPHORYLATION AT TYR-1213, SUBCELLULAR LOCATION, IDENTIFICATION BY
RP   MASS SPECTROMETRY, AND GLYCOSYLATION.
RX   PubMed=11513746; DOI=10.1042/0264-6021:3580465;
RA   Yu Y., Hulmes J.D., Herley M.T., Whitney R.G., Crabb J.W., Sato J.D.;
RT   "Direct identification of a major autophosphorylation site on vascular
RT   endothelial growth factor receptor Flt-1 that mediates
RT   phosphatidylinositol 3'-kinase binding.";
RL   Biochem. J. 358:465-472(2001).
RN   [21]
RP   FUNCTION IN PGF-MEDIATED CHORIOCARCINOMA CELL PROLIFERATION.
RX   PubMed=11811792;
RA   Angelucci C., Lama G., Iacopino F., Maglione D., Sica G.;
RT   "Effect of placenta growth factor-1 on proliferation and release of
RT   nitric oxide, cyclic AMP and cyclic GMP in human epithelial cells
RT   expressing the FLT-1 receptor.";
RL   Growth Factors 19:193-206(2001).
RN   [22]
RP   INTERACTION WITH KDR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND
RP   FUNCTION IN VEGFA SIGNALING; PHOSPHORYLATION OF PLCG AND ACTIVATION OF
RP   PHOSPHATIDYLINOSITOL KINASE AND PHOSPHOLIPASE C.
RX   PubMed=11312102; DOI=10.1016/S1357-2725(01)00019-X;
RA   Huang K., Andersson C., Roomans G.M., Ito N., Claesson-Welsh L.;
RT   "Signaling properties of VEGF receptor-1 and -2 homo- and
RT   heterodimers.";
RL   Int. J. Biochem. Cell Biol. 33:315-324(2001).
RN   [23]
RP   FUNCTION IN SIGNALING VIA ACTIVATION OF THE PHOSPHATIDYLINOSITOL
RP   KINASE PATHWAY AND POSITIVE REGULATION OF ANGIOGENESIS IN RESPONSE TO
RP   PGF AND VEGFA.
RX   PubMed=14633857; DOI=10.2337/diabetes.52.12.2959;
RA   Cai J., Ahmad S., Jiang W.G., Huang J., Kontos C.D., Boulton M.,
RA   Ahmed A.;
RT   "Activation of vascular endothelial growth factor receptor-1 sustains
RT   angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-
RT   kinase pathway in endothelial cells.";
RL   Diabetes 52:2959-2968(2003).
RN   [24]
RP   INTERACTION WITH PGF AND KDR, FUNCTION IN PHOSPHORYLATION OF KDR;
RP   VEGFA AND PGF SIGNALING, CATALYTIC ACTIVITY, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND PHOSPHORYLATION AT TYR-1213; TYR-1327 AND TYR-1309.
RX   PubMed=12796773; DOI=10.1038/nm884;
RA   Autiero M., Waltenberger J., Communi D., Kranz A., Moons L.,
RA   Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S.,
RA   Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U.,
RA   Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P.,
RA   Dehio C., Hicklin D.J., Persico G., Herbert J.M., Communi D.,
RA   Shibuya M., Collen D., Conway E.M., Carmeliet P.;
RT   "Role of PlGF in the intra- and intermolecular cross talk between the
RT   VEGF receptors Flt1 and Flk1.";
RL   Nat. Med. 9:936-943(2003).
RN   [25]
RP   INTERACTION WITH CBL AND CD2AP, UBIQUITINATION, AUTOPHOSPHORYLATION IN
RP   RESPONSE TO VEGFA, MUTAGENESIS OF TYR-1333, AND SUBCELLULAR LOCATION.
RX   PubMed=15001553; DOI=10.1096/fj.03-0767fje;
RA   Kobayashi S., Sawano A., Nojima Y., Shibuya M., Maru Y.;
RT   "The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and
RT   degradation of Flt-1 (VEGFR-1).";
RL   FASEB J. 18:929-931(2004).
RN   [26]
RP   FUNCTION IN VEGFA AND VEGFB SIGNALING; CANCER CELL MIGRATION;
RP   INVASIVENESS AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1.
RX   PubMed=15735759; DOI=10.1038/sj.onc.1208246;
RA   Fan F., Wey J.S., McCarty M.F., Belcheva A., Liu W., Bauer T.W.,
RA   Somcio R.J., Wu Y., Hooper A., Hicklin D.J., Ellis L.M.;
RT   "Expression and function of vascular endothelial growth factor
RT   receptor-1 on human colorectal cancer cells.";
RL   Oncogene 24:2647-2653(2005).
RN   [27]
RP   FUNCTION IN CELL MIGRATION AND PHOSPHORYLATION OF PTK2/FAK1; YES1 AND
RP   SRC.
RX   PubMed=16685275; DOI=10.1038/sj.bjc.6603143;
RA   Lesslie D.P., Summy J.M., Parikh N.U., Fan F., Trevino J.G.,
RA   Sawyer T.K., Metcalf C.A., Shakespeare W.C., Hicklin D.J., Ellis L.M.,
RA   Gallick G.E.;
RT   "Vascular endothelial growth factor receptor-1 mediates migration of
RT   human colorectal carcinoma cells by activation of Src family
RT   kinases.";
RL   Br. J. Cancer 94:1710-1717(2006).
RN   [28]
RP   MUTAGENESIS OF ASN-1050.
RX   PubMed=16286478; DOI=10.1074/jbc.M506454200;
RA   Meyer R.D., Mohammadi M., Rahimi N.;
RT   "A single amino acid substitution in the activation loop defines the
RT   decoy characteristic of VEGFR-1/FLT-1.";
RL   J. Biol. Chem. 281:867-875(2006).
RN   [29]
RP   FUNCTION IN PGF AND VEGFA SIGNALING; PHOSPHORYLATION OF AKT1;
RP   MAPK3/ERK1 AND MAP KINASES; CHEMOTAXIS AND ACTIVATION OF
RP   PHOSPHATIDYLINOSITOL 3-KINASE, AND AUTOPHOSPHORYLATION IN RESPONSE TO
RP   PGF AND VEGFA.
RX   PubMed=18079407; DOI=10.1161/ATVBAHA.107.158022;
RA   Tchaikovski V., Fellbrich G., Waltenberger J.;
RT   "The molecular basis of VEGFR-1 signal transduction pathways in
RT   primary human monocytes.";
RL   Arterioscler. Thromb. Vasc. Biol. 28:322-328(2008).
RN   [30]
RP   FUNCTION IN ENDOTHELIAL CELL SURVIVAL AND ANGIOGENESIS.
RX   PubMed=18583712; DOI=10.1161/CIRCRESAHA.108.174128;
RA   Nishi J., Minamino T., Miyauchi H., Nojima A., Tateno K., Okada S.,
RA   Orimo M., Moriya J., Fong G.H., Sunagawa K., Shibuya M., Komuro I.;
RT   "Vascular endothelial growth factor receptor-1 regulates postnatal
RT   angiogenesis through inhibition of the excessive activation of Akt.";
RL   Circ. Res. 103:261-268(2008).
RN   [31]
RP   FUNCTION IN CANCER CELL MIGRATION AND ACTIVATION OF MAPK1/ERK2 AND/OR
RP   MAPK3/ERK1.
RX   PubMed=20551949; DOI=10.1038/sj.bjc.6605746;
RA   Taylor A.P., Leon E., Goldenberg D.M.;
RT   "Placental growth factor (PlGF) enhances breast cancer cell motility
RT   by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement.";
RL   Br. J. Cancer 103:82-89(2010).
RN   [32]
RP   INTERACTION WITH GNB2L1.
RX   PubMed=21212275; DOI=10.1074/jbc.M110.165605;
RA   Wang F., Yamauchi M., Muramatsu M., Osawa T., Tsuchida R., Shibuya M.;
RT   "RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a
RT   PI3-K/Akt pathway.";
RL   J. Biol. Chem. 286:9097-9106(2011).
RN   [33]
RP   INTERACTION WITH PSEN1 AND PTPRB, DEPHOSPHORYLATION BY PTPRB,
RP   MUTAGENESIS OF VAL-767, AND PROTEOLYTIC CLEAVAGE BY PSEN1 AT VAL-767.
RX   PubMed=22016384; DOI=10.1074/jbc.M111.296590;
RA   Cai J., Chen Z., Ruan Q., Han S., Liu L., Qi X., Boye S.L.,
RA   Hauswirth W.W., Grant M.B., Boulton M.E.;
RT   "gamma-Secretase and presenilin mediate cleavage and phosphorylation
RT   of vascular endothelial growth factor receptor-1.";
RL   J. Biol. Chem. 286:42514-42523(2011).
RN   [34]
RP   FUNCTION AS DECOY RECEPTORS; REGULATION OF VEGFA SIGNALING AND
RP   REGULATION OF KDR ACTIVITY (ISOFORMS 2/3/4), AND ROLE IN PREECLAMPSIA.
RX   PubMed=21752276; DOI=10.1186/2045-824X-3-15;
RA   Ahmad S., Hewett P.W., Al-Ani B., Sissaoui S., Fujisawa T.,
RA   Cudmore M.J., Ahmed A.;
RT   "Autocrine activity of soluble Flt-1 controls endothelial cell
RT   function and angiogenesis.";
RL   Vasc. Cell 3:15-15(2011).
RN   [35]
RP   REVIEW ON FUNCTION AS NEGATIVE REGULATOR OF ANGIOGENESIS DURING
RP   EMBRYONIC DEVELOPMENT; POSITIVE REGULATION OF MACROPHAGE FUNCTION IN
RP   ADULTHOOD; ROLE IN CARCINOGENESIS AND INFLAMMATION.
RX   PubMed=17002866;
RA   Shibuya M.;
RT   "Differential roles of vascular endothelial growth factor receptor-1
RT   and receptor-2 in angiogenesis.";
RL   J. Biochem. Mol. Biol. 39:469-478(2006).
RN   [36]
RP   REVIEW ON STRUCTURE AND FUNCTION.
RX   PubMed=18680722; DOI=10.1016/j.bbrc.2008.07.121;
RA   Roskoski R. Jr.;
RT   "VEGF receptor protein-tyrosine kinases: structure and regulation.";
RL   Biochem. Biophys. Res. Commun. 375:287-291(2008).
RN   [37]
RP   REVIEW ON ROLE IN ANGIOGENESIS AND CANCER.
RX   PubMed=19230644; DOI=10.1016/j.ceb.2008.12.012;
RA   Lohela M., Bry M., Tammela T., Alitalo K.;
RT   "VEGFs and receptors involved in angiogenesis versus
RT   lymphangiogenesis.";
RL   Curr. Opin. Cell Biol. 21:154-165(2009).
RN   [38]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=19761875; DOI=10.1016/j.bbapap.2009.09.002;
RA   Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K.;
RT   "Structure-function analysis of VEGF receptor activation and the role
RT   of coreceptors in angiogenic signaling.";
RL   Biochim. Biophys. Acta 1804:567-580(2010).
RN   [39]
RP   REVIEW ON ROLE IN CANCER.
RX   PubMed=20127948; DOI=10.1002/cncr.24789;
RA   Schwartz J.D., Rowinsky E.K., Youssoufian H., Pytowski B., Wu Y.;
RT   "Vascular endothelial growth factor receptor-1 in human cancer:
RT   concise review and rationale for development of IMC-18F1 (Human
RT   antibody targeting vascular endothelial growth factor receptor-1).";
RL   Cancer 116:1027-1032(2010).
RN   [40]
RP   REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND
RP   SIGNALING.
RX   PubMed=21711246; DOI=10.1042/BJ20110301;
RA   Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L.;
RT   "Signal transduction by vascular endothelial growth factor
RT   receptors.";
RL   Biochem. J. 437:169-183(2011).
RN   [41]
RP   REVIEW ON ROLE IN CANCER AND PREECLAMPSIA.
RX   PubMed=21558755; DOI=10.2183/pjab.87.167;
RA   Shibuya M.;
RT   "Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia.";
RL   Proc. Jpn. Acad., B, Phys. Biol. Sci. 87:167-178(2011).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 132-226 IN COMPLEX WITH
RP   VEGFA, AND DOMAIN.
RX   PubMed=9393862; DOI=10.1016/S0092-8674(00)80456-0;
RA   Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A.,
RA   de Vos A.M.;
RT   "Crystal structure at 1.7 A resolution of VEGF in complex with domain
RT   2 of the Flt-1 receptor.";
RL   Cell 91:695-704(1997).
RN   [43]
RP   STRUCTURE BY NMR OF 129-229, X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF
RP   129-229 IN COMPLEX WITH VEGFA, SUBUNIT, AND INTERACTION WITH VEGFA.
RX   PubMed=10543948; DOI=10.1006/jmbi.1999.3134;
RA   Starovasnik M.A., Christinger H.W., Wiesmann C., Champe M.A.,
RA   de Vos A.M., Skelton N.J.;
RT   "Solution structure of the VEGF-binding domain of Flt-1: comparison of
RT   its free and bound states.";
RL   J. Mol. Biol. 293:531-544(1999).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 130-229 IN COMPLEX WITH PGF.
RX   PubMed=14684734; DOI=10.1074/jbc.M313237200;
RA   Christinger H.W., Fuh G., de Vos A.M., Wiesmann C.;
RT   "The crystal structure of placental growth factor in complex with
RT   domain 2 of vascular endothelial growth factor receptor-1.";
RL   J. Biol. Chem. 279:10382-10388(2004).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF 129-226 IN COMPLEX WITH
RP   VEGFB, INTERACTION WITH VEGFB, SUBUNIT, AND DOMAIN.
RX   PubMed=20501651; DOI=10.1074/jbc.M110.130658;
RA   Iyer S., Darley P.I., Acharya K.R.;
RT   "Structural insights into the binding of vascular endothelial growth
RT   factor-B by VEGFR-1(D2): recognition and specificity.";
RL   J. Biol. Chem. 285:23779-23789(2010).
RN   [46]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-60; LYS-144; GLN-281; ILE-422;
RP   GLN-781; VAL-938; ALA-982 AND VAL-1061.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface
CC       receptor for VEGFA, VEGFB and PGF, and plays an essential role in
CC       the development of embryonic vasculature, the regulation of
CC       angiogenesis, cell survival, cell migration, macrophage function,
CC       chemotaxis, and cancer cell invasion. May play an essential role
CC       as a negative regulator of embryonic angiogenesis by inhibiting
CC       excessive proliferation of endothelial cells. Can promote
CC       endothelial cell proliferation, survival and angiogenesis in
CC       adulthood. Its function in promoting cell proliferation seems to
CC       be cell-type specific. Promotes PGF-mediated proliferation of
CC       endothelial cells, proliferation of some types of cancer cells,
CC       but does not promote proliferation of normal fibroblasts (in
CC       vitro). Has very high affinity for VEGFA and relatively low
CC       protein kinase activity; may function as a negative regulator of
CC       VEGFA signaling by limiting the amount of free VEGFA and
CC       preventing its binding to KDR. Likewise, isoforms lacking a
CC       transmembrane domain, such as isoform 2, isoform 3 and isoform 4,
CC       may function as decoy receptors for VEGFA. Modulates KDR signaling
CC       by forming heterodimers with KDR. Ligand binding leads to the
CC       activation of several signaling cascades. Activation of PLCG leads
CC       to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate and the activation
CC       of protein kinase C. Mediates phosphorylation of PIK3R1, the
CC       regulatory subunit of phosphatidylinositol 3-kinase, leading to
CC       activation of phosphatidylinositol kinase and the downstream
CC       signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1
CC       and the MAP kinase signaling pathway, as well as of the AKT1
CC       signaling pathway. Phosphorylates SRC and YES1, and may also
CC       phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes
CC       phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of
CC       PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases
CC       phosphorylation of SRC at 'Tyr-418' by unknown means and promotes
CC       tumor cell invasion. {ECO:0000269|PubMed:11141500,
CC       ECO:0000269|PubMed:11312102, ECO:0000269|PubMed:11811792,
CC       ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:14633857,
CC       ECO:0000269|PubMed:15735759, ECO:0000269|PubMed:16685275,
CC       ECO:0000269|PubMed:18079407, ECO:0000269|PubMed:18515749,
CC       ECO:0000269|PubMed:18583712, ECO:0000269|PubMed:18593464,
CC       ECO:0000269|PubMed:20512933, ECO:0000269|PubMed:20551949,
CC       ECO:0000269|PubMed:21752276, ECO:0000269|PubMed:7824266,
CC       ECO:0000269|PubMed:8248162, ECO:0000269|PubMed:8605350,
CC       ECO:0000269|PubMed:9299537}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11312102,
CC       ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:7824266,
CC       ECO:0000269|PubMed:9299537, ECO:0000269|PubMed:9722576}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of VEGFA, VEGFB or PGF leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues.
CC   -!- SUBUNIT: Interacts with VEGFA, VEGFB and PGF. Monomer in the
CC       absence of bound VEGFA, VEGFB or PGF. Homodimer in the presence of
CC       bound VEGFA, VEGFB and PGF. Can also form a heterodimer with KDR.
CC       Interacts (when tyrosine phosphorylated) with CBL, CRK, GRB2,
CC       NCK1, PIK3R1, PLCG, PSEN1 and PTPN11. Probably interacts also with
CC       PTPRB. Interacts with GNB2L1/RACK1. Identified in a complex with
CC       CBL and CD2AP. {ECO:0000269|PubMed:10471394,
CC       ECO:0000269|PubMed:10543948, ECO:0000269|PubMed:11312102,
CC       ECO:0000269|PubMed:11513746, ECO:0000269|PubMed:12796773,
CC       ECO:0000269|PubMed:14684734, ECO:0000269|PubMed:15001553,
CC       ECO:0000269|PubMed:20501651, ECO:0000269|PubMed:21212275,
CC       ECO:0000269|PubMed:22016384, ECO:0000269|PubMed:7824266,
CC       ECO:0000269|PubMed:8248162, ECO:0000269|PubMed:9299537,
CC       ECO:0000269|PubMed:9393862, ECO:0000269|PubMed:9600074,
CC       ECO:0000269|PubMed:9722576}.
CC   -!- INTERACTION:
CC       P22681:CBL; NbExp=2; IntAct=EBI-1026718, EBI-518228;
CC       P46109:CRKL; NbExp=9; IntAct=EBI-1026718, EBI-910;
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-1026718, EBI-491549;
CC       P08631:HCK; NbExp=2; IntAct=EBI-1026718, EBI-346340;
CC       P98160:HSPG2; NbExp=2; IntAct=EBI-6530464, EBI-6896259;
CC       P49763:PGF; NbExp=2; IntAct=EBI-1026718, EBI-1037633;
CC       P27986:PIK3R1; NbExp=2; IntAct=EBI-1026718, EBI-79464;
CC       P19174:PLCG1; NbExp=2; IntAct=EBI-1026718, EBI-79387;
CC       Q05397:PTK2; NbExp=2; IntAct=EBI-1026718, EBI-702142;
CC       Q06124:PTPN11; NbExp=2; IntAct=EBI-1026718, EBI-297779;
CC       Q12913:PTPRJ; NbExp=2; IntAct=EBI-1026718, EBI-2264500;
CC       P15692:VEGFA; NbExp=4; IntAct=EBI-1026718, EBI-1026643;
CC       P15692-4:VEGFA; NbExp=3; IntAct=EBI-1026718, EBI-1026691;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Endosome. Note=Autophosphorylation promotes
CC       ubiquitination and endocytosis.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted
CC       {ECO:0000269|PubMed:8248162}.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Cytoplasm {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 6: Cytoplasm {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 7: Cytoplasm {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=Flt1;
CC         IsoId=P17948-1; Sequence=Displayed;
CC       Name=2; Synonyms=sFlt1;
CC         IsoId=P17948-2; Sequence=VSP_002955, VSP_002956;
CC       Name=3; Synonyms=sFlt1-14;
CC         IsoId=P17948-3; Sequence=VSP_041927, VSP_041928;
CC       Name=4;
CC         IsoId=P17948-4; Sequence=VSP_041929, VSP_041930;
CC       Name=5; Synonyms=i15;
CC         IsoId=P17948-5; Sequence=VSP_041985;
CC       Name=6; Synonyms=i18;
CC         IsoId=P17948-6; Sequence=VSP_041984;
CC       Name=7; Synonyms=i21;
CC         IsoId=P17948-7; Sequence=VSP_041983;
CC       Name=8;
CC         IsoId=P17948-8; Sequence=VSP_047759, VSP_047760;
CC   -!- TISSUE SPECIFICITY: Detected in normal lung, but also in placenta,
CC       liver, kidney, heart and brain tissues. Specifically expressed in
CC       most of the vascular endothelial cells, and also expressed in
CC       peripheral blood monocytes. Isoform 2 is strongly expressed in
CC       placenta. Isoform 3 is expressed in corneal epithelial cells (at
CC       protein level). Isoform 3 is expressed in vascular smooth muscle
CC       cells (VSMC). {ECO:0000269|PubMed:18515749,
CC       ECO:0000269|PubMed:20512933}.
CC   -!- INDUCTION: Up-regulated in coculture of VSMC/endothelial cell (EC)
CC       or by direct exposure to VEGF of VSMC monoculture. Up-regulated
CC       from the second trimester of pregnancy to the term and in the
CC       placenta of women with preeclampsia (PE). Up-regulated in
CC       monocytes exposed to bacterial lipopolysaccharide (LPS).
CC       {ECO:0000269|PubMed:18515749, ECO:0000269|PubMed:8605350}.
CC   -!- DOMAIN: The second and third Ig-like C2-type (immunoglobulin-like)
CC       domains are sufficient for VEGFA binding.
CC       {ECO:0000269|PubMed:20501651, ECO:0000269|PubMed:9393862}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:10471394,
CC       ECO:0000269|PubMed:11513746}.
CC   -!- PTM: Ubiquitinated after VEGFA-mediated autophosphorylation,
CC       leading to proteolytic degradation. {ECO:0000269|PubMed:15001553}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-1169 is important for interaction
CC       with PLCG. Phosphorylation at Tyr-1213 is important for
CC       interaction with PIK3R1, PTPN11, GRB2, and PLCG. Phosphorylation
CC       at Tyr-1333 is important for endocytosis and for interaction with
CC       CBL, NCK1 and CRK. Is probably dephosphorylated by PTPRB.
CC       {ECO:0000269|PubMed:11513746, ECO:0000269|PubMed:12796773,
CC       ECO:0000269|PubMed:9299537, ECO:0000269|PubMed:9600074,
CC       ECO:0000269|PubMed:9722576}.
CC   -!- DISEASE: Note=Can contribute to cancer cell survival,
CC       proliferation, migration, and invasion, and tumor angiogenesis and
CC       metastasis. May contribute to cancer pathogenesis by promoting
CC       inflammatory responses and recruitment of tumor-infiltrating
CC       macrophages.
CC   -!- DISEASE: Note=Abnormally high expression of soluble isoforms
CC       (isoform 2, isoform 3 or isoform 4) may be a cause of
CC       preeclampsia.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 7 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X51602; CAA35946.1; -; mRNA.
DR   EMBL; U01134; AAC50060.1; -; mRNA.
DR   EMBL; AF063657; AAC16449.2; -; mRNA.
DR   EMBL; EU826561; ACF47597.1; -; mRNA.
DR   EMBL; EU368830; ACA62948.1; -; mRNA.
DR   EMBL; DQ836394; ABI53803.1; -; mRNA.
DR   EMBL; DQ836395; ABI53804.1; -; mRNA.
DR   EMBL; DQ836396; ABI53805.1; -; mRNA.
DR   EMBL; EF491868; ABS32268.1; -; mRNA.
DR   EMBL; EF491869; ABS32269.1; -; mRNA.
DR   EMBL; EF491870; ABS32270.1; -; mRNA.
DR   EMBL; EU360600; ACB05747.1; -; mRNA.
DR   EMBL; EU332841; ABY87530.1; -; Genomic_DNA.
DR   EMBL; AK292936; BAF85625.1; -; mRNA.
DR   EMBL; AK300392; BAG62125.1; -; mRNA.
DR   EMBL; AL138712; CAI14846.1; -; Genomic_DNA.
DR   EMBL; AL139005; CAI14846.1; JOINED; Genomic_DNA.
DR   EMBL; AL139005; CAI17096.1; -; Genomic_DNA.
DR   EMBL; AL138712; CAI17096.1; JOINED; Genomic_DNA.
DR   EMBL; CH471075; EAX08431.1; -; Genomic_DNA.
DR   EMBL; CH471075; EAX08432.1; -; Genomic_DNA.
DR   EMBL; BC039007; AAH39007.1; -; mRNA.
DR   EMBL; D00133; BAA00080.1; -; Genomic_DNA.
DR   CCDS; CCDS53860.1; -. [P17948-3]
DR   CCDS; CCDS53861.1; -. [P17948-4]
DR   CCDS; CCDS73556.1; -. [P17948-2]
DR   CCDS; CCDS9330.1; -. [P17948-1]
DR   PIR; A49636; A49636.
DR   PIR; S09982; S09982.
DR   RefSeq; NP_001153392.1; NM_001159920.1. [P17948-2]
DR   RefSeq; NP_001153502.1; NM_001160030.1. [P17948-3]
DR   RefSeq; NP_001153503.1; NM_001160031.1. [P17948-4]
DR   RefSeq; NP_002010.2; NM_002019.4. [P17948-1]
DR   UniGene; Hs.594454; -.
DR   PDB; 1FLT; X-ray; 1.70 A; X/Y=132-226.
DR   PDB; 1QSV; NMR; -; A=129-229.
DR   PDB; 1QSZ; NMR; -; A=129-229.
DR   PDB; 1QTY; X-ray; 2.70 A; T/U/X/Y=129-229.
DR   PDB; 1RV6; X-ray; 2.45 A; X/Y=130-229.
DR   PDB; 2XAC; X-ray; 2.71 A; C/X=129-226.
DR   PDB; 3HNG; X-ray; 2.70 A; A=801-1158.
DR   PDB; 4CKV; X-ray; 2.06 A; X=132-225.
DR   PDB; 4CL7; X-ray; 2.00 A; A/B/C/D=132-225.
DR   PDBsum; 1FLT; -.
DR   PDBsum; 1QSV; -.
DR   PDBsum; 1QSZ; -.
DR   PDBsum; 1QTY; -.
DR   PDBsum; 1RV6; -.
DR   PDBsum; 2XAC; -.
DR   PDBsum; 3HNG; -.
DR   PDBsum; 4CKV; -.
DR   PDBsum; 4CL7; -.
DR   ProteinModelPortal; P17948; -.
DR   SMR; P17948; 32-750, 787-1196.
DR   BioGrid; 108609; 12.
DR   DIP; DIP-643N; -.
DR   IntAct; P17948; 30.
DR   MINT; MINT-127610; -.
DR   STRING; 9606.ENSP00000282397; -.
DR   BindingDB; P17948; -.
DR   ChEMBL; CHEMBL2111480; -.
DR   DrugBank; DB06626; Axitinib.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   GuidetoPHARMACOLOGY; 1812; -.
DR   iPTMnet; P17948; -.
DR   PhosphoSite; P17948; -.
DR   UniCarbKB; P17948; -.
DR   BioMuta; FLT1; -.
DR   DMDM; 143811474; -.
DR   MaxQB; P17948; -.
DR   PaxDb; P17948; -.
DR   PRIDE; P17948; -.
DR   DNASU; 2321; -.
DR   Ensembl; ENST00000282397; ENSP00000282397; ENSG00000102755. [P17948-1]
DR   Ensembl; ENST00000539099; ENSP00000442630; ENSG00000102755. [P17948-4]
DR   Ensembl; ENST00000541932; ENSP00000437631; ENSG00000102755. [P17948-3]
DR   Ensembl; ENST00000543394; ENSP00000437841; ENSG00000102755. [P17948-8]
DR   Ensembl; ENST00000615840; ENSP00000484039; ENSG00000102755. [P17948-2]
DR   GeneID; 2321; -.
DR   KEGG; hsa:2321; -.
DR   UCSC; uc001usa.3; human. [P17948-5]
DR   UCSC; uc001usb.3; human. [P17948-1]
DR   UCSC; uc001usc.3; human. [P17948-2]
DR   UCSC; uc010aap.2; human. [P17948-7]
DR   UCSC; uc010aaq.2; human. [P17948-6]
DR   UCSC; uc010aar.1; human. [P17948-3]
DR   UCSC; uc010tdp.1; human. [P17948-4]
DR   CTD; 2321; -.
DR   GeneCards; FLT1; -.
DR   H-InvDB; HIX0130593; -.
DR   HGNC; HGNC:3763; FLT1.
DR   HPA; CAB068189; -.
DR   HPA; CAB068190; -.
DR   HPA; HPA011740; -.
DR   HPA; HPA014290; -.
DR   MIM; 165070; gene.
DR   neXtProt; NX_P17948; -.
DR   PharmGKB; PA28180; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000037949; -.
DR   HOVERGEN; HBG053432; -.
DR   InParanoid; P17948; -.
DR   KO; K05096; -.
DR   OMA; ILTHIGH; -.
DR   OrthoDB; EOG75F4CC; -.
DR   PhylomeDB; P17948; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-194306; Neurophilin interactions with VEGF and VEGFR.
DR   Reactome; R-HSA-195399; VEGF binds to VEGFR leading to receptor dimerization.
DR   SignaLink; P17948; -.
DR   ChiTaRS; FLT1; human.
DR   EvolutionaryTrace; P17948; -.
DR   GeneWiki; FLT1; -.
DR   GenomeRNAi; 2321; -.
DR   NextBio; 35467213; -.
DR   PRO; PR:P17948; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; P17948; -.
DR   CleanEx; HS_FLT1; -.
DR   ExpressionAtlas; P17948; baseline and differential.
DR   Genevisible; P17948; HS.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005615; C:extracellular space; TAS:ProtInc.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:UniProtKB.
DR   GO; GO:0036332; F:placental growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0036326; F:VEGF-A-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0036327; F:VEGF-B-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0048514; P:blood vessel morphogenesis; ISS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0048598; P:embryonic morphogenesis; ISS:UniProtKB.
DR   GO; GO:0030522; P:intracellular receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0002548; P:monocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IMP:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006940; P:regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:ProtInc.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0036323; P:vascular endothelial growth factor receptor-1 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IDA:GOC.
DR   Gene3D; 2.60.40.10; -; 7.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   InterPro; IPR009135; VEGFR1_rcpt.
DR   Pfam; PF07679; I-set; 3.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR01833; VEGFRECEPTR1.
DR   SMART; SM00409; IG; 5.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 8.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 6.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell membrane; Chemotaxis; Complete proteome; Cytoplasm;
KW   Developmental protein; Differentiation; Direct protein sequencing;
KW   Disulfide bond; Endosome; Glycoprotein; Immunoglobulin domain; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     26       {ECO:0000269|PubMed:8248162}.
FT   CHAIN        27   1338       Vascular endothelial growth factor
FT                                receptor 1.
FT                                /FTId=PRO_0000016768.
FT   TOPO_DOM     27    758       Extracellular. {ECO:0000255}.
FT   TRANSMEM    759    780       Helical. {ECO:0000255}.
FT   TOPO_DOM    781   1338       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       32    123       Ig-like C2-type 1.
FT   DOMAIN      151    214       Ig-like C2-type 2.
FT   DOMAIN      230    327       Ig-like C2-type 3.
FT   DOMAIN      335    421       Ig-like C2-type 4.
FT   DOMAIN      428    553       Ig-like C2-type 5.
FT   DOMAIN      556    654       Ig-like C2-type 6.
FT   DOMAIN      661    747       Ig-like C2-type 7.
FT   DOMAIN      827   1158       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     833    841       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE   1022   1022       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     861    861       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        767    768       Cleavage; by PSEN1. {ECO:0000305}.
FT   MOD_RES     914    914       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:9722576}.
FT   MOD_RES    1053   1053       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1169   1169       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:9299537}.
FT   MOD_RES    1213   1213       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11513746,
FT                                ECO:0000269|PubMed:12796773,
FT                                ECO:0000269|PubMed:9299537,
FT                                ECO:0000269|PubMed:9600074,
FT                                ECO:0000269|PubMed:9722576}.
FT   MOD_RES    1242   1242       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:9722576}.
FT   MOD_RES    1309   1309       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12796773}.
FT   MOD_RES    1327   1327       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12796773,
FT                                ECO:0000269|PubMed:9722576}.
FT   MOD_RES    1333   1333       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:9722576}.
FT   CARBOHYD    100    100       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    164    164       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    196    196       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    251    251       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    323    323       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    402    402       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    417    417       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    474    474       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    547    547       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    597    597       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    620    620       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    625    625       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    666    666       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     53    107       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    158    207
FT   DISULFID    252    311       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    454    535       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    577    636       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    682    731       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ       1    995       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:20512933}.
FT                                /FTId=VSP_041983.
FT   VAR_SEQ       1    875       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:20512933}.
FT                                /FTId=VSP_041984.
FT   VAR_SEQ       1    782       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:20512933}.
FT                                /FTId=VSP_041985.
FT   VAR_SEQ       1      7       MVSYWDT -> MNSDLLV (in isoform 8).
FT                                {ECO:0000303|PubMed:20512933}.
FT                                /FTId=VSP_047759.
FT   VAR_SEQ       8    984       Missing (in isoform 8).
FT                                {ECO:0000303|PubMed:20512933}.
FT                                /FTId=VSP_047760.
FT   VAR_SEQ     518    541       MASTLVVADSRISGIYICIASNKV -> LPPANSSFMLPPT
FT                                SFSSNYFHFLP (in isoform 4).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041929.
FT   VAR_SEQ     542   1338       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041930.
FT   VAR_SEQ     657    687       DQEAPYLLRNLSDHTVAISSSTTLDCHANGV -> GEHCNK
FT                                KAVFSRISKFKSTRNDCTTQSNVKH (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8248162}.
FT                                /FTId=VSP_002955.
FT   VAR_SEQ     688   1338       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8248162}.
FT                                /FTId=VSP_002956.
FT   VAR_SEQ     706    733       GIILGPGSSTLFIERVTEEDEGVYHCKA -> ELYTSTSPS
FT                                SSSSSPLSSSSSSSSSSSS (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:18515749,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_041927.
FT   VAR_SEQ     734   1338       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:18515749,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_041928.
FT   VARIANT      60     60       K -> T (in dbSNP:rs56409818).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042045.
FT   VARIANT     128    128       I -> L (in dbSNP:rs35073261).
FT                                /FTId=VAR_049719.
FT   VARIANT     144    144       E -> K (in dbSNP:rs55974987).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042046.
FT   VARIANT     281    281       R -> Q (in dbSNP:rs55687105).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042047.
FT   VARIANT     422    422       L -> I (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042048.
FT   VARIANT     781    781       R -> Q (in a glioma low grade
FT                                oligodendroglioma sample; somatic
FT                                mutation). {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042049.
FT   VARIANT     938    938       M -> V (in dbSNP:rs35549791).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042050.
FT   VARIANT     982    982       E -> A (in dbSNP:rs35832528).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042051.
FT   VARIANT    1061   1061       L -> V (in a bladder transitional cell
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042052.
FT   MUTAGEN     767    767       V->A: Abolishes proteolytic cleavage by
FT                                PSEN1. {ECO:0000269|PubMed:22016384}.
FT   MUTAGEN     861    861       K->M: Abolishes enzyme activity.
FT                                Abolishes interaction with PLCG.
FT                                {ECO:0000269|PubMed:9299537}.
FT   MUTAGEN     914    914       Y->F: Reduces phosphorylation at other
FT                                tyrosine residues.
FT                                {ECO:0000269|PubMed:9722576}.
FT   MUTAGEN    1050   1050       N->D: Strongly increases kinase activity.
FT                                Increases activity in promoting
FT                                proliferation of endothelial cells.
FT                                {ECO:0000269|PubMed:16286478}.
FT   MUTAGEN    1169   1169       Y->F: Loss of phosphorylation site.
FT                                Abolishes interaction with PLCG.
FT                                {ECO:0000269|PubMed:9299537}.
FT   MUTAGEN    1213   1213       Y->F: Loss of phosphorylation site.
FT                                Abolishes interaction with PIK3R1.
FT                                {ECO:0000269|PubMed:9722576}.
FT   MUTAGEN    1242   1242       Y->F: Loss of phosphorylation site.
FT                                {ECO:0000269|PubMed:9722576}.
FT   MUTAGEN    1327   1327       Y->F: Loss of phosphorylation site.
FT                                {ECO:0000269|PubMed:9722576}.
FT   MUTAGEN    1333   1333       Y->F: Loss of phosphorylation site.
FT                                Abolishes interaction with CBL.
FT                                {ECO:0000269|PubMed:15001553,
FT                                ECO:0000269|PubMed:9722576}.
FT   CONFLICT    490    490       F -> S (in Ref. 3; AAC16449).
FT                                {ECO:0000305}.
FT   CONFLICT    779    779       F -> L (in Ref. 1; CAA35946).
FT                                {ECO:0000305}.
FT   CONFLICT   1029   1029       L -> F (in Ref. 6; ABI53803/ABI53804).
FT                                {ECO:0000305}.
FT   TURN        130    132       {ECO:0000244|PDB:1QSV}.
FT   STRAND      135    137       {ECO:0000244|PDB:1FLT}.
FT   STRAND      140    142       {ECO:0000244|PDB:4CL7}.
FT   STRAND      144    148       {ECO:0000244|PDB:1FLT}.
FT   STRAND      150    152       {ECO:0000244|PDB:1QSZ}.
FT   STRAND      154    156       {ECO:0000244|PDB:1FLT}.
FT   STRAND      160    162       {ECO:0000244|PDB:1RV6}.
FT   HELIX       163    165       {ECO:0000244|PDB:1QSV}.
FT   STRAND      168    171       {ECO:0000244|PDB:1FLT}.
FT   TURN        172    174       {ECO:0000244|PDB:1FLT}.
FT   STRAND      175    177       {ECO:0000244|PDB:1FLT}.
FT   STRAND      181    187       {ECO:0000244|PDB:1FLT}.
FT   TURN        188    190       {ECO:0000244|PDB:1FLT}.
FT   STRAND      191    196       {ECO:0000244|PDB:1FLT}.
FT   HELIX       199    201       {ECO:0000244|PDB:1FLT}.
FT   STRAND      203    211       {ECO:0000244|PDB:1FLT}.
FT   STRAND      214    224       {ECO:0000244|PDB:1FLT}.
FT   HELIX       806    809       {ECO:0000244|PDB:3HNG}.
FT   HELIX       817    820       {ECO:0000244|PDB:3HNG}.
FT   HELIX       824    826       {ECO:0000244|PDB:3HNG}.
FT   STRAND      827    835       {ECO:0000244|PDB:3HNG}.
FT   STRAND      837    848       {ECO:0000244|PDB:3HNG}.
FT   HELIX       849    851       {ECO:0000244|PDB:3HNG}.
FT   STRAND      854    863       {ECO:0000244|PDB:3HNG}.
FT   HELIX       869    883       {ECO:0000244|PDB:3HNG}.
FT   STRAND      894    898       {ECO:0000244|PDB:3HNG}.
FT   STRAND      906    910       {ECO:0000244|PDB:3HNG}.
FT   HELIX       917    922       {ECO:0000244|PDB:3HNG}.
FT   HELIX       996   1014       {ECO:0000244|PDB:3HNG}.
FT   TURN       1015   1017       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1025   1027       {ECO:0000244|PDB:3HNG}.
FT   STRAND     1028   1030       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1032   1034       {ECO:0000244|PDB:3HNG}.
FT   STRAND     1036   1038       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1042   1044       {ECO:0000244|PDB:3HNG}.
FT   TURN       1047   1049       {ECO:0000244|PDB:3HNG}.
FT   STRAND     1053   1055       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1063   1065       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1068   1073       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1078   1093       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1107   1113       {ECO:0000244|PDB:3HNG}.
FT   TURN       1114   1116       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1127   1136       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1141   1143       {ECO:0000244|PDB:3HNG}.
FT   HELIX      1147   1157       {ECO:0000244|PDB:3HNG}.
SQ   SEQUENCE   1338 AA;  150769 MW;  FF3381EEFAF0787C CRC64;
     MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPELSLKGTQ HIMQAGQTLH LQCRGEAAHK
     WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLTLNTAQAN HTGFYSCKYL AVPTSKKKET
     ESAIYIFISD TGRPFVEMYS EIPEIIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD
     GKRIIWDSRK GFIISNATYK EIGLLTCEAT VNGHLYKTNY LTHRQTNTII DVQISTPRPV
     KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSNSHAN IFYSVLTIDK
     MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK
     AFPSPEVVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA
     TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC
     DFCSNNEESF ILDADSNMGN RIESITQRMA IIEGKNKMAS TLVVADSRIS GIYICIASNK
     VGTVGRNISF YITDVPNGFH VNLEKMPTEG EDLKLSCTVN KFLYRDVTWI LLRTVNNRTM
     HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGEEILQK KEITIRDQEA
     PYLLRNLSDH TVAISSSTTL DCHANGVPEP QITWFKNNHK IQQEPGIILG PGSSTLFIER
     VTEEDEGVYH CKATNQKGSV ESSAYLTVQG TSDKSNLELI TLTCTCVAAT LFWLLLTLFI
     RKMKRSSSEI KTDYLSIIMD PDEVPLDEQC ERLPYDASKW EFARERLKLG KSLGRGAFGK
     VVQASAFGIK KSPTCRTVAV KMLKEGATAS EYKALMTELK ILTHIGHHLN VVNLLGACTK
     QGGPLMVIVE YCKYGNLSNY LKSKRDLFFL NKDAALHMEP KKEKMEPGLE QGKKPRLDSV
     TSSESFASSG FQEDKSLSDV EEEEDSDGFY KEPITMEDLI SYSFQVARGM EFLSSRKCIH
     RDLAARNILL SENNVVKICD FGLARDIYKN PDYVRKGDTR LPLKWMAPES IFDKIYSTKS
     DVWSYGVLLW EIFSLGGSPY PGVQMDEDFC SRLREGMRMR APEYSTPEIY QIMLDCWHRD
     PKERPRFAEL VEKLGDLLQA NVQQDGKDYI PINAILTGNS GFTYSTPAFS EDFFKESISA
     PKFNSGSSDD VRYVNAFKFM SLERIKTFEE LLPNATSMFD DYQGDSSTLL ASPMLKRFTW
     TDSKPKASLK IDLRVTSKSK ESGLSDVSRP SFCHSSCGHV SEGKRRFTYD HAELERKIAC
     CSPPPDYNSV VLYSTPPI
//
ID   DECA_DROME              Reviewed;         588 AA.
AC   P07713; A4V009; P91651; Q6AWM1; Q8I0M7; Q8ITK4; Q9VQC6;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2005, sequence version 2.
DT   09-DEC-2015, entry version 151.
DE   RecName: Full=Protein decapentaplegic;
DE            Short=Protein DPP-C;
DE   Flags: Precursor;
GN   Name=dpp; ORFNames=CG9885;
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta;
OC   Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3467201; DOI=10.1038/325081a0;
RA   Padgett R.W., St Johnston R.D., Gelbart W.M.;
RT   "A transcript from a Drosophila pattern gene predicts a protein
RT   homologous to the transforming growth factor-beta family.";
RL   Nature 325:81-84(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-59 AND MET-121.
RC   STRAIN=DP CN BW;
RX   PubMed=9071586;
RA   Richter B., Long M., Lewontin R.C., Nitasaka E.;
RT   "Nucleotide variation and conservation at the dpp locus, a gene
RT   controlling early development in Drosophila.";
RL   Genetics 145:311-323(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley;
RX   PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA   Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C.L., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.J.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA   Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S.C., Zhu X.,
RA   Smith H.O., Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [4]
RP   GENOME REANNOTATION.
RC   STRAIN=Berkeley;
RX   PubMed=12537572; DOI=10.1186/gb-2002-3-12-research0083;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Berkeley; TISSUE=Embryo;
RA   Stapleton M., Carlson J.W., Chavez C., Frise E., George R.A.,
RA   Pacleb J.M., Park S., Wan K.H., Yu C., Rubin G.M., Celniker S.E.;
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 291-509, AND VARIANT ALA-439.
RX   PubMed=12618399;
RA   Mousset S., Brazier L., Cariou M.L., Chartois F., Depaulis F.,
RA   Veuille M.;
RT   "Evidence of a high rate of selective sweeps in African Drosophila
RT   melanogaster.";
RL   Genetics 163:599-609(2003).
RN   [7]
RP   PROTEIN SEQUENCE OF 457-476, FUNCTION, SUBCELLULAR LOCATION, AND
RP   CLEAVAGE AT ARG-457.
RX   PubMed=1692958;
RA   Panganiban G.E.F., Rashka K.E., Neitzel M.D., Hoffmann F.M.;
RT   "Biochemical characterization of the Drosophila dpp protein, a member
RT   of the transforming growth factor beta family of growth factors.";
RL   Mol. Cell. Biol. 10:2669-2677(1990).
RN   [8]
RP   FUNCTION.
RX   PubMed=3123323; DOI=10.1101/gad.1.8.868;
RA   Irish V.F., Gelbart W.M.;
RT   "The decapentaplegic gene is required for dorsal-ventral patterning of
RT   the Drosophila embryo.";
RL   Genes Dev. 1:868-879(1987).
RN   [9]
RP   FUNCTION.
RX   PubMed=8252627; DOI=10.1016/0092-8674(93)90535-X;
RA   Heberlein U., Wolff T., Rubin G.M.;
RT   "The TGF beta homolog dpp and the segment polarity gene hedgehog are
RT   required for propagation of a morphogenetic wave in the Drosophila
RT   retina.";
RL   Cell 75:913-926(1993).
RN   [10]
RP   FUNCTION.
RX   PubMed=7720583;
RA   Sturtevant M.A., Bier E.;
RT   "Analysis of the genetic hierarchy guiding wing vein development in
RT   Drosophila.";
RL   Development 121:785-801(1995).
RN   [11]
RP   FUNCTION.
RX   PubMed=7700357; DOI=10.1038/374464a0;
RA   Frasch M.;
RT   "Induction of visceral and cardiac mesoderm by ectodermal Dpp in the
RT   early Drosophila embryo.";
RL   Nature 374:464-467(1995).
RN   [12]
RP   FUNCTION.
RX   PubMed=9226445;
RA   Vincent S., Ruberte E., Grieder N.C., Chen C.-K., Haerry T., Schuh R.,
RA   Affolter M.;
RT   "DPP controls tracheal cell migration along the dorsoventral body axis
RT   of the Drosophila embryo.";
RL   Development 124:2741-2750(1997).
RN   [13]
RP   FUNCTION.
RX   PubMed=9695953; DOI=10.1016/S0092-8674(00)81424-5;
RA   Xie T., Spradling A.C.;
RT   "decapentaplegic is essential for the maintenance and division of
RT   germline stem cells in the Drosophila ovary.";
RL   Cell 94:251-260(1998).
RN   [14]
RP   FUNCTION.
RX   PubMed=9636086;
RA   Khalsa O., Yoon J.-W., Torres-Schumann S., Wharton K.A.;
RT   "TGF-beta/BMP superfamily members, Gbb-60A and Dpp, cooperate to
RT   provide pattern information and establish cell identity in the
RT   Drosophila wing.";
RL   Development 125:2723-2734(1998).
RN   [15]
RP   FUNCTION.
RX   PubMed=10495279; DOI=10.1016/S0925-4773(99)00157-4;
RA   Steneberg P., Hemphala J., Samakovlis C.;
RT   "Dpp and Notch specify the fusion cell fate in the dorsal branches of
RT   the Drosophila trachea.";
RL   Mech. Dev. 87:153-163(1999).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11136981; DOI=10.1016/S0092-8674(00)00199-9;
RA   Teleman A.A., Cohen S.M.;
RT   "Dpp gradient formation in the Drosophila wing imaginal disc.";
RL   Cell 103:971-980(2000).
RN   [17]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11136982; DOI=10.1016/S0092-8674(00)00200-2;
RA   Entchev E.V., Schwabedissen A., Gonzalez-Gaitan M.;
RT   "Gradient formation of the TGF-beta homolog Dpp.";
RL   Cell 103:981-991(2000).
RN   [18]
RP   FUNCTION, AND DEVELOPMENTAL STAGE.
RX   PubMed=10903186;
RA   Araujo H., Bier E.;
RT   "sog and dpp exert opposing maternal functions to modify toll
RT   signaling and pattern the dorsoventral axis of the Drosophila
RT   embryo.";
RL   Development 127:3631-3644(2000).
RN   [19]
RP   REVIEW.
RX   PubMed=11432817; DOI=10.1093/emboj/20.13.3298;
RA   Affolter M., Marty T., Vigano M.A., Jazwinska A.;
RT   "Nuclear interpretation of Dpp signaling in Drosophila.";
RL   EMBO J. 20:3298-3305(2001).
RN   [20]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=11231061; DOI=10.1016/S0925-4773(00)00555-4;
RA   Takashima S., Murakami R.;
RT   "Regulation of pattern formation in the Drosophila hindgut by wg, hh,
RT   dpp, and en.";
RL   Mech. Dev. 101:79-90(2001).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH SOG AND TSG.
RX   PubMed=11260716; DOI=10.1038/35068578;
RA   Ross J.J., Shimmi O., Vilmos P., Petryk A., Kim H., Gaudenz K.,
RA   Hermanson S., Ekker S.C., O'Connor M.B., Marsh J.L.;
RT   "Twisted gastrulation is a conserved extracellular BMP antagonist.";
RL   Nature 410:479-483(2001).
RN   [22]
RP   FUNCTION.
RX   PubMed=12135920;
RA   Cavodeassi F., Rodriguez I., Modolell J.;
RT   "Dpp signalling is a key effector of the wing-body wall subdivision of
RT   the Drosophila mesothorax.";
RL   Development 129:3815-3823(2002).
RN   [23]
RP   FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=15797386; DOI=10.1016/j.cell.2005.02.009;
RA   Shimmi O., Umulis D., Othmer H., O'Connor M.B.;
RT   "Facilitated transport of a Dpp/Scw heterodimer by Sog/Tsg leads to
RT   robust patterning of the Drosophila blastoderm embryo.";
RL   Cell 120:873-886(2005).
RN   [24]
RP   REVIEW.
RX   PubMed=15867930; DOI=10.1038/ncb0505-456;
RA   Schuldt A.;
RT   "Dpp gets in shape.";
RL   Nat. Cell Biol. 7:456-456(2005).
CC   -!- FUNCTION: Required during oogenesis for eggshell patterning and
CC       dorsal/ventral patterning of the embryo. Acts as a morphogen
CC       during embryogenesis to pattern the dorsal/ventral axis,
CC       specifying dorsal ectoderm and amnioserosa cell fate within the
CC       dorsal half of the embryo; this activity is antagonized by binding
CC       to sog and tsg. Induces the formation of visceral mesoderm and the
CC       heart in early embryos. Required later in embryogenesis for dorsal
CC       closure and patterning of the hindgut. Also functions
CC       postembryonically as a long-range morphogen during imaginal disk
CC       development; is responsible for the progression of the
CC       morphogenetic furrow during eye development. Patterns the wing
CC       imaginal disk along its anterior/posterior axis and has a role in
CC       positioning pro-veins. Also required to subdivide the wing disk
CC       along the proximal/distal axis into body wall (notum) and wing.
CC       Ensures the correct architecture of wing epithelial cells. Has
CC       multiple roles in the developing tracheal system, controlling
CC       directed tracheal cell migration during embryogenesis and later
CC       specifying the fate of fusion cells in the tracheal branches.
CC       Required for viability of larvae. Essential for the maintenance
CC       and division of germline stem cells in the ovary. Signals via the
CC       type I receptor tkv, the type II receptor punt, and in some
CC       tissues via the type I receptor sax, in a signaling cascade that
CC       leads to activation and repression of target genes.
CC       {ECO:0000269|PubMed:10495279, ECO:0000269|PubMed:10903186,
CC       ECO:0000269|PubMed:11136981, ECO:0000269|PubMed:11231061,
CC       ECO:0000269|PubMed:11260716, ECO:0000269|PubMed:12135920,
CC       ECO:0000269|PubMed:15797386, ECO:0000269|PubMed:1692958,
CC       ECO:0000269|PubMed:3123323, ECO:0000269|PubMed:7700357,
CC       ECO:0000269|PubMed:7720583, ECO:0000269|PubMed:8252627,
CC       ECO:0000269|PubMed:9226445, ECO:0000269|PubMed:9636086,
CC       ECO:0000269|PubMed:9695953}.
CC   -!- SUBUNIT: Heterodimers of scw/dpp are the active subunit, dpp/dpp
CC       homodimers elicit a basal response and scw/scw homodimers alone
CC       are ineffective in specifying a dorsal pattern. Component of a
CC       complex composed of dpp, sog and tsg.
CC       {ECO:0000269|PubMed:15797386}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:11136981,
CC       ECO:0000269|PubMed:11136982, ECO:0000269|PubMed:1692958}. Note=Is
CC       internalized by receptor-mediated endocytosis.
CC   -!- TISSUE SPECIFICITY: Expressed in the dorsal region of the embryo,
CC       and becomes enriched in a dorsal midline stripe just prior to
CC       gastrulation. Expressed in midgut mesoderm and in two overlapping
CC       regions of the embryonic large intestine. Expressed in a long-
CC       range concentration gradient in the wing imaginal disk.
CC       {ECO:0000269|PubMed:11136981, ECO:0000269|PubMed:11136982,
CC       ECO:0000269|PubMed:11231061, ECO:0000269|PubMed:15797386}.
CC   -!- DEVELOPMENTAL STAGE: Expressed both maternally and zygotically.
CC       First detected during stages 8 to 10 of oogenesis.
CC       {ECO:0000269|PubMed:10903186}.
CC   -!- SIMILARITY: Belongs to the TGF-beta family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M30116; AAA28482.1; -; mRNA.
DR   EMBL; U63857; AAC47552.1; -; Genomic_DNA.
DR   EMBL; AE014134; AAF51250.1; -; Genomic_DNA.
DR   EMBL; AE014134; AAN10431.1; -; Genomic_DNA.
DR   EMBL; AE014134; AAN10432.1; -; Genomic_DNA.
DR   EMBL; AE014134; AAN10434.1; -; Genomic_DNA.
DR   EMBL; BT015227; AAT94456.1; -; mRNA.
DR   EMBL; AF459545; AAN61361.1; -; Genomic_DNA.
DR   EMBL; AF459546; AAN61362.1; -; Genomic_DNA.
DR   EMBL; AF459547; AAN61363.1; -; Genomic_DNA.
DR   EMBL; AF459548; AAN61364.1; -; Genomic_DNA.
DR   EMBL; AF459549; AAN61365.1; -; Genomic_DNA.
DR   EMBL; AF459550; AAN61366.1; -; Genomic_DNA.
DR   EMBL; AF459551; AAN61367.1; -; Genomic_DNA.
DR   EMBL; AF459552; AAN61368.1; -; Genomic_DNA.
DR   EMBL; AF459553; AAN61369.1; -; Genomic_DNA.
DR   EMBL; AF459554; AAN61370.1; -; Genomic_DNA.
DR   EMBL; AF459555; AAN61371.1; -; Genomic_DNA.
DR   EMBL; AF459556; AAN61372.1; -; Genomic_DNA.
DR   EMBL; AF459557; AAN61373.1; -; Genomic_DNA.
DR   EMBL; AF459558; AAN61374.1; -; Genomic_DNA.
DR   EMBL; AF459559; AAN61375.1; -; Genomic_DNA.
DR   EMBL; AF459560; AAN61376.1; -; Genomic_DNA.
DR   EMBL; AF459561; AAN61377.1; -; Genomic_DNA.
DR   EMBL; AF459562; AAN61378.1; -; Genomic_DNA.
DR   EMBL; AF459563; AAN61379.1; -; Genomic_DNA.
DR   EMBL; AF459564; AAN61380.1; -; Genomic_DNA.
DR   PIR; A26158; A26158.
DR   RefSeq; NP_477311.1; NM_057963.5.
DR   RefSeq; NP_722810.1; NM_164485.2.
DR   RefSeq; NP_722811.1; NM_164486.2.
DR   RefSeq; NP_722813.1; NM_164488.2.
DR   UniGene; Dm.4767; -.
DR   ProteinModelPortal; P07713; -.
DR   SMR; P07713; 486-588.
DR   BioGrid; 59659; 55.
DR   DIP; DIP-19N; -.
DR   MINT; MINT-1025264; -.
DR   STRING; 7227.FBpp0077451; -.
DR   PaxDb; P07713; -.
DR   EnsemblMetazoa; FBtr0077771; FBpp0077451; FBgn0000490.
DR   EnsemblMetazoa; FBtr0077772; FBpp0077452; FBgn0000490.
DR   EnsemblMetazoa; FBtr0077773; FBpp0077453; FBgn0000490.
DR   EnsemblMetazoa; FBtr0077775; FBpp0077455; FBgn0000490.
DR   GeneID; 33432; -.
DR   KEGG; dme:Dmel_CG9885; -.
DR   UCSC; CG9885-RB; d. melanogaster.
DR   CTD; 33432; -.
DR   FlyBase; FBgn0000490; dpp.
DR   eggNOG; KOG3900; Eukaryota.
DR   eggNOG; ENOG410XT8Z; LUCA.
DR   GeneTree; ENSGT00760000118883; -.
DR   InParanoid; P07713; -.
DR   KO; K04662; -.
DR   OMA; RQFNEVH; -.
DR   OrthoDB; EOG7WHH9D; -.
DR   PhylomeDB; P07713; -.
DR   Reactome; R-DME-201451; Signaling by BMP.
DR   Reactome; R-DME-2129379; Molecules associated with elastic fibres.
DR   SignaLink; P07713; -.
DR   GenomeRNAi; 33432; -.
DR   NextBio; 783529; -.
DR   PRO; PR:P07713; -.
DR   Proteomes; UP000000803; Chromosome 2L.
DR   Bgee; P07713; -.
DR   Genevisible; P07713; DM.
DR   GO; GO:0005615; C:extracellular space; IDA:FlyBase.
DR   GO; GO:0005622; C:intracellular; IDA:FlyBase.
DR   GO; GO:0005518; F:collagen binding; IDA:FlyBase.
DR   GO; GO:0005125; F:cytokine activity; IBA:GO_Central.
DR   GO; GO:0008201; F:heparin binding; IDA:FlyBase.
DR   GO; GO:0016015; F:morphogen activity; NAS:FlyBase.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0005160; F:transforming growth factor beta receptor binding; IBA:GO_Central.
DR   GO; GO:0007378; P:amnioserosa formation; NAS:FlyBase.
DR   GO; GO:0061327; P:anterior Malpighian tubule development; IMP:FlyBase.
DR   GO; GO:0009948; P:anterior/posterior axis specification; TAS:FlyBase.
DR   GO; GO:0007448; P:anterior/posterior pattern specification, imaginal disc; NAS:FlyBase.
DR   GO; GO:0030509; P:BMP signaling pathway; NAS:FlyBase.
DR   GO; GO:0061353; P:BMP signaling pathway involved in Malpighian tubule cell chemotaxis; IDA:FlyBase.
DR   GO; GO:0035147; P:branch fusion, open tracheal system; TAS:FlyBase.
DR   GO; GO:0046845; P:branched duct epithelial cell fate determination, open tracheal system; TAS:FlyBase.
DR   GO; GO:0010002; P:cardioblast differentiation; IMP:FlyBase.
DR   GO; GO:0001709; P:cell fate determination; TAS:FlyBase.
DR   GO; GO:0001708; P:cell fate specification; NAS:FlyBase.
DR   GO; GO:0007304; P:chorion-containing eggshell formation; IMP:FlyBase.
DR   GO; GO:0001745; P:compound eye morphogenesis; IMP:FlyBase.
DR   GO; GO:0048066; P:developmental pigmentation; TAS:FlyBase.
DR   GO; GO:0046843; P:dorsal appendage formation; IMP:FlyBase.
DR   GO; GO:0007391; P:dorsal closure; IGI:FlyBase.
DR   GO; GO:0007393; P:dorsal closure, leading edge cell fate determination; NAS:FlyBase.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IMP:UniProtKB.
DR   GO; GO:0007450; P:dorsal/ventral pattern formation, imaginal disc; TAS:FlyBase.
DR   GO; GO:0007398; P:ectoderm development; TAS:FlyBase.
DR   GO; GO:0001715; P:ectodermal cell fate specification; NAS:FlyBase.
DR   GO; GO:0048619; P:embryonic hindgut morphogenesis; IMP:UniProtKB.
DR   GO; GO:0007425; P:epithelial cell fate determination, open tracheal system; TAS:FlyBase.
DR   GO; GO:0007427; P:epithelial cell migration, open tracheal system; IMP:UniProtKB.
DR   GO; GO:0035214; P:eye-antennal disc development; IMP:FlyBase.
DR   GO; GO:0007455; P:eye-antennal disc morphogenesis; IMP:FlyBase.
DR   GO; GO:0036099; P:female germ-line stem cell population maintenance; IMP:FlyBase.
DR   GO; GO:0007440; P:foregut morphogenesis; TAS:FlyBase.
DR   GO; GO:0035156; P:fusion cell fate specification; IMP:UniProtKB.
DR   GO; GO:0035224; P:genital disc anterior/posterior pattern formation; IEP:FlyBase.
DR   GO; GO:0035215; P:genital disc development; IMP:FlyBase.
DR   GO; GO:0035263; P:genital disc sexually dimorphic development; IMP:FlyBase.
DR   GO; GO:0007281; P:germ cell development; IMP:FlyBase.
DR   GO; GO:0008354; P:germ cell migration; IMP:FlyBase.
DR   GO; GO:0042078; P:germ-line stem cell division; IMP:FlyBase.
DR   GO; GO:0030718; P:germ-line stem cell population maintenance; IMP:FlyBase.
DR   GO; GO:0060323; P:head morphogenesis; IMP:FlyBase.
DR   GO; GO:0007507; P:heart development; IMP:UniProtKB.
DR   GO; GO:0007516; P:hemocyte development; IMP:FlyBase.
DR   GO; GO:0007442; P:hindgut morphogenesis; IMP:FlyBase.
DR   GO; GO:0007444; P:imaginal disc development; IMP:FlyBase.
DR   GO; GO:0007446; P:imaginal disc growth; TAS:FlyBase.
DR   GO; GO:0007447; P:imaginal disc pattern formation; NAS:FlyBase.
DR   GO; GO:0007476; P:imaginal disc-derived wing morphogenesis; IMP:FlyBase.
DR   GO; GO:0008586; P:imaginal disc-derived wing vein morphogenesis; IMP:FlyBase.
DR   GO; GO:0007474; P:imaginal disc-derived wing vein specification; IMP:FlyBase.
DR   GO; GO:0035217; P:labial disc development; IMP:FlyBase.
DR   GO; GO:0035168; P:larval lymph gland hemocyte differentiation; IMP:FlyBase.
DR   GO; GO:0007479; P:leg disc proximal/distal pattern formation; NAS:FlyBase.
DR   GO; GO:0048542; P:lymph gland development; IMP:FlyBase.
DR   GO; GO:0007443; P:Malpighian tubule morphogenesis; IMP:FlyBase.
DR   GO; GO:0007313; P:maternal specification of dorsal/ventral axis, oocyte, soma encoded; IMP:FlyBase.
DR   GO; GO:0007498; P:mesoderm development; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:FlyBase.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:FlyBase.
DR   GO; GO:0045705; P:negative regulation of salivary gland boundary specification; TAS:FlyBase.
DR   GO; GO:0045476; P:nurse cell apoptotic process; NAS:FlyBase.
DR   GO; GO:0048477; P:oogenesis; TAS:FlyBase.
DR   GO; GO:0007424; P:open tracheal system development; NAS:FlyBase.
DR   GO; GO:0030707; P:ovarian follicle cell development; TAS:FlyBase.
DR   GO; GO:0061320; P:pericardial nephrocyte differentiation; IMP:FlyBase.
DR   GO; GO:0048636; P:positive regulation of muscle organ development; IMP:FlyBase.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0007458; P:progression of morphogenetic furrow involved in compound eye morphogenesis; IMP:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0045595; P:regulation of cell differentiation; IMP:FlyBase.
DR   GO; GO:0042127; P:regulation of cell proliferation; NAS:FlyBase.
DR   GO; GO:0008360; P:regulation of cell shape; TAS:UniProtKB.
DR   GO; GO:0045570; P:regulation of imaginal disc growth; IMP:FlyBase.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0046620; P:regulation of organ growth; TAS:FlyBase.
DR   GO; GO:0035158; P:regulation of tube diameter, open tracheal system; IMP:FlyBase.
DR   GO; GO:0007423; P:sensory organ development; TAS:FlyBase.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IBA:GO_Central.
DR   GO; GO:0030721; P:spectrosome organization; IMP:FlyBase.
DR   GO; GO:0017145; P:stem cell division; TAS:FlyBase.
DR   GO; GO:0019827; P:stem cell population maintenance; NAS:FlyBase.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; NAS:FlyBase.
DR   GO; GO:0035309; P:wing and notum subfield formation; IMP:UniProtKB.
DR   GO; GO:0048100; P:wing disc anterior/posterior pattern formation; TAS:FlyBase.
DR   GO; GO:0035222; P:wing disc pattern formation; IMP:UniProtKB.
DR   GO; GO:0007473; P:wing disc proximal/distal pattern formation; TAS:FlyBase.
DR   GO; GO:0007354; P:zygotic determination of anterior/posterior axis, embryo; TAS:FlyBase.
DR   GO; GO:0007352; P:zygotic specification of dorsal/ventral axis; IMP:UniProtKB.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR002405; Inhibin_asu.
DR   InterPro; IPR001839; TGF-b_C.
DR   InterPro; IPR001111; TGF-b_N.
DR   InterPro; IPR015615; TGF-beta-rel.
DR   InterPro; IPR017948; TGFb_CS.
DR   PANTHER; PTHR11848; PTHR11848; 1.
DR   Pfam; PF00019; TGF_beta; 1.
DR   Pfam; PF00688; TGFb_propeptide; 1.
DR   PRINTS; PR00669; INHIBINA.
DR   SMART; SM00204; TGFB; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00250; TGF_BETA_1; 1.
DR   PROSITE; PS51362; TGF_BETA_2; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Developmental protein; Differentiation;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Growth factor; Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   PROPEP       24    456       {ECO:0000269|PubMed:1692958}.
FT                                /FTId=PRO_0000033664.
FT   CHAIN       457    588       Protein decapentaplegic.
FT                                /FTId=PRO_0000033665.
FT   CARBOHYD    120    120       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    342    342       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    377    377       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    529    529       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    487    553       {ECO:0000250}.
FT   DISULFID    516    585       {ECO:0000250}.
FT   DISULFID    520    587       {ECO:0000250}.
FT   DISULFID    552    552       Interchain. {ECO:0000250}.
FT   VARIANT      59     59       V -> G (in strain: dp cn bw).
FT                                {ECO:0000269|PubMed:9071586}.
FT   VARIANT     121    121       K -> M (in strain: dp cn bw).
FT                                {ECO:0000269|PubMed:9071586}.
FT   VARIANT     439    439       P -> A. {ECO:0000269|PubMed:12618399}.
FT   CONFLICT    473    474       QP -> HA (in Ref. 1; AAA28482).
FT                                {ECO:0000305}.
FT   CONFLICT    556    556       T -> K (in Ref. 5; AAT94456).
FT                                {ECO:0000305}.
FT   CONFLICT    568    568       D -> G (in Ref. 5; AAT94456).
FT                                {ECO:0000305}.
SQ   SEQUENCE   588 AA;  65868 MW;  2C8166C1BD2F666B CRC64;
     MRAWLLLLAV LATFQTIVRV ASTEDISQRF IAAIAPVAAH IPLASASGSG SGRSGSRSVG
     ASTSTALAKA FNPFSEPASF SDSDKSHRSK TNKKPSKSDA NRQFNEVHKP RTDQLENSKN
     KSKQLVNKPN HNKMAVKEQR SHHKKSHHHR SHQPKQASAS TESHQSSSIE SIFVEEPTLV
     LDREVASINV PANAKAIIAE QGPSTYSKEA LIKDKLKPDP STLVEIEKSL LSLFNMKRPP
     KIDRSKIIIP EPMKKLYAEI MGHELDSVNI PKPGLLTKSA NTVRSFTHKD SKIDDRFPHH
     HRFRLHFDVK SIPADEKLKA AELQLTRDAL SQQVVASRSS ANRTRYQVLV YDITRVGVRG
     QREPSYLLLD TKTVRLNSTD TVSLDVQPAV DRWLASPQRN YGLLVEVRTV RSLKPAPHHH
     VRLRRSADEA HERWQHKQPL LFTYTDDGRH KARSIRDVSG GEGGGKGGRN KRQPRRPTRR
     KNHDDTCRRH SLYVDFSDVG WDDWIVAPLG YDAYYCHGKC PFPLADHFNS TNHAVVQTLV
     NNMNPGKVPK ACCVPTQLDS VAMLYLNDQS TVVLKNYQEM TVVGCGCR
//
ID   ITB1_MOUSE              Reviewed;         798 AA.
AC   P09055; F6R105; Q3TIW5; Q3TWH6; Q60993; Q61126; Q8BTU0; Q8BVU1;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1988, sequence version 1.
DT   17-FEB-2016, entry version 176.
DE   RecName: Full=Integrin beta-1;
DE   AltName: Full=Fibronectin receptor subunit beta;
DE   AltName: Full=VLA-4 subunit beta;
DE   AltName: CD_antigen=CD29;
DE   Flags: Precursor;
GN   Name=Itgb1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=BALB/cJ;
RX   PubMed=3262537; DOI=10.1016/0014-5793(88)80503-9;
RA   Tominaga S.;
RT   "Murine mRNA for the beta-subunit of integrin is increased in BALB/c-
RT   3T3 cells entering the G1 phase from the G0 state.";
RL   FEBS Lett. 238:315-319(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J, and NOD;
RC   TISSUE=Head, Osteoclast, Placenta, and Thymocyte;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-798 (ISOFORM 1).
RC   STRAIN=BALB/cJ;
RX   PubMed=2523953; DOI=10.1084/jem.169.5.1589;
RA   Holers V.M., Ruff T.G., Parks D.L., McDonald J.A., Ballard L.L.,
RA   Brown E.J.;
RT   "Molecular cloning of a murine fibronectin receptor and its expression
RT   during inflammation. Expression of VLA-5 is increased in activated
RT   peritoneal macrophages in a manner discordant from major
RT   histocompatibility complex class II.";
RL   J. Exp. Med. 169:1589-1605(1989).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 595-798 (ISOFORM 1).
RX   PubMed=2521606; DOI=10.1016/0014-4827(89)90080-3;
RA   Ryseck R.P., MacDonald-Bravo H., Zerial M., Bravo R.;
RT   "Coordinate induction of fibronectin, fibronectin receptor,
RT   tropomyosin, and actin genes in serum-stimulated fibroblasts.";
RL   Exp. Cell Res. 180:537-545(1989).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 718-798 (ISOFORM 2), FUNCTION,
RP   INTERACTION WITH ITGA7, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RC   TISSUE=Myoblast;
RX   PubMed=8567725; DOI=10.1083/jcb.132.1.211;
RA   Belkin A.M., Zhidkova N.I., Balzac F., Altruda F., Tomatis D.,
RA   Maier A., Tarone G., Koteliansky V.E., Burridge K.;
RT   "Beta 1D integrin displaces the beta 1A isoform in striated muscles:
RT   localization at junctional structures and signaling potential in
RT   nonmuscle cells.";
RL   J. Cell Biol. 132:211-226(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 723-798.
RC   TISSUE=Skeletal muscle;
RX   PubMed=8870969;
RA   Baudoin C., Van der Flier A., Borradori L., Sonnenberg A.;
RT   "Genomic organization of the mouse beta 1 gene: conservation of the
RT   beta 1D but not of the beta 1B and beta 1C integrin splice variants.";
RL   Cell Adhes. Commun. 4:1-11(1996).
RN   [10]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=9553049; DOI=10.1101/gad.12.8.1202;
RA   Baudoin C., Goumans M.J., Mummery C., Sonnenberg A.;
RT   "Knockout and knockin of the beta1 exon D define distinct roles for
RT   integrin splice variants in heart function and embryonic
RT   development.";
RL   Genes Dev. 12:1202-1216(1998).
RN   [11]
RP   INTERACTION WITH FBLN5.
RX   PubMed=11805835; DOI=10.1038/415171a;
RA   Nakamura T., Lozano P.R., Ikeda Y., Iwanaga Y., Hinek A.,
RA   Minamisawa S., Cheng C.F., Kobuke K., Dalton N., Takada Y.,
RA   Tashiro K., Ross J., Honjo T., Chien K.R.;
RT   "Fibulin-5/DANCE is essential for elastogenesis in vivo.";
RL   Nature 415:171-175(2002).
RN   [12]
RP   INTERACTION WITH EMP2.
RX   PubMed=12189152; DOI=10.1074/jbc.M206868200;
RA   Wadehra M., Iyer R., Goodglick L., Braun J.;
RT   "The tetraspan protein epithelial membrane protein-2 interacts with
RT   beta1 integrins and regulates adhesion.";
RL   J. Biol. Chem. 277:41094-41100(2002).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH NMRK2.
RX   PubMed=12941630; DOI=10.1016/S0012-1606(03)00304-X;
RA   Li J., Rao H., Burkin D., Kaufman S.J., Wu C.;
RT   "The muscle integrin binding protein (MIBP) interacts with alpha7beta1
RT   integrin and regulates cell adhesion and laminin matrix deposition.";
RL   Dev. Biol. 261:209-219(2003).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH ITGA3; LGALS3 AND CSPG4.
RX   PubMed=15181153; DOI=10.1091/mbc.E04-03-0236;
RA   Fukushi J., Makagiansar I.T., Stallcup W.B.;
RT   "NG2 proteoglycan promotes endothelial cell motility and angiogenesis
RT   via engagement of galectin-3 and alpha3beta1 integrin.";
RL   Mol. Biol. Cell 15:3580-3590(2004).
RN   [15]
RP   INTERACTION WITH DAB2.
RX   PubMed=15734730; DOI=10.1074/jbc.M500974200;
RA   Prunier C., Howe P.H.;
RT   "Disabled-2 (Dab2) is required for transforming growth factor beta-
RT   induced epithelial to mesenchymal transition (EMT).";
RL   J. Biol. Chem. 280:17540-17548(2005).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-783, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Mast cell;
RX   PubMed=17947660; DOI=10.4049/jimmunol.179.9.5864;
RA   Cao L., Yu K., Banh C., Nguyen V., Ritz A., Raphael B.J., Kawakami Y.,
RA   Kawakami T., Salomon A.R.;
RT   "Quantitative time-resolved phosphoproteomic analysis of mast cell
RT   signaling.";
RL   J. Immunol. 179:5864-5876(2007).
RN   [17]
RP   FUNCTION, AND MUTAGENESIS OF TYR-783 AND TYR-795.
RX   PubMed=18804435; DOI=10.1016/j.devcel.2008.08.001;
RA   Pellinen T., Tuomi S., Arjonen A., Wolf M., Edgren H., Meyer H.,
RA   Grosse R., Kitzing T., Rantala J.K., Kallioniemi O., Faessler R.,
RA   Kallio M., Ivaska J.;
RT   "Integrin trafficking regulated by Rab21 is necessary for
RT   cytokinesis.";
RL   Dev. Cell 15:371-385(2008).
RN   [18]
RP   INTERACTION WITH FERMT2.
RX   PubMed=18483218; DOI=10.1101/gad.469408;
RA   Montanez E., Ussar S., Schifferer M., Bosl M., Zent R., Moser M.,
RA   Fassler R.;
RT   "Kindlin-2 controls bidirectional signaling of integrins.";
RL   Genes Dev. 22:1325-1330(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-777, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-363; ASN-366; ASN-376 AND
RP   ASN-669.
RC   TISSUE=Myoblast;
RX   PubMed=19656770; DOI=10.1074/mcp.M900195-MCP200;
RA   Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I.,
RA   Bausch-Fluck D., Elliott S.T., Boheler K.R., Van Eyk J.E.,
RA   Wollscheid B.;
RT   "The mouse C2C12 myoblast cell surface N-linked glycoproteome:
RT   identification, glycosite occupancy, and membrane orientation.";
RL   Mol. Cell. Proteomics 8:2555-2569(2009).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung,
RC   Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH FGR AND HCK.
RX   PubMed=19903482; DOI=10.1016/j.febslet.2009.11.009;
RA   Baruzzi A., Iacobucci I., Soverini S., Lowell C.A., Martinelli G.,
RA   Berton G.;
RT   "c-Abl and Src-family kinases cross-talk in regulation of myeloid cell
RT   migration.";
RL   FEBS Lett. 584:15-21(2010).
RN   [23]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21768292; DOI=10.1083/jcb.201007108;
RA   Brunner M., Millon-Fremillon A., Chevalier G., Nakchbandi I.A.,
RA   Mosher D., Block M.R., Albiges-Rizo C., Bouvard D.;
RT   "Osteoblast mineralization requires beta1 integrin/ICAP-1-dependent
RT   fibronectin deposition.";
RL   J. Cell Biol. 194:307-322(2011).
CC   -!- FUNCTION: Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-
CC       1 and alpha-11/beta-1 are receptors for collagen. Integrins alpha-
CC       1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated
CC       sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-
CC       3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/beta-1, alpha-
CC       10/beta-1, alpha-11/beta-1 and alpha-V/beta-1 are receptors for
CC       fibronectin. Alpha-4/beta-1 recognizes one or more domains within
CC       the alternatively spliced CS-1 and CS-5 regions of fibronectin.
CC       Integrin alpha-5/beta-1 is a receptor for fibrinogen. Integrin
CC       alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1
CC       are receptors for lamimin. Integrin alpha-4/beta-1 is a receptor
CC       for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1. Integrin
CC       alpha-9/beta-1 is a receptor for VCAM1, cytotactin and
CC       osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in
CC       cytotactin. Integrin alpha-3/beta-1 is a receptor for epiligrin,
CC       thrombospondin and CSPG4. Integrin alpha-3/beta-1 provides a
CC       docking site for FAP (seprase) at invadopodia plasma membranes in
CC       a collagen-dependent manner and hence may participate in the
CC       adhesion, formation of invadopodia and matrix degradation
CC       processes, promoting cell invasion. Alpha-3/beta-1 may mediate
CC       with LGALS3 the stimulation by CSPG4 of endothelial cells
CC       migration. Integrin alpha-V/beta-1 is a receptor for vitronectin.
CC       Beta-1 integrins recognize the sequence R-G-D in a wide array of
CC       ligands. When associated with alpha-7/beta-1 integrin, regulates
CC       cell adhesion and laminin matrix deposition. Involved in promoting
CC       endothelial cell motility and angiogenesis. Involved in osteoblast
CC       compaction through the fibronectin fibrillogenesis cell-mediated
CC       matrix assembly process and the formation of mineralized bone
CC       nodules. May be involved in up-regulation of the activity of
CC       kinases such as PKC via binding to KRT1. Together with KRT1 and
CC       GNB2L1, serves as a platform for SRC activation or inactivation.
CC       Plays a mechanistic adhesive role during telophase, required for
CC       the successful completion of cytokinesis.
CC       {ECO:0000250|UniProtKB:P05556, ECO:0000269|PubMed:12941630,
CC       ECO:0000269|PubMed:15181153, ECO:0000269|PubMed:18804435,
CC       ECO:0000269|PubMed:19903482, ECO:0000269|PubMed:21768292,
CC       ECO:0000269|PubMed:8567725}.
CC   -!- FUNCTION: Isoform 2: Isoform 2 displaces isoform 1 in striated
CC       muscles.
CC   -!- SUBUNIT: Interacts with seprase FAP (seprase); the interaction
CC       occurs at the cell surface of invadopodia membrane in a collagen-
CC       dependent manner (By similarity). Heterodimer of an alpha and a
CC       beta subunit. Beta-1 associates with either alpha-1, alpha-2,
CC       alpha-3, alpha-4, alpha-5, alpha-6, alpha-7, alpha-8, alpha-9,
CC       alpha-10, alpha-11 or alpha-V. Binds LGALS3BP and NMRK2, when
CC       associated with alpha-7, but not with alpha-5. Interacts with
CC       FLNA, FLNB, FLNC and RANBP9. Interacts with KRT1 in the presence
CC       of GNB2L1 and SRC. Interacts with AMICA1; integrin alpha-4/beta-1
CC       may regulate leukocyte to endothelial cells adhesion by
CC       controlling AMICA1 homodimerization. Interacts with RAB21.
CC       Interacts (via the cytoplasmic region) with RAB25 (via the
CC       hypervariable C-terminal region). Interacts with MYO10. Interacts
CC       with ITGB1BP1 (via C-terminal region); the interaction is a
CC       prerequisite for focal adhesion disassembly. Interacts with TLN1;
CC       the interaction is prevented by competitive binding of ITGB1BP1.
CC       Interacts with ACAP1; required for ITGB1 recycling. Interacts with
CC       ASAP3. Interacts with FERMT2; the interaction is inhibited in
CC       presence of ITGB1BP1. Interacts with DAB2. Interacts with FGR and
CC       HCK. Isoform 2 interacts with alpha-7A and alpha-7B in adult
CC       skeletal muscle. Isoform 2 interacts with alpha-7B in
CC       cardiomyocytes of adult heart. Interacts with EMP2; the
CC       interaction may be direct or indirect and ITGB1 has an heterodimer
CC       form (PubMed:12189152). ITGA5:ITGB1 interacts with NOV (By
CC       similarity). {ECO:0000250|UniProtKB:P05556,
CC       ECO:0000269|PubMed:12189152, ECO:0000269|PubMed:12941630,
CC       ECO:0000269|PubMed:15181153, ECO:0000269|PubMed:15734730,
CC       ECO:0000269|PubMed:18483218, ECO:0000269|PubMed:19903482,
CC       ECO:0000269|PubMed:8567725}.
CC   -!- INTERACTION:
CC       P26955:Csf2rb; NbExp=2; IntAct=EBI-644224, EBI-1810026;
CC       Q01768:Nme2; NbExp=3; IntAct=EBI-644224, EBI-642573;
CC       Q6F5E0:Tmem158; NbExp=3; IntAct=EBI-644224, EBI-645317;
CC       Q91YD9:Wasl; NbExp=2; IntAct=EBI-644224, EBI-642417;
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000250|UniProtKB:P05556}; Single-pass type I membrane
CC       protein {ECO:0000255}. Cell projection, invadopodium membrane
CC       {ECO:0000250|UniProtKB:P05556}; Single-pass type I membrane
CC       protein {ECO:0000255}. Cell projection, ruffle membrane
CC       {ECO:0000250|UniProtKB:P05556}; Single-pass type I membrane
CC       protein {ECO:0000255}. Recycling endosome
CC       {ECO:0000269|PubMed:21768292, ECO:0000269|PubMed:8567725}.
CC       Melanosome {ECO:0000250}. Cell projection, lamellipodium
CC       {ECO:0000250}. Cell projection, ruffle {ECO:0000250}.
CC       Note=Colocalizes with ITGB1BP1 and metastatic suppressor protein
CC       NME2 at the edge or peripheral ruffles and lamellipodia during the
CC       early stages of cell spreading on fibronectin or collagen.
CC       Translocates from peripheral focal adhesions to fibrillar
CC       adhesions in an ITGB1BP1-dependent manner. Enriched preferentially
CC       at invadopodia, cell membrane protrusions that correspond to sites
CC       of cell invasion, in a collagen-dependent manner. Localized at
CC       plasma and ruffle membranes in a collagen-independent manner.
CC       {ECO:0000250|UniProtKB:P05556}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane, sarcolemma. Cell
CC       junction. Note=In cardiac muscle, isoform 2 is found in costameres
CC       and intercalated disks.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Beta-1A;
CC         IsoId=P09055-1; Sequence=Displayed;
CC       Name=2; Synonyms=Beta-1D;
CC         IsoId=P09055-2; Sequence=VSP_053581, VSP_053582;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is expressed in skeletal and cardiac
CC       muscles only (at protein level). Isoform 1 is very weakly
CC       expressed in striated muscles and not detected in adult skeletal
CC       muscle fibers and cardiomyocytes. {ECO:0000269|PubMed:8567725}.
CC   -!- DEVELOPMENTAL STAGE: Isoform 2 is not detected in proliferating
CC       myoblasts, but it appears immediately after myoblast fusion and
CC       its amount continues to rise during myotube growth and maturation
CC       reaching its highest level at day 9 through day 10, when mature
CC       differentiated myotubes appear in cell culture. Isoform 1
CC       expression is down-regulated during myodifferentiation in culture
CC       and it is completely displaced by isoform 2 in mature
CC       differentiated myotubes. {ECO:0000269|PubMed:8567725}.
CC   -!- PTM: The cysteine residues are involved in intrachain disulfide
CC       bonds. {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Isoform 2 knockout mice are viable and
CC       fertile, but male mice display a mild abnormality of cardiac
CC       function reflected by an increased expression of atrial
CC       natriuretic peptide and beta myosin heavy chain. Muscles do not
CC       show any histological or ultrastructural alterations. Replacement
CC       of isoform 1 by isoform 2 results in embryonic lethality before
CC       16.5 dpc with a plethora of developmental defects including open
CC       neural tube, which is abnormally waved both rostrally and
CC       caudally. Some embryos lack part of the hindbrain and in most
CC       embryos the first branchial arch is shortened, which in some of
CC       the embryos leaves the tongue exposed. Abnormally strong
CC       fibronectin staining is seen in the mesenchyme under the open
CC       neural tube. Extravasation of red blood cells is evident in
CC       various tissues and they are also found in the pericardial cavity.
CC       Choroid plexus is virtually absent correlating with the presence
CC       of an abnormally smooth head and small brain cavities. At later
CC       developmental stages, a striking feature is the lack of a lower
CC       jaw and a dysmorphic lower face. These defects are in part caused
CC       by the abnormal migration of neuroepithelial cells.
CC       {ECO:0000269|PubMed:9553049}.
CC   -!- SIMILARITY: Belongs to the integrin beta chain family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 VWFA domain. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC36379.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00769; CAA68738.1; -; mRNA.
DR   EMBL; AK076526; BAC36379.1; ALT_INIT; mRNA.
DR   EMBL; AK088729; BAC40532.1; -; mRNA.
DR   EMBL; AK159689; BAE35290.1; -; mRNA.
DR   EMBL; AK167682; BAE39731.1; -; mRNA.
DR   EMBL; AC156608; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH466525; EDL11832.1; -; Genomic_DNA.
DR   EMBL; BC050906; AAH50906.1; -; mRNA.
DR   EMBL; X15202; CAA33272.1; -; mRNA.
DR   EMBL; U37029; AAA80243.1; -; mRNA.
DR   EMBL; U47283; AAA88821.1; -; Genomic_DNA.
DR   CCDS; CCDS22791.1; -. [P09055-1]
DR   PIR; PL0104; IJMSFB.
DR   PIR; S01659; S01659.
DR   RefSeq; NP_034708.1; NM_010578.2. [P09055-1]
DR   UniGene; Mm.263396; -.
DR   ProteinModelPortal; P09055; -.
DR   SMR; P09055; 25-787.
DR   BioGrid; 200826; 9.
DR   DIP; DIP-46247N; -.
DR   IntAct; P09055; 60.
DR   MINT; MINT-1573412; -.
DR   STRING; 10090.ENSMUSP00000087457; -.
DR   iPTMnet; P09055; -.
DR   PhosphoSite; P09055; -.
DR   SwissPalm; P09055; -.
DR   MaxQB; P09055; -.
DR   PaxDb; P09055; -.
DR   PRIDE; P09055; -.
DR   Ensembl; ENSMUST00000090006; ENSMUSP00000087457; ENSMUSG00000025809. [P09055-1]
DR   GeneID; 16412; -.
DR   KEGG; mmu:16412; -.
DR   UCSC; uc009nzv.2; mouse. [P09055-1]
DR   CTD; 3688; -.
DR   MGI; MGI:96610; Itgb1.
DR   eggNOG; KOG1226; Eukaryota.
DR   eggNOG; ENOG410XP60; LUCA.
DR   GeneTree; ENSGT00760000119064; -.
DR   HOGENOM; HOG000252936; -.
DR   HOVERGEN; HBG006190; -.
DR   InParanoid; P09055; -.
DR   KO; K05719; -.
DR   OMA; ADENRCL; -.
DR   OrthoDB; EOG7T7GSB; -.
DR   PhylomeDB; P09055; -.
DR   TreeFam; TF105392; -.
DR   Reactome; R-MMU-1566948; Elastic fibre formation.
DR   Reactome; R-MMU-1566977; Fibronectin matrix formation.
DR   Reactome; R-MMU-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-MMU-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-MMU-210991; Basigin interactions.
DR   Reactome; R-MMU-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-MMU-216083; Integrin cell surface interactions.
DR   Reactome; R-MMU-3000157; Laminin interactions.
DR   Reactome; R-MMU-3000170; Syndecan interactions.
DR   Reactome; R-MMU-3000178; ECM proteoglycans.
DR   Reactome; R-MMU-445144; Signal transduction by L1.
DR   Reactome; R-MMU-446343; Localization of the PINCH-ILK-PARVIN complex to focal adhesions.
DR   ChiTaRS; Itgb1; mouse.
DR   NextBio; 289597; -.
DR   PRO; PR:P09055; -.
DR   Proteomes; UP000000589; Chromosome 8.
DR   Bgee; P09055; -.
DR   CleanEx; MM_ITGB1; -.
DR   ExpressionAtlas; P09055; baseline and differential.
DR   Genevisible; P09055; MM.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0005604; C:basement membrane; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0043197; C:dendritic spine; IDA:MGI.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0030175; C:filopodium; ISO:MGI.
DR   GO; GO:0005925; C:focal adhesion; ISO:MGI.
DR   GO; GO:0030056; C:hemidesmosome; IEA:Ensembl.
DR   GO; GO:0034665; C:integrin alpha1-beta1 complex; ISO:MGI.
DR   GO; GO:0034680; C:integrin alpha10-beta1 complex; ISO:MGI.
DR   GO; GO:0034681; C:integrin alpha11-beta1 complex; ISO:MGI.
DR   GO; GO:0034666; C:integrin alpha2-beta1 complex; ISO:MGI.
DR   GO; GO:0034667; C:integrin alpha3-beta1 complex; ISO:MGI.
DR   GO; GO:0034677; C:integrin alpha7-beta1 complex; IDA:MGI.
DR   GO; GO:0034679; C:integrin alpha9-beta1 complex; IEA:Ensembl.
DR   GO; GO:0014704; C:intercalated disc; IDA:MGI.
DR   GO; GO:0071438; C:invadopodium membrane; ISS:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; ISO:MGI.
DR   GO; GO:0035748; C:myelin sheath abaxonal region; IDA:BHF-UCL.
DR   GO; GO:0031594; C:neuromuscular junction; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0055037; C:recycling endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042383; C:sarcolemma; IDA:MGI.
DR   GO; GO:0045202; C:synapse; IDA:MGI.
DR   GO; GO:0097060; C:synaptic membrane; IDA:MGI.
DR   GO; GO:0003779; F:actin binding; ISO:MGI.
DR   GO; GO:0050839; F:cell adhesion molecule binding; ISO:MGI.
DR   GO; GO:0098639; F:collagen binding involved in cell-matrix adhesion; ISO:MGI.
DR   GO; GO:0001968; F:fibronectin binding; ISO:MGI.
DR   GO; GO:0005178; F:integrin binding; IPI:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042277; F:peptide binding; IEA:Ensembl.
DR   GO; GO:0002020; F:protease binding; ISO:MGI.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISS:UniProtKB.
DR   GO; GO:0004872; F:receptor activity; IEA:InterPro.
DR   GO; GO:0048675; P:axon extension; IMP:MGI.
DR   GO; GO:0070830; P:bicellular tight junction assembly; IEA:Ensembl.
DR   GO; GO:0007161; P:calcium-independent cell-matrix adhesion; ISO:MGI.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; IMP:MGI.
DR   GO; GO:0048738; P:cardiac muscle tissue development; IMP:MGI.
DR   GO; GO:0001708; P:cell fate specification; IMP:MGI.
DR   GO; GO:0016477; P:cell migration; IMP:MGI.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IMP:MGI.
DR   GO; GO:0033631; P:cell-cell adhesion mediated by integrin; IEA:Ensembl.
DR   GO; GO:0007160; P:cell-matrix adhesion; IMP:MGI.
DR   GO; GO:0031589; P:cell-substrate adhesion; ISO:MGI.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0071404; P:cellular response to low-density lipoprotein particle stimulus; IDA:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0071305; P:cellular response to vitamin D; IEA:Ensembl.
DR   GO; GO:0048813; P:dendrite morphogenesis; IMP:MGI.
DR   GO; GO:0021943; P:formation of radial glial scaffolds; IMP:MGI.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:MGI.
DR   GO; GO:0008354; P:germ cell migration; IMP:MGI.
DR   GO; GO:0034113; P:heterotypic cell-cell adhesion; ISO:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; ISO:MGI.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; ISO:MGI.
DR   GO; GO:0050901; P:leukocyte tethering or rolling; ISO:MGI.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEA:Ensembl.
DR   GO; GO:0048333; P:mesodermal cell differentiation; IEA:Ensembl.
DR   GO; GO:2000811; P:negative regulation of anoikis; ISO:MGI.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IMP:MGI.
DR   GO; GO:0031345; P:negative regulation of cell projection organization; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0035024; P:negative regulation of Rho protein signal transduction; IGI:MGI.
DR   GO; GO:0031175; P:neuron projection development; IMP:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:MGI.
DR   GO; GO:0010811; P:positive regulation of cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IEA:Ensembl.
DR   GO; GO:0090004; P:positive regulation of establishment of protein localization to plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISO:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0032594; P:protein transport within lipid bilayer; IEA:Ensembl.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:MGI.
DR   GO; GO:0010710; P:regulation of collagen catabolic process; ISS:UniProtKB.
DR   GO; GO:0008277; P:regulation of G-protein coupled receptor protein signaling pathway; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0034698; P:response to gonadotropin; IEA:Ensembl.
DR   GO; GO:0071559; P:response to transforming growth factor beta; IEA:Ensembl.
DR   GO; GO:0045214; P:sarcomere organization; IMP:MGI.
DR   GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl.
DR   GO; GO:0008542; P:visual learning; IMP:MGI.
DR   Gene3D; 1.20.5.630; -; 1.
DR   Gene3D; 3.40.50.410; -; 1.
DR   InterPro; IPR013111; EGF_extracell.
DR   InterPro; IPR027071; Integrin_beta-1.
DR   InterPro; IPR015812; Integrin_bsu.
DR   InterPro; IPR014836; Integrin_bsu_cyt_dom.
DR   InterPro; IPR002369; Integrin_bsu_N.
DR   InterPro; IPR012896; Integrin_bsu_tail.
DR   InterPro; IPR032695; Integrin_dom.
DR   InterPro; IPR016201; Plexin-like_fold.
DR   InterPro; IPR002035; VWF_A.
DR   PANTHER; PTHR10082; PTHR10082; 1.
DR   PANTHER; PTHR10082:SF28; PTHR10082:SF28; 1.
DR   Pfam; PF07974; EGF_2; 1.
DR   Pfam; PF08725; Integrin_b_cyt; 1.
DR   Pfam; PF07965; Integrin_B_tail; 1.
DR   Pfam; PF00362; Integrin_beta; 1.
DR   PIRSF; PIRSF002512; Integrin_B; 1.
DR   PRINTS; PR01186; INTEGRINB.
DR   SMART; SM00187; INB; 1.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00327; VWA; 1.
DR   SUPFAM; SSF103575; SSF103575; 1.
DR   SUPFAM; SSF53300; SSF53300; 1.
DR   SUPFAM; SSF69179; SSF69179; 1.
DR   SUPFAM; SSF69687; SSF69687; 1.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS00243; INTEGRIN_BETA; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Cell adhesion; Cell junction;
KW   Cell membrane; Cell projection; Complete proteome; Disulfide bond;
KW   Endosome; Glycoprotein; Integrin; Magnesium; Membrane; Metal-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     20
FT   CHAIN        21    798       Integrin beta-1.
FT                                /FTId=PRO_0000016335.
FT   TOPO_DOM     21    728       Extracellular. {ECO:0000255}.
FT   TRANSMEM    729    751       Helical. {ECO:0000255}.
FT   TOPO_DOM    752    798       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      140    378       VWFA.
FT   REPEAT      466    515       I.
FT   REPEAT      516    559       II.
FT   REPEAT      560    598       III.
FT   REPEAT      599    635       IV.
FT   REGION      466    635       Cysteine-rich tandem repeats.
FT   REGION      762    767       Signal for sorting from recycling
FT                                endosomes; interaction with ACAP1.
FT                                {ECO:0000250}.
FT   REGION      785    792       Interaction with ITGB1BP1. {ECO:0000250}.
FT   METAL       152    152       Magnesium. {ECO:0000250}.
FT   METAL       154    154       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL       156    156       Calcium 1. {ECO:0000250}.
FT   METAL       157    157       Calcium 1. {ECO:0000250}.
FT   METAL       189    189       Calcium 2. {ECO:0000250}.
FT   METAL       244    244       Calcium 2. {ECO:0000250}.
FT   METAL       246    246       Calcium 2. {ECO:0000250}.
FT   METAL       248    248       Calcium 2; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL       249    249       Calcium 2. {ECO:0000250}.
FT   METAL       249    249       Magnesium. {ECO:0000250}.
FT   MOD_RES     777    777       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19144319}.
FT   MOD_RES     783    783       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:17947660}.
FT   MOD_RES     785    785       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P05556}.
FT   MOD_RES     789    789       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P05556}.
FT   MOD_RES     794    794       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P05556}.
FT   CARBOHYD     50     50       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     94     94       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     97     97       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    212    212       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    269    269       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    363    363       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    366    366       N-linked (GlcNAc...); atypical.
FT                                {ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    376    376       N-linked (GlcNAc...); atypical.
FT                                {ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    406    406       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    417    417       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    481    481       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    520    520       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    584    584       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    669    669       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19656770}.
FT   DISULFID     27     45       {ECO:0000250}.
FT   DISULFID     35    464       {ECO:0000250}.
FT   DISULFID     38     75       {ECO:0000250}.
FT   DISULFID     48     64       {ECO:0000250}.
FT   DISULFID    207    213       {ECO:0000250}.
FT   DISULFID    261    301       {ECO:0000250}.
FT   DISULFID    401    415       {ECO:0000250}.
FT   DISULFID    435    462       {ECO:0000250}.
FT   DISULFID    466    691       {ECO:0000250}.
FT   DISULFID    477    489       {ECO:0000250}.
FT   DISULFID    486    525       {ECO:0000250}.
FT   DISULFID    491    500       {ECO:0000250}.
FT   DISULFID    502    516       {ECO:0000250}.
FT   DISULFID    531    536       {ECO:0000250}.
FT   DISULFID    533    568       {ECO:0000250}.
FT   DISULFID    538    553       {ECO:0000250}.
FT   DISULFID    555    560       {ECO:0000250}.
FT   DISULFID    574    579       {ECO:0000250}.
FT   DISULFID    576    607       {ECO:0000250}.
FT   DISULFID    581    590       {ECO:0000250}.
FT   DISULFID    592    599       {ECO:0000250}.
FT   DISULFID    613    618       {ECO:0000250}.
FT   DISULFID    615    661       {ECO:0000250}.
FT   DISULFID    620    630       {ECO:0000250}.
FT   DISULFID    633    636       {ECO:0000250}.
FT   DISULFID    640    649       {ECO:0000250}.
FT   DISULFID    646    723       {ECO:0000250}.
FT   DISULFID    665    699       {ECO:0000250}.
FT   VAR_SEQ     778    778       G -> Q (in isoform 2).
FT                                {ECO:0000303|PubMed:8567725}.
FT                                /FTId=VSP_053581.
FT   VAR_SEQ     786    798       AVTTVVNPKYEGK -> PINNFKNPNYGRKAGL (in
FT                                isoform 2). {ECO:0000303|PubMed:8567725}.
FT                                /FTId=VSP_053582.
FT   MUTAGEN     783    783       Y->F: Reduced endocytosis; when
FT                                associated with F-795.
FT                                {ECO:0000269|PubMed:18804435}.
FT   MUTAGEN     795    795       Y->F: Reduced endocytosis; when
FT                                associated with F-783.
FT                                {ECO:0000269|PubMed:18804435}.
FT   CONFLICT      5      5       L -> Q (in Ref. 2; BAC40532).
FT                                {ECO:0000305}.
FT   CONFLICT     72     72       K -> E (in Ref. 2; BAE35290).
FT                                {ECO:0000305}.
FT   CONFLICT    385    385       E -> D (in Ref. 2; BAC36379).
FT                                {ECO:0000305}.
FT   CONFLICT    385    385       E -> P (in Ref. 6; CAA33272).
FT                                {ECO:0000305}.
FT   CONFLICT    392    392       G -> A (in Ref. 6; CAA33272).
FT                                {ECO:0000305}.
FT   CONFLICT    407    407       G -> E (in Ref. 2; BAC36379).
FT                                {ECO:0000305}.
FT   CONFLICT    443    445       IKI -> HSKL (in Ref. 6; CAA33272).
FT                                {ECO:0000305}.
SQ   SEQUENCE   798 AA;  88231 MW;  26788F7F0A168B56 CRC64;
     MNLQLVSWIG LISLICSVFG QTDKNRCLKA NAKSCGECIQ AGPNCGWCTN TTFLQEGMPT
     SARCDDLEAL KKKGCQPSDI ENPRGSQTIK KNKNVTNRSK GMAEKLRPED ITQIQPQQLL
     LKLRSGEPQK FTLKFKRAED YPIDLYYLMD LSYSMKDDLE NVKSLGTDLM NEMRRITSDF
     RIGFGSFVEK TVMPYISTTP AKLRNPCTSE QNCTSPFSYK NVLSLTDRGE FFNELVGQQR
     ISGNLDSPEG GFDAIMQVAV CGSLIGWRNV TRLLVFSTDA GFHFAGDGKL GGIVLPNDGQ
     CHLENNVYTM SHYYDYPSIA HLVQKLSENN IQTIFAVTEE FQPVYKELKN LIPKSAVGTL
     SGNSSNVIQL IIDAYNSLSS EVILENSKLP DGVTINYKSY CKNGVNGTGE NGRKCSNISI
     GDEVQFEISI TANKCPNKES ETIKIKPLGF TEEVEVVLQF ICKCNCQSHG IPASPKCHEG
     NGTFECGACR CNEGRVGRHC ECSTDEVNSE DMDAYCRKEN SSEICSNNGE CVCGQCVCRK
     RDNTNEIYSG KFCECDNFNC DRSNGLICGG NGVCRCRVCE CYPNYTGSAC DCSLDTGPCL
     ASNGQICNGR GICECGACKC TDPKFQGPTC ETCQTCLGVC AEHKECVQCR AFNKGEKKDT
     CAQECSHFNL TKVESREKLP QPVQVDPVTH CKEKDIDDCW FYFTYSVNGN NEAIVHVVET
     PDCPTGPDII PIVAGVVAGI VLIGLALLLI WKLLMIIHDR REFAKFEKEK MNAKWDTGEN
     PIYKSAVTTV VNPKYEGK
//
ID   GALNS_HUMAN             Reviewed;         522 AA.
AC   P34059; Q86VK3;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   20-JAN-2016, entry version 157.
DE   RecName: Full=N-acetylgalactosamine-6-sulfatase;
DE            EC=3.1.6.4;
DE   AltName: Full=Chondroitinsulfatase;
DE            Short=Chondroitinase;
DE   AltName: Full=Galactose-6-sulfate sulfatase;
DE            Short=GalN6S;
DE   AltName: Full=N-acetylgalactosamine-6-sulfate sulfatase;
DE            Short=GalNAc6S sulfatase;
DE   Flags: Precursor;
GN   Name=GALNS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Placenta;
RX   PubMed=1755850; DOI=10.1016/0006-291X(91)91244-7;
RA   Tomatsu S., Fukuda S., Masue M., Sukegawa K., Fukao T., Yamagishi A.,
RA   Hori T., Iwata H., Ogawa T., Nakashima Y., Hanyu Y., Hashimoto T.,
RA   Titani K., Oyama R., Suzuki M., Yagi K., Hayashi Y., Orii T.;
RT   "Morquio disease: isolation, characterization and expression of full-
RT   length cDNA for human N-acetylgalactosamine-6-sulfate sulfatase.";
RL   Biochem. Biophys. Res. Commun. 181:677-683(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8001980; DOI=10.1006/geno.1994.1443;
RA   Morris C.P., Guo X.H., Apostolou S., Hopwood J.J., Scott H.S.;
RT   "Morquio A syndrome: cloning, sequence, and structure of the human N-
RT   acetylgalactosamine 6-sulfatase (GALNS) gene.";
RL   Genomics 22:652-654(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-423.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 27-522, GLYCOSYLATION AT
RP   ASN-204 AND ASN-423, OXOALANINE AT CYS-79, SUBUNIT, COFACTOR,
RP   CATALYTIC ACTIVITY, CALCIUM-BINDING SITES, AND DISULFIDE BONDS.
RX   PubMed=22940367; DOI=10.1016/j.jmb.2012.08.020;
RA   Rivera-Colon Y., Schutsky E.K., Kita A.Z., Garman S.C.;
RT   "The structure of human GALNS reveals the molecular basis for
RT   mucopolysaccharidosis IV A.";
RL   J. Mol. Biol. 423:736-751(2012).
RN   [7]
RP   INVOLVEMENT IN MPS4A, AND VARIANT MPS4A LYS-204.
RX   PubMed=1522213; DOI=10.1172/JCI115919;
RA   Fukuda S., Tomatsu S., Masue M., Sukegawa K., Iwata H., Ogawa T.,
RA   Nakashima Y., Hori T., Yamagishi A., Hanyu Y., Morooka K., Kiman T.,
RA   Hashimoto T., Orii T.;
RT   "Mucopolysaccharidosis type IVA. N-acetylgalactosamine-6-sulfate
RT   sulfatase exonic point mutations in classical Morquio and mild
RT   cases.";
RL   J. Clin. Invest. 90:1049-1053(1992).
RN   [8]
RP   VARIANTS MPS4A ARG-77; TRP-90; VAL-96; PHE-113; LEU-151; GLY-230;
RP   THR-291; CYS-386 AND SER-487.
RX   PubMed=7668283;
RA   Tomatsu S., Fukuda S., Cooper A., Wraith J.E., Maruf Rezvi G.,
RA   Yamagishi A., Yamada N., Kato Z., Isogai K., Sukegawa K., Kondo N.,
RA   Suzuki Y., Shimozawa N., Orii T.;
RT   "Mucopolysaccharidosis IVA: identification of a common missense
RT   mutation I113F in the N-Acetylgalactosamine-6-sulfate sulfatase
RT   gene.";
RL   Am. J. Hum. Genet. 57:556-563(1995).
RN   [9]
RP   VARIANTS MPS4A.
RX   PubMed=7795586; DOI=10.1093/hmg/4.3.341;
RA   Ogawa T., Tomatsu S., Fukuda S., Yamagishi A., Maruf Rezvi G.,
RA   Sukegawa K., Kondo N., Suzuki Y., Shimozawa N., Orii T.;
RT   "Mucopolysaccharidosis IVA: screening and identification of mutations
RT   of the N-acetylgalactosamine-6-sulfate sulfatase gene.";
RL   Hum. Mol. Genet. 4:341-349(1995).
RN   [10]
RP   VARIANTS MPS4A ARG-77; TRP-90; VAL-96; LEU-151; GLY-230 AND THR-291.
RX   PubMed=7633425; DOI=10.1093/hmg/4.4.741;
RA   Tomatsu S., Fukuda S., Cooper A., Wraith J.E., Maruf Rezvi G.,
RA   Yamagishi A., Yamada N., Kato Z., Isogai K., Sukegawa K., Kondo N.,
RA   Suzuki Y., Shimozawa N., Orii T.;
RT   "Mucopolysaccharidosis type IVA: identification of six novel mutations
RT   among non-Japanese patients.";
RL   Hum. Mol. Genet. 4:741-743(1995).
RN   [11]
RP   VARIANT MPS4A SER-487.
RX   PubMed=7581409; DOI=10.1002/humu.1380060218;
RA   Tomatsu S., Fukuda S., Cooper A., Wraith J.E., Yamada N., Isogai K.,
RA   Kato Z., Sukegawa K., Kondo N., Suzuki Y., Shimozawa N., Orii T.;
RT   "Two new mutations, Q473X and N487S, in a Caucasian patient with
RT   mucopolysaccharidosis IVA (Morquio disease).";
RL   Hum. Mutat. 6:195-196(1995).
RN   [12]
RP   VARIANTS MPS4A ALA-138; SER-151 AND LEU-151.
RX   PubMed=8651279;
RA   Tomatsu S., Fukuda S., Yamagishi A., Cooper A., Wraith J.E., Hori T.,
RA   Kato Z., Yamada N., Isogai K., Sukegawa K., Kondo N., Suzuki Y.,
RA   Shimozawa N., Orii T.;
RT   "Mucopolysaccharidosis IVA: four new exonic mutations in patients with
RT   N-acetylgalactosamine-6-sulfate sulfatase deficiency.";
RL   Am. J. Hum. Genet. 58:950-962(1996).
RN   [13]
RP   VARIANTS MPS4A CYS-94 AND VAL-97.
RX   PubMed=8826435;
RX   DOI=10.1002/(SICI)1096-8628(19960628)63:4<558::AID-AJMG9>3.3.CO;2-V;
RA   Cole D.E.C., Fukuda S., Gordon B.A., Rip J.W., Lecouteur A.N.,
RA   Rupar C.A., Tomatsu S., Ogawa T., Sukegawa K., Orii T.;
RT   "Heteroallelic missense mutations of the galactosamine-6-sulfate
RT   sulfatase (GALNS) gene in a mild form of Morquio disease (MPS IVA).";
RL   Am. J. Med. Genet. 63:558-565(1996).
RN   [14]
RP   VARIANTS MPS4A.
RX   PubMed=9298823;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:3<223::AID-HUMU8>3.3.CO;2-M;
RA   Bunge S., Kleijer W.J., Tylki-Szymanska A., Steglich C., Beck M.,
RA   Tomatsu S., Fukuda S., Poorthuis B.J.H.M., Czartoryska B., Orii T.,
RA   Gal A.;
RT   "Identification of 31 novel mutations in the N-acetylgalactosamine-6-
RT   sulfatase gene reveals excessive allelic heterogeneity among patients
RT   with Morquio A syndrome.";
RL   Hum. Mutat. 10:223-232(1997).
RN   [15]
RP   VARIANTS MPS4A LEU-80; CYS-94; VAL-97; LEU-125; SER-139; GLN-166;
RP   GLY-185; SER-290; ARG-309; VAL-351; CYS-386; VAL-391 AND PRO-395.
RX   PubMed=9375852;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:5<368::AID-HUMU6>3.0.CO;2-B;
RA   Tomatsu S., Fukuda S., Cooper A., Wraith J.E., Ferreira P.,
RA   di Natale P., Tortora P., Fujimoto A., Kato Z., Yamada N., Isogai K.,
RA   Yamagishi A., Sukegawa K., Suzuki Y., Shimozawa N., Kondo N.,
RA   Sly W.S., Orii T.;
RT   "Fourteen novel mucopolysaccharidosis IVA producing mutations in GALNS
RT   gene.";
RL   Hum. Mutat. 10:368-375(1997).
RN   [16]
RP   VARIANTS MPS4A VAL-96; PHE-113; ARG-135; CYS-156; LEU-179; THR-257;
RP   VAL-284; SER-312; GLN-376 AND VAL-395.
RX   PubMed=9521421;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:3<202::AID-HUMU4>3.0.CO;2-J;
RA   Yamada N., Fukuda S., Tomatsu S., Muller V., Hopwood J.J., Nelson J.,
RA   Kato Z., Yamagishi A., Sukegawa K., Kondo N., Orii T.;
RT   "Molecular heterogeneity in mucopolysaccharidosis IVA in Australia and
RT   Northern Ireland: nine novel mutations including T312S, a common
RT   allele that confers a mild phenotype.";
RL   Hum. Mutat. 11:202-208(1998).
RN   [17]
RP   VARIANTS SER-393 AND MET-488.
RX   PubMed=9452036;
RA   Tomatsu S., Fukuda S., Cooper A., Wraith J.E., Yamagishi A., Kato Z.,
RA   Yamada N., Isogai K., Sukegawa K., Suzuki Y., Shimozawa N., Kondo N.,
RA   Orii T.;
RT   "Fifteen polymorphisms in the N-acetylgalactosamine-6-sulfate
RT   sulfatase (GALNS) gene: diagnostic implications in Morquio disease.";
RL   Hum. Mutat. Suppl. 1:S42-S46(1998).
RN   [18]
RP   VARIANTS MPS4A MET-15; 17-LEU-SER-18 DEL; ARG-23; PRO-36; LEU-41;
RP   GLU-42; 52-PRO--GLU-55 DEL; PHE-53; TRP-61; VAL-69; 71-ASN--SER-74
RP   DELINS THR; TYR-79; LEU-94; THR-107; SER-116; CYS-141; TYR-150;
RP   GLU-155; PHE-162; THR-164; VAL-167; ALA-171; SER-179; VAL-203;
RP   ASN-233; PHE-239; TRP-253; ASP-260; PHE-285 DEL; PRO-307; ASN-310;
RP   CYS-325; ASP-340; ARG-341; PRO-345; PRO-352; LEU-357; PRO-369;
RP   THR-380; SER-380; HIS-386; ASN-388; VAL-392; ASP-398; TYR-401;
RP   403-TRP-THR-404 DEL; ILE-452; PRO-470 AND SER-484, AND VARIANTS
RP   MET-67; VAL-178; MET-200; GLY-231; SER-393; VAL-459 AND MET-488.
RX   PubMed=16287098; DOI=10.1002/humu.20257;
RA   Tomatsu S., Montano A.M., Nishioka T., Gutierrez M.A., Pena O.M.,
RA   Tranda Firescu G.G., Lopez P., Yamaguchi S., Noguchi A., Orii T.;
RT   "Mutation and polymorphism spectrum of the GALNS gene in
RT   mucopolysaccharidosis IVA (Morquio A).";
RL   Hum. Mutat. 26:500-512(2005).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] TRP-61 AND THR-510.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [20]
RP   VARIANTS MPS4A GLU-16; ARG-36; ASN-40; GLY-48; LYS-51; ARG-77; LEU-80;
RP   LEU-81; GLU-84; TRP-90; PRO-91; CYS-94; LEU-94; PHE-113; VAL-116;
RP   SER-116; SER-139; ARG-141; TYR-145; LEU-151; ARG-155; LEU-156;
RP   ARG-166; SER-179; GLU-201; PRO-214; SER-216; GLY-230; ASN-233;
RP   LYS-235; THR-264; LEU-287; THR-291; CYS-301; SER-312; ARG-318;
RP   LEU-357; GLY-380; THR-380; CYS-386; HIS-386; VAL-391; VAL-392;
RP   HIS-407; VAL-415; THR-416; ARG-420; THR-492; VAL-494; SER-500 AND
RP   PHE-507, VARIANTS PHE-74; ASP-121; CYS-159; TYR-165; GLN-251; CYS-254;
RP   LYS-260 AND LYS-495, AND CHARACTERIZATION OF VARIANTS MPS4A GLU-16;
RP   ARG-36; LYS-51; LEU-81; GLU-84; PRO-91; VAL-116; TYR-145; LEU-156;
RP   ARG-166; GLU-201; PRO-214; SER-216; THR-264; GLY-380; VAL-415;
RP   THR-416; ARG-420; THR-492 AND SER-500.
RX   PubMed=24726177; DOI=10.1016/j.ymgme.2014.03.004;
RA   Morrone A., Tylee K.L., Al-Sayed M., Brusius-Facchin A.C.,
RA   Caciotti A., Church H.J., Coll M.J., Davidson K., Fietz M.J., Gort L.,
RA   Hegde M., Kubaski F., Lacerda L., Laranjeira F., Leistner-Segal S.,
RA   Mooney S., Pajares S., Pollard L., Ribeiro I., Wang R.Y., Miller N.;
RT   "Molecular testing of 163 patients with Morquio A
RT   (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.";
RL   Mol. Genet. Metab. 112:160-170(2014).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of the 6-sulfate groups of the N-
CC       acetyl-D-galactosamine 6-sulfate units of chondroitin sulfate and
CC       of the D-galactose 6-sulfate units of keratan sulfate.
CC       {ECO:0000269|PubMed:22940367}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:22940367};
CC       Note=Binds 1 Ca(2+) ion per subunit.
CC       {ECO:0000269|PubMed:22940367};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:22940367}.
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity. {ECO:0000269|PubMed:22940367}.
CC   -!- DISEASE: Mucopolysaccharidosis 4A (MPS4A) [MIM:253000]: A form of
CC       mucopolysaccharidosis type 4, an autosomal recessive lysosomal
CC       storage disease characterized by intracellular accumulation of
CC       keratan sulfate and chondroitin-6-sulfate. Key clinical features
CC       include short stature, skeletal dysplasia, dental anomalies, and
CC       corneal clouding. Intelligence is normal and there is no direct
CC       central nervous system involvement, although the skeletal changes
CC       may result in neurologic complications. There is variable
CC       severity, but patients with the severe phenotype usually do not
CC       survive past the second or third decade of life.
CC       {ECO:0000269|PubMed:1522213, ECO:0000269|PubMed:16287098,
CC       ECO:0000269|PubMed:24726177, ECO:0000269|PubMed:7581409,
CC       ECO:0000269|PubMed:7633425, ECO:0000269|PubMed:7668283,
CC       ECO:0000269|PubMed:7795586, ECO:0000269|PubMed:8651279,
CC       ECO:0000269|PubMed:8826435, ECO:0000269|PubMed:9298823,
CC       ECO:0000269|PubMed:9375852, ECO:0000269|PubMed:9521421}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the sulfatase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D17629; BAA04535.1; -; Genomic_DNA.
DR   EMBL; U06088; AAC51350.1; -; Genomic_DNA.
DR   EMBL; U06078; AAC51350.1; JOINED; Genomic_DNA.
DR   EMBL; U06079; AAC51350.1; JOINED; Genomic_DNA.
DR   EMBL; U06080; AAC51350.1; JOINED; Genomic_DNA.
DR   EMBL; U06081; AAC51350.1; JOINED; Genomic_DNA.
DR   EMBL; U06082; AAC51350.1; JOINED; Genomic_DNA.
DR   EMBL; U06083; AAC51350.1; JOINED; Genomic_DNA.
DR   EMBL; U06084; AAC51350.1; JOINED; Genomic_DNA.
DR   EMBL; U06085; AAC51350.1; JOINED; Genomic_DNA.
DR   EMBL; U06086; AAC51350.1; JOINED; Genomic_DNA.
DR   EMBL; U06087; AAC51350.1; JOINED; Genomic_DNA.
DR   EMBL; BC050684; AAH50684.2; -; mRNA.
DR   EMBL; BC056151; AAH56151.1; -; mRNA.
DR   CCDS; CCDS10970.1; -.
DR   PIR; JQ1299; KJHUG6.
DR   RefSeq; NP_000503.1; NM_000512.4.
DR   UniGene; Hs.271383; -.
DR   PDB; 4FDI; X-ray; 2.20 A; A/B=27-522.
DR   PDB; 4FDJ; X-ray; 2.81 A; A/B=27-522.
DR   PDBsum; 4FDI; -.
DR   PDBsum; 4FDJ; -.
DR   ProteinModelPortal; P34059; -.
DR   SMR; P34059; 29-522.
DR   BioGrid; 108860; 29.
DR   STRING; 9606.ENSP00000268695; -.
DR   DrugBank; DB09051; Elosulfase alfa.
DR   PhosphoSite; P34059; -.
DR   BioMuta; GALNS; -.
DR   DMDM; 462148; -.
DR   MaxQB; P34059; -.
DR   PaxDb; P34059; -.
DR   PRIDE; P34059; -.
DR   DNASU; 2588; -.
DR   Ensembl; ENST00000268695; ENSP00000268695; ENSG00000141012.
DR   GeneID; 2588; -.
DR   KEGG; hsa:2588; -.
DR   UCSC; uc002fly.4; human.
DR   CTD; 2588; -.
DR   GeneCards; GALNS; -.
DR   GeneReviews; GALNS; -.
DR   H-InvDB; HIX0134371; -.
DR   HGNC; HGNC:4122; GALNS.
DR   HPA; CAB026404; -.
DR   MalaCards; GALNS; -.
DR   MIM; 253000; phenotype.
DR   MIM; 612222; gene.
DR   neXtProt; NX_P34059; -.
DR   Orphanet; 309297; Mucopolysaccharidosis type 4A.
DR   PharmGKB; PA28535; -.
DR   eggNOG; KOG3867; Eukaryota.
DR   eggNOG; COG3119; LUCA.
DR   GeneTree; ENSGT00760000119062; -.
DR   HOGENOM; HOG000135352; -.
DR   HOVERGEN; HBG004283; -.
DR   InParanoid; P34059; -.
DR   KO; K01132; -.
DR   OMA; WRVEHAF; -.
DR   OrthoDB; EOG7QZG9J; -.
DR   PhylomeDB; P34059; -.
DR   TreeFam; TF314186; -.
DR   BioCyc; MetaCyc:HS06790-MONOMER; -.
DR   BRENDA; 3.1.6.4; 2681.
DR   Reactome; R-HSA-2022857; Keratan sulfate degradation.
DR   Reactome; R-HSA-2206290; MPS IV - Morquio syndrome A.
DR   ChiTaRS; GALNS; human.
DR   GeneWiki; Galactosamine-6_sulfatase; -.
DR   GenomeRNAi; 2588; -.
DR   NextBio; 10237; -.
DR   PRO; PR:P34059; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; P34059; -.
DR   CleanEx; HS_GALNS; -.
DR   ExpressionAtlas; P34059; baseline and differential.
DR   Genevisible; P34059; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003943; F:N-acetylgalactosamine-4-sulfatase activity; TAS:ProtInc.
DR   GO; GO:0043890; F:N-acetylgalactosamine-6-sulfatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008484; F:sulfuric ester hydrolase activity; IDA:MGI.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0042340; P:keratan sulfate catabolic process; TAS:Reactome.
DR   GO; GO:0042339; P:keratan sulfate metabolic process; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   InterPro; IPR000917; Sulfatase_N.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; SSF53649; 1.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Dwarfism; Glycoprotein; Hydrolase;
KW   Lysosome; Metal-binding; Mucopolysaccharidosis; Polymorphism;
KW   Reference proteome; Signal.
FT   SIGNAL        1     26
FT   CHAIN        27    522       N-acetylgalactosamine-6-sulfatase.
FT                                /FTId=PRO_0000033411.
FT   REGION       27    379       Catalytic domain.
FT   METAL        39     39       Calcium. {ECO:0000269|PubMed:22940367}.
FT   METAL        40     40       Calcium. {ECO:0000269|PubMed:22940367}.
FT   METAL        79     79       Calcium; via 3-oxoalanine.
FT                                {ECO:0000269|PubMed:22940367}.
FT   METAL       288    288       Calcium. {ECO:0000269|PubMed:22940367}.
FT   METAL       289    289       Calcium. {ECO:0000269|PubMed:22940367}.
FT   MOD_RES      79     79       3-oxoalanine (Cys).
FT                                {ECO:0000269|PubMed:22940367}.
FT   CARBOHYD    204    204       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:22940367}.
FT   CARBOHYD    423    423       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:22940367}.
FT   DISULFID    308    419       {ECO:0000269|PubMed:22940367}.
FT   DISULFID    489    518       {ECO:0000269|PubMed:22940367}.
FT   DISULFID    501    507       {ECO:0000269|PubMed:22940367}.
FT   VARIANT      15     15       L -> M (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024873.
FT   VARIANT      16     16       V -> E (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071569.
FT   VARIANT      17     18       Missing (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024874.
FT   VARIANT      23     23       G -> R (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024875.
FT   VARIANT      36     36       L -> P (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024876.
FT   VARIANT      36     36       L -> R (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071570.
FT   VARIANT      40     40       D -> N (in MPS4A).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071571.
FT   VARIANT      41     41       M -> L (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024877.
FT   VARIANT      42     42       G -> E (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024878.
FT   VARIANT      47     47       G -> R (in MPS4A; severe form).
FT                                /FTId=VAR_007172.
FT   VARIANT      48     48       V -> G (in MPS4A).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071572.
FT   VARIANT      51     51       E -> K (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071573.
FT   VARIANT      52     55       Missing (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024879.
FT   VARIANT      53     53       S -> F (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024880.
FT   VARIANT      60     60       D -> N (in MPS4A; mild form).
FT                                /FTId=VAR_007173.
FT   VARIANT      61     61       R -> W (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_024881.
FT   VARIANT      67     67       L -> M (associated with S-409 in a MPS4A
FT                                patient; dbSNP:rs11862754).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_007174.
FT   VARIANT      69     69       F -> V (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024882.
FT   VARIANT      71     74       NFYS -> T (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024883.
FT   VARIANT      74     74       S -> F. {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071574.
FT   VARIANT      77     77       P -> R (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:7633425,
FT                                ECO:0000269|PubMed:7668283}.
FT                                /FTId=VAR_007175.
FT   VARIANT      79     79       C -> Y (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024884.
FT   VARIANT      80     80       S -> L (in MPS4A; intermediate form).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007177.
FT   VARIANT      81     81       P -> L (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071575.
FT   VARIANT      84     84       A -> E (in MPS4A; loss of enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071576.
FT   VARIANT      90     90       R -> W (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:7633425,
FT                                ECO:0000269|PubMed:7668283}.
FT                                /FTId=VAR_007178.
FT   VARIANT      91     91       L -> P (in MPS4A; loss of enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071577.
FT   VARIANT      94     94       R -> C (in MPS4A; mild/intermediate
FT                                form). {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:8826435,
FT                                ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007179.
FT   VARIANT      94     94       R -> G (in MPS4A; mild/intermediate
FT                                form).
FT                                /FTId=VAR_007180.
FT   VARIANT      94     94       R -> L (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_024885.
FT   VARIANT      96     96       G -> C (in MPS4A).
FT                                /FTId=VAR_007181.
FT   VARIANT      96     96       G -> V (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:7633425,
FT                                ECO:0000269|PubMed:7668283,
FT                                ECO:0000269|PubMed:9521421}.
FT                                /FTId=VAR_007182.
FT   VARIANT      97     97       F -> V (in MPS4A; mild form).
FT                                {ECO:0000269|PubMed:8826435,
FT                                ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007183.
FT   VARIANT     107    107       A -> T (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024886.
FT   VARIANT     111    111       Q -> R (in MPS4A; intermediate form).
FT                                /FTId=VAR_007184.
FT   VARIANT     113    113       I -> F (in MPS4A; severe form; common
FT                                mutation; found in patients with Irish-
FT                                British ancestry).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:7668283,
FT                                ECO:0000269|PubMed:9521421}.
FT                                /FTId=VAR_007185.
FT   VARIANT     116    116       G -> S (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_024887.
FT   VARIANT     116    116       G -> V (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071578.
FT   VARIANT     121    121       E -> D. {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071579.
FT   VARIANT     125    125       P -> L (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007186.
FT   VARIANT     135    135       S -> R (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9521421}.
FT                                /FTId=VAR_007187.
FT   VARIANT     138    138       V -> A (in MPS4A; mild/severe/
FT                                intermediate form).
FT                                {ECO:0000269|PubMed:8651279}.
FT                                /FTId=VAR_007188.
FT   VARIANT     139    139       G -> S (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007189.
FT   VARIANT     141    141       W -> C (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024888.
FT   VARIANT     141    141       W -> R (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_007190.
FT   VARIANT     145    145       H -> Y (in MPS4A; reduced enzymatic
FT                                activity; dbSNP:rs577334837).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071580.
FT   VARIANT     150    150       H -> Y (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024889.
FT   VARIANT     151    151       P -> L (in MPS4A; severe form;
FT                                dbSNP:rs559063128).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:7633425,
FT                                ECO:0000269|PubMed:7668283,
FT                                ECO:0000269|PubMed:8651279}.
FT                                /FTId=VAR_007191.
FT   VARIANT     151    151       P -> S (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:8651279}.
FT                                /FTId=VAR_007192.
FT   VARIANT     155    155       G -> E (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024890.
FT   VARIANT     155    155       G -> R (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_007193.
FT   VARIANT     156    156       F -> C (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9521421}.
FT                                /FTId=VAR_007194.
FT   VARIANT     156    156       F -> L (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071581.
FT   VARIANT     156    156       F -> S (in MPS4A; mild form).
FT                                /FTId=VAR_007195.
FT   VARIANT     159    159       W -> C. {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071582.
FT   VARIANT     162    162       S -> F (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024891.
FT   VARIANT     164    164       N -> T (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024892.
FT   VARIANT     165    165       C -> Y. {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071583.
FT   VARIANT     166    166       H -> Q (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007196.
FT   VARIANT     166    166       H -> R (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071584.
FT   VARIANT     167    167       F -> V (in MPS4A; dbSNP:rs148565559).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024893.
FT   VARIANT     168    168       G -> R (in MPS4A).
FT                                /FTId=VAR_007197.
FT   VARIANT     171    171       D -> A (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024894.
FT   VARIANT     178    178       I -> V. {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_007198.
FT   VARIANT     179    179       P -> H (in MPS4A; severe form).
FT                                /FTId=VAR_007199.
FT   VARIANT     179    179       P -> L (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9521421}.
FT                                /FTId=VAR_007200.
FT   VARIANT     179    179       P -> S (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_024895.
FT   VARIANT     185    185       E -> G (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007201.
FT   VARIANT     200    200       T -> M (in dbSNP:rs7187889).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_007202.
FT   VARIANT     201    201       G -> E (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071585.
FT   VARIANT     203    203       A -> V (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024896.
FT   VARIANT     204    204       N -> K (in MPS4A; mild form).
FT                                {ECO:0000269|PubMed:1522213}.
FT                                /FTId=VAR_007203.
FT   VARIANT     214    214       L -> P (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071586.
FT   VARIANT     216    216       F -> S (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071587.
FT   VARIANT     230    230       W -> G (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:7633425,
FT                                ECO:0000269|PubMed:7668283}.
FT                                /FTId=VAR_007204.
FT   VARIANT     231    231       A -> G (in dbSNP:rs34745339).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_007205.
FT   VARIANT     233    233       D -> N (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_024897.
FT   VARIANT     235    235       T -> K (in MPS4A).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071588.
FT   VARIANT     239    239       V -> F (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024898.
FT   VARIANT     247    247       G -> D (in MPS4A).
FT                                /FTId=VAR_007206.
FT   VARIANT     251    251       R -> Q. {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071589.
FT   VARIANT     253    253       R -> W (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024899.
FT   VARIANT     254    254       Y -> C. {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071590.
FT   VARIANT     257    257       A -> T (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9521421}.
FT                                /FTId=VAR_007207.
FT   VARIANT     259    259       R -> Q (in MPS4A; mild form).
FT                                /FTId=VAR_007208.
FT   VARIANT     260    260       E -> D (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024900.
FT   VARIANT     260    260       E -> K. {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071591.
FT   VARIANT     264    264       S -> T (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071592.
FT   VARIANT     279    287       Missing (in MPS4A; mild form).
FT                                /FTId=VAR_007209.
FT   VARIANT     284    284       F -> V (in MPS4A; severe form;
FT                                dbSNP:rs144067930).
FT                                {ECO:0000269|PubMed:9521421}.
FT                                /FTId=VAR_007210.
FT   VARIANT     285    285       Missing (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024901.
FT   VARIANT     287    287       S -> L (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_007211.
FT   VARIANT     290    290       G -> S (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007212.
FT   VARIANT     291    291       A -> D (in MPS4A; mild form).
FT                                /FTId=VAR_007213.
FT   VARIANT     291    291       A -> T (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:7633425,
FT                                ECO:0000269|PubMed:7668283}.
FT                                /FTId=VAR_007214.
FT   VARIANT     295    295       S -> F (in MPS4A; mild form).
FT                                /FTId=VAR_007215.
FT   VARIANT     301    301       G -> C (in MPS4A; severe form;
FT                                dbSNP:rs118204443).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_007216.
FT   VARIANT     307    307       L -> P (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024902.
FT   VARIANT     309    309       G -> R (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007217.
FT   VARIANT     310    310       K -> N (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024903.
FT   VARIANT     312    312       T -> S (in MPS4A; mild/intermediate/
FT                                severe form).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:9521421}.
FT                                /FTId=VAR_007218.
FT   VARIANT     318    318       M -> R (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_007219.
FT   VARIANT     325    325       W -> C (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024904.
FT   VARIANT     325    325       Missing (in MPS4A).
FT                                /FTId=VAR_007220.
FT   VARIANT     340    340       G -> D (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024905.
FT   VARIANT     341    341       S -> R (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024906.
FT   VARIANT     343    343       M -> R (in MPS4A; severe form).
FT                                /FTId=VAR_007221.
FT   VARIANT     344    344       D -> E (in MPS4A).
FT                                /FTId=VAR_007222.
FT   VARIANT     344    344       D -> N (in MPS4A; severe form).
FT                                /FTId=VAR_007223.
FT   VARIANT     345    345       L -> P (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024907.
FT   VARIANT     346    346       F -> L (in MPS4A; severe form).
FT                                /FTId=VAR_007224.
FT   VARIANT     351    351       A -> V (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007225.
FT   VARIANT     352    352       L -> P (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024908.
FT   VARIANT     357    357       P -> L (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_024909.
FT   VARIANT     361    361       R -> G (in MPS4A).
FT                                /FTId=VAR_007226.
FT   VARIANT     369    369       L -> P (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024910.
FT   VARIANT     376    376       R -> Q (in MPS4A; severe form;
FT                                dbSNP:rs150734270).
FT                                {ECO:0000269|PubMed:9521421}.
FT                                /FTId=VAR_007227.
FT   VARIANT     380    380       R -> G (in MPS4A; loss of enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071593.
FT   VARIANT     380    380       R -> S (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024911.
FT   VARIANT     380    380       R -> T (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_024912.
FT   VARIANT     386    386       R -> C (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:7668283,
FT                                ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007228.
FT   VARIANT     386    386       R -> H (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_024913.
FT   VARIANT     388    388       D -> N (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024914.
FT   VARIANT     391    391       M -> V (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177,
FT                                ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007229.
FT   VARIANT     392    392       A -> V (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_024915.
FT   VARIANT     393    393       A -> S (in dbSNP:rs2303269).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:9452036}.
FT                                /FTId=VAR_007230.
FT   VARIANT     395    395       L -> P (in MPS4A).
FT                                {ECO:0000269|PubMed:9375852}.
FT                                /FTId=VAR_007231.
FT   VARIANT     395    395       L -> V (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:9521421}.
FT                                /FTId=VAR_007232.
FT   VARIANT     398    398       H -> D (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024916.
FT   VARIANT     401    401       H -> Y (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024917.
FT   VARIANT     403    404       Missing (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024918.
FT   VARIANT     407    407       N -> H (in MPS4A).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_007233.
FT   VARIANT     409    409       W -> S (in MPS4A; associated with M-67 in
FT                                a patient).
FT                                /FTId=VAR_007234.
FT   VARIANT     415    415       G -> V (in MPS4A; loss of enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071594.
FT   VARIANT     416    416       I -> T (in MPS4A; reduced enzymatic
FT                                activity; dbSNP:rs142822371).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071595.
FT   VARIANT     420    420       P -> R (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071596.
FT   VARIANT     450    450       E -> V (in MPS4A; severe form).
FT                                /FTId=VAR_007235.
FT   VARIANT     452    452       F -> I (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024919.
FT   VARIANT     459    459       A -> V (in dbSNP:rs114703967).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_007236.
FT   VARIANT     470    470       S -> P (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024920.
FT   VARIANT     484    484       P -> S (in MPS4A).
FT                                {ECO:0000269|PubMed:16287098}.
FT                                /FTId=VAR_024921.
FT   VARIANT     487    487       N -> S (in MPS4A).
FT                                {ECO:0000269|PubMed:7581409,
FT                                ECO:0000269|PubMed:7668283}.
FT                                /FTId=VAR_007237.
FT   VARIANT     488    488       V -> M (in dbSNP:rs78127134).
FT                                {ECO:0000269|PubMed:16287098,
FT                                ECO:0000269|PubMed:9452036}.
FT                                /FTId=VAR_007238.
FT   VARIANT     492    492       A -> T (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071597.
FT   VARIANT     494    494       M -> V (in MPS4A; severe form).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_007239.
FT   VARIANT     495    495       N -> K. {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071598.
FT   VARIANT     500    500       G -> S (in MPS4A; reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071599.
FT   VARIANT     507    507       C -> F (in MPS4A).
FT                                {ECO:0000269|PubMed:24726177}.
FT                                /FTId=VAR_071600.
FT   VARIANT     510    510       P -> T (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036493.
FT   STRAND       32     40       {ECO:0000244|PDB:4FDI}.
FT   HELIX        47     49       {ECO:0000244|PDB:4FDI}.
FT   HELIX        57     64       {ECO:0000244|PDB:4FDI}.
FT   STRAND       66     68       {ECO:0000244|PDB:4FDI}.
FT   STRAND       70     73       {ECO:0000244|PDB:4FDI}.
FT   STRAND       75     78       {ECO:0000244|PDB:4FDI}.
FT   HELIX        79     88       {ECO:0000244|PDB:4FDI}.
FT   HELIX        92     95       {ECO:0000244|PDB:4FDI}.
FT   HELIX       124    128       {ECO:0000244|PDB:4FDI}.
FT   HELIX       129    131       {ECO:0000244|PDB:4FDI}.
FT   STRAND      134    139       {ECO:0000244|PDB:4FDI}.
FT   HELIX       147    149       {ECO:0000244|PDB:4FDI}.
FT   HELIX       151    153       {ECO:0000244|PDB:4FDI}.
FT   STRAND      157    161       {ECO:0000244|PDB:4FDI}.
FT   STRAND      172    175       {ECO:0000244|PDB:4FDI}.
FT   STRAND      179    182       {ECO:0000244|PDB:4FDI}.
FT   STRAND      185    190       {ECO:0000244|PDB:4FDI}.
FT   TURN        191    193       {ECO:0000244|PDB:4FDI}.
FT   TURN        198    200       {ECO:0000244|PDB:4FDI}.
FT   HELIX       205    220       {ECO:0000244|PDB:4FDI}.
FT   TURN        221    223       {ECO:0000244|PDB:4FDI}.
FT   STRAND      226    231       {ECO:0000244|PDB:4FDI}.
FT   STRAND      236    238       {ECO:0000244|PDB:4FDI}.
FT   HELIX       243    245       {ECO:0000244|PDB:4FDI}.
FT   HELIX       252    274       {ECO:0000244|PDB:4FDI}.
FT   HELIX       278    280       {ECO:0000244|PDB:4FDI}.
FT   STRAND      281    289       {ECO:0000244|PDB:4FDI}.
FT   TURN        296    298       {ECO:0000244|PDB:4FDI}.
FT   STRAND      312    314       {ECO:0000244|PDB:4FDI}.
FT   HELIX       315    318       {ECO:0000244|PDB:4FDI}.
FT   STRAND      322    325       {ECO:0000244|PDB:4FDI}.
FT   TURN        327    329       {ECO:0000244|PDB:4FDI}.
FT   HELIX       344    353       {ECO:0000244|PDB:4FDI}.
FT   STRAND      359    361       {ECO:0000244|PDB:4FDI}.
FT   HELIX       369    374       {ECO:0000244|PDB:4FDI}.
FT   STRAND      382    386       {ECO:0000244|PDB:4FDI}.
FT   STRAND      389    395       {ECO:0000244|PDB:4FDI}.
FT   STRAND      398    404       {ECO:0000244|PDB:4FDI}.
FT   HELIX       409    413       {ECO:0000244|PDB:4FDI}.
FT   TURN        425    427       {ECO:0000244|PDB:4FDI}.
FT   STRAND      436    438       {ECO:0000244|PDB:4FDI}.
FT   STRAND      440    443       {ECO:0000244|PDB:4FDI}.
FT   TURN        444    446       {ECO:0000244|PDB:4FDI}.
FT   HELIX       459    477       {ECO:0000244|PDB:4FDI}.
FT   STRAND      485    489       {ECO:0000244|PDB:4FDI}.
FT   HELIX       491    493       {ECO:0000244|PDB:4FDI}.
FT   STRAND      494    497       {ECO:0000244|PDB:4FDI}.
FT   HELIX       501    504       {ECO:0000244|PDB:4FDI}.
SQ   SEQUENCE   522 AA;  58026 MW;  1D086E528AAAE949 CRC64;
     MAAVVAATRW WQLLLVLSAA GMGASGAPQP PNILLLLMDD MGWGDLGVYG EPSRETPNLD
     RMAAEGLLFP NFYSANPLCS PSRAALLTGR LPIRNGFYTT NAHARNAYTP QEIVGGIPDS
     EQLLPELLKK AGYVSKIVGK WHLGHRPQFH PLKHGFDEWF GSPNCHFGPY DNKARPNIPV
     YRDWEMVGRY YEEFPINLKT GEANLTQIYL QEALDFIKRQ ARHHPFFLYW AVDATHAPVY
     ASKPFLGTSQ RGRYGDAVRE IDDSIGKILE LLQDLHVADN TFVFFTSDNG AALISAPEQG
     GSNGPFLCGK QTTFEGGMRE PALAWWPGHV TAGQVSHQLG SIMDLFTTSL ALAGLTPPSD
     RAIDGLNLLP TLLQGRLMDR PIFYYRGDTL MAATLGQHKA HFWTWTNSWE NFRQGIDFCP
     GQNVSGVTTH NLEDHTKLPL IFHLGRDPGE RFPLSFASAE YQEALSRITS VVQQHQEALV
     PAQPQLNVCN WAVMNWAPPG CEKLGKCLTP PESIPKKCLW SH
//
ID   CO3_HUMAN               Reviewed;        1663 AA.
AC   P01024; A7E236;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   12-DEC-2006, sequence version 2.
DT   20-JAN-2016, entry version 202.
DE   RecName: Full=Complement C3;
DE   AltName: Full=C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1;
DE   Contains:
DE     RecName: Full=Complement C3 beta chain;
DE   Contains:
DE     RecName: Full=C3-beta-c;
DE              Short=C3bc;
DE   Contains:
DE     RecName: Full=Complement C3 alpha chain;
DE   Contains:
DE     RecName: Full=C3a anaphylatoxin;
DE   Contains:
DE     RecName: Full=Acylation stimulating protein;
DE              Short=ASP;
DE     AltName: Full=C3adesArg;
DE   Contains:
DE     RecName: Full=Complement C3b alpha' chain;
DE   Contains:
DE     RecName: Full=Complement C3c alpha' chain fragment 1;
DE   Contains:
DE     RecName: Full=Complement C3dg fragment;
DE   Contains:
DE     RecName: Full=Complement C3g fragment;
DE   Contains:
DE     RecName: Full=Complement C3d fragment;
DE   Contains:
DE     RecName: Full=Complement C3f fragment;
DE   Contains:
DE     RecName: Full=Complement C3c alpha' chain fragment 2;
DE   Flags: Precursor;
GN   Name=C3; Synonyms=CPAMD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-314.
RX   PubMed=2579379; DOI=10.1073/pnas.82.3.708;
RA   de Bruijn M.H.L., Fey G.H.;
RT   "Human complement component C3: cDNA coding sequence and derived
RT   primary structure.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:708-712(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-102; LEU-314;
RP   LYS-863; ASP-1224 AND THR-1367.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF N-TERMINUS, IDENTIFICATION BY MASS SPECTROMETRY,
RP   AND FUNCTION.
RX   PubMed=8376604; DOI=10.1172/JCI116733;
RA   Baldo A., Sniderman A.D., St-Luce S., Avramoglu R.K., Maslowska M.,
RA   Hoang B., Monge J.C., Bell A., Mulay S., Cianflone K.;
RT   "The adipsin-acylation stimulating protein system and regulation of
RT   intracellular triglyceride synthesis.";
RL   J. Clin. Invest. 92:1543-1547(1993).
RN   [6]
RP   PROTEIN SEQUENCE OF 672-748.
RX   PubMed=1238393;
RA   Hugli T.E.;
RT   "Human anaphylatoxin (C3a) from the third component of complement.
RT   Primary structure.";
RL   J. Biol. Chem. 250:8293-8301(1975).
RN   [7]
RP   PROTEIN SEQUENCE OF 955-966, AND SUBUNIT.
RC   TISSUE=Serum;
RX   PubMed=7539791; DOI=10.1074/jbc.270.23.13645;
RA   Oxvig C., Haaning J., Kristensen L., Wagner J.M., Rubin I.,
RA   Stigbrand T., Gleich G.J., Sottrup-Jensen L.;
RT   "Identification of angiotensinogen and complement C3dg as novel
RT   proteins binding the proform of eosinophil major basic protein in
RT   human pregnancy serum and plasma.";
RL   J. Biol. Chem. 270:13645-13651(1995).
RN   [8]
RP   PROTEIN SEQUENCE OF 988-1036.
RX   PubMed=6175959; DOI=10.1073/pnas.79.4.1054;
RA   Thomas M.L., Janatova J., Gray W.R., Tack B.F.;
RT   "Third component of human complement: localization of the internal
RT   thiolester bond.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:1054-1058(1982).
RN   [9]
RP   PROTEIN SEQUENCE OF 1409-1563.
RX   PubMed=3279119;
RA   Daoudaki M.E., Becherer J.D., Lambris J.D.;
RT   "A 34-amino acid peptide of the third component of complement mediates
RT   properdin binding.";
RL   J. Immunol. 140:1577-1580(1988).
RN   [10]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS HHV-1 AND HHV-2 GYCOPROTEIN C.
RX   PubMed=2849025; DOI=10.1016/0882-4010(87)90012-X;
RA   Eisenberg R.J., Ponce de Leon M., Friedman H.M., Fries L.F.,
RA   Frank M.M., Hastings J.C., Cohen G.H.;
RT   "Complement component C3b binds directly to purified glycoprotein C of
RT   herpes simplex virus types 1 and 2.";
RL   Microb. Pathog. 3:423-435(1987).
RN   [11]
RP   FUNCTION.
RX   PubMed=2909530;
RA   Cianflone K.M., Sniderman A.D., Walsh M.J., Vu H.T., Gagnon J.,
RA   Rodriguez M.A.;
RT   "Purification and characterization of acylation stimulating protein.";
RL   J. Biol. Chem. 264:426-430(1989).
RN   [12]
RP   MUTAGENESIS OF THE THIOESTER BOND REGION.
RX   PubMed=1577777;
RA   Isaac L., Isenman D.E.;
RT   "Structural requirements for thioester bond formation in human
RT   complement component C3. Reassessment of the role of thioester bond
RT   integrity on the conformation of C3.";
RL   J. Biol. Chem. 267:10062-10069(1992).
RN   [13]
RP   DISULFIDE BONDS.
RX   PubMed=8416818; DOI=10.1016/0014-5793(93)81139-Q;
RA   Dolmer K., Sottrup-Jensen L.;
RT   "Disulfide bridges in human complement component C3b.";
RL   FEBS Lett. 315:85-90(1993).
RN   [14]
RP   FUNCTION.
RX   PubMed=9059512; DOI=10.1016/S0005-2760(96)00144-0;
RA   Tao Y., Cianflone K., Sniderman A.D., Colby-Germinario S.P.,
RA   Germinario R.J.;
RT   "Acylation-stimulating protein (ASP) regulates glucose transport in
RT   the rat L6 muscle cell line.";
RL   Biochim. Biophys. Acta 1344:221-229(1997).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY, TISSUE SPECIFICITY, AND FUNCTION.
RX   PubMed=9555951;
RA   Saleh J., Summers L.K., Cianflone K., Fielding B.A., Sniderman A.D.,
RA   Frayn K.N.;
RT   "Coordinated release of acylation stimulating protein (ASP) and
RT   triacylglycerol clearance by human adipose tissue in vivo in the
RT   postprandial period.";
RL   J. Lipid Res. 39:884-891(1998).
RN   [16]
RP   FUNCTION.
RX   PubMed=10432298; DOI=10.1042/0264-6021:3420041;
RA   Murray I., Kohl J., Cianflone K.;
RT   "Acylation-stimulating protein (ASP): structure-function determinants
RT   of cell surface binding and triacylglycerol synthetic activity.";
RL   Biochem. J. 342:41-48(1999).
RN   [17]
RP   INTERACTION WITH C5AR2.
RX   PubMed=11773063; DOI=10.1074/jbc.C100714200;
RA   Cain S.A., Monk P.N.;
RT   "The orphan receptor C5L2 has high affinity binding sites for
RT   complement fragments C5a and C5a des Arg(74).";
RL   J. Biol. Chem. 277:7165-7169(2002).
RN   [18]
RP   INTERACTION WITH C5AR2.
RX   PubMed=12540846; DOI=10.1074/jbc.M206169200;
RA   Kalant D., Cain S.A., Maslowska M., Sniderman A.D., Cianflone K.,
RA   Monk P.N.;
RT   "The chemoattractant receptor-like protein C5L2 binds the C3a des-
RT   Arg77/acylation-stimulating protein.";
RL   J. Biol. Chem. 278:11123-11129(2003).
RN   [19]
RP   GLYCOSYLATION AT ASN-85.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-939.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [21]
RP   EFFECTS OF EXERCISE.
RX   PubMed=15809665; DOI=10.1038/sj.ijo.0802949;
RA   Schrauwen P., Hesselink M.K., Jain M., Cianflone K.;
RT   "Acylation-stimulating protein: effect of acute exercise and endurance
RT   training.";
RL   Int. J. Obes. Relat. Metab. Disord. 29:632-638(2005).
RN   [22]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15833747; DOI=10.1074/jbc.M406921200;
RA   Kalant D., MacLaren R., Cui W., Samanta R., Monk P.N., Laporte S.A.,
RA   Cianflone K.;
RT   "C5L2 is a functional receptor for acylation-stimulating protein.";
RL   J. Biol. Chem. 280:23936-23944(2005).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-85; ASN-939 AND ASN-1617.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [24]
RP   ASSOCIATION WITH TYPE 2 DIABETES.
RX   PubMed=16302015; DOI=10.1038/sj.ijo.0803173;
RA   Yang Y., Lu H.L., Zhang J., Yu H.Y., Wang H.W., Zhang M.X.,
RA   Cianflone K.;
RT   "Relationships among acylation stimulating protein, adiponectin and
RT   complement C3 in lean vs obese type 2 diabetes.";
RL   Int. J. Obes. Relat. Metab. Disord. 30:439-446(2006).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND FUNCTION.
RX   PubMed=16333141; DOI=10.1194/jlr.M500500-JLR200;
RA   Maslowska M., Legakis H., Assadi F., Cianflone K.;
RT   "Targeting the signaling pathway of acylation stimulating protein.";
RL   J. Lipid Res. 47:643-652(2006).
RN   [26]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-85.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [27]
RP   ASSOCIATION WITH OBESITY.
RX   PubMed=18805911; DOI=10.1530/EJE-08-0467;
RA   Wamba P.C., Mi J., Zhao X.Y., Zhang M.X., Wen Y., Cheng H., Hou D.Q.,
RA   Cianflone K.;
RT   "Acylation stimulating protein but not complement C3 associates with
RT   metabolic syndrome components in Chinese children and adolescents.";
RL   Eur. J. Endocrinol. 159:781-790(2008).
RN   [28]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-85.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [29]
RP   FUNCTION.
RX   PubMed=19615750; DOI=10.1016/j.molimm.2009.06.007;
RA   Cui W., Simaan M., Laporte S., Lodge R., Cianflone K.;
RT   "C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are
RT   lost in S323I-C5L2 mutation.";
RL   Mol. Immunol. 46:3086-3098(2009).
RN   [30]
RP   MUTAGENESIS OF ASP-1029; GLU-1030; GLU-1032; GLU-1035; ARG-1042;
RP   ASP-1140; GLU-1153; ASP-1156; GLU-1159; GLU-1160; ASN-1163 AND
RP   LYS-1284, AND INTERACTION WITH CR2 AND S.AUREUS SBI.
RX   PubMed=20083651; DOI=10.4049/jimmunol.0902919;
RA   Isenman D.E., Leung E., Mackay J.D., Bagby S., van den Elsen J.M.;
RT   "Mutational analyses reveal that the staphylococcal immune evasion
RT   molecule Sbi and complement receptor 2 (CR2) share overlapping contact
RT   residues on C3d: implications for the controversy regarding the
RT   CR2/C3d cocrystal structure.";
RL   J. Immunol. 184:1946-1955(2010).
RN   [31]
RP   MUTAGENESIS OF ASP-1029; GLU-1030; GLU-1032; GLU-1110; ASP-1115;
RP   ASP-1121; ASP-1140; GLU-1153; ASP-1156; GLU-1159; GLU-1160 AND
RP   ASN-1163, AND INTERACTION WITH CR2.
RX   PubMed=20951140; DOI=10.1016/j.jmb.2010.10.005;
RA   Shaw C.D., Storek M.J., Young K.A., Kovacs J.M., Thurman J.M.,
RA   Holers V.M., Hannan J.P.;
RT   "Delineation of the complement receptor type 2-C3d complex by site-
RT   directed mutagenesis and molecular docking.";
RL   J. Mol. Biol. 404:697-710(2010).
RN   [32]
RP   ASSOCIATION WITH CORONARY HEART DISEASE.
RX   PubMed=19913840; DOI=10.1016/j.metabol.2009.09.006;
RA   Onat A., Hergenc G., Can G., Kaya Z., Yuksel H.;
RT   "Serum complement C3: a determinant of cardiometabolic risk, additive
RT   to the metabolic syndrome, in middle-aged population.";
RL   Metabolism 59:628-634(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   PHOSPHORYLATION AT SER-38; SER-70; SER-297; SER-303; SER-672; SER-968;
RP   SER-1321 AND SER-1573.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [36]
RP   STRUCTURE BY NMR OF C3A.
RX   PubMed=3260670; DOI=10.1073/pnas.85.14.5036;
RA   Nettesheim D.G., Edalji R.P., Mollison K.W., Greer J.,
RA   Zuiderweg E.R.P.;
RT   "Secondary structure of complement component C3a anaphylatoxin in
RT   solution as determined by NMR spectroscopy: differences between
RT   crystal and solution conformations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:5036-5040(1988).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF C3D.
RX   PubMed=9596584; DOI=10.1126/science.280.5367.1277;
RA   Nagar B., Jones R.G., Diefenbach R.J., Isenman D.E., Rini J.M.;
RT   "X-ray crystal structure of C3d: a C3 fragment and ligand for
RT   complement receptor 2.";
RL   Science 280:1277-1281(1998).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF C3D IN COMPLEX WITH CR2, AND
RP   MUTAGENESIS OF 1108-ILE-LEU-1109 AND ASN-1163.
RX   PubMed=11387479; DOI=10.1126/science.1059118;
RA   Szakonyi G., Guthridge J.M., Li D., Young K., Holers V.M., Chen X.S.;
RT   "Structure of complement receptor 2 in complex with its C3d ligand.";
RL   Science 292:1725-1728(2001).
RN   [39]
RP   X-RAY SCATTERING SOLUTION STRUCTURE OF C3D IN COMPLEX WITH CR2.
RX   PubMed=15713468; DOI=10.1016/j.jmb.2004.12.006;
RA   Gilbert H.E., Eaton J.T., Hannan J.P., Holers V.M., Perkins S.J.;
RT   "Solution structure of the complex between CR2 SCR 1-2 and C3d of
RT   human complement: an X-ray scattering and sedimentation modelling
RT   study.";
RL   J. Mol. Biol. 346:859-873(2005).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF C3C, AND X-RAY
RP   CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF C3.
RX   PubMed=16177781; DOI=10.1038/nature04005;
RA   Janssen B.J.C., Huizinga E.G., Raaijmakers H.C.A., Roos A., Daha M.R.,
RA   Nilsson-Ekdahl K., Nilsson B., Gros P.;
RT   "Structures of complement component C3 provide insights into the
RT   function and evolution of immunity.";
RL   Nature 437:505-511(2005).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS) OF C3B.
RX   PubMed=17051160; DOI=10.1038/nature05172;
RA   Janssen B.J.C., Christodoulidou A., McCarthy A., Lambris J.D.,
RA   Gros P.;
RT   "Structure of C3b reveals conformational changes that underlie
RT   complement activity.";
RL   Nature 444:213-216(2006).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF C3C IN COMPLEX WITH VSIG4,
RP   X-RAY CRYSTALLOGRAPHY (4.1 ANGSTROMS) OF C3B IN COMPLEX WITH VSIG4,
RP   AND GLYCOSYLATION AT ASN-85 AND ASN-939.
RX   PubMed=17051150; DOI=10.1038/nature05263;
RA   Wiesmann C., Katschke K.J., Yin J., Helmy K.Y., Steffek M.,
RA   Fairbrother W.J., McCallum S.A., Embuscado L., DeForge L., Hass P.E.,
RA   van Lookeren Campagne M.;
RT   "Structure of C3b in complex with CRIg gives insights into regulation
RT   of complement activation.";
RL   Nature 444:217-220(2006).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 23-936 AND 1321-1663 IN
RP   COMPLEX WITH INHIBITOR COMPSTATIN, DISULFIDE BONDS, AND GLYCOSYLATION
RP   AT ASN-85.
RX   PubMed=17684013; DOI=10.1074/jbc.M704587200;
RA   Janssen B.J., Halff E.F., Lambris J.D., Gros P.;
RT   "Structure of compstatin in complex with complement component C3c
RT   reveals a new mechanism of complement inhibition.";
RL   J. Biol. Chem. 282:29241-29247(2007).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 996-1287 IN COMPLEX WITH
RP   S.AUREUS FIB.
RX   PubMed=17351618; DOI=10.1038/ni1450;
RA   Hammel M., Sfyroera G., Ricklin D., Magotti P., Lambris J.D.,
RA   Geisbrecht B.V.;
RT   "A structural basis for complement inhibition by Staphylococcus
RT   aureus.";
RL   Nat. Immunol. 8:430-437(2007).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 996-1303 IN COMPLEX WITH
RP   S.AUREUS SBI, AND SUBUNIT.
RX   PubMed=21055811; DOI=10.1016/j.molimm.2010.09.017;
RA   Clark E.A., Crennell S., Upadhyay A., Zozulya A.V., Mackay J.D.,
RA   Svergun D.I., Bagby S., van den Elsen J.M.;
RT   "A structural basis for Staphylococcal complement subversion: X-ray
RT   structure of the complement-binding domain of Staphylococcus aureus
RT   protein Sbi in complex with ligand C3d.";
RL   Mol. Immunol. 48:452-462(2011).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (3.16 ANGSTROMS) OF 996-1303 IN COMPLEX WITH
RP   CR2, AND INTERACTION WITH CR2.
RX   PubMed=21527715; DOI=10.1126/science.1201954;
RA   van den Elsen J.M., Isenman D.E.;
RT   "A crystal structure of the complex between human complement receptor
RT   2 and its ligand C3d.";
RL   Science 332:608-611(2011).
RN   [47]
RP   VARIANT C3S ASN-1216.
RX   PubMed=2473125;
RA   Poznansky M.C., Clissold P.M., Lachmann P.J.;
RT   "The difference between human C3F and C3S results from a single amino
RT   acid change from an asparagine to an aspartate residue at position
RT   1216 on the alpha-chain of the complement component, C3.";
RL   J. Immunol. 143:1254-1258(1989).
RN   [48]
RP   ERRATUM, AND RETRACTION.
RX   PubMed=2584723;
RA   Poznansky M.C., Clissold P.M., Lachmann P.J.;
RL   J. Immunol. 143:3860-3862(1989).
RN   [49]
RP   VARIANTS GLY-102 AND LEU-314.
RX   PubMed=1976733; DOI=10.1084/jem.172.4.1011;
RA   Botto M., Yong Fong K., So A.K., Koch C., Walport M.J.;
RT   "Molecular basis of polymorphisms of human complement component C3.";
RL   J. Exp. Med. 172:1011-1017(1990).
RN   [50]
RP   VARIANT C3D ASN-549.
RX   PubMed=7961791;
RA   Singer L., Whitehead W.T., Akama H., Katz Y., Fishelson Z.,
RA   Wetsel R.A.;
RT   "Inherited human complement C3 deficiency. An amino acid substitution
RT   in the beta-chain (Asp549 to Asn) impairs C3 secretion.";
RL   J. Biol. Chem. 269:28494-28499(1994).
RN   [51]
RP   ASSOCIATION OF VARIANT GLY-102 WITH ARMD9.
RX   PubMed=17634448; DOI=10.1056/NEJMoa072618;
RA   Yates J.R.W., Sepp T., Matharu B.K., Khan J.C., Thurlby D.A.,
RA   Shahid H., Clayton D.G., Hayward C., Morgan J., Wright A.F.,
RA   Armbrecht A.M., Dhillon B., Deary I.J., Redmond E., Bird A.C.,
RA   Moore A.T.;
RT   "Complement C3 variant and the risk of age-related macular
RT   degeneration.";
RL   N. Engl. J. Med. 357:553-561(2007).
RN   [52]
RP   VARIANTS AHUS5 GLN-592; TRP-592; TRP-735; VAL-1094; ASN-1115;
RP   TRP-1158; LYS-1161 AND ASP-1464, AND CHARACTERIZATION OF VARIANTS
RP   AHUS5 GLN-592; TRP-592; VAL-1094; ASN-1115 AND LYS-1161.
RX   PubMed=18796626; DOI=10.1182/blood-2008-01-133702;
RA   Fremeaux-Bacchi V., Miller E.C., Liszewski M.K., Strain L., Blouin J.,
RA   Brown A.L., Moghal N., Kaplan B.S., Weiss R.A., Lhotta K., Kapur G.,
RA   Mattoo T., Nivet H., Wong W., Gie S., Hurault de Ligny B.,
RA   Fischbach M., Gupta R., Hauhart R., Meunier V., Loirat C.,
RA   Dragon-Durey M.A., Fridman W.H., Janssen B.J., Goodship T.H.,
RA   Atkinson J.P.;
RT   "Mutations in complement C3 predispose to development of atypical
RT   hemolytic uremic syndrome.";
RL   Blood 112:4948-4952(2008).
RN   [53]
RP   VARIANTS AHUS5 VAL-603 AND LEU-1042.
RX   PubMed=20513133; DOI=10.1002/humu.21256;
RA   Maga T.K., Nishimura C.J., Weaver A.E., Frees K.L., Smith R.J.H.;
RT   "Mutations in alternative pathway complement proteins in American
RT   patients with atypical hemolytic uremic syndrome.";
RL   Hum. Mutat. 31:E1445-E1460(2010).
RN   [54]
RP   VARIANT ASN-549, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H.,
RA   Lin X., Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
RN   [55]
RP   CHARACTERIZATION OF VARIANT GLY-102.
RX   PubMed=21555552; DOI=10.1073/pnas.1019338108;
RA   Heurich M., Martinez-Barricarte R., Francis N.J., Roberts D.L.,
RA   Rodriguez de Cordoba S., Morgan B.P., Harris C.L.;
RT   "Common polymorphisms in C3, factor B, and factor H collaborate to
RT   determine systemic complement activity and disease risk.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:8761-8766(2011).
RN   [56]
RP   VARIANT ARMD9 GLN-155, AND CHARACTERIZATION OF VARIANT ARMD9 GLN-155.
RX   PubMed=24036952; DOI=10.1038/ng.2741;
RA   Seddon J.M., Yu Y., Miller E.C., Reynolds R., Tan P.L.,
RA   Gowrisankar S., Goldstein J.I., Triebwasser M., Anderson H.E.,
RA   Zerbib J., Kavanagh D., Souied E., Katsanis N., Daly M.J.,
RA   Atkinson J.P., Raychaudhuri S.;
RT   "Rare variants in CFI, C3 and C9 are associated with high risk of
RT   advanced age-related macular degeneration.";
RL   Nat. Genet. 45:1366-1370(2013).
CC   -!- FUNCTION: C3 plays a central role in the activation of the
CC       complement system. Its processing by C3 convertase is the central
CC       reaction in both classical and alternative complement pathways.
CC       After activation C3b can bind covalently, via its reactive
CC       thioester, to cell surface carbohydrates or immune aggregates.
CC   -!- FUNCTION: Derived from proteolytic degradation of complement C3,
CC       C3a anaphylatoxin is a mediator of local inflammatory process. In
CC       chronic inflammation, acts as a chemoattractant for neutrophils
CC       (By similarity). It induces the contraction of smooth muscle,
CC       increases vascular permeability and causes histamine release from
CC       mast cells and basophilic leukocytes. {ECO:0000250}.
CC   -!- FUNCTION: C3-beta-c: Acts as a chemoattractant for neutrophils in
CC       chronic inflammation. {ECO:0000250}.
CC   -!- FUNCTION: Acylation stimulating protein: adipogenic hormone that
CC       stimulates triglyceride (TG) synthesis and glucose transport in
CC       adipocytes, regulating fat storage and playing a role in
CC       postprandial TG clearance. Appears to stimulate TG synthesis via
CC       activation of the PLC, MAPK and AKT signaling pathways. Ligand for
CC       C5AR2. Promotes the phosphorylation, ARRB2-mediated
CC       internalization and recycling of C5AR2 (PubMed:8376604,
CC       PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747,
CC       PubMed:16333141, PubMed:19615750). {ECO:0000269|PubMed:10432298,
CC       ECO:0000269|PubMed:15833747, ECO:0000269|PubMed:16333141,
CC       ECO:0000269|PubMed:19615750, ECO:0000269|PubMed:2909530,
CC       ECO:0000269|PubMed:8376604, ECO:0000269|PubMed:9059512}.
CC   -!- SUBUNIT: C3 precursor is first processed by the removal of 4 Arg
CC       residues, forming two chains, beta and alpha, linked by a
CC       disulfide bond. C3 convertase activates C3 by cleaving the alpha
CC       chain, releasing C3a anaphylatoxin and generating C3b (beta chain
CC       + alpha' chain). C3dg interacts with CR2 (via the N-terminal Sushi
CC       domains 1 and 2). During pregnancy, C3dg exists as a complex
CC       (probably a 2:2:2 heterohexamer) with AGT and the proform of PRG2.
CC       Interacts with VSIG4. C3b interacts with herpes simplex virus 1
CC       (HHV-1) and herpes simplex virus 2 (HHV-2) envelope glycoprotein
CC       C; this interaction inhibits the activation of the complement
CC       system. Interacts with S.aureus immunoglobulin-binding protein
CC       sbi, this prevents interaction between C3dg and CR2. Interacts
CC       with S.aureus fib. Interacts (both C3a and ASP) with C5AR2; the
CC       interaction occurs with higher affinity for ASP, enhancing the
CC       phosphorylation and activation of C5AR2, recruitment of ARRB2 to
CC       the cell surface and endocytosis of GRP77.
CC       {ECO:0000269|PubMed:11387479, ECO:0000269|PubMed:11773063,
CC       ECO:0000269|PubMed:12540846, ECO:0000269|PubMed:17051150,
CC       ECO:0000269|PubMed:17351618, ECO:0000269|PubMed:17684013,
CC       ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140,
CC       ECO:0000269|PubMed:21055811, ECO:0000269|PubMed:21527715,
CC       ECO:0000269|PubMed:2849025, ECO:0000269|PubMed:7539791}.
CC   -!- INTERACTION:
CC       P08603:CFH; NbExp=2; IntAct=EBI-6863106, EBI-1223708;
CC       Q9Y279-1:VSIG4; NbExp=5; IntAct=EBI-905851, EBI-903144;
CC       Q9Y279-2:VSIG4; NbExp=2; IntAct=EBI-905851, EBI-903148;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Plasma. The acylation stimulating protein
CC       (ASP) is expressed in adipocytes and released into the plasma
CC       during both the fasting and postprandial periods.
CC       {ECO:0000269|PubMed:15833747, ECO:0000269|PubMed:9555951}.
CC   -!- PTM: C3b is rapidly split in two positions by factor I and a
CC       cofactor to form iC3b (inactivated C3b) and C3f which is released.
CC       Then iC3b is slowly cleaved (possibly by factor I) to form C3c
CC       (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2),
CC       C3dg and C3f. Other proteases produce other fragments such as C3d
CC       or C3g. C3a is further processed by carboxypeptidases to release
CC       the C-terminal arginine residue generating the acylation
CC       stimulating protein (ASP). Levels of ASP are increased in
CC       adipocytes in the postprandial period and by insulin and dietary
CC       chylomicrons.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- POLYMORPHISM: There are two alleles: C3S (C3 slow), the most
CC       common allele in all races and C3F (C3 fast), relatively frequent
CC       in Caucasians, less common in Black Americans, extremely rare in
CC       Orientals.
CC   -!- DISEASE: Complement component 3 deficiency (C3D) [MIM:613779]: A
CC       rare defect of the complement classical pathway. Patients develop
CC       recurrent, severe, pyogenic infections because of ineffective
CC       opsonization of pathogens. Some patients may also develop
CC       autoimmune disorders, such as arthralgia and vasculitic rashes,
CC       lupus-like syndrome and membranoproliferative glomerulonephritis.
CC       {ECO:0000269|PubMed:7961791}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Macular degeneration, age-related, 9 (ARMD9)
CC       [MIM:611378]: A form of age-related macular degeneration, a
CC       multifactorial eye disease and the most common cause of
CC       irreversible vision loss in the developed world. In most patients,
CC       the disease is manifest as ophthalmoscopically visible yellowish
CC       accumulations of protein and lipid that lie beneath the retinal
CC       pigment epithelium and within an elastin-containing structure
CC       known as Bruch membrane. {ECO:0000269|PubMed:17634448,
CC       ECO:0000269|PubMed:24036952}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Hemolytic uremic syndrome atypical 5 (AHUS5)
CC       [MIM:612925]: An atypical form of hemolytic uremic syndrome. It is
CC       a complex genetic disease characterized by microangiopathic
CC       hemolytic anemia, thrombocytopenia, renal failure and absence of
CC       episodes of enterocolitis and diarrhea. In contrast to typical
CC       hemolytic uremic syndrome, atypical forms have a poorer prognosis,
CC       with higher death rates and frequent progression to end-stage
CC       renal disease. {ECO:0000269|PubMed:18796626,
CC       ECO:0000269|PubMed:20513133}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry. Other genes may play a role in modifying the phenotype.
CC   -!- DISEASE: Note=Increased levels of C3 and its cleavage product ASP,
CC       are associated with obesity, diabetes and coronary heart disease.
CC       Short-term endurance training reduces baseline ASP levels and
CC       subsequently fat storage.
CC   -!- SIMILARITY: Contains 1 anaphylatoxin-like domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00022}.
CC   -!- SIMILARITY: Contains 1 NTR domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00295}.
CC   -!- CAUTION: According to PubMed:21527715, the interaction surface
CC       between C3 and CR2 reported in PubMed:11387479 is artifactual and
CC       can be ascribed to the presence of zinc acetate in the buffer.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=C3base; Note=C3 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/C3base/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Complement C3 entry;
CC       URL="https://en.wikipedia.org/wiki/Complement_c3";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/c3/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K02765; AAA85332.1; -; mRNA.
DR   EMBL; AY513239; AAR89906.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69071.1; -; Genomic_DNA.
DR   EMBL; BC150179; AAI50180.1; -; mRNA.
DR   EMBL; BC150200; AAI50201.1; -; mRNA.
DR   CCDS; CCDS32883.1; -.
DR   PIR; A94065; C3HU.
DR   RefSeq; NP_000055.2; NM_000064.3.
DR   UniGene; Hs.529053; -.
DR   PDB; 1C3D; X-ray; 1.80 A; A=996-1287.
DR   PDB; 1GHQ; X-ray; 2.04 A; A=996-1300.
DR   PDB; 1W2S; X-ray; -; A=996-1299.
DR   PDB; 2A73; X-ray; 3.30 A; A=23-665, B=673-1663.
DR   PDB; 2A74; X-ray; 2.40 A; A/D=23-665, B/E=749-936, C/F=1321-1663.
DR   PDB; 2GOX; X-ray; 2.20 A; A/C=996-1287.
DR   PDB; 2HR0; X-ray; 2.26 A; A=23-667, B=749-1663.
DR   PDB; 2I07; X-ray; 4.00 A; A=23-667, B=749-1663.
DR   PDB; 2ICE; X-ray; 3.10 A; A/D=23-664, B/E=749-954, C/F=1321-1663.
DR   PDB; 2ICF; X-ray; 4.10 A; A=23-664, B=749-1663.
DR   PDB; 2NOJ; X-ray; 2.70 A; A/C/E/G=996-1287.
DR   PDB; 2QKI; X-ray; 2.40 A; A/D=23-665, B/E=749-936, C/F=1321-1663.
DR   PDB; 2WII; X-ray; 2.70 A; A=23-667, B=749-1663.
DR   PDB; 2WIN; X-ray; 3.90 A; A/C/E/G=23-667, B/D/F/H=749-1663.
DR   PDB; 2WY7; X-ray; 1.70 A; A=996-1303.
DR   PDB; 2WY8; X-ray; 1.70 A; A=996-1303.
DR   PDB; 2XQW; X-ray; 2.31 A; A/B=996-1287.
DR   PDB; 2XWB; X-ray; 3.49 A; A/C=23-664, B/D=752-1663.
DR   PDB; 2XWJ; X-ray; 4.00 A; A/C/E/G=23-667, B/D/F/H=749-1663.
DR   PDB; 3D5R; X-ray; 2.10 A; A/B=996-1287.
DR   PDB; 3D5S; X-ray; 2.30 A; A/B=996-1287.
DR   PDB; 3G6J; X-ray; 3.10 A; A/C=23-666, B/D=749-1663.
DR   PDB; 3L3O; X-ray; 3.40 A; A/D=23-667, B/E=749-954, C/F=1321-1663.
DR   PDB; 3L5N; X-ray; 7.54 A; A=23-667, B=749-1663.
DR   PDB; 3NMS; X-ray; 4.10 A; A=23-667, B=749-954, C=1321-1663.
DR   PDB; 3OED; X-ray; 3.16 A; A/B=996-1303.
DR   PDB; 3OHX; X-ray; 3.50 A; A/D=23-667, B/E=749-954, C/F=1321-1663.
DR   PDB; 3OXU; X-ray; 2.10 A; A/B/C=996-1303.
DR   PDB; 3RJ3; X-ray; 2.35 A; A/B/C=996-1303.
DR   PDB; 3T4A; X-ray; 3.40 A; A/D=23-667, B/E=749-954, C/F=1321-1663.
DR   PDB; 4HW5; X-ray; 2.25 A; A/B=672-748.
DR   PDB; 4HWJ; X-ray; 2.60 A; A=672-747.
DR   PDB; 4I6O; X-ray; 2.14 A; A=672-748.
DR   PDB; 4M76; X-ray; 2.80 A; A=994-1288.
DR   PDB; 4ONT; X-ray; 2.15 A; A/B/C=996-1303.
DR   PDBsum; 1C3D; -.
DR   PDBsum; 1GHQ; -.
DR   PDBsum; 1W2S; -.
DR   PDBsum; 2A73; -.
DR   PDBsum; 2A74; -.
DR   PDBsum; 2GOX; -.
DR   PDBsum; 2HR0; -.
DR   PDBsum; 2I07; -.
DR   PDBsum; 2ICE; -.
DR   PDBsum; 2ICF; -.
DR   PDBsum; 2NOJ; -.
DR   PDBsum; 2QKI; -.
DR   PDBsum; 2WII; -.
DR   PDBsum; 2WIN; -.
DR   PDBsum; 2WY7; -.
DR   PDBsum; 2WY8; -.
DR   PDBsum; 2XQW; -.
DR   PDBsum; 2XWB; -.
DR   PDBsum; 2XWJ; -.
DR   PDBsum; 3D5R; -.
DR   PDBsum; 3D5S; -.
DR   PDBsum; 3G6J; -.
DR   PDBsum; 3L3O; -.
DR   PDBsum; 3L5N; -.
DR   PDBsum; 3NMS; -.
DR   PDBsum; 3OED; -.
DR   PDBsum; 3OHX; -.
DR   PDBsum; 3OXU; -.
DR   PDBsum; 3RJ3; -.
DR   PDBsum; 3T4A; -.
DR   PDBsum; 4HW5; -.
DR   PDBsum; 4HWJ; -.
DR   PDBsum; 4I6O; -.
DR   PDBsum; 4M76; -.
DR   PDBsum; 4ONT; -.
DR   ProteinModelPortal; P01024; -.
DR   SMR; P01024; 23-664, 673-1663.
DR   BioGrid; 107179; 25.
DR   DIP; DIP-35180N; -.
DR   IntAct; P01024; 10.
DR   MINT; MINT-5003988; -.
DR   STRING; 9606.ENSP00000245907; -.
DR   BindingDB; P01024; -.
DR   ChEMBL; CHEMBL4917; -.
DR   DrugBank; DB00028; Intravenous Immunoglobulin.
DR   MEROPS; I39.950; -.
DR   iPTMnet; P01024; -.
DR   PhosphoSite; P01024; -.
DR   UniCarbKB; P01024; -.
DR   BioMuta; C3; -.
DR   DMDM; 119370332; -.
DR   DOSAC-COBS-2DPAGE; P01024; -.
DR   SWISS-2DPAGE; P01024; -.
DR   PaxDb; P01024; -.
DR   PeptideAtlas; P01024; -.
DR   PRIDE; P01024; -.
DR   Ensembl; ENST00000245907; ENSP00000245907; ENSG00000125730.
DR   GeneID; 718; -.
DR   KEGG; hsa:718; -.
DR   UCSC; uc002mfm.3; human.
DR   CTD; 718; -.
DR   GeneCards; C3; -.
DR   GeneReviews; C3; -.
DR   H-InvDB; HIX0020036; -.
DR   HGNC; HGNC:1318; C3.
DR   HPA; CAB004209; -.
DR   HPA; HPA003563; -.
DR   HPA; HPA020432; -.
DR   MalaCards; C3; -.
DR   MIM; 120700; gene.
DR   MIM; 611378; phenotype.
DR   MIM; 612925; phenotype.
DR   MIM; 613779; phenotype.
DR   neXtProt; NX_P01024; -.
DR   Orphanet; 279; Age-related macular degeneration.
DR   Orphanet; 93575; Atypical hemolytic-uremic syndrome with C3 anomaly.
DR   Orphanet; 280133; Complement component 3 deficiency.
DR   PharmGKB; PA25897; -.
DR   eggNOG; KOG1366; Eukaryota.
DR   eggNOG; ENOG410XRED; LUCA.
DR   HOGENOM; HOG000286028; -.
DR   HOVERGEN; HBG005110; -.
DR   InParanoid; P01024; -.
DR   KO; K03990; -.
DR   OMA; DETEQWE; -.
DR   OrthoDB; EOG77HDCX; -.
DR   PhylomeDB; P01024; -.
DR   TreeFam; TF313285; -.
DR   BRENDA; 3.4.21.47; 2681.
DR   Reactome; R-HSA-173736; Alternative complement activation.
DR   Reactome; R-HSA-174577; Activation of C3 and C5.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   ChiTaRS; C3; human.
DR   EvolutionaryTrace; P01024; -.
DR   GeneWiki; Complement_component_3; -.
DR   GenomeRNAi; 718; -.
DR   NextBio; 2922; -.
DR   PMAP-CutDB; P01024; -.
DR   PRO; PR:P01024; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P01024; -.
DR   CleanEx; HS_C3; -.
DR   ExpressionAtlas; P01024; baseline and differential.
DR   Genevisible; P01024; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031715; F:C5L2 anaphylatoxin chemotactic receptor binding; IDA:UniProtKB.
DR   GO; GO:0048037; F:cofactor binding; IEA:Ensembl.
DR   GO; GO:0004866; F:endopeptidase inhibitor activity; IEA:InterPro.
DR   GO; GO:0008289; F:lipid binding; IEA:Ensembl.
DR   GO; GO:0005102; F:receptor binding; TAS:ProtInc.
DR   GO; GO:0007596; P:blood coagulation; IEA:Ensembl.
DR   GO; GO:0006956; P:complement activation; IMP:BHF-UCL.
DR   GO; GO:0006957; P:complement activation, alternative pathway; TAS:Reactome.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0006631; P:fatty acid metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0001970; P:positive regulation of activation of membrane attack complex; IEA:Ensembl.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:2000427; P:positive regulation of apoptotic cell clearance; IMP:BHF-UCL.
DR   GO; GO:0048639; P:positive regulation of developmental growth; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0045745; P:positive regulation of G-protein coupled receptor protein signaling pathway; IDA:UniProtKB.
DR   GO; GO:0010828; P:positive regulation of glucose transport; IDA:UniProtKB.
DR   GO; GO:0010884; P:positive regulation of lipid storage; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001798; P:positive regulation of type IIa hypersensitivity; IEA:Ensembl.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IDA:BHF-UCL.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0010866; P:regulation of triglyceride biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0032026; P:response to magnesium ion; IEA:Ensembl.
DR   GO; GO:0032570; P:response to progesterone; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002507; P:tolerance induction; IEA:Ensembl.
DR   Gene3D; 1.20.91.20; -; 1.
DR   Gene3D; 1.50.10.20; -; 1.
DR   Gene3D; 2.60.40.690; -; 1.
DR   InterPro; IPR009048; A-macroglobulin_rcpt-bd.
DR   InterPro; IPR011626; A2M_comp.
DR   InterPro; IPR002890; A2M_N.
DR   InterPro; IPR011625; A2M_N_2.
DR   InterPro; IPR000020; Anaphylatoxin/fibulin.
DR   InterPro; IPR018081; Anaphylatoxin_comp_syst.
DR   InterPro; IPR001840; Anaphylatoxn_comp_syst_dom.
DR   InterPro; IPR001599; Macroglobln_a2.
DR   InterPro; IPR019742; MacrogloblnA2_CS.
DR   InterPro; IPR019565; MacrogloblnA2_thiol-ester-bond.
DR   InterPro; IPR001134; Netrin_domain.
DR   InterPro; IPR018933; Netrin_module_non-TIMP.
DR   InterPro; IPR008930; Terpenoid_cyclase/PrenylTrfase.
DR   InterPro; IPR008993; TIMP-like_OB-fold.
DR   Pfam; PF00207; A2M; 1.
DR   Pfam; PF07678; A2M_comp; 1.
DR   Pfam; PF01835; A2M_N; 1.
DR   Pfam; PF07703; A2M_N_2; 1.
DR   Pfam; PF07677; A2M_recep; 1.
DR   Pfam; PF01821; ANATO; 1.
DR   Pfam; PF01759; NTR; 1.
DR   Pfam; PF10569; Thiol-ester_cl; 1.
DR   PRINTS; PR00004; ANAPHYLATOXN.
DR   SMART; SM00104; ANATO; 1.
DR   SMART; SM00643; C345C; 1.
DR   SUPFAM; SSF47686; SSF47686; 1.
DR   SUPFAM; SSF48239; SSF48239; 1.
DR   SUPFAM; SSF49410; SSF49410; 1.
DR   SUPFAM; SSF50242; SSF50242; 1.
DR   PROSITE; PS00477; ALPHA_2_MACROGLOBULIN; 1.
DR   PROSITE; PS01177; ANAPHYLATOXIN_1; 1.
DR   PROSITE; PS01178; ANAPHYLATOXIN_2; 1.
DR   PROSITE; PS50189; NTR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Age-related macular degeneration;
KW   Cleavage on pair of basic residues; Complement alternate pathway;
KW   Complement pathway; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Fatty acid metabolism; Glycoprotein;
KW   Hemolytic uremic syndrome; Immunity; Inflammatory response;
KW   Innate immunity; Lipid metabolism; Phosphoprotein; Polymorphism;
KW   Reference proteome; Secreted; Signal; Thioester bond.
FT   SIGNAL        1     22       {ECO:0000269|PubMed:8376604}.
FT   CHAIN        23   1663       Complement C3.
FT                                /FTId=PRO_0000005907.
FT   CHAIN        23    667       Complement C3 beta chain.
FT                                /FTId=PRO_0000005908.
FT   CHAIN       569    667       C3-beta-c. {ECO:0000250}.
FT                                /FTId=PRO_0000430430.
FT   CHAIN       672   1663       Complement C3 alpha chain.
FT                                /FTId=PRO_0000005909.
FT   CHAIN       672    748       C3a anaphylatoxin.
FT                                /FTId=PRO_0000005910.
FT   CHAIN       672    747       Acylation stimulating protein.
FT                                /FTId=PRO_0000419935.
FT   CHAIN       749   1663       Complement C3b alpha' chain.
FT                                /FTId=PRO_0000005911.
FT   CHAIN       749    954       Complement C3c alpha' chain fragment 1.
FT                                /FTId=PRO_0000005912.
FT   CHAIN       955   1303       Complement C3dg fragment.
FT                                /FTId=PRO_0000005913.
FT   CHAIN       955   1001       Complement C3g fragment.
FT                                /FTId=PRO_0000005914.
FT   CHAIN      1002   1303       Complement C3d fragment.
FT                                /FTId=PRO_0000005915.
FT   PEPTIDE    1304   1320       Complement C3f fragment.
FT                                {ECO:0000269|PubMed:8376604}.
FT                                /FTId=PRO_0000005916.
FT   CHAIN      1321   1663       Complement C3c alpha' chain fragment 2.
FT                                /FTId=PRO_0000273948.
FT   DOMAIN      693    728       Anaphylatoxin-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00022}.
FT   DOMAIN     1518   1661       NTR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00295}.
FT   REGION     1424   1456       Properdin-binding.
FT   SITE        747    748       Cleavage; by carboxypeptidases.
FT   SITE        748    749       Cleavage; by C3 convertase.
FT   SITE        954    955       Cleavage; by factor I. {ECO:0000255}.
FT   SITE       1303   1304       Cleavage; by factor I.
FT   SITE       1320   1321       Cleavage; by factor I.
FT   MOD_RES      38     38       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES      70     70       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     297    297       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     303    303       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     672    672       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     968    968       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES    1321   1321       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES    1573   1573       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   CARBOHYD     85     85       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:17051150,
FT                                ECO:0000269|PubMed:17684013,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:2579379}.
FT   CARBOHYD    939    939       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:17051150}.
FT   CARBOHYD   1617   1617       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   DISULFID    559    816       Interchain (between beta and alpha
FT                                chains).
FT   DISULFID    627    662
FT   DISULFID    693    720       {ECO:0000269|PubMed:8416818}.
FT   DISULFID    694    727
FT   DISULFID    707    728
FT   DISULFID    873   1513
FT   DISULFID   1101   1158
FT   DISULFID   1358   1489
FT   DISULFID   1389   1458
FT   DISULFID   1506   1511
FT   DISULFID   1518   1590
FT   DISULFID   1537   1661
FT   DISULFID   1637   1646
FT   CROSSLNK   1010   1013       Isoglutamyl cysteine thioester (Cys-Gln).
FT   VARIANT     102    102       R -> G (in allele C3F; associated with
FT                                susceptibility to ARMD9; results in
FT                                decreased binding affinity for regulator
FT                                factor H; results in reduced sensitivity
FT                                to cleavage by factor I;
FT                                dbSNP:rs2230199).
FT                                {ECO:0000269|PubMed:1976733,
FT                                ECO:0000269|PubMed:21555552,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_001983.
FT   VARIANT     155    155       K -> Q (in ARMD9; results in resistance
FT                                to proteolytic inactivation by CFH and
FT                                CFI). {ECO:0000269|PubMed:24036952}.
FT                                /FTId=VAR_070941.
FT   VARIANT     314    314       P -> L (in dbSNP:rs1047286).
FT                                {ECO:0000269|PubMed:1976733,
FT                                ECO:0000269|PubMed:2579379,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_001984.
FT   VARIANT     469    469       E -> D (in dbSNP:rs11569422).
FT                                /FTId=VAR_020262.
FT   VARIANT     549    549       D -> N (in C3D; impairs secretion;
FT                                variant confirmed at protein level).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|PubMed:7961791}.
FT                                /FTId=VAR_001985.
FT   VARIANT     592    592       R -> Q (in AHUS5; leads to impaired
FT                                binding to the regulator CD46/MCP and
FT                                resistance to cleavage by factor I).
FT                                {ECO:0000269|PubMed:18796626}.
FT                                /FTId=VAR_063213.
FT   VARIANT     592    592       R -> W (in AHUS5; leads to impaired
FT                                binding to the regulator CD46/MCP and
FT                                resistance to cleavage by factor I).
FT                                {ECO:0000269|PubMed:18796626}.
FT                                /FTId=VAR_063214.
FT   VARIANT     603    603       F -> V (in AHUS5).
FT                                {ECO:0000269|PubMed:20513133}.
FT                                /FTId=VAR_063654.
FT   VARIANT     735    735       R -> W (in AHUS5; dbSNP:rs117793540).
FT                                {ECO:0000269|PubMed:18796626}.
FT                                /FTId=VAR_063215.
FT   VARIANT     863    863       R -> K (in dbSNP:rs11569472).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_019206.
FT   VARIANT    1042   1042       R -> L (in AHUS5).
FT                                {ECO:0000269|PubMed:20513133}.
FT                                /FTId=VAR_063655.
FT   VARIANT    1094   1094       A -> V (in AHUS5; leads to impaired
FT                                binding to the regulator CD46/MCP and
FT                                resistance to cleavage by factor I).
FT                                {ECO:0000269|PubMed:18796626}.
FT                                /FTId=VAR_063216.
FT   VARIANT    1115   1115       D -> N (in AHUS5; leads to impaired
FT                                binding to the regulator CD46/MCP and
FT                                resistance to cleavage by factor I).
FT                                {ECO:0000269|PubMed:18796626}.
FT                                /FTId=VAR_063217.
FT   VARIANT    1158   1158       C -> W (in AHUS5).
FT                                {ECO:0000269|PubMed:18796626}.
FT                                /FTId=VAR_063218.
FT   VARIANT    1161   1161       Q -> K (in AHUS5; leads to impaired
FT                                binding to the regulator CD46/MCP and
FT                                resistance to cleavage by factor I).
FT                                {ECO:0000269|PubMed:18796626}.
FT                                /FTId=VAR_063219.
FT   VARIANT    1216   1216       D -> N (in C3S).
FT                                {ECO:0000269|PubMed:2473125}.
FT                                /FTId=VAR_022761.
FT   VARIANT    1224   1224       G -> D (in dbSNP:rs11569534).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_019207.
FT   VARIANT    1367   1367       I -> T (in dbSNP:rs11569541).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_019208.
FT   VARIANT    1464   1464       H -> D (in AHUS5).
FT                                {ECO:0000269|PubMed:18796626}.
FT                                /FTId=VAR_063220.
FT   VARIANT    1521   1521       Q -> R (in dbSNP:rs7256789).
FT                                /FTId=VAR_029792.
FT   VARIANT    1601   1601       H -> N (in dbSNP:rs1803225).
FT                                /FTId=VAR_029793.
FT   VARIANT    1619   1619       S -> R (in dbSNP:rs2230210).
FT                                /FTId=VAR_029326.
FT   MUTAGEN    1029   1029       D->A: Minor effect on binding of C3d to
FT                                CR2. {ECO:0000269|PubMed:20083651,
FT                                ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1030   1030       E->A: Impaired binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20083651,
FT                                ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1032   1032       E->A: Impaired binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20083651,
FT                                ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1035   1035       E->A: No effect on binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20083651}.
FT   MUTAGEN    1042   1042       R->M: Impaired binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20083651}.
FT   MUTAGEN    1108   1109       IL->RR: Impaired binding of C3d to CR2;
FT                                when associated with A-1163.
FT                                {ECO:0000269|PubMed:11387479}.
FT   MUTAGEN    1110   1110       E->A: No effect on binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1115   1115       D->A: No effect on binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1121   1121       D->A: No effect on binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1140   1140       D->A: No effect on binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20083651,
FT                                ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1153   1153       E->A: Impaired binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20083651,
FT                                ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1156   1156       D->A: Impaired binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20083651,
FT                                ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1159   1159       E->A: Impaired binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20083651,
FT                                ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1160   1160       E->A: Minor effect on binding of C3d to
FT                                CR2. {ECO:0000269|PubMed:20083651,
FT                                ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1163   1163       N->A: No effect on binding of C3d to CR2.
FT                                Impaired binding of C3d to CR2; when
FT                                associated with 1108-R-R-1109.
FT                                {ECO:0000269|PubMed:11387479,
FT                                ECO:0000269|PubMed:20083651,
FT                                ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1163   1163       N->R: Impaired binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:11387479,
FT                                ECO:0000269|PubMed:20083651,
FT                                ECO:0000269|PubMed:20951140}.
FT   MUTAGEN    1284   1284       K->A: Impaired binding of C3d to CR2.
FT                                {ECO:0000269|PubMed:20083651}.
FT   CONFLICT    681    681       D -> N (in Ref. 6; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    700    700       E -> Q (in Ref. 6; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT   1026   1026       H -> S (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   STRAND       28     35       {ECO:0000244|PDB:2HR0}.
FT   STRAND       36     41       {ECO:0000244|PDB:2A74}.
FT   STRAND       43     47       {ECO:0000244|PDB:2A74}.
FT   STRAND       54     56       {ECO:0000244|PDB:2HR0}.
FT   STRAND       59     61       {ECO:0000244|PDB:2HR0}.
FT   TURN         62     64       {ECO:0000244|PDB:2WII}.
FT   STRAND       67     69       {ECO:0000244|PDB:2ICE}.
FT   STRAND       73     75       {ECO:0000244|PDB:2HR0}.
FT   HELIX        78     80       {ECO:0000244|PDB:2HR0}.
FT   STRAND       87     89       {ECO:0000244|PDB:2A74}.
FT   HELIX        94     97       {ECO:0000244|PDB:2ICE}.
FT   STRAND      105    112       {ECO:0000244|PDB:2HR0}.
FT   STRAND      115    124       {ECO:0000244|PDB:2HR0}.
FT   STRAND      129    135       {ECO:0000244|PDB:2HR0}.
FT   STRAND      137    139       {ECO:0000244|PDB:2A74}.
FT   STRAND      143    152       {ECO:0000244|PDB:2HR0}.
FT   STRAND      162    168       {ECO:0000244|PDB:2HR0}.
FT   STRAND      174    181       {ECO:0000244|PDB:2HR0}.
FT   TURN        183    187       {ECO:0000244|PDB:2HR0}.
FT   STRAND      188    194       {ECO:0000244|PDB:2HR0}.
FT   STRAND      202    210       {ECO:0000244|PDB:2HR0}.
FT   STRAND      216    223       {ECO:0000244|PDB:2HR0}.
FT   STRAND      233    244       {ECO:0000244|PDB:2HR0}.
FT   STRAND      251    258       {ECO:0000244|PDB:2HR0}.
FT   STRAND      267    277       {ECO:0000244|PDB:2HR0}.
FT   STRAND      280    283       {ECO:0000244|PDB:2HR0}.
FT   HELIX       285    287       {ECO:0000244|PDB:2HR0}.
FT   STRAND      289    294       {ECO:0000244|PDB:2HR0}.
FT   STRAND      297    302       {ECO:0000244|PDB:2HR0}.
FT   HELIX       304    308       {ECO:0000244|PDB:2HR0}.
FT   TURN        310    312       {ECO:0000244|PDB:3L3O}.
FT   HELIX       316    319       {ECO:0000244|PDB:2HR0}.
FT   STRAND      323    336       {ECO:0000244|PDB:2HR0}.
FT   STRAND      338    350       {ECO:0000244|PDB:2HR0}.
FT   STRAND      354    356       {ECO:0000244|PDB:2HR0}.
FT   STRAND      358    360       {ECO:0000244|PDB:2HR0}.
FT   STRAND      362    364       {ECO:0000244|PDB:2A74}.
FT   STRAND      368    377       {ECO:0000244|PDB:2HR0}.
FT   STRAND      379    383       {ECO:0000244|PDB:2HR0}.
FT   STRAND      389    394       {ECO:0000244|PDB:2HR0}.
FT   HELIX       395    397       {ECO:0000244|PDB:2QKI}.
FT   STRAND      398    400       {ECO:0000244|PDB:2ICE}.
FT   STRAND      405    412       {ECO:0000244|PDB:2HR0}.
FT   STRAND      420    426       {ECO:0000244|PDB:2HR0}.
FT   TURN        429    431       {ECO:0000244|PDB:2A74}.
FT   TURN        433    435       {ECO:0000244|PDB:2HR0}.
FT   STRAND      438    444       {ECO:0000244|PDB:2HR0}.
FT   HELIX       449    451       {ECO:0000244|PDB:2A74}.
FT   STRAND      455    460       {ECO:0000244|PDB:2HR0}.
FT   STRAND      469    478       {ECO:0000244|PDB:2HR0}.
FT   TURN        481    483       {ECO:0000244|PDB:2A74}.
FT   TURN        484    486       {ECO:0000244|PDB:2HR0}.
FT   STRAND      489    496       {ECO:0000244|PDB:2HR0}.
FT   STRAND      499    507       {ECO:0000244|PDB:2HR0}.
FT   STRAND      513    520       {ECO:0000244|PDB:2HR0}.
FT   HELIX       523    525       {ECO:0000244|PDB:2A74}.
FT   STRAND      527    538       {ECO:0000244|PDB:2HR0}.
FT   STRAND      540    554       {ECO:0000244|PDB:2HR0}.
FT   STRAND      564    567       {ECO:0000244|PDB:2HR0}.
FT   TURN        568    570       {ECO:0000244|PDB:2ICE}.
FT   STRAND      571    573       {ECO:0000244|PDB:3G6J}.
FT   STRAND      580    588       {ECO:0000244|PDB:2HR0}.
FT   STRAND      592    598       {ECO:0000244|PDB:2HR0}.
FT   HELIX       600    603       {ECO:0000244|PDB:2HR0}.
FT   HELIX       613    621       {ECO:0000244|PDB:2HR0}.
FT   STRAND      628    630       {ECO:0000244|PDB:2HR0}.
FT   STRAND      633    636       {ECO:0000244|PDB:2HR0}.
FT   HELIX       637    640       {ECO:0000244|PDB:2HR0}.
FT   TURN        641    643       {ECO:0000244|PDB:2HR0}.
FT   STRAND      644    647       {ECO:0000244|PDB:2HR0}.
FT   STRAND      649    651       {ECO:0000244|PDB:2HR0}.
FT   HELIX       675    684       {ECO:0000244|PDB:4HW5}.
FT   HELIX       688    697       {ECO:0000244|PDB:4I6O}.
FT   HELIX       707    710       {ECO:0000244|PDB:4I6O}.
FT   TURN        712    714       {ECO:0000244|PDB:4HW5}.
FT   HELIX       718    743       {ECO:0000244|PDB:4I6O}.
FT   STRAND      753    755       {ECO:0000244|PDB:2HR0}.
FT   HELIX       758    760       {ECO:0000244|PDB:2A74}.
FT   STRAND      769    771       {ECO:0000244|PDB:2A74}.
FT   STRAND      775    777       {ECO:0000244|PDB:2HR0}.
FT   STRAND      786    794       {ECO:0000244|PDB:2HR0}.
FT   STRAND      800    810       {ECO:0000244|PDB:2HR0}.
FT   TURN        811    813       {ECO:0000244|PDB:2HR0}.
FT   STRAND      814    817       {ECO:0000244|PDB:2HR0}.
FT   STRAND      821    825       {ECO:0000244|PDB:2HR0}.
FT   STRAND      828    834       {ECO:0000244|PDB:2HR0}.
FT   STRAND      837    840       {ECO:0000244|PDB:2HR0}.
FT   STRAND      845    853       {ECO:0000244|PDB:2HR0}.
FT   STRAND      860    866       {ECO:0000244|PDB:2HR0}.
FT   STRAND      872    875       {ECO:0000244|PDB:2A74}.
FT   STRAND      878    880       {ECO:0000244|PDB:2HR0}.
FT   STRAND      882    888       {ECO:0000244|PDB:2HR0}.
FT   STRAND      892    902       {ECO:0000244|PDB:2HR0}.
FT   STRAND      906    919       {ECO:0000244|PDB:2HR0}.
FT   STRAND      922    932       {ECO:0000244|PDB:2HR0}.
FT   HELIX       942    947       {ECO:0000244|PDB:2HR0}.
FT   HELIX       949    952       {ECO:0000244|PDB:2WII}.
FT   STRAND      956    962       {ECO:0000244|PDB:2HR0}.
FT   STRAND      968    970       {ECO:0000244|PDB:2WII}.
FT   STRAND      983    988       {ECO:0000244|PDB:2HR0}.
FT   HELIX       989    995       {ECO:0000244|PDB:2HR0}.
FT   HELIX       997    999       {ECO:0000244|PDB:2WY8}.
FT   HELIX      1001   1003       {ECO:0000244|PDB:2WY7}.
FT   STRAND     1009   1012       {ECO:0000244|PDB:3G6J}.
FT   HELIX      1013   1031       {ECO:0000244|PDB:2WY7}.
FT   HELIX      1034   1037       {ECO:0000244|PDB:2WY7}.
FT   HELIX      1041   1057       {ECO:0000244|PDB:2WY7}.
FT   TURN       1062   1064       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1067   1072       {ECO:0000244|PDB:2HR0}.
FT   HELIX      1076   1089       {ECO:0000244|PDB:2WY7}.
FT   TURN       1090   1092       {ECO:0000244|PDB:2WY7}.
FT   HELIX      1097   1111       {ECO:0000244|PDB:2WY7}.
FT   TURN       1114   1116       {ECO:0000244|PDB:2NOJ}.
FT   HELIX      1127   1133       {ECO:0000244|PDB:2WY7}.
FT   HELIX      1139   1158       {ECO:0000244|PDB:2WY7}.
FT   TURN       1159   1161       {ECO:0000244|PDB:2WY7}.
FT   HELIX      1165   1179       {ECO:0000244|PDB:2WY7}.
FT   HELIX      1180   1182       {ECO:0000244|PDB:2WY7}.
FT   HELIX      1186   1198       {ECO:0000244|PDB:2WY7}.
FT   HELIX      1204   1213       {ECO:0000244|PDB:2WY7}.
FT   TURN       1216   1218       {ECO:0000244|PDB:2WY7}.
FT   STRAND     1223   1225       {ECO:0000244|PDB:1GHQ}.
FT   HELIX      1226   1243       {ECO:0000244|PDB:2WY7}.
FT   TURN       1246   1248       {ECO:0000244|PDB:2WY7}.
FT   HELIX      1249   1258       {ECO:0000244|PDB:2WY7}.
FT   STRAND     1262   1265       {ECO:0000244|PDB:2HR0}.
FT   HELIX      1269   1285       {ECO:0000244|PDB:2WY7}.
FT   TURN       1297   1299       {ECO:0000244|PDB:3OXU}.
FT   STRAND     1303   1305       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1307   1312       {ECO:0000244|PDB:2WII}.
FT   STRAND     1313   1316       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1320   1326       {ECO:0000244|PDB:2WII}.
FT   STRAND     1331   1333       {ECO:0000244|PDB:3G6J}.
FT   STRAND     1337   1339       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1340   1350       {ECO:0000244|PDB:2A73}.
FT   STRAND     1359   1369       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1381   1392       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1394   1396       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1400   1406       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1409   1413       {ECO:0000244|PDB:2HR0}.
FT   HELIX      1415   1423       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1424   1426       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1430   1432       {ECO:0000244|PDB:2HR0}.
FT   TURN       1438   1440       {ECO:0000244|PDB:2A74}.
FT   STRAND     1443   1449       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1453   1455       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1459   1467       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1469   1471       {ECO:0000244|PDB:2A73}.
FT   STRAND     1475   1481       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1484   1493       {ECO:0000244|PDB:2HR0}.
FT   TURN       1495   1498       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1504   1507       {ECO:0000244|PDB:2A74}.
FT   STRAND     1510   1513       {ECO:0000244|PDB:2A74}.
FT   TURN       1515   1517       {ECO:0000244|PDB:2WII}.
FT   STRAND     1518   1520       {ECO:0000244|PDB:2HR0}.
FT   TURN       1524   1526       {ECO:0000244|PDB:2WII}.
FT   HELIX      1529   1535       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1537   1540       {ECO:0000244|PDB:2ICE}.
FT   STRAND     1541   1554       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1556   1570       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1581   1587       {ECO:0000244|PDB:2HR0}.
FT   HELIX      1588   1590       {ECO:0000244|PDB:2HR0}.
FT   HELIX      1591   1594       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1601   1607       {ECO:0000244|PDB:2HR0}.
FT   HELIX      1608   1610       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1611   1613       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1615   1617       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1619   1621       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1627   1631       {ECO:0000244|PDB:2HR0}.
FT   HELIX      1634   1636       {ECO:0000244|PDB:2HR0}.
FT   STRAND     1637   1639       {ECO:0000244|PDB:2A74}.
FT   TURN       1640   1642       {ECO:0000244|PDB:2HR0}.
FT   HELIX      1643   1657       {ECO:0000244|PDB:2HR0}.
SQ   SEQUENCE   1663 AA;  187148 MW;  30C2832A9E75FFC4 CRC64;
     MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ GDVPVTVTVH
     DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK GRNKFVTVQA TFGTQVVEKV
     VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF TVNHKLLPVG RTVMVNIENP EGIPVKQDSL
     SSQNQLGVLP LSWDIPELVN MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE
     KFYYIYNEKG LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV
     VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT SPYQIHFTKT
     PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL TQGDGVAKLS INTHPSQKPL
     SITVRTKKQE LSEAEQATRT MQALPYSTVG NSNNYLHLSV LRTELRPGET LNVNFLLRMD
     RAHEAKIRYY TYLIMNKGRL LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA
     SGQREVVADS VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK
     GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS GQQTAQRAEL
     QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE NPMRFSCQRR TRFISLGEAC
     KKVFLDCCNY ITELRRQHAR ASHLGLARSN LDEDIIAEEN IVSRSEFPES WLWNVEDLKE
     PPKNGISTKL MNIFLKDSIT TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV
     RNEQVEIRAV LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTVTIPP KSSLSVPYVI
     VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE RLGREGVQKE
     DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL KHLIVTPSGC GEQNMIGMTP
     TVIAVHYLDE TEQWEKFGLE KRQGALELIK KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA
     YVVKVFSLAV NLIAIDSQVL CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD
     MALTAFVLIS LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG
     RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP PVVRWLNEQR
     YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL PSRSSKITHR IHWESASLLR
     SEETKENEGF TVTAEGKGQG TLSVVTMYHA KAKDQLTCNK FDLKVTIKPA PETEKRPQDA
     KNTMILEICT RYRGDQDATM SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD
     RNTLIIYLDK VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG
     KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV KVQLSNDFDE
     YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK HYLMWGLSSD FWGEKPNLSY
     IIGKDTWVEH WPEEDECQDE ENQKQCQDLG AFTESMVVFG CPN
//
ID   CO7A1_HUMAN             Reviewed;        2944 AA.
AC   Q02388; Q14054; Q16507;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   17-FEB-2016, entry version 189.
DE   RecName: Full=Collagen alpha-1(VII) chain;
DE   AltName: Full=Long-chain collagen;
DE            Short=LC collagen;
DE   Flags: Precursor;
GN   Name=COL7A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=8088784; DOI=10.1006/geno.1994.1239;
RA   Christiano A.M., Hoffman G.G., Chung-Honet L.C., Lee S., Cheng W.,
RA   Uitto J., Greenspan D.S.;
RT   "Structural organization of the human type VII collagen gene (COL7A1),
RT   composed of more exons than any previously characterized gene.";
RL   Genomics 21:169-179(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8051117;
RA   Christiano A.M., Greenspan D.S., Lee S., Uitto J.;
RT   "Cloning of human type VII collagen. Complete primary sequence of the
RT   alpha 1(VII) chain and identification of intragenic polymorphisms.";
RL   J. Biol. Chem. 269:20256-20262(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 128-1493, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=1307247; DOI=10.1093/hmg/1.7.475;
RA   Christiano A.M., Rosenbaum L.M., Chung-Honet L.C., Parente M.G.,
RA   Woodley D.T., Pan T.C., Zhang R.Z., Chu M.-L., Burgeson R.E.,
RA   Uitto J.;
RT   "The large non-collagenous domain (NC-1) of type VII collagen is
RT   amino-terminal and chimeric. Homology to cartilage matrix protein, the
RT   type III domains of fibronectin and the A domains of von Willebrand
RT   factor.";
RL   Hum. Mol. Genet. 1:475-481(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 195-1275.
RC   TISSUE=Keratinocyte;
RX   PubMed=1567409; DOI=10.1016/S0006-291X(05)80283-9;
RA   Tanaka T., Takahashi K., Furukawa F., Imamura S.;
RT   "Molecular cloning and characterization of type VII collagen cDNA.";
RL   Biochem. Biophys. Res. Commun. 183:958-963(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 369-1255.
RX   PubMed=1469284; DOI=10.1111/1523-1747.ep12614080;
RA   Gammon W.R., Abernethy M.L., Padilla K.M., Prisayanh P.S., Cook M.E.,
RA   Wright J., Briggaman R.A., Hunt S.W. III;
RT   "Noncollagenous (NC1) domain of collagen VII resembles multidomain
RT   adhesion proteins involved in tissue-specific organization of
RT   extracellular matrix.";
RL   J. Invest. Dermatol. 99:691-696(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 815-1439.
RX   PubMed=1871109; DOI=10.1073/pnas.88.16.6931;
RA   Parente M.G., Chung L.C., Ryynaenen J., Woodley D.T., Wynn K.W.,
RA   Bauer E.A., Mattei M.-G., Chu M.-L., Uitto J.;
RT   "Human type VII collagen: cDNA cloning and chromosomal mapping of the
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6931-6935(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2395-2944.
RX   PubMed=8499916; DOI=10.1093/hmg/2.3.273;
RA   Greenspan D.S.;
RT   "The carboxyl-terminal half of type VII collagen, including the non-
RT   collagenous NC-2 domain and intron/exon organization of the
RT   corresponding region of the COL7A1 gene.";
RL   Hum. Mol. Genet. 2:273-278(1993).
RN   [8]
RP   PARTIAL PROTEIN SEQUENCE, AND HYDROXYLATION.
RX   PubMed=2537292;
RA   Seltzer J.L., Eisen A.Z., Bauer E.A., Morris N.P., Glanville R.W.,
RA   Burgeson R.E.;
RT   "Cleavage of type VII collagen by interstitial collagenase and type IV
RT   collagenase (gelatinase) derived from human skin.";
RL   J. Biol. Chem. 264:3822-3826(1989).
RN   [9]
RP   INTERACTION WITH MIA3.
RX   PubMed=19269366; DOI=10.1016/j.cell.2008.12.025;
RA   Saito K., Chen M., Bard F., Chen S., Zhou H., Woodley D.,
RA   Polischuk R., Schekman R., Malhotra V.;
RT   "TANGO1 facilitates cargo loading at endoplasmic reticulum exit
RT   sites.";
RL   Cell 136:891-902(2009).
RN   [10]
RP   REVIEW ON VARIANTS.
RX   PubMed=9375848;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:5<338::AID-HUMU2>3.3.CO;2-T;
RA   Jaervikallio A., Pulkkinen L., Uitto J.;
RT   "Molecular basis of dystrophic epidermolysis bullosa: mutations in the
RT   type VII collagen gene (COL7A1).";
RL   Hum. Mutat. 10:338-347(1997).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   VARIANT EBDSC ARG-2034.
RX   PubMed=2653224; DOI=10.1001/archderm.125.5.633;
RA   Fine J.-D., Johnson L., Wright T.;
RT   "Epidermolysis bullosa simplex superficialis. A new variant of
RT   epidermolysis bullosa characterized by subcorneal skin cleavage
RT   mimicking peeling skin syndrome.";
RL   Arch. Dermatol. 125:633-638(1989).
RN   [13]
RP   VARIANT HS-DEB LYS-2798.
RX   PubMed=8513326; DOI=10.1038/ng0593-62;
RA   Christiano A.M., Greenspan D.S., Hoffman G.G., Zhang X., Tamai Y.,
RA   Lin A.N., Dietz H.C., Hovnanian A., Uitto J.;
RT   "A missense mutation in type VII collagen in two affected siblings
RT   with recessive dystrophic epidermolysis bullosa.";
RL   Nat. Genet. 4:62-66(1993).
RN   [14]
RP   VARIANT P-DEB SER-2040.
RX   PubMed=8170945; DOI=10.1073/pnas.91.9.3549;
RA   Christiano A.M., Ryynaenen M., Uitto J.;
RT   "Dominant dystrophic epidermolysis bullosa: identification of a
RT   Gly-->Ser substitution in the triple-helical domain of type VII
RT   collagen.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:3549-3553(1994).
RN   [15]
RP   VARIANT PR-DEB CYS-2623.
RX   PubMed=8541842; DOI=10.1093/hmg/4.9.1579;
RA   Christiano A.M., Lee J.Y.-Y., Chen W.J., Laforgia S., Uitto J.;
RT   "Pretibial epidermolysis bullosa: genetic linkage to COL7A1 and
RT   identification of a glycine-to-cysteine substitution in the triple-
RT   helical domain of type VII collagen.";
RL   Hum. Mol. Genet. 4:1579-1583(1995).
RN   [16]
RP   VARIANT DDEB ARG-2043.
RX   PubMed=7861014; DOI=10.1111/1523-1747.ep12666033;
RA   Christiano A.M., Morricone A., Paradisi M., Angelo C., Mazzanti C.,
RA   Cavalieri R., Uitto J.;
RT   "A glycine-to-arginine substitution in the triple-helical domain of
RT   type VII collagen in a family with dominant dystrophic epidermolysis
RT   bullosa.";
RL   J. Invest. Dermatol. 104:438-440(1995).
RN   [17]
RP   VARIANTS DEB.
RX   PubMed=8644729;
RA   Christiano A.M., McGrath J.A., Tan K.C., Uitto J.;
RT   "Glycine substitutions in the triple-helical region of type VII
RT   collagen result in a spectrum of dystrophic epidermolysis bullosa
RT   phenotypes and patterns of inheritance.";
RL   Am. J. Hum. Genet. 58:671-681(1996).
RN   [18]
RP   VARIANT HS-DEB ARG-2575.
RX   PubMed=8592061; DOI=10.1111/1523-1747.ep12329600;
RA   Shimizu H., McGrath J.A., Christiano A.M., Nishikawa T., Uitto J.;
RT   "Molecular basis of recessive dystrophic epidermolysis bullosa:
RT   genotype/phenotype correlation in a case of moderate clinical
RT   severity.";
RL   J. Invest. Dermatol. 106:119-124(1996).
RN   [19]
RP   VARIANT RDEB ARG-1782.
RX   PubMed=8618018; DOI=10.1111/1523-1747.ep12345814;
RA   Christiano A.M., McGrath J.A., Uitto J.;
RT   "Influence of the second COL7A1 mutation in determining the phenotypic
RT   severity of recessive dystrophic epidermolysis bullosa.";
RL   J. Invest. Dermatol. 106:766-770(1996).
RN   [20]
RP   VARIANT RDEB ASP-2073.
RX   PubMed=8757758; DOI=10.1111/1523-1747.ep12329570;
RA   Dunnill M.G.S., McGrath J.A., Richards A.J., Christiano A.M.,
RA   Uitto J., Pope F.M., Eady R.A.J.;
RT   "Clinicopathological correlations of compound heterozygous COL7A1
RT   mutations in recessive dystrophic epidermolysis bullosa.";
RL   J. Invest. Dermatol. 107:171-177(1996).
RN   [21]
RP   VARIANTS HS-DEB TRP-1982; GLY-2008; ALA-2025; GLU-2049; TRP-2063 AND
RP   ARG-2575.
RX   PubMed=9326325; DOI=10.1086/515495;
RA   Hovnanian A., Rochat A., Bodemer C., Petit E., Rivers C.A., Prost C.,
RA   Fraitag S., Christiano A.M., Uitto J., Lathrop M., Barrandon Y.,
RA   de Prost Y.;
RT   "Characterization of 18 new mutations in COL7A1 in recessive
RT   dystrophic epidermolysis bullosa provides evidence for distinct
RT   molecular mechanisms underlying defective anchoring fibril
RT   formation.";
RL   Am. J. Hum. Genet. 61:599-610(1997).
RN   [22]
RP   VARIANT RDEB ARG-1652.
RX   PubMed=9444387; DOI=10.1007/s004030050253;
RA   Cserhalmi-Friedman P.B., Karpati S., Horvath A., Christiano A.M.;
RT   "Identification of a glycine substitution and a splice site mutation
RT   in the type VII collagen gene in a proband with mitis recessive
RT   dystrophic epidermolysis bullosa.";
RL   Arch. Dermatol. Res. 289:640-645(1997).
RN   [23]
RP   VARIANT RDEB ARG-2009, AND VARIANT DDEB ARG-2043.
RX   PubMed=9215684; DOI=10.1093/hmg/6.7.1125;
RA   Winberg J.-O., Hammami-Hauasli N., Nilssen O., Anton-Lamprecht I.,
RA   Naylor S.L., Kerbacher K., Zimmermann M., Krajci P.,
RA   Gedde-Dahl T. Jr., Bruckner-Tuderman L.;
RT   "Modulation of disease severity of dystrophic epidermolysis bullosa by
RT   a splice site mutation in combination with a missense mutation in the
RT   COL7A1 gene.";
RL   Hum. Mol. Genet. 6:1125-1135(1997).
RN   [24]
RP   VARIANTS DDEB ASP-1519; ASP-2006; GLU-2015 AND ARG-2034.
RX   PubMed=9668111; DOI=10.1074/jbc.273.30.19228;
RA   Hammami-Hauasli N., Schumann H., Raghunath M., Kilgus O., Luethi U.,
RA   Luger T., Bruckner-Tuderman L.;
RT   "Some, but not all, glycine substitution mutations in COL7A1 result in
RT   intracellular accumulation of collagen VII, loss of anchoring fibrils,
RT   and skin blistering.";
RL   J. Biol. Chem. 273:19228-19234(1998).
RN   [25]
RP   VARIANT HS-DEB CYS-2008, VARIANT DDEB ARG-2207, AND VARIANT RDEB
RP   SER-2775.
RX   PubMed=9740253; DOI=10.1046/j.1523-1747.1998.00326.x;
RA   Kon A., Pulkkinen L., Ishida-Yamamoto A., Hashimoto I., Uitto J.;
RT   "Novel COL7A1 mutations in dystrophic forms of epidermolysis
RT   bullosa.";
RL   J. Invest. Dermatol. 111:534-537(1998).
RN   [26]
RP   VARIANT RDEB ARG-1347.
RX   PubMed=9804332; DOI=10.1046/j.1523-1747.1998.00397.x;
RA   Terracina M., Posteraro P., Schubert M., Sonego G., Atzori F.,
RA   Zambruno G., Bruckner-Tuderman L., Castiglia D.;
RT   "Compound heterozygosity for a recessive glycine substitution and a
RT   splice site mutation in the COL7A1 gene causes an unusually mild form
RT   of localized recessive dystrophic epidermolysis bullosa.";
RL   J. Invest. Dermatol. 111:744-750(1998).
RN   [27]
RP   VARIANTS DDEB TRP-2034; VAL-2040; ARG-2043; ARG-2064 AND ASP-2713.
RX   PubMed=9856843; DOI=10.1046/j.1523-1747.1998.00422.x;
RA   Rouan F., Pulkkinen L., Jonkman M.F., Bauer J.W.,
RA   Cserhalmi-Friedman P.B., Christiano A.M., Uitto J.;
RT   "Novel and de novo glycine substitution mutations in the type VII
RT   collagen gene (COL7A1) in dystrophic epidermolysis bullosa:
RT   implications for genetic counseling.";
RL   J. Invest. Dermatol. 111:1210-1213(1998).
RN   [28]
RP   VARIANTS TBDN ASP-1519 AND GLU-2251.
RX   PubMed=9856844; DOI=10.1046/j.1523-1747.1998.00394.x;
RA   Hammami-Hauasli N., Raghunath M., Kuester W., Bruckner-Tuderman L.;
RT   "Transient bullous dermolysis of the newborn associated with compound
RT   heterozygosity for recessive and dominant COL7A1 mutations.";
RL   J. Invest. Dermatol. 111:1214-1219(1998).
RN   [29]
RP   VARIANTS DDEB/RDEB TRP-2063 AND SER-2366, AND VARIANT DDEB GLU-2079.
RX   PubMed=10232406; DOI=10.1111/j.1600-0625.1999.tb00362.x;
RA   Hashimoto I., Kon A., Tamai K., Uitto J.;
RT   "Diagnostic dilemma of 'sporadic' cases of dystrophic epidermolysis
RT   bullosa: a new dominant or mitis recessive mutation?";
RL   Exp. Dermatol. 8:140-142(1999).
RN   [30]
RP   VARIANT DDEB/RDEB ARG-2348.
RX   PubMed=10232407; DOI=10.1111/j.1600-0625.1999.tb00363.x;
RA   Cserhalmi-Friedman P.B., Grossman J., Karpati S., Ahmad W.,
RA   Horvath A., Christiano A.M.;
RT   "Identification of a de novo glycine substitution in the type VII
RT   collagen gene in a proband with mild dystrophic epidermolysis
RT   bullosa.";
RL   Exp. Dermatol. 8:143-145(1999).
RN   [31]
RP   VARIANT DDEB ARG-2079.
RX   PubMed=10232408; DOI=10.1111/j.1600-0625.1999.tb00364.x;
RA   Christiano A.M., Crollick J., Pincus S., Uitto J.;
RT   "Squamous cell carcinoma in a family with dominant dystrophic
RT   epidermolysis bullosa: a molecular genetic study.";
RL   Exp. Dermatol. 8:146-152(1999).
RN   [32]
RP   VARIANTS DDEB ASP-2006; GLU-2015; ARG-2034; TRP-2034; ARG-2043 AND
RP   TRP-2043, VARIANTS HS-DEB CYS-2008 AND GLY-2008, AND VARIANT RDEB
RP   ARG-2009.
RX   PubMed=10084325; DOI=10.1046/j.1523-1747.1999.00518.x;
RA   Mecklenbeck S., Hammami-Hauasli N., Hoepfner B., Schumann H.,
RA   Kramer A., Kuester W., Bruckner-Tuderman L.;
RT   "Clustering of COL7A1 mutations in exon 73: implications for mutation
RT   analysis in dystrophic epidermolysis bullosa.";
RL   J. Invest. Dermatol. 112:398-400(1999).
RN   [33]
RP   VARIANT P-DEB GLU-2037.
RX   PubMed=10233777; DOI=10.1046/j.1523-1747.1999.00568.x;
RA   Jonkman M.F., Moreno G., Rouan F., Oranje A.P., Pulkkinen L.,
RA   Uitto J.;
RT   "Dominant dystrophic epidermolysis bullosa (Pasini) caused by a novel
RT   glycine substitution mutation in the type VII collagen gene
RT   (COL7A1).";
RL   J. Invest. Dermatol. 112:815-817(1999).
RN   [34]
RP   VARIANTS EBP GLU-1791; ARG-2242; SER-2369 AND ARG-2713.
RX   PubMed=10383749; DOI=10.1046/j.1523-1747.1999.00614.x;
RA   Mellerio J.E., Ashton G.H.S., Mohammedi R., Lyon C.C., Kirby B.,
RA   Harman K.E., Salas-Alanis J.C., Atherton D.J., Harrison P.V.,
RA   Griffiths W.A.D., Black M.M., Eady R.A.J., McGrath J.A.;
RT   "Allelic heterogeneity of dominant and recessive COL7A1 mutations
RT   underlying epidermolysis bullosa pruriginosa.";
RL   J. Invest. Dermatol. 112:984-987(1999).
RN   [35]
RP   VARIANTS ARG-2287 AND ARG-2316.
RX   PubMed=10469344; DOI=10.1046/j.1523-1747.1999.00713.x;
RA   Shimizu H., Hammami-Hauasli N., Hatta N., Nishikawa T.,
RA   Bruckner-Tuderman L.;
RT   "Compound heterozygosity for silent and dominant glycine substitution
RT   mutations in COL7A1 leads to a marked transient intracytoplasmic
RT   retention of procollagen VII and a moderately severe dystrophic
RT   epidermolysis bullosa phenotype.";
RL   J. Invest. Dermatol. 113:419-421(1999).
RN   [36]
RP   VARIANTS DEB.
RX   PubMed=10504458; DOI=10.1046/j.1523-1747.1999.00732.x;
RA   Whittock N.V., Ashton G.H.S., Mohammedi R., Mellerio J.E.,
RA   Mathew C.G., Abbs S.J., Eady R.A.J., McGrath J.A.;
RT   "Comparative mutation detection screening of the type VII collagen
RT   gene (COL7A1) using the protein truncation test, fluorescent chemical
RT   cleavage of mismatch, and conformation sensitive gel
RT   electrophoresis.";
RL   J. Invest. Dermatol. 113:673-686(1999).
RN   [37]
RP   VARIANT DDEB ARG-2028.
RX   PubMed=10836608; DOI=10.1007/s004030050472;
RA   Lee J.Y.-Y., Li C., Chao S.-C., Pulkkinen L., Uitto J.;
RT   "A de novo glycine substitution mutation in the collagenous domain of
RT   COL7A1 in dominant dystrophic epidermolysis bullosa.";
RL   Arch. Dermatol. Res. 292:159-163(2000).
RN   [38]
RP   VARIANT DDEB ALA-2028, AND VARIANT EBP ARG-2028.
RX   PubMed=11142768; DOI=10.1007/s004030000162;
RA   Murata T., Masunaga T., Shimizu H., Takizawa Y., Ishiko A., Hatta N.,
RA   Nishikawa T.;
RT   "Glycine substitution mutations by different amino acids in the same
RT   codon of COL7A1 lead to heterogeneous clinical phenotypes of dominant
RT   dystrophic epidermolysis bullosa.";
RL   Arch. Dermatol. Res. 292:477-481(2000).
RN   [39]
RP   VARIANT RDEB ARG-1812.
RX   PubMed=10620140; DOI=10.1046/j.1523-1747.2000.00848.x;
RA   Masunaga T., Shimizu H., Takizawa Y., Uitto J., Nishikawa T.;
RT   "Combination of novel premature termination codon and glycine
RT   substitution mutations in COL7A1 leads to moderately severe recessive
RT   dystrophic epidermolysis bullosa.";
RL   J. Invest. Dermatol. 114:204-205(2000).
RN   [40]
RP   VARIANT RDEB SER-2031.
RX   PubMed=11167698; DOI=10.1046/j.1365-2133.2001.03966.x;
RA   Nordal E.J., Mecklenbeck S., Hausser I., Skranes J.,
RA   Bruckner-Tuderman L., Gedde-Dahl T. Jr.;
RT   "Generalized dystrophic epidermolysis bullosa: identification of a
RT   novel, homozygous glycine substitution, G2031S, in exon 73 of COL7A1
RT   in monozygous triplets.";
RL   Br. J. Dermatol. 144:151-157(2001).
RN   [41]
RP   VARIANTS NDNC8 ARG-1595 AND ARG-1815.
RX   PubMed=11843659; DOI=10.1001/archderm.138.2.269;
RA   Sato-Matsumura K.C., Yasukawa K., Tomita Y., Shimizu H.;
RT   "Toenail dystrophy with COL7A1 glycine substitution mutations
RT   segregates as an autosomal dominant trait in 2 families with
RT   dystrophic epidermolysis bullosa.";
RL   Arch. Dermatol. 138:269-271(2002).
RN   [42]
RP   VARIANT EBDSC ARG-2034.
RX   PubMed=11874498; DOI=10.1046/j.0022-202x.2001.01702.x;
RA   Martinez-Mir A., Liu J., Gordon D., Weiner M.S., Ahmad W., Fine J.D.,
RA   Ott J., Gilliam T.C., Christiano A.M.;
RT   "EB simplex superficialis resulting from a mutation in the type VII
RT   collagen gene.";
RL   J. Invest. Dermatol. 118:547-549(2002).
RN   [43]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-119; THR-1364 AND TRP-1366.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [44]
RP   VARIANT ALA-2221.
RX   PubMed=20108428;
RA   Garcia M., Escamez M.J., Cuadrado-Corrales N., Sanchez-Jimeno C.,
RA   Illera N., Lopez-Martinez M.A., Trujillo-Tiebas M.J., Ayuso C.,
RA   Del Rio M.;
RT   "Novel human pathological mutations. Gene symbol: COL7A1. Disease:
RT   Epidermolysis bullosa dystrophica.";
RL   Hum. Genet. 127:116-117(2010).
RN   [45]
RP   VARIANTS RDEB ARG-1845; ARG-1981; GLU-2049; TRP-2063; CYS-2069;
RP   GLU-2296; ARG-2557 AND TRP-2622, AND VARIANTS DDEB ARG-2003; ASP-2040;
RP   ARG-2043; ARG-2064; ARG-2070 AND ASP-2076.
RX   PubMed=20598510; DOI=10.1016/j.jdermsci.2010.05.007;
RA   Jerabkova B., Kopeckova L., Buckova H., Vesely K., Valickova J.,
RA   Fajkusova L.;
RT   "Analysis of the COL7A1 gene in Czech patients with dystrophic
RT   epidermolysis bullosa reveals novel and recurrent mutations.";
RL   J. Dermatol. Sci. 59:136-140(2010).
CC   -!- FUNCTION: Stratified squamous epithelial basement membrane protein
CC       that forms anchoring fibrils which may contribute to epithelial
CC       basement membrane organization and adherence by interacting with
CC       extracellular matrix (ECM) proteins such as type IV collagen.
CC   -!- SUBUNIT: Homotrimer. Interacts with MIA3/TANGO1; facilitating its
CC       loading into transport carriers and subsequent secretion.
CC       {ECO:0000269|PubMed:19269366}.
CC   -!- INTERACTION:
CC       Q5JRA6:MIA3; NbExp=2; IntAct=EBI-724237, EBI-2291868;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix, basement membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q02388-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q02388-2; Sequence=VSP_024026;
CC   -!- PTM: Prolines at the third position of the tripeptide repeating
CC       unit (G-X-Y) are hydroxylated in some or all of the chains.
CC       {ECO:0000269|PubMed:2537292}.
CC   -!- DISEASE: Note=Epidermolysis bullosa acquisita (EBA) is an
CC       autoimmune acquired blistering skin disease resulting from
CC       autoantibodies to type VII collagen.
CC   -!- DISEASE: Epidermolysis bullosa dystrophica, autosomal dominant
CC       (DDEB) [MIM:131750]: A group of autosomal dominant blistering skin
CC       diseases characterized by tissue separation which occurs below the
CC       dermal-epidermal basement membrane at the level of the anchoring
CC       fibrils. Various clinical types with different severity are
CC       recognized, ranging from severe mutilating forms to mild forms
CC       with limited and localized scarring, and less frequent
CC       extracutaneous manifestations. {ECO:0000269|PubMed:10084325,
CC       ECO:0000269|PubMed:10232406, ECO:0000269|PubMed:10232407,
CC       ECO:0000269|PubMed:10232408, ECO:0000269|PubMed:10836608,
CC       ECO:0000269|PubMed:11142768, ECO:0000269|PubMed:20598510,
CC       ECO:0000269|PubMed:7861014, ECO:0000269|PubMed:9215684,
CC       ECO:0000269|PubMed:9668111, ECO:0000269|PubMed:9740253,
CC       ECO:0000269|PubMed:9856843}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Epidermolysis bullosa dystrophica, autosomal recessive
CC       (RDEB) [MIM:226600]: A group of autosomal recessive blistering
CC       skin diseases characterized by tissue separation which occurs
CC       below the dermal-epidermal basement membrane at the level of the
CC       anchoring fibrils. Various clinical types with different severity
CC       are recognized, ranging from severe mutilating forms to mild forms
CC       with limited and localized scarring, and less frequent
CC       extracutaneous manifestations. Mild forms include epidermolysis
CC       bullosa mitis and epidermolysis bullosa localisata.
CC       {ECO:0000269|PubMed:10084325, ECO:0000269|PubMed:10620140,
CC       ECO:0000269|PubMed:11167698, ECO:0000269|PubMed:20598510,
CC       ECO:0000269|PubMed:8618018, ECO:0000269|PubMed:8757758,
CC       ECO:0000269|PubMed:9215684, ECO:0000269|PubMed:9444387,
CC       ECO:0000269|PubMed:9740253, ECO:0000269|PubMed:9804332}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Epidermolysis bullosa dystrophica, Pasini type (P-DEB)
CC       [MIM:131750]: A severe, dominantly inherited form of dystrophic
CC       epidermolysis bullosa characterized by albopapuloid Pasini papule,
CC       dorsal extremity blistering, milia formation and red atrophic
CC       scarring after recurrent blisters. {ECO:0000269|PubMed:10233777,
CC       ECO:0000269|PubMed:8170945}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Epidermolysis bullosa dystrophica, Hallopeau-Siemens type
CC       (HS-DEB) [MIM:226600]: The most severe recessive form of
CC       dystrophic epidermolysis bullosa. It manifests with mutilating
CC       scarring, joint contractures, corneal erosions, esophagus
CC       structures, and propensity to formation of cutaneous squamous cell
CC       carcinomas leading to premature demise of the affected
CC       individuals. {ECO:0000269|PubMed:10084325,
CC       ECO:0000269|PubMed:8513326, ECO:0000269|PubMed:8592061,
CC       ECO:0000269|PubMed:9326325, ECO:0000269|PubMed:9740253}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Transient bullous dermolysis of the newborn (TBDN)
CC       [MIM:131705]: TBDN is a neonatal form of dystrophic epidermolysis
CC       bullosa characterized by sub-epidermal blisters, reduced or
CC       abnormal anchoring fibrils at the dermo-epidermal junction, and
CC       electron-dense inclusions in keratinocytes. TBDN heals
CC       spontaneously or strongly improves within the first months and
CC       years of life. {ECO:0000269|PubMed:9856844}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Epidermolysis bullosa dystrophica, pretibial type (PR-
CC       DEB) [MIM:131850]: A form of dystrophic epidermolysis bullosa
CC       characterized by pretibial blisters that develop into prurigo-like
CC       hyperkeratotic lesions. It predominantly affects the pretibial
CC       areas, sparing the knees and other parts of the skin. Other
CC       clinical features include nail dystrophy, albopapuloid skin
CC       lesions, and hypertrophic scars without pretibial predominance.
CC       The phenotype shows considerable interindividual variability.
CC       Inheritance is autosomal dominant. {ECO:0000269|PubMed:8541842}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Epidermolysis bullosa dystrophica, Bart type (B-DEB)
CC       [MIM:132000]: An autosomal dominant form of dystrophic
CC       epidermolysis bullosa characterized by congenital localized
CC       absence of skin, skin fragility and deformity of nails. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Epidermolysis bullosa pruriginosa (EBP) [MIM:604129]: A
CC       distinct clinical subtype of epidermolysis bullosa dystrophica. It
CC       is characterized by skin fragility, blistering, scar formation,
CC       intense pruritus and excoriated prurigo nodules. Onset is in early
CC       childhood, but in some cases is delayed until the second or third
CC       decade of life. Inheritance can be autosomal dominant or
CC       recessive. {ECO:0000269|PubMed:10383749,
CC       ECO:0000269|PubMed:11142768}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Nail disorder, non-syndromic congenital, 8 (NDNC8)
CC       [MIM:607523]: A nail disorder characterized by isolated toenail
CC       dystrophy. The nail changes are most severe in the great toes and
CC       consist of the nail plate being buried in the nail bed with a
CC       deformed and narrow free edge. {ECO:0000269|PubMed:11843659}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Epidermolysis bullosa dystrophica, with subcorneal
CC       cleavage (EBDSC) [MIM:131750]: A bullous skin disorder with
CC       variable sized clefts just beneath the level of the stratum
CC       corneum. Clinical features include blisters, milia, atrophic
CC       scarring, nail dystrophy, and oral and conjunctival involvement,
CC       as seen in dystrophic epidermolysis bullosa.
CC       {ECO:0000269|PubMed:11874498, ECO:0000269|PubMed:2653224}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00031}.
CC   -!- SIMILARITY: Contains 9 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 2 VWFA domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00219}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA02853.1; Type=Frameshift; Positions=275, 282, 476, 494, 523, 541, 543; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L23982; AAA58965.1; -; Genomic_DNA.
DR   EMBL; L02870; AAA75438.1; -; mRNA.
DR   EMBL; D13694; BAA02853.1; ALT_FRAME; mRNA.
DR   EMBL; M96984; AAA36357.2; -; mRNA.
DR   EMBL; S51236; AAB24637.1; -; mRNA.
DR   EMBL; M65158; AAA96439.1; -; mRNA.
DR   EMBL; L06862; AAA89196.1; -; mRNA.
DR   CCDS; CCDS2773.1; -. [Q02388-1]
DR   PIR; A54849; A54849.
DR   RefSeq; NP_000085.1; NM_000094.3. [Q02388-1]
DR   RefSeq; XP_011531639.1; XM_011533337.1. [Q02388-1]
DR   UniGene; Hs.476218; -.
DR   ProteinModelPortal; Q02388; -.
DR   SMR; Q02388; 38-215, 233-1041, 1051-1225, 2876-2933.
DR   BioGrid; 107691; 10.
DR   IntAct; Q02388; 13.
DR   MINT; MINT-1390694; -.
DR   STRING; 9606.ENSP00000332371; -.
DR   MEROPS; I02.967; -.
DR   iPTMnet; Q02388; -.
DR   PhosphoSite; Q02388; -.
DR   BioMuta; COL7A1; -.
DR   DMDM; 1345650; -.
DR   MaxQB; Q02388; -.
DR   PaxDb; Q02388; -.
DR   PRIDE; Q02388; -.
DR   Ensembl; ENST00000328333; ENSP00000332371; ENSG00000114270. [Q02388-1]
DR   GeneID; 1294; -.
DR   KEGG; hsa:1294; -.
DR   UCSC; uc003ctz.2; human. [Q02388-1]
DR   CTD; 1294; -.
DR   GeneCards; COL7A1; -.
DR   GeneReviews; COL7A1; -.
DR   HGNC; HGNC:2214; COL7A1.
DR   HPA; CAB016357; -.
DR   HPA; HPA042420; -.
DR   MalaCards; COL7A1; -.
DR   MIM; 120120; gene.
DR   MIM; 131705; phenotype.
DR   MIM; 131750; phenotype.
DR   MIM; 131850; phenotype.
DR   MIM; 132000; phenotype.
DR   MIM; 226600; phenotype.
DR   MIM; 604129; phenotype.
DR   MIM; 607523; phenotype.
DR   neXtProt; NX_Q02388; -.
DR   Orphanet; 158673; Acral dystrophic epidermolysis bullosa.
DR   Orphanet; 89841; Centripetalis recessive dystrophic epidermolysis bullosa.
DR   Orphanet; 89843; Dystrophic epidermolysis bullosa pruriginosa.
DR   Orphanet; 158676; Dystrophic epidermolysis bullosa, nails only.
DR   Orphanet; 89839; Epidermolysis bullosa simplex superficialis.
DR   Orphanet; 231568; Generalized dominant dystrophic epidermolysis bullosa.
DR   Orphanet; 79410; Pretibial dystrophic epidermolysis bullosa.
DR   Orphanet; 79409; Recessive dystrophic epidermolysis bullosa inversa.
DR   Orphanet; 89842; Recessive dystrophic epidermolysis bullosa-generalized other.
DR   Orphanet; 79408; Severe generalized recessive dystrophic epidermolysis bullosa.
DR   Orphanet; 79411; Transient bullous dermolysis of the newborn.
DR   PharmGKB; PA26730; -.
DR   eggNOG; KOG3544; Eukaryota.
DR   eggNOG; ENOG410XNMM; LUCA.
DR   GeneTree; ENSGT00830000128243; -.
DR   HOGENOM; HOG000111866; -.
DR   HOVERGEN; HBG051053; -.
DR   InParanoid; Q02388; -.
DR   KO; K16628; -.
DR   OMA; DTEYTVH; -.
DR   OrthoDB; EOG7CG6Z4; -.
DR   PhylomeDB; Q02388; -.
DR   TreeFam; TF351645; -.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474244; Extracellular matrix organization.
DR   Reactome; R-HSA-1650814; Collagen biosynthesis and modifying enzymes.
DR   Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-HSA-204005; COPII (Coat Protein 2) Mediated Vesicle Transport.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-2214320; Anchoring fibril formation.
DR   Reactome; R-HSA-3000157; Laminin interactions.
DR   Reactome; R-HSA-5694530; Cargo concentration in the ER.
DR   ChiTaRS; COL7A1; human.
DR   GeneWiki; Collagen,_type_VII,_alpha_1; -.
DR   GenomeRNAi; 1294; -.
DR   NextBio; 5251; -.
DR   PRO; PR:Q02388; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; Q02388; -.
DR   CleanEx; HS_COL7A1; -.
DR   ExpressionAtlas; Q02388; baseline and differential.
DR   Genevisible; Q02388; HS.
DR   GO; GO:0005604; C:basement membrane; TAS:ProtInc.
DR   GO; GO:0005590; C:collagen type VII trimer; TAS:ProtInc.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; TAS:Reactome.
DR   GO; GO:0030134; C:ER to Golgi transport vesicle; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:GOC.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IEA:UniProtKB-KW.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0030574; P:collagen catabolic process; TAS:Reactome.
DR   GO; GO:0048208; P:COPII vesicle coating; TAS:Reactome.
DR   GO; GO:0035987; P:endodermal cell differentiation; IEP:UniProtKB.
DR   GO; GO:0008544; P:epidermis development; TAS:ProtInc.
DR   GO; GO:0006888; P:ER to Golgi vesicle-mediated transport; TAS:Reactome.
DR   GO; GO:0022617; P:extracellular matrix disassembly; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0018279; P:protein N-linked glycosylation via asparagine; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 9.
DR   Gene3D; 3.40.50.410; -; 2.
DR   Gene3D; 4.10.410.10; -; 1.
DR   InterPro; IPR008160; Collagen.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR002223; Kunitz_BPTI.
DR   InterPro; IPR020901; Prtase_inh_Kunz-CS.
DR   InterPro; IPR002035; VWF_A.
DR   Pfam; PF01391; Collagen; 15.
DR   Pfam; PF00041; fn3; 8.
DR   Pfam; PF00014; Kunitz_BPTI; 1.
DR   Pfam; PF00092; VWA; 2.
DR   PRINTS; PR00759; BASICPTASE.
DR   SMART; SM00060; FN3; 9.
DR   SMART; SM00327; VWA; 1.
DR   SUPFAM; SSF49265; SSF49265; 5.
DR   SUPFAM; SSF53300; SSF53300; 2.
DR   SUPFAM; SSF57362; SSF57362; 1.
DR   PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR   PROSITE; PS50279; BPTI_KUNITZ_2; 1.
DR   PROSITE; PS50853; FN3; 9.
DR   PROSITE; PS50234; VWFA; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Basement membrane; Cell adhesion; Collagen;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Epidermolysis bullosa; Extracellular matrix;
KW   Glycoprotein; Hydroxylation; Polymorphism; Protease inhibitor;
KW   Reference proteome; Repeat; Secreted; Serine protease inhibitor;
KW   Signal.
FT   SIGNAL        1     16       {ECO:0000255}.
FT   CHAIN        17   2944       Collagen alpha-1(VII) chain.
FT                                /FTId=PRO_0000005761.
FT   DOMAIN       38    211       VWFA 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00219}.
FT   DOMAIN      234    329       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      330    416       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      417    507       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      510    597       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      600    687       Fibronectin type-III 5.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      688    775       Fibronectin type-III 6.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      778    866       Fibronectin type-III 7.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      869    957       Fibronectin type-III 8.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      958   1051       Fibronectin type-III 9.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1054   1229       VWFA 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00219}.
FT   DOMAIN     2872   2944       BPTI/Kunitz inhibitor.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   REGION       17   1253       Nonhelical region (NC1).
FT   REGION     1254   2784       Triple-helical region.
FT   REGION     1254   1477       Interrupted collagenous region.
FT   REGION     2785   2944       Nonhelical region (NC2).
FT   MOTIF      1170   1172       Cell attachment site. {ECO:0000255}.
FT   MOTIF      1334   1336       Cell attachment site. {ECO:0000255}.
FT   MOTIF      2008   2010       Cell attachment site. {ECO:0000255}.
FT   MOTIF      2553   2555       Cell attachment site. {ECO:0000255}.
FT   SITE       2886   2887       Reactive bond. {ECO:0000250}.
FT   MOD_RES    2167   2167       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:2537292}.
FT   MOD_RES    2176   2176       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:2537292}.
FT   MOD_RES    2185   2185       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:2537292}.
FT   MOD_RES    2188   2188       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:2537292}.
FT   MOD_RES    2625   2625       5-hydroxylysine; alternate.
FT                                {ECO:0000269|PubMed:2537292}.
FT   MOD_RES    2631   2631       5-hydroxylysine; alternate.
FT                                {ECO:0000269|PubMed:2537292}.
FT   MOD_RES    2664   2664       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:2537292}.
FT   MOD_RES    2667   2667       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:2537292}.
FT   MOD_RES    2673   2673       4-hydroxyproline.
FT                                {ECO:0000269|PubMed:2537292}.
FT   CARBOHYD    337    337       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    786    786       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1109   1109       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2625   2625       O-linked (Gal...); alternate.
FT   CARBOHYD   2631   2631       O-linked (Gal...); alternate.
FT   DISULFID   2634   2634       Interchain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00031}.
FT   DISULFID   2802   2802       Interchain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00031}.
FT   DISULFID   2804   2804       Interchain. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00031}.
FT   DISULFID   2876   2929       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID   2885   2912       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   DISULFID   2904   2925       {ECO:0000255|PROSITE-ProRule:PRU00031}.
FT   VAR_SEQ    1869   1900       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_024026.
FT   VARIANT     119    119       T -> P (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035740.
FT   VARIANT     142    142       K -> R (in RDEB).
FT                                /FTId=VAR_001809.
FT   VARIANT     547    547       V -> F (in dbSNP:rs2229823).
FT                                /FTId=VAR_048765.
FT   VARIANT     595    595       P -> L (in RDEB; dbSNP:rs2228561).
FT                                /FTId=VAR_001810.
FT   VARIANT    1120   1120       R -> K (in dbSNP:rs2228563).
FT                                /FTId=VAR_048766.
FT   VARIANT    1277   1277       P -> L (in RDEB; dbSNP:rs35761247).
FT                                /FTId=VAR_001811.
FT   VARIANT    1347   1347       G -> R (in RDEB; localized type; mild).
FT                                {ECO:0000269|PubMed:9804332}.
FT                                /FTId=VAR_011160.
FT   VARIANT    1364   1364       P -> T (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035741.
FT   VARIANT    1366   1366       R -> W (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035742.
FT   VARIANT    1519   1519       G -> D (in TBDN; compound heterozygous
FT                                with E-2251; clinically silent when
FT                                heterozygous with a normal allele).
FT                                {ECO:0000269|PubMed:9668111,
FT                                ECO:0000269|PubMed:9856844}.
FT                                /FTId=VAR_011161.
FT   VARIANT    1522   1522       G -> E (in DDEB).
FT                                /FTId=VAR_011162.
FT   VARIANT    1557   1557       G -> R (in DDEB).
FT                                /FTId=VAR_001812.
FT   VARIANT    1595   1595       G -> R (in NDNC8).
FT                                {ECO:0000269|PubMed:11843659}.
FT                                /FTId=VAR_015519.
FT   VARIANT    1604   1604       G -> R (in RDEB).
FT                                /FTId=VAR_011163.
FT   VARIANT    1652   1652       G -> R (in RDEB; mitis type).
FT                                {ECO:0000269|PubMed:9444387}.
FT                                /FTId=VAR_011164.
FT   VARIANT    1703   1703       G -> E (in RDEB).
FT                                /FTId=VAR_011165.
FT   VARIANT    1772   1772       R -> W (in RDEB).
FT                                /FTId=VAR_011166.
FT   VARIANT    1776   1776       G -> R (in DDEB).
FT                                /FTId=VAR_011167.
FT   VARIANT    1782   1782       G -> R (in RDEB; mitis type).
FT                                {ECO:0000269|PubMed:8618018}.
FT                                /FTId=VAR_001813.
FT   VARIANT    1791   1791       G -> E (in EBP).
FT                                {ECO:0000269|PubMed:10383749}.
FT                                /FTId=VAR_011168.
FT   VARIANT    1812   1812       G -> R (in RDEB).
FT                                {ECO:0000269|PubMed:10620140}.
FT                                /FTId=VAR_011169.
FT   VARIANT    1815   1815       G -> R (in NDNC8).
FT                                {ECO:0000269|PubMed:11843659}.
FT                                /FTId=VAR_015520.
FT   VARIANT    1845   1845       G -> R (in RDEB).
FT                                {ECO:0000269|PubMed:20598510}.
FT                                /FTId=VAR_064994.
FT   VARIANT    1981   1981       K -> R (in RDEB; mild form).
FT                                {ECO:0000269|PubMed:20598510}.
FT                                /FTId=VAR_064995.
FT   VARIANT    1982   1982       G -> W (in HS-DEB).
FT                                {ECO:0000269|PubMed:9326325}.
FT                                /FTId=VAR_001814.
FT   VARIANT    2003   2003       G -> R (in DDEB).
FT                                {ECO:0000269|PubMed:20598510}.
FT                                /FTId=VAR_001815.
FT   VARIANT    2006   2006       G -> A (in DDEB).
FT                                /FTId=VAR_011170.
FT   VARIANT    2006   2006       G -> D (in DDEB; interferes with collagen
FT                                VII folding and secretion).
FT                                {ECO:0000269|PubMed:10084325,
FT                                ECO:0000269|PubMed:9668111}.
FT                                /FTId=VAR_011171.
FT   VARIANT    2008   2008       R -> C (in HS-DEB; also in a milder
FT                                localized type).
FT                                {ECO:0000269|PubMed:10084325,
FT                                ECO:0000269|PubMed:9740253}.
FT                                /FTId=VAR_011172.
FT   VARIANT    2008   2008       R -> G (in HS-DEB).
FT                                {ECO:0000269|PubMed:10084325,
FT                                ECO:0000269|PubMed:9326325}.
FT                                /FTId=VAR_001816.
FT   VARIANT    2009   2009       G -> R (in RDEB).
FT                                {ECO:0000269|PubMed:10084325,
FT                                ECO:0000269|PubMed:9215684}.
FT                                /FTId=VAR_011173.
FT   VARIANT    2015   2015       G -> E (in DDEB; interferes with collagen
FT                                VII folding and secretion).
FT                                {ECO:0000269|PubMed:10084325,
FT                                ECO:0000269|PubMed:9668111}.
FT                                /FTId=VAR_011174.
FT   VARIANT    2025   2025       G -> A (in RDEB; mitis type).
FT                                {ECO:0000269|PubMed:9326325}.
FT                                /FTId=VAR_001817.
FT   VARIANT    2028   2028       G -> A (in DDEB).
FT                                {ECO:0000269|PubMed:11142768}.
FT                                /FTId=VAR_011175.
FT   VARIANT    2028   2028       G -> R (in DDEB and EBP).
FT                                {ECO:0000269|PubMed:10836608,
FT                                ECO:0000269|PubMed:11142768}.
FT                                /FTId=VAR_011176.
FT   VARIANT    2031   2031       G -> S (in RDEB; severe phenotype).
FT                                {ECO:0000269|PubMed:11167698}.
FT                                /FTId=VAR_011177.
FT   VARIANT    2034   2034       G -> R (in DDEB and EBDSC; interferes
FT                                with collagen VII folding and secretion).
FT                                {ECO:0000269|PubMed:10084325,
FT                                ECO:0000269|PubMed:11874498,
FT                                ECO:0000269|PubMed:2653224,
FT                                ECO:0000269|PubMed:9668111}.
FT                                /FTId=VAR_001818.
FT   VARIANT    2034   2034       G -> W (in DDEB).
FT                                {ECO:0000269|PubMed:10084325,
FT                                ECO:0000269|PubMed:9856843}.
FT                                /FTId=VAR_011178.
FT   VARIANT    2037   2037       G -> E (in P-DEB).
FT                                {ECO:0000269|PubMed:10233777}.
FT                                /FTId=VAR_011179.
FT   VARIANT    2040   2040       G -> D (in DDEB).
FT                                {ECO:0000269|PubMed:20598510}.
FT                                /FTId=VAR_011180.
FT   VARIANT    2040   2040       G -> S (in P-DEB).
FT                                {ECO:0000269|PubMed:8170945}.
FT                                /FTId=VAR_001819.
FT   VARIANT    2040   2040       G -> V (in DDEB).
FT                                {ECO:0000269|PubMed:9856843}.
FT                                /FTId=VAR_011181.
FT   VARIANT    2043   2043       G -> R (in DDEB).
FT                                {ECO:0000269|PubMed:10084325,
FT                                ECO:0000269|PubMed:20598510,
FT                                ECO:0000269|PubMed:7861014,
FT                                ECO:0000269|PubMed:9215684,
FT                                ECO:0000269|PubMed:9856843}.
FT                                /FTId=VAR_001820.
FT   VARIANT    2043   2043       G -> W (in DDEB; localized type).
FT                                {ECO:0000269|PubMed:10084325}.
FT                                /FTId=VAR_011182.
FT   VARIANT    2046   2046       G -> V (in DDEB).
FT                                /FTId=VAR_011183.
FT   VARIANT    2049   2049       G -> E (in HS-DEB).
FT                                {ECO:0000269|PubMed:20598510,
FT                                ECO:0000269|PubMed:9326325}.
FT                                /FTId=VAR_001821.
FT   VARIANT    2055   2055       G -> E (in DDEB).
FT                                /FTId=VAR_001822.
FT   VARIANT    2063   2063       R -> W (in HS-DEB; also in a mild form).
FT                                {ECO:0000269|PubMed:10232406,
FT                                ECO:0000269|PubMed:20598510,
FT                                ECO:0000269|PubMed:9326325}.
FT                                /FTId=VAR_001823.
FT   VARIANT    2064   2064       G -> R (in DDEB).
FT                                {ECO:0000269|PubMed:20598510,
FT                                ECO:0000269|PubMed:9856843}.
FT                                /FTId=VAR_011184.
FT   VARIANT    2069   2069       R -> C (in RDEB).
FT                                {ECO:0000269|PubMed:20598510}.
FT                                /FTId=VAR_064996.
FT   VARIANT    2070   2070       G -> R (in DDEB).
FT                                {ECO:0000269|PubMed:20598510}.
FT                                /FTId=VAR_064997.
FT   VARIANT    2073   2073       G -> D (in RDEB; mitis type).
FT                                {ECO:0000269|PubMed:8757758}.
FT                                /FTId=VAR_001825.
FT   VARIANT    2076   2076       G -> D (in DDEB; also in recessive
FT                                forms). {ECO:0000269|PubMed:20598510}.
FT                                /FTId=VAR_001826.
FT   VARIANT    2079   2079       G -> E (in DDEB).
FT                                {ECO:0000269|PubMed:10232406}.
FT                                /FTId=VAR_001827.
FT   VARIANT    2079   2079       G -> R (in DDEB; associated with squamous
FT                                cell carcinoma).
FT                                {ECO:0000269|PubMed:10232408}.
FT                                /FTId=VAR_011185.
FT   VARIANT    2132   2132       G -> D (in RDEB).
FT                                /FTId=VAR_011186.
FT   VARIANT    2192   2192       G -> S (in RDEB).
FT                                /FTId=VAR_011187.
FT   VARIANT    2207   2207       G -> R (in DDEB).
FT                                {ECO:0000269|PubMed:9740253}.
FT                                /FTId=VAR_011188.
FT   VARIANT    2221   2221       G -> A (in RDEB).
FT                                {ECO:0000269|PubMed:20108428}.
FT                                /FTId=VAR_064998.
FT   VARIANT    2242   2242       G -> R (in EBP).
FT                                {ECO:0000269|PubMed:10383749}.
FT                                /FTId=VAR_001828.
FT   VARIANT    2251   2251       G -> E (in TBDN; compound heterozygous
FT                                with D-1519; leads to isolated toenail
FT                                dystrophy when heterozygous with a normal
FT                                allele). {ECO:0000269|PubMed:9856844}.
FT                                /FTId=VAR_011189.
FT   VARIANT    2263   2263       G -> V (in RDEB).
FT                                /FTId=VAR_011190.
FT   VARIANT    2287   2287       G -> R (in RDEB; moderately severe
FT                                phenotype when compound heterozygous with
FT                                R-2316; leads to isolated toenail
FT                                dystrophy when heterozygous with a normal
FT                                allele). {ECO:0000269|PubMed:10469344}.
FT                                /FTId=VAR_011191.
FT   VARIANT    2296   2296       G -> E (in RDEB).
FT                                {ECO:0000269|PubMed:20598510}.
FT                                /FTId=VAR_064999.
FT   VARIANT    2316   2316       G -> R (in RDEB; moderately severe
FT                                phenotype when compound heterozygous with
FT                                R-2287). {ECO:0000269|PubMed:10469344}.
FT                                /FTId=VAR_011192.
FT   VARIANT    2348   2348       G -> R (in DDEB/RDEB; mild form).
FT                                {ECO:0000269|PubMed:10232407}.
FT                                /FTId=VAR_011193.
FT   VARIANT    2351   2351       G -> R (in a patient with dystrophic
FT                                epidermolysis bullosa; mitis type;
FT                                dbSNP:rs1800013).
FT                                /FTId=VAR_001829.
FT   VARIANT    2366   2366       G -> S (in RDEB; mitis type).
FT                                {ECO:0000269|PubMed:10232406}.
FT                                /FTId=VAR_011194.
FT   VARIANT    2369   2369       G -> S (in EBP).
FT                                {ECO:0000269|PubMed:10383749}.
FT                                /FTId=VAR_011195.
FT   VARIANT    2429   2429       P -> L (in dbSNP:rs2229822).
FT                                /FTId=VAR_033786.
FT   VARIANT    2557   2557       G -> R (in RDEB).
FT                                {ECO:0000269|PubMed:20598510}.
FT                                /FTId=VAR_065000.
FT   VARIANT    2569   2569       G -> R (in RDEB; severe and mitis type).
FT                                /FTId=VAR_001830.
FT   VARIANT    2575   2575       G -> R (in HS-DEB; also in a mild form).
FT                                {ECO:0000269|PubMed:8592061,
FT                                ECO:0000269|PubMed:9326325}.
FT                                /FTId=VAR_001831.
FT   VARIANT    2622   2622       R -> W (in RDEB).
FT                                {ECO:0000269|PubMed:20598510}.
FT                                /FTId=VAR_065001.
FT   VARIANT    2623   2623       G -> C (in PR-DEB; dominant).
FT                                {ECO:0000269|PubMed:8541842}.
FT                                /FTId=VAR_001832.
FT   VARIANT    2653   2653       G -> R (in RDEB; mitis type).
FT                                /FTId=VAR_001833.
FT   VARIANT    2671   2671       G -> V (in RDEB).
FT                                /FTId=VAR_001834.
FT   VARIANT    2674   2674       G -> D (in RDEB).
FT                                /FTId=VAR_011196.
FT   VARIANT    2674   2674       G -> R (in RDEB; mitis type).
FT                                /FTId=VAR_001835.
FT   VARIANT    2713   2713       G -> D (in DDEB).
FT                                {ECO:0000269|PubMed:9856843}.
FT                                /FTId=VAR_011197.
FT   VARIANT    2713   2713       G -> R (in EBP).
FT                                {ECO:0000269|PubMed:10383749}.
FT                                /FTId=VAR_011198.
FT   VARIANT    2740   2740       G -> A (in RDEB).
FT                                /FTId=VAR_011199.
FT   VARIANT    2749   2749       G -> R (in HS-DEB; also in a mild form;
FT                                dbSNP:rs121912853).
FT                                /FTId=VAR_001836.
FT   VARIANT    2775   2775       G -> S (in RDEB; mitis type).
FT                                {ECO:0000269|PubMed:9740253}.
FT                                /FTId=VAR_011200.
FT   VARIANT    2791   2791       R -> W (in DDEB; dbSNP:rs142566193).
FT                                /FTId=VAR_011201.
FT   VARIANT    2798   2798       M -> K (in HS-DEB; also in a mild form).
FT                                {ECO:0000269|PubMed:8513326}.
FT                                /FTId=VAR_001837.
FT   CONFLICT    195    197       FFF -> EFR (in Ref. 4; BAA02853).
FT                                {ECO:0000305}.
FT   CONFLICT    369    371       QQQ -> EFR (in Ref. 5; AAA36357/
FT                                AAB24637). {ECO:0000305}.
FT   CONFLICT    518    519       EL -> DV (in Ref. 5; AAA36357/AAB24637).
FT                                {ECO:0000305}.
FT   CONFLICT    529    529       S -> C (in Ref. 4; BAA02853).
FT                                {ECO:0000305}.
FT   CONFLICT    541    541       V -> W (in Ref. 5; AAA36357/AAB24637).
FT                                {ECO:0000305}.
FT   CONFLICT    851    851       R -> H (in Ref. 4; BAA02853).
FT                                {ECO:0000305}.
FT   CONFLICT    893    893       A -> E (in Ref. 1; AAA58965, 4; BAA02853
FT                                and 6; AAA96439). {ECO:0000305}.
FT   CONFLICT   1122   1122       R -> L (in Ref. 4; BAA02853).
FT                                {ECO:0000305}.
FT   CONFLICT   1463   1464       SP -> LR (in Ref. 3; AA sequence).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2944 AA;  295220 MW;  96D8BF6D0FD387DB CRC64;
     MTLRLLVAAL CAGILAEAPR VRAQHRERVT CTRLYAADIV FLLDGSSSIG RSNFREVRSF
     LEGLVLPFSG AASAQGVRFA TVQYSDDPRT EFGLDALGSG GDVIRAIREL SYKGGNTRTG
     AAILHVADHV FLPQLARPGV PKVCILITDG KSQDLVDTAA QRLKGQGVKL FAVGIKNADP
     EELKRVASQP TSDFFFFVND FSILRTLLPL VSRRVCTTAG GVPVTRPPDD STSAPRDLVL
     SEPSSQSLRV QWTAASGPVT GYKVQYTPLT GLGQPLPSER QEVNVPAGET SVRLRGLRPL
     TEYQVTVIAL YANSIGEAVS GTARTTALEG PELTIQNTTA HSLLVAWRSV PGATGYRVTW
     RVLSGGPTQQ QELGPGQGSV LLRDLEPGTD YEVTVSTLFG RSVGPATSLM ARTDASVEQT
     LRPVILGPTS ILLSWNLVPE ARGYRLEWRR ETGLEPPQKV VLPSDVTRYQ LDGLQPGTEY
     RLTLYTLLEG HEVATPATVV PTGPELPVSP VTDLQATELP GQRVRVSWSP VPGATQYRII
     VRSTQGVERT LVLPGSQTAF DLDDVQAGLS YTVRVSARVG PREGSASVLT VRREPETPLA
     VPGLRVVVSD ATRVRVAWGP VPGASGFRIS WSTGSGPESS QTLPPDSTAT DITGLQPGTT
     YQVAVSVLRG REEGPAAVIV ARTDPLGPVR TVHVTQASSS SVTITWTRVP GATGYRVSWH
     SAHGPEKSQL VSGEATVAEL DGLEPDTEYT VHVRAHVAGV DGPPASVVVR TAPEPVGRVS
     RLQILNASSD VLRITWVGVT GATAYRLAWG RSEGGPMRHQ ILPGNTDSAE IRGLEGGVSY
     SVRVTALVGD REGTPVSIVV TTPPEAPPAL GTLHVVQRGE HSLRLRWEPV PRAQGFLLHW
     QPEGGQEQSR VLGPELSSYH LDGLEPATQY RVRLSVLGPA GEGPSAEVTA RTESPRVPSI
     ELRVVDTSID SVTLAWTPVS RASSYILSWR PLRGPGQEVP GSPQTLPGIS SSQRVTGLEP
     GVSYIFSLTP VLDGVRGPEA SVTQTPVCPR GLADVVFLPH ATQDNAHRAE ATRRVLERLV
     LALGPLGPQA VQVGLLSYSH RPSPLFPLNG SHDLGIILQR IRDMPYMDPS GNNLGTAVVT
     AHRYMLAPDA PGRRQHVPGV MVLLVDEPLR GDIFSPIREA QASGLNVVML GMAGADPEQL
     RRLAPGMDSV QTFFAVDDGP SLDQAVSGLA TALCQASFTT QPRPEPCPVY CPKGQKGEPG
     EMGLRGQVGP PGDPGLPGRT GAPGPQGPPG SATAKGERGF PGADGRPGSP GRAGNPGTPG
     APGLKGSPGL PGPRGDPGER GPRGPKGEPG APGQVIGGEG PGLPGRKGDP GPSGPPGPRG
     PLGDPGPRGP PGLPGTAMKG DKGDRGERGP PGPGEGGIAP GEPGLPGLPG SPGPQGPVGP
     PGKKGEKGDS EDGAPGLPGQ PGSPGEQGPR GPPGAIGPKG DRGFPGPLGE AGEKGERGPP
     GPAGSRGLPG VAGRPGAKGP EGPPGPTGRQ GEKGEPGRPG DPAVVGPAVA GPKGEKGDVG
     PAGPRGATGV QGERGPPGLV LPGDPGPKGD PGDRGPIGLT GRAGPPGDSG PPGEKGDPGR
     PGPPGPVGPR GRDGEVGEKG DEGPPGDPGL PGKAGERGLR GAPGVRGPVG EKGDQGDPGE
     DGRNGSPGSS GPKGDRGEPG PPGPPGRLVD TGPGAREKGE PGDRGQEGPR GPKGDPGLPG
     APGERGIEGF RGPPGPQGDP GVRGPAGEKG DRGPPGLDGR SGLDGKPGAA GPSGPNGAAG
     KAGDPGRDGL PGLRGEQGLP GPSGPPGLPG KPGEDGKPGL NGKNGEPGDP GEDGRKGEKG
     DSGASGREGR DGPKGERGAP GILGPQGPPG LPGPVGPPGQ GFPGVPGGTG PKGDRGETGS
     KGEQGLPGER GLRGEPGSVP NVDRLLETAG IKASALREIV ETWDESSGSF LPVPERRRGP
     KGDSGEQGPP GKEGPIGFPG ERGLKGDRGD PGPQGPPGLA LGERGPPGPS GLAGEPGKPG
     IPGLPGRAGG VGEAGRPGER GERGEKGERG EQGRDGPPGL PGTPGPPGPP GPKVSVDEPG
     PGLSGEQGPP GLKGAKGEPG SNGDQGPKGD RGVPGIKGDR GEPGPRGQDG NPGLPGERGM
     AGPEGKPGLQ GPRGPPGPVG GHGDPGPPGA PGLAGPAGPQ GPSGLKGEPG ETGPPGRGLT
     GPTGAVGLPG PPGPSGLVGP QGSPGLPGQV GETGKPGAPG RDGASGKDGD RGSPGVPGSP
     GLPGPVGPKG EPGPTGAPGQ AVVGLPGAKG EKGAPGGLAG DLVGEPGAKG DRGLPGPRGE
     KGEAGRAGEP GDPGEDGQKG APGPKGFKGD PGVGVPGSPG PPGPPGVKGD LGLPGLPGAP
     GVVGFPGQTG PRGEMGQPGP SGERGLAGPP GREGIPGPLG PPGPPGSVGP PGASGLKGDK
     GDPGVGLPGP RGERGEPGIR GEDGRPGQEG PRGLTGPPGS RGERGEKGDV GSAGLKGDKG
     DSAVILGPPG PRGAKGDMGE RGPRGLDGDK GPRGDNGDPG DKGSKGEPGD KGSAGLPGLR
     GLLGPQGQPG AAGIPGDPGS PGKDGVPGIR GEKGDVGFMG PRGLKGERGV KGACGLDGEK
     GDKGEAGPPG RPGLAGHKGE MGEPGVPGQS GAPGKEGLIG PKGDRGFDGQ PGPKGDQGEK
     GERGTPGIGG FPGPSGNDGS AGPPGPPGSV GPRGPEGLQG QKGERGPPGE RVVGAPGVPG
     APGERGEQGR PGPAGPRGEK GEAALTEDDI RGFVRQEMSQ HCACQGQFIA SGSRPLPSYA
     ADTAGSQLHA VPVLRVSHAE EEERVPPEDD EYSEYSEYSV EEYQDPEAPW DSDDPCSLPL
     DEGSCTAYTL RWYHRAVTGS TEACHPFVYG GCGGNANRFG TREACERRCP PRVVQSQGTG
     TAQD
//
ID   ARSA_HUMAN              Reviewed;         507 AA.
AC   P15289; B2RCA6; B7XD04; F8WCC8; Q6ICI5; Q96CJ0;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 3.
DT   20-JAN-2016, entry version 183.
DE   RecName: Full=Arylsulfatase A;
DE            Short=ASA;
DE            EC=3.1.6.8;
DE   AltName: Full=Cerebroside-sulfatase;
DE   Contains:
DE     RecName: Full=Arylsulfatase A component B;
DE   Contains:
DE     RecName: Full=Arylsulfatase A component C;
DE   Flags: Precursor;
GN   Name=ARSA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2562955;
RA   Stein C., Gieselmann V., Kreysing J., Schmidt B., Pohlmann R.,
RA   Waheed A., Meyer H.E., O'Brien J.S., von Figura K.;
RT   "Cloning and expression of human arylsulfatase A.";
RL   J. Biol. Chem. 264:1252-1259(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1975241; DOI=10.1111/j.1432-1033.1990.tb19167.x;
RA   Kreysing J., von Figura K., Gieselmann V.;
RT   "Structure of the arylsulfatase A gene.";
RL   Eur. J. Biochem. 191:627-631(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=19262745;
RA   Oshikawa M., Usami R., Kato S.;
RT   "Characterization of the arylsulfatase I (ARSI) gene preferentially
RT   expressed in the human retinal pigment epithelium cell line ARPE-19.";
RL   Mol. Vis. 15:482-494(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   SER-391.
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-82; CYS-193;
RP   SER-350; VAL-356; SER-391; SER-440 AND HIS-496.
RG   NIEHS SNPs program;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   SER-391.
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 19-33 AND 434-479, AND SUBUNIT.
RX   PubMed=1352993; DOI=10.1016/0167-4838(92)90132-W;
RA   Fujii T., Kobayashi T., Honke K., Gasa S., Ishikawa M., Shimizu T.,
RA   Makita A.;
RT   "Proteolytic processing of human lysosomal arylsulfatase A.";
RL   Biochim. Biophys. Acta 1122:93-98(1992).
RN   [10]
RP   PARTIAL PROTEIN SEQUENCE, IDENTIFICATION BY MASS SPECTROMETRY,
RP   OXOALANINE AT CYS-69, AND ABSENCE OF OXOALANINE IN MSD.
RX   PubMed=7628016; DOI=10.1016/0092-8674(95)90314-3;
RA   Schmidt B., Selmer T., Ingendoh A., von Figura K.;
RT   "A novel amino acid modification in sulfatases that is defective in
RT   multiple sulfatase deficiency.";
RL   Cell 82:271-278(1995).
RN   [11]
RP   INVOLVEMENT IN MSD.
RX   PubMed=15146462; DOI=10.1002/humu.20040;
RA   Cosma M.P., Pepe S., Parenti G., Settembre C., Annunziata I.,
RA   Wade-Martins R., Domenico C.D., Natale P.D., Mankad A., Cox B.,
RA   Uziel G., Mancini G.M., Zammarchi E., Donati M.A., Kleijer W.J.,
RA   Filocamo M., Carrozzo R., Carella M., Ballabio A.;
RT   "Molecular and functional analysis of SUMF1 mutations in multiple
RT   sulfatase deficiency.";
RL   Hum. Mutat. 23:576-581(2004).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-158 AND ASN-350.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS), AND OLIGOMERIZATION.
RX   PubMed=9521684; DOI=10.1021/bi9714924;
RA   Lukatela G., Krauss N., Theis K., Selmer T., Gieselmann V.,
RA   von Figura K., Saenger W.;
RT   "Crystal structure of human arylsulfatase A: the aldehyde function and
RT   the metal ion at the active site suggest a novel mechanism for sulfate
RT   ester hydrolysis.";
RL   Biochemistry 37:3654-3664(1998).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS), AND MUTAGENESIS OF CYS-69.
RX   PubMed=11124905; DOI=10.1006/jmbi.2000.4297;
RA   von Buelow R., Schmidt B., Dierks T., von Figura K., Uson I.;
RT   "Crystal structure of an enzyme-substrate complex provides insight
RT   into the interaction between human arylsulfatase A and its substrates
RT   during catalysis.";
RL   J. Mol. Biol. 305:269-277(2001).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 19-507, SUBUNIT,
RP   GLYCOSYLATION AT ASN-158 AND ASN-184, ACTIVE SITE, ENZYME REGULATION,
RP   CALCIUM-BINDING, AND COFACTOR.
RX   PubMed=12888274; DOI=10.1016/S0162-0134(03)00176-4;
RA   Chruszcz M., Laidler P., Monkiewicz M., Ortlund E., Lebioda L.,
RA   Lewinski K.;
RT   "Crystal structure of a covalent intermediate of endogenous human
RT   arylsulfatase A.";
RL   J. Inorg. Biochem. 96:386-392(2003).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 69-73 IN COMPLEX WITH SUMF1.
RX   PubMed=16368756; DOI=10.1073/pnas.0507592102;
RA   Roeser D., Preusser-Kunze A., Schmidt B., Gasow K., Wittmann J.G.,
RA   Dierks T., von Figura K., Rudolph M.G.;
RT   "A general binding mechanism for all human sulfatases by the
RT   formylglycine-generating enzyme.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:81-86(2006).
RN   [17]
RP   REVIEW ON MLD VARIANTS.
RX   PubMed=7866401; DOI=10.1002/humu.1380040402;
RA   Gieselmann V., Zlotogora J., Harris A., Wenger D.A., Morris C.P.;
RT   "Molecular genetics of metachromatic leukodystrophy.";
RL   Hum. Mutat. 4:233-242(1994).
RN   [18]
RP   VARIANT SER-350, AND ASSOCIATION WITH ARYLSULFATASE A
RP   PSEUDODEFICIENCY.
RX   PubMed=2574462; DOI=10.1073/pnas.86.23.9436;
RA   Gieselmann V., Polten A., Kreysing J., von Figura K.;
RT   "Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal
RT   and N-glycosylation site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9436-9440(1989).
RN   [19]
RP   VARIANT MLD ASP-99.
RX   PubMed=1673291;
RA   Kondo R., Wakamatsu N., Yoshino H., Fukuhara N., Miyatake T.,
RA   Tsuji S.;
RT   "Identification of a mutation in the arylsulfatase A gene of a patient
RT   with adult-type metachromatic leukodystrophy.";
RL   Am. J. Hum. Genet. 48:971-978(1991).
RN   [20]
RP   VARIANT MLD PHE-96.
RX   PubMed=1678251;
RA   Gieselmann V., Fluharty A.L., Toennesen T., von Figura K.;
RT   "Mutations in the arylsulfatase A pseudodeficiency allele causing
RT   metachromatic leukodystrophy.";
RL   Am. J. Hum. Genet. 49:407-413(1991).
RN   [21]
RP   VARIANT MLD LEU-426, AND VARIANTS CYS-193 AND SER-391.
RX   PubMed=1670590; DOI=10.1056/NEJM199101033240104;
RA   Polten A., Fluharty A.L., Fluharty C.B., Kappler J., von Figura K.,
RA   Gieselmann V.;
RT   "Molecular basis of different forms of metachromatic leukodystrophy.";
RL   N. Engl. J. Med. 324:18-22(1991).
RN   [22]
RP   VARIANT MLD GLN-84.
RX   PubMed=1353340; DOI=10.1002/ana.410310305;
RA   Kappler J., von Figura K., Gieselmann V.;
RT   "Late-onset metachromatic leukodystrophy: molecular pathology in two
RT   siblings.";
RL   Ann. Neurol. 31:256-261(1992).
RN   [23]
RP   VARIANT MLD SER-309.
RX   PubMed=8101038;
RA   Kreysing J., Bohne W., Bosenberg C., Marchesini S., Turpin J.C.,
RA   Baumann N., von Figura K., Gieselmann V.;
RT   "High residual arylsulfatase A (ARSA) activity in a patient with late-
RT   infantile metachromatic leukodystrophy.";
RL   Am. J. Hum. Genet. 53:339-346(1993).
RN   [24]
RP   VARIANT MLD ARG-245.
RX   PubMed=8101083; DOI=10.1089/dna.1993.12.493;
RA   Hasegawa Y., Kawame H., Eto Y.;
RT   "Mutations in the arylsulfatase A gene of Japanese patients with
RT   metachromatic leukodystrophy.";
RL   DNA Cell Biol. 12:493-498(1993).
RN   [25]
RP   VARIANT MLD LEU-426.
RX   PubMed=8095918; DOI=10.1007/BF00230227;
RA   Barth M.L., Fensom A., Harris A.;
RT   "Prevalence of common mutations in the arylsulphatase A gene in
RT   metachromatic leukodystrophy patients diagnosed in Britain.";
RL   Hum. Genet. 91:73-77(1993).
RN   [26]
RP   VARIANT MLD SER-122.
RX   PubMed=7902317; DOI=10.1007/BF00216449;
RA   Honke K., Kobayashi T., Fujii T., Gasa S., Xu M., Takamaru Y.,
RA   Kondo R., Tsuji S., Makita A.;
RT   "An adult-type metachromatic leukodystrophy caused by substitution of
RT   serine for glycine-122 in arylsulfatase A.";
RL   Hum. Genet. 92:451-456(1993).
RN   [27]
RP   VARIANTS MLD VAL-212; VAL-224 AND TYR-295.
RX   PubMed=7906588; DOI=10.1093/hmg/2.12.2117;
RA   Barth M.L., Fensom A., Harris A.;
RT   "Missense mutations in the arylsulphatase A genes of metachromatic
RT   leukodystrophy patients.";
RL   Hum. Mol. Genet. 2:2117-2121(1993).
RN   [28]
RP   VARIANT MLD MET-274.
RX   PubMed=8104633; DOI=10.1002/humu.1380020405;
RA   Harvey J.S., Nelson P.V., Carey W.F., Robertson E.F., Morris C.P.;
RT   "An arylsulfatase A (ARSA) missense mutation (T274M) causing late-
RT   infantile metachromatic leukodystrophy.";
RL   Hum. Mutat. 2:261-267(1993).
RN   [29]
RP   VARIANT MLD ILE-409.
RX   PubMed=7909527; DOI=10.1007/BF00201666;
RA   Hasegawa Y., Kawame H., Ida H., Ohashi T., Eto Y.;
RT   "Single exon mutation in arylsulfatase A gene has two effects: loss of
RT   enzyme activity and aberrant splicing.";
RL   Hum. Genet. 93:415-420(1994).
RN   [30]
RP   VARIANTS MLD ASP-86; LEU-96; HIS-190; MET-274 AND TRP-370, AND
RP   CHARACTERIZATION OF VARIANTS MLD ASP-86; LEU-96; HIS-190; MET-274 AND
RP   TRP-370.
RX   PubMed=7825603;
RA   Heinisch U., Zlotogora J., Kafert S., Gieselmann V.;
RT   "Multiple mutations are responsible for the high frequency of
RT   metachromatic leukodystrophy in a small geographic area.";
RL   Am. J. Hum. Genet. 56:51-57(1995).
RN   [31]
RP   VARIANT MLD LEU-136.
RX   PubMed=7860068; DOI=10.1007/BF00209402;
RA   Kafert S., Heinisch U., Zlotogora J., Gieselmann V.;
RT   "A missense mutation P136L in the arylsulfatase A gene causes
RT   instability and loss of activity of the mutant enzyme.";
RL   Hum. Genet. 95:201-204(1995).
RN   [32]
RP   VARIANTS MLD LEU-82; TYR-172; CYS-201; GLN-311; VAL-335 AND TRP-390.
RX   PubMed=7581401; DOI=10.1002/humu.1380060210;
RA   Barth M.L., Fensom A., Harris A.;
RT   "Identification of seven novel mutations associated with metachromatic
RT   leukodystrophy.";
RL   Hum. Mutat. 6:170-176(1995).
RN   [33]
RP   VARIANTS MLD HIS-153 AND VAL-308, AND CHARACTERIZATION OF VARIANTS MLD
RP   HIS-153 AND VAL-308.
RX   PubMed=8891236; DOI=10.1016/0387-7604(96)00041-1;
RA   Tsuda T., Hasegawa Y., Eto Y.;
RT   "Two novel mutations in a Japanese patient with the late-infantile
RT   form of metachromatic leukodystrophy.";
RL   Brain Dev. 18:400-403(1996).
RN   [34]
RP   CHARACTERIZATION OF VARIANTS MET-274 AND VAL-335.
RX   PubMed=8723680;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:4<311::AID-HUMU4>3.0.CO;2-B;
RA   Hess B., Kafert S., Heinisch U., Wenger D.A., Zlotogora J.,
RA   Gieselmann V.;
RT   "Characterization of two arylsulfatase A missense mutations D335V and
RT   T274M causing late infantile metachromatic leukodystrophy.";
RL   Hum. Mutat. 7:311-317(1996).
RN   [35]
RP   VARIANT MLD PRO-428.
RX   PubMed=9272717;
RA   Regis S., Filocamo M., Stroppiano M., Corsolini F., Gatti R.;
RT   "A T > C transition causing a Leu > Pro substitution in a conserved
RT   region of the arylsulfatase A gene in a late infantile metachromatic
RT   leukodystrophy patient.";
RL   Clin. Genet. 52:65-67(1997).
RN   [36]
RP   VARIANTS MLD ASN-95; ARG-119; TYR-152; HIS-244; TYR-250; THR-314;
RP   ASN-367 AND CYS-384, AND VARIANT HIS-496.
RX   PubMed=9090526;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:3<234::AID-HUMU4>3.0.CO;2-7;
RA   Draghia R., Letourneur F., Drugan C., Manicom J., Blanchot C.,
RA   Kahn A., Poenaru L., Caillaud C.;
RT   "Metachromatic leukodystrophy: identification of the first deletion in
RT   exon 1 and of nine novel point mutations in the arylsulfatase A
RT   gene.";
RL   Hum. Mutat. 9:234-242(1997).
RN   [37]
RP   VARIANT MLD 406-SER--THR-408 DEL.
RX   PubMed=9490297; DOI=10.1007/s004390050652;
RA   Regis S., Filocamo M., Stroppiano M., Corsolini F., Caroli F.,
RA   Gatti R.;
RT   "A 9-bp deletion (2320del9) on the background of the arylsulfatase A
RT   pseudodeficiency allele in a metachromatic leukodystrophy patient and
RT   in a patient with nonprogressive neurological symptoms.";
RL   Hum. Genet. 102:50-53(1998).
RN   [38]
RP   VARIANTS MLD PRO-135 AND SER-179.
RX   PubMed=9600244; DOI=10.1007/s004390050721;
RA   Gomez-Lira M., Perusi C., Mottes M., Pignatti P.F., Manfredi M.,
RA   Rizzuto N., Salviati A.;
RT   "Molecular genetic characterization of two metachromatic
RT   leukodystrophy patients who carry the T799G mutation and show
RT   different phenotypes; description of a novel null-type mutation.";
RL   Hum. Genet. 102:459-463(1998).
RN   [39]
RP   ERRATUM.
RA   Gomez-Lira M., Perusi C., Mottes M., Pignatti P.F., Manfredi M.,
RA   Rizzuto N., Salviati A.;
RL   Hum. Genet. 102:602-602(1998).
RN   [40]
RP   VARIANT HIS-496.
RX   PubMed=9744473;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:4<238::AID-HUMU3>3.3.CO;2-N;
RA   Ricketts M.H., Poretz R.D., Manowitz P.;
RT   "The R496H mutation of arylsulfatase A does not cause metachromatic
RT   leukodystrophy.";
RL   Hum. Mutat. 12:238-239(1998).
RN   [41]
RP   VARIANTS MLD GLN-390 AND TYR-397.
RX   PubMed=9452102;
RA   Coulter-Mackie M.B., Gagnier L.;
RT   "Two novel mutations in the arylsulfatase A gene associated with
RT   juvenile (R390Q) and adult onset (H397Y) metachromatic
RT   leukodystrophy.";
RL   Hum. Mutat. Suppl. 1:S254-S256(1998).
RN   [42]
RP   VARIANT MLD SER-298, AND CHARACTERIZATION OF VARIANT MLD SER-298.
RX   PubMed=9819708; DOI=10.1023/A:1005405418215;
RA   Kurosawa K., Ida H., Eto Y.;
RT   "Prevalence of arylsulphatase A mutations in 11 Japanese patients with
RT   metachromatic leukodystrophy: identification of two novel mutations.";
RL   J. Inherit. Metab. Dis. 21:781-782(1998).
RN   [43]
RP   VARIANTS PRO-76; CYS-193; SER-391 AND VAL-464.
RX   PubMed=9888390;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:1<61::AID-HUMU7>3.0.CO;2-H;
RA   Berger J., Gmach M., Mayr U., Molzer B., Bernheimer H.;
RT   "Coincidence of two novel arylsulfatase A alleles and mutation
RT   459+1G>A within a family with metachromatic leukodystrophy: molecular
RT   basis of phenotypic heterogeneity.";
RL   Hum. Mutat. 13:61-68(1999).
RN   [44]
RP   VARIANTS MLD PHE-300 AND THR-425.
RX   PubMed=10220151;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:4<337::AID-HUMU14>3.0.CO;2-9;
RA   Marcao A., Amaral O., Pinto E., Pinto R., Sa Miranda M.C.;
RT   "Metachromatic leucodystrophy in Portugal-finding of four new
RT   molecular lesions: C300F, P425T, g.1190-1191insC, and g.2408delC.";
RL   Hum. Mutat. 13:337-338(1999).
RN   [45]
RP   VARIANTS MLD SER-32; PRO-68; TRP-84; ALA-94; VAL-99; SER-136; VAL-212;
RP   TYR-227; HIS-255; HIS-288; ASP-308; ILE-327 AND LEU-377, AND VARIANTS
RP   CYS-193; SER-350 AND SER-391.
RX   PubMed=10477432;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:3<240::AID-HUMU7>3.0.CO;2-L;
RA   Gort L., Coll M.J., Chabas A.;
RT   "Identification of 12 novel mutations and two new polymorphisms in the
RT   arylsulfatase A gene: haplotype and genotype-phenotype correlation
RT   studies in Spanish metachromatic leukodystrophy patients.";
RL   Hum. Mutat. 14:240-248(1999).
RN   [46]
RP   VARIANTS MLD SER-179 AND TYR-281.
RX   PubMed=10533072;
RX   DOI=10.1002/(SICI)1098-1004(199911)14:5<447::AID-HUMU12>3.0.CO;2-1;
RA   Halsall D.J., Halligan E.P., Elsey T.S., Cox T.M.;
RT   "Metachromatic leucodystrophy: a newly identified mutation in
RT   arylsulphatase A, D281Y, found as a compound heterozygote with I179L
RT   in an adult onset case.";
RL   Hum. Mutat. 14:447-447(1999).
RN   [47]
RP   VARIANTS MLD LEU-148; THR-191; VAL-335; TYR-397 AND LEU-426.
RX   PubMed=10381328; DOI=10.1006/mgme.1999.2865;
RA   Qu Y., Shapira E., Desnick R.J.;
RT   "Metachromatic leukodystrophy: subtype genotype/phenotype correlations
RT   and identification of novel missense mutations (P148L and P191T)
RT   causing the juvenile-onset disease.";
RL   Mol. Genet. Metab. 67:206-212(1999).
RN   [48]
RP   VARIANTS MLD ASP-86; CYS-201; HIS-255 AND ASP-312, AND
RP   CHARACTERIZATION OF VARIANTS MLD ASP-86; CYS-201; HIS-255 AND ASP-312.
RX   PubMed=10751093;
RX   DOI=10.1002/(SICI)1096-8628(20000306)91:1<68::AID-AJMG13>3.0.CO;2-G;
RA   Hermann S., Schestag F., Polten A., Kafert S., Penzien J.,
RA   Zlotogora J., Baumann N., Gieselmann V.;
RT   "Characterization of four arylsulfatase A missense mutations G86D,
RT   Y201C, D255H, and E312D causing metachromatic leukodystrophy.";
RL   Am. J. Med. Genet. 91:68-73(2000).
RN   [49]
RP   VARIANT MLD PRO-286, AND VARIANT SER-391.
RX   PubMed=11061266; DOI=10.1212/WNL.55.7.1036;
RA   Felice K.J., Gomez Lira M., Natowicz M., Grunnet M.L., Tsongalis G.J.,
RA   Sima A.A.F., Kaplan R.F.;
RT   "Adult-onset MLD: a gene mutation with isolated polyneuropathy.";
RL   Neurology 55:1036-1039(2000).
RN   [50]
RP   VARIANT MLD GLY-143, AND CHARACTERIZATION OF VARIANT MLD GLY-143.
RX   PubMed=11020646; DOI=10.1016/S0887-8994(00)00164-8;
RA   Arbour L.T., Silver K., Hechtman P., Treacy E.P., Coulter-Mackie M.B.;
RT   "Variable onset of metachromatic leukodystrophy in a Vietnamese
RT   family.";
RL   Pediatr. Neurol. 23:173-176(2000).
RN   [51]
RP   VARIANT MLD ILE-408, AND VARIANTS CYS-193 AND SER-391.
RX   PubMed=11456299; DOI=10.1002/ana.1076;
RA   Comabella M., Waye J.S., Raguer N., Eng B., Dominguez C., Navarro C.,
RA   Borras C., Krivit W., Montalban X.;
RT   "Late-onset metachromatic leukodystrophy clinically presenting as
RT   isolated peripheral neuropathy: compound heterozygosity for the
RT   IVS2+1G-->A mutation and a newly identified missense mutation
RT   (Thr408Ile) in a Spanish family.";
RL   Ann. Neurol. 50:108-112(2001).
RN   [52]
RP   VARIANT MLD LYS-253, AND VARIANTS SER-350; SER-391 AND LEU-426.
RX   PubMed=11941485; DOI=10.1007/s00439-002-0701-y;
RA   Regis S., Corsolini F., Stroppiano M., Cusano R., Filocamo M.;
RT   "Contribution of arylsulfatase A mutations located on the same allele
RT   to enzyme activity reduction and metachromatic leukodystrophy
RT   severity.";
RL   Hum. Genet. 110:351-355(2002).
RN   [53]
RP   CHARACTERIZATION OF VARIANTS MLD PHE-300 AND THR-425.
RX   PubMed=12503099; DOI=10.1002/ajmg.a.10822;
RA   Marcao A., Simonis H., Schestag F., Sa Miranda M.C., Gieselmann V.;
RT   "Biochemical characterization of two (C300F, P425T) arylsulfatase A
RT   missense mutations.";
RL   Am. J. Med. Genet. A 116:238-242(2003).
RN   [54]
RP   CHARACTERIZATION OF VARIANTS MLD PHE-300 AND THR-425.
RX   PubMed=12788103; DOI=10.1016/S0006-291X(03)00969-0;
RA   Marcao A., Azevedo J.E., Gieselmann V., Sa Miranda M.C.;
RT   "Oligomerization capacity of two arylsulfatase A mutants: C300F and
RT   P425T.";
RL   Biochem. Biophys. Res. Commun. 306:293-297(2003).
RN   [55]
RP   VARIANTS MLD LEU-155; GLN-181; VAL-212; HIS-306; SER-325; VAL-335;
RP   LEU-426 AND SER-429.
RX   PubMed=14517960; DOI=10.1002/humu.9190;
RA   Eng B., Nakamura L.N., O'Reilly N., Schokman N., Nowaczyk M.M.J.,
RA   Krivit W., Waye J.S.;
RT   "Identification of nine novel arylsulfatase A (ARSA) gene mutations in
RT   patients with metachromatic leukodystrophy (MLD).";
RL   Hum. Mutat. 22:418-419(2003).
RN   [56]
RP   VARIANTS MLD SER-136; SER-247; GLU-381 LEU-426 AND GLY-469.
RX   PubMed=14680985; DOI=10.1016/j.ymgme.2003.08.004;
RA   Olkhovich N.V., Takamura N., Pichkur N.A., Gorovenko N.G., Aoyagi K.,
RA   Yamashita S.;
RT   "Novel mutations in arylsulfatase A gene in three Ukrainian families
RT   with metachromatic leukodystrophy.";
RL   Mol. Genet. Metab. 80:360-363(2003).
RN   [57]
RP   VARIANTS MLD ASN-29; ARG-156; SER-179; SER-293; TYR-294; SER-309 AND
RP   LEU-426, VARIANTS CYS-193 AND SER-391, AND CHARACTERIZATION OF
RP   VARIANTS MLD ASN-29; ARG-156; SER-293 AND TYR-294.
RX   PubMed=15326627; DOI=10.1002/ajmg.a.30118;
RA   Berna L., Gieselmann V., Poupetova H., Hrebicek M., Elleder M.,
RA   Ledvinova J.;
RT   "Novel mutations associated with metachromatic leukodystrophy:
RT   phenotype and expression studies in nine Czech and Slovak patients.";
RL   Am. J. Med. Genet. A 129:277-281(2004).
RN   [58]
RP   VARIANTS MLD ASP-293 AND GLY-489, AND VARIANT SER-350.
RX   PubMed=15026521; DOI=10.1136/jnnp.2003.017400;
RA   Gallo S., Randi D., Bertelli M., Salviati A., Pandolfo M.;
RT   "Late onset MLD with normal nerve conduction associated with two novel
RT   missense mutations in the ASA gene.";
RL   J. Neurol. Neurosurg. Psych. 75:655-657(2004).
RN   [59]
RP   VARIANT MLD VAL-219, AND CHARACTERIZATION OF VARIANT MLD VAL-219.
RX   PubMed=15710861; DOI=10.1001/archneur.62.2.309;
RA   Marcao A.M., Wiest R., Schindler K., Wiesmann U., Weis J., Schroth G.,
RA   Miranda M.C.S., Sturzenegger M., Gieselmann V.;
RT   "Adult onset metachromatic leukodystrophy without electroclinical
RT   peripheral nervous system involvement: a new mutation in the ARSA
RT   gene.";
RL   Arch. Neurol. 62:309-313(2005).
RN   [60]
RP   VARIANTS MLD ASP-18; HIS-30; GLN-84; PRO-137 DEL; ASP-154; SER-179;
RP   CYS-201; PRO-212; HIS-217; LYS-253; SER-282; ASN-302; TRP-370;
RP   ASN-376; TRP-390 AND PRO-428, AND CHARACTERIZATION OF VARIANTS MLD
RP   ASP-18; HIS-30; PRO-212; HIS-217; SER-282; ASN-302; TRP-370 AND
RP   ASN-376.
RX   PubMed=18693274; DOI=10.1002/humu.20851;
RA   Grossi S., Regis S., Rosano C., Corsolini F., Uziel G., Sessa M.,
RA   Di Rocco M., Parenti G., Deodato F., Leuzzi V., Biancheri R.,
RA   Filocamo M.;
RT   "Molecular analysis of ARSA and PSAP genes in twenty-one Italian
RT   patients with metachromatic leukodystrophy: identification and
RT   functional characterization of 11 novel ARSA alleles.";
RL   Hum. Mutat. 29:E220-E230(2008).
RN   [61]
RP   VARIANTS MLD PRO-52; ASP-138; PRO-212; MET-304; LYS-307 AND GLY-406,
RP   AND CHARACTERIZATION OF VARIANTS MLD PRO-52; ASP-138; PRO-212;
RP   MET-304; LYS-307 AND GLY-406.
RX   PubMed=19606494; DOI=10.1002/humu.21093;
RA   Cesani M., Capotondo A., Plati T., Sergi L.S., Fumagalli F.,
RA   Roncarolo M.G., Naldini L., Comi G., Sessa M., Biffi A.;
RT   "Characterization of new arylsulfatase A gene mutations reinforces
RT   genotype-phenotype correlation in metachromatic leukodystrophy.";
RL   Hum. Mutat. 30:E936-E945(2009).
RN   [62]
RP   VARIANTS MLD SER-179; SER-247; CYS-288; VAL-335; LYS-382; GLN-390;
RP   TRP-390; TYR-397 AND LEU-426.
RX   PubMed=20339381; DOI=10.1038/jhg.2010.25;
RA   Lugowska A., Ploski R., Wlodarski P., Tylki-Szymanska A.;
RT   "Molecular bases of metachromatic leukodystrophy in Polish patients.";
RL   J. Hum. Genet. 55:394-396(2010).
RN   [63]
RP   VARIANTS MLD ASP-99 AND ILE-409.
RX   PubMed=21265945; DOI=10.1111/j.1440-1819.2010.02169.x;
RA   Hayashi T., Nakamura M., Ichiba M., Matsuda M., Kato M., Shiokawa N.,
RA   Shimo H., Tomiyasu A., Mori S., Tomiyasu Y., Ishizuka T., Inamori Y.,
RA   Okamoto Y., Umehara F., Arimura K., Nakabeppu Y., Sano A.;
RT   "Adult-type metachromatic leukodystrophy with compound heterozygous
RT   ARSA mutations: a case report and phenotypic comparison with a
RT   previously reported case.";
RL   Psychiatry Clin. Neurosci. 65:105-108(2011).
CC   -!- FUNCTION: Hydrolyzes cerebroside sulfate.
CC   -!- CATALYTIC ACTIVITY: A cerebroside 3-sulfate + H(2)O = a
CC       cerebroside + sulfate.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:12888274};
CC       Note=Binds 1 Ca(2+) ion per subunit.
CC       {ECO:0000269|PubMed:12888274};
CC   -!- ENZYME REGULATION: Inhibited by phosphate. The phosphate forms a
CC       covalent bond with the active site 3-oxoalanine.
CC       {ECO:0000269|PubMed:12888274}.
CC   -!- SUBUNIT: Homodimer at neutral pH and homooctamer at acidic pH.
CC       Exists both as a single chain of 58 kDa (component A) or as a
CC       chain of 50 kDa (component B) linked by disulfide bond(s) to a 7
CC       kDa chain (component C). Interacts with SUMF1.
CC       {ECO:0000269|PubMed:12888274, ECO:0000269|PubMed:1352993,
CC       ECO:0000269|PubMed:16368756}.
CC   -!- INTERACTION:
CC       Q15645:TRIP13; NbExp=4; IntAct=EBI-2117357, EBI-358993;
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P15289-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15289-2; Sequence=VSP_046190;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity. This post-translational modification is
CC       severely defective in multiple sulfatase deficiency (MSD).
CC       {ECO:0000269|PubMed:7628016}.
CC   -!- DISEASE: Leukodystrophy metachromatic (MLD) [MIM:250100]: A
CC       leukodystrophy due to a lysosomal storage defect. Characterized by
CC       intralysosomal storage of cerebroside-3-sulfate in neural and non-
CC       neural tissues, with a diffuse loss of myelin in the central
CC       nervous system. Progressive demyelination causes a variety of
CC       neurological symptoms, including gait disturbances, ataxias,
CC       optical atrophy, dementia, seizures, and spastic tetraparesis.
CC       Three forms of the disease can be distinguished according to the
CC       age at onset: late-infantile, juvenile and adult.
CC       {ECO:0000269|PubMed:10220151, ECO:0000269|PubMed:10381328,
CC       ECO:0000269|PubMed:10477432, ECO:0000269|PubMed:10533072,
CC       ECO:0000269|PubMed:10751093, ECO:0000269|PubMed:11020646,
CC       ECO:0000269|PubMed:11061266, ECO:0000269|PubMed:11456299,
CC       ECO:0000269|PubMed:11941485, ECO:0000269|PubMed:1353340,
CC       ECO:0000269|PubMed:14517960, ECO:0000269|PubMed:14680985,
CC       ECO:0000269|PubMed:15026521, ECO:0000269|PubMed:15326627,
CC       ECO:0000269|PubMed:15710861, ECO:0000269|PubMed:1670590,
CC       ECO:0000269|PubMed:1673291, ECO:0000269|PubMed:1678251,
CC       ECO:0000269|PubMed:18693274, ECO:0000269|PubMed:19606494,
CC       ECO:0000269|PubMed:20339381, ECO:0000269|PubMed:21265945,
CC       ECO:0000269|PubMed:7581401, ECO:0000269|PubMed:7825603,
CC       ECO:0000269|PubMed:7860068, ECO:0000269|PubMed:7902317,
CC       ECO:0000269|PubMed:7906588, ECO:0000269|PubMed:7909527,
CC       ECO:0000269|PubMed:8095918, ECO:0000269|PubMed:8101038,
CC       ECO:0000269|PubMed:8101083, ECO:0000269|PubMed:8104633,
CC       ECO:0000269|PubMed:8891236, ECO:0000269|PubMed:9090526,
CC       ECO:0000269|PubMed:9272717, ECO:0000269|PubMed:9452102,
CC       ECO:0000269|PubMed:9490297, ECO:0000269|PubMed:9600244,
CC       ECO:0000269|PubMed:9819708}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Multiple sulfatase deficiency (MSD) [MIM:272200]: A
CC       clinically and biochemically heterogeneous disorder caused by the
CC       simultaneous impairment of all sulfatases, due to defective post-
CC       translational modification and activation. It combines features of
CC       individual sulfatase deficiencies such as metachromatic
CC       leukodystrophy, mucopolysaccharidosis, chondrodysplasia punctata,
CC       hydrocephalus, ichthyosis, neurologic deterioration and
CC       developmental delay. {ECO:0000269|PubMed:15146462}. Note=The
CC       protein represented in this entry is involved in disease
CC       pathogenesis. Arylsulfatase A activity is impaired in multiple
CC       sulfatase deficiency due to mutations in SUMF1 (PubMed:15146462).
CC       SUMF1 mutations result in defective post-translational
CC       modification of ARSA at residue Cys-69 that is not converted to 3-
CC       oxoalanine (PubMed:7628016). {ECO:0000269|PubMed:15146462,
CC       ECO:0000269|PubMed:7628016}.
CC   -!- MISCELLANEOUS: The metal cofactor was first identified as
CC       magnesium ion, based on the structure of the recombinant protein,
CC       but when purified from human placenta, the protein contains 1
CC       calcium ion per subunit.
CC   -!- SIMILARITY: Belongs to the sulfatase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB03341.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAH11167.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/arsa/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Arylsulfatase A entry;
CC       URL="https://en.wikipedia.org/wiki/Arylsulfatase_A";
CC   -!- WEB RESOURCE: Name=Arylsulfatase A (ARSA); Note=Leiden Open
CC       Variation Database (LOVD);
CC       URL="http://grenada.lumc.nl/LOVD2/mendelian_genes/home.php?select_db=ARSA";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52151; CAA36399.1; -; mRNA.
DR   EMBL; X52150; CAA36398.1; -; Genomic_DNA.
DR   EMBL; AB448736; BAH11167.1; ALT_INIT; mRNA.
DR   EMBL; CR456383; CAG30269.1; -; mRNA.
DR   EMBL; AK098659; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK315011; BAG37503.1; -; mRNA.
DR   EMBL; AY271820; AAP03431.1; -; Genomic_DNA.
DR   EMBL; U62317; AAB03341.1; ALT_INIT; Genomic_DNA.
DR   EMBL; BC014210; AAH14210.2; -; mRNA.
DR   CCDS; CCDS46736.1; -. [P15289-2]
DR   PIR; S11031; KJHUAA.
DR   RefSeq; NP_000478.3; NM_000487.5.
DR   RefSeq; NP_001078894.2; NM_001085425.2.
DR   RefSeq; NP_001078895.2; NM_001085426.2.
DR   RefSeq; NP_001078896.2; NM_001085427.2.
DR   RefSeq; NP_001078897.1; NM_001085428.2. [P15289-2]
DR   RefSeq; XP_011528992.1; XM_011530690.1. [P15289-2]
DR   UniGene; Hs.731715; -.
DR   UniGene; Hs.88251; -.
DR   PDB; 1AUK; X-ray; 2.10 A; A=19-507.
DR   PDB; 1E1Z; X-ray; 2.40 A; P=19-507.
DR   PDB; 1E2S; X-ray; 2.35 A; P=19-507.
DR   PDB; 1E33; X-ray; 2.50 A; P=19-507.
DR   PDB; 1E3C; X-ray; 2.65 A; P=19-507.
DR   PDB; 1N2K; X-ray; 2.75 A; A=19-507.
DR   PDB; 1N2L; X-ray; 3.20 A; A=19-507.
DR   PDB; 2AIJ; X-ray; 1.55 A; P=69-73.
DR   PDB; 2AIK; X-ray; 1.73 A; P=68-74.
DR   PDB; 2HI8; X-ray; 1.64 A; P=69-73.
DR   PDBsum; 1AUK; -.
DR   PDBsum; 1E1Z; -.
DR   PDBsum; 1E2S; -.
DR   PDBsum; 1E33; -.
DR   PDBsum; 1E3C; -.
DR   PDBsum; 1N2K; -.
DR   PDBsum; 1N2L; -.
DR   PDBsum; 2AIJ; -.
DR   PDBsum; 2AIK; -.
DR   PDBsum; 2HI8; -.
DR   ProteinModelPortal; P15289; -.
DR   SMR; P15289; 19-504.
DR   BioGrid; 106903; 21.
DR   IntAct; P15289; 6.
DR   STRING; 9606.ENSP00000216124; -.
DR   ChEMBL; CHEMBL2193; -.
DR   DrugBank; DB01141; Micafungin.
DR   DrugBank; DB04786; Suramin.
DR   SwissLipids; SLP:000000913; -.
DR   UniCarbKB; P15289; -.
DR   BioMuta; ARSA; -.
DR   MaxQB; P15289; -.
DR   PaxDb; P15289; -.
DR   PRIDE; P15289; -.
DR   DNASU; 410; -.
DR   Ensembl; ENST00000453344; ENSP00000412542; ENSG00000100299. [P15289-2]
DR   GeneID; 410; -.
DR   KEGG; hsa:410; -.
DR   UCSC; uc003bmz.5; human. [P15289-1]
DR   CTD; 410; -.
DR   GeneCards; ARSA; -.
DR   GeneReviews; ARSA; -.
DR   HGNC; HGNC:713; ARSA.
DR   HPA; CAB025183; -.
DR   HPA; HPA005554; -.
DR   MalaCards; ARSA; -.
DR   MIM; 250100; phenotype.
DR   MIM; 272200; phenotype.
DR   MIM; 607574; gene.
DR   neXtProt; NX_P15289; -.
DR   Orphanet; 309271; Metachromatic leukodystrophy, adult form.
DR   Orphanet; 309263; Metachromatic leukodystrophy, juvenile form.
DR   Orphanet; 309256; Metachromatic leukodystrophy, late infantile form.
DR   Orphanet; 751; Pseudoarylsulfatase A deficiency.
DR   PharmGKB; PA25005; -.
DR   eggNOG; KOG3867; Eukaryota.
DR   eggNOG; COG3119; LUCA.
DR   GeneTree; ENSGT00760000119062; -.
DR   HOGENOM; HOG000135352; -.
DR   HOVERGEN; HBG004283; -.
DR   InParanoid; P15289; -.
DR   KO; K01134; -.
DR   OrthoDB; EOG7QZG9J; -.
DR   PhylomeDB; P15289; -.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   Reactome; R-HSA-1663150; The activation of arylsulfatases.
DR   ChiTaRS; ARSA; human.
DR   EvolutionaryTrace; P15289; -.
DR   GeneWiki; Arylsulfatase_A; -.
DR   GenomeRNAi; 410; -.
DR   NextBio; 1725; -.
DR   PMAP-CutDB; P15289; -.
DR   PRO; PR:P15289; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; P15289; -.
DR   CleanEx; HS_ARSA; -.
DR   ExpressionAtlas; P15289; baseline and differential.
DR   Genevisible; P15289; HS.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; TAS:ProtInc.
DR   GO; GO:0004065; F:arylsulfatase activity; TAS:ProtInc.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0004098; F:cerebroside-sulfatase activity; TAS:Reactome.
DR   GO; GO:0008484; F:sulfuric ester hydrolase activity; IDA:MGI.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006665; P:sphingolipid metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   InterPro; IPR000917; Sulfatase_N.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; SSF53649; 1.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hydrolase; Ichthyosis; Leukodystrophy; Lysosome;
KW   Metachromatic leukodystrophy; Metal-binding; Polymorphism;
KW   Reference proteome; Signal.
FT   SIGNAL        1     18       {ECO:0000269|PubMed:1352993}.
FT   CHAIN        19    507       Arylsulfatase A.
FT                                /FTId=PRO_0000033417.
FT   CHAIN        19    444       Arylsulfatase A component B.
FT                                /FTId=PRO_0000033418.
FT   CHAIN       448    507       Arylsulfatase A component C.
FT                                /FTId=PRO_0000033419.
FT   ACT_SITE    125    125       {ECO:0000269|PubMed:12888274}.
FT   METAL        29     29       Calcium.
FT   METAL        30     30       Calcium.
FT   METAL        69     69       Calcium; via 3-oxoalanine.
FT   METAL       281    281       Calcium.
FT   METAL       282    282       Calcium.
FT   BINDING     123    123       Substrate.
FT   BINDING     150    150       Substrate.
FT   BINDING     229    229       Substrate.
FT   BINDING     302    302       Substrate.
FT   MOD_RES      69     69       3-oxoalanine (Cys).
FT                                {ECO:0000269|PubMed:7628016}.
FT   CARBOHYD    158    158       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12888274,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    184    184       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12888274}.
FT   CARBOHYD    350    350       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   DISULFID    156    172
FT   DISULFID    161    168
FT   DISULFID    300    414
FT   DISULFID    488    500
FT   DISULFID    489    502
FT   DISULFID    493    499
FT   VAR_SEQ       1     84       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046190.
FT   VARIANT      18     18       A -> D (in MLD; enzyme activity reduced
FT                                to 5% of wild-type enzyme;
FT                                dbSNP:rs199476339).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054164.
FT   VARIANT      29     29       D -> N (in MLD; infantile-onset; causes a
FT                                severe reduction of enzyme activity;
FT                                dbSNP:rs199476346).
FT                                {ECO:0000269|PubMed:15326627}.
FT                                /FTId=VAR_054165.
FT   VARIANT      30     30       D -> H (in MLD; enzyme activity reduced
FT                                to 2.4% of wild-type enzyme;
FT                                dbSNP:rs199476340).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054166.
FT   VARIANT      32     32       G -> S (in MLD; late-infantile form;
FT                                dbSNP:rs199476350).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054167.
FT   VARIANT      52     52       L -> P (in MLD; loss of enzymatic
FT                                activity; dbSNP:rs199476357).
FT                                {ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_067414.
FT   VARIANT      68     68       L -> P (in MLD; late-infantile form;
FT                                dbSNP:rs199476351).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054168.
FT   VARIANT      76     76       L -> P (in dbSNP:rs199476362).
FT                                {ECO:0000269|PubMed:9888390}.
FT                                /FTId=VAR_007243.
FT   VARIANT      82     82       P -> L (in MLD; late-infantile-onset;
FT                                dbSNP:rs6151411).
FT                                {ECO:0000269|PubMed:7581401,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_007244.
FT   VARIANT      84     84       R -> Q (in MLD; mild; dbSNP:rs74315458).
FT                                {ECO:0000269|PubMed:1353340,
FT                                ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_007245.
FT   VARIANT      84     84       R -> W (in MLD; juvenile form;
FT                                dbSNP:rs199476352).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054169.
FT   VARIANT      86     86       G -> D (in MLD; severe; no enzyme
FT                                residual activity; leads to a decreased
FT                                stability of the mutant enzyme; causes an
FT                                arrest of the mutant enzyme polypeptide
FT                                in a prelysosomal compartment;
FT                                dbSNP:rs74315460).
FT                                {ECO:0000269|PubMed:10751093,
FT                                ECO:0000269|PubMed:7825603}.
FT                                /FTId=VAR_007246.
FT   VARIANT      94     94       P -> A (in MLD; adult form;
FT                                dbSNP:rs199476353).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054170.
FT   VARIANT      95     95       S -> N (in MLD; dbSNP:rs199476363).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007247.
FT   VARIANT      96     96       S -> F (in MLD; severe;
FT                                dbSNP:rs74315456).
FT                                {ECO:0000269|PubMed:1678251}.
FT                                /FTId=VAR_007248.
FT   VARIANT      96     96       S -> L (in MLD; severe; no enzyme
FT                                residual activity; dbSNP:rs199476371).
FT                                {ECO:0000269|PubMed:7825603}.
FT                                /FTId=VAR_007249.
FT   VARIANT      99     99       G -> D (in MLD; adult type;
FT                                dbSNP:rs74315455).
FT                                {ECO:0000269|PubMed:1673291,
FT                                ECO:0000269|PubMed:21265945}.
FT                                /FTId=VAR_007250.
FT   VARIANT      99     99       G -> V (in MLD; late-infantile form;
FT                                dbSNP:rs74315455).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054171.
FT   VARIANT     119    119       G -> R (in MLD; juvenile-onset;
FT                                dbSNP:rs199476364).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007251.
FT   VARIANT     122    122       G -> S (in MLD; adult type;
FT                                dbSNP:rs74315461).
FT                                {ECO:0000269|PubMed:7902317}.
FT                                /FTId=VAR_007252.
FT   VARIANT     135    135       L -> P (in MLD; dbSNP:rs121434215).
FT                                {ECO:0000269|PubMed:9600244}.
FT                                /FTId=VAR_007253.
FT   VARIANT     136    136       P -> L (in MLD; severe late-infantile
FT                                type; loss of enzymatic activity;
FT                                dbSNP:rs74315462).
FT                                {ECO:0000269|PubMed:7860068}.
FT                                /FTId=VAR_007254.
FT   VARIANT     136    136       P -> S (in MLD; late-infantile form;
FT                                dbSNP:rs60504011).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:14680985}.
FT                                /FTId=VAR_054172.
FT   VARIANT     137    137       Missing (in MLD).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054173.
FT   VARIANT     138    138       H -> D (in MLD; significantly lower
FT                                activity than wild-type protein;
FT                                dbSNP:rs199476358).
FT                                {ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_067415.
FT   VARIANT     143    143       R -> G (in MLD; juvenile/adult-onset;
FT                                generates 5% as much activity as the
FT                                parallel normal control;
FT                                dbSNP:rs199476373).
FT                                {ECO:0000269|PubMed:11020646}.
FT                                /FTId=VAR_054174.
FT   VARIANT     148    148       P -> L (in MLD; juvenile-onset;
FT                                dbSNP:rs199476375).
FT                                {ECO:0000269|PubMed:10381328}.
FT                                /FTId=VAR_054175.
FT   VARIANT     152    152       D -> Y (in MLD; dbSNP:rs199476365).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007255.
FT   VARIANT     153    153       Q -> H (in MLD; late-infantile form; no
FT                                enzyme residual activity;
FT                                dbSNP:rs199476377).
FT                                {ECO:0000269|PubMed:8891236}.
FT                                /FTId=VAR_054176.
FT   VARIANT     154    154       G -> D (in MLD; dbSNP:rs74315463).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_007256.
FT   VARIANT     155    155       P -> L (in MLD; juvenile-onset;
FT                                dbSNP:rs74315464).
FT                                {ECO:0000269|PubMed:14517960}.
FT                                /FTId=VAR_054177.
FT   VARIANT     155    155       P -> R (in MLD; dbSNP:rs74315464).
FT                                /FTId=VAR_007257.
FT   VARIANT     156    156       C -> R (in MLD; adult type; enzyme
FT                                activity reduced to 50% of wild-type
FT                                enzyme; dbSNP:rs199476348).
FT                                {ECO:0000269|PubMed:15326627}.
FT                                /FTId=VAR_054178.
FT   VARIANT     167    167       P -> R (in MLD; dbSNP:rs74315465).
FT                                /FTId=VAR_007258.
FT   VARIANT     169    169       D -> N (in MLD; dbSNP:rs74315466).
FT                                /FTId=VAR_007259.
FT   VARIANT     172    172       C -> Y (in MLD; juvenile-onset;
FT                                dbSNP:rs199476381).
FT                                {ECO:0000269|PubMed:7581401}.
FT                                /FTId=VAR_007260.
FT   VARIANT     179    179       I -> S (in MLD; mild; dbSNP:rs74315457).
FT                                {ECO:0000269|PubMed:10533072,
FT                                ECO:0000269|PubMed:15326627,
FT                                ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:9600244}.
FT                                /FTId=VAR_007261.
FT   VARIANT     181    181       L -> Q (in MLD; infantile form;
FT                                dbSNP:rs199476378).
FT                                {ECO:0000269|PubMed:14517960}.
FT                                /FTId=VAR_054179.
FT   VARIANT     190    190       Q -> H (in MLD; no enzyme residual
FT                                activity; dbSNP:rs199476372).
FT                                {ECO:0000269|PubMed:7825603}.
FT                                /FTId=VAR_054180.
FT   VARIANT     191    191       P -> T (in MLD; juvenile-onset;
FT                                dbSNP:rs199476374).
FT                                {ECO:0000269|PubMed:10381328}.
FT                                /FTId=VAR_054181.
FT   VARIANT     193    193       W -> C (in dbSNP:rs6151415).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:11456299,
FT                                ECO:0000269|PubMed:15326627,
FT                                ECO:0000269|PubMed:1670590,
FT                                ECO:0000269|PubMed:9888390,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_007262.
FT   VARIANT     201    201       Y -> C (in MLD; juvenile-onset; results
FT                                in higly reduced enzyme activity and
FT                                stability; the mutant enzyme is kept in a
FT                                prelysosomal compartment;
FT                                dbSNP:rs199476345).
FT                                {ECO:0000269|PubMed:10751093,
FT                                ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:7581401}.
FT                                /FTId=VAR_007263.
FT   VARIANT     212    212       A -> P (in MLD; loss of enzymatic
FT                                activity; dbSNP:rs199476341).
FT                                {ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_054182.
FT   VARIANT     212    212       A -> V (in MLD; dbSNP:rs74315467).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:14517960,
FT                                ECO:0000269|PubMed:7906588}.
FT                                /FTId=VAR_007264.
FT   VARIANT     217    217       R -> H (in MLD; enzyme activity reduced
FT                                to 15.6% of wild-type enzyme;
FT                                dbSNP:rs148403406).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054183.
FT   VARIANT     219    219       F -> V (in MLD; enzyme activity reduced
FT                                to less than 1% of normal activity;
FT                                dbSNP:rs199476383).
FT                                {ECO:0000269|PubMed:15710861}.
FT                                /FTId=VAR_054184.
FT   VARIANT     224    224       A -> V (in MLD; dbSNP:rs74315468).
FT                                {ECO:0000269|PubMed:7906588}.
FT                                /FTId=VAR_007265.
FT   VARIANT     227    227       H -> Y (in MLD; late-infantile form;
FT                                dbSNP:rs199476354).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054185.
FT   VARIANT     231    231       P -> T (in MLD; dbSNP:rs74315469).
FT                                /FTId=VAR_007266.
FT   VARIANT     244    244       R -> C (in MLD; juvenile-onset;
FT                                dbSNP:rs74315470).
FT                                /FTId=VAR_007267.
FT   VARIANT     244    244       R -> H (in MLD; infantile-onset;
FT                                dbSNP:rs199476366).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007268.
FT   VARIANT     245    245       G -> R (in MLD; severe;
FT                                dbSNP:rs74315471).
FT                                {ECO:0000269|PubMed:8101083}.
FT                                /FTId=VAR_007269.
FT   VARIANT     247    247       F -> S (in MLD; dbSNP:rs199476384).
FT                                {ECO:0000269|PubMed:14680985,
FT                                ECO:0000269|PubMed:20339381}.
FT                                /FTId=VAR_054186.
FT   VARIANT     250    250       S -> Y (in MLD; infantile-onset;
FT                                dbSNP:rs199476367).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007270.
FT   VARIANT     253    253       E -> K (in MLD; late-infantile;
FT                                dbSNP:rs74315483).
FT                                {ECO:0000269|PubMed:11941485,
FT                                ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054187.
FT   VARIANT     255    255       D -> H (in MLD; late-infantile form; no
FT                                enzyme residual activity; leads to a
FT                                decreased stability of the mutant enzyme;
FT                                causes an arrest of the mutant enzyme
FT                                polypeptide in a prelysosomal
FT                                compartment; dbSNP:rs80338819).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:10751093}.
FT                                /FTId=VAR_054188.
FT   VARIANT     274    274       T -> M (in MLD; severe; 35% of normal
FT                                activity; dbSNP:rs74315472).
FT                                {ECO:0000269|PubMed:7825603,
FT                                ECO:0000269|PubMed:8104633,
FT                                ECO:0000269|PubMed:8723680}.
FT                                /FTId=VAR_007271.
FT   VARIANT     281    281       D -> Y (in MLD; dbSNP:rs199476386).
FT                                {ECO:0000269|PubMed:10533072}.
FT                                /FTId=VAR_054189.
FT   VARIANT     282    282       N -> S (in MLD; enzyme activity reduced
FT                                to 0.6% of wild-type enzyme;
FT                                dbSNP:rs199476342).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054190.
FT   VARIANT     286    286       T -> P (in MLD; adult type;
FT                                dbSNP:rs28940894).
FT                                {ECO:0000269|PubMed:11061266}.
FT                                /FTId=VAR_054191.
FT   VARIANT     288    288       R -> C (in MLD; dbSNP:rs74315473).
FT                                {ECO:0000269|PubMed:20339381}.
FT                                /FTId=VAR_007272.
FT   VARIANT     288    288       R -> H (in MLD; adult form;
FT                                dbSNP:rs199476355).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054192.
FT   VARIANT     293    293       G -> D (in MLD; late-onset;
FT                                dbSNP:rs199476387).
FT                                {ECO:0000269|PubMed:15026521}.
FT                                /FTId=VAR_054193.
FT   VARIANT     293    293       G -> S (in MLD; adult type; causes a
FT                                severe reduction of enzyme activity;
FT                                dbSNP:rs199476349).
FT                                {ECO:0000269|PubMed:15326627}.
FT                                /FTId=VAR_054194.
FT   VARIANT     294    294       C -> Y (in MLD; juvenile-onset; causes a
FT                                severe reduction of enzyme activity;
FT                                dbSNP:rs199476347).
FT                                {ECO:0000269|PubMed:15326627}.
FT                                /FTId=VAR_054195.
FT   VARIANT     295    295       S -> Y (in MLD; severe;
FT                                dbSNP:rs74315474).
FT                                {ECO:0000269|PubMed:7906588}.
FT                                /FTId=VAR_007273.
FT   VARIANT     298    298       L -> S (in MLD; late-infantile form;
FT                                complete loss of enzyme activity;
FT                                dbSNP:rs199476389).
FT                                {ECO:0000269|PubMed:9819708}.
FT                                /FTId=VAR_054196.
FT   VARIANT     300    300       C -> F (in MLD; late-infantile-onset;
FT                                enzyme activity reduced to less than 1%;
FT                                the mutant protein is more rapidly
FT                                degraded in lysosomes; strongly
FT                                interferes with the octamerization
FT                                process of the enzyme at low pH;
FT                                dbSNP:rs74315484).
FT                                {ECO:0000269|PubMed:10220151,
FT                                ECO:0000269|PubMed:12503099,
FT                                ECO:0000269|PubMed:12788103}.
FT                                /FTId=VAR_008132.
FT   VARIANT     302    302       K -> N (in MLD; enzyme activity reduced
FT                                to 2.8% of wild-type enzyme;
FT                                dbSNP:rs199476343).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054197.
FT   VARIANT     304    304       T -> M (in MLD; loss of enzymatic
FT                                activity; dbSNP:rs199476359).
FT                                {ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_067416.
FT   VARIANT     306    306       Y -> H (in MLD; juvenile-onset;
FT                                dbSNP:rs199476379).
FT                                {ECO:0000269|PubMed:14517960}.
FT                                /FTId=VAR_054198.
FT   VARIANT     307    307       E -> K (in MLD; loss of enzymatic
FT                                activity; dbSNP:rs199476360).
FT                                {ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_067417.
FT   VARIANT     308    308       G -> D (in MLD; late-infantile form;
FT                                dbSNP:rs199476356).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054199.
FT   VARIANT     308    308       G -> V (in MLD; late-infantile form; no
FT                                enzyme residual activity;
FT                                dbSNP:rs199476356).
FT                                {ECO:0000269|PubMed:8891236}.
FT                                /FTId=VAR_054200.
FT   VARIANT     309    309       G -> S (in MLD; severe; 13% of normal
FT                                activity; dbSNP:rs74315459).
FT                                {ECO:0000269|PubMed:15326627,
FT                                ECO:0000269|PubMed:8101038}.
FT                                /FTId=VAR_007274.
FT   VARIANT     311    311       R -> Q (in MLD; juvenile-onset;
FT                                dbSNP:rs199476382).
FT                                {ECO:0000269|PubMed:7581401}.
FT                                /FTId=VAR_007275.
FT   VARIANT     312    312       E -> D (in MLD; low amounts of residual
FT                                enzyme activity; leads to a decreased
FT                                stability of the mutant enzyme;
FT                                dbSNP:rs199476390).
FT                                {ECO:0000269|PubMed:10751093}.
FT                                /FTId=VAR_054201.
FT   VARIANT     314    314       A -> T (in MLD; infantile-onset;
FT                                dbSNP:rs199476368).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007276.
FT   VARIANT     325    325       G -> S (in MLD; juvenile-onset;
FT                                dbSNP:rs148092995).
FT                                {ECO:0000269|PubMed:14517960}.
FT                                /FTId=VAR_054202.
FT   VARIANT     327    327       T -> I (in MLD; late-infantile form).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054203.
FT   VARIANT     335    335       D -> V (in MLD; late-infantile-onset;
FT                                loss of enzymatic activity;
FT                                dbSNP:rs74315475).
FT                                {ECO:0000269|PubMed:10381328,
FT                                ECO:0000269|PubMed:14517960,
FT                                ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:7581401,
FT                                ECO:0000269|PubMed:8723680}.
FT                                /FTId=VAR_007277.
FT   VARIANT     350    350       N -> S (associated with arylsulfatase A
FT                                pseudodeficiency; appears to be
FT                                responsible for the small size of the
FT                                enzyme produced by pseudodeficiency
FT                                fibroblasts because it leads to loss of
FT                                an N-glycosylation site;
FT                                dbSNP:rs2071421).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:11941485,
FT                                ECO:0000269|PubMed:15026521,
FT                                ECO:0000269|PubMed:2574462,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_007278.
FT   VARIANT     356    356       F -> V (in dbSNP:rs6151422).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018838.
FT   VARIANT     367    367       K -> N (in MLD; dbSNP:rs199476369).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007279.
FT   VARIANT     370    370       R -> Q (in MLD; mild; dbSNP:rs74315477).
FT                                /FTId=VAR_007280.
FT   VARIANT     370    370       R -> W (in MLD; severe; no enzyme
FT                                residual activity; dbSNP:rs74315476).
FT                                {ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:7825603}.
FT                                /FTId=VAR_007281.
FT   VARIANT     376    376       Y -> N (in MLD; enzyme activity reduced
FT                                to 4.7% of wild-type enzyme;
FT                                dbSNP:rs199476344).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054204.
FT   VARIANT     377    377       P -> L (in MLD; severe;
FT                                dbSNP:rs74315478).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_007282.
FT   VARIANT     381    381       D -> E (in MLD; early-infantile form;
FT                                dbSNP:rs6151425).
FT                                /FTId=VAR_054205.
FT   VARIANT     382    382       E -> K (in MLD; intermediate;
FT                                dbSNP:rs74315479).
FT                                {ECO:0000269|PubMed:20339381}.
FT                                /FTId=VAR_007283.
FT   VARIANT     384    384       R -> C (in MLD; dbSNP:rs199476370).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007284.
FT   VARIANT     390    390       R -> Q (in MLD; juvenile-onset;
FT                                dbSNP:rs199476391).
FT                                {ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:9452102}.
FT                                /FTId=VAR_007285.
FT   VARIANT     390    390       R -> W (in MLD; late-infantile and
FT                                juvenile-onset; dbSNP:rs74315480).
FT                                {ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:7581401}.
FT                                /FTId=VAR_007286.
FT   VARIANT     391    391       T -> S (in dbSNP:rs743616).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:11061266,
FT                                ECO:0000269|PubMed:11456299,
FT                                ECO:0000269|PubMed:11941485,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15326627,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:1670590,
FT                                ECO:0000269|PubMed:9888390,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_007287.
FT   VARIANT     397    397       H -> Y (in MLD; adult-onset;
FT                                dbSNP:rs199476376).
FT                                {ECO:0000269|PubMed:10381328,
FT                                ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:9452102}.
FT                                /FTId=VAR_007288.
FT   VARIANT     398    398       Missing (in MLD).
FT                                /FTId=VAR_007289.
FT   VARIANT     406    408       Missing (in MLD; late-infantile-onset).
FT                                {ECO:0000269|PubMed:9490297}.
FT                                /FTId=VAR_007290.
FT   VARIANT     406    406       S -> G (in MLD; loss of enzymatic
FT                                activity; dbSNP:rs199476361).
FT                                {ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_067418.
FT   VARIANT     408    408       T -> I (in MLD; adult type;
FT                                dbSNP:rs28940895).
FT                                {ECO:0000269|PubMed:11456299}.
FT                                /FTId=VAR_054206.
FT   VARIANT     409    409       T -> I (in MLD; mild; dbSNP:rs74315481).
FT                                {ECO:0000269|PubMed:21265945,
FT                                ECO:0000269|PubMed:7909527}.
FT                                /FTId=VAR_054207.
FT   VARIANT     425    425       P -> T (in MLD; juvenile-onset; retains
FT                                about 12% of specific enzyme activity;
FT                                the mutant protein is unstable; results
FT                                in more rapid enzyme degradation in
FT                                lysosomes; addition of the cysteine
FT                                protease inhibitor leupeptin increases
FT                                the amount of the enzyme activity;
FT                                displays a modest reduction in the
FT                                octamerization process of the enzyme at
FT                                low pH; dbSNP:rs74315485).
FT                                {ECO:0000269|PubMed:10220151,
FT                                ECO:0000269|PubMed:12503099,
FT                                ECO:0000269|PubMed:12788103}.
FT                                /FTId=VAR_008133.
FT   VARIANT     426    426       P -> L (in MLD; juvenile/adult-onset;
FT                                mild; common mutation; dbSNP:rs28940893).
FT                                {ECO:0000269|PubMed:10381328,
FT                                ECO:0000269|PubMed:11941485,
FT                                ECO:0000269|PubMed:14517960,
FT                                ECO:0000269|PubMed:14680985,
FT                                ECO:0000269|PubMed:15326627,
FT                                ECO:0000269|PubMed:1670590,
FT                                ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:8095918}.
FT                                /FTId=VAR_007291.
FT   VARIANT     428    428       L -> P (in MLD; late-infantile form;
FT                                dbSNP:rs199476392).
FT                                {ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:9272717}.
FT                                /FTId=VAR_054208.
FT   VARIANT     429    429       Y -> S (in MLD; adult-onset;
FT                                dbSNP:rs199476380).
FT                                {ECO:0000269|PubMed:14517960}.
FT                                /FTId=VAR_054209.
FT   VARIANT     440    440       N -> S (in dbSNP:rs6151427).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018839.
FT   VARIANT     464    464       A -> V. {ECO:0000269|PubMed:9888390}.
FT                                /FTId=VAR_007292.
FT   VARIANT     469    469       A -> G (in MLD; early-infantile form;
FT                                dbSNP:rs199476385).
FT                                {ECO:0000269|PubMed:14680985}.
FT                                /FTId=VAR_054210.
FT   VARIANT     489    489       C -> G (in MLD; late-onset;
FT                                dbSNP:rs199476388).
FT                                {ECO:0000269|PubMed:15026521}.
FT                                /FTId=VAR_054211.
FT   VARIANT     496    496       R -> H (in dbSNP:rs6151428).
FT                                {ECO:0000269|PubMed:9090526,
FT                                ECO:0000269|PubMed:9744473,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_007293.
FT   MUTAGEN      69     69       C->A: Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:11124905}.
FT   MUTAGEN      69     69       C->S: Strongly decreases enzyme activity.
FT                                {ECO:0000269|PubMed:11124905}.
FT   CONFLICT    290    290       S -> P (in Ref. 5; AK098659).
FT                                {ECO:0000305}.
FT   STRAND       22     30       {ECO:0000244|PDB:1AUK}.
FT   HELIX        37     39       {ECO:0000244|PDB:1AUK}.
FT   HELIX        47     54       {ECO:0000244|PDB:1AUK}.
FT   STRAND       56     63       {ECO:0000244|PDB:1AUK}.
FT   STRAND       65     68       {ECO:0000244|PDB:1AUK}.
FT   HELIX        69     78       {ECO:0000244|PDB:1AUK}.
FT   HELIX        82     85       {ECO:0000244|PDB:1AUK}.
FT   HELIX       107    112       {ECO:0000244|PDB:1AUK}.
FT   TURN        113    115       {ECO:0000244|PDB:1AUK}.
FT   STRAND      117    122       {ECO:0000244|PDB:1AUK}.
FT   HELIX       130    132       {ECO:0000244|PDB:1AUK}.
FT   HELIX       136    139       {ECO:0000244|PDB:1AUK}.
FT   STRAND      142    146       {ECO:0000244|PDB:1AUK}.
FT   STRAND      153    155       {ECO:0000244|PDB:1AUK}.
FT   STRAND      159    162       {ECO:0000244|PDB:1AUK}.
FT   TURN        163    165       {ECO:0000244|PDB:1AUK}.
FT   STRAND      181    183       {ECO:0000244|PDB:1AUK}.
FT   STRAND      186    191       {ECO:0000244|PDB:1AUK}.
FT   HELIX       194    196       {ECO:0000244|PDB:1AUK}.
FT   HELIX       197    214       {ECO:0000244|PDB:1AUK}.
FT   STRAND      219    224       {ECO:0000244|PDB:1AUK}.
FT   STRAND      229    231       {ECO:0000244|PDB:1AUK}.
FT   TURN        236    241       {ECO:0000244|PDB:1AUK}.
FT   STRAND      242    244       {ECO:0000244|PDB:1AUK}.
FT   HELIX       245    267       {ECO:0000244|PDB:1AUK}.
FT   HELIX       271    273       {ECO:0000244|PDB:1AUK}.
FT   STRAND      274    282       {ECO:0000244|PDB:1AUK}.
FT   HELIX       286    291       {ECO:0000244|PDB:1AUK}.
FT   STRAND      304    306       {ECO:0000244|PDB:1AUK}.
FT   HELIX       307    310       {ECO:0000244|PDB:1AUK}.
FT   STRAND      315    317       {ECO:0000244|PDB:1AUK}.
FT   TURN        319    321       {ECO:0000244|PDB:1AUK}.
FT   STRAND      324    327       {ECO:0000244|PDB:1AUK}.
FT   HELIX       333    335       {ECO:0000244|PDB:1AUK}.
FT   HELIX       336    343       {ECO:0000244|PDB:1AUK}.
FT   HELIX       359    363       {ECO:0000244|PDB:1AUK}.
FT   STRAND      372    375       {ECO:0000244|PDB:1AUK}.
FT   TURN        382    384       {ECO:0000244|PDB:1AUK}.
FT   STRAND      387    391       {ECO:0000244|PDB:1AUK}.
FT   STRAND      394    400       {ECO:0000244|PDB:1AUK}.
FT   HELIX       404    406       {ECO:0000244|PDB:1AUK}.
FT   STRAND      408    410       {ECO:0000244|PDB:1E1Z}.
FT   HELIX       412    414       {ECO:0000244|PDB:1AUK}.
FT   STRAND      421    430       {ECO:0000244|PDB:1AUK}.
FT   TURN        431    433       {ECO:0000244|PDB:1AUK}.
FT   HELIX       450    469       {ECO:0000244|PDB:1AUK}.
FT   HELIX       477    479       {ECO:0000244|PDB:1AUK}.
FT   HELIX       483    485       {ECO:0000244|PDB:1AUK}.
FT   TURN        496    499       {ECO:0000244|PDB:1AUK}.
SQ   SEQUENCE   507 AA;  53588 MW;  3DDBE1378B4176A6 CRC64;
     MGAPRSLLLA LAAGLAVARP PNIVLIFADD LGYGDLGCYG HPSSTTPNLD QLAAGGLRFT
     DFYVPVSLCT PSRAALLTGR LPVRMGMYPG VLVPSSRGGL PLEEVTVAEV LAARGYLTGM
     AGKWHLGVGP EGAFLPPHQG FHRFLGIPYS HDQGPCQNLT CFPPATPCDG GCDQGLVPIP
     LLANLSVEAQ PPWLPGLEAR YMAFAHDLMA DAQRQDRPFF LYYASHHTHY PQFSGQSFAE
     RSGRGPFGDS LMELDAAVGT LMTAIGDLGL LEETLVIFTA DNGPETMRMS RGGCSGLLRC
     GKGTTYEGGV REPALAFWPG HIAPGVTHEL ASSLDLLPTL AALAGAPLPN VTLDGFDLSP
     LLLGTGKSPR QSLFFYPSYP DEVRGVFAVR TGKYKAHFFT QGSAHSDTTA DPACHASSSL
     TAHEPPLLYD LSKDPGENYN LLGGVAGATP EVLQALKQLQ LLKAQLDAAV TFGPSQVARG
     EDPALQICCH PGCTPRPACC HCPDPHA
//
ID   TGFR2_HUMAN             Reviewed;         567 AA.
AC   P37173; B4DTV5; Q15580; Q6DKT6; Q99474;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   17-FEB-2016, entry version 192.
DE   RecName: Full=TGF-beta receptor type-2;
DE            Short=TGFR-2;
DE            EC=2.7.11.30;
DE   AltName: Full=TGF-beta type II receptor;
DE   AltName: Full=Transforming growth factor-beta receptor type II;
DE            Short=TGF-beta receptor type II;
DE            Short=TbetaR-II;
DE   Flags: Precursor;
GN   Name=TGFBR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-439, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Liver;
RX   PubMed=1310899; DOI=10.1016/0092-8674(92)90152-3;
RA   Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.;
RT   "Expression cloning of the TGF-beta type II receptor, a functional
RT   transmembrane serine/threonine kinase.";
RL   Cell 68:775-785(1992).
RN   [2]
RP   ERRATUM.
RX   PubMed=1525823;
RA   Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.;
RL   Cell 70:1069-1069(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Glial cell;
RX   PubMed=7959019; DOI=10.1016/0378-1119(94)90178-3;
RA   Nikawa J.;
RT   "A cDNA encoding the human transforming growth factor beta receptor
RT   suppresses the growth defect of a yeast mutant.";
RL   Gene 149:367-372(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439.
RX   PubMed=8812462; DOI=10.1006/geno.1996.0471;
RA   Takenoshita S., Hagiwara K., Nagashima M., Gemma A., Bennett W.P.,
RA   Harris C.C.;
RT   "The genomic structure of the gene encoding the human transforming
RT   growth factor beta type II receptor (TGF-beta RII).";
RL   Genomics 36:341-344(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439.
RX   PubMed=8840968;
RA   Lu S.-L., Zhang W.C., Akiyama Y., Nomizu T., Yuasa Y.;
RT   "Genomic structure of the transforming growth factor beta type II
RT   receptor gene and its mutations in hereditary nonpolyposis colorectal
RT   cancers.";
RL   Cancer Res. 56:4595-4598(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-439.
RC   TISSUE=Liver;
RX   PubMed=8973329; DOI=10.1016/S0378-1119(96)00501-X;
RA   Ogasa H., Noma T., Murata H., Kawai S., Nakazawa A.;
RT   "Cloning of a cDNA encoding the human transforming growth factor-beta
RT   type II receptor: heterogeneity of the mRNA.";
RL   Gene 181:185-190(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-36.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   PROTEIN SEQUENCE OF 23-37.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF TGFBR1.
RX   PubMed=7774578;
RA   Wieser R., Wrana J.L., Massague J.;
RT   "GS domain mutations that constitutively activate T beta R-I, the
RT   downstream signaling component in the TGF-beta receptor complex.";
RL   EMBO J. 14:2199-2208(1995).
RN   [12]
RP   INTERACTION WITH ZFYVE9.
RX   PubMed=9865696; DOI=10.1016/S0092-8674(00)81701-8;
RA   Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.;
RT   "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta
RT   receptor.";
RL   Cell 95:779-791(1998).
RN   [13]
RP   HOMODIMERIZATION.
RX   PubMed=9472030; DOI=10.1083/jcb.140.4.767;
RA   Gilboa L., Wells R.G., Lodish H.F., Henis Y.I.;
RT   "Oligomeric structure of type I and type II transforming growth factor
RT   beta receptors: homodimers form in the ER and persist at the plasma
RT   membrane.";
RL   J. Cell Biol. 140:767-777(1998).
RN   [14]
RP   INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-277.
RX   PubMed=11483955; DOI=10.1038/35087019;
RA   Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A.;
RT   "TGF-beta-induced apoptosis is mediated by the adapter protein Daxx
RT   that facilitates JNK activation.";
RL   Nat. Cell Biol. 3:708-714(2001).
RN   [15]
RP   INTERACTION WITH VPS39.
RX   PubMed=12941698; DOI=10.1093/emboj/cdg428;
RA   Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M.,
RA   Karpova T.S., McNally J.G., Roberts A.B.;
RT   "TLP, a novel modulator of TGF-beta signaling, has opposite effects on
RT   Smad2- and Smad3-dependent signaling.";
RL   EMBO J. 22:4465-4477(2003).
RN   [16]
RP   INTERACTION WITH TCTEX1D4.
RX   PubMed=16982625; DOI=10.1074/jbc.M608614200;
RA   Meng Q.-J., Lux A., Holloschi A., Li J., Hughes J.M.X., Foerg T.,
RA   McCarthy J.E.G., Heagerty A.M., Kioschis P., Hafner M., Garland J.M.;
RT   "Identification of Tctex2beta, a novel dynein light chain family
RT   member that interacts with different transforming growth factor-beta
RT   receptors.";
RL   J. Biol. Chem. 281:37069-37080(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [19]
RP   INTERACTION WITH SCUBE3.
RX   PubMed=21441952; DOI=10.1038/onc.2011.85;
RA   Wu Y.Y., Peck K., Chang Y.L., Pan S.H., Cheng Y.F., Lin J.C.,
RA   Yang R.B., Hong T.M., Yang P.C.;
RT   "SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the
RT   epithelial-mesenchymal transition in lung cancer.";
RL   Oncogene 30:3682-3693(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 38-159 IN COMPLEX WITH
RP   TGF-BETA3, AND DISULFIDE BONDS.
RX   PubMed=11850637; DOI=10.1038/nsb766;
RA   Hart P.J., Deep S., Taylor A.B., Shu Z., Hinck C.S., Hinck A.P.;
RT   "Crystal structure of the human TbetaR2 ectodomain--TGF-beta3
RT   complex.";
RL   Nat. Struct. Biol. 9:203-208(2002).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS) OF 49-159, AND DISULFIDE BONDS.
RX   PubMed=12121646; DOI=10.1016/S0969-2126(02)00780-3;
RA   Boesen C.C., Radaev S., Motyka S.A., Patamawenu A., Sun P.D.;
RT   "The 1.1 A crystal structure of human TGF-beta type II receptor ligand
RT   binding domain.";
RL   Structure 10:913-919(2002).
RN   [23]
RP   STRUCTURE BY NMR OF 38-159, AND DISULFIDE BONDS.
RX   PubMed=12939140; DOI=10.1021/bi034366a;
RA   Deep S., Walker K.P. III, Shu Z., Hinck A.P.;
RT   "Solution structure and backbone dynamics of the TGFbeta type II
RT   receptor extracellular domain.";
RL   Biochemistry 42:10126-10139(2003).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 43-149 IN COMPLEX WITH
RP   TGFBR1 AND TGFB3, AND DISULFIDE BONDS.
RX   PubMed=18243111; DOI=10.1016/j.molcel.2007.11.039;
RA   Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C.,
RA   Schuermann J.P., Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P.;
RT   "Cooperative assembly of TGF-beta superfamily signaling complexes is
RT   mediated by two disparate mechanisms and distinct modes of receptor
RT   binding.";
RL   Mol. Cell 29:157-168(2008).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 38-153 IN COMPLEX WITH
RP   TGFBR1 AND TGFB1, RECEPTOR AFFINITY FOR LIGANDS, AND DISULFIDE BONDS.
RX   PubMed=20207738; DOI=10.1074/jbc.M109.079921;
RA   Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D.;
RT   "Ternary complex of transforming growth factor-beta1 reveals isoform-
RT   specific ligand recognition and receptor recruitment in the
RT   superfamily.";
RL   J. Biol. Chem. 285:14806-14814(2010).
RN   [26]
RP   VARIANT HNPCC6 MET-315.
RX   PubMed=9590282; DOI=10.1038/ng0598-17;
RA   Lu S.-L., Kawabata M., Imamura T., Akiyama Y., Nomizu T., Miyazono K.,
RA   Yuasa Y.;
RT   "HNPCC associated with germline mutation in the TGF-beta type II
RT   receptor gene.";
RL   Nat. Genet. 19:17-18(1998).
RN   [27]
RP   VARIANT ESOPHAGEAL CANCER GLN-526.
RX   PubMed=10789724; DOI=10.1054/bjoc.1999.1178;
RA   Tanaka S., Mori M., Mafune K., Ohno S., Sugimachi K.;
RT   "A dominant negative mutation of transforming growth factor-beta
RT   receptor type II gene in microsatellite stable oesophageal
RT   carcinoma.";
RL   Br. J. Cancer 82:1557-1560(2000).
RN   [28]
RP   VARIANTS BREAST TUMOR MET-387; SER-435; ALA-447 AND MET-452, AND
RP   CHARACTERIZATION OF VARIANTS BREAST TUMOR SER-435; ALA-447 AND
RP   MET-452.
RX   PubMed=11212236;
RA   Luecke C.D., Philpott A., Metcalfe J.C., Thompson A.M.,
RA   Hughes-Davies L., Kemp P.R., Hesketh R.;
RT   "Inhibiting mutations in the transforming growth factor beta type 2
RT   receptor in recurrent human breast cancer.";
RL   Cancer Res. 61:482-485(2001).
RN   [29]
RP   VARIANT ILE-191.
RX   PubMed=12202987; DOI=10.1007/s100380200069;
RA   Watanabe Y., Kinoshita A., Yamada T., Ohta T., Kishino T.,
RA   Matsumoto N., Ishikawa M., Niikawa N., Yoshiura K.;
RT   "A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other
RT   types of variations in genes for transforming growth factor-beta1
RT   (TGF-beta1) and its signaling pathway.";
RL   J. Hum. Genet. 47:478-483(2002).
RN   [30]
RP   VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537, AND CHARACTERIZATION OF
RP   VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537.
RX   PubMed=15235604; DOI=10.1038/ng1392;
RA   Mizuguchi T., Collod-Beroud G., Akiyama T., Abifadel M., Harada N.,
RA   Morisaki T., Allard D., Varret M., Claustres M., Morisaki H.,
RA   Ihara M., Kinoshita A., Yoshiura K., Junien C., Kajii T., Jondeau G.,
RA   Ohta T., Kishino T., Furukawa Y., Nakamura Y., Niikawa N., Boileau C.,
RA   Matsumoto N.;
RT   "Heterozygous TGFBR2 mutations in Marfan syndrome.";
RL   Nat. Genet. 36:855-860(2004).
RN   [31]
RP   VARIANTS LDS2 CYS-460 AND HIS-460.
RX   PubMed=16027248; DOI=10.1161/CIRCULATIONAHA.105.537340;
RA   Pannu H., Fadulu V.T., Chang J., Lafont A., Hasham S.N., Sparks E.,
RA   Giampietro P.F., Zaleski C., Estrera A.L., Safi H.J., Shete S.,
RA   Willing M.C., Raman C.S., Milewicz D.M.;
RT   "Mutations in transforming growth factor-beta receptor type II cause
RT   familial thoracic aortic aneurysms and dissections.";
RL   Circulation 112:513-520(2005).
RN   [32]
RP   VARIANTS LDS2 ASN-336; PRO-355; TRP-357; HIS-528 AND CYS-528.
RX   PubMed=15731757; DOI=10.1038/ng1511;
RA   Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T.,
RA   Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A.,
RA   Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y.,
RA   Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B.,
RA   De Paepe A.M., Dietz H.C.;
RT   "A syndrome of altered cardiovascular, craniofacial, neurocognitive
RT   and skeletal development caused by mutations in TGFBR1 or TGFBR2.";
RL   Nat. Genet. 37:275-281(2005).
RN   [33]
RP   VARIANT LDS2 ASN-446.
RX   PubMed=16251899; DOI=10.1038/sj.ejhg.5201502;
RA   Disabella E., Grasso M., Marziliano N., Ansaldi S., Lucchelli C.,
RA   Porcu E., Tagliani M., Pilotto A., Diegoli M., Lanzarini L.,
RA   Malattia C., Pelliccia A., Ficcadenti A., Gabrielli O., Arbustini E.;
RT   "Two novel and one known mutation of the TGFBR2 gene in Marfan
RT   syndrome not associated with FBN1 gene defects.";
RL   Eur. J. Hum. Genet. 14:34-38(2006).
RN   [34]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-73 AND HIS-528.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-61; ILE-191; MET-315; TYR-328;
RP   ILE-373; MET-387 AND SER-490.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [36]
RP   VARIANT LDS2 SER-510.
RX   PubMed=19883511; DOI=10.1186/1750-1172-4-24;
RA   Drera B., Ritelli M., Zoppi N., Wischmeijer A., Gnoli M., Fattori R.,
RA   Calzavara-Pinton P.G., Barlati S., Colombi M.;
RT   "Loeys-Dietz syndrome type I and type II: clinical findings and novel
RT   mutations in two Italian patients.";
RL   Orphanet J. Rare Dis. 4:24-24(2009).
RN   [37]
RP   VARIANT LDS2 LYS-457.
RX   PubMed=20101701; DOI=10.1002/ajmg.a.33263;
RA   Muramatsu Y., Kosho T., Magota M., Yokotsuka T., Ito M., Yasuda A.,
RA   Kito O., Suzuki C., Nagata Y., Kawai S., Ikoma M., Hatano T.,
RA   Nakayama M., Kawamura R., Wakui K., Morisaki H., Morisaki T.,
RA   Fukushima Y.;
RT   "Progressive aortic root and pulmonary artery aneurysms in a neonate
RT   with Loeys-Dietz syndrome type 1B.";
RL   Am. J. Med. Genet. A 152:417-421(2010).
RN   [38]
RP   VARIANTS LDS2 PRO-308 AND ARG-521.
RX   PubMed=20358619; DOI=10.1002/ajmg.a.33356;
RA   Kirmani S., Tebben P.J., Lteif A.N., Gordon D., Clarke B.L.,
RA   Hefferan T.E., Yaszemski M.J., McGrann P.S., Lindor N.M.,
RA   Ellison J.W.;
RT   "Germline TGF-beta receptor mutations and skeletal fragility: a report
RT   on two patients with Loeys-Dietz syndrome.";
RL   Am. J. Med. Genet. A 152:1016-1019(2010).
RN   [39]
RP   VARIANTS LDS2 GLN-306 DELINS HIS-GLU; ARG-377; PHE-449 AND ARG-514.
RX   PubMed=22113417; DOI=10.1038/jhg.2011.130;
RA   Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K.,
RA   Lee H.J., Kim D.K.;
RT   "Clinical features and genetic analysis of Korean patients with Loeys-
RT   Dietz syndrome.";
RL   J. Hum. Genet. 57:52-56(2012).
RN   [40]
RP   VARIANTS LDS2 VAL-509 AND PHE-510.
RX   PubMed=21949523; DOI=10.3345/kjp.2011.54.6.272;
RA   Ha J.S., Kim Y.H.;
RT   "A sporadic case of Loeys-Dietz syndrome type I with two novel
RT   mutations of the TGFBR2 gene.";
RL   Korean J. Pediatr. 54:272-275(2011).
CC   -!- FUNCTION: Transmembrane serine/threonine kinase forming with the
CC       TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-
CC       promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and
CC       TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell
CC       surface to the cytoplasm and is thus regulating a plethora of
CC       physiological and pathological processes including cell cycle
CC       arrest in epithelial and hematopoietic cells, control of
CC       mesenchymal cell proliferation and differentiation, wound healing,
CC       extracellular matrix production, immunosuppression and
CC       carcinogenesis. The formation of the receptor complex composed of
CC       2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the
CC       cytokine dimer results in the phosphorylation and the activation
CC       of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1
CC       phosphorylates SMAD2 which dissociates from the receptor and
CC       interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently
CC       translocated to the nucleus where it modulates the transcription
CC       of the TGF-beta-regulated genes. This constitutes the canonical
CC       SMAD-dependent TGF-beta signaling cascade. Also involved in non-
CC       canonical, SMAD-independent TGF-beta signaling pathways.
CC       {ECO:0000269|PubMed:7774578}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Homodimer. Heterohexamer; TGFB1, TGFB2 and TGFB3
CC       homodimeric ligands assemble a functional receptor composed of two
CC       TGFBR1 and TGFBR2 heterodimers to form a ligand-receptor
CC       heterohexamer. The respective affinity of TGFRB1 and TGFRB2 for
CC       the ligands may modulate the kinetics of assembly of the receptor
CC       and may explain the different biological activities of TGFB1,
CC       TGFB2 and TGFB3. Interacts with DAXX. Interacts with TCTEX1D4.
CC       Interacts with ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to the TGF-
CC       beta receptor. Interacts with and is activated by SCUBE3; this
CC       interaction does not affect TGFB1-binding to TGFBR2. Interacts
CC       with VPS39; this interaction is independent of the receptor kinase
CC       activity and of the presence of TGF-beta.
CC       {ECO:0000269|PubMed:11483955, ECO:0000269|PubMed:11850637,
CC       ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:16982625,
CC       ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738,
CC       ECO:0000269|PubMed:21441952, ECO:0000269|PubMed:9865696}.
CC   -!- INTERACTION:
CC       Q9UER7:DAXX; NbExp=2; IntAct=EBI-296151, EBI-77321;
CC       Q93074:MED12; NbExp=3; IntAct=EBI-296151, EBI-394357;
CC       A2AGH6:Med12 (xeno); NbExp=3; IntAct=EBI-296151, EBI-5744969;
CC       Q8IX30:SCUBE3; NbExp=6; IntAct=EBI-296151, EBI-4479975;
CC       P01137:TGFB1; NbExp=6; IntAct=EBI-296151, EBI-779636;
CC       P07200:TGFB1 (xeno); NbExp=2; IntAct=EBI-296151, EBI-907660;
CC       P10600:TGFB3; NbExp=8; IntAct=EBI-296151, EBI-1033020;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1310899};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:1310899}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P37173-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P37173-2; Sequence=VSP_012157;
CC   -!- PTM: Phosphorylated on a Ser/Thr residue in the cytoplasmic
CC       domain.
CC   -!- DISEASE: Hereditary non-polyposis colorectal cancer 6 (HNPCC6)
CC       [MIM:614331]: An autosomal dominant disease associated with marked
CC       increase in cancer susceptibility. It is characterized by a
CC       familial predisposition to early-onset colorectal carcinoma (CRC)
CC       and extra-colonic tumors of the gastrointestinal, urological and
CC       female reproductive tracts. HNPCC is reported to be the most
CC       common form of inherited colorectal cancer in the Western world.
CC       Clinically, HNPCC is often divided into two subgroups. Type I is
CC       characterized by hereditary predisposition to colorectal cancer, a
CC       young age of onset, and carcinoma observed in the proximal colon.
CC       Type II is characterized by increased risk for cancers in certain
CC       tissues such as the uterus, ovary, breast, stomach, small
CC       intestine, skin, and larynx in addition to the colon. Diagnosis of
CC       classical HNPCC is based on the Amsterdam criteria: 3 or more
CC       relatives affected by colorectal cancer, one a first degree
CC       relative of the other two; 2 or more generation affected; 1 or
CC       more colorectal cancers presenting before 50 years of age;
CC       exclusion of hereditary polyposis syndromes. The term 'suspected
CC       HNPCC' or 'incomplete HNPCC' can be used to describe families who
CC       do not or only partially fulfill the Amsterdam criteria, but in
CC       whom a genetic basis for colon cancer is strongly suspected.
CC       {ECO:0000269|PubMed:9590282}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of
CC       the esophagus. The most common types are esophageal squamous cell
CC       carcinoma and adenocarcinoma. Cancer of the esophagus remains a
CC       devastating disease because it is usually not detected until it
CC       has progressed to an advanced incurable stage.
CC       {ECO:0000269|PubMed:10789724}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Loeys-Dietz syndrome 2 (LDS2) [MIM:610168]: An aortic
CC       aneurysm syndrome with widespread systemic involvement,
CC       characterized by arterial tortuosity and aneurysms, hypertelorism,
CC       and bifid uvula or cleft palate. Physical findings include
CC       prominent joint laxity, easy bruising, wide and atrophic scars,
CC       velvety and translucent skin with easily visible veins,
CC       spontaneous rupture of the spleen or bowel, and catastrophic
CC       complications of pregnancy, including rupture of the gravid uterus
CC       and the arteries, either during pregnancy or in the immediate
CC       postpartum period. Some patients have craniosynostosis, exotropy,
CC       micrognathia and retrognathia, structural brain abnormalities, and
CC       intellectual deficit. {ECO:0000269|PubMed:15235604,
CC       ECO:0000269|PubMed:15731757, ECO:0000269|PubMed:16027248,
CC       ECO:0000269|PubMed:16251899, ECO:0000269|PubMed:19883511,
CC       ECO:0000269|PubMed:20101701, ECO:0000269|PubMed:20358619,
CC       ECO:0000269|PubMed:21949523, ECO:0000269|PubMed:22113417}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry. TGFBR2 mutations Cys-460 and His-460
CC       have been reported to be associated with thoracic aortic aneurysms
CC       and dissection (TAAD). This phenotype, also known as thoracic
CC       aortic aneurysms type 3 (AAT3), is distinguised from LDS2 by
CC       having aneurysms restricted to thoracic aorta. As individuals
CC       carrying these mutations also exhibit descending aortic disease
CC       and aneurysms of other arteries (PubMed:16027248), they have been
CC       considered as LDS2 by the OMIM resource.
CC       {ECO:0000269|PubMed:16027248}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tgfbr2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M85079; AAA61164.1; -; mRNA.
DR   EMBL; D28131; BAA05673.1; -; mRNA.
DR   EMBL; U52246; AAB17553.1; -; Genomic_DNA.
DR   EMBL; U52240; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52241; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52242; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52244; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52245; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U69152; AAB40916.1; -; Genomic_DNA.
DR   EMBL; U69146; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69147; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69148; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69149; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69150; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69151; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; D50683; BAA09332.1; -; mRNA.
DR   EMBL; AY675319; AAT70724.1; -; Genomic_DNA.
DR   EMBL; AK300383; BAG62117.1; -; mRNA.
DR   EMBL; CH471055; EAW64412.1; -; Genomic_DNA.
DR   CCDS; CCDS2648.1; -. [P37173-1]
DR   CCDS; CCDS33727.1; -. [P37173-2]
DR   PIR; A42100; A42100.
DR   RefSeq; NP_001020018.1; NM_001024847.2. [P37173-2]
DR   RefSeq; NP_003233.4; NM_003242.5. [P37173-1]
DR   UniGene; Hs.604277; -.
DR   UniGene; Hs.82028; -.
DR   PDB; 1KTZ; X-ray; 2.15 A; B=38-159.
DR   PDB; 1M9Z; X-ray; 1.05 A; A=49-159.
DR   PDB; 1PLO; NMR; -; A=38-159.
DR   PDB; 2PJY; X-ray; 3.00 A; B=42-149.
DR   PDB; 3KFD; X-ray; 3.00 A; E/F/G/H=38-153.
DR   PDB; 4P7U; X-ray; 1.50 A; A=49-159.
DR   PDB; 4XJJ; X-ray; 1.40 A; A=50-159.
DR   PDBsum; 1KTZ; -.
DR   PDBsum; 1M9Z; -.
DR   PDBsum; 1PLO; -.
DR   PDBsum; 2PJY; -.
DR   PDBsum; 3KFD; -.
DR   PDBsum; 4P7U; -.
DR   PDBsum; 4XJJ; -.
DR   ProteinModelPortal; P37173; -.
DR   SMR; P37173; 48-153, 244-539.
DR   BioGrid; 112906; 80.
DR   DIP; DIP-5939N; -.
DR   IntAct; P37173; 22.
DR   MINT; MINT-206666; -.
DR   STRING; 9606.ENSP00000351905; -.
DR   BindingDB; P37173; -.
DR   ChEMBL; CHEMBL4267; -.
DR   GuidetoPHARMACOLOGY; 1795; -.
DR   iPTMnet; P37173; -.
DR   PhosphoSite; P37173; -.
DR   BioMuta; TGFBR2; -.
DR   DMDM; 116242818; -.
DR   MaxQB; P37173; -.
DR   PaxDb; P37173; -.
DR   PRIDE; P37173; -.
DR   DNASU; 7048; -.
DR   Ensembl; ENST00000295754; ENSP00000295754; ENSG00000163513. [P37173-1]
DR   Ensembl; ENST00000359013; ENSP00000351905; ENSG00000163513. [P37173-2]
DR   GeneID; 7048; -.
DR   KEGG; hsa:7048; -.
DR   UCSC; uc003ceo.3; human. [P37173-1]
DR   CTD; 7048; -.
DR   GeneCards; TGFBR2; -.
DR   GeneReviews; TGFBR2; -.
DR   H-InvDB; HIX0024332; -.
DR   HGNC; HGNC:11773; TGFBR2.
DR   MalaCards; TGFBR2; -.
DR   MIM; 133239; phenotype.
DR   MIM; 190182; gene.
DR   MIM; 610168; phenotype.
DR   MIM; 614331; phenotype.
DR   neXtProt; NX_P37173; -.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   Orphanet; 144; Hereditary nonpolyposis colon cancer.
DR   Orphanet; 60030; Loeys-Dietz syndrome.
DR   Orphanet; 284973; Marfan syndrome type 2.
DR   PharmGKB; PA36486; -.
DR   eggNOG; KOG3653; Eukaryota.
DR   eggNOG; ENOG410XS2Z; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000231495; -.
DR   HOVERGEN; HBG104975; -.
DR   InParanoid; P37173; -.
DR   KO; K04388; -.
DR   OMA; TRHIISW; -.
DR   OrthoDB; EOG7JHM5B; -.
DR   PhylomeDB; P37173; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer.
DR   Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer.
DR   Reactome; R-HSA-3642279; TGFBR2 MSI Frameshift Mutants in Cancer.
DR   Reactome; R-HSA-3645790; TGFBR2 Kinase Domain Mutants in Cancer.
DR   Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer.
DR   Reactome; R-HSA-3656535; TGFBR1 LBD Mutants in Cancer.
DR   SignaLink; P37173; -.
DR   ChiTaRS; TGFBR2; human.
DR   EvolutionaryTrace; P37173; -.
DR   GeneWiki; TGF_beta_receptor_2; -.
DR   GenomeRNAi; 7048; -.
DR   NextBio; 27541; -.
DR   PRO; PR:P37173; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; P37173; -.
DR   CleanEx; HS_TGFBR2; -.
DR   ExpressionAtlas; P37173; baseline and differential.
DR   Genevisible; P37173; HS.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0070022; C:transforming growth factor beta receptor homodimeric complex; IC:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005539; F:glycosaminoglycan binding; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004702; F:receptor signaling protein serine/threonine kinase activity; IEA:InterPro.
DR   GO; GO:0046332; F:SMAD binding; IDA:BHF-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IDA:BHF-UCL.
DR   GO; GO:0005026; F:transforming growth factor beta receptor activity, type II; IEA:InterPro.
DR   GO; GO:0005024; F:transforming growth factor beta-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0034713; F:type I transforming growth factor beta receptor binding; IDA:BHF-UCL.
DR   GO; GO:0034714; F:type III transforming growth factor beta receptor binding; IDA:BHF-UCL.
DR   GO; GO:0032147; P:activation of protein kinase activity; ISS:BHF-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0001568; P:blood vessel development; TAS:BHF-UCL.
DR   GO; GO:0007420; P:brain development; ISS:BHF-UCL.
DR   GO; GO:0060434; P:bronchus morphogenesis; IEA:Ensembl.
DR   GO; GO:0007182; P:common-partner SMAD protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0048565; P:digestive tract development; IEA:Ensembl.
DR   GO; GO:0007566; P:embryo implantation; IEA:Ensembl.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0035162; P:embryonic hemopoiesis; ISS:BHF-UCL.
DR   GO; GO:0007369; P:gastrulation; IEA:Ensembl.
DR   GO; GO:0003430; P:growth plate cartilage chondrocyte growth; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:1990086; P:lens fiber cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0060463; P:lung lobe morphogenesis; IEA:Ensembl.
DR   GO; GO:0060443; P:mammary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0060044; P:negative regulation of cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; ISS:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0001569; P:patterning of blood vessels; ISS:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0002663; P:positive regulation of B cell tolerance induction; ISS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IEA:Ensembl.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0051138; P:positive regulation of NK T cell differentiation; ISS:BHF-UCL.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0043415; P:positive regulation of skeletal muscle tissue regeneration; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0002666; P:positive regulation of T cell tolerance induction; ISS:BHF-UCL.
DR   GO; GO:0002651; P:positive regulation of tolerance induction to self antigen; ISS:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IDA:BHF-UCL.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0060440; P:trachea formation; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001570; P:vasculogenesis; ISS:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   InterPro; IPR017194; Transform_growth_fac-b_typ-2.
DR   InterPro; IPR015013; Transforming_GF_b_rcpt_2_ecto.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF08917; ecTbetaR2; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF037393; TGFRII; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Aortic aneurysm; Apoptosis;
KW   ATP-binding; Cell membrane; Complete proteome; Differentiation;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Growth regulation;
KW   Hereditary nonpolyposis colorectal cancer; Kinase; Magnesium;
KW   Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Serine/threonine-protein kinase; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     22       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        23    567       TGF-beta receptor type-2.
FT                                /FTId=PRO_0000024426.
FT   TOPO_DOM     23    166       Extracellular. {ECO:0000255}.
FT   TRANSMEM    167    187       Helical. {ECO:0000255}.
FT   TOPO_DOM    188    567       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      244    544       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     250    258       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    379    379       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     277    277       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     409    409       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62312}.
FT   MOD_RES     548    548       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     553    553       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62312}.
FT   CARBOHYD     70     70       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     94     94       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    154    154       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     51     84       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     54     71       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     61     67       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     77    101       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID    121    136       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID    138    143       {ECO:0000269|PubMed:11850637,
FT                                ECO:0000269|PubMed:12121646,
FT                                ECO:0000269|PubMed:12939140,
FT                                ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   VAR_SEQ      31     32       SV -> SDVEMEAQKDEIICPSCNRTAHPLRHI (in
FT                                isoform 2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:7959019}.
FT                                /FTId=VSP_012157.
FT   VARIANT      36     36       M -> V (in dbSNP:rs17025864).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_020510.
FT   VARIANT      61     61       C -> R (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041414.
FT   VARIANT      73     73       I -> V (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036070.
FT   VARIANT     191    191       V -> I (in dbSNP:rs56105708).
FT                                {ECO:0000269|PubMed:12202987,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_017606.
FT   VARIANT     306    306       Q -> HE (in LDS2).
FT                                {ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_066723.
FT   VARIANT     308    308       L -> P (in LDS2; has a negative effect on
FT                                TGF-beta signaling; dbSNP:rs28934568).
FT                                {ECO:0000269|PubMed:15235604,
FT                                ECO:0000269|PubMed:20358619}.
FT                                /FTId=VAR_022351.
FT   VARIANT     315    315       T -> M (in HNPCC6; dbSNP:rs34833812).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9590282}.
FT                                /FTId=VAR_008156.
FT   VARIANT     328    328       H -> Y (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041415.
FT   VARIANT     336    336       Y -> N (in LDS2).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022352.
FT   VARIANT     355    355       A -> P (in LDS2).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022353.
FT   VARIANT     357    357       G -> W (in LDS2).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022354.
FT   VARIANT     373    373       M -> I (in dbSNP:rs35719192).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041416.
FT   VARIANT     377    377       H -> R (in LDS2).
FT                                {ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_066724.
FT   VARIANT     387    387       V -> M (in a breast tumor;
FT                                dbSNP:rs35766612).
FT                                {ECO:0000269|PubMed:11212236,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_022355.
FT   VARIANT     435    435       N -> S (in a breast tumor; signaling of
FT                                TGF-beta significantly inhibited).
FT                                {ECO:0000269|PubMed:11212236}.
FT                                /FTId=VAR_022356.
FT   VARIANT     439    439       V -> A (in dbSNP:rs1050833).
FT                                {ECO:0000269|PubMed:1310899,
FT                                ECO:0000269|PubMed:8812462,
FT                                ECO:0000269|PubMed:8840968,
FT                                ECO:0000269|PubMed:8973329}.
FT                                /FTId=VAR_028063.
FT   VARIANT     446    446       D -> N (in LDS2).
FT                                {ECO:0000269|PubMed:16251899}.
FT                                /FTId=VAR_066725.
FT   VARIANT     447    447       V -> A (in a breast tumor; signaling of
FT                                TGF-beta significantly inhibited).
FT                                {ECO:0000269|PubMed:11212236}.
FT                                /FTId=VAR_022357.
FT   VARIANT     449    449       S -> F (in LDS2; has a negative effect on
FT                                TGF-beta signaling).
FT                                {ECO:0000269|PubMed:15235604,
FT                                ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_022358.
FT   VARIANT     452    452       L -> M (in a breast tumor; signaling of
FT                                TGF-beta significantly inhibited).
FT                                {ECO:0000269|PubMed:11212236}.
FT                                /FTId=VAR_022359.
FT   VARIANT     457    457       M -> K (in LDS2).
FT                                {ECO:0000269|PubMed:20101701}.
FT                                /FTId=VAR_066726.
FT   VARIANT     460    460       R -> C (in LDS2).
FT                                {ECO:0000269|PubMed:16027248}.
FT                                /FTId=VAR_029760.
FT   VARIANT     460    460       R -> H (in LDS2).
FT                                {ECO:0000269|PubMed:16027248}.
FT                                /FTId=VAR_029761.
FT   VARIANT     490    490       N -> S (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041417.
FT   VARIANT     509    509       G -> V (in LDS2).
FT                                {ECO:0000269|PubMed:21949523}.
FT                                /FTId=VAR_066727.
FT   VARIANT     510    510       I -> F (in LDS2).
FT                                {ECO:0000269|PubMed:21949523}.
FT                                /FTId=VAR_066728.
FT   VARIANT     510    510       I -> S (in LDS2).
FT                                {ECO:0000269|PubMed:19883511}.
FT                                /FTId=VAR_066729.
FT   VARIANT     514    514       C -> R (in LDS2).
FT                                {ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_066730.
FT   VARIANT     521    521       W -> R (in LDS2).
FT                                {ECO:0000269|PubMed:20358619}.
FT                                /FTId=VAR_066731.
FT   VARIANT     526    526       E -> Q (in esophageal cancer).
FT                                {ECO:0000269|PubMed:10789724}.
FT                                /FTId=VAR_015816.
FT   VARIANT     528    528       R -> C (in LDS2).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022360.
FT   VARIANT     528    528       R -> H (in LDS2).
FT                                {ECO:0000269|PubMed:15731757,
FT                                ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_022361.
FT   VARIANT     537    537       R -> C (in LDS2; has a negative effect on
FT                                TGF-beta signaling; dbSNP:rs28934869).
FT                                {ECO:0000269|PubMed:15235604}.
FT                                /FTId=VAR_022362.
FT   MUTAGEN     277    277       K->R: Abolishes kinase activity, TGF-beta
FT                                signaling and interaction with DAXX.
FT                                {ECO:0000269|PubMed:11483955}.
FT   CONFLICT    381    381       K -> N (in Ref. 6; BAA09332).
FT                                {ECO:0000305}.
FT   STRAND       40     45       {ECO:0000244|PDB:1PLO}.
FT   STRAND       50     52       {ECO:0000244|PDB:1M9Z}.
FT   STRAND       55     58       {ECO:0000244|PDB:1M9Z}.
FT   STRAND       65     68       {ECO:0000244|PDB:1M9Z}.
FT   STRAND       74     76       {ECO:0000244|PDB:1M9Z}.
FT   STRAND       78     81       {ECO:0000244|PDB:1PLO}.
FT   STRAND       83     90       {ECO:0000244|PDB:1M9Z}.
FT   STRAND       95    102       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      106    110       {ECO:0000244|PDB:3KFD}.
FT   TURN        114    117       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      119    122       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      124    126       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      131    138       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      140    142       {ECO:0000244|PDB:1PLO}.
FT   HELIX       143    145       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      146    148       {ECO:0000244|PDB:1M9Z}.
FT   STRAND      149    154       {ECO:0000244|PDB:1PLO}.
SQ   SEQUENCE   567 AA;  64568 MW;  C541DA751FFBDBEB CRC64;
     MGRGLLRGLW PLHIVLWTRI ASTIPPHVQK SVNNDMIVTD NNGAVKFPQL CKFCDVRFST
     CDNQKSCMSN CSITSICEKP QEVCVAVWRK NDENITLETV CHDPKLPYHD FILEDAASPK
     CIMKEKKKPG ETFFMCSCSS DECNDNIIFS EEYNTSNPDL LLVIFQVTGI SLLPPLGVAI
     SVIIIFYCYR VNRQQKLSST WETGKTRKLM EFSEHCAIIL EDDRSDISST CANNINHNTE
     LLPIELDTLV GKGRFAEVYK AKLKQNTSEQ FETVAVKIFP YEEYASWKTE KDIFSDINLK
     HENILQFLTA EERKTELGKQ YWLITAFHAK GNLQEYLTRH VISWEDLRKL GSSLARGIAH
     LHSDHTPCGR PKMPIVHRDL KSSNILVKND LTCCLCDFGL SLRLDPTLSV DDLANSGQVG
     TARYMAPEVL ESRMNLENVE SFKQTDVYSM ALVLWEMTSR CNAVGEVKDY EPPFGSKVRE
     HPCVESMKDN VLRDRGRPEI PSFWLNHQGI QMVCETLTEC WDHDPEARLT AQCVAERFSE
     LEHLDRLSGR SCSEEKIPED GSLNTTK
//
ID   TLR4_MOUSE              Reviewed;         835 AA.
AC   Q9QUK6; Q9D691; Q9QZF5; Q9Z203;
DT   11-FEB-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   20-JAN-2016, entry version 145.
DE   RecName: Full=Toll-like receptor 4;
DE   AltName: CD_antigen=CD284;
DE   Flags: Precursor;
GN   Name=Tlr4; Synonyms=Lps;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=C3H/HeJ;
RX   PubMed=10087992; DOI=10.1006/bcmd.1998.0201;
RA   Poltorak A., Smirnova I., He X., Liu M.-Y., Van Huffel C.,
RA   Birdwell D., Alejos E., Silva M., Du X., Thompson P., Chan E.K.L.,
RA   Ledesma J., Roe B., Clifton S., Vogel S.N., Beutler B.;
RT   "Genetic and physical mapping of the Lps locus: identification of the
RT   Toll-4 receptor as a candidate gene in the critical region.";
RL   Blood Cells Mol. Dis. 24:340-355(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND VARIANT LPS-TOLERANT
RP   HIS-712.
RC   STRAIN=C3H/HeJ;
RX   PubMed=9851930; DOI=10.1126/science.282.5396.2085;
RA   Poltorak A., He X., Smirnova I., Liu M.-Y., Van Huffel C., Du X.,
RA   Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M.,
RA   Ricciardi-Castagnoli P., Layton B., Beutler B.;
RT   "Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations
RT   in Tlr4 gene.";
RL   Science 282:2085-2088(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND VARIANT LPS-TOLERANT
RP   HIS-712.
RC   STRAIN=C57BL/6J;
RX   PubMed=9989976; DOI=10.1084/jem.189.4.615;
RA   Qureshi S.T., Lariviere L., Leveque G., Clermont S., Moore K.J.,
RA   Gros P., Malo D.;
RT   "Endotoxin-tolerant mice have mutations in Toll-like receptor 4
RT   (Tlr4).";
RL   J. Exp. Med. 189:615-625(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Macrophage;
RX   PubMed=10548109; DOI=10.1038/44605;
RA   Underhill D.M., Ozinsky A., Hajjar A.M., Stevens A., Wilson C.B.,
RA   Bassetti M., Aderem A.;
RT   "The Toll-like receptor 2 is recruited to macrophage phagosomes and
RT   discriminates between pathogens.";
RL   Nature 401:811-815(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ASN-94; ILE-209;
RP   GLY-219; ILE-254; LEU-423; SER-477; ALA-516; ASP-593; ILE-600;
RP   VAL-607; ILE-637; HIS-761 AND LYS-811.
RC   STRAIN=Various strains;
RX   PubMed=11104518; DOI=10.1186/gb-2000-1-1-research002;
RA   Smirnova I., Poltorak A., Chan E.K.L., McBride C., Beutler B.;
RT   "Phylogenetic variation and polymorphism at the Toll-like receptor 4
RT   locus (TLR4).";
RL   Genome Biol. 1:RESEARCH002.1-RESEARCH002.10(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-154.
RC   STRAIN=C57BL/6J; TISSUE=Skin;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [7]
RP   FUNCTION.
RX   PubMed=10952994; DOI=10.1074/jbc.M007386200;
RA   Rhee S.H., Hwang D.;
RT   "Murine Toll-like receptor 4 confers lipopolysaccharide responsiveness
RT   as determined by activation of NF kappa B and expression of the
RT   inducible cyclooxygenase.";
RL   J. Biol. Chem. 275:34035-34040(2000).
RN   [8]
RP   FUNCTION.
RX   PubMed=17478729; DOI=10.1161/CIRCRESAHA.106.142851;
RA   Kim F., Pham M., Luttrell I., Bannerman D.D., Tupper J., Thaler J.,
RA   Hawn T.R., Raines E.W., Schwartz M.W.;
RT   "Toll-like receptor-4 mediates vascular inflammation and insulin
RT   resistance in diet-induced obesity.";
RL   Circ. Res. 100:1589-1596(2007).
RN   [9]
RP   INTERACTION WITH CNPY3.
RX   PubMed=18780723; DOI=10.1093/intimm/dxn098;
RA   Kiyokawa T., Akashi-Takamura S., Shibata T., Matsumoto F.,
RA   Nishitani C., Kuroki Y., Seto Y., Miyake K.;
RT   "A single base mutation in the PRAT4A gene reveals differential
RT   interaction of PRAT4A with Toll-like receptors.";
RL   Int. Immunol. 20:1407-1415(2008).
RN   [10]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=20133493; DOI=10.1093/intimm/dxq005;
RA   Tsukamoto H., Fukudome K., Takao S., Tsuneyoshi N., Kimoto M.;
RT   "Lipopolysaccharide-binding protein-mediated Toll-like receptor 4
RT   dimerization enables rapid signal transduction against
RT   lipopolysaccharide stimulation on membrane-associated CD14-expressing
RT   cells.";
RL   Int. Immunol. 22:271-280(2010).
RN   [11]
RP   INTERACTION WITH HSP90B1.
RX   PubMed=20865800; DOI=10.1038/ncomms1070;
RA   Liu B., Yang Y., Qiu Z., Staron M., Hong F., Li Y., Wu S., Li Y.,
RA   Hao B., Bona R., Han D., Li Z.;
RT   "Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a
RT   substrate-specific cochaperone.";
RL   Nat. Commun. 1:79-79(2010).
RN   [12]
RP   ERRATUM.
RA   Liu B., Yang Y., Qiu Z., Staron M., Hong F., Li Y., Wu S., Li Y.,
RA   Hao B., Bona R., Han D., Li Z.;
RL   Nat. Commun. 3:653-653(2012).
RN   [13]
RP   FUNCTION.
RX   PubMed=20037584; DOI=10.1038/ni.1836;
RA   Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J.,
RA   Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A.,
RA   Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J.;
RT   "CD36 ligands promote sterile inflammation through assembly of a Toll-
RT   like receptor 4 and 6 heterodimer.";
RL   Nat. Immunol. 11:155-161(2010).
RN   [14]
RP   FUNCTION, DISRUPTION PHENOTYPE, AND TISSUE SPECIFICITY.
RX   PubMed=23812099; DOI=10.1038/ni.2639;
RA   Sheedy F.J., Grebe A., Rayner K.J., Kalantari P., Ramkhelawon B.,
RA   Carpenter S.B., Becker C.E., Ediriweera H.N., Mullick A.E.,
RA   Golenbock D.T., Stuart L.M., Latz E., Fitzgerald K.A., Moore K.J.;
RT   "CD36 coordinates NLRP3 inflammasome activation by facilitating
RT   intracellular nucleation of soluble ligands into particulate ligands
RT   in sterile inflammation.";
RL   Nat. Immunol. 14:812-820(2013).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH TIRAP AND TICAM2.
RX   PubMed=24380872; DOI=10.1093/intimm/dxt071;
RA   Tanimura N., Saitoh S., Ohto U., Akashi-Takamura S., Fujimoto Y.,
RA   Fukase K., Shimizu T., Miyake K.;
RT   "The attenuated inflammation of MPL is due to the lack of CD14-
RT   dependent tight dimerization of the TLR4/MD2 complex at the plasma
RT   membrane.";
RL   Int. Immunol. 26:307-314(2014).
RN   [16]
RP   INTERACTION WITH WDFY1 AND TICAM1.
RX   PubMed=25736436; DOI=10.15252/embr.201439637;
RA   Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B.,
RA   Liu Y.;
RT   "WDFY1 mediates TLR3/4 signaling by recruiting TRIF.";
RL   EMBO Rep. 16:447-455(2015).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.84 ANGSTROMS) OF 27-625 IN COMPLEX WITH LY96,
RP   DISULFIDE BOND, AND GLYCOSYLATION AT ASN-34; ASN-75; ASN-172; ASN-204;
RP   ASN-237; ASN-307; ASN-492; ASN-524 AND ASN-572.
RX   PubMed=17803912; DOI=10.1016/j.cell.2007.08.002;
RA   Kim H.M., Park B.S., Kim J.-I., Kim S.E., Lee J., Oh S.C.,
RA   Enkhbayar P., Matsushima N., Lee H., Yoo O.J., Lee J.-O.;
RT   "Crystal structure of the TLR4-MD-2 complex with bound endotoxin
RT   antagonist Eritoran.";
RL   Cell 130:906-917(2007).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS) OF 22-627 IN COMPLEX WITH LY96,
RP   SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-172; ASN-204;
RP   ASN-524 AND ASN-572.
RX   PubMed=22532668; DOI=10.1073/pnas.1201193109;
RA   Ohto U., Fukase K., Miyake K., Shimizu T.;
RT   "Structural basis of species-specific endotoxin sensing by innate
RT   immune receptor TLR4/MD-2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:7421-7426(2012).
CC   -!- FUNCTION: Cooperates with LY96 and CD14 to mediate the innate
CC       immune response to bacterial lipopolysaccharide (LPS)
CC       (PubMed:9851930, PubMed:9989976, PubMed:20133493). Acts via MYD88,
CC       TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine
CC       secretion and the inflammatory response (PubMed:24380872). Also
CC       involved in LPS-independent inflammatory responses triggered by
CC       free fatty acids, such as palmitate. In complex with TLR6,
CC       promotes sterile inflammation in monocytes/macrophages in response
CC       to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In
CC       this context, the initial signal is provided by oxLDL- or amyloid-
CC       beta 42-binding to CD36. This event induces the formation of a
CC       heterodimer of TLR4 and TLR6, which is rapidly internalized and
CC       triggers inflammatory response, leading to the NF-kappa-B-
CC       dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88
CC       signaling pathway, and CCL5 cytokine, via TICAM1 signaling
CC       pathway, as well as IL1B secretion. Binds electronegative LDL
CC       (LDL(-)) and mediates the cytokine release induced by LDL(-) (By
CC       similarity). {ECO:0000250|UniProtKB:O00206,
CC       ECO:0000269|PubMed:10952994, ECO:0000269|PubMed:17478729,
CC       ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:20133493,
CC       ECO:0000269|PubMed:23812099, ECO:0000269|PubMed:24380872,
CC       ECO:0000269|PubMed:9851930, ECO:0000269|PubMed:9989976}.
CC   -!- SUBUNIT: Belongs to the lipopolysaccharide (LPS) receptor, a
CC       multi-protein complex containing at least CD14, LY96 and TLR4
CC       (PubMed:24380872). Binding to bacterial LPS leads to
CC       homodimerization (PubMed:20133493, PubMed:24380872,
CC       PubMed:22532668). Interacts with LY96 via the extracellular domain
CC       (PubMed:17803912, PubMed:22532668). Interacts with MYD88 (via the
CC       TIR domain). Interacts with TICAM2 and TIRAP (PubMed:24380872).
CC       Interacts with NOX4 (By similarity). Interacts with CNPY3 and
CC       HSP90B1; this interaction is required for proper folding in the
CC       endoplasmic reticulum (PubMed:18780723, PubMed:20865800).
CC       Interacts with MLK4; this interaction leads to negative regulation
CC       of TLR4 signaling (By similarity). Interacts with CD36, following
CC       CD36 stimulation by oxLDL or amyloid-beta 42, and forms a
CC       heterodimer with TLR6. The trimeric complex is internalized and
CC       triggers inflammatory response. LYN kinase activity facilitates
CC       TLR4-TLR6 heterodimerization and signal initiation (By
CC       similarity). Interacts with TICAM1 in response to LPS in a WDFY1-
CC       dependent manner (PubMed:25736436). Interacts with WDFY1 in
CC       response to LPS (PubMed:25736436). {ECO:0000250|UniProtKB:O00206,
CC       ECO:0000269|PubMed:17803912, ECO:0000269|PubMed:18780723,
CC       ECO:0000269|PubMed:20133493, ECO:0000269|PubMed:20865800,
CC       ECO:0000269|PubMed:22532668, ECO:0000269|PubMed:24380872,
CC       ECO:0000269|PubMed:25736436}.
CC   -!- INTERACTION:
CC       Q9JHF9:Ly96; NbExp=3; IntAct=EBI-1534575, EBI-1534566;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20133493};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:20133493}.
CC       Note=Upon complex formation with CD36 and TLR6, internalized
CC       through dynamin-dependent endocytosis.
CC       {ECO:0000250|UniProtKB:O00206}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, spleen, lung and
CC       muscle. Lower levels are found in liver and kidney. Expressed in
CC       macrophages. {ECO:0000269|PubMed:23812099}.
CC   -!- DOMAIN: The TIR domain mediates interaction with NOX4.
CC       {ECO:0000250|UniProtKB:O00206}.
CC   -!- POLYMORPHISM: Interstrain analyzes reveals that TLR4 is a
CC       polymorphic protein and that the extracellular domain is far more
CC       variable than the cytoplasmic domain, which is variable at the C-
CC       terminal. {ECO:0000305|PubMed:11104518}.
CC   -!- DISEASE: Note=The protein is encoded by the Lps locus, an
CC       important susceptibility locus, influencing the propensity to
CC       develop a disseminated Gram-negative infection.
CC       {ECO:0000269|PubMed:9851930, ECO:0000269|PubMed:9989976}.
CC   -!- DISRUPTION PHENOTYPE: Animals with a double knockout of APOE and
CC       TLR4, fed a Western diet for 12 weeks, have less aortic plaque
CC       formation than single APOE knockout mice. They also show lower
CC       serum concentrations of IL1A, ILB and IL18.
CC       {ECO:0000269|PubMed:23812099}.
CC   -!- SIMILARITY: Belongs to the Toll-like receptor family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 19 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 LRRCT domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 TIR domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00204}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF095353; AAC99411.1; -; mRNA.
DR   EMBL; AF110133; AAD29272.1; -; mRNA.
DR   EMBL; AF185285; AAF04278.1; -; mRNA.
DR   EMBL; AF177767; AAF05317.1; -; Genomic_DNA.
DR   EMBL; AK014533; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS18271.1; -.
DR   RefSeq; NP_067272.1; NM_021297.3.
DR   UniGene; Mm.38049; -.
DR   PDB; 2Z64; X-ray; 2.84 A; A=27-625.
DR   PDB; 3VQ1; X-ray; 2.70 A; A/B=22-627.
DR   PDB; 3VQ2; X-ray; 2.48 A; A/B=22-627.
DR   PDBsum; 2Z64; -.
DR   PDBsum; 3VQ1; -.
DR   PDBsum; 3VQ2; -.
DR   ProteinModelPortal; Q9QUK6; -.
DR   SMR; Q9QUK6; 27-814.
DR   BioGrid; 204224; 23.
DR   DIP; DIP-38573N; -.
DR   IntAct; Q9QUK6; 8.
DR   STRING; 10090.ENSMUSP00000045770; -.
DR   BindingDB; Q9QUK6; -.
DR   ChEMBL; CHEMBL3038514; -.
DR   PhosphoSite; Q9QUK6; -.
DR   MaxQB; Q9QUK6; -.
DR   PaxDb; Q9QUK6; -.
DR   PRIDE; Q9QUK6; -.
DR   Ensembl; ENSMUST00000048096; ENSMUSP00000045770; ENSMUSG00000039005.
DR   GeneID; 21898; -.
DR   KEGG; mmu:21898; -.
DR   UCSC; uc008thv.1; mouse.
DR   CTD; 7099; -.
DR   MGI; MGI:96824; Tlr4.
DR   eggNOG; KOG4641; Eukaryota.
DR   eggNOG; COG4886; LUCA.
DR   GeneTree; ENSGT00760000119006; -.
DR   HOGENOM; HOG000037951; -.
DR   HOVERGEN; HBG018823; -.
DR   InParanoid; Q9QUK6; -.
DR   KO; K10160; -.
DR   OMA; SVACICE; -.
DR   OrthoDB; EOG7ZKS9G; -.
DR   PhylomeDB; Q9QUK6; -.
DR   TreeFam; TF351113; -.
DR   Reactome; R-MMU-166016; Toll Like Receptor 4 (TLR4) Cascade.
DR   Reactome; R-MMU-166166; MyD88-independent TLR3/TLR4 cascade.
DR   EvolutionaryTrace; Q9QUK6; -.
DR   NextBio; 301436; -.
DR   PRO; PR:Q9QUK6; -.
DR   Proteomes; UP000000589; Chromosome 4.
DR   Bgee; Q9QUK6; -.
DR   CleanEx; MM_TLR4; -.
DR   ExpressionAtlas; Q9QUK6; baseline.
DR   Genevisible; Q9QUK6; MM.
DR   GO; GO:0009986; C:cell surface; ISO:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:MGI.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISO:MGI.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; ISO:MGI.
DR   GO; GO:0046696; C:lipopolysaccharide receptor complex; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0001530; F:lipopolysaccharide binding; ISO:MGI.
DR   GO; GO:0001875; F:lipopolysaccharide receptor activity; ISS:UniProtKB.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IEA:InterPro.
DR   GO; GO:0002218; P:activation of innate immune response; IMP:MGI.
DR   GO; GO:0000187; P:activation of MAPK activity; IMP:BHF-UCL.
DR   GO; GO:0007250; P:activation of NF-kappaB-inducing kinase activity; NAS:UniProtKB.
DR   GO; GO:0014002; P:astrocyte development; IMP:MGI.
DR   GO; GO:0002322; P:B cell proliferation involved in immune response; IMP:MGI.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IMP:BHF-UCL.
DR   GO; GO:0071223; P:cellular response to lipoteichoic acid; IMP:MGI.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IMP:MGI.
DR   GO; GO:0032497; P:detection of lipopolysaccharide; TAS:BHF-UCL.
DR   GO; GO:0007252; P:I-kappaB phosphorylation; IMP:MGI.
DR   GO; GO:0045087; P:innate immune response; TAS:BHF-UCL.
DR   GO; GO:0032609; P:interferon-gamma production; IGI:MGI.
DR   GO; GO:0050702; P:interleukin-1 beta secretion; IDA:UniProtKB.
DR   GO; GO:0060729; P:intestinal epithelial structure maintenance; IMP:BHF-UCL.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IDA:MGI.
DR   GO; GO:0042116; P:macrophage activation; ISS:UniProtKB.
DR   GO; GO:0045576; P:mast cell activation; NAS:UniProtKB.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IMP:BHF-UCL.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; IMP:BHF-UCL.
DR   GO; GO:0032707; P:negative regulation of interleukin-23 production; IMP:BHF-UCL.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IMP:BHF-UCL.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IMP:BHF-UCL.
DR   GO; GO:0002537; P:nitric oxide production involved in inflammatory response; IMP:MGI.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IMP:MGI.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:MGI.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:MGI.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; IDA:BHF-UCL.
DR   GO; GO:0045359; P:positive regulation of interferon-beta biosynthetic process; IMP:MGI.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; IDA:BHF-UCL.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IMP:BHF-UCL.
DR   GO; GO:0045362; P:positive regulation of interleukin-1 biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0032732; P:positive regulation of interleukin-1 production; IDA:BHF-UCL.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; IDA:BHF-UCL.
DR   GO; GO:0045084; P:positive regulation of interleukin-12 biosynthetic process; ISO:MGI.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IDA:BHF-UCL.
DR   GO; GO:0045368; P:positive regulation of interleukin-13 biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0045410; P:positive regulation of interleukin-6 biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0045416; P:positive regulation of interleukin-8 biosynthetic process; ISO:MGI.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; ISO:MGI.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:MGI.
DR   GO; GO:0050671; P:positive regulation of lymphocyte proliferation; IMP:MGI.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; IMP:MGI.
DR   GO; GO:0045348; P:positive regulation of MHC class II biosynthetic process; IMP:MGI.
DR   GO; GO:0042346; P:positive regulation of NF-kappaB import into nucleus; ISO:MGI.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISO:MGI.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:MGI.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0070430; P:positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway; IDA:MGI.
DR   GO; GO:0070434; P:positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway; IDA:MGI.
DR   GO; GO:0010572; P:positive regulation of platelet activation; IMP:BHF-UCL.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; IDA:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0042535; P:positive regulation of tumor necrosis factor biosynthetic process; ISO:MGI.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:BHF-UCL.
DR   GO; GO:0050707; P:regulation of cytokine secretion; IEA:InterPro.
DR   GO; GO:0002730; P:regulation of dendritic cell cytokine production; IDA:MGI.
DR   GO; GO:0050727; P:regulation of inflammatory response; IMP:BHF-UCL.
DR   GO; GO:0009617; P:response to bacterium; IMP:MGI.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IMP:MGI.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IEA:InterPro.
DR   Gene3D; 3.40.50.10140; -; 1.
DR   Gene3D; 3.80.10.10; -; 4.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR027168; TLR4.
DR   PANTHER; PTHR24365:SF230; PTHR24365:SF230; 2.
DR   Pfam; PF00560; LRR_1; 1.
DR   Pfam; PF13855; LRR_8; 2.
DR   Pfam; PF01582; TIR; 1.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00255; TIR; 1.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF52200; SSF52200; 1.
DR   PROSITE; PS50104; TIR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome; Disease mutation;
KW   Disulfide bond; Glycoprotein; Immunity; Inflammatory response;
KW   Innate immunity; Leucine-rich repeat; Membrane; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26    835       Toll-like receptor 4.
FT                                /FTId=PRO_0000034723.
FT   TOPO_DOM     26    638       Extracellular. {ECO:0000255}.
FT   TRANSMEM    639    659       Helical. {ECO:0000255}.
FT   TOPO_DOM    660    835       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       54     75       LRR 1.
FT   REPEAT       78     99       LRR 2.
FT   REPEAT      102    123       LRR 3.
FT   REPEAT      126    147       LRR 4.
FT   REPEAT      150    171       LRR 5.
FT   REPEAT      175    198       LRR 6.
FT   REPEAT      204    224       LRR 7.
FT   REPEAT      226    247       LRR 8.
FT   REPEAT      248    269       LRR 9.
FT   REPEAT      329    349       LRR 10.
FT   REPEAT      350    370       LRR 11.
FT   REPEAT      372    392       LRR 12.
FT   REPEAT      398    420       LRR 13.
FT   REPEAT      421    442       LRR 14.
FT   REPEAT      446    467       LRR 15.
FT   REPEAT      470    490       LRR 16.
FT   REPEAT      495    516       LRR 17.
FT   REPEAT      519    540       LRR 18.
FT   REPEAT      543    564       LRR 19.
FT   DOMAIN      576    627       LRRCT.
FT   DOMAIN      670    816       TIR. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00204}.
FT   CARBOHYD     34     34       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17803912}.
FT   CARBOHYD     75     75       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17803912}.
FT   CARBOHYD    172    172       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17803912}.
FT   CARBOHYD    204    204       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17803912}.
FT   CARBOHYD    237    237       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17803912}.
FT   CARBOHYD    307    307       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17803912}.
FT   CARBOHYD    492    492       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17803912}.
FT   CARBOHYD    495    495       N-linked (GlcNAc...).
FT   CARBOHYD    524    524       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17803912}.
FT   CARBOHYD    572    572       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:17803912}.
FT   CARBOHYD    575    575       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    613    613       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    621    621       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    622    622       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     28     39       {ECO:0000269|PubMed:17803912}.
FT   DISULFID    280    304       {ECO:0000269|PubMed:17803912}.
FT   DISULFID    388    389       {ECO:0000269|PubMed:17803912}.
FT   DISULFID    580    606       {ECO:0000269|PubMed:17803912}.
FT   DISULFID    582    625       {ECO:0000269|PubMed:17803912}.
FT   VARIANT      94     94       D -> N (in strain: KK/HLJ).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     209    209       M -> I (in strain: A/J, BALB/cJ, P/J,
FT                                SODL/EI, SEA/GNJ, NZW/LACJ and VM/DK).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     219    219       D -> G (in strain: SEA/GNJ).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     254    254       V -> I (in strain: A/J, BALB/cJ and SEA/
FT                                GNJ). {ECO:0000269|PubMed:11104518}.
FT   VARIANT     423    423       Q -> L (in strain: SEA/GNJ).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     477    477       A -> S (in strain: P/J).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     516    516       T -> A (in strain: LP/J).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     593    593       E -> D (in strain: A/J, BALB/cJ, P/J,
FT                                SODL/EI, SEA/GNJ, NZW/LACJ and VM/DK).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     600    600       N -> I (in strain: KK/HLJ).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     607    607       A -> V (in strain: P/J).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     637    637       V -> I (in strain: P/J).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     712    712       P -> H (in Lps-tolerant mice).
FT                                {ECO:0000269|PubMed:9851930,
FT                                ECO:0000269|PubMed:9989976}.
FT   VARIANT     761    761       R -> H (in strain: A/J, BALB/cJ, SODL/EI,
FT                                SEA/GNJ, NZW/LACJ and VM/DK).
FT                                {ECO:0000269|PubMed:11104518}.
FT   VARIANT     811    811       N -> K (in strain: P/J).
FT                                {ECO:0000269|PubMed:11104518}.
FT   CONFLICT     87    154       CEIETIEDKAWHGLHHLSNLILTGNPIQSFSPGSFSGLTSL
FT                                ENLVAVETKLASLESFPIGQLITLKKL -> EMNTESKSSE
FT                                AHALALSHILSPCQPSRRKLRVKLGSLSYQRAEEGVRSSEI
FT                                GYSCLHVDTRHDINAVD (in Ref. 6).
FT                                {ECO:0000305}.
FT   STRAND       29     32       {ECO:0000244|PDB:3VQ2}.
FT   TURN         33     35       {ECO:0000244|PDB:3VQ2}.
FT   STRAND       36     38       {ECO:0000244|PDB:3VQ2}.
FT   STRAND       40     42       {ECO:0000244|PDB:2Z64}.
FT   STRAND       49     51       {ECO:0000244|PDB:2Z64}.
FT   STRAND       57     59       {ECO:0000244|PDB:3VQ2}.
FT   TURN         70     75       {ECO:0000244|PDB:3VQ2}.
FT   STRAND       81     83       {ECO:0000244|PDB:3VQ2}.
FT   TURN         94     99       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      105    107       {ECO:0000244|PDB:3VQ2}.
FT   TURN        118    123       {ECO:0000244|PDB:3VQ1}.
FT   STRAND      129    131       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      140    143       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      153    155       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       168    171       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      178    180       {ECO:0000244|PDB:3VQ2}.
FT   TURN        191    194       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       195    199       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      206    208       {ECO:0000244|PDB:3VQ2}.
FT   TURN        219    224       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      226    234       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       239    247       {ECO:0000244|PDB:3VQ2}.
FT   TURN        248    251       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      253    260       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       273    276       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       279    281       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      282    289       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       297    300       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       303    305       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      309    315       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      331    337       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      353    358       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      375    377       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      380    382       {ECO:0000244|PDB:2Z64}.
FT   STRAND      383    388       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       391    394       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      401    403       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      408    412       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      424    426       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      430    434       {ECO:0000244|PDB:3VQ2}.
FT   TURN        435    443       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      449    451       {ECO:0000244|PDB:3VQ2}.
FT   TURN        462    467       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      473    475       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       482    484       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      498    500       {ECO:0000244|PDB:3VQ2}.
FT   TURN        511    516       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      522    524       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      532    534       {ECO:0000244|PDB:2Z64}.
FT   HELIX       535    537       {ECO:0000244|PDB:3VQ2}.
FT   TURN        538    540       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      546    548       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      557    559       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       561    563       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      570    572       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       582    584       {ECO:0000244|PDB:3VQ1}.
FT   HELIX       585    588       {ECO:0000244|PDB:3VQ2}.
FT   TURN        589    593       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      594    600       {ECO:0000244|PDB:3VQ2}.
FT   HELIX       601    603       {ECO:0000244|PDB:3VQ2}.
FT   STRAND      608    610       {ECO:0000244|PDB:2Z64}.
FT   HELIX       616    618       {ECO:0000244|PDB:2Z64}.
SQ   SEQUENCE   835 AA;  95519 MW;  9C83B59F9A220C17 CRC64;
     MMPPWLLART LIMALFFSCL TPGSLNPCIE VVPNITYQCM DQKLSKVPDD IPSSTKNIDL
     SFNPLKILKS YSFSNFSELQ WLDLSRCEIE TIEDKAWHGL HHLSNLILTG NPIQSFSPGS
     FSGLTSLENL VAVETKLASL ESFPIGQLIT LKKLNVAHNF IHSCKLPAYF SNLTNLVHVD
     LSYNYIQTIT VNDLQFLREN PQVNLSLDMS LNPIDFIQDQ AFQGIKLHEL TLRGNFNSSN
     IMKTCLQNLA GLHVHRLILG EFKDERNLEI FEPSIMEGLC DVTIDEFRLT YTNDFSDDIV
     KFHCLANVSA MSLAGVSIKY LEDVPKHFKW QSLSIIRCQL KQFPTLDLPF LKSLTLTMNK
     GSISFKKVAL PSLSYLDLSR NALSFSGCCS YSDLGTNSLR HLDLSFNGAI IMSANFMGLE
     ELQHLDFQHS TLKRVTEFSA FLSLEKLLYL DISYTNTKID FDGIFLGLTS LNTLKMAGNS
     FKDNTLSNVF ANTTNLTFLD LSKCQLEQIS WGVFDTLHRL QLLNMSHNNL LFLDSSHYNQ
     LYSLSTLDCS FNRIETSKGI LQHFPKSLAF FNLTNNSVAC ICEHQKFLQW VKEQKQFLVN
     VEQMTCATPV EMNTSLVLDF NNSTCYMYKT IISVSVVSVI VVSTVAFLIY HFYFHLILIA
     GCKKYSRGES IYDAFVIYSS QNEDWVRNEL VKNLEEGVPR FHLCLHYRDF IPGVAIAANI
     IQEGFHKSRK VIVVVSRHFI QSRWCIFEYE IAQTWQFLSS RSGIIFIVLE KVEKSLLRQQ
     VELYRLLSRN TYLEWEDNPL GRHIFWRRLK NALLDGKASN PEQTAEEEQE TATWT
//
ID   EGLN_HUMAN              Reviewed;         658 AA.
AC   P17813; Q14248; Q14926; Q5T9C0;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   17-FEB-2016, entry version 174.
DE   RecName: Full=Endoglin;
DE   AltName: CD_antigen=CD105;
DE   Flags: Precursor;
GN   Name=ENG; Synonyms=END;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RX   PubMed=8370410; DOI=10.1002/eji.1830230943;
RA   Bellon T., Corbi A., Lastres P., Cales C., Cebrian M., Vera S.,
RA   Cheifetz S., Massague J., Letarte M., Bernabeu C.;
RT   "Identification and expression of two forms of the human transforming
RT   growth factor-beta-binding protein endoglin with distinct cytoplasmic
RT   regions.";
RL   Eur. J. Immunol. 23:2340-2345(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 14-658, AND PROTEIN
RP   SEQUENCE OF 26-36 (ISOFORM LONG).
RC   TISSUE=Umbilical vein;
RX   PubMed=1692830;
RA   Gougos A., Letarte M.;
RT   "Primary structure of endoglin, an RGD-containing glycoprotein of
RT   human endothelial cells.";
RL   J. Biol. Chem. 265:8361-8364(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 122-378.
RX   PubMed=7894484; DOI=10.1038/ng1294-345;
RA   McAllister K.A., Grogg K.M., Johnson D.W., Gallione C.J.,
RA   Baldwin M.A., Jackson C.E., Helmbold E.A., Markel D.S., McKinnon W.C.,
RA   Murrell J., McCormick M.K., Pericak-Vance M.A., Heutink P.,
RA   Oostra B.A., Haitjema T., Westerman C.J., Porteous M.E.,
RA   Guttmacher A.E., Letarte M., Marchuk D.A.;
RT   "Endoglin, a TGF-beta binding protein of endothelial cells, is the
RT   gene for hereditary haemorrhagic telangiectasia type 1.";
RL   Nat. Genet. 8:345-351(1994).
RN   [6]
RP   INTERACTION WITH TCTEX1D4.
RX   PubMed=16982625; DOI=10.1074/jbc.M608614200;
RA   Meng Q.-J., Lux A., Holloschi A., Li J., Hughes J.M.X., Foerg T.,
RA   McCarthy J.E.G., Heagerty A.M., Kioschis P., Hafner M., Garland J.M.;
RT   "Identification of Tctex2beta, a novel dynein light chain family
RT   member that interacts with different transforming growth factor-beta
RT   receptors.";
RL   J. Biol. Chem. 281:37069-37080(2006).
RN   [7]
RP   INTERACTION WITH ARRB2.
RX   PubMed=17540773; DOI=10.1074/jbc.M700176200;
RA   Lee N.Y., Blobe G.C.;
RT   "The interaction of endoglin with beta-arrestin2 regulates
RT   transforming growth factor-beta-mediated ERK activation and migration
RT   in endothelial cells.";
RL   J. Biol. Chem. 282:21507-21517(2007).
RN   [8]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-134.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH GDF2.
RX   PubMed=21737454; DOI=10.1074/jbc.M111.260133;
RA   Castonguay R., Werner E.D., Matthews R.G., Presman E., Mulivor A.W.,
RA   Solban N., Sako D., Pearsall R.S., Underwood K.W., Seehra J.,
RA   Kumar R., Grinberg A.V.;
RT   "Soluble endoglin specifically binds bone morphogenetic proteins 9 and
RT   10 via its orphan domain, inhibits blood vessel formation, and
RT   suppresses tumor growth.";
RL   J. Biol. Chem. 286:30034-30046(2011).
RN   [10]
RP   INTERACTION WITH GDF2.
RX   PubMed=22347366; DOI=10.1371/journal.pone.0029948;
RA   Alt A., Miguel-Romero L., Donderis J., Aristorena M., Blanco F.J.,
RA   Round A., Rubio V., Bernabeu C., Marina A.;
RT   "Structural and functional insights into endoglin ligand recognition
RT   and binding.";
RL   PLoS ONE 7:E29948-E29948(2012).
RN   [11]
RP   FUNCTION.
RX   PubMed=23300529; DOI=10.1371/journal.pone.0050920;
RA   Nolan-Stevaux O., Zhong W., Culp S., Shaffer K., Hoover J.,
RA   Wickramasinghe D., Ruefli-Brasse A.;
RT   "Endoglin requirement for BMP9 signaling in endothelial cells reveals
RT   new mechanism of action for selective anti-endoglin antibodies.";
RL   PLoS ONE 7:E50920-E50920(2012).
RN   [12]
RP   VARIANT HHT1 192-ARG--PRO-198 DEL, AND VARIANT MET-5.
RX   PubMed=9245986; DOI=10.1086/513906;
RA   Shovlin C.L., Hughes J.M.B., Scott J., Seidman C.E., Seidman J.G.;
RT   "Characterization of endoglin and identification of novel mutations in
RT   hereditary hemorrhagic telangiectasia.";
RL   Am. J. Hum. Genet. 61:68-79(1997).
RN   [13]
RP   VARIANT HHT1 ASP-160.
RX   PubMed=9157574;
RA   Yamaguchi H., Azuma H., Shigekiyo T., Inoue H., Saito S.;
RT   "A novel missense mutation in the endoglin gene in hereditary
RT   hemorrhagic telangiectasia.";
RL   Thromb. Haemost. 77:243-247(1997).
RN   [14]
RP   VARIANTS HHT1 VAL-52; ARG-53; CYS-149 AND PRO-306.
RX   PubMed=9554745;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<286::AID-HUMU6>3.3.CO;2-2;
RA   Gallione C.J., Klaus D.J., Yeh E.Y., Stenzel T.T., Xue Y.,
RA   Anthony K.B., McAllister K.A., Baldwin M.A., Berg J.N., Lux A.,
RA   Smith J.D., Vary C.P.H., Craigen W.J., Westermann C.J.J., Warner M.L.,
RA   Miller Y.E., Jackson C.E., Guttmacher A.E., Marchuk D.A.;
RT   "Mutation and expression analysis of the endoglin gene in hereditary
RT   hemorrhagic telangiectasia reveals null alleles.";
RL   Hum. Mutat. 11:286-294(1998).
RN   [15]
RP   VARIANTS HHT1 VAL-52; ARG-53; CYS-149 AND PRO-221.
RX   PubMed=10545596; DOI=10.1093/hmg/8.12.2171;
RA   Pece-Barbara N., Cymerman U., Vera S., Marchuk D.A., Letarte M.;
RT   "Expression analysis of four endoglin missense mutations suggests that
RT   haploinsufficiency is the predominant mechanism for hereditary
RT   hemorrhagic telangiectasia type 1.";
RL   Hum. Mol. Genet. 8:2171-2181(1999).
RN   [16]
RP   VARIANT HHT1 VAL-413.
RX   PubMed=10982033; DOI=10.1007/s004390050008;
RA   Gallione C.J., Scheessele E.A., Reinhardt D., Duits A.J., Berg J.N.,
RA   Westermann C.J.J., Marchuk D.A.;
RT   "Two common endoglin mutations in families with hereditary hemorrhagic
RT   telangiectasia in the Netherlands Antilles: evidence for a founder
RT   effect.";
RL   Hum. Genet. 107:40-44(2000).
RN   [17]
RP   VARIANT HHT1 ARG-53.
RX   PubMed=10625079; DOI=10.1203/00006450-200001000-00008;
RA   Cymerman U., Vera S., Pece-Barbara N., Bourdeau A., White R.I. Jr.,
RA   Dunn J., Letarte M.;
RT   "Identification of hereditary hemorrhagic telangiectasia type 1 in
RT   newborns by protein expression and mutation analysis of endoglin.";
RL   Pediatr. Res. 47:24-35(2000).
RN   [18]
RP   VARIANTS HHT1 PRO-8; PHE-49; ARG-107; CYS-207 DEL; THR-263;
RP   ARG-232-233-THR DEL; ILE-263 DEL; SER-412 AND MET-504.
RX   PubMed=15024723; DOI=10.1002/humu.20017;
RG   French Rendu-Osler network;
RA   Lesca G., Plauchu H., Coulet F., Lefebvre S., Plessis G., Odent S.,
RA   Riviere S., Leheup B., Goizet C., Carette M.-F., Cordier J.-F.,
RA   Pinson S., Soubrier F., Calender A., Giraud S.;
RT   "Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary
RT   hemorrhagic telangiectasia in France.";
RL   Hum. Mutat. 23:289-299(2004).
RN   [19]
RP   VARIANTS HHT1 PRO-221; ILE-263 DEL AND LEU-615.
RX   PubMed=15712270; DOI=10.1002/humu.9311;
RA   Kuehl H.K.A., Caselitz M., Hasenkamp S., Wagner S., El-Harith E.-H.A.,
RA   Manns M.P., Stuhrmann M.;
RT   "Hepatic manifestation is associated with ALK1 in hereditary
RT   hemorrhagic telangiectasia: identification of five novel ALK1 and one
RT   novel ENG mutations.";
RL   Hum. Mutat. 25:320-320(2005).
RN   [20]
RP   VARIANTS HHT1 ASP-11; ASP-105; GLU-175; THR-220; ASP-308; SER-363;
RP   TRP-437; SER-490; HIS-529; PRO-547 AND ASP-604.
RX   PubMed=16752392; DOI=10.1002/humu.20342;
RA   Bossler A.D., Richards J., George C., Godmilow L., Ganguly A.;
RT   "Novel mutations in ENG and ACVRL1 identified in a series of 200
RT   individuals undergoing clinical genetic testing for hereditary
RT   hemorrhagic telangiectasia (HHT): correlation of genotype with
RT   phenotype.";
RL   Hum. Mutat. 27:667-675(2006).
RN   [21]
RP   VARIANTS HHT1 193-THR-LEU-194 DELINS VAL-LEU-GLN AND ASP-545.
RX   PubMed=16525724;
RA   Argyriou L., Twelkemeyer S., Panchulidze I., Wehner L.E., Teske U.,
RA   Engel W., Nayernia K.;
RT   "Novel mutations in the ENG and ACVRL1 genes causing hereditary
RT   hemorrhagic teleangiectasia.";
RL   Int. J. Mol. Med. 17:655-659(2006).
RN   [22]
RP   VARIANTS PRO-150; PRO-205; MET-236; MET-315; GLU-374; ARG-414;
RP   SER-545; TYR-549 AND ALA-561, AND VARIANTS HHT1 GLN-221; GLU-238;
RP   SER-263; ARG-269; TYR-394; PRO-529 AND ARG-603.
RX   PubMed=20414677; DOI=10.1007/s00439-010-0825-4;
RA   Richards-Yutz J., Grant K., Chao E.C., Walther S.E., Ganguly A.;
RT   "Update on molecular diagnosis of hereditary hemorrhagic
RT   telangiectasia.";
RL   Hum. Genet. 128:61-77(2010).
CC   -!- FUNCTION: Major glycoprotein of vascular endothelium. Involved in
CC       the regulation of angiogenesis. May play a critical role in the
CC       binding of endothelial cells to integrins and/or other RGD
CC       receptors. Acts as TGF-beta coreceptor and is involved in the TGF-
CC       beta/BMP signaling cascade. Required for GDF2/BMP9 signaling
CC       through SMAD1 in endothelial cells and modulates TGF-beta1
CC       signaling through SMAD3. {ECO:0000269|PubMed:21737454,
CC       ECO:0000269|PubMed:23300529}.
CC   -!- SUBUNIT: Homodimer that forms a heteromeric complex with the
CC       signaling receptors for transforming growth factor-beta: TGFBR1
CC       and/or TGFBR2. It is able to bind TGF-beta 1, and 3 efficiently
CC       and TGF-beta 2 less efficiently. Interacts with TCTEX1D4.
CC       Interacts with ARRB2. Interacts with GDF2.
CC       {ECO:0000269|PubMed:16982625, ECO:0000269|PubMed:17540773,
CC       ECO:0000269|PubMed:21737454, ECO:0000269|PubMed:22347366}.
CC   -!- INTERACTION:
CC       P08648:ITGA5; NbExp=4; IntAct=EBI-2834630, EBI-1382311;
CC       P05556:ITGB1; NbExp=3; IntAct=EBI-2834630, EBI-703066;
CC       P01137:TGFB1; NbExp=2; IntAct=EBI-2834630, EBI-779636;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P17813-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P17813-2; Sequence=VSP_004233;
CC   -!- TISSUE SPECIFICITY: Endoglin is restricted to endothelial cells in
CC       all tissues except bone marrow.
CC   -!- DISEASE: Telangiectasia, hereditary hemorrhagic, 1 (HHT1)
CC       [MIM:187300]: A multisystemic vascular dysplasia leading to
CC       dilation of permanent blood vessels and arteriovenous
CC       malformations of skin, mucosa, and viscera. The disease is
CC       characterized by recurrent epistaxis and gastro-intestinal
CC       hemorrhage. Visceral involvement includes arteriovenous
CC       malformations of the lung, liver, and brain.
CC       {ECO:0000269|PubMed:10545596, ECO:0000269|PubMed:10625079,
CC       ECO:0000269|PubMed:10982033, ECO:0000269|PubMed:15024723,
CC       ECO:0000269|PubMed:15712270, ECO:0000269|PubMed:16525724,
CC       ECO:0000269|PubMed:16752392, ECO:0000269|PubMed:20414677,
CC       ECO:0000269|PubMed:9157574, ECO:0000269|PubMed:9245986,
CC       ECO:0000269|PubMed:9554745}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ENGID40452ch9q34.html";
CC   -!- WEB RESOURCE: Name=Hereditary Hemorrhagic Telangiectasia and ENG;
CC       URL="http://arup.utah.edu/database/ENG/ENG_welcome.php";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X72012; CAA50891.1; -; mRNA.
DR   EMBL; AL157935; CAI12604.1; -; Genomic_DNA.
DR   EMBL; AL162586; CAI12604.1; JOINED; Genomic_DNA.
DR   EMBL; AL162586; CAI39764.1; -; Genomic_DNA.
DR   EMBL; AL157935; CAI39764.1; JOINED; Genomic_DNA.
DR   EMBL; CH471090; EAW87702.1; -; Genomic_DNA.
DR   EMBL; J05481; AAA35800.1; -; mRNA.
DR   EMBL; U37439; AAC63386.1; -; Genomic_DNA.
DR   EMBL; AF036969; AAC63386.1; JOINED; Genomic_DNA.
DR   EMBL; U37447; AAC63386.1; JOINED; Genomic_DNA.
DR   EMBL; AF036970; AAC63386.1; JOINED; Genomic_DNA.
DR   EMBL; U37446; AAC63386.1; JOINED; Genomic_DNA.
DR   EMBL; U37445; AAC63386.1; JOINED; Genomic_DNA.
DR   EMBL; AF036971; AAC63386.1; JOINED; Genomic_DNA.
DR   EMBL; U37442; AAC63386.1; JOINED; Genomic_DNA.
DR   EMBL; U37441; AAC63386.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS48029.1; -. [P17813-1]
DR   CCDS; CCDS6880.1; -. [P17813-2]
DR   PIR; S50831; S50831.
DR   RefSeq; NP_000109.1; NM_000118.3. [P17813-2]
DR   RefSeq; NP_001108225.1; NM_001114753.2. [P17813-1]
DR   RefSeq; NP_001265067.1; NM_001278138.1.
DR   UniGene; Hs.76753; -.
DR   ProteinModelPortal; P17813; -.
DR   BioGrid; 108337; 12.
DR   DIP; DIP-6246N; -.
DR   IntAct; P17813; 8.
DR   MINT; MINT-4529566; -.
DR   STRING; 9606.ENSP00000362299; -.
DR   iPTMnet; P17813; -.
DR   PhosphoSite; P17813; -.
DR   SwissPalm; P17813; -.
DR   DMDM; 3041681; -.
DR   MaxQB; P17813; -.
DR   PaxDb; P17813; -.
DR   PRIDE; P17813; -.
DR   DNASU; 2022; -.
DR   Ensembl; ENST00000344849; ENSP00000341917; ENSG00000106991. [P17813-2]
DR   Ensembl; ENST00000373203; ENSP00000362299; ENSG00000106991. [P17813-1]
DR   GeneID; 2022; -.
DR   KEGG; hsa:2022; -.
DR   UCSC; uc004bsj.5; human. [P17813-1]
DR   CTD; 2022; -.
DR   GeneCards; ENG; -.
DR   GeneReviews; ENG; -.
DR   HGNC; HGNC:3349; ENG.
DR   HPA; CAB000096; -.
DR   HPA; HPA011862; -.
DR   MalaCards; ENG; -.
DR   MIM; 131195; gene.
DR   MIM; 187300; phenotype.
DR   neXtProt; NX_P17813; -.
DR   Orphanet; 231160; Familial cerebral saccular aneurysm.
DR   Orphanet; 329971; Generalized juvenile polyposis/juvenile polyposis coli.
DR   Orphanet; 774; Hereditary hemorrhagic telangiectasia.
DR   PharmGKB; PA27785; -.
DR   eggNOG; ENOG410IQ57; Eukaryota.
DR   eggNOG; ENOG410YK9H; LUCA.
DR   GeneTree; ENSGT00530000063861; -.
DR   HOGENOM; HOG000112346; -.
DR   HOVERGEN; HBG005573; -.
DR   InParanoid; P17813; -.
DR   KO; K06526; -.
DR   OMA; MGHTLEW; -.
DR   OrthoDB; EOG70S754; -.
DR   PhylomeDB; P17813; -.
DR   TreeFam; TF337375; -.
DR   ChiTaRS; ENG; human.
DR   GeneWiki; Endoglin; -.
DR   GenomeRNAi; 2022; -.
DR   NextBio; 8193; -.
DR   PRO; PR:P17813; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; P17813; -.
DR   CleanEx; HS_ENG; -.
DR   ExpressionAtlas; P17813; baseline and differential.
DR   Genevisible; P17813; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0072563; C:endothelial microparticle; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IPI:BHF-UCL.
DR   GO; GO:0070022; C:transforming growth factor beta receptor homodimeric complex; IC:BHF-UCL.
DR   GO; GO:0048185; F:activin binding; TAS:BHF-UCL.
DR   GO; GO:0005534; F:galactose binding; IDA:BHF-UCL.
DR   GO; GO:0005539; F:glycosaminoglycan binding; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IPI:BHF-UCL.
DR   GO; GO:0005072; F:transforming growth factor beta receptor, cytoplasmic mediator activity; IDA:BHF-UCL.
DR   GO; GO:0005024; F:transforming growth factor beta-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; NAS:BHF-UCL.
DR   GO; GO:0034713; F:type I transforming growth factor beta receptor binding; IPI:BHF-UCL.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; IPI:BHF-UCL.
DR   GO; GO:0048844; P:artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IMP:BHF-UCL.
DR   GO; GO:0003273; P:cell migration involved in endocardial cushion formation; IEA:Ensembl.
DR   GO; GO:0048870; P:cell motility; IMP:BHF-UCL.
DR   GO; GO:0022009; P:central nervous system vasculogenesis; IMP:BHF-UCL.
DR   GO; GO:0001300; P:chronological cell aging; IEP:BHF-UCL.
DR   GO; GO:0070483; P:detection of hypoxia; IDA:BHF-UCL.
DR   GO; GO:0022617; P:extracellular matrix disassembly; IMP:BHF-UCL.
DR   GO; GO:0001947; P:heart looping; ISS:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:GOC.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0051001; P:negative regulation of nitric-oxide synthase activity; IMP:BHF-UCL.
DR   GO; GO:0060394; P:negative regulation of pathway-restricted SMAD protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0031953; P:negative regulation of protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0001569; P:patterning of blood vessels; ISS:BHF-UCL.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0030155; P:regulation of cell adhesion; TAS:BHF-UCL.
DR   GO; GO:0042127; P:regulation of cell proliferation; TAS:BHF-UCL.
DR   GO; GO:0042325; P:regulation of phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:HGNC.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IDA:HGNC.
DR   GO; GO:0001666; P:response to hypoxia; IDA:BHF-UCL.
DR   GO; GO:0048745; P:smooth muscle tissue development; ISS:BHF-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0001570; P:vasculogenesis; IMP:BHF-UCL.
DR   GO; GO:0048845; P:venous blood vessel morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; IMP:BHF-UCL.
DR   InterPro; IPR001507; ZP_dom.
DR   Pfam; PF00100; Zona_pellucida; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Angiogenesis; Cell adhesion; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Glycoprotein; Membrane;
KW   Phosphoprotein; Polymorphism; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     25
FT   CHAIN        26    658       Endoglin.
FT                                /FTId=PRO_0000021156.
FT   TOPO_DOM     26    586       Extracellular. {ECO:0000255}.
FT   TRANSMEM    587    611       Helical. {ECO:0000255}.
FT   TOPO_DOM    612    658       Cytoplasmic. {ECO:0000255}.
FT   REGION       26    337       Required for interaction with EGL.
FT   MOTIF       399    401       Cell attachment site. {ECO:0000255}.
FT   COMPBIAS    336    576       Ser/Thr-rich.
FT   MOD_RES     646    646       Phosphoserine; by TGFBR1. {ECO:0000250}.
FT   MOD_RES     649    649       Phosphoserine; by TGFBR1. {ECO:0000250}.
FT   CARBOHYD     88     88       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    134    134       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    307    307       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     619    658       SPSKREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMA
FT                                -> EYPRPPQ (in isoform Short).
FT                                {ECO:0000303|PubMed:8370410}.
FT                                /FTId=VSP_004233.
FT   VARIANT       5      5       T -> M (in dbSNP:rs35400405).
FT                                {ECO:0000269|PubMed:9245986}.
FT                                /FTId=VAR_005192.
FT   VARIANT       8      8       L -> P (in HHT1).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026774.
FT   VARIANT      11     11       A -> D (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070279.
FT   VARIANT      49     49       V -> F (in HHT1).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026775.
FT   VARIANT      52     52       G -> V (in HHT1).
FT                                {ECO:0000269|PubMed:10545596,
FT                                ECO:0000269|PubMed:9554745}.
FT                                /FTId=VAR_005193.
FT   VARIANT      53     53       C -> R (in HHT1).
FT                                {ECO:0000269|PubMed:10545596,
FT                                ECO:0000269|PubMed:10625079,
FT                                ECO:0000269|PubMed:9554745}.
FT                                /FTId=VAR_005194.
FT   VARIANT     105    105       V -> D (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070280.
FT   VARIANT     107    107       L -> R (in HHT1).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026776.
FT   VARIANT     149    149       W -> C (in HHT1).
FT                                {ECO:0000269|PubMed:10545596,
FT                                ECO:0000269|PubMed:9554745}.
FT                                /FTId=VAR_005195.
FT   VARIANT     150    150       A -> P (found in a family with hereditary
FT                                hemorrhagic talagiectasia; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070281.
FT   VARIANT     160    160       A -> D (in HHT1).
FT                                {ECO:0000269|PubMed:9157574}.
FT                                /FTId=VAR_009120.
FT   VARIANT     175    175       A -> E (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070282.
FT   VARIANT     192    198       Missing (in HHT1).
FT                                {ECO:0000269|PubMed:9245986}.
FT                                /FTId=VAR_005196.
FT   VARIANT     193    194       TL -> VLQ (in HHT1).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070283.
FT   VARIANT     205    205       R -> P. {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070284.
FT   VARIANT     207    207       Missing (in HHT1).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026777.
FT   VARIANT     220    220       I -> T (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070285.
FT   VARIANT     221    221       L -> P (in HHT1).
FT                                {ECO:0000269|PubMed:10545596,
FT                                ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_009121.
FT   VARIANT     221    221       L -> Q (in HHT1).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070286.
FT   VARIANT     232    233       Missing (in HHT1).
FT                                /FTId=VAR_026778.
FT   VARIANT     236    236       V -> M (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070287.
FT   VARIANT     238    238       V -> E (in HHT1).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070288.
FT   VARIANT     263    263       I -> S (in HHT1).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070289.
FT   VARIANT     263    263       I -> T (in HHT1).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026780.
FT   VARIANT     263    263       Missing (in HHT1).
FT                                {ECO:0000269|PubMed:15024723,
FT                                ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026779.
FT   VARIANT     269    269       M -> R (in HHT1).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070290.
FT   VARIANT     306    306       L -> P (in HHT1).
FT                                {ECO:0000269|PubMed:9554745}.
FT                                /FTId=VAR_005197.
FT   VARIANT     308    308       A -> D (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070291.
FT   VARIANT     315    315       V -> M (found in a family with hereditary
FT                                hemorrhagic talagiectasia; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070292.
FT   VARIANT     363    363       C -> S (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070293.
FT   VARIANT     366    366       D -> H (in dbSNP:rs1800956).
FT                                /FTId=VAR_014764.
FT   VARIANT     374    374       K -> E (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070294.
FT   VARIANT     394    394       C -> Y (in HHT1).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070295.
FT   VARIANT     412    412       C -> S (in HHT1).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026781.
FT   VARIANT     413    413       G -> V (in HHT1).
FT                                {ECO:0000269|PubMed:10982033}.
FT                                /FTId=VAR_037140.
FT   VARIANT     414    414       M -> R (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070296.
FT   VARIANT     437    437       R -> W (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070297.
FT   VARIANT     490    490       L -> S (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070298.
FT   VARIANT     504    504       V -> M (in HHT1; dbSNP:rs116330805).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026782.
FT   VARIANT     529    529       R -> H (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070299.
FT   VARIANT     529    529       R -> P (in HHT1).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070300.
FT   VARIANT     545    545       G -> D (in HHT1).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070301.
FT   VARIANT     545    545       G -> S. {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070302.
FT   VARIANT     547    547       L -> P (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070303.
FT   VARIANT     549    549       C -> Y (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070304.
FT   VARIANT     561    561       D -> A. {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070305.
FT   VARIANT     603    603       G -> R (in HHT1).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070306.
FT   VARIANT     604    604       A -> D (in HHT1).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070307.
FT   VARIANT     615    615       S -> L (in HHT1).
FT                                {ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026783.
FT   CONFLICT     14     14       L -> G (in Ref. 4; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    122    130       SSLVTFQEP -> FQPGHLPRA (in Ref. 5).
FT                                {ECO:0000305}.
SQ   SEQUENCE   658 AA;  70578 MW;  49CA2CE013298D17 CRC64;
     MDRGTLPLAV ALLLASCSLS PTSLAETVHC DLQPVGPERG EVTYTTSQVS KGCVAQAPNA
     ILEVHVLFLE FPTGPSQLEL TLQASKQNGT WPREVLLVLS VNSSVFLHLQ ALGIPLHLAY
     NSSLVTFQEP PGVNTTELPS FPKTQILEWA AERGPITSAA ELNDPQSILL RLGQAQGSLS
     FCMLEASQDM GRTLEWRPRT PALVRGCHLE GVAGHKEAHI LRVLPGHSAG PRTVTVKVEL
     SCAPGDLDAV LILQGPPYVS WLIDANHNMQ IWTTGEYSFK IFPEKNIRGF KLPDTPQGLL
     GEARMLNASI VASFVELPLA SIVSLHASSC GGRLQTSPAP IQTTPPKDTC SPELLMSLIQ
     TKCADDAMTL VLKKELVAHL KCTITGLTFW DPSCEAEDRG DKFVLRSAYS SCGMQVSASM
     ISNEAVVNIL SSSSPQRKKV HCLNMDSLSF QLGLYLSPHF LQASNTIEPG QQSFVQVRVS
     PSVSEFLLQL DSCHLDLGPE GGTVELIQGR AAKGNCVSLL SPSPEGDPRF SFLLHFYTVP
     IPKTGTLSCT VALRPKTGSQ DQEVHRTVFM RLNIISPDLS GCTSKGLVLP AVLGITFGAF
     LIGALLTAAL WYIYSHTRSP SKREPVVAVA APASSESSST NHSIGSTQST PCSTSSMA
//
ID   EDN1_HUMAN              Reviewed;         212 AA.
AC   P05305; Q96DA1;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1988, sequence version 1.
DT   20-JAN-2016, entry version 176.
DE   RecName: Full=Endothelin-1;
DE   AltName: Full=Preproendothelin-1;
DE            Short=PPET1;
DE   Contains:
DE     RecName: Full=Endothelin-1;
DE              Short=ET-1;
DE   Contains:
DE     RecName: Full=Big endothelin-1;
DE   Flags: Precursor;
GN   Name=EDN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=3282927; DOI=10.1016/0014-5793(88)80867-6;
RA   Itoh Y., Yanagisawa M., Ohkubo S., Kimura C., Kosaka T., Inoue A.,
RA   Ishida N., Mitsui Y., Onda H., Fujino M., Masaki T.;
RT   "Cloning and sequence analysis of cDNA encoding the precursor of a
RT   human endothelium-derived vasoconstrictor peptide, endothelin:
RT   identity of human and porcine endothelin.";
RL   FEBS Lett. 231:440-444(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2670930;
RA   Inoue A., Yanagisawa M., Takuwa Y., Mitsui Y., Kobayashi M.,
RA   Masaki T.;
RT   "The human preproendothelin-1 gene. Complete nucleotide sequence and
RT   regulation of expression.";
RL   J. Biol. Chem. 264:14954-14959(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2659594;
RA   Bloch K.D., Friedrich S.P., Lee M.E., Eddy R.L., Shows T.B.,
RA   Quertermous T.;
RT   "Structural organization and chromosomal assignment of the gene
RT   encoding endothelin.";
RL   J. Biol. Chem. 264:10851-10857(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8450044; DOI=10.1172/JCI116274;
RA   Benatti L., Bonecchi L., Cozzi L., Sarmientos P.;
RT   "Two preproendothelin 1 mRNAs transcribed by alternative promoters.";
RL   J. Clin. Invest. 91:1149-1156(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASN-198.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-198.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 27-67.
RX   PubMed=2649896; DOI=10.1073/pnas.86.8.2863;
RA   Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K.,
RA   Masaki T.;
RT   "The human endothelin family: three structurally and pharmacologically
RT   distinct isopeptides predicted by three separate genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:2863-2867(1989).
RN   [9]
RP   PARTIAL PROTEIN SEQUENCE, CLEAVAGE BY KELL, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=10438732;
RA   Lee S., Lin M., Mele A., Cao Y., Farmar J., Russo D., Redman C.;
RT   "Proteolytic processing of big endothelin-3 by the kell blood group
RT   protein.";
RL   Blood 94:1440-1450(1999).
RN   [10]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=1864385; DOI=10.1016/0014-5793(91)80948-3;
RA   Fabbrini M.S., Valsasina B., Nitti G., Benatti L., Vitale A.;
RT   "The signal peptide of human preproendothelin-1.";
RL   FEBS Lett. 286:91-94(1991).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=9284755; DOI=10.1210/jc.82.9.3116;
RA   Bourgeois C., Robert B., Rebourcet R., Mondon F., Mignot T.-M.,
RA   Duc-Goiran P., Ferre F.;
RT   "Endothelin-1 and ETA receptor expression in vascular smooth muscle
RT   cells from human placenta: a new ETA receptor messenger ribonucleic
RT   acid is generated by alternative splicing of exon 3.";
RL   J. Clin. Endocrinol. Metab. 82:3116-3123(1997).
RN   [12]
RP   VARIANT ASN-198, AND CHARACTERIZATION OF VARIANT ASN-198.
RX   PubMed=17357073; DOI=10.1086/513286;
RA   Pare G., Serre D., Brisson D., Anand S.S., Montpetit A., Tremblay G.,
RA   Engert J.C., Hudson T.J., Gaudet D.;
RT   "Genetic analysis of 103 candidate genes for coronary artery disease
RT   and associated phenotypes in a founder population reveals a new
RT   association between endothelin-1 and high-density lipoprotein
RT   cholesterol.";
RL   Am. J. Hum. Genet. 80:673-682(2007).
RN   [13]
RP   VARIANT ASN-198.
RX   PubMed=18288492; DOI=10.1007/s00439-008-0481-0;
RA   Wiltshire S., Powell B.L., Jennens M., McCaskie P.A., Carter K.W.,
RA   Palmer L.J., Thompson P.L., McQuillan B.M., Hung J., Beilby J.P.;
RT   "Investigating the association between K198N coding polymorphism in
RT   EDN1 and hypertension, lipoprotein levels, the metabolic syndrome and
RT   cardiovascular disease.";
RL   Hum. Genet. 123:307-313(2008).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF ET-1.
RX   PubMed=1515112;
RA   Wolff M., Day J., Greenwood A., Larson S., McPherson A.;
RT   "Crystallization and preliminary X-ray analysis of human endothelin.";
RL   Acta Crystallogr. B 48:239-240(1992).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.18 ANGSTROMS) OF ET-1, AND DISULFIDE BONDS.
RX   PubMed=7664037; DOI=10.1038/nsb0594-311;
RA   Janes R.W., Peapus D.H., Wallace B.A.;
RT   "The crystal structure of human endothelin.";
RL   Nat. Struct. Biol. 1:311-319(1994).
RN   [16]
RP   STRUCTURE BY NMR OF ET-1.
RX   PubMed=1859417; DOI=10.1016/0006-291X(91)90146-X;
RA   Reily M.D., Dunbar J.B. Jr.;
RT   "The conformation of endothelin-1 in aqueous solution: NMR-derived
RT   constraints combined with distance geometry and molecular dynamics
RT   calculations.";
RL   Biochem. Biophys. Res. Commun. 178:570-577(1991).
RN   [17]
RP   STRUCTURE BY NMR OF ET-1.
RX   PubMed=1736987; DOI=10.1021/bi00120a003;
RA   Andersen N.H., Chen C., Marschner T.M., Krystek S.R. Jr.,
RA   Bassolino D.A.;
RT   "Conformational isomerism of endothelin in acidic aqueous media: a
RT   quantitative NOESY analysis.";
RL   Biochemistry 31:1280-1295(1992).
RN   [18]
RP   STRUCTURE BY NMR OF 53-90.
RX   PubMed=1422154; DOI=10.1007/BF02192805;
RA   Donlan M.L., Brown F.K., Jeffs P.W.;
RT   "Solution conformation of human big endothelin-1.";
RL   J. Biomol. NMR 2:407-420(1992).
RN   [19]
RP   COMPARISON OF NMR STRUCTURE WITH X-RAY STRUCTURE.
RX   PubMed=7773179; DOI=10.1002/pro.5560040110;
RA   Wallace B.A., Janes R.W., Bassolino D.A., Krystek S.R. Jr.;
RT   "A comparison of X-ray and NMR structures for human endothelin-1.";
RL   Protein Sci. 4:75-83(1995).
RN   [20]
RP   STRUCTURE BY NMR OF ET1 AGONIST.
RX   PubMed=10231710; DOI=10.1034/j.1399-3011.1999.00001.x;
RA   Hewage C.M., Jiang L., Parkinson J.A., Ramage R., Sadler I.H.;
RT   "Solution structure of a novel ETB receptor selective agonist ET1-21
RT   [Cys(Acm)1,15, Aib3,11, Leu7] by nuclear magnetic resonance
RT   spectroscopy and molecular modelling.";
RL   J. Pept. Res. 53:223-233(1999).
RN   [21]
RP   VARIANT ASN-198.
RX   PubMed=10334806; DOI=10.1161/01.HYP.33.5.1169;
RA   Tiret L., Poirier O., Hallet V., McDonagh T.A., Morrison C.,
RA   McMurray J.J., Dargie H.J., Arveiler D., Ruidavets J.B., Luc G.,
RA   Evans A., Cambien F.;
RT   "The Lys198Asn polymorphism in the endothelin-1 gene is associated
RT   with blood pressure in overweight people.";
RL   Hypertension 33:1169-1174(1999).
RN   [22]
RP   VARIANT ASN-198.
RX   PubMed=10391210; DOI=10.1038/10297;
RA   Halushka M.K., Fan J.-B., Bentley K., Hsie L., Shen N., Weder A.,
RA   Cooper R., Lipshutz R., Chakravarti A.;
RT   "Patterns of single-nucleotide polymorphisms in candidate genes for
RT   blood-pressure homeostasis.";
RL   Nat. Genet. 22:239-247(1999).
RN   [23]
RP   VARIANT QME ASP-64, AND VARIANTS ARCND3 HIS-77 AND GLU-91.
RX   PubMed=24268655; DOI=10.1016/j.ajhg.2013.10.023;
RA   Gordon C.T., Petit F., Kroisel P.M., Jakobsen L., Zechi-Ceide R.M.,
RA   Oufadem M., Bole-Feysot C., Pruvost S., Masson C., Tores F., Hieu T.,
RA   Nitschke P., Lindholm P., Pellerin P., Guion-Almeida M.L.,
RA   Kokitsu-Nakata N.M., Vendramini-Pittoli S., Munnich A., Lyonnet S.,
RA   Holder-Espinasse M., Amiel J.;
RT   "Mutations in endothelin 1 cause recessive auriculocondylar syndrome
RT   and dominant isolated question-mark ears.";
RL   Am. J. Hum. Genet. 93:1118-1125(2013).
CC   -!- FUNCTION: Endothelins are endothelium-derived vasoconstrictor
CC       peptides.
CC   -!- INTERACTION:
CC       P25101:EDNRA; NbExp=2; IntAct=EBI-715181, EBI-6624559;
CC       P24530:EDNRB; NbExp=2; IntAct=EBI-715181, EBI-6624656;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed in lung, placental stem villi
CC       vessels and in cultured placental vascular smooth muscle cells.
CC       {ECO:0000269|PubMed:9284755}.
CC   -!- DISEASE: Question mark ears, isolated (QME) [MIM:612798]: An
CC       auricular abnormality characterized by a cleft between the lobule
CC       and the lower part of the helix, sometimes accompanied by a
CC       prominent or deficient upper part of the helix, shallow skin
CC       dimple on the posterior surface of the ear, or transposition of
CC       the ear lobe/antitragus. {ECO:0000269|PubMed:24268655}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Auriculocondylar syndrome 3 (ARCND3) [MIM:615706]: A
CC       craniofacial malformation syndrome characterized by variable
CC       mandibular anomalies, including mild to severe micrognathia,
CC       temporomandibular joint ankylosis, cleft palate, and a
CC       characteristic ear malformation that consists of separation of the
CC       lobule from the external ear, giving the appearance of a question
CC       mark (question-mark ear). Other frequently described features
CC       include prominent cheeks, cupped and posteriorly rotated ears,
CC       preauricular tags, and microstomia. {ECO:0000269|PubMed:24268655}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the endothelin/sarafotoxin family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/edn1/";
CC   -!- WEB RESOURCE: Name=R&D Systems' cytokine source book: Endothelin-
CC       1;
CC       URL="http://www.rndsystems.com/molecule_detail.aspx?m=1364";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Endothelin entry;
CC       URL="https://en.wikipedia.org/wiki/Endothelin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00749; CAA68718.1; -; mRNA.
DR   EMBL; M25380; AAA52407.1; -; Genomic_DNA.
DR   EMBL; M25377; AAA52407.1; JOINED; Genomic_DNA.
DR   EMBL; M25378; AAA52407.1; JOINED; Genomic_DNA.
DR   EMBL; M25379; AAA52407.1; JOINED; Genomic_DNA.
DR   EMBL; J05008; AAA52339.1; -; Genomic_DNA.
DR   EMBL; S56805; AAB25760.1; -; mRNA.
DR   EMBL; AY434104; AAQ96600.1; -; Genomic_DNA.
DR   EMBL; Z98050; CAB10846.1; -; Genomic_DNA.
DR   EMBL; BC009720; AAH09720.1; -; mRNA.
DR   EMBL; M25549; AAA52338.1; -; Genomic_DNA.
DR   CCDS; CCDS4522.1; -.
DR   PIR; A36517; ANHU1.
DR   RefSeq; NP_001161791.1; NM_001168319.1.
DR   RefSeq; NP_001946.3; NM_001955.4.
DR   RefSeq; XP_011512632.1; XM_011514330.1.
DR   RefSeq; XP_011512633.1; XM_011514331.1.
DR   UniGene; Hs.511899; -.
DR   UniGene; Hs.713645; -.
DR   PDB; 1EDN; X-ray; 2.18 A; A=53-73.
DR   PDB; 1EDP; NMR; -; A=53-69.
DR   PDB; 1T7H; X-ray; 1.13 A; A/B=51-68.
DR   PDB; 1V6R; NMR; -; A=53-73.
DR   PDBsum; 1EDN; -.
DR   PDBsum; 1EDP; -.
DR   PDBsum; 1T7H; -.
DR   PDBsum; 1V6R; -.
DR   ProteinModelPortal; P05305; -.
DR   BioGrid; 108228; 5.
DR   IntAct; P05305; 5.
DR   MINT; MINT-1387120; -.
DR   STRING; 9606.ENSP00000368683; -.
DR   iPTMnet; P05305; -.
DR   PhosphoSite; P05305; -.
DR   BioMuta; EDN1; -.
DR   DMDM; 119610; -.
DR   PaxDb; P05305; -.
DR   PRIDE; P05305; -.
DR   DNASU; 1906; -.
DR   Ensembl; ENST00000379375; ENSP00000368683; ENSG00000078401.
DR   GeneID; 1906; -.
DR   KEGG; hsa:1906; -.
DR   UCSC; uc003nad.3; human.
DR   CTD; 1906; -.
DR   GeneCards; EDN1; -.
DR   H-InvDB; HIX0033211; -.
DR   HGNC; HGNC:3176; EDN1.
DR   HPA; CAB032500; -.
DR   HPA; CAB037291; -.
DR   HPA; HPA031976; -.
DR   MalaCards; EDN1; -.
DR   MIM; 131240; gene.
DR   MIM; 612798; phenotype.
DR   MIM; 615706; phenotype.
DR   neXtProt; NX_P05305; -.
DR   Orphanet; 137888; Auriculocondylar syndrome.
DR   PharmGKB; PA27614; -.
DR   eggNOG; ENOG410IWVG; Eukaryota.
DR   eggNOG; ENOG4111WED; LUCA.
DR   HOGENOM; HOG000231110; -.
DR   HOVERGEN; HBG051441; -.
DR   InParanoid; P05305; -.
DR   KO; K16366; -.
DR   OMA; CASQKDK; -.
DR   OrthoDB; EOG7PS1H7; -.
DR   PhylomeDB; P05305; -.
DR   TreeFam; TF333184; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   EvolutionaryTrace; P05305; -.
DR   GeneWiki; Endothelin_1; -.
DR   GenomeRNAi; 1906; -.
DR   NextBio; 7757; -.
DR   PMAP-CutDB; P05305; -.
DR   PRO; PR:P05305; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; P05305; -.
DR   CleanEx; HS_EDN1; -.
DR   ExpressionAtlas; P05305; baseline and differential.
DR   Genevisible; P05305; HS.
DR   GO; GO:0045178; C:basal part of cell; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:GOC.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0048237; C:rough endoplasmic reticulum lumen; IEA:Ensembl.
DR   GO; GO:0033093; C:Weibel-Palade body; IEA:Ensembl.
DR   GO; GO:0005125; F:cytokine activity; IDA:BHF-UCL.
DR   GO; GO:0031707; F:endothelin A receptor binding; IDA:BHF-UCL.
DR   GO; GO:0031708; F:endothelin B receptor binding; IDA:BHF-UCL.
DR   GO; GO:0005179; F:hormone activity; IDA:BHF-UCL.
DR   GO; GO:0014824; P:artery smooth muscle contraction; IDA:BHF-UCL.
DR   GO; GO:0007589; P:body fluid secretion; IEA:Ensembl.
DR   GO; GO:0019722; P:calcium-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0051216; P:cartilage development; IEA:Ensembl.
DR   GO; GO:0016049; P:cell growth; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; IDA:BHF-UCL.
DR   GO; GO:0071277; P:cellular response to calcium ion; IEA:Ensembl.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0071398; P:cellular response to fatty acid; IEA:Ensembl.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEA:Ensembl.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0071389; P:cellular response to mineralocorticoid stimulus; IEA:Ensembl.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IEA:Ensembl.
DR   GO; GO:0042045; P:epithelial fluid transport; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0015758; P:glucose transport; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0001821; P:histamine secretion; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0048016; P:inositol phosphate-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0045321; P:leukocyte activation; TAS:BHF-UCL.
DR   GO; GO:0060137; P:maternal process involved in parturition; IEA:Ensembl.
DR   GO; GO:0051899; P:membrane depolarization; IEA:Ensembl.
DR   GO; GO:0042474; P:middle ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0010259; P:multicellular organismal aging; IEA:Ensembl.
DR   GO; GO:0030195; P:negative regulation of blood coagulation; TAS:BHF-UCL.
DR   GO; GO:0030818; P:negative regulation of cAMP biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032269; P:negative regulation of cellular protein metabolic process; IDA:BHF-UCL.
DR   GO; GO:0046888; P:negative regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0051771; P:negative regulation of nitric-oxide synthase biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0014032; P:neural crest cell development; IEA:Ensembl.
DR   GO; GO:0030185; P:nitric oxide transport; IDA:BHF-UCL.
DR   GO; GO:0001569; P:patterning of blood vessels; IEA:Ensembl.
DR   GO; GO:0030072; P:peptide hormone secretion; IDA:BHF-UCL.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0031583; P:phospholipase D-activating G-protein coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045793; P:positive regulation of cell size; IDA:BHF-UCL.
DR   GO; GO:0070101; P:positive regulation of chemokine-mediated signaling pathway; IC:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:BHF-UCL.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway; IEA:Ensembl.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; TAS:BHF-UCL.
DR   GO; GO:0010460; P:positive regulation of heart rate; IDA:BHF-UCL.
DR   GO; GO:0046887; P:positive regulation of hormone secretion; IDA:BHF-UCL.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IDA:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IDA:BHF-UCL.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; TAS:BHF-UCL.
DR   GO; GO:0042482; P:positive regulation of odontogenesis; IEA:Ensembl.
DR   GO; GO:0032308; P:positive regulation of prostaglandin secretion; IEA:Ensembl.
DR   GO; GO:0060585; P:positive regulation of prostaglandin-endoperoxide synthase activity; IMP:BHF-UCL.
DR   GO; GO:0010870; P:positive regulation of receptor biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0060298; P:positive regulation of sarcomere organization; IMP:BHF-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0035810; P:positive regulation of urine volume; IEA:Ensembl.
DR   GO; GO:0001516; P:prostaglandin biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0042313; P:protein kinase C deactivation; IDA:BHF-UCL.
DR   GO; GO:0007205; P:protein kinase C-activating G-protein coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006885; P:regulation of pH; IEA:Ensembl.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0003100; P:regulation of systemic arterial blood pressure by endothelin; IDA:BHF-UCL.
DR   GO; GO:0019229; P:regulation of vasoconstriction; IEA:InterPro.
DR   GO; GO:0007585; P:respiratory gaseous exchange; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl.
DR   GO; GO:0044321; P:response to leptin; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl.
DR   GO; GO:0035094; P:response to nicotine; IEA:Ensembl.
DR   GO; GO:0010193; P:response to ozone; IEA:Ensembl.
DR   GO; GO:0034696; P:response to prostaglandin F; IEA:Ensembl.
DR   GO; GO:1902074; P:response to salt; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0043179; P:rhythmic excitation; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0042554; P:superoxide anion generation; IEA:Ensembl.
DR   GO; GO:0042310; P:vasoconstriction; IDA:BHF-UCL.
DR   GO; GO:0014826; P:vein smooth muscle contraction; IDA:BHF-UCL.
DR   InterPro; IPR020475; Bibrotoxin/Sarafotoxin-D.
DR   InterPro; IPR019764; Endothelin_toxin_CS.
DR   InterPro; IPR001928; Endothln-like_toxin.
DR   Pfam; PF00322; Endothelin; 1.
DR   PRINTS; PR00365; ENDOTHELIN.
DR   SMART; SM00272; END; 2.
DR   PROSITE; PS00270; ENDOTHELIN; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Polymorphism; Reference proteome; Secreted; Signal; Vasoactive;
KW   Vasoconstrictor.
FT   SIGNAL        1     17
FT   PROPEP       18     50
FT                                /FTId=PRO_0000008058.
FT   PEPTIDE      53     90       Big endothelin-1.
FT                                /FTId=PRO_0000008059.
FT   PEPTIDE      53     73       Endothelin-1.
FT                                /FTId=PRO_0000008060.
FT   PROPEP       74    212
FT                                /FTId=PRO_0000008061.
FT   REGION      109    123       Endothelin-like.
FT   SITE         73     74       Cleavage; by KEL.
FT   DISULFID     53     67       {ECO:0000269|PubMed:7664037}.
FT   DISULFID     55     63       {ECO:0000269|PubMed:7664037}.
FT   DISULFID    109    123       {ECO:0000250}.
FT   DISULFID    111    119       {ECO:0000250}.
FT   VARIANT      64     64       V -> D (in QME).
FT                                {ECO:0000269|PubMed:24268655}.
FT                                /FTId=VAR_071152.
FT   VARIANT      77     77       P -> H (in ARCND3).
FT                                {ECO:0000269|PubMed:24268655}.
FT                                /FTId=VAR_071153.
FT   VARIANT      91     91       K -> E (in ARCND3).
FT                                {ECO:0000269|PubMed:24268655}.
FT                                /FTId=VAR_071154.
FT   VARIANT     186    186       V -> I (in dbSNP:rs6413478).
FT                                /FTId=VAR_048933.
FT   VARIANT     198    198       K -> N (polymorphism associated with HDL
FT                                cholesterol levels is some populations
FT                                and in a sex-specific manner;
FT                                dbSNP:rs5370).
FT                                {ECO:0000269|PubMed:10334806,
FT                                ECO:0000269|PubMed:10391210,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17357073,
FT                                ECO:0000269|PubMed:18288492,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_014188.
FT   STRAND       53     56       {ECO:0000244|PDB:1T7H}.
FT   STRAND       57     59       {ECO:0000244|PDB:1EDN}.
FT   HELIX        61     67       {ECO:0000244|PDB:1T7H}.
FT   TURN         68     70       {ECO:0000244|PDB:1EDN}.
SQ   SEQUENCE   212 AA;  24425 MW;  E2DA0EB86755BC3D CRC64;
     MDYLLMIFSL LFVACQGAPE TAVLGAELSA VGENGGEKPT PSPPWRLRRS KRCSCSSLMD
     KECVYFCHLD IIWVNTPEHV VPYGLGSPRS KRALENLLPT KATDRENRCQ CASQKDKKCW
     NFCQAGKELR AEDIMEKDWN NHKKGKDCSK LGKKCIYQQL VRGRKIRRSS EEHLRQTRSE
     TMRNSVKSSF HDPKLKGKPS RERYVTHNRA HW
//
ID   FIBA_HUMAN              Reviewed;         866 AA.
AC   P02671; A8K3E4; D3DP14; D3DP15; Q4QQH7; Q9BX62; Q9UCH2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   17-FEB-2016, entry version 205.
DE   RecName: Full=Fibrinogen alpha chain;
DE   Contains:
DE     RecName: Full=Fibrinopeptide A;
DE   Contains:
DE     RecName: Full=Fibrinogen alpha chain;
DE   Flags: Precursor;
GN   Name=FGA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS
RP   1 AND 2).
RX   PubMed=1457396; DOI=10.1021/bi00163a002;
RA   Fu Y., Weissbach L., Plant P.W., Oddoux C., Cao Y., Liang T.J.,
RA   Roy S.N., Redman C.M., Grieninger G.;
RT   "Carboxy-terminal-extended variant of the human fibrinogen alpha
RT   subunit: a novel exon conferring marked homology to beta and gamma
RT   subunits.";
RL   Biochemistry 31:11968-11972(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1).
RA   Chung D.W., Grieninger G.;
RT   "Fibrinogen DNA and protein sequences.";
RL   (In) Ebert R.F. (eds.);
RL   Index of variant human fibrinogens, pp.13-24, CRC Press, Boca Raton
RL   (1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-6; ALA-331 AND
RP   ALA-456.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   ALA-331.
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 1-655 (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=2102623;
RA   Chung D.W., Harris J.E., Davie E.W.;
RT   "Nucleotide sequences of the three genes coding for human
RT   fibrinogen.";
RL   Adv. Exp. Med. Biol. 281:39-48(1990).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=6575389; DOI=10.1073/pnas.80.13.3953;
RA   Kant J.A., Lord S.T., Crabtree G.R.;
RT   "Partial mRNA sequences for human A alpha, B beta, and gamma
RT   fibrinogen chains: evolutionary and functional implications.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:3953-3957(1983).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-629.
RX   PubMed=6688355; DOI=10.1021/bi00282a031;
RA   Rixon M.W., Chan W.-Y., Davie E.W., Chung D.W.;
RT   "Characterization of a complementary deoxyribonucleic acid coding for
RT   the alpha chain of human fibrinogen.";
RL   Biochemistry 22:3237-3244(1983).
RN   [10]
RP   PROTEIN SEQUENCE OF 20-629.
RA   Henschen A., Lottspeich F., Southan C., Topfer-Petersen E.;
RT   "Human fibrinogen: sequence, sulfur bridges, glycosylation and some
RT   structural variants.";
RL   (In) Peeters H. (eds.);
RL   Protides of the biological fluids, Proc. 28th colloquium, pp.51-56,
RL   Pergamon Press, Oxford (1980).
RN   [11]
RP   PROTEIN SEQUENCE OF 20-629, DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=518846; DOI=10.1021/bi00591a024;
RA   Watt K.W.K., Cottrell B.A., Strong D.D., Doolittle R.F.;
RT   "Amino acid sequence studies on the alpha chain of human fibrinogen.
RT   Overlapping sequences providing the complete sequence.";
RL   Biochemistry 18:5410-5416(1979).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 110-156.
RX   PubMed=6689067; DOI=10.1093/nar/11.21.7427;
RA   Imam A.M.A., Eaton M.A.W., Williamson R., Humphries S.;
RT   "Isolation and characterisation of cDNA clones for the A alpha- and
RT   gamma-chains of human fibrinogen.";
RL   Nucleic Acids Res. 11:7427-7434(1983).
RN   [13]
RP   NUCLEOTIDE SEQUENCE OF 605-644 (ISOFORM 2).
RX   PubMed=6575700; DOI=10.1111/j.1749-6632.1983.tb23265.x;
RA   Chung D.W., Rixon M.W., Que B.G., Davie E.W.;
RT   "Cloning of fibrinogen genes and their cDNA.";
RL   Ann. N. Y. Acad. Sci. 408:449-456(1983).
RN   [14]
RP   PROTEIN SEQUENCE OF 20-35.
RA   Blombaeck B., Blombaeck M., Grondahl N.J., Guthrie C., Hinton M.;
RT   "Studies on fibrinopeptides from primates.";
RL   Acta Chem. Scand. 19:1788-1789(1965).
RN   [15]
RP   DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=741445; DOI=10.1016/0049-3848(78)90142-1;
RA   Bouma H., Takagi T., Doolittle R.F.;
RT   "The arrangement of disulfide bonds in fragment D from human
RT   fibrinogen.";
RL   Thromb. Res. 13:557-562(1978).
RN   [16]
RP   CROSS-LINKING ACCEPTOR SITES.
RX   PubMed=518845; DOI=10.1021/bi00591a023;
RA   Cottrell B.A., Strong D.D., Watt K.W.K., Doolittle R.F.;
RT   "Amino acid sequence studies on the alpha chain of human fibrinogen.
RT   Exact location of cross-linking acceptor sites.";
RL   Biochemistry 18:5405-5410(1979).
RN   [17]
RP   CROSS-LINKING ACCEPTOR SITES.
RX   PubMed=632262;
RA   Fretto L.J., Ferguson E.W., Steinman H.M., McKee P.A.;
RT   "Localization of the alpha-chain cross-link acceptor sites of human
RT   fibrin.";
RL   J. Biol. Chem. 253:2184-2195(1978).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-686.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [19]
RP   DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=936108; DOI=10.1016/0049-3848(76)90245-0;
RA   Blombaeck B., Hessel B., Hogg D.;
RT   "Disulfide bridges in NH2-terminal part of human fibrinogen.";
RL   Thromb. Res. 8:639-658(1976).
RN   [20]
RP   REVIEW, ELECTRON MICROSCOPY, POLYMERIZATION, AND LIGANDS.
RX   PubMed=6383194;
RA   Doolittle R.F.;
RT   "Fibrinogen and fibrin.";
RL   Annu. Rev. Biochem. 53:195-229(1984).
RN   [21]
RP   CROSS-LINKING SITE FOR ALPHA-2-PLASMIN INHIBITOR.
RX   PubMed=2877981;
RA   Kimura S., Aoki N.;
RT   "Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor.";
RL   J. Biol. Chem. 261:15591-15595(1986).
RN   [22]
RP   PHOSPHORYLATION.
RX   PubMed=6318767; DOI=10.1016/0006-291X(83)91247-0;
RA   Itarte E., Plana M., Guasch M.D., Martos C.;
RT   "Phosphorylation of fibrinogen by casein kinase 1.";
RL   Biochem. Biophys. Res. Commun. 117:631-636(1983).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Pituitary;
RX   PubMed=16807684; DOI=10.1007/s11102-006-8916-x;
RA   Beranova-Giorgianni S., Zhao Y., Desiderio D.M., Giorgianni F.;
RT   "Phosphoproteomic analysis of the human pituitary.";
RL   Pituitary 9:109-120(2006).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-412 AND SER-609, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [25]
RP   HYDROXYLATION AT PRO-565.
RX   PubMed=19696023; DOI=10.1074/jbc.M109.041749;
RA   Ono M., Matsubara J., Honda K., Sakuma T., Hashiguchi T., Nose H.,
RA   Nakamori S., Okusaka T., Kosuge T., Sata N., Nagai H., Ioka T.,
RA   Tanaka S., Tsuchida A., Aoki T., Shimahara M., Yasunami Y., Itoi T.,
RA   Moriyasu F., Negishi A., Kuwabara H., Shoji A., Hirohashi S.,
RA   Yamada T.;
RT   "Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein
RT   modification revealed by plasma proteomics.";
RL   J. Biol. Chem. 284:29041-29049(2009).
RN   [26]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-686.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [27]
RP   CLEAVAGE BY HEMENTIN AND PLASMIN.
RX   PubMed=2143188;
RA   Kirschbaum N.E., Budzynski A.Z.;
RT   "A unique proteolytic fragment of human fibrinogen containing the A
RT   alpha COOH-terminal domain of the native molecule.";
RL   J. Biol. Chem. 265:13669-13676(1990).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   GLYCOSYLATION AT THR-320 AND SER-351.
RX   PubMed=23050552; DOI=10.1021/pr3005937;
RA   Zauner G., Hoffmann M., Rapp E., Koeleman C.A., Dragan I.,
RA   Deelder A.M., Wuhrer M., Hensbergen P.J.;
RT   "Glycoproteomic analysis of human fibrinogen reveals novel regions of
RT   O-glycosylation.";
RL   J. Proteome Res. 11:5804-5814(2012).
RN   [30]
RP   LACK OF GLYCOSYLATION.
RX   PubMed=23151259; DOI=10.1021/pr300813h;
RA   Adamczyk B., Struwe W.B., Ercan A., Nigrovic P.A., Rudd P.M.;
RT   "Characterization of fibrinogen glycosylation and its importance for
RT   serum/plasma N-glycome analysis.";
RL   J. Proteome Res. 12:444-454(2013).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-45; SER-50; SER-281;
RP   SER-291; SER-294; THR-412; SER-451; SER-501; THR-505 AND SER-609, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   PHOSPHORYLATION AT SER-45; SER-56; SER-364; SER-524; SER-560 AND
RP   SER-609.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-39.
RX   PubMed=1560020;
RA   Martin P.D., Robertson W., Turk D., Huber R., Bode W., Edwards B.F.P.;
RT   "The structure of residues 7-16 of the A alpha-chain of human
RT   fibrinogen bound to bovine thrombin at 2.3-A resolution.";
RL   J. Biol. Chem. 267:7911-7920(1992).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 130-216, DISULFIDE BONDS,
RP   AND SUBUNIT.
RX   PubMed=9333233; DOI=10.1038/38947;
RA   Spraggon G., Everse S.J., Doolittle R.F.;
RT   "Crystal structures of fragment D from human fibrinogen and its
RT   crosslinked counterpart from fibrin.";
RL   Nature 389:455-462(1997).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 130-216, SUBUNIT, DISULFIDE
RP   BONDS, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND COILED COIL
RP   DOMAIN.
RX   PubMed=9628725; DOI=10.1021/bi9804129;
RA   Everse S.J., Spraggon G., Veerapandian L., Riley M., Doolittle R.F.;
RT   "Crystal structure of fragment double-D from human fibrin with two
RT   different bound ligands.";
RL   Biochemistry 37:8637-8642(1998).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 666-866 IN COMPLEX WITH
RP   CALCIUM IONS, GLYCOSYLATION AT ASN-686, DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=9689040; DOI=10.1073/pnas.95.16.9099;
RA   Spraggon G., Applegate D., Everse S.J., Zhang J.Z., Veerapandian L.,
RA   Redman C., Doolittle R.F., Grieninger G.;
RT   "Crystal structure of a recombinant alphaEC domain from human
RT   fibrinogen-420.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9099-9104(1998).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 130-216, AND DISULFIDE
RP   BONDS.
RX   PubMed=10074346; DOI=10.1021/bi982626w;
RA   Everse S.J., Spraggon G., Veerapandian L., Doolittle R.F.;
RT   "Conformational changes in fragments D and double-D from human
RT   fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Pro-amide.";
RL   Biochemistry 38:2941-2946(1999).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 20-581, SUBUNIT, DISULFIDE
RP   BONDS, COILED COIL DOMAIN, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=19296670; DOI=10.1021/bi802205g;
RA   Kollman J.M., Pandi L., Sawaya M.R., Riley M., Doolittle R.F.;
RT   "Crystal structure of human fibrinogen.";
RL   Biochemistry 48:3877-3886(2009).
RN   [39]
RP   VARIANT KYOTO-2 LEU-37.
RX   PubMed=2070049;
RA   Yoshida N., Okuma M., Hirata H., Matsuda M., Yamazumi K., Asakura S.;
RT   "Fibrinogen Kyoto II, a new congenitally abnormal molecule,
RT   characterized by the replacement of A alpha proline-18 by leucine.";
RL   Blood 78:149-153(1991).
RN   [40]
RP   VARIANT LIMA SER-160.
RX   PubMed=1634621; DOI=10.1172/JCI115857;
RA   Maekawa H., Yamazumi K., Muramatsu S., Kaneko M., Hirata H.,
RA   Takahashi N., Arocha-Pinango C.L., Rodriguez S., Nagy H.,
RA   Perez-Requejo J.L., Matsuda M.;
RT   "Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-
RT   141 to serine substitution associated with extra N-glycosylation at A
RT   alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-
RT   facilitated plasminogen activation catalyzed by tissue-type
RT   plasminogen activator.";
RL   J. Clin. Invest. 90:67-76(1992).
RN   [41]
RP   VARIANT CARACAS-2 ASN-453.
RX   PubMed=1675636;
RA   Maekawa H., Yamazumi K., Muramatsu S., Kaneko M., Hirata H.,
RA   Takahashi N., de Bosch N.B., Carvajal Z., Ojeda A.,
RA   Arocha-Pinango C.L., Matsuda M.;
RT   "An A alpha Ser-434 to N-glycosylated Asn substitution in a
RT   dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin
RT   gel formation.";
RL   J. Biol. Chem. 266:11575-11581(1991).
RN   [42]
RP   INVOLVEMENT IN DYSFIBRIN, AND VARIANT DYSFIBRIN CYS-573.
RX   PubMed=8473507; DOI=10.1172/JCI116371;
RA   Koopman J., Haverkate F., Grimbergen J., Lord S.T., Mosesson M.W.,
RA   Diorio J.P., Siebenlist K.S., Legrand C., Soria J., Soria C.,
RA   Caen J.P.;
RT   "Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its
RT   association with abnormal fibrin polymerization and thrombophilia.";
RL   J. Clin. Invest. 91:1637-1643(1993).
RN   [43]
RP   VARIANT AMYL8 LEU-573.
RX   PubMed=8097946; DOI=10.1038/ng0393-252;
RA   Benson M.D., Liepnieks J., Uemichi T., Wheeler G., Correa R.;
RT   "Hereditary renal amyloidosis associated with a mutant fibrinogen
RT   alpha-chain.";
RL   Nat. Genet. 3:252-255(1993).
RN   [44]
RP   VARIANT OSAKA IV HIS-35.
RX   PubMed=8461606; DOI=10.1007/BF00308999;
RA   Yamazumi K., Terukina S., Matsuda M., Kanbayashi J., Sakon M.,
RA   Tsujinaka T.;
RT   "Fibrinogen Osaka IV: a congenital dysfibrinogenemia found in a
RT   patient originally reported in relation to surgery, now defined to
RT   have an A alpha arginine-16 to histidine substitution.";
RL   Surg. Today 23:45-50(1993).
RN   [45]
RP   VARIANT CANTERBURY ASP-39.
RX   PubMed=8675656; DOI=10.1172/JCI118356;
RA   Brennan S.O., Hammonds B., George P.M.;
RT   "Aberrant hepatic processing causes removal of activation peptide and
RT   primary polymerisation site from fibrinogen Canterbury (A-alpha 20
RT   Val-to-Asp).";
RL   J. Clin. Invest. 96:2854-2858(1995).
RN   [46]
RP   VARIANTS ALA-331 AND GLU-446.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [47]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [48]
RP   INVOLVEMENT IN DYSFIBRIN, AND VARIANT DYSFIBRIN CYS-35.
RX   PubMed=16846481; DOI=10.1111/j.1365-2141.2006.06129.x;
RA   Flood V.H., Al-Mondhiry H.A., Farrell D.H.;
RT   "The fibrinogen Aalpha R16C mutation results in fibrinolytic
RT   resistance.";
RL   Br. J. Haematol. 134:220-226(2006).
RN   [49]
RP   INVOLVEMENT IN CAFBN; VARIANTS CAFBN ARG-55; PRO-129 AND TRP-184, AND
RP   CHARACTERIZATION OF VARIANTS CAFBN ARG-55; PRO-129 AND TRP-184.
RX   PubMed=25427968; DOI=10.1160/TH14-07-0629;
RA   Asselta R., Plate M., Robusto M., Borhany M., Guella I., Solda G.,
RA   Afrasiabi A., Menegatti M., Shamsi T., Peyvandi F., Duga S.;
RT   "Clinical and molecular characterisation of 21 patients affected by
RT   quantitative fibrinogen deficiency.";
RL   Thromb. Haemost. 113:567-576(2015).
CC   -!- FUNCTION: Cleaved by the protease thrombin to yield monomers
CC       which, together with fibrinogen beta (FGB) and fibrinogen gamma
CC       (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a
CC       major function in hemostasis as one of the primary components of
CC       blood clots. In addition, functions during the early stages of
CC       wound repair to stabilize the lesion and guide cell migration
CC       during re-epithelialization. Was originally thought to be
CC       essential for platelet aggregation, based on in vitro studies
CC       using anticoagulated blood. However, subsequent studies have shown
CC       that it is not absolutely required for thrombus formation in vivo.
CC       Enhances expression of SELP in activated platelets via an ITGB3-
CC       dependent pathway. Maternal fibrinogen is essential for successful
CC       pregnancy. Fibrin deposition is also associated with infection,
CC       where it protects against IFNG-mediated hemorrhage. May also
CC       facilitate the immune response via both innate and T-cell mediated
CC       pathways. {ECO:0000250|UniProtKB:E9PV24}.
CC   -!- SUBUNIT: Heterohexamer; disulfide linked. Contains 2 sets of 3
CC       non-identical chains (alpha, beta and gamma). The 2 heterotrimers
CC       are in head to head conformation with the N-termini in a small
CC       central domain. {ECO:0000269|PubMed:518846,
CC       ECO:0000269|PubMed:741445, ECO:0000269|PubMed:9333233,
CC       ECO:0000269|PubMed:936108, ECO:0000269|PubMed:9628725,
CC       ECO:0000269|PubMed:9689040}.
CC   -!- INTERACTION:
CC       P02647:APOA1; NbExp=2; IntAct=EBI-348571, EBI-701692;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9628725}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Alpha-E;
CC         IsoId=P02671-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha;
CC         IsoId=P02671-2; Sequence=VSP_001531, VSP_001532;
CC         Note=Ref.3 (AAK31372) sequence is in conflict in positions:
CC         640:PSLSP->LPCPPRLS. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level).
CC       {ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9628725}.
CC   -!- DOMAIN: A long coiled coil structure formed by 3 polypeptide
CC       chains connects the central nodule to the C-terminal domains
CC       (distal nodules). The long C-terminal ends of the alpha chains
CC       fold back, contributing a fourth strand to the coiled coil
CC       structure. {ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9628725, ECO:0000305}.
CC   -!- PTM: The alpha chain is normally not N-glycosylated
CC       (PubMed:23151259), even though glycosylation at Asn-686 was
CC       observed when a fragment of the protein was expressed in insect
CC       cells (PubMed:9689040). It is well known that heterologous
CC       expression of isolated domains can lead to adventitious protein
CC       modifications. Besides, glycosylation at Asn-686 is supported by
CC       large-scale glycoproteomics studies (PubMed:16335952 and
CC       PubMed:19159218), but the evidence is still quite tenuous. Most
CC       likely, Asn-686 is not glycosylated in the healthy human body, or
CC       only with low efficiency. {ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23151259,
CC       ECO:0000269|PubMed:9689040, ECO:0000305}.
CC   -!- PTM: O-glycosylated. {ECO:0000269|PubMed:23050552}.
CC   -!- PTM: Forms F13A-mediated cross-links between a glutamine and the
CC       epsilon-amino group of a lysine residue, forming fibronectin-
CC       fibrinogen heteropolymers.
CC   -!- PTM: About one-third of the alpha chains in the molecules in blood
CC       were found to be phosphorylated.
CC   -!- PTM: Conversion of fibrinogen to fibrin is triggered by thrombin,
CC       which cleaves fibrinopeptides A and B from alpha and beta chains,
CC       and thus exposes the N-terminal polymerization sites responsible
CC       for the formation of the soft clot. The soft clot is converted
CC       into the hard clot by factor XIIIA which catalyzes the epsilon-
CC       (gamma-glutamyl)lysine cross-linking between gamma chains
CC       (stronger) and between alpha chains (weaker) of different
CC       monomers. {ECO:0000269|PubMed:2143188}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- DISEASE: Congenital afibrinogenemia (CAFBN) [MIM:202400]: Rare
CC       autosomal recessive disorder is characterized by bleeding that
CC       varies from mild to severe and by complete absence or extremely
CC       low levels of plasma and platelet fibrinogen.
CC       {ECO:0000269|PubMed:25427968}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. The
CC       majority of cases of afibrinogenemia are due to truncating
CC       mutations. Variations in position Arg-35 (the site of cleavage of
CC       fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
CC   -!- DISEASE: Amyloidosis 8 (AMYL8) [MIM:105200]: A hereditary
CC       generalized amyloidosis due to deposition of apolipoprotein A1,
CC       fibrinogen and lysozyme amyloids. Viscera are particularly
CC       affected. There is no involvement of the nervous system. Clinical
CC       features include renal amyloidosis resulting in nephrotic
CC       syndrome, arterial hypertension, hepatosplenomegaly, cholestasis,
CC       petechial skin rash. {ECO:0000269|PubMed:8097946}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Dysfibrinogenemia, congenital (DYSFIBRIN) [MIM:616004]: A
CC       disorder characterized by qualitative abnormalities
CC       (dysfibrinogenemia) of the circulating fibrinogen. Affected
CC       individuals are frequently asymptomatic, but some patients have
CC       bleeding diathesis, thromboembolic complications, or both. In some
CC       cases, dysfibrinogenemia is associated with low circulating
CC       fibrinogen levels (hypodysfibrinogenemia).
CC       {ECO:0000269|PubMed:16846481, ECO:0000269|PubMed:8473507}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Contains 1 fibrinogen C-terminal domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00739}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=FGA";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Fibrinogen entry;
CC       URL="https://en.wikipedia.org/wiki/Fibrinogen";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/fga/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M64982; AAA17056.1; -; Genomic_DNA.
DR   EMBL; M64982; AAA17055.1; -; Genomic_DNA.
DR   EMBL; M58569; AAC97142.1; -; Transcribed_RNA.
DR   EMBL; M58569; AAC97143.1; -; Transcribed_RNA.
DR   EMBL; AF361104; AAK31372.1; -; Genomic_DNA.
DR   EMBL; AF361104; AAK31373.1; -; Genomic_DNA.
DR   EMBL; AK290559; BAF83248.1; -; mRNA.
DR   EMBL; CH471056; EAX04925.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04926.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04927.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04928.1; -; Genomic_DNA.
DR   EMBL; BC098280; AAH98280.1; -; mRNA.
DR   EMBL; BC099706; AAH99706.1; -; mRNA.
DR   EMBL; BC099720; AAH99720.1; -; mRNA.
DR   EMBL; BC101935; AAI01936.1; -; mRNA.
DR   EMBL; J00128; AAA52427.1; -; mRNA.
DR   EMBL; J00127; AAA52426.1; -; mRNA.
DR   EMBL; K02272; AAA52428.1; -; mRNA.
DR   EMBL; M26878; AAA52444.1; -; mRNA.
DR   CCDS; CCDS3787.1; -. [P02671-1]
DR   CCDS; CCDS47152.1; -. [P02671-2]
DR   PIR; A93956; FGHUA.
DR   PIR; D44234; D44234.
DR   RefSeq; NP_000499.1; NM_000508.3. [P02671-1]
DR   RefSeq; NP_068657.1; NM_021871.2. [P02671-2]
DR   UniGene; Hs.351593; -.
DR   PDB; 1BBR; X-ray; 2.30 A; F/G/I=26-35.
DR   PDB; 1DM4; X-ray; 2.50 A; C=26-35.
DR   PDB; 1FPH; X-ray; 2.50 A; F=26-35.
DR   PDB; 1FZA; X-ray; 2.90 A; A/D=130-216.
DR   PDB; 1FZB; X-ray; 2.90 A; A/D=130-216.
DR   PDB; 1FZC; X-ray; 2.30 A; A/D=130-216.
DR   PDB; 1FZD; X-ray; 2.10 A; A/B/C/D/E/F/G/H=666-866.
DR   PDB; 1FZE; X-ray; 3.00 A; A/D=130-216.
DR   PDB; 1FZF; X-ray; 2.70 A; A/D=130-216.
DR   PDB; 1FZG; X-ray; 2.50 A; A/D=130-216.
DR   PDB; 1LT9; X-ray; 2.80 A; A/D=145-210.
DR   PDB; 1LTJ; X-ray; 2.80 A; A/D=145-210.
DR   PDB; 1N86; X-ray; 3.20 A; A/D=130-216.
DR   PDB; 1N8E; X-ray; 4.50 A; A/D=130-218.
DR   PDB; 1RE3; X-ray; 2.45 A; A/D=145-210.
DR   PDB; 1RE4; X-ray; 2.70 A; A/D=145-210.
DR   PDB; 1RF0; X-ray; 2.81 A; A/D=145-210.
DR   PDB; 1RF1; X-ray; 2.53 A; A/D=145-210.
DR   PDB; 1YCP; X-ray; 2.50 A; F/N=20-42.
DR   PDB; 2A45; X-ray; 3.65 A; G/J=36-92.
DR   PDB; 2FFD; X-ray; 2.89 A; A/D=145-210.
DR   PDB; 2H43; X-ray; 2.70 A; A/D=130-216.
DR   PDB; 2HLO; X-ray; 2.60 A; A/D=130-216.
DR   PDB; 2HOD; X-ray; 2.90 A; A/D/G/J=130-216.
DR   PDB; 2HPC; X-ray; 2.90 A; A/D/G/J=130-216.
DR   PDB; 2OYH; X-ray; 2.40 A; A/D=145-210.
DR   PDB; 2OYI; X-ray; 2.70 A; A/D=145-210.
DR   PDB; 2Q9I; X-ray; 2.80 A; A/D=130-216.
DR   PDB; 2XNX; X-ray; 3.30 A; A/D/G/J=130-216.
DR   PDB; 2XNY; X-ray; 7.50 A; A/D=130-216.
DR   PDB; 2Z4E; X-ray; 2.70 A; A/D=130-216.
DR   PDB; 3AT0; X-ray; 2.50 A; B=332-347.
DR   PDB; 3BVH; X-ray; 2.60 A; A/D=148-209.
DR   PDB; 3E1I; X-ray; 2.30 A; A/D=130-216.
DR   PDB; 3GHG; X-ray; 2.90 A; A/D/G/J=20-581.
DR   PDB; 3H32; X-ray; 3.60 A; A/D=20-216.
DR   PDB; 3HUS; X-ray; 3.04 A; A/D=145-210.
DR   PDB; 4F27; X-ray; 1.92 A; Q=336-347.
DR   PDB; 5CFA; X-ray; 1.45 A; C/D=580-594.
DR   PDBsum; 1BBR; -.
DR   PDBsum; 1DM4; -.
DR   PDBsum; 1FPH; -.
DR   PDBsum; 1FZA; -.
DR   PDBsum; 1FZB; -.
DR   PDBsum; 1FZC; -.
DR   PDBsum; 1FZD; -.
DR   PDBsum; 1FZE; -.
DR   PDBsum; 1FZF; -.
DR   PDBsum; 1FZG; -.
DR   PDBsum; 1LT9; -.
DR   PDBsum; 1LTJ; -.
DR   PDBsum; 1N86; -.
DR   PDBsum; 1N8E; -.
DR   PDBsum; 1RE3; -.
DR   PDBsum; 1RE4; -.
DR   PDBsum; 1RF0; -.
DR   PDBsum; 1RF1; -.
DR   PDBsum; 1YCP; -.
DR   PDBsum; 2A45; -.
DR   PDBsum; 2FFD; -.
DR   PDBsum; 2H43; -.
DR   PDBsum; 2HLO; -.
DR   PDBsum; 2HOD; -.
DR   PDBsum; 2HPC; -.
DR   PDBsum; 2OYH; -.
DR   PDBsum; 2OYI; -.
DR   PDBsum; 2Q9I; -.
DR   PDBsum; 2XNX; -.
DR   PDBsum; 2XNY; -.
DR   PDBsum; 2Z4E; -.
DR   PDBsum; 3AT0; -.
DR   PDBsum; 3BVH; -.
DR   PDBsum; 3E1I; -.
DR   PDBsum; 3GHG; -.
DR   PDBsum; 3H32; -.
DR   PDBsum; 3HUS; -.
DR   PDBsum; 4F27; -.
DR   PDBsum; 5CFA; -.
DR   ProteinModelPortal; P02671; -.
DR   SMR; P02671; 46-231, 411-524, 596-866.
DR   BioGrid; 108534; 25.
DR   DIP; DIP-29643N; -.
DR   IntAct; P02671; 15.
DR   MINT; MINT-1033042; -.
DR   STRING; 9606.ENSP00000306361; -.
DR   ChEMBL; CHEMBL2364709; -.
DR   DrugBank; DB00009; Alteplase.
DR   DrugBank; DB00029; Anistreplase.
DR   DrugBank; DB00015; Reteplase.
DR   DrugBank; DB00364; Sucralfate.
DR   DrugBank; DB00031; Tenecteplase.
DR   iPTMnet; P02671; -.
DR   PhosphoSite; P02671; -.
DR   SwissPalm; P02671; -.
DR   UniCarbKB; P02671; -.
DR   BioMuta; FGA; -.
DR   DMDM; 1706799; -.
DR   OGP; P02671; -.
DR   SWISS-2DPAGE; P02671; -.
DR   MaxQB; P02671; -.
DR   PaxDb; P02671; -.
DR   PeptideAtlas; P02671; -.
DR   PRIDE; P02671; -.
DR   DNASU; 2243; -.
DR   Ensembl; ENST00000302053; ENSP00000306361; ENSG00000171560. [P02671-1]
DR   Ensembl; ENST00000403106; ENSP00000385981; ENSG00000171560. [P02671-2]
DR   GeneID; 2243; -.
DR   KEGG; hsa:2243; -.
DR   UCSC; uc003iod.1; human. [P02671-1]
DR   UCSC; uc003ioe.1; human. [P02671-2]
DR   CTD; 2243; -.
DR   GeneCards; FGA; -.
DR   HGNC; HGNC:3661; FGA.
DR   HPA; CAB016776; -.
DR   HPA; HPA051370; -.
DR   MalaCards; FGA; -.
DR   MIM; 105200; phenotype.
DR   MIM; 134820; gene+phenotype.
DR   MIM; 202400; phenotype.
DR   MIM; 616004; phenotype.
DR   neXtProt; NX_P02671; -.
DR   Orphanet; 98880; Familial afibrinogenemia.
DR   Orphanet; 98881; Familial dysfibrinogenemia.
DR   Orphanet; 248408; Familial hypodysfibrinogenemia.
DR   Orphanet; 101041; Familial hypofibrinogenemia.
DR   Orphanet; 93562; Familial renal amyloidosis due to fibrinogen A alpha-chain variant.
DR   PharmGKB; PA429; -.
DR   eggNOG; KOG2579; Eukaryota.
DR   eggNOG; ENOG410ZYS4; LUCA.
DR   GeneTree; ENSGT00830000128240; -.
DR   HOGENOM; HOG000285947; -.
DR   HOVERGEN; HBG005668; -.
DR   InParanoid; P02671; -.
DR   KO; K03903; -.
DR   OMA; PGSTGTW; -.
DR   OrthoDB; EOG7X9G60; -.
DR   PhylomeDB; P02671; -.
DR   TreeFam; TF351984; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   ChiTaRS; FGA; human.
DR   EvolutionaryTrace; P02671; -.
DR   GeneWiki; Fibrinogen_alpha_chain; -.
DR   GenomeRNAi; 2243; -.
DR   NextBio; 35464018; -.
DR   PMAP-CutDB; P02671; -.
DR   PRO; PR:P02671; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; P02671; -.
DR   CleanEx; HS_FGA; -.
DR   ExpressionAtlas; P02671; baseline and differential.
DR   Genevisible; P02671; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031091; C:platelet alpha granule; IDA:BHF-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005198; F:structural molecule activity; IDA:BHF-UCL.
DR   GO; GO:0006953; P:acute-phase response; IEA:Ensembl.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0072377; P:blood coagulation, common pathway; IMP:BHF-UCL.
DR   GO; GO:0072378; P:blood coagulation, fibrin clot formation; IDA:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:BHF-UCL.
DR   GO; GO:0043623; P:cellular protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:1990643; P:cellular response to granulocyte colony-stimulating factor; IEA:Ensembl.
DR   GO; GO:0071354; P:cellular response to interleukin-6; IEA:Ensembl.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0042730; P:fibrinolysis; IDA:UniProtKB.
DR   GO; GO:0043152; P:induction of bacterial agglutination; IDA:CACAO.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:2000261; P:negative regulation of blood coagulation, common pathway; TAS:BHF-UCL.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0031639; P:plasminogen activation; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0070527; P:platelet aggregation; IMP:UniProtKB.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IDA:BHF-UCL.
DR   GO; GO:0034116; P:positive regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0090277; P:positive regulation of peptide hormone secretion; IDA:BHF-UCL.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; NAS:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IDA:BHF-UCL.
DR   GO; GO:0006461; P:protein complex assembly; IMP:UniProtKB.
DR   GO; GO:0051258; P:protein polymerization; IDA:BHF-UCL.
DR   GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL.
DR   GO; GO:0046898; P:response to cycloheximide; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0033595; P:response to genistein; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR   Gene3D; 3.90.215.10; -; 1.
DR   Gene3D; 4.10.530.10; -; 1.
DR   InterPro; IPR014716; Fibrinogen_a/b/g_C_1.
DR   InterPro; IPR014715; Fibrinogen_a/b/g_C_2.
DR   InterPro; IPR002181; Fibrinogen_a/b/g_C_dom.
DR   InterPro; IPR012290; Fibrinogen_a/b/g_coil_dom.
DR   InterPro; IPR021996; Fibrinogen_aC.
DR   InterPro; IPR020837; Fibrinogen_CS.
DR   Pfam; PF08702; Fib_alpha; 1.
DR   Pfam; PF12160; Fibrinogen_aC; 1.
DR   Pfam; PF00147; Fibrinogen_C; 1.
DR   SMART; SM00186; FBG; 1.
DR   SUPFAM; SSF56496; SSF56496; 1.
DR   PROSITE; PS00514; FIBRINOGEN_C_1; 1.
DR   PROSITE; PS51406; FIBRINOGEN_C_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Amyloid;
KW   Amyloidosis; Blood coagulation; Calcium; Coiled coil;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Hemostasis; Hydroxylation; Immunity;
KW   Innate immunity; Isopeptide bond; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     19       {ECO:0000269|PubMed:518846,
FT                                ECO:0000269|Ref.10, ECO:0000269|Ref.14}.
FT   PEPTIDE      20     35       Fibrinopeptide A.
FT                                /FTId=PRO_0000009021.
FT   CHAIN        36    866       Fibrinogen alpha chain.
FT                                /FTId=PRO_0000009022.
FT   DOMAIN      623    864       Fibrinogen C-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00739}.
FT   REGION       36     38       Alpha-chain polymerization, binding
FT                                distal domain of another fibrin gamma
FT                                chain.
FT   COILED       68    631       {ECO:0000305|PubMed:19296670}.
FT   METAL       791    791       Calcium. {ECO:0000244|PDB:1FZD,
FT                                ECO:0000269|PubMed:9689040}.
FT   METAL       793    793       Calcium. {ECO:0000244|PDB:1FZD,
FT                                ECO:0000269|PubMed:9689040}.
FT   METAL       795    795       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1FZD,
FT                                ECO:0000269|PubMed:9689040}.
FT   METAL       797    797       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1FZD,
FT                                ECO:0000269|PubMed:9689040}.
FT   SITE         35     36       Cleavage; by thrombin; to release
FT                                fibrinopeptide A.
FT   SITE        100    101       Cleavage; by plasmin; to break down
FT                                fibrin clots.
FT   SITE        121    122       Cleavage; by hementin; to prevent blood
FT                                coagulation.
FT   SITE        123    124       Cleavage; by plasmin; to break down
FT                                fibrin clots.
FT   MOD_RES      22     22       Phosphoserine.
FT                                {ECO:0000244|PubMed:16807684}.
FT   MOD_RES      45     45       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   MOD_RES      50     50       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      56     56       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     281    281       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     291    291       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     294    294       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     364    364       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     412    412       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     451    451       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     501    501       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     505    505       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     524    524       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     560    560       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     565    565       4-hydroxyproline; by P4HA1.
FT                                {ECO:0000269|PubMed:19696023}.
FT   MOD_RES     609    609       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   CARBOHYD    320    320       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:23050552}.
FT   CARBOHYD    351    351       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:23050552}.
FT   CARBOHYD    453    453       N-linked (GlcNAc...); in variant Caracas-
FT                                2.
FT   CARBOHYD    686    686       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:9689040}.
FT   DISULFID     47     47       Interchain.
FT                                {ECO:0000269|PubMed:19296670}.
FT   DISULFID     55     55       Interchain (with C-95 in beta chain).
FT                                {ECO:0000269|PubMed:19296670}.
FT   DISULFID     64     64       Interchain (with C-49 in gamma chain).
FT                                {ECO:0000269|PubMed:19296670}.
FT   DISULFID     68     68       Interchain (with C-106 in beta chain).
FT                                {ECO:0000269|PubMed:19296670}.
FT   DISULFID    180    180       Interchain (with C-165 in gamma chain).
FT                                {ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:741445,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   DISULFID    184    184       Interchain (with C-223 in beta chain).
FT                                {ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:741445,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   DISULFID    461    491       {ECO:0000250|UniProtKB:P02672}.
FT   DISULFID    799    812       {ECO:0000244|PDB:1FZD,
FT                                ECO:0000269|PubMed:9689040}.
FT   CROSSLNK    322    322       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-41 in alpha-2-
FT                                antiplasmin).
FT   CROSSLNK    347    347       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-?).
FT   CROSSLNK    385    385       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-?).
FT   CROSSLNK    527    527       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-?). {ECO:0000255}.
FT   CROSSLNK    558    558       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-?). {ECO:0000255}.
FT   CROSSLNK    575    575       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-?). {ECO:0000255}.
FT   CROSSLNK    581    581       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-?). {ECO:0000255}.
FT   CROSSLNK    599    599       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-?). {ECO:0000255}.
FT   VAR_SEQ     631    644       DCDDVLQTHPSGTQ -> GIHTSPLGKPSLSP (in
FT                                isoform 2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:6575389}.
FT                                /FTId=VSP_001531.
FT   VAR_SEQ     645    866       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:6575389}.
FT                                /FTId=VSP_001532.
FT   VARIANT       6      6       I -> V (in dbSNP:rs2070025).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_011609.
FT   VARIANT      26     26       D -> N (in Lille-1).
FT                                /FTId=VAR_002390.
FT   VARIANT      31     31       G -> V (in Rouen-1).
FT                                /FTId=VAR_002391.
FT   VARIANT      35     35       R -> C (in DYSFIBRIN; fibrinogen Metz 1/
FT                                Hershey III).
FT                                {ECO:0000269|PubMed:16846481}.
FT                                /FTId=VAR_002392.
FT   VARIANT      35     35       R -> H. {ECO:0000269|PubMed:8461606}.
FT                                /FTId=VAR_002393.
FT   VARIANT      37     37       P -> L (in Kyoto-2).
FT                                {ECO:0000269|PubMed:2070049}.
FT                                /FTId=VAR_002394.
FT   VARIANT      38     38       R -> G (in Aarhus-1).
FT                                /FTId=VAR_002397.
FT   VARIANT      38     38       R -> N (in Munich-1; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_002395.
FT   VARIANT      38     38       R -> S (in Detroit-1).
FT                                /FTId=VAR_002396.
FT   VARIANT      39     39       V -> D (in Canterbury).
FT                                {ECO:0000269|PubMed:8675656}.
FT                                /FTId=VAR_010730.
FT   VARIANT      55     55       C -> R (in CAFBN; hypofibrinogenemia;
FT                                heterozygous; decreased fibrinogen
FT                                complex assembly; no effect on fibrinogen
FT                                complex secretion).
FT                                {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072721.
FT   VARIANT      66     66       S -> T.
FT                                /FTId=VAR_002398.
FT   VARIANT     129    129       R -> P (in CAFBN; hypofibrinogenemia;
FT                                heterozygous; no effect on fibrinogen
FT                                complex assembly; no effect on fibrinogen
FT                                complex secretion).
FT                                {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072722.
FT   VARIANT     160    160       R -> S (in Lima).
FT                                {ECO:0000269|PubMed:1634621}.
FT                                /FTId=VAR_002399.
FT   VARIANT     184    184       C -> W (in CAFBN; hypofibrinogenemia;
FT                                heterozygous; impaired fibrinogen complex
FT                                assembly). {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072723.
FT   VARIANT     331    331       T -> A (in dbSNP:rs6050).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_011610.
FT   VARIANT     446    446       K -> E (in dbSNP:rs6052).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_014168.
FT   VARIANT     453    453       S -> N (in Caracas-2).
FT                                {ECO:0000269|PubMed:1675636}.
FT                                /FTId=VAR_002400.
FT   VARIANT     456    456       T -> A (in dbSNP:rs2070031).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_011611.
FT   VARIANT     545    545       E -> V (in AMYL8).
FT                                /FTId=VAR_010731.
FT   VARIANT     573    573       R -> C (in DYSFIBRIN; fibrinogen Dusart/
FT                                Paris-5). {ECO:0000269|PubMed:8473507}.
FT                                /FTId=VAR_002401.
FT   VARIANT     573    573       R -> L (in AMYL8).
FT                                {ECO:0000269|PubMed:8097946}.
FT                                /FTId=VAR_010732.
FT   CONFLICT    177    177       I -> V (in Ref. 4; BAF83248).
FT                                {ECO:0000305}.
FT   CONFLICT    215    216       SR -> RS (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    299    299       S -> G (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    304    304       S -> G (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    317    318       GT -> SG (in Ref. 11; AA sequence).
FT                                {ECO:0000305}.
FT   TURN         27     31       {ECO:0000244|PDB:1BBR}.
FT   STRAND       57     60       {ECO:0000244|PDB:3GHG}.
FT   STRAND       63     65       {ECO:0000244|PDB:3GHG}.
FT   HELIX        67     92       {ECO:0000244|PDB:3GHG}.
FT   HELIX        94    111       {ECO:0000244|PDB:3GHG}.
FT   HELIX       116    129       {ECO:0000244|PDB:3GHG}.
FT   TURN        133    135       {ECO:0000244|PDB:1FZA}.
FT   TURN        139    141       {ECO:0000244|PDB:1FZC}.
FT   HELIX       142    178       {ECO:0000244|PDB:1FZC}.
FT   TURN        179    183       {ECO:0000244|PDB:1FZC}.
FT   STRAND      184    186       {ECO:0000244|PDB:1RE3}.
FT   HELIX       195    209       {ECO:0000244|PDB:1FZC}.
FT   TURN        226    228       {ECO:0000244|PDB:3GHG}.
FT   STRAND      337    343       {ECO:0000244|PDB:4F27}.
FT   STRAND      582    587       {ECO:0000244|PDB:5CFA}.
FT   STRAND      673    681       {ECO:0000244|PDB:1FZD}.
FT   HELIX       689    694       {ECO:0000244|PDB:1FZD}.
FT   HELIX       711    718       {ECO:0000244|PDB:1FZD}.
FT   STRAND      723    729       {ECO:0000244|PDB:1FZD}.
FT   STRAND      735    744       {ECO:0000244|PDB:1FZD}.
FT   TURN        747    751       {ECO:0000244|PDB:1FZD}.
FT   STRAND      753    762       {ECO:0000244|PDB:1FZD}.
FT   TURN        765    768       {ECO:0000244|PDB:1FZD}.
FT   TURN        771    773       {ECO:0000244|PDB:1FZD}.
FT   HELIX       775    778       {ECO:0000244|PDB:1FZD}.
FT   STRAND      793    797       {ECO:0000244|PDB:1FZD}.
FT   HELIX       799    803       {ECO:0000244|PDB:1FZD}.
FT   STRAND      810    812       {ECO:0000244|PDB:1FZD}.
FT   STRAND      814    816       {ECO:0000244|PDB:1FZD}.
FT   STRAND      823    826       {ECO:0000244|PDB:1FZD}.
FT   HELIX       829    831       {ECO:0000244|PDB:1FZD}.
FT   STRAND      840    843       {ECO:0000244|PDB:1FZD}.
FT   HELIX       844    847       {ECO:0000244|PDB:1FZD}.
FT   STRAND      854    861       {ECO:0000244|PDB:1FZD}.
SQ   SEQUENCE   866 AA;  94973 MW;  EA73A81204D8AEC4 CRC64;
     MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS DWPFCSDEDW
     NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK DSHSLTTNIM EILRGDFSSA
     NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC
     RGSCSRALAR EVDLKDYEDQ QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ
     LQKVPPEWKA LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS
     GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS TGSWNSGSSG TGSTGNQNPG SPRPGSTGTW
     NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS GNARPNNPDW GTFEEVSGNV
     SPGTRREYHT EKLVTSKGDK ELRTGKEKVT SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK
     EVVTSEDGSD CPEAMDLGTL SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF
     VSETESRGSE SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS
     YKMADEAGSE ADHEGTHSTK RGHAKSRPVR DCDDVLQTHP SGTQSGIFNI KLPGSSKIFS
     VYCDQETSLG GWLLIQQRMD GSLNFNRTWQ DYKRGFGSLN DEGEGEFWLG NDYLHLLTQR
     GSVLRVELED WAGNEAYAEY HFRVGSEAEG YALQVSSYEG TAGDALIEGS VEEGAEYTSH
     NNMQFSTFDR DADQWEENCA EVYGGGWWYN NCQAANLNGI YYPGGSYDPR NNSPYEIENG
     VVWVSFRGAD YSLRAVRMKI RPLVTQ
//
ID   PROC_HUMAN              Reviewed;         461 AA.
AC   P04070; B4DPQ7; Q15189; Q15190; Q16001; Q53S74; Q9UC55;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1986, sequence version 1.
DT   20-JAN-2016, entry version 212.
DE   RecName: Full=Vitamin K-dependent protein C;
DE            EC=3.4.21.69;
DE   AltName: Full=Anticoagulant protein C;
DE   AltName: Full=Autoprothrombin IIA;
DE   AltName: Full=Blood coagulation factor XIV;
DE   Contains:
DE     RecName: Full=Vitamin K-dependent protein C light chain;
DE   Contains:
DE     RecName: Full=Vitamin K-dependent protein C heavy chain;
DE   Contains:
DE     RecName: Full=Activation peptide;
DE   Flags: Precursor;
GN   Name=PROC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2991859; DOI=10.1093/nar/13.14.5233;
RA   Beckmann R.J., Schmidt R.J., Santerre R.F., Plutzky J., Crabtree G.R.,
RA   Long G.L.;
RT   "The structure and evolution of a 461 amino acid human protein C
RT   precursor and its messenger RNA, based upon the DNA sequence of cloned
RT   human liver cDNAs.";
RL   Nucleic Acids Res. 13:5233-5247(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], HYDROXYLATION AT ASP-113,
RP   GLYCOSYLATION AT ASN-290; ASN-355 AND ASN-371, AND
RP   GAMMA-CARBOXYGLUTAMATION AT GLU-48; GLU-49; GLU-56; GLU-58; GLU-61;
RP   GLU-62; GLU-67; GLU-68 AND GLU-71.
RX   PubMed=2991887; DOI=10.1073/pnas.82.14.4673;
RA   Foster D.C., Yoshitake S., Davie E.W.;
RT   "The nucleotide sequence of the gene for human protein C.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:4673-4677(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3511471; DOI=10.1073/pnas.83.3.546;
RA   Plutzky J., Hoskins J.A., Long G.L., Crabtree G.R.;
RT   "Evolution and organization of the human protein C gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:546-550(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 42-57, AND VARIANT THPH3 SER-42.
RC   TISSUE=Blood;
RX   PubMed=8560401;
RA   Miyata T., Zheng Y.-Z., Sakata T., Kato H.;
RT   "Protein C Osaka 10 with aberrant propeptide processing: loss of
RT   anticoagulant activity due to an amino acid substitution in the
RT   protein C precursor.";
RL   Thromb. Haemost. 74:1003-1008(1995).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 43-64, AND VARIANT PROC
RP   DEFICIENCY GLY-57.
RX   PubMed=8477066;
RA   Mimuro J., Muramatsu S., Kaneko M., Yoshitake S., Iijima K.,
RA   Nakamura K., Sakata Y., Matsuda M.;
RT   "An abnormal protein C (protein C Yonago) with an amino acid
RT   substitution of Gly for Arg-15 caused by a single base mutation of C
RT   to G in codon 57 (CGG-->GGG). Deteriorated calcium-dependent
RT   conformation of the gamma-carboxyglutamic acid domain relevant to a
RT   thrombotic tendency.";
RL   Int. J. Hematol. 57:9-14(1993).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 106-461 (ISOFORM 1).
RX   PubMed=6589623; DOI=10.1073/pnas.81.15.4766;
RA   Foster D.C., Davie E.W.;
RT   "Characterization of a cDNA coding for human protein C.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:4766-4770(1984).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 134-178 AND 267-332, AND VARIANTS
RP   THPH4 PRO-178 AND HIS-328.
RX   PubMed=7878626;
RA   Long G.L., Tomczak J.A., Rainville I.R., Dreyfus M., Schramm W.,
RA   Schwarz H.P.;
RT   "Homozygous type I protein C deficiency in two unrelated families
RT   exhibiting thrombophilia related to Ala136-->Pro or Arg286-->His
RT   mutations.";
RL   Thromb. Haemost. 72:526-533(1994).
RN   [13]
RP   GLYCOSYLATION AT ASN-371.
RX   PubMed=1694179;
RA   Miletich J.P., Broze G.J. Jr.;
RT   "Beta protein C is not glycosylated at asparagine 329. The rate of
RT   translation may influence the frequency of usage at asparagine-X-
RT   cysteine sites.";
RL   J. Biol. Chem. 265:11397-11404(1990).
RN   [14]
RP   HYDROXYLATION.
RX   PubMed=1544894;
RA   Harris R.J., Ling V.T., Spellman M.W.;
RT   "O-linked fucose is present in the first epidermal growth factor
RT   domain of factor XII but not protein C.";
RL   J. Biol. Chem. 267:5102-5107(1992).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-290.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [16]
RP   GLYCOSYLATION AT THR-19, STRUCTURE OF CARBOHYDRATES, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22171320; DOI=10.1074/mcp.M111.013649;
RA   Halim A., Nilsson J., Ruetschi U., Hesse C., Larson G.;
RT   "Human urinary glycoproteomics; attachment site specific analysis of
RT   N-and O-linked glycosylations by CID and ECD.";
RL   Mol. Cell. Proteomics 0:0-0(2011).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   PHOSPHORYLATION AT SER-347.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [19]
RP   3D-STRUCTURE MODELING OF 175-450.
RX   PubMed=8003977; DOI=10.1002/pro.5560030407;
RA   Fisher C.L., Greengard J.S., Griffin J.H.;
RT   "Models of the serine protease domain of the human antithrombotic
RT   plasma factor activated protein C and its zymogen.";
RL   Protein Sci. 3:588-599(1994).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 84-461.
RX   PubMed=9003757;
RA   Mather T., Oganessyan V., Hof P., Huber R., Foundling S., Esmon C.,
RA   Bode W.;
RT   "The 2.8 A crystal structure of Gla-domainless activated protein C.";
RL   EMBO J. 15:6822-6831(1996).
RN   [21]
RP   REVIEW ON PROC VARIANTS.
RX   PubMed=8446940;
RA   Reitsma P.H., Poort S.R., Bernardi F., Gandrille S., Long G.L.,
RA   Sala N., Cooper D.N.;
RT   "Protein C deficiency: a database of mutations.";
RL   Thromb. Haemost. 69:77-84(1993).
RN   [22]
RP   VARIANT THPH3 CYS-444.
RX   PubMed=2437584; DOI=10.1073/pnas.84.9.2829;
RA   Romeo G., Hassan H.J., Staempfli S., Roncuzzi L., Cianetti L.,
RA   Leonardi A., Vicente V., Mannucci P.M., Bertina R.M., Peschle C.,
RA   Cortese R.;
RT   "Hereditary thrombophilia: identification of nonsense and missense
RT   mutations in the protein C gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:2829-2832(1987).
RN   [23]
RP   VARIANT THPH3 TRP-211.
RX   PubMed=2602169; DOI=10.1093/nar/17.24.10513;
RA   Grundy C.B., Chitolie A., Talbot S., Bevan D., Kakkar V.V.,
RA   Cooper D.N.;
RT   "Protein C London 1: recurrent mutation at Arg-169 (CGG-->TGG) in the
RT   protein C gene causing thrombosis.";
RL   Nucleic Acids Res. 17:10513-10513(1989).
RN   [24]
RP   VARIANT THPH3 CYS-272.
RX   PubMed=1868249;
RA   Reitsma P.H., Poort S.R., Allaart C.F., Briet E., Bertina R.M.;
RT   "The spectrum of genetic defects in a panel of 40 Dutch families with
RT   symptomatic protein C deficiency type I: heterogeneity and founder
RT   effects.";
RL   Blood 78:890-894(1991).
RN   [25]
RP   VARIANTS THPH3 ALA-62 AND MET-76.
RX   PubMed=1347706;
RA   Bovill E.G., Tomczak J.A., Grant B., Bhushan F., Pillemer E.,
RA   Rainville I.R., Long G.L.;
RT   "Protein CVermont: symptomatic type II protein C deficiency associated
RT   with two GLA domain mutations.";
RL   Blood 79:1456-1465(1992).
RN   [26]
RP   VARIANT THPH4 ASP-418.
RX   PubMed=1611081;
RA   Sugahara Y., Miura O., Yuen P., Aoki N.;
RT   "Protein C deficiency Hong Kong 1 and 2: hereditary protein C
RT   deficiency caused by two mutant alleles, a 5-nucleotide deletion and a
RT   missense mutation.";
RL   Blood 80:126-133(1992).
RN   [27]
RP   VARIANT THPH4 LEU-289.
RX   PubMed=1511988;
RA   Grundy C.B., Chisholm M., Kakkar V.V., Cooper D.N.;
RT   "A novel homozygous missense mutation in the protein C (PROC) gene
RT   causing recurrent venous thrombosis.";
RL   Hum. Genet. 89:683-684(1992).
RN   [28]
RP   VARIANTS THPH3 GLN-220 AND TRP-220.
RX   PubMed=1511989;
RA   Grundy C.B., Schulman S., Tengborn L., Kakkar V.V., Cooper D.N.;
RT   "Two different missense mutations at Arg 178 of the protein C (PROC)
RT   gene causing recurrent venous thrombosis.";
RL   Hum. Genet. 89:685-686(1992).
RN   [29]
RP   VARIANT THPH3 GLN-220.
RX   PubMed=1301959; DOI=10.1002/humu.1380010607;
RA   Gandrille S., Vidaud M., Aiach M., Alhenc-Gelas M., Fischer A.M.,
RA   Gouault-Heilman M., Toulon P., Fiessinger J.-N., Goossens M.;
RT   "Two novel mutations responsible for hereditary type I protein C
RT   deficiency: characterization by denaturing gradient gel
RT   electrophoresis.";
RL   Hum. Mutat. 1:491-500(1992).
RN   [30]
RP   VARIANT THPH4 SER-334.
RX   PubMed=1593215;
RA   Yamamoto K., Matsushita T., Sugiura I., Takamatsu J., Iwasaki E.,
RA   Wada H., Deguchi K., Shirakawa S., Saito H.;
RT   "Homozygous protein C deficiency: identification of a novel missense
RT   mutation that causes impaired secretion of the mutant protein C.";
RL   J. Lab. Clin. Med. 119:682-689(1992).
RN   [31]
RP   VARIANTS TRP-38; CYS-42; HIS-42; GLN-271 AND ASN-294.
RX   PubMed=8324221;
RA   Gandrille S., Alhenc-Gelas M., Gaussem P., Aillaud M.-F., Dupuy E.,
RA   Juhan-Vague I., Aiach M.;
RT   "Five novel mutations located in exons III and IX of the protein C
RT   gene in patients presenting with defective protein C anticoagulant
RT   activity.";
RL   Blood 82:159-168(1993).
RN   [32]
RP   VARIANTS GLY-14; GLN-211; TYR-244; GLN-253; LEU-321; CYS-328; ILE-385;
RP   THR-388 AND VAL-388.
RX   PubMed=8499565;
RA   Poort S.R., Pabinger-Fasching I., Mannhalter C., Reitsma P.H.,
RA   Bertina R.M.;
RT   "Twelve novel and two recurrent mutations in 14 Austrian families with
RT   hereditary protein C deficiency.";
RL   Blood Coagul. Fibrinolysis 4:273-280(1993).
RN   [33]
RP   VARIANT THPH3 TRP-57.
RX   PubMed=8499568;
RA   Millar D.S., Grundy C.B., Bignell P., Moffat E.H., Martin R.,
RA   Kakkar V.V., Cooper D.N.;
RT   "A Gla domain mutation (Arg 15-->Trp) in the protein C (PROC) gene
RT   causing type 2 protein C deficiency and recurrent venous thrombosis.";
RL   Blood Coagul. Fibrinolysis 4:345-347(1993).
RN   [34]
RP   VARIANTS THPH3 ARG-145; LEU-210; TRP-211; THR-243; LEU-321; MET-340
RP   AND TYR-426.
RX   PubMed=8292730;
RA   Tsay W., Greengard J.S., Montgomery R.R., McPherson R.A., Fucci J.C.,
RA   Koerper M.A., Coughlin J., Griffin J.H.;
RT   "Genetic mutations in ten unrelated American patients with symptomatic
RT   type 1 protein C deficiency.";
RL   Blood Coagul. Fibrinolysis 4:791-796(1993).
RN   [35]
RP   VARIANT THPH3 SER-423.
RX   PubMed=8398832; DOI=10.1111/j.1365-2141.1993.tb03066.x;
RA   Marchetti G., Patracchini P., Gemmati D., Castaman G., Rodeghiero F.,
RA   Wacey A., Cooper D.N., Tuddenham E.G., Bernardi F.;
RT   "Symptomatic type II protein C deficiency caused by a missense
RT   mutation (Gly 381-->Ser) in the substrate-binding pocket.";
RL   Br. J. Haematol. 84:285-289(1993).
RN   [36]
RP   VARIANT PRO-312.
RX   PubMed=7919373;
RA   Gandrille S., Jude B., Alhenc-Gelas M., Emmerich J., Aiach M.;
RT   "First de novo mutations in the protein C gene of two patients with
RT   type I deficiency: a missense mutation and a splice site deletion.";
RL   Blood 84:2566-2570(1994).
RN   [37]
RP   VARIANT THPH4 144-ASN-GLY-145 DELINS LYS.
RX   PubMed=7841323;
RA   Millar D.S., Allgrove J., Rodeck C., Kakkar V.V., Cooper D.N.;
RT   "A homozygous deletion/insertion mutation in the protein C (PROC) gene
RT   causing neonatal Purpura fulminans: prenatal diagnosis in an at-risk
RT   pregnancy.";
RL   Blood Coagul. Fibrinolysis 5:647-649(1994).
RN   [38]
RP   VARIANT THPH4 ALA-367.
RX   PubMed=7841324;
RA   Witt I., Beck S., Seydewitz H.H., Tasangil C., Schenck W.;
RT   "A novel homozygous missense mutation (Val 325-->Ala) in the protein C
RT   gene causing neonatal purpura fulminans.";
RL   Blood Coagul. Fibrinolysis 5:651-653(1994).
RN   [39]
RP   VARIANTS THPH3 LEU-369; ARG-392; ASN-401 AND HIS-441.
RX   PubMed=7865674;
RA   Zheng Y.-Z., Sakata T., Matsusue T., Umeyama H., Kato H., Miyata T.;
RT   "Six missense mutations associated with type I and type II protein C
RT   deficiency and implications obtained from molecular modelling.";
RL   Blood Coagul. Fibrinolysis 5:687-696(1994).
RN   [40]
RP   VARIANT ASP-49.
RX   PubMed=7974343;
RA   Gaussem P., Gandrille S., Duchemin J., Emmerich J., Alhenc-Gelas M.,
RA   Aillaud M.-F., Aiach M.;
RT   "Influence of six mutations of the protein C gene on the Gla domain
RT   conformation and calcium affinity.";
RL   Thromb. Haemost. 71:748-754(1994).
RN   [41]
RP   VARIANTS CYS-89; PRO-220 AND THR-301.
RX   PubMed=7605880;
RA   Millar D.S., Bevan D., Chitolie A., Reynaud J., Chisholm M.,
RA   Kakkar V.V., Cooper D.N.;
RT   "Three novel mutations in the protein C (PROC) gene causing venous
RT   thrombosis.";
RL   Blood Coagul. Fibrinolysis 6:138-140(1995).
RN   [42]
RP   VARIANTS THPH3 TRP-57; ARG-114; ARG-324; CYS-328 AND LEU-369, AND
RP   VARIANT THR-43.
RX   PubMed=7792728;
RA   Lind B., Schwartz M., Thorsen S.;
RT   "Six different point mutations in seven Danish families with
RT   symptomatic protein C deficiency.";
RL   Thromb. Haemost. 73:186-193(1995).
RN   [43]
RP   VARIANTS THPH3 CYS-32 AND ASN-436.
RX   PubMed=8829639;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:2<176::AID-HUMU16>3.3.CO;2-W;
RA   Ireland H.A., Boisclair M.D., Taylor J., Thompson E., Thein S.L.,
RA   Girolami A., de Caterina M., Scopacasa F., de Stefano V., Leone G.,
RA   Finazzi G., Cohen H., Lane D.A.;
RT   "Two novel (R(-11)C; T394D) and two repeat missense mutations in the
RT   protein C gene associated with venous thrombosis in six kindreds.";
RL   Hum. Mutat. 7:176-179(1996).
RN   [44]
RP   VARIANTS THPH3 GLN-220 AND MET-340.
RX   PubMed=9798967;
RA   Couture P., Demers C., Morissette J., Delage R., Jomphe M.,
RA   Couture L., Simard J.;
RT   "Type I protein C deficiency in French Canadians: evidence of a
RT   founder effect and association of specific protein C gene mutations
RT   with plasma protein C levels.";
RL   Thromb. Haemost. 80:551-556(1998).
RN   [45]
RP   VARIANT SER-317, CHARACTERIZATION OF SER-317, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=22531345; DOI=10.1097/PAT.0b013e328353a218;
RA   Yu T., Dai J., Liu H., Wang J., Ding Q., Wang H., Wang X., Fu Q.;
RT   "Homozygous protein C deficiency with late onset venous thrombosis:
RT   identification and in vitro expression study of a novel Pro275Ser
RT   mutation.";
RL   Pathology 44:348-353(2012).
RN   [46]
RP   VARIANTS GLU-70; GLY-106; ALA-118; TYR-175; VAL-181; TRP-189; GLN-211;
RP   TRP-220; ARG-223; GLY-240; HIS-297; LEU-312; VAL-327 AND LEU-420.
RX   PubMed=22545135; DOI=10.1371/journal.pone.0035773;
RA   Tang L., Guo T., Yang R., Mei H., Wang H., Lu X., Yu J., Wang Q.,
RA   Hu Y.;
RT   "Genetic background analysis of protein C deficiency demonstrates a
RT   recurrent mutation associated with venous thrombosis in Chinese
RT   population.";
RL   PLoS ONE 7:E35773-E35773(2012).
RN   [47]
RP   VARIANT ALA-357, CHARACTERIZATION OF ALA-357, AND FUNCTION.
RX   PubMed=25651845; DOI=10.1182/blood-2014-12-617274;
RA   Ding Q., Yang L., Dinarvand P., Wang X., Rezaie A.R.;
RT   "Protein C Thr315Ala variant results in gain of function but manifests
RT   as type II deficiency in diagnostic assays.";
RL   Blood 125:2428-2434(2015).
RN   [48]
RP   VARIANTS THPH3 HIS-297 AND LEU-420, CHARACTERIZATION OF VARIANTS THPH3
RP   HIS-297 AND LEU-420, AND SUBCELLULAR LOCATION.
RX   PubMed=25748729; DOI=10.1016/j.gene.2015.03.002;
RA   Liu H., Wang H.F., Tang L., Yang Y., Wang Q.Y., Zeng W., Wu Y.Y.,
RA   Cheng Z.P., Hu B., Guo T., Hu Y.;
RT   "Compound heterozygous protein C deficiency in a family with venous
RT   thrombosis: Identification and in vitro study of p.Asp297His and
RT   p.Val420Leu mutations.";
RL   Gene 563:35-40(2015).
RN   [49]
RP   VARIANTS THPH4 GLY-77 AND GLU-163, VARIANT THPH3 VAL-163, FUNCTION AS
RP   ANTICOAGULANT, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS
RP   THPH4 GLY-77 AND GLU-163, AND CHARACTERIZATION OF VARIANT THPH3
RP   VAL-163.
RX   PubMed=25618265; DOI=10.1016/j.thromres.2015.01.011;
RA   Kovacs K.B., Pataki I., Bardos H., Fekete A., Pfliegler G.,
RA   Haramura G., Gindele R., Komaromi I., Balla G., Adany R., Muszbek L.,
RA   Bereczky Z.;
RT   "Molecular characterization of p.Asp77Gly and the novel p.Ala163Val
RT   and p.Ala163Glu mutations causing protein C deficiency.";
RL   Thromb. Res. 135:718-726(2015).
CC   -!- FUNCTION: Protein C is a vitamin K-dependent serine protease that
CC       regulates blood coagulation by inactivating factors Va and VIIIa
CC       in the presence of calcium ions and phospholipids
CC       (PubMed:25618265). Exerts a protective effect on the endothelial
CC       cell barrier function (PubMed:25651845).
CC       {ECO:0000269|PubMed:25618265, ECO:0000269|PubMed:25651845}.
CC   -!- CATALYTIC ACTIVITY: Degradation of blood coagulation factors Va
CC       and VIIIa.
CC   -!- SUBUNIT: Synthesized as a single chain precursor, which is cleaved
CC       into a light chain and a heavy chain held together by a disulfide
CC       bond. The enzyme is then activated by thrombin, which cleaves a
CC       tetradecapeptide from the amino end of the heavy chain; this
CC       reaction, which occurs at the surface of endothelial cells, is
CC       strongly promoted by thrombomodulin.
CC   -!- INTERACTION:
CC       P51511:MMP15; NbExp=2; IntAct=EBI-1383018, EBI-1383043;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:25618265}.
CC       Golgi apparatus {ECO:0000269|PubMed:22531345,
CC       ECO:0000269|PubMed:25748729}. Endoplasmic reticulum
CC       {ECO:0000269|PubMed:22531345, ECO:0000269|PubMed:25748729}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P04070-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P04070-2; Sequence=VSP_054393, VSP_054394;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Plasma; synthesized in the liver.
CC   -!- PTM: The vitamin K-dependent, enzymatic carboxylation of some Glu
CC       residues allows the modified protein to bind calcium.
CC   -!- PTM: N- and O-glycosylated. Partial (70%) N-glycosylation of Asn-
CC       371 with an atypical N-X-C site produces a higher molecular weight
CC       form referred to as alpha. The lower molecular weight form, not N-
CC       glycosylated at Asn-371, is beta. O-glycosylated with core 1 or
CC       possibly core 8 glycans. {ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:1694179, ECO:0000269|PubMed:22171320,
CC       ECO:0000269|PubMed:2991887}.
CC   -!- PTM: The iron and 2-oxoglutarate dependent 3-hydroxylation of
CC       aspartate and asparagine is (R) stereospecific within EGF domains.
CC       {ECO:0000269|PubMed:1544894, ECO:0000269|PubMed:2991887}.
CC   -!- PTM: May be phosphorylated on a Ser or Thr in a region (AA 25-30)
CC       of the propeptide.
CC   -!- DISEASE: Thrombophilia due to protein C deficiency, autosomal
CC       dominant (THPH3) [MIM:176860]: A hemostatic disorder characterized
CC       by impaired regulation of blood coagulation and a tendency to
CC       recurrent venous thrombosis. Individuals with decreased amounts of
CC       protein C are classically referred to as having type I protein C
CC       deficiency and those with normal amounts of a functionally
CC       defective protein as having type II deficiency.
CC       {ECO:0000269|PubMed:1301959, ECO:0000269|PubMed:1347706,
CC       ECO:0000269|PubMed:1511989, ECO:0000269|PubMed:1868249,
CC       ECO:0000269|PubMed:2437584, ECO:0000269|PubMed:25618265,
CC       ECO:0000269|PubMed:25748729, ECO:0000269|PubMed:2602169,
CC       ECO:0000269|PubMed:7792728, ECO:0000269|PubMed:7865674,
CC       ECO:0000269|PubMed:8292730, ECO:0000269|PubMed:8398832,
CC       ECO:0000269|PubMed:8499568, ECO:0000269|PubMed:8560401,
CC       ECO:0000269|PubMed:8829639, ECO:0000269|PubMed:9798967}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Thrombophilia due to protein C deficiency, autosomal
CC       recessive (THPH4) [MIM:612304]: A hemostatic disorder
CC       characterized by impaired regulation of blood coagulation and a
CC       tendency to recurrent venous thrombosis. It results in a
CC       thrombotic condition that can manifest as a severe neonatal
CC       disorder or as a milder disorder with late-onset thrombophilia.
CC       The severe form leads to neonatal death through massive neonatal
CC       venous thrombosis. Often associated with ecchymotic skin lesions
CC       which can turn necrotic called purpura fulminans, this disorder is
CC       very rare. {ECO:0000269|PubMed:1511988,
CC       ECO:0000269|PubMed:1593215, ECO:0000269|PubMed:1611081,
CC       ECO:0000269|PubMed:25618265, ECO:0000269|PubMed:7841323,
CC       ECO:0000269|PubMed:7841324, ECO:0000269|PubMed:7878626}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: Calcium also binds, with stronger affinity to
CC       another site, beyond the GLA domain. This GLA-independent binding
CC       site is necessary for the recognition of the thrombin-
CC       thrombomodulin complex.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00274}.
CC   -!- SIMILARITY: Contains 2 EGF-like domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00076}.
CC   -!- SIMILARITY: Contains 1 Gla (gamma-carboxy-glutamate) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00463}.
CC   -!- SIMILARITY: Contains 1 peptidase S1 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00274}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=S76088; Type=Erroneous termination; Positions=151; Note=Translated as Cys.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Protein C entry;
CC       URL="https://en.wikipedia.org/wiki/Protein_C";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/proc/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X02750; CAA26528.1; -; mRNA.
DR   EMBL; M11228; AAA60166.1; -; Genomic_DNA.
DR   EMBL; M12712; AAA60165.1; -; Genomic_DNA.
DR   EMBL; M12683; AAA60165.1; JOINED; Genomic_DNA.
DR   EMBL; M12684; AAA60165.1; JOINED; Genomic_DNA.
DR   EMBL; M12685; AAA60165.1; JOINED; Genomic_DNA.
DR   EMBL; M12686; AAA60165.1; JOINED; Genomic_DNA.
DR   EMBL; M12687; AAA60165.1; JOINED; Genomic_DNA.
DR   EMBL; AF378903; AAK56377.1; -; Genomic_DNA.
DR   EMBL; AK298454; BAG60669.1; -; mRNA.
DR   EMBL; AC068282; AAY15044.1; -; Genomic_DNA.
DR   EMBL; CH471103; EAW95320.1; -; Genomic_DNA.
DR   EMBL; BC034377; AAH34377.1; -; mRNA.
DR   EMBL; S58668; AAB26335.1; -; Genomic_DNA.
DR   EMBL; K02059; AAA60164.1; -; mRNA.
DR   EMBL; S76088; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S76090; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS2145.1; -. [P04070-1]
DR   PIR; A22331; KXHU.
DR   RefSeq; NP_000303.1; NM_000312.3. [P04070-1]
DR   RefSeq; XP_005263773.1; XM_005263716.3. [P04070-2]
DR   UniGene; Hs.224698; -.
DR   PDB; 1AUT; X-ray; 2.80 A; C=212-461, L=84-197.
DR   PDB; 1LQV; X-ray; 1.60 A; C/D=43-75.
DR   PDB; 1PCU; Model; -; A=175-450.
DR   PDB; 2PCT; Model; -; A=175-450.
DR   PDB; 3F6U; X-ray; 2.80 A; H=212-451, L=91-188.
DR   PDB; 3JTC; X-ray; 1.60 A; C/D=43-75.
DR   PDB; 4DT7; X-ray; 1.90 A; E/F=204-223.
DR   PDBsum; 1AUT; -.
DR   PDBsum; 1LQV; -.
DR   PDBsum; 1PCU; -.
DR   PDBsum; 2PCT; -.
DR   PDBsum; 3F6U; -.
DR   PDBsum; 3JTC; -.
DR   PDBsum; 4DT7; -.
DR   ProteinModelPortal; P04070; -.
DR   SMR; P04070; 43-451.
DR   BioGrid; 111608; 11.
DR   IntAct; P04070; 3.
DR   MINT; MINT-8247437; -.
DR   STRING; 9606.ENSP00000234071; -.
DR   BindingDB; P04070; -.
DR   ChEMBL; CHEMBL4444; -.
DR   DrugBank; DB00025; Antihemophilic Factor (Recombinant).
DR   DrugBank; DB00170; Menadione.
DR   DrugBank; DB00464; Sodium Tetradecyl Sulfate.
DR   GuidetoPHARMACOLOGY; 2396; -.
DR   MEROPS; S01.218; -.
DR   iPTMnet; P04070; -.
DR   PhosphoSite; P04070; -.
DR   UniCarbKB; P04070; -.
DR   BioMuta; PROC; -.
DR   DMDM; 131067; -.
DR   MaxQB; P04070; -.
DR   PaxDb; P04070; -.
DR   PeptideAtlas; P04070; -.
DR   PRIDE; P04070; -.
DR   DNASU; 5624; -.
DR   Ensembl; ENST00000234071; ENSP00000234071; ENSG00000115718. [P04070-1]
DR   GeneID; 5624; -.
DR   KEGG; hsa:5624; -.
DR   UCSC; uc002tok.3; human. [P04070-1]
DR   UCSC; uc010yzk.2; human.
DR   CTD; 5624; -.
DR   GeneCards; PROC; -.
DR   HGNC; HGNC:9451; PROC.
DR   HPA; CAB016721; -.
DR   HPA; CAB016792; -.
DR   HPA; HPA005550; -.
DR   MalaCards; PROC; -.
DR   MIM; 176860; phenotype.
DR   MIM; 612283; gene.
DR   MIM; 612304; phenotype.
DR   neXtProt; NX_P04070; -.
DR   Orphanet; 745; Hereditary thrombophilia due to congenital protein C deficiency.
DR   PharmGKB; PA33799; -.
DR   eggNOG; ENOG410IJRM; Eukaryota.
DR   eggNOG; COG5640; LUCA.
DR   GeneTree; ENSGT00760000118890; -.
DR   HOGENOM; HOG000251821; -.
DR   HOVERGEN; HBG013304; -.
DR   InParanoid; P04070; -.
DR   KO; K01344; -.
DR   PhylomeDB; P04070; -.
DR   TreeFam; TF327329; -.
DR   BRENDA; 3.4.21.69; 2681.
DR   Reactome; R-HSA-140837; Intrinsic Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-159740; Gamma-carboxylation of protein precursors.
DR   Reactome; R-HSA-159763; Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus.
DR   Reactome; R-HSA-159782; Removal of aminoterminal propeptides from gamma-carboxylated proteins.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   EvolutionaryTrace; P04070; -.
DR   GeneWiki; Protein_C; -.
DR   GenomeRNAi; 5624; -.
DR   NextBio; 21860; -.
DR   PMAP-CutDB; P04070; -.
DR   PRO; PR:P04070; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; P04070; -.
DR   CleanEx; HS_PROC; -.
DR   ExpressionAtlas; P04070; baseline and differential.
DR   Genevisible; P04070; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IMP:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0030195; P:negative regulation of blood coagulation; TAS:UniProtKB.
DR   GO; GO:0050819; P:negative regulation of coagulation; IMP:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IMP:UniProtKB.
DR   GO; GO:0017187; P:peptidyl-glutamic acid carboxylation; TAS:Reactome.
DR   GO; GO:1903142; P:positive regulation of establishment of endothelial barrier; IMP:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0006508; P:proteolysis; NAS:UniProtKB.
DR   Gene3D; 4.10.740.10; -; 1.
DR   InterPro; IPR017857; Coagulation_fac_subgr_Gla_dom.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR000294; GLA_domain.
DR   InterPro; IPR012224; Pept_S1A_FX.
DR   InterPro; IPR018114; Peptidase_S1_AS.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR001254; Trypsin_dom.
DR   Pfam; PF00008; EGF; 1.
DR   Pfam; PF00594; Gla; 1.
DR   Pfam; PF00089; Trypsin; 1.
DR   PIRSF; PIRSF001143; Factor_X; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   PRINTS; PR00001; GLABLOOD.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00179; EGF_CA; 1.
DR   SMART; SM00069; GLA; 1.
DR   SMART; SM00020; Tryp_SPc; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF57630; SSF57630; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 2.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS01187; EGF_CA; 1.
DR   PROSITE; PS00011; GLA_1; 1.
DR   PROSITE; PS50998; GLA_2; 1.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Blood coagulation; Calcium;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   EGF-like domain; Endoplasmic reticulum; Gamma-carboxyglutamic acid;
KW   Glycoprotein; Golgi apparatus; Hemostasis; Hydrolase; Hydroxylation;
KW   Phosphoprotein; Polymorphism; Protease; Reference proteome; Repeat;
KW   Secreted; Serine protease; Signal; Thrombophilia; Zymogen.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   PROPEP       19     42
FT                                /FTId=PRO_0000028107.
FT   CHAIN        43    461       Vitamin K-dependent protein C.
FT                                /FTId=PRO_0000028108.
FT   CHAIN        43    197       Vitamin K-dependent protein C light
FT                                chain.
FT                                /FTId=PRO_0000028109.
FT   CHAIN       200    461       Vitamin K-dependent protein C heavy
FT                                chain.
FT                                /FTId=PRO_0000028110.
FT   PEPTIDE     200    211       Activation peptide.
FT                                /FTId=PRO_0000028111.
FT   DOMAIN       43     88       Gla. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463}.
FT   DOMAIN       97    132       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      136    176       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      212    450       Peptidase S1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00274}.
FT   ACT_SITE    253    253       Charge relay system.
FT   ACT_SITE    299    299       Charge relay system.
FT   ACT_SITE    402    402       Charge relay system.
FT   SITE        211    212       Cleavage; by thrombin.
FT   MOD_RES      48     48       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2991887}.
FT   MOD_RES      49     49       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2991887}.
FT   MOD_RES      56     56       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2991887}.
FT   MOD_RES      58     58       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2991887}.
FT   MOD_RES      61     61       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2991887}.
FT   MOD_RES      62     62       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2991887}.
FT   MOD_RES      67     67       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2991887}.
FT   MOD_RES      68     68       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2991887}.
FT   MOD_RES      71     71       4-carboxyglutamate. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00463,
FT                                ECO:0000269|PubMed:2991887}.
FT   MOD_RES     113    113       (3R)-3-hydroxyaspartate.
FT                                {ECO:0000269|PubMed:2991887}.
FT   MOD_RES     347    347       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   CARBOHYD     19     19       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:22171320}.
FT   CARBOHYD    139    139       N-linked (GlcNAc...).
FT   CARBOHYD    290    290       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:2991887}.
FT   CARBOHYD    355    355       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:2991887}.
FT   CARBOHYD    371    371       N-linked (GlcNAc...); atypical; partial.
FT                                {ECO:0000269|PubMed:1694179,
FT                                ECO:0000269|PubMed:2991887}.
FT   DISULFID     59     64
FT   DISULFID     92    111
FT   DISULFID    101    106
FT   DISULFID    105    120
FT   DISULFID    122    131
FT   DISULFID    140    151
FT   DISULFID    147    160
FT   DISULFID    162    175
FT   DISULFID    183    319       Interchain (between light and heavy
FT                                chains).
FT   DISULFID    238    254
FT   DISULFID    373    387
FT   DISULFID    398    426
FT   VAR_SEQ       1      1       M -> MAAGRRTCSISTTRPCASASRM (in isoform
FT                                2). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054393.
FT   VAR_SEQ     133    133       R -> RGEGERWMLAGGGAGLGPGWGRGTSTSCPRPPLPA
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054394.
FT   VARIANT      14     14       W -> G (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:8499565}.
FT                                /FTId=VAR_006634.
FT   VARIANT      32     32       R -> C (in THPH3).
FT                                {ECO:0000269|PubMed:8829639}.
FT                                /FTId=VAR_006635.
FT   VARIANT      38     38       R -> W (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:8324221}.
FT                                /FTId=VAR_006636.
FT   VARIANT      42     42       R -> C (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:8324221}.
FT                                /FTId=VAR_006638.
FT   VARIANT      42     42       R -> H (in Malakoff; low anticoagulant
FT                                activity). {ECO:0000269|PubMed:8324221}.
FT                                /FTId=VAR_006637.
FT   VARIANT      42     42       R -> S (in THPH3; type II; Osaka-10;
FT                                alters proteolytic processing so that S-
FT                                42 is the N-terminus of the mature
FT                                protein). {ECO:0000269|PubMed:8560401}.
FT                                /FTId=VAR_055074.
FT   VARIANT      43     43       A -> T. {ECO:0000269|PubMed:7792728}.
FT                                /FTId=VAR_006639.
FT   VARIANT      49     49       E -> D (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:7974343}.
FT                                /FTId=VAR_006640.
FT   VARIANT      51     51       R -> C (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006641.
FT   VARIANT      57     57       R -> G (in Yonago; defective
FT                                anticoagulant activity).
FT                                {ECO:0000269|PubMed:8477066}.
FT                                /FTId=VAR_006643.
FT   VARIANT      57     57       R -> Q (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006644.
FT   VARIANT      57     57       R -> W (in THPH3).
FT                                {ECO:0000269|PubMed:7792728,
FT                                ECO:0000269|PubMed:8499568}.
FT                                /FTId=VAR_006642.
FT   VARIANT      62     62       E -> A (in THPH3; Vermont-1).
FT                                {ECO:0000269|PubMed:1347706}.
FT                                /FTId=VAR_006645.
FT   VARIANT      70     70       K -> E (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_074296.
FT   VARIANT      76     76       V -> M (in THPH3; Vermont-1).
FT                                {ECO:0000269|PubMed:1347706}.
FT                                /FTId=VAR_006646.
FT   VARIANT      77     77       D -> G (in THPH4; no effect on secretion;
FT                                no effect on catalytic activity in
FT                                vitro). {ECO:0000269|PubMed:25618265}.
FT                                /FTId=VAR_073145.
FT   VARIANT      89     89       G -> C (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:7605880}.
FT                                /FTId=VAR_006647.
FT   VARIANT     106    106       C -> G (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_074297.
FT   VARIANT     108    108       H -> N (in patients with PROC deficiency;
FT                                La Jolla-1).
FT                                /FTId=VAR_006648.
FT   VARIANT     109    109       G -> R (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006649.
FT   VARIANT     114    118       Missing (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006650.
FT   VARIANT     114    114       G -> R (in THPH3).
FT                                {ECO:0000269|PubMed:7792728}.
FT                                /FTId=VAR_006651.
FT   VARIANT     118    118       F -> A (in patients with PROC deficiency;
FT                                requires 2 nucleotide substitutions).
FT                                {ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_074298.
FT   VARIANT     118    118       F -> L (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006652.
FT   VARIANT     119    124       Missing (in patients with PROC
FT                                deficiency; St Louis-2).
FT                                /FTId=VAR_006653.
FT   VARIANT     120    125       Missing (in patients with PROC
FT                                deficiency; St Louis-3).
FT                                /FTId=VAR_006654.
FT   VARIANT     144    145       NG -> K (in THPH4; neonatal purpura
FT                                fulminans). {ECO:0000269|PubMed:7841323}.
FT                                /FTId=VAR_006655.
FT   VARIANT     145    145       G -> R (in THPH3).
FT                                {ECO:0000269|PubMed:8292730}.
FT                                /FTId=VAR_006656.
FT   VARIANT     147    147       C -> Y (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006657.
FT   VARIANT     149    149       H -> P (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006658.
FT   VARIANT     161    161       S -> R (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006659.
FT   VARIANT     163    163       A -> E (in THPH4; drastically reduced
FT                                secretion; colocalizes with 26S
FT                                proteasome).
FT                                {ECO:0000269|PubMed:25618265}.
FT                                /FTId=VAR_073146.
FT   VARIANT     163    163       A -> V (in THPH3; drastically reduced
FT                                secretion; colocalizes with 26S
FT                                proteasome).
FT                                {ECO:0000269|PubMed:25618265}.
FT                                /FTId=VAR_073147.
FT   VARIANT     175    175       C -> Y (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_074299.
FT   VARIANT     178    178       A -> P (in THPH4; Clamart).
FT                                {ECO:0000269|PubMed:7878626}.
FT                                /FTId=VAR_006660.
FT   VARIANT     181    181       F -> V (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_074300.
FT   VARIANT     183    183       C -> R (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006661.
FT   VARIANT     189    189       R -> W (in patients with PROC deficiency;
FT                                La Jolla-3; dbSNP:rs146922325).
FT                                {ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_006662.
FT   VARIANT     194    194       R -> C (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006663.
FT   VARIANT     210    210       P -> L (in THPH3).
FT                                {ECO:0000269|PubMed:8292730}.
FT                                /FTId=VAR_006664.
FT   VARIANT     211    211       R -> Q (in patients with PROC deficiency;
FT                                dbSNP:rs28933987).
FT                                {ECO:0000269|PubMed:22545135,
FT                                ECO:0000269|PubMed:8499565}.
FT                                /FTId=VAR_006666.
FT   VARIANT     211    211       R -> W (in THPH3; London-1/Tochigi;
FT                                dbSNP:rs28933986).
FT                                {ECO:0000269|PubMed:2602169,
FT                                ECO:0000269|PubMed:8292730}.
FT                                /FTId=VAR_006665.
FT   VARIANT     220    220       R -> P (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:7605880}.
FT                                /FTId=VAR_006667.
FT   VARIANT     220    220       R -> Q (in THPH3; Vermont-3).
FT                                {ECO:0000269|PubMed:1301959,
FT                                ECO:0000269|PubMed:1511989,
FT                                ECO:0000269|PubMed:9798967}.
FT                                /FTId=VAR_006669.
FT   VARIANT     220    220       R -> W (in THPH3).
FT                                {ECO:0000269|PubMed:1511989,
FT                                ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_006668.
FT   VARIANT     223    223       S -> R (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_074301.
FT   VARIANT     226    226       Q -> H (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006670.
FT   VARIANT     240    240       A -> G (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_074302.
FT   VARIANT     243    243       I -> T (in THPH3).
FT                                {ECO:0000269|PubMed:8292730}.
FT                                /FTId=VAR_006671.
FT   VARIANT     244    244       H -> Y (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:8499565}.
FT                                /FTId=VAR_006672.
FT   VARIANT     253    253       H -> Q (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:8499565}.
FT                                /FTId=VAR_006673.
FT   VARIANT     265    265       L -> F (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006674.
FT   VARIANT     271    271       R -> Q (in Marseille; low anticoagulant
FT                                activity). {ECO:0000269|PubMed:8324221}.
FT                                /FTId=VAR_006675.
FT   VARIANT     271    271       R -> W (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006676.
FT   VARIANT     272    272       R -> C (in THPH3).
FT                                {ECO:0000269|PubMed:1868249}.
FT                                /FTId=VAR_006677.
FT   VARIANT     281    281       D -> DLD (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006678.
FT   VARIANT     289    289       P -> L (in THPH4).
FT                                {ECO:0000269|PubMed:1511988}.
FT                                /FTId=VAR_006679.
FT   VARIANT     294    294       S -> N (in Paris; low anticoagulant
FT                                activity). {ECO:0000269|PubMed:8324221}.
FT                                /FTId=VAR_006680.
FT   VARIANT     297    297       D -> H (in THPH3; also found in patients
FT                                with PROC deficiency; decrease in
FT                                vitamin-K dependent serine protease
FT                                activity; decreased Golgi localization).
FT                                {ECO:0000269|PubMed:22545135,
FT                                ECO:0000269|PubMed:25748729}.
FT                                /FTId=VAR_074303.
FT   VARIANT     298    298       N -> D (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006681.
FT   VARIANT     301    301       A -> T (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:7605880}.
FT                                /FTId=VAR_006682.
FT   VARIANT     301    301       A -> V (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006683.
FT   VARIANT     309    309       A -> T (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006684.
FT   VARIANT     312    312       S -> L (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_006685.
FT   VARIANT     312    312       S -> P (in a patient with PROC
FT                                deficiency; sporadic case).
FT                                {ECO:0000269|PubMed:7919373}.
FT                                /FTId=VAR_006686.
FT   VARIANT     317    317       P -> S (in patients with PROC deficiency;
FT                                abolishes Golgi localization).
FT                                {ECO:0000269|PubMed:22531345}.
FT                                /FTId=VAR_074304.
FT   VARIANT     321    321       P -> L (in THPH3).
FT                                {ECO:0000269|PubMed:8292730,
FT                                ECO:0000269|PubMed:8499565}.
FT                                /FTId=VAR_006687.
FT   VARIANT     324    324       G -> R (in THPH3).
FT                                {ECO:0000269|PubMed:7792728}.
FT                                /FTId=VAR_006688.
FT   VARIANT     327    327       E -> V (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:22545135}.
FT                                /FTId=VAR_074305.
FT   VARIANT     328    328       R -> C (in THPH3).
FT                                {ECO:0000269|PubMed:7792728,
FT                                ECO:0000269|PubMed:8499565}.
FT                                /FTId=VAR_006689.
FT   VARIANT     328    328       R -> H (in THPH4; Muenchen).
FT                                {ECO:0000269|PubMed:7878626}.
FT                                /FTId=VAR_006690.
FT   VARIANT     334    334       G -> S (in THPH4).
FT                                {ECO:0000269|PubMed:1593215}.
FT                                /FTId=VAR_006691.
FT   VARIANT     340    340       T -> M (in THPH3; Vermont-2).
FT                                {ECO:0000269|PubMed:8292730,
FT                                ECO:0000269|PubMed:9798967}.
FT                                /FTId=VAR_006692.
FT   VARIANT     343    343       G -> D (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006693.
FT   VARIANT     357    357       T -> A (gain of function mutation;
FT                                abolishes glycosylation at N-313;
FT                                decreases its catalytic activity;
FT                                significant loss of its protective effect
FT                                on endothelial barrier function;
FT                                increased activation by thrombin).
FT                                {ECO:0000269|PubMed:25651845}.
FT                                /FTId=VAR_074306.
FT   VARIANT     363    363       Missing (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006694.
FT   VARIANT     367    367       V -> A (in THPH4; neonatal purpura
FT                                fulminans). {ECO:0000269|PubMed:7841324}.
FT                                /FTId=VAR_006695.
FT   VARIANT     369    369       P -> L (in THPH3; Osaka-6).
FT                                {ECO:0000269|PubMed:7792728,
FT                                ECO:0000269|PubMed:7865674}.
FT                                /FTId=VAR_006696.
FT   VARIANT     385    385       M -> I (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:8499565}.
FT                                /FTId=VAR_006697.
FT   VARIANT     388    388       A -> T (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:8499565}.
FT                                /FTId=VAR_006698.
FT   VARIANT     388    388       A -> V (in patients with PROC
FT                                deficiency).
FT                                {ECO:0000269|PubMed:8499565}.
FT                                /FTId=VAR_006699.
FT   VARIANT     392    392       G -> R (in THPH3; Osaka-9).
FT                                {ECO:0000269|PubMed:7865674}.
FT                                /FTId=VAR_006700.
FT   VARIANT     394    394       R -> W (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006701.
FT   VARIANT     401    401       D -> N (in THPH3; La Jolla-2/Osaka-7 and
FT                                -8). {ECO:0000269|PubMed:7865674}.
FT                                /FTId=VAR_006702.
FT   VARIANT     418    418       G -> D (in THPH4; Hong Kong-2).
FT                                {ECO:0000269|PubMed:1611081}.
FT                                /FTId=VAR_006703.
FT   VARIANT     420    420       V -> L (in THPH3; also found in patients
FT                                with PROC deficiency; decrease in
FT                                vitamin-K dependent serine protease
FT                                activity). {ECO:0000269|PubMed:22545135,
FT                                ECO:0000269|PubMed:25748729}.
FT                                /FTId=VAR_074307.
FT   VARIANT     423    423       G -> S (in THPH3).
FT                                {ECO:0000269|PubMed:8398832}.
FT                                /FTId=VAR_006704.
FT   VARIANT     426    426       C -> Y (in THPH3).
FT                                {ECO:0000269|PubMed:8292730}.
FT                                /FTId=VAR_006705.
FT   VARIANT     433    433       G -> S (in patients with PROC deficiency;
FT                                Purmerend).
FT                                /FTId=VAR_006706.
FT   VARIANT     436    436       T -> N (in THPH3).
FT                                {ECO:0000269|PubMed:8829639}.
FT                                /FTId=VAR_006707.
FT   VARIANT     441    441       Y -> H (in THPH3; Osaka-4).
FT                                {ECO:0000269|PubMed:7865674}.
FT                                /FTId=VAR_006708.
FT   VARIANT     444    444       W -> C (in THPH3).
FT                                {ECO:0000269|PubMed:2437584}.
FT                                /FTId=VAR_006709.
FT   VARIANT     445    445       I -> M (in patients with PROC
FT                                deficiency).
FT                                /FTId=VAR_006710.
FT   CONFLICT    106    106       C -> Q (in Ref. 11; AAA60164).
FT                                {ECO:0000305}.
FT   CONFLICT    445    445       I -> IL (in Ref. 3; AAA60165).
FT                                {ECO:0000305}.
FT   HELIX        48     50       {ECO:0000244|PDB:1LQV}.
FT   HELIX        55     59       {ECO:0000244|PDB:1LQV}.
FT   HELIX        66     73       {ECO:0000244|PDB:1LQV}.
FT   STRAND      100    103       {ECO:0000244|PDB:1AUT}.
FT   TURN        104    107       {ECO:0000244|PDB:1AUT}.
FT   STRAND      108    111       {ECO:0000244|PDB:1AUT}.
FT   STRAND      120    122       {ECO:0000244|PDB:1AUT}.
FT   STRAND      126    128       {ECO:0000244|PDB:1AUT}.
FT   STRAND      137    142       {ECO:0000244|PDB:1AUT}.
FT   HELIX       143    146       {ECO:0000244|PDB:1AUT}.
FT   STRAND      148    153       {ECO:0000244|PDB:1AUT}.
FT   STRAND      155    161       {ECO:0000244|PDB:1AUT}.
FT   STRAND      166    168       {ECO:0000244|PDB:1AUT}.
FT   STRAND      175    177       {ECO:0000244|PDB:1AUT}.
FT   STRAND      179    181       {ECO:0000244|PDB:1AUT}.
FT   STRAND      226    230       {ECO:0000244|PDB:1AUT}.
FT   STRAND      236    244       {ECO:0000244|PDB:1AUT}.
FT   STRAND      247    250       {ECO:0000244|PDB:1AUT}.
FT   HELIX       252    254       {ECO:0000244|PDB:1AUT}.
FT   STRAND      255    257       {ECO:0000244|PDB:1AUT}.
FT   STRAND      262    266       {ECO:0000244|PDB:1AUT}.
FT   STRAND      269    272       {ECO:0000244|PDB:3F6U}.
FT   STRAND      278    287       {ECO:0000244|PDB:1AUT}.
FT   TURN        293    296       {ECO:0000244|PDB:1AUT}.
FT   STRAND      301    307       {ECO:0000244|PDB:1AUT}.
FT   HELIX       323    328       {ECO:0000244|PDB:1AUT}.
FT   TURN        329    331       {ECO:0000244|PDB:1AUT}.
FT   STRAND      336    341       {ECO:0000244|PDB:1AUT}.
FT   STRAND      357    359       {ECO:0000244|PDB:1AUT}.
FT   STRAND      361    368       {ECO:0000244|PDB:1AUT}.
FT   HELIX       370    376       {ECO:0000244|PDB:1AUT}.
FT   STRAND      385    388       {ECO:0000244|PDB:1AUT}.
FT   STRAND      405    410       {ECO:0000244|PDB:1AUT}.
FT   STRAND      413    422       {ECO:0000244|PDB:1AUT}.
FT   STRAND      424    427       {ECO:0000244|PDB:1AUT}.
FT   STRAND      433    436       {ECO:0000244|PDB:1AUT}.
FT   HELIX       438    440       {ECO:0000244|PDB:1AUT}.
FT   HELIX       442    449       {ECO:0000244|PDB:1AUT}.
SQ   SEQUENCE   461 AA;  52071 MW;  3531B0AE5345B39A CRC64;
     MWQLTSLLLF VATWGISGTP APLDSVFSSS ERAHQVLRIR KRANSFLEEL RHSSLERECI
     EEICDFEEAK EIFQNVDDTL AFWSKHVDGD QCLVLPLEHP CASLCCGHGT CIDGIGSFSC
     DCRSGWEGRF CQREVSFLNC SLDNGGCTHY CLEEVGWRRC SCAPGYKLGD DLLQCHPAVK
     FPCGRPWKRM EKKRSHLKRD TEDQEDQVDP RLIDGKMTRR GDSPWQVVLL DSKKKLACGA
     VLIHPSWVLT AAHCMDESKK LLVRLGEYDL RRWEKWELDL DIKEVFVHPN YSKSTTDNDI
     ALLHLAQPAT LSQTIVPICL PDSGLAEREL NQAGQETLVT GWGYHSSREK EAKRNRTFVL
     NFIKIPVVPH NECSEVMSNM VSENMLCAGI LGDRQDACEG DSGGPMVASF HGTWFLVGLV
     SWGEGCGLLH NYGVYTKVSR YLDWIHGHIR DKEAPQKSWA P
//
ID   CAD23_HUMAN             Reviewed;        3354 AA.
AC   Q9H251; C4IXS9; F6U049; Q5QGS1; Q5QGS2; Q5QGS5; Q5QGS6; Q5XKN2;
AC   Q6UWW1; Q96JL3; Q9H4K9;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2012, sequence version 2.
DT   17-FEB-2016, entry version 153.
DE   RecName: Full=Cadherin-23;
DE   AltName: Full=Otocadherin;
DE   Flags: Precursor;
GN   Name=CDH23; Synonyms=KIAA1774, KIAA1812; ORFNames=UNQ1894/PRO4340;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, VARIANTS USH1D
RP   MET-1281 DEL; HIS-1496 AND GLN-1746, AND VARIANTS CYS-3; ALA-490;
RP   ASN-496; THR-1222; CYS-1349; ASP-1351; THR-1575; SER-1671; ILE-1675;
RP   GLN-1804; SER-1999; LYS-2044; GLN-2358; LEU-2380; GLN-2588 AND
RP   LEU-3125.
RX   PubMed=11138009; DOI=10.1038/83667;
RA   Bolz H., Von Brederlow B., Ramirez A., Bryda E.C., Kutsche K.,
RA   Nothwang H.G., Seeliger M., Del C.-Salcedo Cabrera M.,
RA   Vila Caballero M., Pelaez Molina O., Gal A., Kubisch C.;
RT   "Mutation of CDH23, encoding a new member of the cadherin gene family,
RT   causes Usher syndrome type 1D.";
RL   Nat. Genet. 27:108-112(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5), AND VARIANT CYS-3.
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 7; 9; 10 AND 11).
RC   TISSUE=Retina;
RX   PubMed=15882574; DOI=10.1016/j.ydbio.2005.01.015;
RA   Lagziel A., Ahmed Z.M., Schultz J.M., Morell R.J., Belyantseva I.A.,
RA   Friedman T.B.;
RT   "Spatiotemporal pattern and isoforms of cadherin 23 in wild type and
RT   waltzer mice during inner ear hair cell development.";
RL   Dev. Biol. 280:295-306(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 410-3354 (ISOFORM 6), AND
RP   VARIANT ASN-496.
RC   TISSUE=Brain;
RX   PubMed=11347906; DOI=10.1093/dnares/8.2.85;
RA   Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XX.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 8:85-95(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 803-3354, ALTERNATIVE SPLICING, AND
RP   VARIANTS DFNB12 ASN-990; ASP-1351; THR-1575; ASN-2045; ASN-2202;
RP   ASN-2950; CYS-2956 AND THR-3059.
RX   PubMed=11090341; DOI=10.1086/316954;
RA   Bork J.M., Peters L.M., Riazuddin S., Bernstein S.L., Ahmed Z.M.,
RA   Ness S.L., Polomeno R., Ramesh A., Schloss M., Srisailpathy C.R.S.,
RA   Wayne S., Bellman S., Desmukh D., Ahmed Z., Khan S.N.,
RA   Kaloustian V.M.D., Li X.C., Lalwani A., Riazuddin S.,
RA   Bitner-Glindzicz M., Nance W.E., Liu X.-Z., Wistow G., Smith R.J.H.,
RA   Griffith A.J., Wilcox E.R., Friedman T.B., Morell R.J.;
RT   "Usher syndrome 1D and nonsyndromic autosomal recessive deafness
RT   DFNB12 are caused by allelic mutations of the novel cadherin-like gene
RT   CDH23.";
RL   Am. J. Hum. Genet. 68:26-37(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2173-3354 (ISOFORM 4).
RC   TISSUE=Brain;
RX   PubMed=11597768; DOI=10.1016/S0169-328X(01)00218-2;
RA   Nakajima D., Nakayama M., Kikuno R., Hirosawa M., Nagase T., Ohara O.;
RT   "Identification of three novel non-classical cadherin genes through
RT   comprehensive analysis of large cDNAs.";
RL   Brain Res. Mol. Brain Res. 94:85-95(2001).
RN   [9]
RP   INTERACTION WITH USH1G.
RX   PubMed=21436032; DOI=10.1073/pnas.1017114108;
RA   Caberlotto E., Michel V., Foucher I., Bahloul A., Goodyear R.J.,
RA   Pepermans E., Michalski N., Perfettini I., Alegria-Prevot O.,
RA   Chardenoux S., Do Cruzeiro M., Hardelin J.P., Richardson G.P.,
RA   Avan P., Weil D., Petit C.;
RT   "Usher type 1G protein sans is a critical component of the tip-link
RT   complex, a structure controlling actin polymerization in
RT   stereocilia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:5825-5830(2011).
RN   [10]
RP   STRUCTURE BY NMR OF 3183-3354 IN COMPLEX WITH USH1C, AND INTERACTION
RP   WITH USH1C.
RX   PubMed=19297620; DOI=10.1073/pnas.0901819106;
RA   Pan L., Yan J., Wu L., Zhang M.;
RT   "Assembling stable hair cell tip link complex via multidentate
RT   interactions between harmonin and cadherin 23.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:5575-5580(2009).
RN   [11]
RP   VARIANTS DFNB12 GLY-124; SER-452; GLN-480; GLN-582; TRP-1060;
RP   ASP-1186; PRO-1586; LYS-1595; ASN-1846; TRP-2465 AND HIS-2608,
RP   VARIANTS USH1D PRO-484; ARG-1206; ALA-1209; GLY-2517; SER-2744;
RP   GLY-2833 AND HIS-3175, AND VARIANTS CYS-3; ALA-490; ASN-496; THR-1222;
RP   GLN-1437; MET-1620; ILE-1675; GLN-1804; ILE-1887; SER-1999; LYS-2044;
RP   GLN-2066; ILE-2283; GLN-2358; LEU-2380; GLN-2588; GLU-2933; ASN-2954
RP   AND SER-2962.
RX   PubMed=12075507; DOI=10.1086/341558;
RA   Astuto L.M., Bork J.M., Weston M.D., Askew J.W., Fields R.R.,
RA   Orten D.J., Ohliger S.J., Riazuddin S., Morell R.J., Khan S.,
RA   Riazuddin S., Kremer H., van Hauwe P., Moller C.G., Cremers C.W.R.J.,
RA   Ayuso C., Heckenlively J.R., Rohrschneider K., Spandau U.,
RA   Greenberg J., Ramesar R., Reardon W., Bitoun P., Millan J., Legge R.,
RA   Friedman T.B., Kimberling W.J.;
RT   "CDH23 mutation and phenotype heterogeneity: a profile of 107 diverse
RT   families with Usher syndrome and nonsyndromic deafness.";
RL   Am. J. Hum. Genet. 71:262-275(2002).
RN   [12]
RP   VARIANTS DFNB12 ASN-1341 AND ASN-2148, AND VARIANTS ILE-2283; GLN-2358
RP   AND LEU-2380.
RX   PubMed=12522556; DOI=10.1007/s00439-002-0833-0;
RA   de Brouwer A.P.M., Pennings R.J.E., Roeters M., Van Hauwe P.,
RA   Astuto L.M., Hoefsloot L.H., Huygen P.L.M., van den Helm B.,
RA   Deutman A.F., Bork J.M., Kimberling W.J., Cremers F.P.M.,
RA   Cremers C.W.R.J., Kremer H.;
RT   "Mutations in the calcium-binding motifs of CDH23 and the 35delG
RT   mutation in GJB2 cause hearing loss in one family.";
RL   Hum. Genet. 112:156-163(2003).
RN   [13]
RP   VARIANTS USH1D THR-366; ALA-1209; GLN-1507; TRP-3189 AND PHE-3245.
RX   PubMed=15660226; DOI=10.1007/s00439-004-1227-2;
RA   Ouyang X.M., Yan D., Du L.L., Hejtmancik J.F., Jacobson S.G.,
RA   Nance W.E., Li A.R., Angeli S., Kaiser M., Newton V., Brown S.D.M.,
RA   Balkany T., Liu X.Z.;
RT   "Characterization of Usher syndrome type I gene mutations in an Usher
RT   syndrome patient population.";
RL   Hum. Genet. 116:292-299(2005).
RN   [14]
RP   VARIANT USH1DF TRP-3189.
RX   PubMed=15537665; DOI=10.1093/hmg/ddi010;
RA   Zheng Q.Y., Yan D., Ouyang X.M., Du L.L., Yu H., Chang B.,
RA   Johnson K.R., Liu X.Z.;
RT   "Digenic inheritance of deafness caused by mutations in genes encoding
RT   cadherin 23 and protocadherin 15 in mice and humans.";
RL   Hum. Mol. Genet. 14:103-111(2005).
RN   [15]
RP   VARIANT DFNB12 SER-1888.
RX   PubMed=15829536; DOI=10.1056/NEJMoa043899;
RA   Schultz J.M., Yang Y., Caride A.J., Filoteo A.G., Penheiter A.R.,
RA   Lagziel A., Morell R.J., Mohiddin S.A., Fananapazir L., Madeo A.C.,
RA   Penniston J.T., Griffith A.J.;
RT   "Modification of human hearing loss by plasma-membrane calcium pump
RT   PMCA2.";
RL   N. Engl. J. Med. 352:1557-1564(2005).
RN   [16]
RP   ERRATUM.
RA   Schultz J.M., Yang Y., Caride A.J., Filoteo A.G., Penheiter A.R.,
RA   Lagziel A., Morell R.J., Mohiddin S.A., Fananapazir L., Madeo A.C.,
RA   Penniston J.T., Griffith A.J.;
RL   N. Engl. J. Med. 352:2362-2362(2005).
RN   [17]
RP   VARIANTS USH1D LYS-247 AND SER-2017, AND VARIANT DFNB12 TRP-1060.
RX   PubMed=16679490; DOI=10.1136/jmg.2006.041954;
RA   Roux A.-F., Faugere V., Le Guedard S., Pallares-Ruiz N., Vielle A.,
RA   Chambert S., Marlin S., Hamel C., Gilbert B., Malcolm S.,
RA   Claustres M.;
RT   "Survey of the frequency of USH1 gene mutations in a cohort of Usher
RT   patients shows the importance of cadherin 23 and protocadherin 15
RT   genes and establishes a detection rate of above 90%.";
RL   J. Med. Genet. 43:763-768(2006).
RN   [18]
RP   VARIANTS DFNB12 LEU-240; GLN-301; PRO-1716 AND TRP-2029, AND VARIANTS
RP   TRP-1417; ILE-1711; MET-1807; ASN-1876; ILE-1908; CYS-2171; PRO-2227;
RP   ILE-2283; PRO-2473; HIS-2489; VAL-2669; VAL-2801 AND CYS-3175.
RX   PubMed=17850630; DOI=10.1111/j.1399-0004.2007.00833.x;
RA   Wagatsuma M., Kitoh R., Suzuki H., Fukuoka H., Takumi Y., Usami S.;
RT   "Distribution and frequencies of CDH23 mutations in Japanese patients
RT   with non-syndromic hearing loss.";
RL   Clin. Genet. 72:339-344(2007).
RN   [19]
RP   VARIANTS USH1D THR-366; TYR-755; ILE-1090; SER-1098; HIS-1496;
RP   LEU-1788; TRP-1912; ASN-1930; SER-2017; VAL-2376; ILE-2530; SER-2771
RP   AND ALA-2968, AND VARIANTS ALA-490; ASN-496; ILE-746; GLY-944;
RP   LYS-960; THR-1222; GLN-1236; SER-1282; CYS-1349; ASP-1351; GLN-1437;
RP   MET-1520; THR-1574; ILE-1675; SER-1999; ILE-2283; LEU-2380; GLN-2588
RP   AND LEU-3125.
RX   PubMed=18429043; DOI=10.1002/humu.20761;
RA   Oshima A., Jaijo T., Aller E., Millan J.M., Carney C., Usami S.,
RA   Moller C., Kimberling W.J.;
RT   "Mutation profile of the CDH23 gene in 56 probands with Usher syndrome
RT   type I.";
RL   Hum. Mutat. 29:E37-E46(2008).
RN   [20]
RP   VARIANTS DFNB12 LEU-240; GLN-301; LYS-956; MET-1368; TRP-1417;
RP   ALA-1626; PRO-1716; TRP-2029; LYS-2287 AND LYS-2438, AND VARIANTS
RP   ASN-160; ILE-803; ILE-1415; GLY-1443; TRP-1588; ILE-1711; MET-1807;
RP   ASN-1876; ILE-1908; VAL-2130; CYS-2171; PRO-2227; PRO-2473; VAL-2669;
RP   VAL-2801; SER-2912 AND CYS-3175.
RX   PubMed=22899989; DOI=10.1371/journal.pone.0040366;
RA   Miyagawa M., Nishio S.Y., Usami S.;
RT   "Prevalence and clinical features of hearing loss patients with CDH23
RT   mutations: a large cohort study.";
RL   PLoS ONE 7:E40366-E40366(2012).
RN   [21]
RP   VARIANTS DFNB12 LEU-240; SER-342 AND LYS-1595, AND VARIANTS SER-361;
RP   MET-424; ASN-428; ALA-490; ASN-496; GLN-964; HIS-1010; SER-1118;
RP   ALA-1335; ASP-1351; GLN-1437; THR-1575; TRP-1588; ILE-1675; GLN-1804;
RP   GLU-1806; SER-1999; LYS-2044; ILE-2283; GLN-2358; LEU-2380; VAL-2531;
RP   VAL-2801; THR-3080 AND LEU-3125.
RX   PubMed=24767429; DOI=10.1186/1471-2350-15-46;
RA   Woo H.M., Park H.J., Park M.H., Kim B.Y., Shin J.W., Yoo W.G.,
RA   Koo S.K.;
RT   "Identification of CDH23 mutations in Korean families with hearing
RT   loss by whole-exome sequencing.";
RL   BMC Med. Genet. 15:46-46(2014).
RN   [22]
RP   VARIANTS GLN-192 AND THR-3062.
RX   PubMed=24916380; DOI=10.1093/hmg/ddu291;
RA   Xie Y.A., Lee W., Cai C., Gambin T., Noupuu K., Sujirakul T.,
RA   Ayuso C., Jhangiani S., Muzny D., Boerwinkle E., Gibbs R.,
RA   Greenstein V.C., Lupski J.R., Tsang S.H., Allikmets R.;
RT   "New syndrome with retinitis pigmentosa is caused by nonsense
RT   mutations in retinol dehydrogenase RDH11.";
RL   Hum. Mol. Genet. 23:5774-5780(2014).
CC   -!- FUNCTION: Cadherins are calcium-dependent cell adhesion proteins.
CC       They preferentially interact with themselves in a homophilic
CC       manner in connecting cells. CDH23 is required for establishing
CC       and/or maintaining the proper organization of the stereocilia
CC       bundle of hair cells in the cochlea and the vestibule during late
CC       embryonic/early postnatal development. It is part of the
CC       functional network formed by USH1C, USH1G, CDH23 and MYO7A that
CC       mediates mechanotransduction in cochlear hair cells. Required for
CC       normal hearing.
CC   -!- SUBUNIT: antiparallel heterodimer with PCDH15 (By similarity).
CC       Interacts with USH1C and USH1G. {ECO:0000250,
CC       ECO:0000269|PubMed:19297620, ECO:0000269|PubMed:21436032}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=Q9H251-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H251-2; Sequence=VSP_000645;
CC       Name=3;
CC         IsoId=Q9H251-3; Sequence=VSP_000646;
CC       Name=4;
CC         IsoId=Q9H251-4; Sequence=VSP_000647;
CC       Name=5;
CC         IsoId=Q9H251-5; Sequence=VSP_013268, VSP_013269;
CC       Name=6;
CC         IsoId=Q9H251-6; Sequence=VSP_035289, VSP_035290;
CC         Note=No experimental confirmation available.;
CC       Name=7; Synonyms=B1;
CC         IsoId=Q9H251-7; Sequence=VSP_044260;
CC       Name=8;
CC         IsoId=Q9H251-8; Sequence=VSP_044261, VSP_000645;
CC         Note=No experimental confirmation available.;
CC       Name=9; Synonyms=B2;
CC         IsoId=Q9H251-9; Sequence=VSP_044260, VSP_000647;
CC       Name=10; Synonyms=C1;
CC         IsoId=Q9H251-10; Sequence=VSP_047923, VSP_047924;
CC       Name=11; Synonyms=C2;
CC         IsoId=Q9H251-11; Sequence=VSP_047923, VSP_047924, VSP_000647;
CC   -!- TISSUE SPECIFICITY: Particularly strong expression in the retina.
CC       Found also in the cochlea.
CC   -!- DOMAIN: Three calcium ions are usually bound at the interface of
CC       each cadherin domain and rigidify the connections, imparting a
CC       strong curvature to the full-length ectodomain. {ECO:0000250}.
CC   -!- DOMAIN: Cadherin repeats 1 and 2 mediate calcium-dependent
CC       heterophilic interaction with PCDH15. {ECO:0000250}.
CC   -!- DISEASE: Usher syndrome 1D (USH1D) [MIM:601067]: USH is a
CC       genetically heterogeneous condition characterized by the
CC       association of retinitis pigmentosa with sensorineural deafness.
CC       Age at onset and differences in auditory and vestibular function
CC       distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2
CC       (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by
CC       profound congenital sensorineural deafness, absent vestibular
CC       function and prepubertal onset of progressive retinitis pigmentosa
CC       leading to blindness. {ECO:0000269|PubMed:11138009,
CC       ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:15660226,
CC       ECO:0000269|PubMed:16679490, ECO:0000269|PubMed:18429043}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Usher syndrome 1D/F (USH1DF) [MIM:601067]: USH1DF
CC       patients are heterozygous for mutations in CDH23 and PCDH15,
CC       indicating a digenic inheritance pattern.
CC       {ECO:0000269|PubMed:15537665}. Note=The disease is caused by
CC       mutations affecting distinct genetic loci, including the gene
CC       represented in this entry.
CC   -!- DISEASE: Deafness, autosomal recessive, 12 (DFNB12) [MIM:601386]:
CC       A form of non-syndromic sensorineural hearing loss. Sensorineural
CC       deafness results from damage to the neural receptors of the inner
CC       ear, the nerve pathways to the brain, or the area of the brain
CC       that receives sound information. {ECO:0000269|PubMed:11090341,
CC       ECO:0000269|PubMed:12075507, ECO:0000269|PubMed:12522556,
CC       ECO:0000269|PubMed:15829536, ECO:0000269|PubMed:16679490,
CC       ECO:0000269|PubMed:17850630, ECO:0000269|PubMed:22899989,
CC       ECO:0000269|PubMed:24767429}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 27 cadherin domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00043}.
CC   -!- WEB RESOURCE: Name=Mutations of the CDH23 gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="http://www.retina-international.org/files/sci-news/cdh23mut.htm";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF312024; AAG48303.1; -; mRNA.
DR   EMBL; AY358617; AAQ88980.1; -; mRNA.
DR   EMBL; AY563161; AAT72161.1; -; mRNA.
DR   EMBL; AY563162; AAT72162.1; -; mRNA.
DR   EMBL; AY563165; AAT72165.1; -; mRNA.
DR   EMBL; AY563166; AAT72166.1; -; mRNA.
DR   EMBL; AC012469; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL359183; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL731541; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL772287; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC011570; AAH11570.1; -; mRNA.
DR   EMBL; BC136976; AAI36977.1; -; mRNA.
DR   EMBL; BC136977; AAI36978.1; -; mRNA.
DR   EMBL; AB058715; BAB47441.1; -; mRNA.
DR   EMBL; AY010111; AAG27034.2; -; mRNA.
DR   EMBL; AB053445; BAB61902.1; -; mRNA.
DR   CCDS; CCDS53540.1; -. [Q9H251-7]
DR   CCDS; CCDS73146.1; -. [Q9H251-9]
DR   RefSeq; NP_001165401.1; NM_001171930.1.
DR   RefSeq; NP_001165402.1; NM_001171931.1.
DR   RefSeq; NP_001165403.1; NM_001171932.1.
DR   RefSeq; NP_001165404.1; NM_001171933.1. [Q9H251-7]
DR   RefSeq; NP_001165405.1; NM_001171934.1. [Q9H251-9]
DR   RefSeq; NP_001165406.1; NM_001171935.1. [Q9H251-10]
DR   RefSeq; NP_001165407.1; NM_001171936.1. [Q9H251-11]
DR   RefSeq; NP_071407.4; NM_022124.5. [Q9H251-1]
DR   RefSeq; NP_443068.1; NM_052836.3. [Q9H251-5]
DR   UniGene; Hs.656032; -.
DR   PDB; 2KBR; NMR; -; B=3183-3200.
DR   PDB; 2KBS; NMR; -; B=3347-3354.
DR   PDB; 2LSR; NMR; -; B=3212-3227.
DR   PDBsum; 2KBR; -.
DR   PDBsum; 2KBS; -.
DR   PDBsum; 2LSR; -.
DR   ProteinModelPortal; Q9H251; -.
DR   SMR; Q9H251; 24-2940.
DR   BioGrid; 122042; 3.
DR   DIP; DIP-48786N; -.
DR   IntAct; Q9H251; 1.
DR   MINT; MINT-4830802; -.
DR   STRING; 9606.ENSP00000381768; -.
DR   iPTMnet; Q9H251; -.
DR   PhosphoSite; Q9H251; -.
DR   BioMuta; CDH23; -.
DR   DMDM; 408359994; -.
DR   PaxDb; Q9H251; -.
DR   PRIDE; Q9H251; -.
DR   Ensembl; ENST00000398788; ENSP00000381768; ENSG00000107736. [Q9H251-7]
DR   Ensembl; ENST00000461841; ENSP00000473454; ENSG00000107736. [Q9H251-5]
DR   Ensembl; ENST00000619887; ENSP00000478374; ENSG00000107736. [Q9H251-9]
DR   GeneID; 64072; -.
DR   KEGG; hsa:64072; -.
DR   UCSC; uc001jrw.4; human. [Q9H251-5]
DR   UCSC; uc001jrx.4; human. [Q9H251-1]
DR   UCSC; uc001jsg.4; human. [Q9H251-7]
DR   CTD; 64072; -.
DR   GeneCards; CDH23; -.
DR   GeneReviews; CDH23; -.
DR   H-InvDB; HIX0008905; -.
DR   HGNC; HGNC:13733; CDH23.
DR   HPA; HPA017232; -.
DR   MalaCards; CDH23; -.
DR   MIM; 276900; phenotype.
DR   MIM; 601067; phenotype.
DR   MIM; 601386; phenotype.
DR   MIM; 605516; gene.
DR   neXtProt; NX_Q9H251; -.
DR   Orphanet; 90636; Autosomal recessive non-syndromic sensorineural deafness type DFNB.
DR   Orphanet; 231169; Usher syndrome type 1.
DR   PharmGKB; PA26296; -.
DR   eggNOG; KOG1219; Eukaryota.
DR   eggNOG; ENOG410XPEI; LUCA.
DR   GeneTree; ENSGT00760000118805; -.
DR   HOGENOM; HOG000139588; -.
DR   HOVERGEN; HBG050768; -.
DR   InParanoid; Q9H251; -.
DR   KO; K06813; -.
DR   OrthoDB; EOG7FFMQP; -.
DR   TreeFam; TF320624; -.
DR   ChiTaRS; CDH23; human.
DR   EvolutionaryTrace; Q9H251; -.
DR   GeneWiki; CDH23; -.
DR   GenomeRNAi; 64072; -.
DR   NextBio; 65849; -.
DR   PRO; PR:Q9H251; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; Q9H251; -.
DR   CleanEx; HS_CDH23; -.
DR   ExpressionAtlas; Q9H251; baseline and differential.
DR   Genevisible; Q9H251; HS.
DR   GO; GO:0005813; C:centrosome; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IMP:GOC.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0060091; C:kinocilium; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0001917; C:photoreceptor inner segment; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0032420; C:stereocilium; ISS:HGNC.
DR   GO; GO:0032426; C:stereocilium tip; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0060088; P:auditory receptor cell stereocilium organization; IEA:Ensembl.
DR   GO; GO:0006816; P:calcium ion transport; IMP:DFLAT.
DR   GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; NAS:UniProtKB.
DR   GO; GO:0051480; P:cytosolic calcium ion homeostasis; IMP:DFLAT.
DR   GO; GO:0050957; P:equilibrioception; IMP:HGNC.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0045494; P:photoreceptor cell maintenance; IMP:HGNC.
DR   GO; GO:0048563; P:post-embryonic organ morphogenesis; IEA:Ensembl.
DR   GO; GO:0050896; P:response to stimulus; IEA:UniProtKB-KW.
DR   GO; GO:0050953; P:sensory perception of light stimulus; IMP:HGNC.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:HGNC.
DR   GO; GO:0007601; P:visual perception; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.60; -; 27.
DR   InterPro; IPR002126; Cadherin.
DR   InterPro; IPR015919; Cadherin-like.
DR   InterPro; IPR020894; Cadherin_CS.
DR   Pfam; PF00028; Cadherin; 24.
DR   PRINTS; PR00205; CADHERIN.
DR   SMART; SM00112; CA; 26.
DR   SUPFAM; SSF49313; SSF49313; 27.
DR   PROSITE; PS00232; CADHERIN_1; 17.
DR   PROSITE; PS50268; CADHERIN_2; 27.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell adhesion;
KW   Cell membrane; Complete proteome; Deafness; Disease mutation;
KW   Glycoprotein; Hearing; Membrane; Metal-binding;
KW   Non-syndromic deafness; Polymorphism; Reference proteome; Repeat;
KW   Retinitis pigmentosa; Sensory transduction; Signal; Transmembrane;
KW   Transmembrane helix; Usher syndrome; Vision.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24   3354       Cadherin-23.
FT                                /FTId=PRO_0000003824.
FT   TOPO_DOM     24   3064       Extracellular. {ECO:0000255}.
FT   TRANSMEM   3065   3085       Helical. {ECO:0000255}.
FT   TOPO_DOM   3086   3354       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       34    132       Cadherin 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      133    236       Cadherin 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      237    348       Cadherin 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      349    460       Cadherin 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      461    561       Cadherin 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      562    671       Cadherin 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      672    784       Cadherin 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      779    890       Cadherin 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      891    995       Cadherin 9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      996   1102       Cadherin 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     1103   1208       Cadherin 11. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     1210   1313       Cadherin 12. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     1314   1418       Cadherin 13. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     1420   1527       Cadherin 14. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     1529   1634       Cadherin 15. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     1635   1744       Cadherin 16. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     1745   1851       Cadherin 17. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     1852   1959       Cadherin 18. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     1960   2069       Cadherin 19. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     2070   2174       Cadherin 20. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     2175   2293       Cadherin 21. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     2297   2402       Cadherin 22. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     2403   2509       Cadherin 23. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     2510   2611       Cadherin 24. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     2614   2722       Cadherin 25. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     2729   2846       Cadherin 26. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN     2847   2975       Cadherin 27. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   CARBOHYD    155    155       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    206    206       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    349    349       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    393    393       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    434    434       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    466    466       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    472    472       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    652    652       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    694    694       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    765    765       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    810    810       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    827    827       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    941    941       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1001   1001       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1018   1018       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1171   1171       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1282   1282       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1315   1315       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1473   1473       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1534   1534       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1651   1651       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1667   1667       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1818   1818       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1857   1857       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1889   1889       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1902   1902       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2013   2013       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2050   2050       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2129   2129       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2168   2168       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2195   2195       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2263   2263       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2357   2357       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2369   2369       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2616   2616       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2749   2749       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2808   2808       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2877   2877       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2896   2896       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2941   2941       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2981   2981       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ       1   2240       Missing (in isoform 7 and isoform 9).
FT                                {ECO:0000303|PubMed:15882574}.
FT                                /FTId=VSP_044260.
FT   VAR_SEQ       1     24       MGRHVATSCHVAWLLVLISGCWGQ -> MRSWFQQDPMVGA
FT                                CTTGTRASHPK (in isoform 10 and isoform
FT                                11). {ECO:0000303|PubMed:15882574}.
FT                                /FTId=VSP_047923.
FT   VAR_SEQ      25   3127       Missing (in isoform 10 and isoform 11).
FT                                {ECO:0000303|PubMed:15882574}.
FT                                /FTId=VSP_047924.
FT   VAR_SEQ     143    143       E -> EVGATG (in isoform 8).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_044261.
FT   VAR_SEQ     379    380       Missing (in isoform 2 and isoform 8).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_000645.
FT   VAR_SEQ     484    530       ATDNDAGTFGEVSYFFSDDPDRFSLDKDTGLIMLIARLDYE
FT                                LIQRFT -> VSPRFTAGPLSSPGPTVVRHPEGFCPRDLSN
FT                                QGRRHPQIPELCLLVY (in isoform 5).
FT                                {ECO:0000303|PubMed:12975309,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_013268.
FT   VAR_SEQ     531   3354       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:12975309,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_013269.
FT   VAR_SEQ    1124   1212       LKATDADEGEFGRVWYRILHGNHGNNFRIHVSNGLLMRGPR
FT                                PLDRERNSSHVLIVEAYNHDLGPMRSSVRVIVYVEDINDEA
FT                                PVFTQQQ -> EEDLASPCISPAPPRRAFQSSGEKETSQFP
FT                                GKELRREPGPSKAQNRAAFTEPLAEAPLLGSKQAQEERAPL
FT                                PREQAQQLQGSEGEKGGP (in isoform 6).
FT                                {ECO:0000303|PubMed:11347906}.
FT                                /FTId=VSP_035289.
FT   VAR_SEQ    1213   3354       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:11347906}.
FT                                /FTId=VSP_035290.
FT   VAR_SEQ    1403   1403       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_000646.
FT   VAR_SEQ    3212   3246       Missing (in isoform 4, isoform 9 and
FT                                isoform 11).
FT                                {ECO:0000303|PubMed:11597768,
FT                                ECO:0000303|PubMed:15882574}.
FT                                /FTId=VSP_000647.
FT   VARIANT       3      3       R -> C (in dbSNP:rs7902757).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:12975309}.
FT                                /FTId=VAR_012166.
FT   VARIANT     124    124       D -> G (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027317.
FT   VARIANT     160    160       D -> N. {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071407.
FT   VARIANT     192    192       E -> Q. {ECO:0000269|PubMed:24916380}.
FT                                /FTId=VAR_072661.
FT   VARIANT     240    240       P -> L (in DFNB12; dbSNP:rs121908354).
FT                                {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_046404.
FT   VARIANT     247    247       E -> K (in USH1D).
FT                                {ECO:0000269|PubMed:16679490}.
FT                                /FTId=VAR_027318.
FT   VARIANT     301    301       R -> Q (in DFNB12).
FT                                {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046405.
FT   VARIANT     342    342       N -> S (in DFNB12).
FT                                {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071408.
FT   VARIANT     361    361       A -> S. {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071409.
FT   VARIANT     366    366       A -> T (in USH1D; dbSNP:rs143282422).
FT                                {ECO:0000269|PubMed:15660226,
FT                                ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_024030.
FT   VARIANT     424    424       V -> M. {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071410.
FT   VARIANT     428    428       D -> N. {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071411.
FT   VARIANT     452    452       N -> S (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027319.
FT   VARIANT     480    480       L -> Q (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027320.
FT   VARIANT     484    484       A -> P (in USH1D).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027321.
FT   VARIANT     490    490       G -> A (in dbSNP:rs1227049).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:18429043,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012167.
FT   VARIANT     496    496       S -> N (in dbSNP:rs10999947).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:11347906,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:18429043,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012168.
FT   VARIANT     582    582       R -> Q (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027322.
FT   VARIANT     746    746       V -> I. {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046406.
FT   VARIANT     755    755       H -> Y (in USH1D).
FT                                {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046407.
FT   VARIANT     803    803       V -> I. {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071412.
FT   VARIANT     944    944       S -> G. {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046408.
FT   VARIANT     956    956       E -> K (in DFNB12).
FT                                {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071413.
FT   VARIANT     960    960       E -> K. {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046409.
FT   VARIANT     964    964       R -> Q. {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071414.
FT   VARIANT     990    990       D -> N (in DFNB12).
FT                                {ECO:0000269|PubMed:11090341}.
FT                                /FTId=VAR_012169.
FT   VARIANT    1010   1010       R -> H. {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071415.
FT   VARIANT    1060   1060       R -> W (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:16679490}.
FT                                /FTId=VAR_027323.
FT   VARIANT    1090   1090       V -> I (in USH1D).
FT                                {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046410.
FT   VARIANT    1098   1098       N -> S (in USH1D; dbSNP:rs41281310).
FT                                {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046411.
FT   VARIANT    1118   1118       G -> S. {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071416.
FT   VARIANT    1186   1186       G -> D (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027324.
FT   VARIANT    1206   1206       P -> R (in USH1D).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027325.
FT   VARIANT    1209   1209       T -> A (in USH1D; dbSNP:rs41281314).
FT                                {ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:15660226}.
FT                                /FTId=VAR_024031.
FT   VARIANT    1222   1222       A -> T (in dbSNP:rs41281316).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_012170.
FT   VARIANT    1236   1236       R -> Q. {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046412.
FT   VARIANT    1281   1281       Missing (in USH1D).
FT                                {ECO:0000269|PubMed:11138009}.
FT                                /FTId=VAR_012171.
FT   VARIANT    1282   1282       N -> S. {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046413.
FT   VARIANT    1335   1335       V -> A. {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071417.
FT   VARIANT    1341   1341       D -> N (in DFNB12).
FT                                {ECO:0000269|PubMed:12522556}.
FT                                /FTId=VAR_027326.
FT   VARIANT    1349   1349       R -> C (in dbSNP:rs41281318).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_012172.
FT   VARIANT    1351   1351       N -> D (in dbSNP:rs1227065).
FT                                {ECO:0000269|PubMed:11090341,
FT                                ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:18429043,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012173.
FT   VARIANT    1368   1368       T -> M (in DFNB12).
FT                                {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071418.
FT   VARIANT    1415   1415       S -> I. {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071419.
FT   VARIANT    1417   1417       R -> W (in DFNB12).
FT                                {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046414.
FT   VARIANT    1437   1437       R -> Q (in dbSNP:rs56181447).
FT                                {ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:18429043,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_027327.
FT   VARIANT    1443   1443       A -> G. {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071420.
FT   VARIANT    1496   1496       Q -> H (in USH1D).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_012174.
FT   VARIANT    1507   1507       R -> Q (in USH1D).
FT                                {ECO:0000269|PubMed:15660226}.
FT                                /FTId=VAR_024032.
FT   VARIANT    1520   1520       I -> M. {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046415.
FT   VARIANT    1574   1574       M -> T. {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046416.
FT   VARIANT    1575   1575       A -> T (in dbSNP:rs1227051).
FT                                {ECO:0000269|PubMed:11090341,
FT                                ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012175.
FT   VARIANT    1586   1586       A -> P (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027328.
FT   VARIANT    1588   1588       R -> W. {ECO:0000269|PubMed:22899989,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071421.
FT   VARIANT    1595   1595       E -> K (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_027329.
FT   VARIANT    1620   1620       V -> M (in dbSNP:rs41281330).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027330.
FT   VARIANT    1626   1626       D -> A (in DFNB12).
FT                                {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071422.
FT   VARIANT    1671   1671       T -> S. {ECO:0000269|PubMed:11138009}.
FT                                /FTId=VAR_012176.
FT   VARIANT    1675   1675       V -> I (in dbSNP:rs17712523).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:18429043,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012177.
FT   VARIANT    1711   1711       V -> I. {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046417.
FT   VARIANT    1716   1716       Q -> P (in DFNB12).
FT                                {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046418.
FT   VARIANT    1746   1746       R -> Q (in USH1D; mild retinal
FT                                affection).
FT                                {ECO:0000269|PubMed:11138009}.
FT                                /FTId=VAR_012178.
FT   VARIANT    1788   1788       P -> L (in USH1D).
FT                                {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046419.
FT   VARIANT    1804   1804       R -> Q (in dbSNP:rs3802711).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012179.
FT   VARIANT    1806   1806       D -> E. {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071423.
FT   VARIANT    1807   1807       V -> M. {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046420.
FT   VARIANT    1846   1846       D -> N (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027331.
FT   VARIANT    1876   1876       S -> N. {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046421.
FT   VARIANT    1887   1887       T -> I. {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027332.
FT   VARIANT    1888   1888       F -> S (in DFNB12).
FT                                {ECO:0000269|PubMed:15829536}.
FT                                /FTId=VAR_027333.
FT   VARIANT    1908   1908       V -> I. {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046422.
FT   VARIANT    1912   1912       R -> W (in USH1D).
FT                                {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046423.
FT   VARIANT    1930   1930       D -> N (in USH1D).
FT                                {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046424.
FT   VARIANT    1999   1999       T -> S (in dbSNP:rs11592462).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:18429043,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012180.
FT   VARIANT    2017   2017       G -> S (in USH1D; most likely affects
FT                                splicing). {ECO:0000269|PubMed:16679490,
FT                                ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_027334.
FT   VARIANT    2029   2029       R -> W (in DFNB12).
FT                                {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046425.
FT   VARIANT    2044   2044       E -> K (in dbSNP:rs10466026).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012181.
FT   VARIANT    2045   2045       D -> N (in DFNB12).
FT                                {ECO:0000269|PubMed:11090341}.
FT                                /FTId=VAR_012182.
FT   VARIANT    2066   2066       R -> Q. {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027335.
FT   VARIANT    2125   2125       I -> M (in dbSNP:rs16929354).
FT                                /FTId=VAR_046426.
FT   VARIANT    2130   2130       A -> V. {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071424.
FT   VARIANT    2148   2148       D -> N (in DFNB12).
FT                                {ECO:0000269|PubMed:12522556}.
FT                                /FTId=VAR_027336.
FT   VARIANT    2171   2171       R -> C. {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046427.
FT   VARIANT    2202   2202       D -> N (in DFNB12).
FT                                {ECO:0000269|PubMed:11090341}.
FT                                /FTId=VAR_012183.
FT   VARIANT    2227   2227       Q -> P. {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046428.
FT   VARIANT    2283   2283       V -> I (in dbSNP:rs41281334).
FT                                {ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:12522556,
FT                                ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:18429043,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_027337.
FT   VARIANT    2287   2287       N -> K (in DFNB12).
FT                                {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071425.
FT   VARIANT    2358   2358       R -> Q (in dbSNP:rs4747194).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:12522556,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012184.
FT   VARIANT    2376   2376       D -> N (in dbSNP:rs9663920).
FT                                /FTId=VAR_027338.
FT   VARIANT    2376   2376       D -> V (in USH1D).
FT                                {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046429.
FT   VARIANT    2380   2380       P -> L (in dbSNP:rs4747195).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:12522556,
FT                                ECO:0000269|PubMed:18429043,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012185.
FT   VARIANT    2438   2438       E -> K (in DFNB12).
FT                                {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071426.
FT   VARIANT    2465   2465       R -> W (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027339.
FT   VARIANT    2473   2473       L -> P. {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046430.
FT   VARIANT    2489   2489       R -> H. {ECO:0000269|PubMed:17850630}.
FT                                /FTId=VAR_046431.
FT   VARIANT    2517   2517       S -> G (in USH1D).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027340.
FT   VARIANT    2530   2530       T -> I (in USH1D).
FT                                {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046432.
FT   VARIANT    2531   2531       M -> V. {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071427.
FT   VARIANT    2588   2588       E -> Q (in dbSNP:rs41281338).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:12075507,
FT                                ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_012186.
FT   VARIANT    2608   2608       R -> H (in DFNB12).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027341.
FT   VARIANT    2669   2669       I -> V. {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046433.
FT   VARIANT    2744   2744       G -> S (in USH1D; atypical).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027342.
FT   VARIANT    2771   2771       G -> S (in USH1D).
FT                                {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046434.
FT   VARIANT    2801   2801       F -> V (in dbSNP:rs3802707).
FT                                {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_046435.
FT   VARIANT    2833   2833       R -> G (in USH1D; atypical).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027343.
FT   VARIANT    2853   2853       A -> Q (requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_046436.
FT   VARIANT    2912   2912       G -> S. {ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_071428.
FT   VARIANT    2933   2933       V -> E. {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027344.
FT   VARIANT    2950   2950       I -> N (in DFNB12).
FT                                {ECO:0000269|PubMed:11090341}.
FT                                /FTId=VAR_012187.
FT   VARIANT    2954   2954       D -> N. {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027345.
FT   VARIANT    2956   2956       R -> C (in DFNB12).
FT                                {ECO:0000269|PubMed:11090341}.
FT                                /FTId=VAR_012188.
FT   VARIANT    2962   2962       N -> S. {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027346.
FT   VARIANT    2968   2968       V -> A (in USH1D).
FT                                {ECO:0000269|PubMed:18429043}.
FT                                /FTId=VAR_046437.
FT   VARIANT    3059   3059       P -> T (in DFNB12).
FT                                {ECO:0000269|PubMed:11090341}.
FT                                /FTId=VAR_012189.
FT   VARIANT    3062   3062       M -> T. {ECO:0000269|PubMed:24916380}.
FT                                /FTId=VAR_072662.
FT   VARIANT    3080   3080       A -> T. {ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_071429.
FT   VARIANT    3125   3125       F -> L (in dbSNP:rs45583140).
FT                                {ECO:0000269|PubMed:11138009,
FT                                ECO:0000269|PubMed:18429043,
FT                                ECO:0000269|PubMed:24767429}.
FT                                /FTId=VAR_012190.
FT   VARIANT    3175   3175       R -> C. {ECO:0000269|PubMed:17850630,
FT                                ECO:0000269|PubMed:22899989}.
FT                                /FTId=VAR_046438.
FT   VARIANT    3175   3175       R -> H (in USH1D).
FT                                {ECO:0000269|PubMed:12075507}.
FT                                /FTId=VAR_027347.
FT   VARIANT    3189   3189       R -> W (in USH1D and USH1DF).
FT                                {ECO:0000269|PubMed:15537665,
FT                                ECO:0000269|PubMed:15660226}.
FT                                /FTId=VAR_024033.
FT   VARIANT    3245   3245       S -> F (in USH1D).
FT                                {ECO:0000269|PubMed:15660226}.
FT                                /FTId=VAR_024034.
FT   CONFLICT    985    985       V -> L (in Ref. 7; AAG27034).
FT                                {ECO:0000305}.
FT   CONFLICT   1403   1403       K -> V (in Ref. 7; AAG27034).
FT                                {ECO:0000305}.
FT   CONFLICT   2173   2236       EFLNPIQTVSVLESAEPGTVIANITAIDHDLNPKLEYHIVG
FT                                IVAKDDTDRLVPNQEDAFAVNIN -> ASWEGQSHVTQAYE
FT                                EAVGPPQPQVPDSTGDRHPLWGLGGFGQEHPWEGQILGGSS
FT                                QAEPGLVWS (in Ref. 8; BAB61902).
FT                                {ECO:0000305}.
FT   HELIX      3187   3198       {ECO:0000244|PDB:2KBR}.
FT   HELIX      3214   3226       {ECO:0000244|PDB:2LSR}.
FT   STRAND     3351   3353       {ECO:0000244|PDB:2KBS}.
SQ   SEQUENCE   3354 AA;  369494 MW;  1B68045A7FFA97BA CRC64;
     MGRHVATSCH VAWLLVLISG CWGQVNRLPF FTNHFFDTYL LISEDTPVGS SVTQLLAQDM
     DNDPLVFGVS GEEASRFFAV EPDTGVVWLR QPLDRETKSE FTVEFSVSDH QGVITRKVNI
     QVGDVNDNAP TFHNQPYSVR IPENTPVGTP IFIVNATDPD LGAGGSVLYS FQPPSQFFAI
     DSARGIVTVI RELDYETTQA YQLTVNATDQ DKTRPLSTLA NLAIIITDVQ DMDPIFINLP
     YSTNIYEHSP PGTTVRIITA IDQDKGRPRG IGYTIVSGNT NSIFALDYIS GVLTLNGLLD
     RENPLYSHGF ILTVKGTELN DDRTPSDATV TTTFNILVID INDNAPEFNS SEYSVAITEL
     AQVGFALPLF IQVVDKDENL GLNSMFEVYL VGNNSHHFII SPTSVQGKAD IRIRVAIPLD
     YETVDRYDFD LFANESVPDH VGYAKVKITL INENDNRPIF SQPLYNISLY ENVTVGTSVL
     TVLATDNDAG TFGEVSYFFS DDPDRFSLDK DTGLIMLIAR LDYELIQRFT LTIIARDGGG
     EETTGRVRIN VLDVNDNVPT FQKDAYVGAL RENEPSVTQL VRLRATDEDS PPNNQITYSI
     VSASAFGSYF DISLYEGYGV ISVSRPLDYE QISNGLIYLT VMAMDAGNPP LNSTVPVTIE
     VFDENDNPPT FSKPAYFVSV VENIMAGATV LFLNATDLDR SREYGQESII YSLEGSTQFR
     INARSGEITT TSLLDRETKS EYILIVRAVD GGVGHNQKTG IATVNITLLD INDNHPTWKD
     APYYINLVEM TPPDSDVTTV VAVDPDLGEN GTLVYSIQPP NKFYSLNSTT GKIRTTHAML
     DRENPDPHEA ELMRKIVVSV TDCGRPPLKA TSSATVFVNL LDLNDNDPTF QNLPFVAEVL
     EGIPAGVSIY QVVAIDLDEG LNGLVSYRMP VGMPRMDFLI NSSSGVVVTT TELDRERIAE
     YQLRVVASDA GTPTKSSTST LTIHVLDVND ETPTFFPAVY NVSVSEDVPR EFRVVWLNCT
     DNDVGLNAEL SYFITGGNVD GKFSVGYRDA VVRTVVGLDR ETTAAYMLIL EAIDNGPVGK
     RHTGTATVFV TVLDVNDNRP IFLQSSYEAS VPEDIPEGHS ILQLKATDAD EGEFGRVWYR
     ILHGNHGNNF RIHVSNGLLM RGPRPLDRER NSSHVLIVEA YNHDLGPMRS SVRVIVYVED
     INDEAPVFTQ QQYSRLGLRE TAGIGTSVIV VQATDRDSGD GGLVNYRILS GAEGKFEIDE
     STGLIITVNY LDYETKTSYM MNVSATDQAP PFNQGFCSVY ITLLNELDEA VQFSNASYEA
     AILENLALGT EIVRVQAYSI DNLNQITYRF NAYTSTQAKA LFKIDAITGV ITVQGLVDRE
     KGDFYTLTVV ADDGGPKVDS TVKVYITVLD ENDNSPRFDF TSDSAVSIPE DCPVGQRVAT
     VKAWDPDAGS NGQVVFSLAS GNIAGAFEIV TTNDSIGEVF VARPLDREEL DHYILQVVAS
     DRGTPPRKKD HILQVTILDI NDNPPVIESP FGYNVSVNEN VGGGTAVVQV RATDRDIGIN
     SVLSYYITEG NKDMAFRMDR ISGEIATRPA PPDRERQSFY HLVATVEDEG TPTLSATTHV
     YVTIVDENDN APMFQQPHYE VLLDEGPDTL NTSLITIQAL DLDEGPNGTV TYAIVAGNIV
     NTFRIDRHMG VITAAKELDY EISHGRYTLI VTATDQCPIL SHRLTSTTTV LVNVNDINDN
     VPTFPRDYEG PFEVTEGQPG PRVWTFLAHD RDSGPNGQVE YSIMDGDPLG EFVISPVEGV
     LRVRKDVELD RETIAFYNLT ICARDRGMPP LSSTMLVGIR VLDINDNDPV LLNLPMNITI
     SENSPVSSFV AHVLASDADS GCNARLTFNI TAGNRERAFF INATTGIVTV NRPLDRERIP
     EYKLTISVKD NPENPRIARR DYDLLLIFLS DENDNHPLFT KSTYQAEVME NSPAGTPLTV
     LNGPILALDA DQDIYAVVTY QLLGAQSGLF DINSSTGVVT VRSGVIIDRE AFSPPILELL
     LLAEDIGLLN STAHLLITIL DDNDNRPTFS PATLTVHLLE NCPPGFSVLQ VTATDEDSGL
     NGELVYRIEA GAQDRFLIHL VTGVIRVGNA TIDREEQESY RLTVVATDRG TVPLSGTAIV
     TILIDDINDS RPEFLNPIQT VSVLESAEPG TVIANITAID HDLNPKLEYH IVGIVAKDDT
     DRLVPNQEDA FAVNINTGSV MVKSPMNREL VATYEVTLSV IDNASDLPER SVSVPNAKLT
     VNVLDVNDNT PQFKPFGITY YMERILEGAT PGTTLIAVAA VDPDKGLNGL VTYTLLDLVP
     PGYVQLEDSS AGKVIANRTV DYEEVHWLNF TVRASDNGSP PRAAEIPVYL EIVDINDNNP
     IFDQPSYQEA VFEDVPVGTI ILTVTATDAD SGNFALIEYS LGDGESKFAI NPTTGDIYVL
     SSLDREKKDH YILTALAKDN PGDVASNRRE NSVQVVIQVL DVNDCRPQFS KPQFSTSVYE
     NEPAGTSVIT MMATDQDEGP NGELTYSLEG PGVEAFHVDM DSGLVTTQRP LQSYEKFSLT
     VVATDGGEPP LWGTTMLLVE VIDVNDNRPV FVRPPNGTIL HIREEIPLRS NVYEVYATDK
     DEGLNGAVRY SFLKTAGNRD WEFFIIDPIS GLIQTAQRLD RESQAVYSLI LVASDLGQPV
     PYETMQPLQV ALEDIDDNEP LFVRPPKGSP QYQLLTVPEH SPRGTLVGNV TGAVDADEGP
     NAIVYYFIAA GNEEKNFHLQ PDGCLLVLRD LDREREAIFS FIVKASSNRS WTPPRGPSPT
     LDLVADLTLQ EVRVVLEDIN DQPPRFTKAE YTAGVATDAK VGSELIQVLA LDADIGNNSL
     VFYSILAIHY FRALANDSED VGQVFTMGSM DGILRTFDLF MAYSPGYFVV DIVARDLAGH
     NDTAIIGIYI LRDDQRVKIV INEIPDRVRG FEEEFIHLLS NITGAIVNTD NVQFHVDKKG
     RVNFAQTELL IHVVNRDTNR ILDVDRVIQM IDENKEQLRN LFRNYNVLDV QPAISVRLPD
     DMSALQMAII VLAILLFLAA MLFVLMNWYY RTVHKRKLKA IVAGSAGNRG FIDIMDMPNT
     NKYSFDGANP VWLDPFCRNL ELAAQAEHED DLPENLSEIA DLWNSPTRTH GTFGREPAAV
     KPDDDRYLRA AIQEYDNIAK LGQIIREGPI KGSLLKVVLE DYLRLKKLFA QRMVQKASSC
     HSSISELIQT ELDEEPGDHS PGQGSLRFRH KPPVELKGPD GIHVVHGSTG TLLATDLNSL
     PEEDQKGLGR SLETLTAAEA TAFERNARTE SAKSTPLHKL RDVIMETPLE ITEL
//
ID   IGF1R_HUMAN             Reviewed;        1367 AA.
AC   P08069; B1B5Y2; Q14CV2; Q9UCC0;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   17-FEB-2016, entry version 191.
DE   RecName: Full=Insulin-like growth factor 1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Insulin-like growth factor I receptor;
DE            Short=IGF-I receptor;
DE   AltName: CD_antigen=CD221;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor alpha chain;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor beta chain;
DE   Flags: Precursor;
GN   Name=IGF1R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 31-56; 446-453;
RP   503-524; 561-579; 668-672 AND 721-729.
RC   TISSUE=Placenta;
RX   PubMed=2877871;
RA   Ullrich A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C.,
RA   Henzel W., Bon T.L., Kathuria S., Chen E., Jacobs S., Francke U.,
RA   Ramachandran J., Fujita-Yamaguchi Y.;
RT   "Insulin-like growth factor I receptor primary structure: comparison
RT   with insulin receptor suggests structural determinants that define
RT   functional specificity.";
RL   EMBO J. 5:2503-2512(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1316909;
RA   Abbot A.M., Bueno R., Pedrini M.T., Murray J.M., Smith R.J.;
RT   "Insulin-like growth factor I receptor gene structure.";
RL   J. Biol. Chem. 267:10759-10763(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Fetal brain;
RA   Nagase T., Kikuno R.F., Yamakawa H., Ohara O.;
RL   Submitted (FEB-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-388 AND HIS-605.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-31.
RX   PubMed=1711844; DOI=10.1016/0006-291X(91)90654-P;
RA   Cooke D.W., Bankert L.A., Roberts C.T. Jr., Leroith D., Casella S.J.;
RT   "Analysis of the human type I insulin-like growth factor receptor
RT   promoter region.";
RL   Biochem. Biophys. Res. Commun. 177:1113-1120(1991).
RN   [8]
RP   PROTEIN SEQUENCE OF 31-45 AND 741-750, FUNCTION, AND FORMATION OF A
RP   HYBRID RECEPTOR WITH INSR.
RC   TISSUE=Placenta;
RX   PubMed=8257688; DOI=10.1021/bi00212a019;
RA   Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A.,
RA   Fujita-Yamaguchi Y.;
RT   "Characterization of human placental insulin-like growth factor-
RT   I/insulin hybrid receptors by protein microsequencing and
RT   purification.";
RL   Biochemistry 32:13531-13536(1993).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1137-1193, AND TISSUE SPECIFICITY.
RC   TISSUE=Melanocyte;
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [10]
RP   FUNCTION, SUBUNIT, AND AUTOPHOSPHORYLATION.
RX   PubMed=1846292; DOI=10.1021/bi00215a008;
RA   Tollefsen S.E., Stoszek R.M., Thompson K.;
RT   "Interaction of the alpha beta dimers of the insulin-like growth
RT   factor I receptor is required for receptor autophosphorylation.";
RL   Biochemistry 30:48-54(1991).
RN   [11]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=8452530;
RA   Soos M.A., Field C.E., Siddle K.;
RT   "Purified hybrid insulin/insulin-like growth factor-I receptors bind
RT   insulin-like growth factor-I, but not insulin, with high affinity.";
RL   Biochem. J. 290:419-426(1993).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, AND AUTOPHOSPHORYLATION.
RX   PubMed=7679099;
RA   Kato H., Faria T.N., Stannard B., Roberts C.T. Jr., LeRoith D.;
RT   "Role of tyrosine kinase activity in signal transduction by the
RT   insulin-like growth factor-I (IGF-I) receptor. Characterization of
RT   kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic
RT   antibody (alpha IR-3).";
RL   J. Biol. Chem. 268:2655-2661(1993).
RN   [13]
RP   INTERACTION WITH IRS1; SHC1 AND PIK3R1, MUTAGENESIS OF TYR-980 AND
RP   LYS-1033, AND PHOSPHORYLATION AT TYR-980.
RX   PubMed=7541045; DOI=10.1074/jbc.270.26.15639;
RA   Craparo A., O'Neill T.J., Gustafson T.A.;
RT   "Non-SH2 domains within insulin receptor substrate-1 and SHC mediate
RT   their phosphotyrosine-dependent interaction with the NPEY motif of the
RT   insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 270:15639-15643(1995).
RN   [14]
RP   FORMATION OF A HYBRID RECEPTOR WITH INSR, AND TISSUE SPECIFICITY.
RX   PubMed=9355755;
RA   Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.;
RT   "Insulin receptor/IGF-I receptor hybrids are widely distributed in
RT   mammalian tissues: quantification of individual receptor species by
RT   selective immunoprecipitation and immunoblotting.";
RL   Biochem. J. 327:209-215(1997).
RN   [15]
RP   INTERACTION WITH 14-3-3 PROTEINS.
RX   PubMed=9581554;
RA   Furlanetto R.W., Dey B.R., Lopaczynski W., Nissley S.P.;
RT   "14-3-3 proteins interact with the insulin-like growth factor receptor
RT   but not the insulin receptor.";
RL   Biochem. J. 327:765-771(1997).
RN   [16]
RP   FORMATION OF A HYBRID RECEPTOR WITH INSR, AND TISSUE SPECIFICITY.
RX   PubMed=9202395; DOI=10.1016/S0303-7207(97)04050-1;
RA   Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D.,
RA   Sesti G.;
RT   "Distribution of insulin/insulin-like growth factor-I hybrid receptors
RT   in human tissues.";
RL   Mol. Cell. Endocrinol. 129:121-126(1997).
RN   [17]
RP   INTERACTION WITH SOCS1 AND SOCS2.
RX   PubMed=9727029; DOI=10.1074/jbc.273.37.24095;
RA   Dey B.R., Spence S.L., Nissley P., Furlanetto R.W.;
RT   "Interaction of human suppressor of cytokine signaling (SOCS)-2 with
RT   the insulin-like growth factor-I receptor.";
RL   J. Biol. Chem. 273:24095-24101(1998).
RN   [18]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=9822622; DOI=10.1074/jbc.273.48.31640;
RA   Lin F.-T., Daaka Y., Lefkowitz R.J.;
RT   "beta-arrestins regulate mitogenic signaling and clathrin-mediated
RT   endocytosis of the insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 273:31640-31643(1998).
RN   [19]
RP   FUNCTION IN CANCER.
RX   PubMed=10579905; DOI=10.1006/excr.1999.4667;
RA   Baserga R.;
RT   "The IGF-I receptor in cancer research.";
RL   Exp. Cell Res. 253:1-6(1999).
RN   [20]
RP   INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-980; TYR-1280; TYR-1281
RP   AND TYR-1346.
RX   PubMed=10454568;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [21]
RP   INTERACTION WITH SOCS3.
RX   PubMed=11071852; DOI=10.1006/bbrc.2000.3762;
RA   Dey B.R., Furlanetto R.W., Nissley P.;
RT   "Suppressor of cytokine signaling (SOCS)-3 protein interacts with the
RT   insulin-like growth factor-I receptor.";
RL   Biochem. Biophys. Res. Commun. 278:38-43(2000).
RN   [22]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=11162456; DOI=10.1006/bbrc.2000.4046;
RA   Lopaczynski W., Terry C., Nissley P.;
RT   "Autophosphorylation of the insulin-like growth factor I receptor
RT   cytoplasmic domain.";
RL   Biochem. Biophys. Res. Commun. 279:955-960(2000).
RN   [23]
RP   FUNCTION IN ACTIVATION OF STAT3.
RX   PubMed=10747872; DOI=10.1074/jbc.M000089200;
RA   Zong C.S., Chan J., Levy D.E., Horvath C., Sadowski H.B., Wang L.H.;
RT   "Mechanism of STAT3 activation by insulin-like growth factor I
RT   receptor.";
RL   J. Biol. Chem. 275:15099-15105(2000).
RN   [24]
RP   TISSUE SPECIFICITY.
RX   PubMed=12019176;
RA   Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F.,
RA   Macaulay V.M.;
RT   "Expression of the type 1 insulin-like growth factor receptor is up-
RT   regulated in primary prostate cancer and commonly persists in
RT   metastatic disease.";
RL   Cancer Res. 62:2942-2950(2002).
RN   [25]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=12138094; DOI=10.1074/jbc.M202766200;
RA   Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.;
RT   "Insulin/insulin-like growth factor I hybrid receptors have different
RT   biological characteristics depending on the insulin receptor isoform
RT   involved.";
RL   J. Biol. Chem. 277:39684-39695(2002).
RN   [26]
RP   INTERACTION WITH GNB2L1.
RX   PubMed=11884618; DOI=10.1128/MCB.22.7.2345-2365.2002;
RA   Hermanto U., Zong C.S., Li W., Wang L.H.;
RT   "RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting
RT   protein, modulates IGF-I-dependent integrin signaling and promotes
RT   cell spreading and contact with extracellular matrix.";
RL   Mol. Cell. Biol. 22:2345-2365(2002).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH MAP3K5.
RX   PubMed=12556535; DOI=10.1074/jbc.M211398200;
RA   Galvan V., Logvinova A., Sperandio S., Ichijo H., Bredesen D.E.;
RT   "Type 1 insulin-like growth factor receptor (IGF-IR) signaling
RT   inhibits apoptosis signal-regulating kinase 1 (ASK1).";
RL   J. Biol. Chem. 278:13325-13332(2003).
RN   [28]
RP   UBIQUITINATION BY MDM2, AND INTERACTION WITH MDM2.
RX   PubMed=12821780; DOI=10.1073/pnas.1431613100;
RA   Girnita L., Girnita A., Larsson O.;
RT   "Mdm2-dependent ubiquitination and degradation of the insulin-like
RT   growth factor 1 receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:8247-8252(2003).
RN   [29]
RP   ENZYME REGULATION.
RX   PubMed=14729630; DOI=10.1158/0008-5472.CAN-03-2522;
RA   Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O.,
RA   Axelson M.;
RT   "Cyclolignans as inhibitors of the insulin-like growth factor-1
RT   receptor and malignant cell growth.";
RL   Cancer Res. 64:236-242(2004).
RN   [30]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=15878855; DOI=10.1074/jbc.M501129200;
RA   Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A.,
RA   Lefkowitz R.J., Larsson O.;
RT   "{beta}-Arrestin is crucial for ubiquitination and down-regulation of
RT   the insulin-like growth factor-1 receptor by acting as adaptor for the
RT   MDM2 E3 ligase.";
RL   J. Biol. Chem. 280:24412-24419(2005).
RN   [31]
RP   INTERACTION WITH STAT3.
RX   PubMed=15998644; DOI=10.1074/jbc.M501316200;
RA   Yadav A., Kalita A., Dhillon S., Banerjee K.;
RT   "JAK/STAT3 pathway is involved in survival of neurons in response to
RT   insulin-like growth factor and negatively regulated by suppressor of
RT   cytokine signaling-3.";
RL   J. Biol. Chem. 280:31830-31840(2005).
RN   [32]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=16831875; DOI=10.1074/jbc.M605189200;
RA   Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C.,
RA   Mathiasen I.S., Brandt J.;
RT   "Hybrid receptors formed by insulin receptor (IR) and insulin-like
RT   growth factor I receptor (IGF-IR) have low insulin and high IGF-1
RT   affinity irrespective of the IR splice variant.";
RL   J. Biol. Chem. 281:25869-25874(2006).
RN   [33]
RP   SUBCELLULAR LOCATION, AND PROTEOLYTIC PROCESSING.
RX   PubMed=17524361; DOI=10.1016/j.bbrc.2007.05.062;
RA   McElroy B., Powell J.C., McCarthy J.V.;
RT   "The insulin-like growth factor 1 (IGF-1) receptor is a substrate for
RT   gamma-secretase-mediated intramembrane proteolysis.";
RL   Biochem. Biophys. Res. Commun. 358:1136-1141(2007).
RN   [34]
RP   REVIEW ON IGF1R IN CANCER.
RX   PubMed=17624760; DOI=10.1016/j.ejca.2007.05.021;
RA   Hartog H., Wesseling J., Boezen H.M., van der Graaf W.T.;
RT   "The insulin-like growth factor 1 receptor in cancer: old focus, new
RT   future.";
RL   Eur. J. Cancer 43:1895-1904(2007).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [37]
RP   SUMOYLATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-
RT   translational modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [39]
RP   UBIQUITINATION AT LYS-1168 AND LYS-1171.
RX   PubMed=21994939; DOI=10.1074/jbc.M111.288514;
RA   Mao Y., Shang Y., Pham V.C., Ernst J.A., Lill J.R., Scales S.J.,
RA   Zha J.;
RT   "Polyubiquitination of insulin-like growth factor I receptor (IGF-IR)
RT   activation loop promotes antibody-induced receptor internalization and
RT   down-regulation.";
RL   J. Biol. Chem. 286:41852-41861(2011).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 31-492, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-51; ASN-135; ASN-244 AND ASN-314.
RX   PubMed=9690478; DOI=10.1038/28668;
RA   Garrett T.P., McKern N.M., Lou M., Frenkel M.J., Bentley J.D.,
RA   Lovrecz G.O., Elleman T.C., Cosgrove L.J., Ward C.W.;
RT   "Crystal structure of the first three domains of the type-1 insulin-
RT   like growth factor receptor.";
RL   Nature 394:395-399(1998).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 988-1286 IN COMPLEX WITH
RP   AMP-PCP AND PEPTIDE SUBSTRATE, CATALYTIC ACTIVITY, ACTIVE SITE, ENZYME
RP   REGULATION, IDENTIFICATION BY MASS SPECTROMETRY, AND PHOSPHORYLATION
RP   AT TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=11694888; DOI=10.1038/nsb721;
RA   Favelyukis S., Till J.H., Hubbard S.R., Miller W.T.;
RT   "Structure and autoregulation of the insulin-like growth factor 1
RT   receptor kinase.";
RL   Nat. Struct. Biol. 8:1058-1063(2001).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 981-1286 IN COMPLEX WITH
RP   ANP, AUTOPHOSPHORYLATION, ACTIVE SITE, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=11591350; DOI=10.1016/S0969-2126(01)00655-4;
RA   Pautsch A., Zoephel A., Ahorn H., Spevak W., Hauptmann R., Nar H.;
RT   "Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight
RT   into domain movements upon kinase activation.";
RL   Structure 9:955-965(2001).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 974-1294.
RX   PubMed=12138114; DOI=10.1074/jbc.M205580200;
RA   Munshi S., Kornienko M., Hall D.L., Reid J.C., Waxman L.,
RA   Stirdivant S.M., Darke P.L., Kuo L.C.;
RT   "Crystal structure of the Apo, unactivated insulin-like growth factor-
RT   1 receptor kinase. Implication for inhibitor specificity.";
RL   J. Biol. Chem. 277:38797-38802(2002).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 974-1294.
RX   PubMed=14501110; DOI=10.1107/S0907444903015415;
RA   Munshi S., Hall D.L., Kornienko M., Darke P.L., Kuo L.C.;
RT   "Structure of apo, unactivated insulin-like growth factor-1 receptor
RT   kinase at 1.5 A resolution.";
RL   Acta Crystallogr. D 59:1725-1730(2003).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   BENZIMIDAZOLE PYRIDINONE INHIBITOR, CATALYTIC ACTIVITY, AND ENZYME
RP   REGULATION.
RX   PubMed=17317169; DOI=10.1016/j.bmcl.2007.01.102;
RA   Velaparthi U., Wittman M., Liu P., Stoffan K., Zimmermann K., Sang X.,
RA   Carboni J., Li A., Attar R., Gottardis M., Greer A., Chang C.Y.,
RA   Jacobsen B.L., Sack J.S., Sun Y., Langley D.R., Balasubramanian B.,
RA   Vyas D.;
RT   "Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-
RT   2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor
RT   (IGF-1R).";
RL   Bioorg. Med. Chem. Lett. 17:2317-2321(2007).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 981-1286, AND
RP   PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=18501599; DOI=10.1016/j.bmcl.2008.04.044;
RA   Mayer S.C., Banker A.L., Boschelli F., Di L., Johnson M., Kenny C.H.,
RA   Krishnamurthy G., Kutterer K., Moy F., Petusky S., Ravi M., Tkach D.,
RA   Tsou H.R., Xu W.;
RT   "Lead identification to generate isoquinolinedione inhibitors of
RT   insulin-like growth factor receptor (IGF-1R) for potential use in
RT   cancer treatment.";
RL   Bioorg. Med. Chem. Lett. 18:3641-3645(2008).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 986-1286 IN COMPLEX WITH
RP   INHIBITOR PQIP, SUBUNIT, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY,
RP   ACTIVE SITE, AND ENZYME REGULATION.
RX   PubMed=18566589; DOI=10.1038/emboj.2008.116;
RA   Wu J., Li W., Craddock B.P., Foreman K.W., Mulvihill M.J., Ji Q.S.,
RA   Miller W.T., Hubbard S.R.;
RT   "Small-molecule inhibition and activation-loop trans-phosphorylation
RT   of the IGF1 receptor.";
RL   EMBO J. 27:1985-1994(2008).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 981-1286 IN COMPLEX WITH
RP   3-CYANOQUINOLINE INHIBITOR, CATALYTIC ACTIVITY, ENZYME REGULATION, AND
RP   PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=19041240; DOI=10.1016/j.bmcl.2008.11.037;
RA   Miller L.M., Mayer S.C., Berger D.M., Boschelli D.H., Boschelli F.,
RA   Di L., Du X., Dutia M., Floyd M.B., Johnson M., Kenny C.H.,
RA   Krishnamurthy G., Moy F., Petusky S., Tkach D., Torres N., Wu B.,
RA   Xu W.;
RT   "Lead identification to generate 3-cyanoquinoline inhibitors of
RT   insulin-like growth factor receptor (IGF-1R) for potential use in
RT   cancer treatment.";
RL   Bioorg. Med. Chem. Lett. 19:62-66(2009).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   BMS-754807, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=19778024; DOI=10.1021/jm900786r;
RA   Wittman M.D., Carboni J.M., Yang Z., Lee F.Y., Antman M., Attar R.,
RA   Balimane P., Chang C., Chen C., Discenza L., Frennesson D.,
RA   Gottardis M.M., Greer A., Hurlburt W., Johnson W., Langley D.R.,
RA   Li A., Li J., Liu P., Mastalerz H., Mathur A., Menard K., Patel K.,
RA   Sack J., Sang X., Saulnier M., Smith D., Stefanski K., Trainor G.,
RA   Velaparthi U., Zhang G., Zimmermann K., Vyas D.M.;
RT   "Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine
RT   inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R)
RT   kinase in clinical development.";
RL   J. Med. Chem. 52:7360-7363(2009).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 983-1286 IN COMPLEX WITH
RP   MSC1609119A-1, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   DOI=10.1021/ml100044h;
RA   Heinrich T., Graedler U., Boettcher H., Blaukat A., Shutes A.;
RT   "Allosteric IGF-1R Inhibitors.";
RL   ACS Med. Chem. Lett. 1:199-203(2010).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.11 ANGSTROMS) OF 982-1286 IN COMPLEXES WITH
RP   INHIBITORS, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=20675137; DOI=10.1016/j.bmcl.2010.07.045;
RA   Sampognaro A.J., Wittman M.D., Carboni J.M., Chang C., Greer A.F.,
RA   Hurlburt W.W., Sack J.S., Vyas D.M.;
RT   "Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-
RT   f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.";
RL   Bioorg. Med. Chem. Lett. 20:5027-5030(2010).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 951-1286 IN COMPLEX WITH
RP   BIS-AZAINDOLE INHIBITOR, AUTOPHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=20545947; DOI=10.1111/j.1747-0285.2010.00991.x;
RA   Nemecek C., Metz W.A., Wentzler S., Ding F.X., Venot C., Souaille C.,
RA   Dagallier A., Maignan S., Guilloteau J.P., Bernard F., Henry A.,
RA   Grapinet S., Lesuisse D.;
RT   "Design of potent IGF1-R inhibitors related to bis-azaindoles.";
RL   Chem. Biol. Drug Des. 76:100-106(2010).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   HYDANTOIN DERIVATIVE, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=21441024; DOI=10.1016/j.bmcl.2011.03.003;
RA   Lesuisse D., Mauger J., Nemecek C., Maignan S., Boiziau J., Harlow G.,
RA   Hittinger A., Ruf S., Strobel H., Nair A., Ritter K., Malleron J.L.,
RA   Dagallier A., El-Ahmad Y., Guilloteau J.P., Guizani H., Bouchard H.,
RA   Venot C.;
RT   "Discovery of the first non-ATP competitive IGF-1R kinase inhibitors:
RT   advantages in comparison with competitive inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:2224-2228(2011).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 988-1286 IN COMPLEX WITH
RP   2,4-BIS-ARYLAMINO-1,3-PYRIMIDINE INHIBITOR, CATALYTIC ACTIVITY, AND
RP   ENZYME REGULATION.
RX   PubMed=21414779; DOI=10.1016/j.bmcl.2011.02.075;
RA   Buchanan J.L., Newcomb J.R., Carney D.P., Chaffee S.C., Chai L.,
RA   Cupples R., Epstein L.F., Gallant P., Gu Y., Harmange J.C., Hodge K.,
RA   Houk B.E., Huang X., Jona J., Joseph S., Jun H.T., Kumar R., Li C.,
RA   Lu J., Menges T., Morrison M.J., Novak P.M., van der Plas S.,
RA   Radinsky R., Rose P.E., Sawant S., Sun J.R., Surapaneni S.,
RA   Turci S.M., Xu K., Yanez E., Zhao H., Zhu X.;
RT   "Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth
RT   factor-1 receptor (IGF-1R) inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:2394-2399(2011).
RN   [55]
RP   VARIANTS IGF1RES GLN-138 AND ASN-145, AND CHARACTERIZATION OF VARIANTS
RP   IGF1RES GLN-138 AND ASN-145.
RX   PubMed=14657428; DOI=10.1056/NEJMoa010107;
RG   The intrauterine growth retardation (IUGR) study group;
RA   Abuzzahab M.J., Schneider A., Goddard A., Grigorescu F., Lautier C.,
RA   Keller E., Kiess W., Klammt J., Kratzsch J., Osgood D., Pfaeffle R.,
RA   Raile K., Seidel B., Smith R.J., Chernausek S.D.;
RT   "IGF-I receptor mutations resulting in intrauterine and postnatal
RT   growth retardation.";
RL   N. Engl. J. Med. 349:2211-2222(2003).
RN   [56]
RP   VARIANT IGF1RES GLN-739, AND CHARACTERIZATION OF VARIANT IGF1RES
RP   GLN-739.
RX   PubMed=15928254; DOI=10.1210/jc.2004-1947;
RA   Kawashima Y., Kanzaki S., Yang F., Kinoshita T., Hanaki K.,
RA   Nagaishi J., Ohtsuka Y., Hisatome I., Ninomoya H., Nanba E.,
RA   Fukushima T., Takahashi S.;
RT   "Mutation at cleavage site of insulin-like growth factor receptor in a
RT   short-stature child born with intrauterine growth retardation.";
RL   J. Clin. Endocrinol. Metab. 90:4679-4687(2005).
RN   [57]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-105; HIS-437; HIS-595; SER-857;
RP   THR-1338 AND VAL-1347.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates actions of
CC       insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity
CC       and IGF2 and insulin (INS) with a lower affinity. The activated
CC       IGF1R is involved in cell growth and survival control. IGF1R is
CC       crucial for tumor transformation and survival of malignant cell.
CC       Ligand binding activates the receptor kinase, leading to receptor
CC       autophosphorylation, and tyrosines phosphorylation of multiple
CC       substrates, that function as signaling adapter proteins including,
CC       the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins.
CC       Phosphorylation of IRSs proteins lead to the activation of two
CC       main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK
CC       pathway. The result of activating the MAPK pathway is increased
CC       cellular proliferation, whereas activating the PI3K pathway
CC       inhibits apoptosis and stimulates protein synthesis.
CC       Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of
CC       PI3K (PIK3R1), leading to activation of several downstream
CC       substrates, including protein AKT/PKB. AKT phosphorylation, in
CC       turn, enhances protein synthesis through mTOR activation and
CC       triggers the antiapoptotic effects of IGFIR through
CC       phosphorylation and inactivation of BAD. In parallel to PI3K-
CC       driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1
CC       or Shc leads to recruitment of Ras and activation of the ras-MAPK
CC       pathway. In addition to these two main signaling pathways IGF1R
CC       signals also through the Janus kinase/signal transducer and
CC       activator of transcription pathway (JAK/STAT). Phosphorylation of
CC       JAK proteins can lead to phosphorylation/activation of signal
CC       transducers and activators of transcription (STAT) proteins. In
CC       particular activation of STAT3, may be essential for the
CC       transforming activity of IGF1R. The JAK/STAT pathway activates
CC       gene transcription and may be responsible for the transforming
CC       activity. JNK kinases can also be activated by the IGF1R. IGF1
CC       exerts inhibiting activities on JNK activation via phosphorylation
CC       and inhibition of MAP3K5/ASK1, which is able to directly associate
CC       with the IGF1R.
CC   -!- FUNCTION: When present in a hybrid receptor with INSR, binds IGF1.
CC       PubMed:12138094 shows that hybrid receptors composed of IGF1R and
CC       INSR isoform Long are activated with a high affinity by IGF1, with
CC       low affinity by IGF2 and not significantly activated by insulin,
CC       and that hybrid receptors composed of IGF1R and INSR isoform Short
CC       are activated by IGF1, IGF2 and insulin. In contrast,
CC       PubMed:16831875 shows that hybrid receptors composed of IGF1R and
CC       INSR isoform Long and hybrid receptors composed of IGF1R and INSR
CC       isoform Short have similar binding characteristics, both bind IGF1
CC       and have a low affinity for insulin.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11694888,
CC       ECO:0000269|PubMed:17317169, ECO:0000269|PubMed:18566589,
CC       ECO:0000269|PubMed:19041240, ECO:0000269|PubMed:19778024,
CC       ECO:0000269|PubMed:20675137, ECO:0000269|PubMed:21414779,
CC       ECO:0000269|PubMed:21441024, ECO:0000269|PubMed:7679099,
CC       ECO:0000269|Ref.50}.
CC   -!- ENZYME REGULATION: Activated by autophosphorylation at Tyr-1165,
CC       Tyr-1161 and Tyr-1166 on the kinase activation loop;
CC       phosphorylation at all three tyrosine residues is required for
CC       optimal kinase activity. Inhibited by MSC1609119A-1, BMS-754807,
CC       PQIP, benzimidazole pyridinone, isoquinolinedione, bis-azaindole,
CC       3-cyanoquinoline, 2,4-bis-arylamino-1,3-pyrimidine,
CC       pyrrolopyrimidine, pyrrole-5-carboxaldehyde, picropodophyllin
CC       (PPP), tyrphostin derivatives. While most inhibitors bind to the
CC       ATP binding pocket, MSC1609119A-1 functions as allosteric
CC       inhibitor and binds close to the DFG motif and the activation
CC       loop. {ECO:0000269|PubMed:11694888, ECO:0000269|PubMed:14729630,
CC       ECO:0000269|PubMed:17317169, ECO:0000269|PubMed:18566589,
CC       ECO:0000269|PubMed:19041240, ECO:0000269|PubMed:19778024,
CC       ECO:0000269|PubMed:20545947, ECO:0000269|PubMed:20675137,
CC       ECO:0000269|PubMed:21414779, ECO:0000269|PubMed:21441024,
CC       ECO:0000269|Ref.50}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chain carries the kinase domain.
CC       Interacts with PIK3R1 and with the PTB/PID domains of IRS1 and
CC       SHC1 in vitro when autophosphorylated on tyrosine residues. Forms
CC       a hybrid receptor with INSR, the hybrid is a tetramer consisting
CC       of 1 alpha chain and 1 beta chain of INSR and 1 alpha chain and 1
CC       beta chain of IGF1R. Interacts with ARRB1 and ARRB2. Interacts
CC       with GRB10. Interacts with GNB2L1/RACK1. Interacts with SOCS1,
CC       SOCS2 and SOCS3. Interacts with 14-3-3 proteins. Interacts with
CC       NMD2. Interacts with MAP3K5. Interacts with STAT3.
CC       {ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:11071852,
CC       ECO:0000269|PubMed:11591350, ECO:0000269|PubMed:11694888,
CC       ECO:0000269|PubMed:11884618, ECO:0000269|PubMed:12556535,
CC       ECO:0000269|PubMed:12821780, ECO:0000269|PubMed:15878855,
CC       ECO:0000269|PubMed:15998644, ECO:0000269|PubMed:17317169,
CC       ECO:0000269|PubMed:1846292, ECO:0000269|PubMed:18566589,
CC       ECO:0000269|PubMed:19041240, ECO:0000269|PubMed:19778024,
CC       ECO:0000269|PubMed:20545947, ECO:0000269|PubMed:21414779,
CC       ECO:0000269|PubMed:21441024, ECO:0000269|PubMed:7541045,
CC       ECO:0000269|PubMed:9581554, ECO:0000269|PubMed:9727029,
CC       ECO:0000269|PubMed:9822622, ECO:0000269|Ref.50}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-475981, EBI-475981;
CC       Q9NZN5:ARHGEF12; NbExp=7; IntAct=EBI-475981, EBI-821440;
CC       P49913:CAMP; NbExp=3; IntAct=EBI-475981, EBI-6378485;
CC       Q64010:Crk (xeno); NbExp=3; IntAct=EBI-475981, EBI-2906540;
CC       P41240:CSK; NbExp=5; IntAct=EBI-475981, EBI-1380630;
CC       P35222:CTNNB1; NbExp=3; IntAct=EBI-475981, EBI-491549;
CC       P05019:IGF1; NbExp=5; IntAct=EBI-475981, EBI-7902275;
CC       P01317:INS (xeno); NbExp=4; IntAct=EBI-475981, EBI-3989070;
CC       Q9Y2W7:KCNIP3; NbExp=3; IntAct=EBI-475981, EBI-751501;
CC       Q9UJU2:LEF1; NbExp=5; IntAct=EBI-475981, EBI-926131;
CC       Q00987:MDM2; NbExp=2; IntAct=EBI-475981, EBI-389668;
CC       P27986:PIK3R1; NbExp=4; IntAct=EBI-475981, EBI-79464;
CC       P18031:PTPN1; NbExp=3; IntAct=EBI-475981, EBI-968788;
CC       Q06124:PTPN11; NbExp=3; IntAct=EBI-475981, EBI-297779;
CC       P29353-2:SHC1; NbExp=2; IntAct=EBI-475981, EBI-1000553;
CC       Q01995:TAGLN; NbExp=2; IntAct=EBI-475981, EBI-1054248;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17524361};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:17524361}.
CC   -!- TISSUE SPECIFICITY: Found as a hybrid receptor with INSR in
CC       muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma,
CC       fibroblasts, spleen and placenta (at protein level). Expressed in
CC       a variety of tissues. Overexpressed in tumors, including
CC       melanomas, cancers of the colon, pancreas prostate and kidney.
CC       {ECO:0000269|PubMed:12019176, ECO:0000269|PubMed:8247543,
CC       ECO:0000269|PubMed:9202395, ECO:0000269|PubMed:9355755}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Autophosphorylation occurs in a sequential manner; Tyr-
CC       1165 is predominantly phosphorylated first, followed by
CC       phosphorylation of Tyr-1161 and Tyr-1166. While every single
CC       phosphorylation increases kinase activity, all three tyrosine
CC       residues in the kinase activation loop (Tyr-1165, Tyr-1161 and
CC       Tyr-1166) have to be phosphorylated for optimal activity. Can be
CC       autophosphorylated at additional tyrosine residues (in vitro).
CC       Autophosphorylated is followed by phosphorylation of juxtamembrane
CC       tyrosines and C-terminal serines. Phosphorylation of Tyr-980 is
CC       required for IRS1- and SHC1-binding. Phosphorylation of Ser-1278
CC       by GSK-3beta restrains kinase activity and promotes cell surface
CC       expression, it requires a priming phosphorylation at Ser-1282.
CC       Dephosphorylated by PTPN1 (By similarity). {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated at Lys-1168 and Lys-1171 through both 'Lys-
CC       48' and 'Lys-29' linkages, promoting receptor endocytosis and
CC       subsequent degradation by the proteasome. Ubiquitination is
CC       facilitated by pre-existing phosphorylation.
CC       {ECO:0000269|PubMed:11694888, ECO:0000269|PubMed:12821780,
CC       ECO:0000269|PubMed:18501599, ECO:0000269|PubMed:19041240,
CC       ECO:0000269|PubMed:21994939, ECO:0000269|PubMed:7541045}.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000269|PubMed:20596523}.
CC   -!- PTM: Controlled by regulated intramembrane proteolysis (RIP).
CC       Undergoes metalloprotease-dependent constitutive ectodomain
CC       shedding to produce a membrane-anchored 52 kDa C-Terminal fragment
CC       which is further processed by presenilin gamma-secretase to yield
CC       an intracellular 50 kDa fragment. {ECO:0000269|PubMed:17524361}.
CC   -!- DISEASE: Insulin-like growth factor 1 resistance (IGF1RES)
CC       [MIM:270450]: A disorder characterized by intrauterine growth
CC       retardation, poor postnatal growth and increased plasma IGF1
CC       levels. {ECO:0000269|PubMed:14657428,
CC       ECO:0000269|PubMed:15928254}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 4 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG11657.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IGF1RID40928ch15q26.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/igf1r/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=IGF-1 receptor entry;
CC       URL="https://en.wikipedia.org/wiki/IGF-1_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04434; CAA28030.1; -; mRNA.
DR   EMBL; AB425196; BAG11657.1; ALT_INIT; mRNA.
DR   EMBL; AY332722; AAP81165.1; -; Genomic_DNA.
DR   EMBL; AC055807; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069029; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118658; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118660; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC113610; AAI13611.1; -; mRNA.
DR   EMBL; BC113612; AAI13613.1; -; mRNA.
DR   EMBL; M69229; AAB59399.1; -; Genomic_DNA.
DR   CCDS; CCDS10378.1; -.
DR   PIR; A25690; IGHUR1.
DR   RefSeq; NP_000866.1; NM_000875.4.
DR   RefSeq; NP_001278787.1; NM_001291858.1.
DR   UniGene; Hs.643120; -.
DR   UniGene; Hs.714012; -.
DR   PDB; 1IGR; X-ray; 2.60 A; A=31-492.
DR   PDB; 1JQH; X-ray; 2.10 A; A/B/C=979-1286.
DR   PDB; 1K3A; X-ray; 2.10 A; A=988-1286.
DR   PDB; 1M7N; X-ray; 2.70 A; A/B=974-1294.
DR   PDB; 1P4O; X-ray; 1.50 A; A/B=974-1294.
DR   PDB; 2OJ9; X-ray; 2.00 A; A=982-1286.
DR   PDB; 2ZM3; X-ray; 2.50 A; A/B/C/D=981-1286.
DR   PDB; 3D94; X-ray; 2.30 A; A=986-1286.
DR   PDB; 3F5P; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L/M/R/S/T=981-1286.
DR   PDB; 3I81; X-ray; 2.08 A; A=982-1286.
DR   PDB; 3LVP; X-ray; 3.00 A; A/B/C/D=951-1286.
DR   PDB; 3LW0; X-ray; 1.79 A; A/B/C/D=983-1286.
DR   PDB; 3NW5; X-ray; 2.14 A; A=982-1286.
DR   PDB; 3NW6; X-ray; 2.20 A; A=982-1286.
DR   PDB; 3NW7; X-ray; 2.11 A; A=982-1286.
DR   PDB; 3O23; X-ray; 2.10 A; A=982-1286.
DR   PDB; 3QQU; X-ray; 2.90 A; A/B/C/D=988-1286.
DR   PDB; 4D2R; X-ray; 2.10 A; A=985-1286.
DR   PDB; 4XSS; X-ray; 3.00 A; F=721-736.
DR   PDBsum; 1IGR; -.
DR   PDBsum; 1JQH; -.
DR   PDBsum; 1K3A; -.
DR   PDBsum; 1M7N; -.
DR   PDBsum; 1P4O; -.
DR   PDBsum; 2OJ9; -.
DR   PDBsum; 2ZM3; -.
DR   PDBsum; 3D94; -.
DR   PDBsum; 3F5P; -.
DR   PDBsum; 3I81; -.
DR   PDBsum; 3LVP; -.
DR   PDBsum; 3LW0; -.
DR   PDBsum; 3NW5; -.
DR   PDBsum; 3NW6; -.
DR   PDBsum; 3NW7; -.
DR   PDBsum; 3O23; -.
DR   PDBsum; 3QQU; -.
DR   PDBsum; 4D2R; -.
DR   PDBsum; 4XSS; -.
DR   ProteinModelPortal; P08069; -.
DR   SMR; P08069; 31-491, 991-1283.
DR   BioGrid; 109701; 55.
DR   DIP; DIP-476N; -.
DR   IntAct; P08069; 54.
DR   MINT; MINT-85902; -.
DR   STRING; 9606.ENSP00000268035; -.
DR   BindingDB; P08069; -.
DR   ChEMBL; CHEMBL1957; -.
DR   DrugBank; DB00047; Insulin Glargine.
DR   DrugBank; DB00046; Insulin Lispro.
DR   DrugBank; DB00030; Insulin Regular.
DR   DrugBank; DB01277; Mecasermin.
DR   GuidetoPHARMACOLOGY; 1801; -.
DR   iPTMnet; P08069; -.
DR   PhosphoSite; P08069; -.
DR   BioMuta; IGF1R; -.
DR   DMDM; 124240; -.
DR   MaxQB; P08069; -.
DR   PaxDb; P08069; -.
DR   PeptideAtlas; P08069; -.
DR   PRIDE; P08069; -.
DR   DNASU; 3480; -.
DR   Ensembl; ENST00000268035; ENSP00000268035; ENSG00000140443.
DR   GeneID; 3480; -.
DR   KEGG; hsa:3480; -.
DR   UCSC; uc002bul.3; human.
DR   CTD; 3480; -.
DR   GeneCards; IGF1R; -.
DR   HGNC; HGNC:5465; IGF1R.
DR   HPA; CAB010268; -.
DR   HPA; HPA045563; -.
DR   MalaCards; IGF1R; -.
DR   MIM; 147370; gene.
DR   MIM; 270450; phenotype.
DR   neXtProt; NX_P08069; -.
DR   Orphanet; 73273; Growth delay due to insulin-like growth factor I resistance.
DR   PharmGKB; PA29698; -.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P08069; -.
DR   KO; K05087; -.
DR   OMA; GYLYRHN; -.
DR   OrthoDB; EOG73RB9N; -.
DR   PhylomeDB; P08069; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2404192; Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R).
DR   Reactome; R-HSA-2428928; IRS-related events triggered by IGF1R.
DR   Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R.
DR   SignaLink; P08069; -.
DR   ChiTaRS; IGF1R; human.
DR   EvolutionaryTrace; P08069; -.
DR   GeneWiki; Insulin-like_growth_factor_1_receptor; -.
DR   GenomeRNAi; 3480; -.
DR   NextBio; 13682; -.
DR   PRO; PR:P08069; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; P08069; -.
DR   CleanEx; HS_IGF1R; -.
DR   ExpressionAtlas; P08069; baseline and differential.
DR   Genevisible; P08069; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IC:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; ISS:AgBase.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043559; F:insulin binding; IPI:BHF-UCL.
DR   GO; GO:0005158; F:insulin receptor binding; IDA:BHF-UCL.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB.
DR   GO; GO:0005520; F:insulin-like growth factor binding; IDA:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL.
DR   GO; GO:0005010; F:insulin-like growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0008544; P:epidermis development; IEA:Ensembl.
DR   GO; GO:0031017; P:exocrine pancreas development; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IMP:BHF-UCL.
DR   GO; GO:0051389; P:inactivation of MAPKK activity; IDA:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030238; P:male sex determination; IEA:Ensembl.
DR   GO; GO:0030879; P:mammary gland development; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IMP:MGI.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IC:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IMP:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IDA:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 4.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Isopeptide bond; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     30       {ECO:0000269|PubMed:2877871,
FT                                ECO:0000269|PubMed:8257688}.
FT   CHAIN        31    736       Insulin-like growth factor 1 receptor
FT                                alpha chain.
FT                                /FTId=PRO_0000016681.
FT   CHAIN       741   1367       Insulin-like growth factor 1 receptor
FT                                beta chain.
FT                                /FTId=PRO_0000016682.
FT   TOPO_DOM    741    935       Extracellular. {ECO:0000255}.
FT   TRANSMEM    936    959       Helical. {ECO:0000255}.
FT   TOPO_DOM    960   1367       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      491    609       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      610    708       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      735    828       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      834    927       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      999   1274       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1005   1013       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       977    980       IRS1- and SHC1-binding.
FT   ACT_SITE   1135   1135       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1033   1033       ATP.
FT   MOD_RES     980    980       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:7541045}.
FT   MOD_RES    1161   1161       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11694888,
FT                                ECO:0000269|PubMed:18501599,
FT                                ECO:0000269|PubMed:19041240}.
FT   MOD_RES    1165   1165       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11694888,
FT                                ECO:0000269|PubMed:18501599,
FT                                ECO:0000269|PubMed:19041240}.
FT   MOD_RES    1166   1166       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11694888,
FT                                ECO:0000269|PubMed:18501599,
FT                                ECO:0000269|PubMed:19041240}.
FT   MOD_RES    1278   1278       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000250}.
FT   MOD_RES    1282   1282       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q60751}.
FT   CARBOHYD     51     51       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    135    135       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    244    244       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    314    314       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    417    417       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    438    438       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    534    534       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    607    607       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    622    622       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    640    640       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    747    747       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    756    756       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    764    764       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    900    900       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    913    913       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     33     52       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    150    178       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    182    205       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    192    211       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    215    224       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    219    230       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    231    239       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    235    248       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    251    260       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    264    276       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    282    303       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    307    321       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    324    328       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    332    353       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    455    488       {ECO:0000269|PubMed:9690478}.
FT   CROSSLNK   1168   1168       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21994939}.
FT   CROSSLNK   1171   1171       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21994939}.
FT   VARIANT     105    105       V -> L (in a renal chromophobe sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041424.
FT   VARIANT     138    138       R -> Q (in IGF1RES; has decreased IGF1R
FT                                function). {ECO:0000269|PubMed:14657428}.
FT                                /FTId=VAR_034891.
FT   VARIANT     145    145       K -> N (in IGF1RES; has decreased IGF1R
FT                                function). {ECO:0000269|PubMed:14657428}.
FT                                /FTId=VAR_034892.
FT   VARIANT     388    388       V -> M (in dbSNP:rs45445894).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018855.
FT   VARIANT     437    437       R -> H (in dbSNP:rs34516635).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_034893.
FT   VARIANT     511    511       R -> Q (in dbSNP:rs33958176).
FT                                /FTId=VAR_034894.
FT   VARIANT     595    595       R -> H (in dbSNP:rs56248469).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041425.
FT   VARIANT     605    605       R -> H (in dbSNP:rs45553041).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018856.
FT   VARIANT     739    739       R -> Q (in IGF1RES; leads to failure of
FT                                processing of the IGF1R proreceptor to
FT                                mature IGF1R).
FT                                {ECO:0000269|PubMed:15928254}.
FT                                /FTId=VAR_034895.
FT   VARIANT     808    808       H -> R (in dbSNP:rs34061581).
FT                                /FTId=VAR_034896.
FT   VARIANT     828    828       A -> T (in dbSNP:rs35224135).
FT                                /FTId=VAR_034897.
FT   VARIANT     857    857       N -> S (in dbSNP:rs45611935).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041426.
FT   VARIANT    1338   1338       A -> T (in dbSNP:rs34102392).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041427.
FT   VARIANT    1347   1347       A -> V (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041428.
FT   MUTAGEN     980    980       Y->F: Reduces tyrosine phosphorylation.
FT                                Abolishes interaction with IRS1 and SHC1.
FT                                Does not abolish interaction with PIK3R1,
FT                                nor with GRB10.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:7541045}.
FT   MUTAGEN    1033   1033       K->A: Kinase inactive. Abolishes tyrosine
FT                                phosphorylation and abolishes interaction
FT                                with IRS1, SHC1 and PIK3R1.
FT                                {ECO:0000269|PubMed:7541045}.
FT   MUTAGEN    1280   1280       Y->F: No effect on GRB10-binding.
FT                                {ECO:0000269|PubMed:10454568}.
FT   MUTAGEN    1281   1281       Y->F: No effect on GRB10-binding.
FT                                {ECO:0000269|PubMed:10454568}.
FT   MUTAGEN    1346   1346       Y->F: Loss of GRB10-binding.
FT                                {ECO:0000269|PubMed:10454568}.
FT   CONFLICT    928    929       TG -> R (in Ref. 3; BAG11657).
FT                                {ECO:0000305}.
FT   STRAND       37     41       {ECO:0000244|PDB:1IGR}.
FT   HELIX        43     49       {ECO:0000244|PDB:1IGR}.
FT   STRAND       53     57       {ECO:0000244|PDB:1IGR}.
FT   STRAND       59     65       {ECO:0000244|PDB:1IGR}.
FT   STRAND       68     70       {ECO:0000244|PDB:1IGR}.
FT   STRAND       80     83       {ECO:0000244|PDB:1IGR}.
FT   STRAND       85     92       {ECO:0000244|PDB:1IGR}.
FT   HELIX        96     98       {ECO:0000244|PDB:1IGR}.
FT   STRAND      115    121       {ECO:0000244|PDB:1IGR}.
FT   STRAND      138    144       {ECO:0000244|PDB:1IGR}.
FT   HELIX       157    160       {ECO:0000244|PDB:1IGR}.
FT   HELIX       164    166       {ECO:0000244|PDB:1IGR}.
FT   STRAND      168    171       {ECO:0000244|PDB:1IGR}.
FT   HELIX       175    178       {ECO:0000244|PDB:1IGR}.
FT   TURN        183    188       {ECO:0000244|PDB:1IGR}.
FT   STRAND      194    199       {ECO:0000244|PDB:1IGR}.
FT   STRAND      201    203       {ECO:0000244|PDB:1IGR}.
FT   STRAND      205    209       {ECO:0000244|PDB:1IGR}.
FT   HELIX       217    219       {ECO:0000244|PDB:1IGR}.
FT   STRAND      235    241       {ECO:0000244|PDB:1IGR}.
FT   STRAND      247    255       {ECO:0000244|PDB:1IGR}.
FT   STRAND      257    263       {ECO:0000244|PDB:1IGR}.
FT   STRAND      269    271       {ECO:0000244|PDB:1IGR}.
FT   TURN        272    274       {ECO:0000244|PDB:1IGR}.
FT   STRAND      275    277       {ECO:0000244|PDB:1IGR}.
FT   HELIX       279    283       {ECO:0000244|PDB:1IGR}.
FT   STRAND      297    299       {ECO:0000244|PDB:1IGR}.
FT   STRAND      302    306       {ECO:0000244|PDB:1IGR}.
FT   STRAND      311    315       {ECO:0000244|PDB:1IGR}.
FT   STRAND      321    323       {ECO:0000244|PDB:1IGR}.
FT   STRAND      325    327       {ECO:0000244|PDB:1IGR}.
FT   STRAND      331    341       {ECO:0000244|PDB:1IGR}.
FT   HELIX       345    347       {ECO:0000244|PDB:1IGR}.
FT   TURN        349    352       {ECO:0000244|PDB:1IGR}.
FT   STRAND      354    362       {ECO:0000244|PDB:1IGR}.
FT   HELIX       375    378       {ECO:0000244|PDB:1IGR}.
FT   STRAND      383    386       {ECO:0000244|PDB:1IGR}.
FT   STRAND      388    392       {ECO:0000244|PDB:1IGR}.
FT   TURN        415    417       {ECO:0000244|PDB:1IGR}.
FT   STRAND      418    423       {ECO:0000244|PDB:1IGR}.
FT   TURN        434    436       {ECO:0000244|PDB:1IGR}.
FT   STRAND      440    443       {ECO:0000244|PDB:1IGR}.
FT   STRAND      445    451       {ECO:0000244|PDB:1IGR}.
FT   HELIX       456    466       {ECO:0000244|PDB:1IGR}.
FT   STRAND      474    477       {ECO:0000244|PDB:1IGR}.
FT   TURN        479    481       {ECO:0000244|PDB:1IGR}.
FT   HELIX       724    730       {ECO:0000244|PDB:4XSS}.
FT   STRAND      980    982       {ECO:0000244|PDB:1P4O}.
FT   HELIX       983    985       {ECO:0000244|PDB:2ZM3}.
FT   TURN        990    992       {ECO:0000244|PDB:2OJ9}.
FT   HELIX       996    998       {ECO:0000244|PDB:1P4O}.
FT   STRAND      999   1007       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1009   1022       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1025   1034       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1037   1039       {ECO:0000244|PDB:3F5P}.
FT   HELIX      1041   1053       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1054   1056       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1065   1069       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1071   1074       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1076   1080       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1087   1100       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1109   1128       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1138   1140       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1141   1143       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1149   1151       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1155   1157       {ECO:0000244|PDB:3D94}.
FT   HELIX      1159   1164       {ECO:0000244|PDB:1P4O}.
FT   TURN       1165   1167       {ECO:0000244|PDB:3LVP}.
FT   HELIX      1168   1170       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1171   1174       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1176   1178       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1181   1186       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1191   1207       {ECO:0000244|PDB:1P4O}.
FT   TURN       1212   1215       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1218   1226       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1239   1248       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1253   1255       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1259   1266       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1267   1269       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1274   1277       {ECO:0000244|PDB:1P4O}.
FT   TURN       1279   1281       {ECO:0000244|PDB:3O23}.
FT   TURN       1283   1285       {ECO:0000244|PDB:3LVP}.
FT   STRAND     1286   1288       {ECO:0000244|PDB:1P4O}.
SQ   SEQUENCE   1367 AA;  154793 MW;  AE8A735F87F745C8 CRC64;
     MKSGSGGGSP TSLWGLLFLS AALSLWPTSG EICGPGIDIR NDYQQLKRLE NCTVIEGYLH
     ILLISKAEDY RSYRFPKLTV ITEYLLLFRV AGLESLGDLF PNLTVIRGWK LFYNYALVIF
     EMTNLKDIGL YNLRNITRGA IRIEKNADLC YLSTVDWSLI LDAVSNNYIV GNKPPKECGD
     LCPGTMEEKP MCEKTTINNE YNYRCWTTNR CQKMCPSTCG KRACTENNEC CHPECLGSCS
     APDNDTACVA CRHYYYAGVC VPACPPNTYR FEGWRCVDRD FCANILSAES SDSEGFVIHD
     GECMQECPSG FIRNGSQSMY CIPCEGPCPK VCEEEKKTKT IDSVTSAQML QGCTIFKGNL
     LINIRRGNNI ASELENFMGL IEVVTGYVKI RHSHALVSLS FLKNLRLILG EEQLEGNYSF
     YVLDNQNLQQ LWDWDHRNLT IKAGKMYFAF NPKLCVSEIY RMEEVTGTKG RQSKGDINTR
     NNGERASCES DVLHFTSTTT SKNRIIITWH RYRPPDYRDL ISFTVYYKEA PFKNVTEYDG
     QDACGSNSWN MVDVDLPPNK DVEPGILLHG LKPWTQYAVY VKAVTLTMVE NDHIRGAKSE
     ILYIRTNASV PSIPLDVLSA SNSSSQLIVK WNPPSLPNGN LSYYIVRWQR QPQDGYLYRH
     NYCSKDKIPI RKYADGTIDI EEVTENPKTE VCGGEKGPCC ACPKTEAEKQ AEKEEAEYRK
     VFENFLHNSI FVPRPERKRR DVMQVANTTM SSRSRNTTAA DTYNITDPEE LETEYPFFES
     RVDNKERTVI SNLRPFTLYR IDIHSCNHEA EKLGCSASNF VFARTMPAEG ADDIPGPVTW
     EPRPENSIFL KWPEPENPNG LILMYEIKYG SQVEDQRECV SRQEYRKYGG AKLNRLNPGN
     YTARIQATSL SGNGSWTDPV FFYVQAKTGY ENFIHLIIAL PVAVLLIVGG LVIMLYVFHR
     KRNNSRLGNG VLYASVNPEY FSAADVYVPD EWEVAREKIT MSRELGQGSF GMVYEGVAKG
     VVKDEPETRV AIKTVNEAAS MRERIEFLNE ASVMKEFNCH HVVRLLGVVS QGQPTLVIME
     LMTRGDLKSY LRSLRPEMEN NPVLAPPSLS KMIQMAGEIA DGMAYLNANK FVHRDLAARN
     CMVAEDFTVK IGDFGMTRDI YETDYYRKGG KGLLPVRWMS PESLKDGVFT TYSDVWSFGV
     VLWEIATLAE QPYQGLSNEQ VLRFVMEGGL LDKPDNCPDM LFELMRMCWQ YNPKMRPSFL
     EIISSIKEEM EPGFREVSFY YSEENKLPEP EELDLEPENM ESVPLDPSAS SSSLPLPDRH
     SGHKAENGPG PGVLVLRASF DERQPYAHMN GGRKNERALP LPQSSTC
//
ID   ERBB3_HUMAN             Reviewed;        1342 AA.
AC   P21860; A8K6L6; B4DIK7; B4DV32; E9PDT8; Q9BUD7;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   20-JAN-2016, entry version 185.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-3;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene-like protein c-ErbB-3;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER3;
DE   Flags: Precursor;
GN   Name=ERBB3; Synonyms=HER3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2687875; DOI=10.1073/pnas.86.23.9193;
RA   Kraus M.H., Issing W., Miki T., Popescu N.C., Aaronson S.A.;
RT   "Isolation and characterization of ERBB3, a third member of the
RT   ERBB/epidermal growth factor receptor family: evidence for
RT   overexpression in a subset of human mammary tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9193-9197(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2164210; DOI=10.1073/pnas.87.13.4905;
RA   Plowman G.D., Whitney G.S., Neubauer M.G., Green J.M., McDonald V.L.,
RA   Todaro G.J., Shoyab M.;
RT   "Molecular cloning and expression of an additional epidermal growth
RT   factor receptor-related gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4905-4909(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=7685162; DOI=10.1006/bbrc.1993.1542;
RA   Katoh M., Yazaki Y., Sugimura T., Terada M.;
RT   "c-erbB3 gene encodes secreted as well as transmembrane receptor
RT   tyrosine kinase.";
RL   Biochem. Biophys. Res. Commun. 192:1189-1197(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 4 AND 5).
RC   TISSUE=Hippocampus, Placenta, and Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH GRB7.
RX   PubMed=9516479; DOI=10.1074/jbc.273.13.7717;
RA   Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H.,
RA   Wallasch C., Daly R.J.;
RT   "Analysis of Grb7 recruitment by heregulin-activated erbB receptors
RT   reveals a novel target selectivity for erbB3.";
RL   J. Biol. Chem. 273:7717-7724(1998).
RN   [9]
RP   INTERACTION WITH PA2G4.
RX   PubMed=11325528; DOI=10.1016/S0303-7207(01)00387-2;
RA   Lessor T.J., Hamburger A.W.;
RT   "Regulation of the ErbB3 binding protein Ebp1 by protein kinase C.";
RL   Mol. Cell. Endocrinol. 175:185-191(2001).
RN   [10]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M.,
RA   Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism
RT   dependent on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [11]
RP   INTERACTION WITH CSPG5, AND FUNCTION.
RX   PubMed=15358134; DOI=10.1016/j.bbrc.2004.07.066;
RA   Kinugasa Y., Ishiguro H., Tokita Y., Oohira A., Ohmoto H.,
RA   Higashiyama S.;
RT   "Neuroglycan C, a novel member of the neuregulin family.";
RL   Biochem. Biophys. Res. Commun. 321:1045-1049(2004).
RN   [12]
RP   INTERACTION WITH PA2G4.
RX   PubMed=16832058; DOI=10.1073/pnas.0602923103;
RA   Liu Z., Ahn J.Y., Liu X., Ye K.;
RT   "Ebp1 isoforms distinctively regulate cell survival and
RT   differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10917-10922(2006).
RN   [13]
RP   INVOLVEMENT IN LCCS2.
RX   PubMed=17701904; DOI=10.1086/520770;
RA   Narkis G., Ofir R., Manor E., Landau D., Elbedour K., Birk O.S.;
RT   "Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a
RT   mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-
RT   kinase/Akt pathway.";
RL   Am. J. Hum. Genet. 81:589-595(2007).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-686 AND SER-982, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 20-640, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-250; ASN-353; ASN-408; ASN-414; ASN-437; ASN-469;
RP   ASN-522 AND ASN-566.
RX   PubMed=12154198; DOI=10.1126/science.1074611;
RA   Cho H.S., Leahy D.J.;
RT   "Structure of the extracellular region of HER3 reveals an interdomain
RT   tether.";
RL   Science 297:1330-1333(2002).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 698-1019 IN COMPLEX WITH
RP   AMP-PNP, AND SUBUNIT.
RX   PubMed=20007378; DOI=10.1073/pnas.0912101106;
RA   Jura N., Shan Y., Cao X., Shaw D.E., Kuriyan J.;
RT   "Structural analysis of the catalytically inactive kinase domain of
RT   the human EGF receptor 3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:21608-21613(2009).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 684-1020 IN COMPLEX WITH
RP   AMP-PNP, CATALYTIC ACTIVITY, MUTAGENESIS OF LYS-742 AND TYR-868,
RP   AUTOPHOSPHORYLATION, AND SUBUNIT.
RX   PubMed=20351256; DOI=10.1073/pnas.1002753107;
RA   Shi F., Telesco S.E., Liu Y., Radhakrishnan R., Lemmon M.A.;
RT   "ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze
RT   autophosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:7692-7697(2010).
RN   [19]
RP   STRUCTURE BY NMR OF 640-670, AND SUBUNIT.
RX   PubMed=21575594; DOI=10.1016/j.bbamem.2011.04.017;
RA   Mineev K.S., Khabibullina N.F., Lyukmanova E.N., Dolgikh D.A.,
RA   Kirpichnikov M.P., Arseniev A.S.;
RT   "Spatial structure and dimer-monomer equilibrium of the ErbB3
RT   transmembrane domain in DPC micelles.";
RL   Biochim. Biophys. Acta 1808:2081-2088(2011).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-20; LEU-30; MET-104; ILE-204;
RP   TRP-683; LEU-717; THR-744; ARG-998; CYS-1119; HIS-1127; ILE-1177 AND
RP   LYS-1254.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Binds and is activated by neuregulins and NTAK. May also
CC       be activated by CSPG5. {ECO:0000269|PubMed:15358134}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000269|PubMed:20351256}.
CC   -!- SUBUNIT: Monomer and homodimer. Heterodimer with each of the other
CC       ERBB receptors (Potential). Interacts with CSPG5, GRB7, and MUC1.
CC       Interacts with MYOC (By similarity). Interacts with isoform 2 of
CC       PA2G4. {ECO:0000250|UniProtKB:Q61526, ECO:0000269|PubMed:16832058,
CC       ECO:0000305}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-720706, EBI-720706;
CC       P42684:ABL2; NbExp=10; IntAct=EBI-720706, EBI-1102694;
CC       P46108:CRK; NbExp=2; IntAct=EBI-720706, EBI-886;
CC       P46109:CRKL; NbExp=3; IntAct=EBI-720706, EBI-910;
CC       P00533:EGFR; NbExp=12; IntAct=EBI-720706, EBI-297353;
CC       P04626:ERBB2; NbExp=25; IntAct=EBI-720706, EBI-641062;
CC       Q15303:ERBB4; NbExp=4; IntAct=EBI-720706, EBI-80371;
CC       P62993:GRB2; NbExp=3; IntAct=EBI-720706, EBI-401755;
CC       Q14451:GRB7; NbExp=7; IntAct=EBI-720706, EBI-970191;
CC       P08631:HCK; NbExp=2; IntAct=EBI-720706, EBI-346340;
CC       P08238:HSP90AB1; NbExp=3; IntAct=EBI-720706, EBI-352572;
CC       O43639:NCK2; NbExp=2; IntAct=EBI-720706, EBI-713635;
CC       Q02297-7:NRG1; NbExp=3; IntAct=EBI-720706, EBI-2460927;
CC       P42336:PIK3CA; NbExp=3; IntAct=EBI-720706, EBI-2116585;
CC       P27986:PIK3R1; NbExp=40; IntAct=EBI-720706, EBI-79464;
CC       O00459:PIK3R2; NbExp=16; IntAct=EBI-720706, EBI-346930;
CC       Q92569:PIK3R3; NbExp=22; IntAct=EBI-720706, EBI-79893;
CC       P19174:PLCG1; NbExp=4; IntAct=EBI-720706, EBI-79387;
CC       P20936:RASA1; NbExp=6; IntAct=EBI-720706, EBI-1026476;
CC       Q9UQQ2:SH2B3; NbExp=2; IntAct=EBI-720706, EBI-7879749;
CC       P29353:SHC1; NbExp=5; IntAct=EBI-720706, EBI-78835;
CC       Q92529:SHC3; NbExp=2; IntAct=EBI-720706, EBI-79084;
CC       P12931:SRC; NbExp=2; IntAct=EBI-720706, EBI-621482;
CC       P43405:SYK; NbExp=6; IntAct=EBI-720706, EBI-78302;
CC       Q63HR2:TNS2; NbExp=3; IntAct=EBI-720706, EBI-949753;
CC       Q68CZ2:TNS3; NbExp=2; IntAct=EBI-720706, EBI-1220488;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=long form;
CC         IsoId=P21860-1; Sequence=Displayed;
CC       Name=2; Synonyms=short form;
CC         IsoId=P21860-2; Sequence=VSP_002893, VSP_002894;
CC       Name=3;
CC         IsoId=P21860-3; Sequence=VSP_041663, VSP_041664;
CC       Name=4;
CC         IsoId=P21860-4; Sequence=VSP_041662;
CC       Name=5;
CC         IsoId=P21860-5; Sequence=VSP_041661;
CC   -!- TISSUE SPECIFICITY: Epithelial tissues and brain.
CC   -!- DEVELOPMENTAL STAGE: Overexpressed in a subset of human mammary
CC       tumors.
CC   -!- DOMAIN: The cytoplasmic part of the receptor may interact with the
CC       SH2 or SH3 domains of many signal-transducing proteins.
CC   -!- PTM: Ligand-binding increases phosphorylation on tyrosine residues
CC       and promotes its association with the p85 subunit of
CC       phosphatidylinositol 3-kinase (By similarity). Subject to
CC       autophosphorylation. {ECO:0000250}.
CC   -!- DISEASE: Lethal congenital contracture syndrome 2 (LCCS2)
CC       [MIM:607598]: A form of lethal congenital contracture syndrome, an
CC       autosomal recessive disorder characterized by degeneration of
CC       anterior horn neurons, extreme skeletal muscle atrophy, and
CC       congenital non-progressive joint contractures (arthrogryposis).
CC       The contractures can involve the upper or lower limbs and/or the
CC       vertebral column, leading to various degrees of flexion or
CC       extension limitations evident at birth. LCCS2 patients manifest
CC       craniofacial/ocular findings, lack of hydrops, multiple pterygia,
CC       and fractures, as well as a normal duration of pregnancy and a
CC       unique feature of a markedly distended urinary bladder (neurogenic
CC       bladder defect). The phenotype suggests a spinal cord neuropathic
CC       etiology. {ECO:0000269|PubMed:17701904}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ERBB3ID40479ch12q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M29366; AAA35790.1; -; mRNA.
DR   EMBL; M34309; AAA35979.1; -; mRNA.
DR   EMBL; S61953; AAB26935.1; -; mRNA.
DR   EMBL; BT007226; AAP35890.1; -; mRNA.
DR   EMBL; AK291681; BAF84370.1; -; mRNA.
DR   EMBL; AK295650; BAG58519.1; -; mRNA.
DR   EMBL; AK300909; BAG62544.1; -; mRNA.
DR   EMBL; AC034102; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC002706; AAH02706.1; -; mRNA.
DR   EMBL; BC082992; AAH82992.1; -; mRNA.
DR   CCDS; CCDS31833.1; -. [P21860-1]
DR   CCDS; CCDS44918.1; -. [P21860-2]
DR   PIR; A36223; A36223.
DR   PIR; JH0803; JH0803.
DR   RefSeq; NP_001005915.1; NM_001005915.1. [P21860-2]
DR   RefSeq; NP_001973.2; NM_001982.3. [P21860-1]
DR   UniGene; Hs.118681; -.
DR   UniGene; Hs.622058; -.
DR   PDB; 1M6B; X-ray; 2.60 A; A/B=20-640.
DR   PDB; 2L9U; NMR; -; A/B=639-670.
DR   PDB; 3KEX; X-ray; 2.80 A; A/B=698-1019.
DR   PDB; 3LMG; X-ray; 2.80 A; A/B=684-1020.
DR   PDB; 3P11; X-ray; 3.70 A; A=20-532.
DR   PDB; 4LEO; X-ray; 2.64 A; C=20-631.
DR   PDB; 4OTW; X-ray; 2.51 A; A=698-1020.
DR   PDB; 4P59; X-ray; 3.40 A; A=20-640.
DR   PDB; 4RIW; X-ray; 3.10 A; A/C=698-1020.
DR   PDB; 4RIX; X-ray; 3.10 A; A/C=698-1020.
DR   PDB; 4RIY; X-ray; 2.98 A; A/C=698-1020.
DR   PDB; 5CUS; X-ray; 3.20 A; A/B/C/D=20-641.
DR   PDBsum; 1M6B; -.
DR   PDBsum; 2L9U; -.
DR   PDBsum; 3KEX; -.
DR   PDBsum; 3LMG; -.
DR   PDBsum; 3P11; -.
DR   PDBsum; 4LEO; -.
DR   PDBsum; 4OTW; -.
DR   PDBsum; 4P59; -.
DR   PDBsum; 4RIW; -.
DR   PDBsum; 4RIX; -.
DR   PDBsum; 4RIY; -.
DR   PDBsum; 5CUS; -.
DR   ProteinModelPortal; P21860; -.
DR   SMR; P21860; 27-630, 637-670, 674-994.
DR   BioGrid; 108377; 74.
DR   DIP; DIP-36441N; -.
DR   IntAct; P21860; 93.
DR   MINT; MINT-158484; -.
DR   STRING; 9606.ENSP00000267101; -.
DR   BindingDB; P21860; -.
DR   ChEMBL; CHEMBL2363049; -.
DR   GuidetoPHARMACOLOGY; 1798; -.
DR   iPTMnet; P21860; -.
DR   PhosphoSite; P21860; -.
DR   BioMuta; ERBB3; -.
DR   DMDM; 119534; -.
DR   MaxQB; P21860; -.
DR   PaxDb; P21860; -.
DR   PRIDE; P21860; -.
DR   DNASU; 2065; -.
DR   Ensembl; ENST00000267101; ENSP00000267101; ENSG00000065361. [P21860-1]
DR   Ensembl; ENST00000411731; ENSP00000415753; ENSG00000065361. [P21860-2]
DR   Ensembl; ENST00000415288; ENSP00000408340; ENSG00000065361. [P21860-4]
DR   Ensembl; ENST00000551242; ENSP00000447510; ENSG00000065361. [P21860-3]
DR   GeneID; 2065; -.
DR   KEGG; hsa:2065; -.
DR   UCSC; uc001sjg.3; human. [P21860-2]
DR   UCSC; uc001sjh.3; human. [P21860-1]
DR   CTD; 2065; -.
DR   GeneCards; ERBB3; -.
DR   HGNC; HGNC:3431; ERBB3.
DR   HPA; CAB025331; -.
DR   HPA; HPA045396; -.
DR   MalaCards; ERBB3; -.
DR   MIM; 190151; gene.
DR   MIM; 607598; phenotype.
DR   neXtProt; NX_P21860; -.
DR   Orphanet; 137776; Lethal congenital contracture syndrome type 2.
DR   PharmGKB; PA27846; -.
DR   eggNOG; KOG1025; Eukaryota.
DR   eggNOG; ENOG410XNSR; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000230982; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; P21860; -.
DR   KO; K05084; -.
DR   OMA; CYHHSLN; -.
DR   OrthoDB; EOG7V49XM; -.
DR   PhylomeDB; P21860; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1236394; Signaling by ERBB4.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling.
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; P21860; -.
DR   ChiTaRS; ERBB3; human.
DR   EvolutionaryTrace; P21860; -.
DR   GeneWiki; ERBB3; -.
DR   GenomeRNAi; 2065; -.
DR   NextBio; 8391; -.
DR   PRO; PR:P21860; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; P21860; -.
DR   CleanEx; HS_ERBB3; -.
DR   ExpressionAtlas; P21860; baseline and differential.
DR   Genevisible; P21860; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005622; C:intracellular; IDA:GOC.
DR   GO; GO:0016328; C:lateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; NAS:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:BHF-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; ISS:BHF-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0021545; P:cranial nerve development; ISS:BHF-UCL.
DR   GO; GO:0003197; P:endocardial cushion development; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0051048; P:negative regulation of secretion; IDA:BHF-UCL.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IDA:BHF-UCL.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007422; P:peripheral nervous system development; ISS:BHF-UCL.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0070886; P:positive regulation of calcineurin-NFAT signaling cascade; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:BHF-UCL.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IMP:BHF-UCL.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0042127; P:regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0014037; P:Schwann cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042060; P:wound healing; NAS:BHF-UCL.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 5.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Secreted; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20   1342       Receptor tyrosine-protein kinase erbB-3.
FT                                /FTId=PRO_0000016672.
FT   TOPO_DOM     20    643       Extracellular. {ECO:0000255}.
FT   TRANSMEM    644    664       Helical. {ECO:0000255}.
FT   TOPO_DOM    665   1342       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      709    966       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     715    723       ATP.
FT   NP_BIND     788    790       ATP.
FT   NP_BIND     834    839       ATP.
FT   ACT_SITE    834    834       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     742    742       ATP.
FT   MOD_RES     686    686       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     982    982       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD    126    126       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    250    250       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    353    353       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    408    408       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    414    414       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    437    437       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    469    469       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    522    522       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    566    566       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12154198}.
FT   CARBOHYD    616    616       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     29     56       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    156    183       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    186    194       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    190    202       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    210    218       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    214    226       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    227    235       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    231    243       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    246    255       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    259    286       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    290    301       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    305    320       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    323    327       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    500    509       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    504    517       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    520    529       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    533    549       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    552    565       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    556    573       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    576    585       {ECO:0000269|PubMed:12154198}.
FT   DISULFID    589    610       {ECO:0000250}.
FT   DISULFID    613    621       {ECO:0000250}.
FT   DISULFID    617    629       {ECO:0000250}.
FT   VAR_SEQ       1    643       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041661.
FT   VAR_SEQ       1     59       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041662.
FT   VAR_SEQ     141    183       EILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGR
FT                                SC -> GQFPMVPSGLTPQPAQDWYLLDDDPRLLTLSASSK
FT                                VPVTLAAV (in isoform 2).
FT                                {ECO:0000303|PubMed:7685162}.
FT                                /FTId=VSP_002893.
FT   VAR_SEQ     184   1342       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:7685162}.
FT                                /FTId=VSP_002894.
FT   VAR_SEQ     331    331       C -> F (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_041663.
FT   VAR_SEQ     332   1342       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_041664.
FT   VARIANT      20     20       S -> Y (in dbSNP:rs34379766).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042101.
FT   VARIANT      30     30       P -> L (in dbSNP:rs56017157).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042102.
FT   VARIANT     104    104       V -> M (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042103.
FT   VARIANT     204    204       T -> I (in dbSNP:rs56107455).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042104.
FT   VARIANT     385    385       N -> S (in dbSNP:rs12320176).
FT                                /FTId=VAR_049710.
FT   VARIANT     683    683       R -> W (in dbSNP:rs56387488).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042105.
FT   VARIANT     717    717       S -> L (in dbSNP:rs35961836).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042106.
FT   VARIANT     744    744       I -> T (in dbSNP:rs55787439).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042107.
FT   VARIANT     998    998       K -> R (in dbSNP:rs56259600).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042108.
FT   VARIANT    1119   1119       S -> C (in dbSNP:rs773123).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042109.
FT   VARIANT    1127   1127       R -> H (in dbSNP:rs2271188).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042110.
FT   VARIANT    1177   1177       L -> I (in dbSNP:rs55699040).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042111.
FT   VARIANT    1254   1254       T -> K (in dbSNP:rs55709407).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042112.
FT   VARIANT    1271   1271       G -> S (in dbSNP:rs11171743).
FT                                /FTId=VAR_049711.
FT   MUTAGEN     742    742       K->M: Strongly reduced
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:20351256}.
FT   MUTAGEN     868    868       Y->E: Strongly reduced tyrosine
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:20351256}.
FT   CONFLICT    560    560       E -> G (in Ref. 2; AAA35979).
FT                                {ECO:0000305}.
FT   CONFLICT    684    684       G -> S (in Ref. 5; BAF84370).
FT                                {ECO:0000305}.
FT   CONFLICT   1064   1064       E -> G (in Ref. 2; AAA35979).
FT                                {ECO:0000305}.
FT   CONFLICT   1078   1078       C -> S (in Ref. 5; BAG62544).
FT                                {ECO:0000305}.
FT   CONFLICT   1163   1163       D -> G (in Ref. 5; BAF84370).
FT                                {ECO:0000305}.
FT   STRAND       28     30       {ECO:0000244|PDB:4LEO}.
FT   HELIX        43     53       {ECO:0000244|PDB:4LEO}.
FT   STRAND       58     61       {ECO:0000244|PDB:1M6B}.
FT   STRAND       63     67       {ECO:0000244|PDB:1M6B}.
FT   HELIX        75     79       {ECO:0000244|PDB:1M6B}.
FT   STRAND       82     85       {ECO:0000244|PDB:1M6B}.
FT   STRAND       87     91       {ECO:0000244|PDB:1M6B}.
FT   STRAND       95     98       {ECO:0000244|PDB:1M6B}.
FT   TURN        112    114       {ECO:0000244|PDB:1M6B}.
FT   STRAND      115    120       {ECO:0000244|PDB:1M6B}.
FT   STRAND      125    128       {ECO:0000244|PDB:4LEO}.
FT   STRAND      133    135       {ECO:0000244|PDB:1M6B}.
FT   STRAND      141    144       {ECO:0000244|PDB:5CUS}.
FT   STRAND      146    150       {ECO:0000244|PDB:1M6B}.
FT   TURN        158    160       {ECO:0000244|PDB:1M6B}.
FT   HELIX       163    166       {ECO:0000244|PDB:1M6B}.
FT   STRAND      174    178       {ECO:0000244|PDB:1M6B}.
FT   HELIX       188    190       {ECO:0000244|PDB:4LEO}.
FT   STRAND      194    198       {ECO:0000244|PDB:1M6B}.
FT   STRAND      214    216       {ECO:0000244|PDB:1M6B}.
FT   STRAND      218    222       {ECO:0000244|PDB:1M6B}.
FT   HELIX       223    225       {ECO:0000244|PDB:5CUS}.
FT   STRAND      231    233       {ECO:0000244|PDB:1M6B}.
FT   STRAND      235    239       {ECO:0000244|PDB:1M6B}.
FT   HELIX       240    242       {ECO:0000244|PDB:1M6B}.
FT   STRAND      243    251       {ECO:0000244|PDB:1M6B}.
FT   STRAND      254    258       {ECO:0000244|PDB:1M6B}.
FT   STRAND      262    265       {ECO:0000244|PDB:1M6B}.
FT   TURN        267    269       {ECO:0000244|PDB:1M6B}.
FT   STRAND      270    274       {ECO:0000244|PDB:1M6B}.
FT   STRAND      280    282       {ECO:0000244|PDB:1M6B}.
FT   STRAND      285    289       {ECO:0000244|PDB:1M6B}.
FT   STRAND      295    297       {ECO:0000244|PDB:1M6B}.
FT   STRAND      300    304       {ECO:0000244|PDB:1M6B}.
FT   STRAND      309    314       {ECO:0000244|PDB:1M6B}.
FT   STRAND      317    322       {ECO:0000244|PDB:1M6B}.
FT   STRAND      324    326       {ECO:0000244|PDB:4LEO}.
FT   STRAND      330    332       {ECO:0000244|PDB:1M6B}.
FT   STRAND      338    342       {ECO:0000244|PDB:5CUS}.
FT   TURN        345    347       {ECO:0000244|PDB:1M6B}.
FT   HELIX       348    351       {ECO:0000244|PDB:1M6B}.
FT   STRAND      356    363       {ECO:0000244|PDB:1M6B}.
FT   HELIX       365    369       {ECO:0000244|PDB:1M6B}.
FT   TURN        372    375       {ECO:0000244|PDB:1M6B}.
FT   HELIX       381    389       {ECO:0000244|PDB:1M6B}.
FT   STRAND      392    395       {ECO:0000244|PDB:1M6B}.
FT   STRAND      397    400       {ECO:0000244|PDB:1M6B}.
FT   HELIX       410    412       {ECO:0000244|PDB:1M6B}.
FT   STRAND      425    433       {ECO:0000244|PDB:1M6B}.
FT   STRAND      451    457       {ECO:0000244|PDB:1M6B}.
FT   HELIX       465    467       {ECO:0000244|PDB:4LEO}.
FT   HELIX       470    473       {ECO:0000244|PDB:1M6B}.
FT   STRAND      482    488       {ECO:0000244|PDB:1M6B}.
FT   HELIX       490    493       {ECO:0000244|PDB:1M6B}.
FT   TURN        494    497       {ECO:0000244|PDB:1M6B}.
FT   STRAND      509    513       {ECO:0000244|PDB:1M6B}.
FT   HELIX       514    516       {ECO:0000244|PDB:1M6B}.
FT   STRAND      517    527       {ECO:0000244|PDB:1M6B}.
FT   STRAND      529    531       {ECO:0000244|PDB:1M6B}.
FT   STRAND      534    536       {ECO:0000244|PDB:1M6B}.
FT   STRAND      538    540       {ECO:0000244|PDB:1M6B}.
FT   STRAND      542    545       {ECO:0000244|PDB:1M6B}.
FT   STRAND      548    551       {ECO:0000244|PDB:1M6B}.
FT   STRAND      560    562       {ECO:0000244|PDB:5CUS}.
FT   STRAND      564    570       {ECO:0000244|PDB:1M6B}.
FT   STRAND      573    581       {ECO:0000244|PDB:1M6B}.
FT   STRAND      584    588       {ECO:0000244|PDB:1M6B}.
FT   STRAND      591    594       {ECO:0000244|PDB:4LEO}.
FT   STRAND      600    604       {ECO:0000244|PDB:1M6B}.
FT   STRAND      608    612       {ECO:0000244|PDB:1M6B}.
FT   STRAND      622    625       {ECO:0000244|PDB:1M6B}.
FT   HELIX       626    628       {ECO:0000244|PDB:4LEO}.
FT   HELIX       641    670       {ECO:0000244|PDB:2L9U}.
FT   HELIX       706    708       {ECO:0000244|PDB:4OTW}.
FT   STRAND      709    716       {ECO:0000244|PDB:4OTW}.
FT   STRAND      722    728       {ECO:0000244|PDB:4OTW}.
FT   STRAND      731    733       {ECO:0000244|PDB:3LMG}.
FT   STRAND      737    744       {ECO:0000244|PDB:4OTW}.
FT   TURN        747    749       {ECO:0000244|PDB:4OTW}.
FT   STRAND      753    755       {ECO:0000244|PDB:4RIY}.
FT   HELIX       758    764       {ECO:0000244|PDB:4OTW}.
FT   STRAND      774    778       {ECO:0000244|PDB:4OTW}.
FT   STRAND      780    788       {ECO:0000244|PDB:4OTW}.
FT   HELIX       795    802       {ECO:0000244|PDB:4OTW}.
FT   HELIX       803    805       {ECO:0000244|PDB:4OTW}.
FT   HELIX       808    827       {ECO:0000244|PDB:4OTW}.
FT   HELIX       837    839       {ECO:0000244|PDB:4OTW}.
FT   STRAND      840    846       {ECO:0000244|PDB:4OTW}.
FT   STRAND      848    850       {ECO:0000244|PDB:4OTW}.
FT   HELIX       855    858       {ECO:0000244|PDB:4OTW}.
FT   HELIX       865    868       {ECO:0000244|PDB:4RIY}.
FT   TURN        870    872       {ECO:0000244|PDB:4RIY}.
FT   HELIX       875    877       {ECO:0000244|PDB:4OTW}.
FT   HELIX       880    885       {ECO:0000244|PDB:4OTW}.
FT   HELIX       890    905       {ECO:0000244|PDB:4OTW}.
FT   TURN        911    914       {ECO:0000244|PDB:4OTW}.
FT   HELIX       917    919       {ECO:0000244|PDB:4OTW}.
FT   HELIX       920    925       {ECO:0000244|PDB:4OTW}.
FT   HELIX       938    947       {ECO:0000244|PDB:4OTW}.
FT   TURN        952    954       {ECO:0000244|PDB:4OTW}.
FT   HELIX       958    968       {ECO:0000244|PDB:4OTW}.
FT   HELIX       972    975       {ECO:0000244|PDB:4OTW}.
FT   STRAND      980    983       {ECO:0000244|PDB:3KEX}.
SQ   SEQUENCE   1342 AA;  148098 MW;  7201E7F66CA374BD CRC64;
     MRANDALQVL GLLFSLARGS EVGNSQAVCP GTLNGLSVTG DAENQYQTLY KLYERCEVVM
     GNLEIVLTGH NADLSFLQWI REVTGYVLVA MNEFSTLPLP NLRVVRGTQV YDGKFAIFVM
     LNYNTNSSHA LRQLRLTQLT EILSGGVYIE KNDKLCHMDT IDWRDIVRDR DAEIVVKDNG
     RSCPPCHEVC KGRCWGPGSE DCQTLTKTIC APQCNGHCFG PNPNQCCHDE CAGGCSGPQD
     TDCFACRHFN DSGACVPRCP QPLVYNKLTF QLEPNPHTKY QYGGVCVASC PHNFVVDQTS
     CVRACPPDKM EVDKNGLKMC EPCGGLCPKA CEGTGSGSRF QTVDSSNIDG FVNCTKILGN
     LDFLITGLNG DPWHKIPALD PEKLNVFRTV REITGYLNIQ SWPPHMHNFS VFSNLTTIGG
     RSLYNRGFSL LIMKNLNVTS LGFRSLKEIS AGRIYISANR QLCYHHSLNW TKVLRGPTEE
     RLDIKHNRPR RDCVAEGKVC DPLCSSGGCW GPGPGQCLSC RNYSRGGVCV THCNFLNGEP
     REFAHEAECF SCHPECQPME GTATCNGSGS DTCAQCAHFR DGPHCVSSCP HGVLGAKGPI
     YKYPDVQNEC RPCHENCTQG CKGPELQDCL GQTLVLIGKT HLTMALTVIA GLVVIFMMLG
     GTFLYWRGRR IQNKRAMRRY LERGESIEPL DPSEKANKVL ARIFKETELR KLKVLGSGVF
     GTVHKGVWIP EGESIKIPVC IKVIEDKSGR QSFQAVTDHM LAIGSLDHAH IVRLLGLCPG
     SSLQLVTQYL PLGSLLDHVR QHRGALGPQL LLNWGVQIAK GMYYLEEHGM VHRNLAARNV
     LLKSPSQVQV ADFGVADLLP PDDKQLLYSE AKTPIKWMAL ESIHFGKYTH QSDVWSYGVT
     VWELMTFGAE PYAGLRLAEV PDLLEKGERL AQPQICTIDV YMVMVKCWMI DENIRPTFKE
     LANEFTRMAR DPPRYLVIKR ESGPGIAPGP EPHGLTNKKL EEVELEPELD LDLDLEAEED
     NLATTTLGSA LSLPVGTLNR PRGSQSLLSP SSGYMPMNQG NLGESCQESA VSGSSERCPR
     PVSLHPMPRG CLASESSEGH VTGSEAELQE KVSMCRSRSR SRSPRPRGDS AYHSQRHSLL
     TPVTPLSPPG LEEEDVNGYV MPDTHLKGTP SSREGTLSSV GLSSVLGTEE EDEDEEYEYM
     NRRRRHSPPH PPRPSSLEEL GYEYMDVGSD LSASLGSTQS CPLHPVPIMP TAGTTPDEDY
     EYMNRQRDGG GPGGDYAAMG ACPASEQGYE EMRAFQGPGH QAPHVHYARL KTLRSLEATD
     SAFDNPDYWH SRLFPKANAQ RT
//
ID   DAG1_HUMAN              Reviewed;         895 AA.
AC   Q14118; A8K6M7; Q969J9;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   17-FEB-2016, entry version 156.
DE   RecName: Full=Dystroglycan;
DE   AltName: Full=Dystrophin-associated glycoprotein 1;
DE   Contains:
DE     RecName: Full=Alpha-dystroglycan;
DE              Short=Alpha-DG;
DE   Contains:
DE     RecName: Full=Beta-dystroglycan;
DE              Short=Beta-DG;
DE   Flags: Precursor;
GN   Name=DAG1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT TRP-14.
RC   TISSUE=Skeletal muscle;
RX   PubMed=8268918; DOI=10.1093/hmg/2.10.1651;
RA   Ibraghimov-Beskrovnaya O., Milatovich A., Ozcelik T., Yang B.,
RA   Koepnick K., Francke U., Campbell K.P.;
RT   "Human dystroglycan: skeletal muscle cDNA, genomic structure, origin
RT   of tissue specific isoforms and chromosomal localization.";
RL   Hum. Mol. Genet. 2:1651-1657(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT TRP-14.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT TRP-14.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT TRP-14.
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH DMD.
RX   PubMed=7592992; DOI=10.1074/jbc.270.45.27305;
RA   Jung D., Yang B., Meyer J., Chamberlain J.S., Campbell K.P.;
RT   "Identification and characterization of the dystrophin anchoring site
RT   on beta-dystroglycan.";
RL   J. Biol. Chem. 270:27305-27310(1995).
RN   [7]
RP   FUNCTION (MICROBIAL INFECTION) AS RECEPTOR FOR MYCOBACTERIUM LEPRAE,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH LAMA2.
RX   PubMed=9851927; DOI=10.1126/science.282.5396.2076;
RA   Rambukkana A., Yamada H., Zanazzi G., Mathus T., Salzer J.L.,
RA   Yurchenco P.D., Campbell K.P., Fischetti V.A.;
RT   "Role of alpha-dystroglycan as a Schwann cell receptor for
RT   Mycobacterium leprae.";
RL   Science 282:2076-2079(1998).
RN   [8]
RP   INTERACTION WITH UTRN.
RX   PubMed=10767429; DOI=10.1016/S0014-5793(00)01400-9;
RA   Tommasi di Vignano A., Di Zenzo G., Sudol M., Cesareni G., Dente L.;
RT   "Contribution of the different modules in the utrophin carboxy-
RT   terminal region to the formation and regulation of the DAP complex.";
RL   FEBS Lett. 471:229-234(2000).
RN   [9]
RP   INTERACTION WITH CAV3.
RX   PubMed=10988290; DOI=10.1074/jbc.M005321200;
RA   Sotgia F., Lee J.K., Das K., Bedford M., Petrucci T.C., Macioce P.,
RA   Sargiacomo M., Bricarelli F.D., Minetti C., Sudol M., Lisanti M.P.;
RT   "Caveolin-3 directly interacts with the C-terminal tail of beta
RT   -dystroglycan. Identification of a central WW-like domain within
RT   caveolin family members.";
RL   J. Biol. Chem. 275:38048-38058(2000).
RN   [10]
RP   PHOSPHORYLATION, AND INTERACTION WITH UTRN.
RX   PubMed=10769203;
RA   James M., Nuttall A., Ilsley J.L., Ottersbach K., Tinsley J.M.,
RA   Sudol M., Winder S.J.;
RT   "Adhesion-dependent tyrosine phosphorylation of (beta)-dystroglycan
RT   regulates its interaction with utrophin.";
RL   J. Cell Sci. 113:1717-1726(2000).
RN   [11]
RP   PHOSPHORYLATION, INTERACTION WITH FYN; CSK; NCK AND SHC, AND POSSIBLE
RP   FUNCTION.
RX   PubMed=11724572; DOI=10.1021/bi011247r;
RA   Sotgia F., Lee H., Bedford M.T., Petrucci T., Sudol M., Lisanti M.P.;
RT   "Tyrosine phosphorylation of beta-dystroglycan at its WW domain
RT   binding motif, PPxY, recruits SH2 domain containing proteins.";
RL   Biochemistry 40:14585-14592(2001).
RN   [12]
RP   PHOSPHORYLATION AT TYR-892, AND INTERACTION WITH DMD.
RX   PubMed=11495720; DOI=10.1016/S0898-6568(01)00188-7;
RA   Ilsley J.L., Sudol M., Winder S.J.;
RT   "The interaction of dystrophin with beta-dystroglycan is regulated by
RT   tyrosine phosphorylation.";
RL   Cell. Signal. 13:625-632(2001).
RN   [13]
RP   GLYCOSYLATION, LIGAND-BINDING, AND ASSOCIATION WITH CONGENITAL
RP   MUSCULAR DYSTROPHIES.
RX   PubMed=12140558; DOI=10.1038/nature00837;
RA   Michele D.E., Barresi R., Kanagawa M., Saito F., Cohn R.D., Satz J.S.,
RA   Dollar J., Nishino I., Kelley R.I., Somer H., Straub V., Mathews K.D.,
RA   Moore S.A., Campbell K.P.;
RT   "Post-translational disruption of dystroglycan-ligand interactions in
RT   congenital muscular dystrophies.";
RL   Nature 418:417-422(2002).
RN   [14]
RP   PHOSPHORYLATION AT TYR-892, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   TYR-892.
RX   PubMed=12795607; DOI=10.1021/bi0271289;
RA   Sotgia F., Bonuccelli G., Bedford M., Brancaccio A., Mayer U.,
RA   Wilson M.T., Campos-Gonzalez R., Brooks J.W., Sudol M., Lisanti M.P.;
RT   "Localization of phospho-beta-dystroglycan (pY892) to an intracellular
RT   vesicular compartment in cultured cells and skeletal muscle fibers in
RT   vivo.";
RL   Biochemistry 42:7110-7123(2003).
RN   [15]
RP   INTERACTION WITH AGR2 AND AGR3.
RX   PubMed=12592373; DOI=10.1038/sj.bjc.6600740;
RA   Fletcher G.C., Patel S., Tyson K., Adam P.J., Schenker M.,
RA   Loader J.A., Daviet L., Legrain P., Parekh R., Harris A.L.,
RA   Terrett J.A.;
RT   "hAG-2 and hAG-3, human homologues of genes involved in
RT   differentiation, are associated with oestrogen receptor-positive
RT   breast tumours and interact with metastasis gene C4.4a and
RT   dystroglycan.";
RL   Br. J. Cancer 88:579-585(2003).
RN   [16]
RP   PROTEOLYTIC PROCESSING OF THE BETA SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=15175026; DOI=10.1111/j.0022-202X.2004.22605.x;
RA   Herzog C., Has C., Franzke C.W., Echtermeyer F.G.,
RA   Schlotzer-Schrehardt U., Kroger S., Gustafsson E., Fassler R.,
RA   Bruckner-Tuderman L.;
RT   "Dystroglycan in skin and cutaneous cells: beta-subunit is shed from
RT   the cell surface.";
RL   J. Invest. Dermatol. 122:1372-1380(2004).
RN   [17]
RP   GLYCOSYLATION, FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH
RP   LYMPHOCYCTIC CHORIOMENINGITIS VIRUS GLYCOPROTEIN.
RX   PubMed=16254364; DOI=10.1128/JVI.79.22.14297-14308.2005;
RA   Imperiali M., Thoma C., Pavoni E., Brancaccio A., Callewaert N.,
RA   Oxenius A.;
RT   "O Mannosylation of alpha-dystroglycan is essential for lymphocytic
RT   choriomeningitis virus receptor function.";
RL   J. Virol. 79:14297-14308(2005).
RN   [18]
RP   DISULFIDE BOND.
RX   PubMed=17212656; DOI=10.1111/j.1365-2443.2006.01033.x;
RA   Watanabe N., Sasaoka T., Noguchi S., Nishino I., Tanaka T.;
RT   "Cys669-Cys713 disulfide bridge formation is a key to dystroglycan
RT   cleavage and subunit association.";
RL   Genes Cells 12:75-88(2007).
RN   [19]
RP   GLYCOSYLATION, AND FUNCTION (MICROBIAL INFECTION) AS RECEPTOR FOR OLD
RP   WORLD AND CLADE C NEW WORLD ARENAVIRUSES.
RX   PubMed=17360738; DOI=10.1128/JVI.02574-06;
RA   Rojek J.M., Spiropoulou C.F., Campbell K.P., Kunz S.;
RT   "Old World and clade C New World arenaviruses mimic the molecular
RT   mechanism of receptor recognition used by alpha-dystroglycan's host-
RT   derived ligands.";
RL   J. Virol. 81:5685-5695(2007).
RN   [20]
RP   PROTEOLYTIC PROCESSING, CLEAVAGE AT GLY-653, GLYCOSYLATION,
RP   LIGAND-BINDING, AND MUTAGENESIS OF SER-654.
RX   PubMed=17905726; DOI=10.1096/fj.07-8354com;
RA   Akhavan A., Crivelli S.N., Singh M., Lingappa V.R., Muschler J.L.;
RT   "SEA domain proteolysis determines the functional composition of
RT   dystroglycan.";
RL   FASEB J. 22:612-621(2008).
RN   [21]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF
RP   SER-654; THR-663; 777-LYS--LYS-780; 793-LYS-LYS-794; LYS-823;
RP   828-PRO-PRO-829 AND TYR-831.
RX   PubMed=18764929; DOI=10.1111/j.1600-0854.2008.00822.x;
RA   Oppizzi M.L., Akhavan A., Singh M., Fata J.E., Muschler J.L.;
RT   "Nuclear translocation of beta-dystroglycan reveals a distinctive
RT   trafficking pattern of autoproteolyzed mucins.";
RL   Traffic 9:2063-2072(2008).
RN   [22]
RP   PROTEOLYTIC PROCESSING OF BETA SUBUNIT, CLEAVAGE AT HIS-715, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=19946898; DOI=10.1002/iub.273;
RA   Bozzi M., Inzitari R., Sbardell D., Monaco S., Pavoni E., Gioia M.,
RA   Marini S., Morlacchi S., Sciandra F., Castagnola M., Giardina B.,
RA   Brancaccio A., Coletta M.;
RT   "Enzymatic processing of beta-dystroglycan recombinant ectodomain by
RT   MMP-9: identification of the main cleavage site.";
RL   IUBMB Life 61:1143-1152(2009).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS], AND STRUCTURE OF CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [24]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH LASSA VIRUS
RP   GLYCOPROTEIN.
RX   PubMed=19324387; DOI=10.1016/j.virol.2009.02.042;
RA   Kunz S.;
RT   "Receptor binding and cell entry of Old World arenaviruses reveal
RT   novel aspects of virus-host interaction.";
RL   Virology 387:245-249(2009).
RN   [25]
RP   STRUCTURE OF CARBOHYDRATES, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   GLYCOSYLATION AT THR-367; THR-369; THR-372 AND THR-455.
RX   PubMed=20507882; DOI=10.1093/glycob/cwq082;
RA   Nilsson J., Nilsson J., Larson G., Grahn A.;
RT   "Characterization of site-specific O-glycan structures within the
RT   mucin-like domain of {alpha}-dystroglycan from human skeletal
RT   muscle.";
RL   Glycobiology 20:1160-1169(2010).
RN   [26]
RP   PHOSPHORYLATION AT TYR-892, NUCLEAR LOCALIZATION SIGNAL, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF 777-LYS--LYS-782 AND TYR-892.
RX   PubMed=20512930; DOI=10.1002/jcb.22581;
RA   Lara-Chacon B., de Leon M.B., Leocadio D., Gomez P., Fuentes-Mera L.,
RA   Martinez-Vieyra I., Ortega A., Jans D.A., Cisneros B.;
RT   "Characterization of an Importin alpha/beta-recognized nuclear
RT   localization signal in beta-dystroglycan.";
RL   J. Cell. Biochem. 110:706-717(2010).
RN   [27]
RP   GLYCOSYLATION AT THR-379; THR-381 AND THR-388, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=20044576; DOI=10.1126/science.1180512;
RA   Yoshida-Moriguchi T., Yu L., Stalnaker S.H., Davis S., Kunz S.,
RA   Madson M., Oldstone M.B., Schachter H., Wells L., Campbell K.P.;
RT   "O-mannosyl phosphorylation of alpha-dystroglycan is required for
RT   laminin binding.";
RL   Science 327:88-92(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   GLYCOSYLATION AT THR-317 AND THR-319, AND MUTAGENESIS OF
RP   317-THR--THR-319 AND 328-THR-THR-329.
RX   PubMed=21987822; DOI=10.1073/pnas.1114836108;
RA   Hara Y., Kanagawa M., Kunz S., Yoshida-Moriguchi T., Satz J.S.,
RA   Kobayashi Y.M., Zhu Z., Burden S.J., Oldstone M.B., Campbell K.P.;
RT   "Like-acetylglucosaminyltransferase (LARGE)-dependent modification of
RT   dystroglycan at Thr-317/319 is required for laminin binding and
RT   arenavirus infection.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:17426-17431(2011).
RN   [30]
RP   GLYCOSYLATION AT THR-63, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23234360; DOI=10.1021/pr300963h;
RA   Halim A., Ruetschi U., Larson G., Nilsson J.;
RT   "LC-MS/MS characterization of O-glycosylation sites and glycan
RT   structures of human cerebrospinal fluid glycoproteins.";
RL   J. Proteome Res. 12:573-584(2013).
RN   [31]
RP   GLYCOSYLATION AT THR-317 AND THR-319, AND MUTAGENESIS OF
RP   317-THR--THR-319.
RX   PubMed=24256719; DOI=10.1038/srep03288;
RA   Yagi H., Nakagawa N., Saito T., Kiyonari H., Abe T., Toda T., Wu S.W.,
RA   Khoo K.H., Oka S., Kato K.;
RT   "AGO61-dependent GlcNAc modification primes the formation of
RT   functional glycans on alpha-dystroglycan.";
RL   Sci. Rep. 3:3288-3288(2013).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-790, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 881-895.
RX   PubMed=10932245; DOI=10.1038/77923;
RA   Huang X., Poy F., Zhang R., Joachimiak A., Sudol M., Eck M.J.;
RT   "Structure of a WW domain containing fragment of dystrophin in complex
RT   with beta-dystroglycan.";
RL   Nat. Struct. Biol. 7:634-638(2000).
RN   [34]
RP   VARIANT MDDGC9 MET-192, AND CHARACTERIZATION OF VARIANT MDDGC9
RP   MET-192.
RX   PubMed=21388311; DOI=10.1056/NEJMoa1006939;
RA   Hara Y., Balci-Hayta B., Yoshida-Moriguchi T., Kanagawa M.,
RA   Beltran-Valero de Bernabe D., Gundesli H., Willer T., Satz J.S.,
RA   Crawford R.W., Burden S.J., Kunz S., Oldstone M.B., Accardi A.,
RA   Talim B., Muntoni F., Topaloglu H., Dincer P., Campbell K.P.;
RT   "A dystroglycan mutation associated with limb-girdle muscular
RT   dystrophy.";
RL   N. Engl. J. Med. 364:939-946(2011).
CC   -!- FUNCTION: The dystroglycan complex is involved in a number of
CC       processes including laminin and basement membrane assembly,
CC       sarcolemmal stability, cell survival, peripheral nerve
CC       myelination, nodal structure, cell migration, and epithelial
CC       polarization.
CC   -!- FUNCTION: Alpha-dystroglycan is an extracellular peripheral
CC       glycoprotein that acts as a receptor for both extracellular matrix
CC       proteins containing laminin-G domains. Receptor for laminin-2
CC       (LAMA2) and agrin in peripheral nerve Schwann cells.
CC   -!- FUNCTION: Beta-dystroglycan is a transmembrane protein that plays
CC       important roles in connecting the extracellular matrix to the
CC       cytoskeleton. Acts as a cell adhesion receptor in both muscle and
CC       non-muscle tissues. Receptor for both DMD and UTRN and, through
CC       these interactions, scaffolds axin to the cytoskeleton. Also
CC       functions in cell adhesion-mediated signaling and implicated in
CC       cell polarity.
CC   -!- FUNCTION: (Microbial infection) Alpha-dystroglycan acts as a
CC       receptor for lassa virus and lymphocytic choriomeningitis virus
CC       glycoprotein and class C new-world arenaviruses (PubMed:16254364,
CC       PubMed:19324387, PubMed:17360738). Alpha-dystroglycan acts as a
CC       Schwann cell receptor for Mycobacterium leprae, the causative
CC       organism of leprosy, but only in the presence of the G-domain of
CC       LAMA2 (PubMed:9851927). {ECO:0000269|PubMed:16254364,
CC       ECO:0000269|PubMed:17360738, ECO:0000269|PubMed:19324387,
CC       ECO:0000269|PubMed:9851927}.
CC   -!- SUBUNIT: Monomer. Heterodimer of alpha- and beta-dystroglycan
CC       subunits which are the central components of the dystrophin-
CC       glycoprotein complex. This complex then can form a dystrophin-
CC       associated glycoprotein complex (DGC) which is composed of three
CC       subcomplexes: a cytoplasmic complex comprised of DMD (or UTRN),
CC       DTNA and a number of syntrophins, such as SNTB1, SNTB2, SNTG1 and
CC       SNTG2, the transmembrane dystroglycan complex, and the
CC       sarcoglycan-sarcospan complex. Interacts (via the N-terminal of
CC       alphaDAG1) with LARGE; the interaction enhances laminin binding
CC       (By similarity). Interacts with SGCD. Interacts with AGR2 and
CC       AGR3. Interacts (betaDAG1) with DMD; the interaction is inhibited
CC       by phosphorylaion on the PPXY motif. Interacts (betaDAG1, via its
CC       PPXY motif) with UTRN (via its WWW and ZZ domains); the
CC       interaction is inhibited by phosphorylation on the PPXY motif.
CC       Interacts (betaDAG1, via its phosphorylated PPXY motif) with the
CC       SH2 domain-containing proteins, FYN, CSK, NCK and SHC. Interacts
CC       (betaDAG1) with CAV3 (via a central WW-like domain); the
CC       interaction disrupts the binding of DMD. BetaDAG1 directly
CC       interacts with ANK3, but not with ANK2; this interaction does not
CC       interfere with DMD-binding and is required for retention at
CC       costameres (By similarity). Identified in a dystroglycan complex
CC       that contains at least PRX, DRP2, UTRN, DMD and DAG1 (By
CC       similarity). (Microbial infection) Interacts with lassa virus and
CC       lymphocytic choriomeningitis virus glycoprotein (PubMed:16254364,
CC       PubMed:19324387). (Microbial infection) Interacts with surface
CC       molecules of mycobacterium leprae (PubMed:9851927).
CC       {ECO:0000250|UniProtKB:Q28685, ECO:0000250|UniProtKB:Q62165,
CC       ECO:0000269|PubMed:16254364, ECO:0000269|PubMed:19324387,
CC       ECO:0000269|PubMed:9851927}.
CC   -!- INTERACTION:
CC       Q3T1J5:Ank3 (xeno); NbExp=2; IntAct=EBI-1755945, EBI-2133962;
CC       P16333:NCK1; NbExp=2; IntAct=EBI-1755945, EBI-389883;
CC   -!- SUBCELLULAR LOCATION: Alpha-dystroglycan: Secreted, extracellular
CC       space.
CC   -!- SUBCELLULAR LOCATION: Beta-dystroglycan: Cell membrane; Single-
CC       pass type I membrane protein. Cytoplasm, cytoskeleton. Nucleus,
CC       nucleoplasm. Cell membrane, sarcolemma {ECO:0000250}. Cell
CC       junction, synapse, postsynaptic cell membrane {ECO:0000250}.
CC       Note=The monomeric form translocates to the nucleus via the action
CC       of importins and depends on RAN. Nuclear transport is inhibited by
CC       Tyr-892 phosphorylation. In skeletal muscle, this phosphorylated
CC       form locates to a vesicular internal membrane compartment. In
CC       muscle cells, sarcolemma localization requires the presence of
CC       ANK2, while localization to costameres requires the presence of
CC       ANK3. Localizes to neuromuscular junctions (NMJs) in the presence
CC       of ANK2 (By similarity). In peripheral nerves, localizes to the
CC       Schwann cell membrane. Colocalizes with ERM proteins in Schwann-
CC       cell microvilli. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in a variety of fetal and adult
CC       tissues. In epidermal tissue, located to the basement membrane.
CC       Also expressed in keratinocytes and fibroblasts.
CC       {ECO:0000269|PubMed:15175026, ECO:0000269|PubMed:8268918}.
CC   -!- PTM: O- and N-glycosylated. Alpha-dystroglycan is heavily O-
CC       glycosylated comprising of up to two thirds of its mass and the
CC       carbohydrate composition differs depending on tissue type. Mucin-
CC       type O-glycosylation is important for ligand binding activity. O-
CC       mannosylation of alpha-DAG1 is found in high abundance in both
CC       brain and muscle where the most abundant glycan is Sia-alpha-2-3-
CC       Gal-beta-1-4-Glc-NAc-beta-1-2-Man. In muscle, glycosylation on
CC       Thr-317, Thr-319 and Thr-379 by a phosphorylated O-mannosyl glycan
CC       with the structure 2-(N-acetylamido)-2-deoxygalactosyl-beta-1,3-2-
CC       (N-acetylamido)-2-deoxyglucosyl-beta-1,4-6-phosphomannose is
CC       mediated by like-acetylglucosaminyltransferase (LARGE) protein and
CC       is required for laminin binding (PubMed:20044576, PubMed:21987822,
CC       PubMed:24256719). O-mannosylation is also required for binding
CC       lymphocytic choriomeningitis virus, Old World Lassa fever virus,
CC       and clade C New World arenaviruses. The O-glycosyl hexose on Thr-
CC       367, Thr-369, Thr-372, Thr-381 and Thr-388 is probably mannose. O-
CC       glycosylated in the N-terminal region with a core 1 or possibly
CC       core 8 glycan. The beta subunit is N-glycosylated.
CC       {ECO:0000269|PubMed:12140558, ECO:0000269|PubMed:16254364,
CC       ECO:0000269|PubMed:17360738, ECO:0000269|PubMed:17905726,
CC       ECO:0000269|PubMed:19838169, ECO:0000269|PubMed:20044576,
CC       ECO:0000269|PubMed:20507882, ECO:0000269|PubMed:21987822,
CC       ECO:0000269|PubMed:23234360, ECO:0000269|PubMed:24256719}.
CC   -!- PTM: Autolytic cleavage produces the alpha and beta subunits. In
CC       cutaneous cells, as well as in certain pathological conditions,
CC       shedding of beta-dystroglcan can occur releasing a peptide of
CC       about 30 kDa. {ECO:0000269|PubMed:15175026,
CC       ECO:0000269|PubMed:17905726, ECO:0000269|PubMed:18764929,
CC       ECO:0000269|PubMed:19946898}.
CC   -!- PTM: SRC-mediated phosphorylation of the PPXY motif of the beta
CC       subunit recruits SH2 domain-containing proteins, but inhibits
CC       binding to WWW domain-containing proteins, DMD and UTRN. This
CC       phosphorylation also inhibits nuclear entry.
CC   -!- DISEASE: Muscular dystrophy-dystroglycanopathy limb-girdle C9
CC       (MDDGC9) [MIM:613818]: An autosomal recessive muscular dystrophy
CC       showing onset in early childhood, and associated with mental
CC       retardation without structural brain anomalies.
CC       {ECO:0000269|PubMed:21388311}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. MDDGC7 is
CC       caused by DAG1 mutations that interfere with normal post-
CC       translational processing, resulting in defective DAG1
CC       glycosylation and impaired interactions with extracellular-matrix
CC       components. Other muscular dystrophy-dystroglycanopathies are
CC       caused by defects in enzymes involved in protein O-glycosylation.
CC   -!- SIMILARITY: Contains 1 peptidase S72 domain. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Dystroglycan entry;
CC       URL="https://en.wikipedia.org/wiki/Dystroglycan";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L19711; AAA81779.1; -; mRNA.
DR   EMBL; AK291692; BAF84381.1; -; mRNA.
DR   EMBL; AC104452; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471055; EAW64989.1; -; Genomic_DNA.
DR   EMBL; BC012740; AAH12740.1; -; mRNA.
DR   EMBL; BC014616; AAH14616.1; -; mRNA.
DR   CCDS; CCDS2799.1; -.
DR   PIR; I54343; I54343.
DR   RefSeq; NP_001159400.2; NM_001165928.3.
DR   RefSeq; NP_001171105.1; NM_001177634.2.
DR   RefSeq; NP_001171106.1; NM_001177635.2.
DR   RefSeq; NP_001171107.1; NM_001177636.2.
DR   RefSeq; NP_001171108.1; NM_001177637.2.
DR   RefSeq; NP_001171109.1; NM_001177638.2.
DR   RefSeq; NP_001171110.1; NM_001177639.2.
DR   RefSeq; NP_001171111.1; NM_001177640.2.
DR   RefSeq; NP_001171112.1; NM_001177641.2.
DR   RefSeq; NP_001171113.1; NM_001177642.2.
DR   RefSeq; NP_001171114.1; NM_001177643.2.
DR   RefSeq; NP_001171115.1; NM_001177644.2.
DR   RefSeq; NP_004384.4; NM_004393.5.
DR   UniGene; Hs.76111; -.
DR   PDB; 1EG4; X-ray; 2.00 A; P=881-895.
DR   PDB; 2MK7; NMR; -; A=419-427.
DR   PDBsum; 1EG4; -.
DR   PDBsum; 2MK7; -.
DR   ProteinModelPortal; Q14118; -.
DR   SMR; Q14118; 60-304.
DR   BioGrid; 107975; 50.
DR   DIP; DIP-40928N; -.
DR   IntAct; Q14118; 9.
DR   MINT; MINT-5004541; -.
DR   STRING; 9606.ENSP00000312435; -.
DR   MEROPS; S72.001; -.
DR   iPTMnet; Q14118; -.
DR   PhosphoSite; Q14118; -.
DR   SwissPalm; Q14118; -.
DR   UniCarbKB; Q14118; -.
DR   BioMuta; DAG1; -.
DR   DMDM; 229462879; -.
DR   MaxQB; Q14118; -.
DR   PaxDb; Q14118; -.
DR   PRIDE; Q14118; -.
DR   DNASU; 1605; -.
DR   Ensembl; ENST00000308775; ENSP00000312435; ENSG00000173402.
DR   Ensembl; ENST00000515359; ENSP00000440705; ENSG00000173402.
DR   Ensembl; ENST00000538711; ENSP00000438421; ENSG00000173402.
DR   Ensembl; ENST00000539901; ENSP00000439334; ENSG00000173402.
DR   Ensembl; ENST00000541308; ENSP00000440590; ENSG00000173402.
DR   Ensembl; ENST00000545947; ENSP00000442600; ENSG00000173402.
DR   GeneID; 1605; -.
DR   KEGG; hsa:1605; -.
DR   UCSC; uc003cxc.4; human.
DR   CTD; 1605; -.
DR   GeneCards; DAG1; -.
DR   HGNC; HGNC:2666; DAG1.
DR   HPA; CAB001960; -.
DR   HPA; CAB016353; -.
DR   MalaCards; DAG1; -.
DR   MIM; 128239; gene.
DR   MIM; 613818; phenotype.
DR   neXtProt; NX_Q14118; -.
DR   Orphanet; 280333; Autosomal recessive limb-girdle muscular dystrophy type 2P.
DR   Orphanet; 370997; Muscle-eye-brain disease with bilateral multicystic leucodystrophy.
DR   PharmGKB; PA27138; -.
DR   eggNOG; KOG3781; Eukaryota.
DR   eggNOG; ENOG410XQTU; LUCA.
DR   GeneTree; ENSGT00390000008429; -.
DR   HOGENOM; HOG000072580; -.
DR   HOVERGEN; HBG000078; -.
DR   InParanoid; Q14118; -.
DR   KO; K06265; -.
DR   OMA; AMICYRK; -.
DR   OrthoDB; EOG7KSX82; -.
DR   PhylomeDB; Q14118; -.
DR   TreeFam; TF328370; -.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   ChiTaRS; DAG1; human.
DR   EvolutionaryTrace; Q14118; -.
DR   GeneWiki; Dystroglycan; -.
DR   GenomeRNAi; 1605; -.
DR   NextBio; 6586; -.
DR   PRO; PR:Q14118; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; Q14118; -.
DR   CleanEx; HS_DAG1; -.
DR   ExpressionAtlas; Q14118; baseline and differential.
DR   Genevisible; Q14118; HS.
DR   GO; GO:0005604; C:basement membrane; IDA:UniProtKB.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0009279; C:cell outer membrane; IEA:Ensembl.
DR   GO; GO:0005913; C:cell-cell adherens junction; IEA:Ensembl.
DR   GO; GO:0070938; C:contractile ring; IDA:UniProtKB.
DR   GO; GO:0043034; C:costamere; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0016011; C:dystroglycan complex; IEA:Ensembl.
DR   GO; GO:0016010; C:dystrophin-associated glycoprotein complex; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0030175; C:filopodium; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0033268; C:node of Ranvier; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042383; C:sarcolemma; IEA:UniProtKB-SubCell.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0051393; F:alpha-actinin binding; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0043237; F:laminin-1 binding; ISS:UniProtKB.
DR   GO; GO:0042169; F:SH2 domain binding; IDA:UniProtKB.
DR   GO; GO:0008307; F:structural constituent of muscle; IMP:UniProtKB.
DR   GO; GO:0015631; F:tubulin binding; IDA:UniProtKB.
DR   GO; GO:0017166; F:vinculin binding; IPI:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0071711; P:basement membrane organization; IEA:Ensembl.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0016340; P:calcium-dependent cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0071679; P:commissural neuron axon guidance; IEA:Ensembl.
DR   GO; GO:0007016; P:cytoskeletal anchoring at plasma membrane; IMP:UniProtKB.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0006509; P:membrane protein ectodomain proteolysis; IDA:UniProtKB.
DR   GO; GO:0034453; P:microtubule anchoring; IMP:UniProtKB.
DR   GO; GO:0019048; P:modulation by virus of host morphology or physiology; IDA:UniProtKB.
DR   GO; GO:0002011; P:morphogenesis of an epithelial sheet; IEA:Ensembl.
DR   GO; GO:0022011; P:myelination in peripheral nervous system; IEA:Ensembl.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0021682; P:nerve maturation; IEA:Ensembl.
DR   GO; GO:0006607; P:NLS-bearing protein import into nucleus; IDA:UniProtKB.
DR   GO; GO:1904261; P:positive regulation of basement membrane assembly involved in embryonic body morphogenesis; IMP:UniProtKB.
DR   GO; GO:0016476; P:regulation of embryonic cell shape; ISS:UniProtKB.
DR   GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; IMP:UniProtKB.
DR   GO; GO:0010470; P:regulation of gastrulation; IMP:UniProtKB.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.30.70.1040; -; 1.
DR   InterPro; IPR027468; Alpha-dystroglycan_domain_2.
DR   InterPro; IPR006644; Cadg.
DR   InterPro; IPR015919; Cadherin-like.
DR   InterPro; IPR008465; DAG1.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR030398; SEA_DG_dom.
DR   Pfam; PF05454; DAG1; 1.
DR   SMART; SM00736; CADG; 2.
DR   SUPFAM; SSF111006; SSF111006; 1.
DR   SUPFAM; SSF49313; SSF49313; 2.
DR   PROSITE; PS51699; SEA_DG; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Autocatalytic cleavage; Cell junction; Cell membrane;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Disease mutation;
KW   Disulfide bond; Dystroglycanopathy; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction;
KW   Limb-girdle muscular dystrophy; Membrane; Nucleus; Phosphoprotein;
KW   Polymorphism; Postsynaptic cell membrane; Receptor;
KW   Reference proteome; Secreted; Signal; Synapse; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     29       {ECO:0000255}.
FT   CHAIN        30    653       Alpha-dystroglycan.
FT                                /FTId=PRO_0000021065.
FT   CHAIN       654    895       Beta-dystroglycan.
FT                                /FTId=PRO_0000021066.
FT   TOPO_DOM    654    749       Extracellular. {ECO:0000255}.
FT   TRANSMEM    750    775       Helical. {ECO:0000255}.
FT   TOPO_DOM    776    895       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      603    712       Peptidase S72.
FT   REGION       30    408       Required for laminin recognition.
FT   REGION      169    200       O-glycosylated at one site.
FT   REGION      316    485       Mucin-like domain.
FT   REGION      463    485       O-glycosylated at seven sites with
FT                                GalNAc.
FT   REGION      819    895       Required for interaction with CAV3.
FT   REGION      880    895       Required for binding DMD and UTRN.
FT   MOTIF       776    782       Nuclear localization signal.
FT                                {ECO:0000269|PubMed:20512930}.
FT   MOTIF       889    892       PPXY motif.
FT   COMPBIAS    317    484       Thr-rich.
FT   COMPBIAS    809    895       Pro-rich.
FT   SITE        653    654       Cleavage; by autolysis.
FT   SITE        715    716       Cleavage; by MMP9.
FT   MOD_RES     790    790       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     892    892       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:11495720,
FT                                ECO:0000269|PubMed:12795607,
FT                                ECO:0000269|PubMed:20512930}.
FT   CARBOHYD     63     63       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:23234360}.
FT   CARBOHYD    141    141       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    317    317       O-linked (Man6P...).
FT                                {ECO:0000269|PubMed:21987822,
FT                                ECO:0000269|PubMed:24256719}.
FT   CARBOHYD    319    319       O-linked (Man6P...).
FT                                {ECO:0000269|PubMed:21987822,
FT                                ECO:0000269|PubMed:24256719}.
FT   CARBOHYD    367    367       O-linked (Hex...).
FT                                {ECO:0000269|PubMed:20507882}.
FT   CARBOHYD    369    369       O-linked (Hex...).
FT                                {ECO:0000269|PubMed:20507882}.
FT   CARBOHYD    372    372       O-linked (Hex...).
FT                                {ECO:0000269|PubMed:20507882}.
FT   CARBOHYD    379    379       O-linked (Man6P...).
FT                                {ECO:0000269|PubMed:20044576}.
FT   CARBOHYD    381    381       O-linked (Hex...).
FT                                {ECO:0000269|PubMed:20044576}.
FT   CARBOHYD    388    388       O-linked (Hex...).
FT                                {ECO:0000269|PubMed:20044576}.
FT   CARBOHYD    455    455       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:20507882}.
FT   CARBOHYD    641    641       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    649    649       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    661    661       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    182    264       {ECO:0000250}.
FT   DISULFID    669    713       {ECO:0000269|PubMed:17212656}.
FT   VARIANT      14     14       S -> W (in dbSNP:rs2131107).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8268918,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_024335.
FT   VARIANT     192    192       T -> M (in MDDGC9; results in impaired
FT                                interaction with LARGE and incomplete
FT                                DAG1 glycosylation).
FT                                {ECO:0000269|PubMed:21388311}.
FT                                /FTId=VAR_065266.
FT   MUTAGEN     317    319       TPT->APA: Impaired laminin-binding.
FT                                {ECO:0000269|PubMed:21987822,
FT                                ECO:0000269|PubMed:24256719}.
FT   MUTAGEN     328    329       TT->AA: Does not affect laminin-binding.
FT                                {ECO:0000269|PubMed:21987822}.
FT   MUTAGEN     654    654       S->A: Abolishes autoproteolysis and
FT                                enhances laminin-binding.
FT                                {ECO:0000269|PubMed:17905726,
FT                                ECO:0000269|PubMed:18764929}.
FT   MUTAGEN     663    663       T->A: Reduced N-linked glycosylation. No
FT                                change in nuclear trnslocation.
FT                                {ECO:0000269|PubMed:18764929}.
FT   MUTAGEN     776    782       RKKRKGK->AKKRKGA: Moderate reduction in
FT                                nuclear accumulation.
FT   MUTAGEN     777    782       KKRKGK->AARKGA: About 50% reduction in
FT                                nuclear accumulation.
FT                                {ECO:0000269|PubMed:20512930}.
FT   MUTAGEN     777    782       KKRKGK->RKKAAGA: Drastic reduction in
FT                                nuclear accumulation.
FT                                {ECO:0000269|PubMed:20512930}.
FT   MUTAGEN     777    780       KKRK->NPGE: Abolishes nuclear
FT                                translocation.
FT                                {ECO:0000269|PubMed:18764929}.
FT   MUTAGEN     779    779       R->A: Significant reduction in nuclear
FT                                accumulation.
FT   MUTAGEN     780    780       K->A: Significant reduction in nuclear
FT                                accumulation.
FT   MUTAGEN     793    794       KK->TA: Abolishes nuclear translocation.
FT                                {ECO:0000269|PubMed:18764929}.
FT   MUTAGEN     823    823       K->A: No change in nuclear location.
FT                                {ECO:0000269|PubMed:18764929}.
FT   MUTAGEN     828    829       PP->AA: No change in nuclear location.
FT                                {ECO:0000269|PubMed:18764929}.
FT   MUTAGEN     831    831       Y->A: No change in nuclear location.
FT                                {ECO:0000269|PubMed:18764929}.
FT   MUTAGEN     892    892       Y->A: Abolishes phosphorylation. No
FT                                change in plasma membrane location.
FT                                {ECO:0000269|PubMed:12795607,
FT                                ECO:0000269|PubMed:20512930}.
FT   MUTAGEN     892    892       Y->E: Redistributes to a vesicular
FT                                internal membrane compartment.
FT                                {ECO:0000269|PubMed:12795607,
FT                                ECO:0000269|PubMed:20512930}.
FT   MUTAGEN     892    892       Y->F: Abolishes phosphorylation. Increase
FT                                in nuclear location.
FT                                {ECO:0000269|PubMed:12795607,
FT                                ECO:0000269|PubMed:20512930}.
FT   CONFLICT    163    163       E -> D (in Ref. 1; AAA81779).
FT                                {ECO:0000305}.
FT   CONFLICT    248    248       A -> P (in Ref. 1; AAA81779).
FT                                {ECO:0000305}.
FT   CONFLICT    319    319       T -> A (in Ref. 2; BAF84381).
FT                                {ECO:0000305}.
FT   CONFLICT    871    871       A -> V (in Ref. 1; AAA81779).
FT                                {ECO:0000305}.
SQ   SEQUENCE   895 AA;  97441 MW;  3AF6CBB0DCF91962 CRC64;
     MRMSVGLSLL LPLSGRTFLL LLSVVMAQSH WPSEPSEAVR DWENQLEASM HSVLSDLHEA
     VPTVVGIPDG TAVVGRSFRV TIPTDLIASS GDIIKVSAAG KEALPSWLHW DSQSHTLEGL
     PLDTDKGVHY ISVSATRLGA NGSHIPQTSS VFSIEVYPED HSELQSVRTA SPDPGEVVSS
     ACAADEPVTV LTVILDADLT KMTPKQRIDL LHRMRSFSEV ELHNMKLVPV VNNRLFDMSA
     FMAGPGNAKK VVENGALLSW KLGCSLNQNS VPDIHGVEAP AREGAMSAQL GYPVVGWHIA
     NKKPPLPKRV RRQIHATPTP VTAIGPPTTA IQEPPSRIVP TPTSPAIAPP TETMAPPVRD
     PVPGKPTVTI RTRGAIIQTP TLGPIQPTRV SEAGTTVPGQ IRPTMTIPGY VEPTAVATPP
     TTTTKKPRVS TPKPATPSTD STTTTTRRPT KKPRTPRPVP RVTTKVSITR LETASPPTRI
     RTTTSGVPRG GEPNQRPELK NHIDRVDAWV GTYFEVKIPS DTFYDHEDTT TDKLKLTLKL
     REQQLVGEKS WVQFNSNSQL MYGLPDSSHV GKHEYFMHAT DKGGLSAVDA FEIHVHRRPQ
     GDRAPARFKA KFVGDPALVL NDIHKKIALV KKLAFAFGDR NCSTITLQNI TRGSIVVEWT
     NNTLPLEPCP KEQIAGLSRR IAEDDGKPRP AFSNALEPDF KATSITVTGS GSCRHLQFIP
     VVPPRRVPSE APPTEVPDRD PEKSSEDDVY LHTVIPAVVV AAILLIAGII AMICYRKKRK
     GKLTLEDQAT FIKKGVPIIF ADELDDSKPP PSSSMPLILQ EEKAPLPPPE YPNQSVPETT
     PLNQDTMGEY TPLRDEDPNA PPYQPPPPFT APMEGKGSRP KNMTPYRSPP PYVPP
//
ID   TYRO_HUMAN              Reviewed;         529 AA.
AC   P14679; Q15675; Q15676; Q15680; Q8TAK4; Q9BYY0; Q9BZX1;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 3.
DT   20-JAN-2016, entry version 186.
DE   RecName: Full=Tyrosinase;
DE            EC=1.14.18.1;
DE   AltName: Full=LB24-AB;
DE   AltName: Full=Monophenol monooxygenase;
DE   AltName: Full=SK29-AB;
DE   AltName: Full=Tumor rejection antigen AB;
DE   Flags: Precursor;
GN   Name=TYR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=1903356; DOI=10.1016/0888-7543(91)90409-8;
RA   Giebel L.B., Strunk K.M., Spritz R.A.;
RT   "Organization and nucleotide sequences of the human tyrosinase gene
RT   and a truncated tyrosinase-related segment.";
RL   Genomics 9:435-445(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2823263; DOI=10.1073/pnas.84.21.7473;
RA   Kwon B.S., Haq A.K., Pomerantz S.H., Halaban R.;
RT   "Isolation and sequence of a cDNA clone for human tyrosinase that maps
RT   at the mouse c-albino locus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7473-7477(1987).
RN   [3]
RP   ERRATUM, AND SEQUENCE REVISION TO 384-398.
RA   Kwon B.S., Haq A.K., Pomerantz S.H., Halaban R.;
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6352-6352(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Melanoma;
RX   PubMed=2499655; DOI=10.1084/jem.169.6.2029;
RA   Bouchard B., Fuller B.B., Vijayasaradhi S., Houghton A.N.;
RT   "Induction of pigmentation in mouse fibroblasts by expression of human
RT   tyrosinase cDNA.";
RL   J. Exp. Med. 169:2029-2042(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1711223; DOI=10.1073/pnas.88.12.5272;
RA   Chintamaneni C.D., Halaban R., Kobayashi Y., Witkop C.J., Kwon B.S.;
RT   "A single base insertion in the putative transmembrane domain of the
RT   tyrosinase gene as a cause for tyrosinase-negative oculocutaneous
RT   albinism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5272-5276(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1).
RC   TISSUE=Melanoma, and T-cell;
RX   PubMed=8340755; DOI=10.1084/jem.178.2.489;
RA   Brichard V., van Pel A., Woelfel T., Woelfel C., de Plaen E.,
RA   Lethe B.G., Coulie P., Boon T.;
RT   "The tyrosinase gene codes for an antigen recognized by autologous
RT   cytolytic T lymphocytes on HLA-A2 melanomas.";
RL   J. Exp. Med. 178:489-495(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT TYR-192.
RX   PubMed=11153699; DOI=10.1034/j.1600-0749.2000.130609.x;
RA   Martinez-Arias R., Comas D., Andres A., Abello M.-T.,
RA   Domingo-Roura X., Bertranpetit J.;
RT   "The tyrosinase gene in gorillas and the albinism of 'Snowflake'.";
RL   Pigment Cell Res. 13:467-470(2000).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-272.
RC   TISSUE=Liver;
RX   PubMed=2480811; DOI=10.1016/0167-4781(89)90115-2;
RA   Kikuchi H., Miura H., Yamamoto H., Takeuchi T., Dei T., Watanabe M.;
RT   "Characteristic sequences in the upstream region of the human
RT   tyrosinase gene.";
RL   Biochim. Biophys. Acta 1009:283-286(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-32.
RX   PubMed=2504160; DOI=10.1016/0006-291X(89)90770-5;
RA   Takeda A., Tomita Y., Okinaga S., Tagami H., Shibahara S.;
RT   "Functional analysis of the cDNA encoding human tyrosinase
RT   precursor.";
RL   Biochem. Biophys. Res. Commun. 162:984-990(1989).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 54-195, AND VARIANT TYR-192.
RX   PubMed=11214319; DOI=10.1038/35054550;
RA   Murphy W.J., Eizirik E., Johnson W.E., Zhang Y.-P., Ryder O.A.,
RA   O'Brien S.J.;
RT   "Molecular phylogenetics and the origins of placental mammals.";
RL   Nature 409:614-618(2001).
RN   [12]
RP   REVIEW ON OCA VARIANTS.
RX   PubMed=8477259; DOI=10.1002/humu.1380020102;
RA   Oetting W.S., King R.A.;
RT   "Molecular basis of type I (tyrosinase-related) oculocutaneous
RT   albinism: mutations and polymorphisms of the human tyrosinase gene.";
RL   Hum. Mutat. 2:1-6(1993).
RN   [13]
RP   REVIEW ON OCA1 VARIANTS.
RX   PubMed=10094567;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:2<99::AID-HUMU2>3.3.CO;2-3;
RA   Oetting W.S., King R.A.;
RT   "Molecular basis of albinism: mutations and polymorphisms of
RT   pigmentation genes associated with albinism.";
RL   Hum. Mutat. 13:99-115(1999).
RN   [14]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=12643545; DOI=10.1021/pr025562r;
RA   Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K.,
RA   Valencia J., Muller J., Vieira W.D., Watabe H., Shabanowitz J.,
RA   Hearing V.J., Hunt D.F., Appella E.;
RT   "Proteomic analysis of early melanosomes: identification of novel
RT   melanosomal proteins.";
RL   J. Proteome Res. 2:69-79(2003).
RN   [15]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [16]
RP   VARIANTS OCA1A LYS-373 AND ASN-383, AND VARIANTS TYR-192 AND GLN-402.
RX   PubMed=2342539; DOI=10.1056/NEJM199006143222407;
RA   Spritz R.A., Strunk K.M., Giebel L.B., King R.A.;
RT   "Detection of mutations in the tyrosinase gene in a patient with type
RT   IA oculocutaneous albinism.";
RL   N. Engl. J. Med. 322:1724-1728(1990).
RN   [17]
RP   VARIANT OCA1A LEU-81.
RX   PubMed=1970634; DOI=10.1073/pnas.87.9.3255;
RA   Giebel L.B., Strunk K.M., King R.A., Hanifin J.M., Spritz R.A.;
RT   "A frequent tyrosinase gene mutation in classic, tyrosinase-negative
RT   (type IA) oculocutaneous albinism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:3255-3258(1990).
RN   [18]
RP   VARIANTS OCA1B PHE-275 AND LEU-406.
RX   PubMed=1903591;
RA   Giebel L.B., Tripathi R.K., Strunk K.M., Hanifin J.M., Jackson C.E.,
RA   King R.A., Spritz R.A.;
RT   "Tyrosinase gene mutations associated with type IB ('yellow')
RT   oculocutaneous albinism.";
RL   Am. J. Hum. Genet. 48:1159-1167(1991).
RN   [19]
RP   ERRATUM.
RA   Giebel L.B., Tripathi R.K., Strunk K.M., Hanifin J.M., Jackson C.E.,
RA   King R.A., Spritz R.A.;
RL   Am. J. Hum. Genet. 49:696-696(1991).
RN   [20]
RP   VARIANTS OCA1A SER-21; TRP-217; HIS-299; SER-403; SER-446 AND ASN-448.
RX   PubMed=1642278; DOI=10.1002/ajmg.1320430523;
RA   Tripathi R.K., Strunk K.M., Giebel L.B., Weleber R.G., Spritz R.A.;
RT   "Tyrosinase gene mutations in type I (tyrosinase-deficient)
RT   oculocutaneous albinism define two clusters of missense
RT   substitutions.";
RL   Am. J. Med. Genet. 43:865-871(1992).
RN   [21]
RP   VARIANT OCA1A ARG-89.
RX   PubMed=1899321;
RA   Spritz R.A., Strunk K.M., Hsieh C.-L., Sekhon G.S., Francke U.;
RT   "Homozygous tyrosinase gene mutation in an American black with
RT   tyrosinase-negative (type IA) oculocutaneous albinism.";
RL   Am. J. Hum. Genet. 48:318-324(1991).
RN   [22]
RP   VARIANT OCA1B GLN-422.
RX   PubMed=1900309; DOI=10.1172/JCI115075;
RA   Giebel L.B., Tripathi R.K., King R.A., Spritz R.A.;
RT   "A tyrosinase gene missense mutation in temperature-sensitive type I
RT   oculocutaneous albinism. A human homologue to the Siamese cat and the
RT   Himalayan mouse.";
RL   J. Clin. Invest. 87:1119-1122(1991).
RN   [23]
RP   VARIANTS OCA1A GLY-42; TYR-55; THR-206 AND ARG-419.
RX   PubMed=1943686;
RA   King R.A., Mentink M.M., Oetting W.S.;
RT   "Non-random distribution of missense mutations within the human
RT   tyrosinase gene in type I (tyrosinase-related) oculocutaneous
RT   albinism.";
RL   Mol. Biol. Med. 8:19-29(1991).
RN   [24]
RP   VARIANTS OCA1A ILE-176 AND GLN-217.
RX   PubMed=1487241; DOI=10.1007/BF00220074;
RA   Oetting W.S., King R.A.;
RT   "Molecular analysis of type I-A (tyrosinase negative) oculocutaneous
RT   albinism.";
RL   Hum. Genet. 90:258-262(1992).
RN   [25]
RP   VARIANTS OCA1A GLN-328; ARG-419 AND LEU-431.
RX   PubMed=7902671;
RA   Tripathi R.K., Bundey S., Musarella M.A., Droetto S., Strunk K.M.,
RA   Holmes S.A., Spritz R.A.;
RT   "Mutations of the tyrosinase gene in Indo-Pakistani patients with type
RT   I (tyrosinase-deficient) oculocutaneous albinism (OCA).";
RL   Am. J. Hum. Genet. 53:1173-1179(1993).
RN   [26]
RP   VARIANTS OCA1A ASP-47; CYS-217 DEL; HIS-299 AND LYS-373, AND VARIANTS
RP   OCA1B SER-152 AND LYS-294.
RX   PubMed=8128955;
RA   Gershoni-Baruch R., Rosenmann A., Droetto S., Holmes S.A.,
RA   Tripathi R.K., Spritz R.A.;
RT   "Mutations of the tyrosinase gene in patients with oculocutaneous
RT   albinism from various ethnic groups in Israel.";
RL   Am. J. Hum. Genet. 54:586-594(1994).
RN   [27]
RP   VARIANTS OCA1A TYR-367; THR-370 AND LYS-373, AND VARIANT GLN-402.
RX   PubMed=7955413; DOI=10.1016/0009-8981(94)90131-7;
RA   Breimer L.H., Winder A.F., Jay B., Jay M.;
RT   "Initiation codon mutation of the tyrosinase gene as a cause of human
RT   albinism.";
RL   Clin. Chim. Acta 227:17-22(1994).
RN   [28]
RP   VARIANTS OCA1A ARG-361 AND TYR-371.
RX   PubMed=8644824; DOI=10.1016/S0002-9394(14)70647-6;
RA   Summers C.G., Oetting W.S., King R.A.;
RT   "Diagnosis of oculocutaneous albinism with molecular analysis.";
RL   Am. J. Ophthalmol. 121:724-726(1996).
RN   [29]
RP   VARIANT GLN-402.
RX   PubMed=9158138; DOI=10.1093/hmg/6.5.659;
RA   Morell R., Spritz R.A., Ho L., Pierpont J., Guo W., Friedman T.B.,
RA   Asher J.H. Jr.;
RT   "Apparent digenic inheritance of Waardenburg syndrome type 2 (WS2) and
RT   autosomal recessive ocular albinism (AROA).";
RL   Hum. Mol. Genet. 6:659-664(1997).
RN   [30]
RP   VARIANTS OCA1A AND OCA1B.
RX   PubMed=9259202;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:2<171::AID-HUMU11>3.0.CO;2-X;
RA   Spritz R.A., Oh J., Fukai K., Holmes S.A., Ho L., Chitayat D.,
RA   France T.D., Musarella M.A., Orlow S.J., Schnur R.E., Weleber R.G.,
RA   Levin A.V.;
RT   "Novel mutations of the tyrosinase (TYR) gene in type I oculocutaneous
RT   albinism (OCA1).";
RL   Hum. Mutat. 10:171-174(1997).
RN   [31]
RP   VARIANTS OCA1A AND OCA1B.
RX   PubMed=10671066;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:6<433::AID-HUMU14>3.3.CO;2-7;
RA   Oetting W.S., Fryer J.P., King R.A.;
RT   "Mutations of the human tyrosinase gene associated with tyrosinase
RT   related oculocutaneous albinism (OCA1).";
RL   Hum. Mutat. 12:433-434(1998).
RN   [32]
RP   ERRATUM.
RA   Oetting W.S., Fryer J.P., King R.A.;
RL   Hum. Mutat. 13:83-83(1999).
RN   [33]
RP   VARIANTS OCA1A TYR-36; GLN-77; TRP-77; LEU-81; ARG-97; GLN-217;
RP   TRP-217; SER-236; CYS-272; ARG-289; GLY-294; LYS-294; PRO-355;
RP   TYR-371; LYS-373; LEU-406; ARG-419; GLN-422; VAL-439; SER-446 AND
RP   ASN-448, VARIANT OCA1B SER-403, AND VARIANTS TYR-192 AND GLN-402.
RX   PubMed=10987646; DOI=10.1007/s004390051090;
RA   Passmore L.A., Kaesmann-Kellner B., Weber B.H.F.;
RT   "Novel and recurrent mutations in the tyrosinase gene and the P gene
RT   in the German albino population.";
RL   Hum. Genet. 105:200-210(1999).
RN   [34]
RP   ERRATUM.
RA   Passmore L.A., Kaesmann-Kellner B., Weber B.H.F.;
RL   Hum. Genet. 108:208-208(2001).
RN   [35]
RP   VARIANTS OCA1A TYR-55; ARG-77 INS; GLY-289; HIS-299; SER-299 AND
RP   LEU-400.
RX   PubMed=10571953;
RX   DOI=10.1002/(SICI)1098-1004(199912)14:6<542::AID-HUMU14>3.0.CO;2-3;
RA   Tsai C.-H., Tsai F.-J., Wu J.-Y., Lin S.-P., Chang J.-G., Yang C.-F.,
RA   Lee C.-C.;
RT   "Insertion/deletion mutations of type I oculocutaneous albinism in
RT   Chinese patients from Taiwan.";
RL   Hum. Mutat. 14:542-542(1999).
RN   [36]
RP   VARIANTS OCA1A ASP-47; GLN-77; ARG-109; THR-205; TYR-256; PHE-275;
RP   LYS-294; GLY-339; PRO-355; LYS-373; ASN-383 AND SER-446.
RX   PubMed=11295837; DOI=10.1002/humu.38;
RA   Camand O., Marchant D., Boutboul S., Pequignot M., Odent S.,
RA   Dollfus H., Sutherland J., Levin A., Menasche M., Marsac C.,
RA   Dufier J.-L., Heon E., Abitbol M.;
RT   "Mutation analysis of the tyrosinase gene in oculocutaneous
RT   albinism.";
RL   Hum. Mutat. 17:352-352(2001).
RN   [37]
RP   VARIANT OCA1A TRP-239.
RX   PubMed=11858948; DOI=10.1016/S0923-1811(01)00141-4;
RA   Nakamura E., Miyamura Y., Matsunaga J., Kano Y., Dakeishi-Hara M.,
RA   Tanita M., Kono M., Tomita Y.;
RT   "A novel mutation of the tyrosinase gene causing oculocutaneous
RT   albinism type 1 (OCA1).";
RL   J. Dermatol. Sci. 28:102-105(2002).
RN   [38]
RP   VARIANTS OCA1A ARG-44; GLY-44; ASP-47; VAL-47; HIS-68; GLN-77; LEU-79;
RP   LEU-81; SER-155; PHE-177; LEU-179; ASN-180; ASN-199; SER-201; SER-217;
RP   LEU-236; VAL-240; THR-243; TYR-256; ARG-289; GLU-318; PRO-329;
RP   THR-332; GLY-345; PRO-355; LYS-373; LYS-378; ASN-383; PHE-393;
RP   ARG-395; VAL-398; ALA-398; LEU-402; SER-403; ASN-404; LEU-405;
RP   LEU-406; HIS-408; ASP-409; SER-416; HIS-417; ARG-419; GLN-422;
RP   PHE-424; LYS-426; GLY-427; ILE-434; ASP-435; GLY-444 AND ASN-448, AND
RP   VARIANTS TYR-192 AND GLN-402.
RX   PubMed=15146472; DOI=10.1002/humu.9248;
RA   Opitz S., Kaesmann-Kellner B., Kaufmann M., Schwinger E., Zuehlke C.;
RT   "Detection of 53 novel DNA variations within the tyrosinase gene and
RT   accumulation of mutations in 17 patients with albinism.";
RL   Hum. Mutat. 23:630-631(2004).
RN   [39]
RP   VARIANT TYR-192, AND ASSOCIATION WITH SHEP3.
RX   PubMed=17999355; DOI=10.1086/522235;
RA   Stokowski R.P., Pant P.V.K., Dadd T., Fereday A., Hinds D.A.,
RA   Jarman C., Filsell W., Ginger R.S., Green M.R., van der Ouderaa F.J.,
RA   Cox D.R.;
RT   "A genomewide association study of skin pigmentation in a South Asian
RT   population.";
RL   Am. J. Hum. Genet. 81:1119-1132(2007).
RN   [40]
RP   VARIANT TYR-192, AND ASSOCIATION WITH SHEP3.
RX   PubMed=17952075; DOI=10.1038/ng.2007.13;
RA   Sulem P., Gudbjartsson D.F., Stacey S.N., Helgason A., Rafnar T.,
RA   Magnusson K.P., Manolescu A., Karason A., Palsson A., Thorleifsson G.,
RA   Jakobsdottir M., Steinberg S., Palsson S., Jonasson F.,
RA   Sigurgeirsson B., Thorisdottir K., Ragnarsson R.,
RA   Benediktsdottir K.R., Aben K.K., Kiemeney L.A., Olafsson J.H.,
RA   Gulcher J., Kong A., Thorsteinsdottir U., Stefansson K.;
RT   "Genetic determinants of hair, eye and skin pigmentation in
RT   Europeans.";
RL   Nat. Genet. 39:1443-1452(2007).
RN   [41]
RP   VARIANT OCA1A TYR-91.
RX   PubMed=22981120; DOI=10.1016/j.ajhg.2012.08.007;
RA   Chong J.X., Ouwenga R., Anderson R.L., Waggoner D.J., Ober C.;
RT   "A population-based study of autosomal-recessive disease-causing
RT   mutations in a founder population.";
RL   Am. J. Hum. Genet. 91:608-620(2012).
RN   [42]
RP   VARIANTS OCA1A LEU-50; TRP-77; PHE-275; TRP-298; VAL-355; HIS-364;
RP   LYS-373; ALA-384 AND ASP-490.
RX   PubMed=23504663; DOI=10.1002/humu.22315;
RA   Simeonov D.R., Wang X., Wang C., Sergeev Y., Dolinska M., Bower M.,
RA   Fischer R., Winer D., Dubrovsky G., Balog J.Z., Huizing M., Hart R.,
RA   Zein W.M., Gahl W.A., Brooks B.P., Adams D.R.;
RT   "DNA variations in oculocutaneous albinism: an updated mutation list
RT   and current outstanding issues in molecular diagnostics.";
RL   Hum. Mutat. 34:827-835(2013).
RN   [43]
RP   VARIANT OCA1A THR-198.
RX   PubMed=24934919; DOI=10.1111/ced.12382;
RA   Shah S.A., Din S.U., Raheem N., Daud S., Mubeen J., Nadeem A.,
RA   Tayyab M., Baloch D.M., Babar M.E., Ahmad J.;
RT   "Identification of a novel mutation (p.Ile198Thr) in gene TYR in a
RT   Pakistani family with nonsyndromic oculocutaneous albinism.";
RL   Clin. Exp. Dermatol. 39:646-648(2014).
CC   -!- FUNCTION: This is a copper-containing oxidase that functions in
CC       the formation of pigments such as melanins and other polyphenolic
CC       compounds. Catalyzes the rate-limiting conversions of tyrosine to
CC       DOPA, DOPA to DOPA-quinone and possibly 5,6-dihydroxyindole to
CC       indole-5,6 quinone.
CC   -!- CATALYTIC ACTIVITY: 2 L-dopa + O(2) = 2 dopaquinone + 2 H(2)O.
CC   -!- CATALYTIC ACTIVITY: L-tyrosine + O(2) = dopaquinone + H(2)O.
CC   -!- COFACTOR:
CC       Name=Cu(2+); Xref=ChEBI:CHEBI:29036;
CC         Evidence={ECO:0000250|UniProtKB:Q9ZP19};
CC       Note=Binds 2 copper ions per subunit.
CC       {ECO:0000250|UniProtKB:Q9ZP19};
CC   -!- SUBCELLULAR LOCATION: Melanosome membrane
CC       {ECO:0000269|PubMed:12643545, ECO:0000269|PubMed:17081065};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:12643545,
CC       ECO:0000269|PubMed:17081065}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P14679-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P14679-2; Sequence=VSP_006701, VSP_006702;
CC         Note=No experimental confirmation available.;
CC   -!- INDUCTION: Increased expression after UVB irradiation.
CC   -!- POLYMORPHISM: Genetic variants in TYR define the skin/hair/eye
CC       pigmentation variation locus 3 (SHEP3) [MIM:601800]. Hair, eye and
CC       skin pigmentation are among the most visible examples of human
CC       phenotypic variation, with a broad normal range that is subject to
CC       substantial geographic stratification. In the case of skin,
CC       individuals tend to have lighter pigmentation with increasing
CC       distance from the equator. By contrast, the majority of variation
CC       in human eye and hair color is found among individuals of European
CC       ancestry, with most other human populations fixed for brown eyes
CC       and black hair. {ECO:0000269|PubMed:17952075,
CC       ECO:0000269|PubMed:17999355}.
CC   -!- POLYMORPHISM: Compound heterozygosity for the R402Q polymorphism
CC       and a mutant allele of TYR is a common cause of autosomal
CC       recessive ocular albinism. The R402Q polymorphism is also found in
CC       Waardenburg syndrome type II with ocular albinism (WS2-OA) in
CC       association with a deletion in the MITF gene.
CC       {ECO:0000269|PubMed:2342539, ECO:0000269|PubMed:7955413,
CC       ECO:0000269|PubMed:9158138}.
CC   -!- DISEASE: Albinism, oculocutaneous, 1A (OCA1A) [MIM:203100]: An
CC       autosomal recessive disorder in which the biosynthesis of melanin
CC       pigment is absent in skin, hair, and eyes. It is characterized by
CC       complete lack of tyrosinase activity due to production of an
CC       inactive enzyme. Patients present with a life-long absence of
CC       melanin pigment after birth, and manifest increased sensitivity to
CC       ultraviolet radiation with predisposition to skin cancer. Visual
CC       anomalies include decreased acuity, nystagmus, strabismus and
CC       photophobia. {ECO:0000269|PubMed:10571953,
CC       ECO:0000269|PubMed:10671066, ECO:0000269|PubMed:10987646,
CC       ECO:0000269|PubMed:11295837, ECO:0000269|PubMed:11858948,
CC       ECO:0000269|PubMed:1487241, ECO:0000269|PubMed:15146472,
CC       ECO:0000269|PubMed:1642278, ECO:0000269|PubMed:1899321,
CC       ECO:0000269|PubMed:1943686, ECO:0000269|PubMed:1970634,
CC       ECO:0000269|PubMed:22981120, ECO:0000269|PubMed:2342539,
CC       ECO:0000269|PubMed:23504663, ECO:0000269|PubMed:24934919,
CC       ECO:0000269|PubMed:7902671, ECO:0000269|PubMed:7955413,
CC       ECO:0000269|PubMed:8128955, ECO:0000269|PubMed:8644824,
CC       ECO:0000269|PubMed:9259202}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Albinism, oculocutaneous, 1B (OCA1B) [MIM:606952]: An
CC       autosomal recessive disorder in which the biosynthesis of melanin
CC       pigment is reduced in skin, hair, and eyes. It is characterized by
CC       partial lack of tyrosinase activity. Patients have white hair at
CC       birth that rapidly turns yellow or blond. They manifest the
CC       development of minimal-to-moderate amounts of cutaneous and ocular
CC       pigment. Some patients may have with white hair in the warmer
CC       areas (scalp and axilla) and progressively darker hair in the
CC       cooler areas (extremities). This variant phenotype is due to a
CC       loss of tyrosinase activity above 35-37 degrees C.
CC       {ECO:0000269|PubMed:10987646, ECO:0000269|PubMed:1900309,
CC       ECO:0000269|PubMed:1903591, ECO:0000269|PubMed:8128955}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the tyrosinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA61241.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAA68756.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Mutations of the TYR gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="http://www.retina-international.org/files/sci-news/tyrmut.htm";
CC   -!- WEB RESOURCE: Name=Albinism database (ADB); Note=TYR mutations;
CC       URL="http://albinismdb.med.umn.edu/oca1mut.html";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Snowy stardom - Issue
CC       49 of August 2004;
CC       URL="http://web.expasy.org/spotlight/back_issues/049";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Tyrosinase entry;
CC       URL="https://en.wikipedia.org/wiki/Tyrosinase";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TYRID42738ch11q14.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M27160; AAB37227.1; -; mRNA.
DR   EMBL; M63239; AAA61242.1; -; Genomic_DNA.
DR   EMBL; M63235; AAA61242.1; JOINED; Genomic_DNA.
DR   EMBL; M63236; AAA61242.1; JOINED; Genomic_DNA.
DR   EMBL; M63237; AAA61242.1; JOINED; Genomic_DNA.
DR   EMBL; M63238; AAA61242.1; JOINED; Genomic_DNA.
DR   EMBL; J03581; AAA61241.1; ALT_INIT; mRNA.
DR   EMBL; Y00819; CAA68756.1; ALT_INIT; mRNA.
DR   EMBL; U01873; AAB60319.1; ALT_SEQ; mRNA.
DR   EMBL; M74314; AAA61244.1; -; mRNA.
DR   EMBL; X16073; CAA34205.1; -; Genomic_DNA.
DR   EMBL; AF237811; AAK00805.1; -; Genomic_DNA.
DR   EMBL; AF237807; AAK00805.1; JOINED; Genomic_DNA.
DR   EMBL; AF237808; AAK00805.1; JOINED; Genomic_DNA.
DR   EMBL; AF237809; AAK00805.1; JOINED; Genomic_DNA.
DR   EMBL; AF237810; AAK00805.1; JOINED; Genomic_DNA.
DR   EMBL; BC027179; AAH27179.1; -; mRNA.
DR   EMBL; AY012019; AAG38762.1; -; Genomic_DNA.
DR   CCDS; CCDS8284.1; -. [P14679-1]
DR   PIR; A38444; YRHU1.
DR   RefSeq; NP_000363.1; NM_000372.4. [P14679-1]
DR   UniGene; Hs.503555; -.
DR   ProteinModelPortal; P14679; -.
DR   SMR; P14679; 172-449.
DR   BioGrid; 113150; 1.
DR   STRING; 9606.ENSP00000263321; -.
DR   BindingDB; P14679; -.
DR   ChEMBL; CHEMBL1973; -.
DR   DrugBank; DB00548; Azelaic Acid.
DR   DrugBank; DB01055; Mimosine.
DR   DrugBank; DB00600; Monobenzone.
DR   iPTMnet; P14679; -.
DR   PhosphoSite; P14679; -.
DR   BioMuta; TYR; -.
DR   DMDM; 401235; -.
DR   PaxDb; P14679; -.
DR   PRIDE; P14679; -.
DR   Ensembl; ENST00000263321; ENSP00000263321; ENSG00000077498. [P14679-1]
DR   GeneID; 7299; -.
DR   KEGG; hsa:7299; -.
DR   UCSC; uc001pcs.3; human. [P14679-1]
DR   CTD; 7299; -.
DR   GeneCards; TYR; -.
DR   GeneReviews; TYR; -.
DR   HGNC; HGNC:12442; TYR.
DR   HPA; CAB000079; -.
DR   MalaCards; TYR; -.
DR   MIM; 103470; phenotype.
DR   MIM; 203100; phenotype.
DR   MIM; 601800; phenotype.
DR   MIM; 606933; gene.
DR   MIM; 606952; phenotype.
DR   neXtProt; NX_P14679; -.
DR   Orphanet; 352734; Minimal pigment oculocutaneous albinism type 1.
DR   Orphanet; 352740; Ocular albinism with congenital sensorineural deafness.
DR   Orphanet; 79431; Oculocutaneous albinism type 1A.
DR   Orphanet; 79434; Oculocutaneous albinism type 1B.
DR   Orphanet; 352737; Temperature-sensitive oculocutaneous albinism type 1.
DR   PharmGKB; PA37095; -.
DR   eggNOG; ENOG410IEZU; Eukaryota.
DR   eggNOG; ENOG410Y42I; LUCA.
DR   GeneTree; ENSGT00500000044790; -.
DR   HOVERGEN; HBG003553; -.
DR   InParanoid; P14679; -.
DR   KO; K00505; -.
DR   OMA; EEYNSHQ; -.
DR   OrthoDB; EOG7TJ3HG; -.
DR   PhylomeDB; P14679; -.
DR   TreeFam; TF315865; -.
DR   BioCyc; MetaCyc:HS01248-MONOMER; -.
DR   BRENDA; 1.14.18.1; 2681.
DR   Reactome; R-HSA-5662702; Melanin biosynthesis.
DR   SABIO-RK; P14679; -.
DR   GeneWiki; Tyrosinase; -.
DR   GenomeRNAi; 7299; -.
DR   NextBio; 28547; -.
DR   PRO; PR:P14679; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; P14679; -.
DR   CleanEx; HS_TYR; -.
DR   ExpressionAtlas; P14679; baseline and differential.
DR   Genevisible; P14679; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005798; C:Golgi-associated vesicle; TAS:ProtInc.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005764; C:lysosome; TAS:UniProtKB.
DR   GO; GO:0042470; C:melanosome; ISS:UniProtKB.
DR   GO; GO:0033162; C:melanosome membrane; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; IMP:UniProtKB.
DR   GO; GO:0004497; F:monooxygenase activity; TAS:Reactome.
DR   GO; GO:0004503; F:monophenol monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
DR   GO; GO:0034641; P:cellular nitrogen compound metabolic process; TAS:Reactome.
DR   GO; GO:0006726; P:eye pigment biosynthetic process; TAS:ProtInc.
DR   GO; GO:0042438; P:melanin biosynthetic process; IDA:CACAO.
DR   GO; GO:0006583; P:melanin biosynthetic process from tyrosine; TAS:ProtInc.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0009411; P:response to UV; IEA:Ensembl.
DR   GO; GO:0033280; P:response to vitamin D; IEA:Ensembl.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   Gene3D; 1.10.1280.10; -; 1.
DR   InterPro; IPR002227; Tyrosinase_Cu-bd.
DR   InterPro; IPR008922; Unchr_di-copper_centre.
DR   Pfam; PF00264; Tyrosinase; 1.
DR   PRINTS; PR00092; TYROSINASE.
DR   SUPFAM; SSF48056; SSF48056; 1.
DR   PROSITE; PS00497; TYROSINASE_1; 1.
DR   PROSITE; PS00498; TYROSINASE_2; 1.
PE   1: Evidence at protein level;
KW   Albinism; Alternative splicing; Complete proteome; Copper; Deafness;
KW   Disease mutation; Glycoprotein; Melanin biosynthesis; Membrane;
KW   Metal-binding; Monooxygenase; Oxidoreductase; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix;
KW   Tumor antigen; Waardenburg syndrome.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    529       Tyrosinase.
FT                                /FTId=PRO_0000035879.
FT   TOPO_DOM     19    476       Lumenal, melanosome. {ECO:0000255}.
FT   TRANSMEM    477    497       Helical. {ECO:0000255}.
FT   TOPO_DOM    498    529       Cytoplasmic. {ECO:0000255}.
FT   METAL       180    180       Copper A. {ECO:0000250|UniProtKB:Q9ZP19}.
FT   METAL       202    202       Copper A. {ECO:0000250|UniProtKB:Q9ZP19}.
FT   METAL       211    211       Copper A. {ECO:0000250|UniProtKB:Q9ZP19}.
FT   METAL       363    363       Copper B. {ECO:0000250|UniProtKB:Q9ZP19}.
FT   METAL       367    367       Copper B. {ECO:0000250|UniProtKB:Q9ZP19}.
FT   METAL       390    390       Copper B. {ECO:0000250|UniProtKB:Q9ZP19}.
FT   CARBOHYD     86     86       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    111    111       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    161    161       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    230    230       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    337    337       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    371    371       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     346    377       GFASPLTGIADASQSSMHNALHIYMNGTMSQV -> EMGFL
FT                                HVGWAGLKLLTSRDPPPWPPKMLGLQA (in isoform
FT                                2). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_006701.
FT   VAR_SEQ     378    529       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_006702.
FT   VARIANT      19     19       H -> Q (in OCA1A).
FT                                /FTId=VAR_007649.
FT   VARIANT      21     21       P -> S (in OCA1A).
FT                                {ECO:0000269|PubMed:1642278}.
FT                                /FTId=VAR_007650.
FT   VARIANT      36     36       C -> Y (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646}.
FT                                /FTId=VAR_021683.
FT   VARIANT      42     42       D -> G (in OCA1A; dbSNP:rs28940878).
FT                                {ECO:0000269|PubMed:1943686}.
FT                                /FTId=VAR_007651.
FT   VARIANT      44     44       S -> G (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021684.
FT   VARIANT      44     44       S -> R (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021685.
FT   VARIANT      47     47       G -> D (in OCA1A; dbSNP:rs61753180).
FT                                {ECO:0000269|PubMed:11295837,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:8128955}.
FT                                /FTId=VAR_007652.
FT   VARIANT      47     47       G -> V (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021686.
FT   VARIANT      50     50       S -> L (in OCA1A).
FT                                {ECO:0000269|PubMed:23504663}.
FT                                /FTId=VAR_072592.
FT   VARIANT      52     52       R -> I (in OCA1).
FT                                /FTId=VAR_007653.
FT   VARIANT      55     55       C -> Y (in OCA1A; dbSNP:rs28940879).
FT                                {ECO:0000269|PubMed:10571953,
FT                                ECO:0000269|PubMed:1943686}.
FT                                /FTId=VAR_007654.
FT   VARIANT      68     68       Q -> H (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021687.
FT   VARIANT      77     77       R -> Q (in OCA1A; dbSNP:rs61753185).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:11295837,
FT                                ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_007655.
FT   VARIANT      77     77       R -> RR (in OCA1A).
FT                                {ECO:0000269|PubMed:10571953}.
FT                                /FTId=VAR_009236.
FT   VARIANT      77     77       R -> W (in OCA1A; dbSNP:rs61753184).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:23504663}.
FT                                /FTId=VAR_007656.
FT   VARIANT      79     79       S -> L (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021688.
FT   VARIANT      80     80       W -> R (in OCA1A).
FT                                /FTId=VAR_007657.
FT   VARIANT      81     81       P -> L (in OCA1A; dbSNP:rs28940876).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:1970634}.
FT                                /FTId=VAR_007658.
FT   VARIANT      89     89       C -> R (in OCA1A; dbSNP:rs28940877).
FT                                {ECO:0000269|PubMed:1899321}.
FT                                /FTId=VAR_007659.
FT   VARIANT      91     91       C -> Y (in OCA1A).
FT                                {ECO:0000269|PubMed:22981120}.
FT                                /FTId=VAR_072593.
FT   VARIANT      97     97       G -> R (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646}.
FT                                /FTId=VAR_007660.
FT   VARIANT     109    109       G -> R (in OCA1A).
FT                                {ECO:0000269|PubMed:11295837}.
FT                                /FTId=VAR_021689.
FT   VARIANT     134    134       F -> C (in dbSNP:rs33955261).
FT                                /FTId=VAR_034576.
FT   VARIANT     142    142       K -> N (in dbSNP:rs11545463).
FT                                /FTId=VAR_042665.
FT   VARIANT     152    152       P -> S (in OCA1B).
FT                                {ECO:0000269|PubMed:8128955}.
FT                                /FTId=VAR_007925.
FT   VARIANT     155    155       T -> S (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021690.
FT   VARIANT     176    176       F -> I (in OCA1A).
FT                                {ECO:0000269|PubMed:1487241}.
FT                                /FTId=VAR_007661.
FT   VARIANT     177    177       V -> F (in OCA1A; dbSNP:rs138487695).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021691.
FT   VARIANT     179    179       M -> L (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021692.
FT   VARIANT     180    180       H -> N (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021693.
FT   VARIANT     192    192       S -> Y (associated with SHEP3; light/dark
FT                                skin; dbSNP:rs1042602).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:11153699,
FT                                ECO:0000269|PubMed:11214319,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:17952075,
FT                                ECO:0000269|PubMed:17999355,
FT                                ECO:0000269|PubMed:2342539}.
FT                                /FTId=VAR_007662.
FT   VARIANT     198    198       I -> T (in OCA1A).
FT                                {ECO:0000269|PubMed:24934919}.
FT                                /FTId=VAR_071756.
FT   VARIANT     199    199       D -> N (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021694.
FT   VARIANT     201    201       A -> S (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021695.
FT   VARIANT     205    205       P -> T (in OCA1A; dbSNP:rs61754362).
FT                                {ECO:0000269|PubMed:11295837}.
FT                                /FTId=VAR_021696.
FT   VARIANT     206    206       A -> T (in OCA1A; dbSNP:rs28940880).
FT                                {ECO:0000269|PubMed:1943686}.
FT                                /FTId=VAR_007663.
FT   VARIANT     216    216       L -> M (in OCA1A).
FT                                /FTId=VAR_007664.
FT   VARIANT     217    217       R -> G (in OCA1A).
FT                                /FTId=VAR_007665.
FT   VARIANT     217    217       R -> Q (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:1487241}.
FT                                /FTId=VAR_007667.
FT   VARIANT     217    217       R -> S (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021697.
FT   VARIANT     217    217       R -> W (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:1642278}.
FT                                /FTId=VAR_007666.
FT   VARIANT     217    217       Missing (in OCA1A).
FT                                /FTId=VAR_007926.
FT   VARIANT     227    227       Missing (in OCA1A).
FT                                /FTId=VAR_021698.
FT   VARIANT     236    236       W -> L (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021699.
FT   VARIANT     236    236       W -> S (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646}.
FT                                /FTId=VAR_021700.
FT   VARIANT     239    239       R -> W (in OCA1A).
FT                                {ECO:0000269|PubMed:11858948}.
FT                                /FTId=VAR_021701.
FT   VARIANT     240    240       D -> V (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021702.
FT   VARIANT     243    243       K -> T (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021703.
FT   VARIANT     253    253       G -> R (in OCA1A).
FT                                /FTId=VAR_007668.
FT   VARIANT     256    256       H -> Y (in OCA1A).
FT                                {ECO:0000269|PubMed:11295837,
FT                                ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021704.
FT   VARIANT     272    272       W -> C (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646}.
FT                                /FTId=VAR_021705.
FT   VARIANT     275    275       V -> F (in OCA1B and OCA1A;
FT                                dbSNP:rs104894314).
FT                                {ECO:0000269|PubMed:11295837,
FT                                ECO:0000269|PubMed:1903591,
FT                                ECO:0000269|PubMed:23504663}.
FT                                /FTId=VAR_007669.
FT   VARIANT     288    288       L -> S (in OCA1A).
FT                                /FTId=VAR_007927.
FT   VARIANT     289    289       C -> G (in OCA1A).
FT                                {ECO:0000269|PubMed:10571953}.
FT                                /FTId=VAR_009237.
FT   VARIANT     289    289       C -> R (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_007670.
FT   VARIANT     294    294       E -> G (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646}.
FT                                /FTId=VAR_021706.
FT   VARIANT     294    294       E -> K (in OCA1A and OCA1B).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:11295837,
FT                                ECO:0000269|PubMed:8128955}.
FT                                /FTId=VAR_007928.
FT   VARIANT     298    298       R -> W (in OCA1A).
FT                                {ECO:0000269|PubMed:23504663}.
FT                                /FTId=VAR_072594.
FT   VARIANT     299    299       R -> H (in OCA1A; dbSNP:rs61754375).
FT                                {ECO:0000269|PubMed:10571953,
FT                                ECO:0000269|PubMed:1642278,
FT                                ECO:0000269|PubMed:8128955}.
FT                                /FTId=VAR_007671.
FT   VARIANT     299    299       R -> S (in OCA1A).
FT                                {ECO:0000269|PubMed:10571953}.
FT                                /FTId=VAR_007672.
FT   VARIANT     308    308       R -> T (in dbSNP:rs1042608).
FT                                /FTId=VAR_011825.
FT   VARIANT     312    312       L -> V (in OCA1).
FT                                /FTId=VAR_007673.
FT   VARIANT     313    313       P -> R (in OCA1).
FT                                /FTId=VAR_007674.
FT   VARIANT     318    318       V -> E (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021707.
FT   VARIANT     325    325       T -> A (in OCA1B).
FT                                /FTId=VAR_007675.
FT   VARIANT     328    328       E -> Q (in OCA1A).
FT                                {ECO:0000269|PubMed:7902671}.
FT                                /FTId=VAR_007929.
FT   VARIANT     329    329       S -> P (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021708.
FT   VARIANT     332    332       M -> T (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021709.
FT   VARIANT     339    339       S -> G (in OCA1A).
FT                                {ECO:0000269|PubMed:11295837}.
FT                                /FTId=VAR_007676.
FT   VARIANT     340    340       F -> L (in OCA1).
FT                                /FTId=VAR_007677.
FT   VARIANT     345    345       E -> G (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021710.
FT   VARIANT     346    346       G -> E (in OCA1A).
FT                                /FTId=VAR_007930.
FT   VARIANT     355    355       A -> E (in OCA1A).
FT                                /FTId=VAR_007931.
FT   VARIANT     355    355       A -> P (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:11295837,
FT                                ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_007678.
FT   VARIANT     355    355       A -> V (in OCA1A).
FT                                {ECO:0000269|PubMed:23504663}.
FT                                /FTId=VAR_072595.
FT   VARIANT     361    361       S -> R (in OCA1A).
FT                                {ECO:0000269|PubMed:8644824}.
FT                                /FTId=VAR_007932.
FT   VARIANT     364    364       N -> H (in OCA1A).
FT                                {ECO:0000269|PubMed:23504663}.
FT                                /FTId=VAR_072596.
FT   VARIANT     367    367       H -> Y (in OCA1A).
FT                                {ECO:0000269|PubMed:7955413}.
FT                                /FTId=VAR_007933.
FT   VARIANT     370    370       M -> T (in OCA1A).
FT                                {ECO:0000269|PubMed:7955413}.
FT                                /FTId=VAR_007934.
FT   VARIANT     371    371       N -> T (in OCA1A).
FT                                /FTId=VAR_007679.
FT   VARIANT     371    371       N -> Y (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:8644824}.
FT                                /FTId=VAR_007935.
FT   VARIANT     373    373       T -> K (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:11295837,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:2342539,
FT                                ECO:0000269|PubMed:23504663,
FT                                ECO:0000269|PubMed:7955413,
FT                                ECO:0000269|PubMed:8128955}.
FT                                /FTId=VAR_007680.
FT   VARIANT     378    378       Q -> K (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021711.
FT   VARIANT     380    380       S -> P (in OCA1B).
FT                                /FTId=VAR_007681.
FT   VARIANT     382    382       N -> K (in OCA1A).
FT                                /FTId=VAR_007682.
FT   VARIANT     383    383       D -> N (in OCA1A).
FT                                {ECO:0000269|PubMed:11295837,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:2342539}.
FT                                /FTId=VAR_007683.
FT   VARIANT     384    384       P -> A (in OCA1A).
FT                                {ECO:0000269|PubMed:23504663}.
FT                                /FTId=VAR_072597.
FT   VARIANT     390    390       H -> D (in OCA1B).
FT                                /FTId=VAR_007684.
FT   VARIANT     393    393       V -> F (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_007936.
FT   VARIANT     395    395       S -> N (in OCA1A).
FT                                /FTId=VAR_007685.
FT   VARIANT     395    395       S -> R (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021712.
FT   VARIANT     398    398       E -> A (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021713.
FT   VARIANT     398    398       E -> V (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021714.
FT   VARIANT     400    400       W -> L (in OCA1A).
FT                                {ECO:0000269|PubMed:10571953}.
FT                                /FTId=VAR_009238.
FT   VARIANT     402    402       R -> G (in OCA1B).
FT                                /FTId=VAR_007937.
FT   VARIANT     402    402       R -> L (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021715.
FT   VARIANT     402    402       R -> Q (in dbSNP:rs1126809).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:2342539,
FT                                ECO:0000269|PubMed:7955413,
FT                                ECO:0000269|PubMed:9158138}.
FT                                /FTId=VAR_007686.
FT   VARIANT     403    403       R -> S (in OCA1A and OCA1B).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:1642278}.
FT                                /FTId=VAR_007687.
FT   VARIANT     404    404       H -> N (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021716.
FT   VARIANT     404    404       H -> P (in OCA-I).
FT                                /FTId=VAR_007688.
FT   VARIANT     405    405       R -> L (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021717.
FT   VARIANT     406    406       P -> L (in OCA1A and OCA1B).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:1903591}.
FT                                /FTId=VAR_007689.
FT   VARIANT     408    408       Q -> H (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021718.
FT   VARIANT     409    409       E -> D (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021719.
FT   VARIANT     416    416       A -> S (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021720.
FT   VARIANT     417    417       P -> H (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021721.
FT   VARIANT     419    419       G -> R (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:1943686,
FT                                ECO:0000269|PubMed:7902671}.
FT                                /FTId=VAR_007690.
FT   VARIANT     422    422       R -> Q (in OCA1A and OCA1B; temperature
FT                                sensitive variant).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:1900309}.
FT                                /FTId=VAR_007691.
FT   VARIANT     424    424       S -> F (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021722.
FT   VARIANT     426    426       M -> K (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021723.
FT   VARIANT     427    427       V -> G (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021724.
FT   VARIANT     431    431       P -> L (in OCA1A).
FT                                {ECO:0000269|PubMed:7902671}.
FT                                /FTId=VAR_007938.
FT   VARIANT     434    434       R -> I (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021725.
FT   VARIANT     435    435       N -> D (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021726.
FT   VARIANT     439    439       F -> V (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646}.
FT                                /FTId=VAR_021727.
FT   VARIANT     444    444       D -> G (in OCA1A).
FT                                {ECO:0000269|PubMed:15146472}.
FT                                /FTId=VAR_021728.
FT   VARIANT     446    446       G -> S (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:11295837,
FT                                ECO:0000269|PubMed:1642278}.
FT                                /FTId=VAR_007692.
FT   VARIANT     448    448       D -> N (in OCA1A).
FT                                {ECO:0000269|PubMed:10987646,
FT                                ECO:0000269|PubMed:15146472,
FT                                ECO:0000269|PubMed:1642278}.
FT                                /FTId=VAR_007693.
FT   VARIANT     490    490       A -> D (in OCA1A).
FT                                {ECO:0000269|PubMed:23504663}.
FT                                /FTId=VAR_072598.
FT   CONFLICT     42     45       DRSP -> TGV (in Ref. 2; AAA61241).
FT                                {ECO:0000305}.
FT   CONFLICT    179    179       M -> I (in Ref. 4; CAA68756).
FT                                {ECO:0000305}.
FT   CONFLICT    373    378       TMSQVQ -> HVPGT (in Ref. 2; AAA61241).
FT                                {ECO:0000305}.
FT   CONFLICT    495    495       L -> P (in Ref. 2; AAA61241/AAA61244).
FT                                {ECO:0000305}.
FT   CONFLICT    520    523       DYHS -> GLPQ (in Ref. 2). {ECO:0000305}.
FT   CONFLICT    525    528       YQSH -> VSEPFIKGLGNRVGPKSPDLTLTQSNVQVPENI
FT                                CWYFL (in Ref. 2). {ECO:0000305}.
SQ   SEQUENCE   529 AA;  60393 MW;  67211A91608A59E1 CRC64;
     MLLAVLYCLL WSFQTSAGHF PRACVSSKNL MEKECCPPWS GDRSPCGQLS GRGSCQNILL
     SNAPLGPQFP FTGVDDRESW PSVFYNRTCQ CSGNFMGFNC GNCKFGFWGP NCTERRLLVR
     RNIFDLSAPE KDKFFAYLTL AKHTISSDYV IPIGTYGQMK NGSTPMFNDI NIYDLFVWMH
     YYVSMDALLG GSEIWRDIDF AHEAPAFLPW HRLFLLRWEQ EIQKLTGDEN FTIPYWDWRD
     AEKCDICTDE YMGGQHPTNP NLLSPASFFS SWQIVCSRLE EYNSHQSLCN GTPEGPLRRN
     PGNHDKSRTP RLPSSADVEF CLSLTQYESG SMDKAANFSF RNTLEGFASP LTGIADASQS
     SMHNALHIYM NGTMSQVQGS ANDPIFLLHH AFVDSIFEQW LRRHRPLQEV YPEANAPIGH
     NRESYMVPFI PLYRNGDFFI SSKDLGYDYS YLQDSDPDSF QDYIKSYLEQ ASRIWSWLLG
     AAMVGAVLTA LLAGLVSLLC RHKRKQLPEE KQPLLMEKED YHSLYQSHL
//
ID   NMDZ1_MOUSE             Reviewed;         938 AA.
AC   P35438; A2AI15; A2AI18; Q8CFS4;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   17-FEB-2016, entry version 172.
DE   RecName: Full=Glutamate receptor ionotropic, NMDA 1;
DE            Short=GluN1;
DE   AltName: Full=Glutamate [NMDA] receptor subunit zeta-1;
DE   AltName: Full=N-methyl-D-aspartate receptor subunit NR1;
DE            Short=NMD-R1;
DE   Flags: Precursor;
GN   Name=Grin1; Synonyms=Glurz1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1532151; DOI=10.1016/0014-5793(92)80160-I;
RA   Yamazaki M., Mori H., Araki K., Mori K.J., Mishina M.;
RT   "Cloning, expression and modulation of a mouse NMDA receptor
RT   subunit.";
RL   FEBS Lett. 300:39-45(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN2A OR GRIN2B AND GRIN3B.
RX   PubMed=12008020; DOI=10.1016/S0169-328X(02)00173-0;
RA   Matsuda K., Kamiya Y., Matsuda S., Yuzaki M.;
RT   "Cloning and characterization of a novel NMDA receptor subunit NR3B: a
RT   dominant subunit that reduces calcium permeability.";
RL   Brain Res. Mol. Brain Res. 100:43-52(2002).
RN   [5]
RP   SUBCELLULAR LOCATION, AND IDENTIFICATION IN A COMPLEX WITH GRIN2A OR
RP   GRIN2B AND GRIN3B.
RX   PubMed=14602821;
RA   Matsuda K., Fletcher M., Kamiya Y., Yuzaki M.;
RT   "Specific assembly with the NMDA receptor 3B subunit controls surface
RT   expression and calcium permeability of NMDA receptors.";
RL   J. Neurosci. 23:10064-10073(2003).
RN   [6]
RP   INTERACTION WITH MYZAP.
RX   PubMed=18849881; DOI=10.1097/WNR.0b013e328317f05f;
RA   Roginski R.S., Goubaeva F., Mikami M., Fried-Cassorla E., Nair M.R.,
RA   Yang J.;
RT   "GRINL1A colocalizes with N-methyl D-aspartate receptor NR1 subunit
RT   and reduces N-methyl D-aspartate toxicity.";
RL   NeuroReport 19:1721-1726(2008).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [8]
RP   INTERACTION WITH SNX27.
RX   PubMed=23524343; DOI=10.1038/nm.3117;
RA   Wang X., Zhao Y., Zhang X., Badie H., Zhou Y., Mu Y., Loo L.S.,
RA   Cai L., Thompson R.C., Yang B., Chen Y., Johnson P.F., Wu C., Bu G.,
RA   Mobley W.C., Zhang D., Gage F.H., Ranscht B., Zhang Y.W., Lipton S.A.,
RA   Hong W., Xu H.;
RT   "Loss of sorting nexin 27 contributes to excitatory synaptic
RT   dysfunction by modulating glutamate receptor recycling in Down's
RT   syndrome.";
RL   Nat. Med. 19:473-480(2013).
CC   -!- FUNCTION: NMDA receptor subtype of glutamate-gated ion channels
CC       possesses high calcium permeability and voltage-dependent
CC       sensitivity to magnesium. Modulated by glycine. This protein plays
CC       a key role in synaptic plasticity, synaptogenesis, excitotoxicity,
CC       memory acquisition and learning. It mediates neuronal functions in
CC       glutamate neurotransmission. Is involved in the cell surface
CC       targeting of NMDA receptors (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Forms heteromeric channel of a zeta subunit (GRIN1), a
CC       epsilon subunit (GRIN2A, GRIN2B, GRIN2C or GRIN2D) and a third
CC       subunit (GRIN3A or GRIN3B); disulfide-linked. Found in a complex
CC       with GRIN2A or GRIN2B and GRIN3B. Found in a complex with GRIN2A
CC       or GRIN2B, GRIN3A and PPP2CB. Interacts with DLG4 and MPDZ (By
CC       similarity). Interacts with LRFN1 and LRFN2 (By similarity).
CC       Interacts with MYZAP. Interacts with SNX27 (via PDZ domain); the
CC       interaction is required for recycling to the plasma membrane when
CC       endocytosed and prevent degradation in lysosomes. {ECO:0000250,
CC       ECO:0000269|PubMed:12008020, ECO:0000269|PubMed:14602821,
CC       ECO:0000269|PubMed:18849881, ECO:0000269|PubMed:23524343}.
CC   -!- INTERACTION:
CC       Q62108:Dlg4; NbExp=10; IntAct=EBI-400084, EBI-300895;
CC       Q924X6:Lrp8; NbExp=4; IntAct=EBI-400084, EBI-432319;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Multi-pass
CC       membrane protein {ECO:0000250}. Cell junction, synapse,
CC       postsynaptic cell membrane {ECO:0000250}. Cell junction, synapse,
CC       postsynaptic cell membrane, postsynaptic density {ECO:0000250}.
CC       Note=Enriched in postsynaptic plasma membrane and postsynaptic
CC       densities. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P35438-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35438-2; Sequence=VSP_014222, VSP_014223;
CC   -!- PTM: NMDA is probably regulated by C-terminal phosphorylation of
CC       an isoform of NR1 by PKC. Dephosphorylated on Ser-897 probably by
CC       protein phosphatase 2A (PPP2CB). Its phosphorylated state is
CC       influenced by the formation of the NMDAR-PPP2CB complex and the
CC       NMDAR channel activity (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel
CC       (TC 1.A.10.1) family. NR1/GRIN1 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D10028; BAA00920.1; -; mRNA.
DR   EMBL; AL732309; CAM14685.1; -; Genomic_DNA.
DR   EMBL; AL732309; CAM14688.1; -; Genomic_DNA.
DR   EMBL; BC039157; AAH39157.1; -; mRNA.
DR   CCDS; CCDS15764.1; -. [P35438-1]
DR   CCDS; CCDS50528.1; -. [P35438-2]
DR   PIR; S21104; S21104.
DR   RefSeq; NP_001171127.1; NM_001177656.2.
DR   RefSeq; NP_001171128.1; NM_001177657.2. [P35438-2]
DR   RefSeq; NP_032195.1; NM_008169.3. [P35438-1]
DR   UniGene; Mm.278672; -.
DR   ProteinModelPortal; P35438; -.
DR   SMR; P35438; 24-833.
DR   BioGrid; 200067; 82.
DR   DIP; DIP-31577N; -.
DR   IntAct; P35438; 124.
DR   MINT; MINT-135802; -.
DR   STRING; 10090.ENSMUSP00000028335; -.
DR   iPTMnet; P35438; -.
DR   PhosphoSite; P35438; -.
DR   MaxQB; P35438; -.
DR   PaxDb; P35438; -.
DR   PRIDE; P35438; -.
DR   Ensembl; ENSMUST00000028335; ENSMUSP00000028335; ENSMUSG00000026959. [P35438-1]
DR   Ensembl; ENSMUST00000114312; ENSMUSP00000109951; ENSMUSG00000026959. [P35438-2]
DR   GeneID; 14810; -.
DR   KEGG; mmu:14810; -.
DR   UCSC; uc008iri.3; mouse. [P35438-2]
DR   UCSC; uc008irk.3; mouse. [P35438-1]
DR   CTD; 2902; -.
DR   MGI; MGI:95819; Grin1.
DR   eggNOG; KOG1053; Eukaryota.
DR   eggNOG; ENOG410XNUR; LUCA.
DR   GeneTree; ENSGT00760000119186; -.
DR   HOGENOM; HOG000231491; -.
DR   HOVERGEN; HBG052638; -.
DR   InParanoid; P35438; -.
DR   KO; K05208; -.
DR   TreeFam; TF351405; -.
DR   Reactome; R-MMU-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-MMU-438066; Unblocking of NMDA receptor, glutamate binding and activation.
DR   Reactome; R-MMU-442729; CREB phosphorylation through the activation of CaMKII.
DR   Reactome; R-MMU-442982; Ras activation uopn Ca2+ infux through NMDA receptor.
DR   Reactome; R-MMU-5673001; RAF/MAP kinase cascade.
DR   NextBio; 286995; -.
DR   PRO; PR:P35438; -.
DR   Proteomes; UP000000589; Chromosome 2.
DR   Bgee; P35438; -.
DR   CleanEx; MM_GRIN1; -.
DR   ExpressionAtlas; P35438; baseline and differential.
DR   Genevisible; P35438; MM.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; IMP:CACAO.
DR   GO; GO:0044307; C:dendritic branch; IEA:Ensembl.
DR   GO; GO:0043197; C:dendritic spine; IDA:MGI.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0030426; C:growth cone; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISO:MGI.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0097481; C:neuronal postsynaptic density; IDA:MGI.
DR   GO; GO:0017146; C:NMDA selective glutamate receptor complex; IPI:MGI.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0014069; C:postsynaptic density; IDA:MGI.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:MGI.
DR   GO; GO:0045202; C:synapse; IDA:MGI.
DR   GO; GO:0043083; C:synaptic cleft; IEA:Ensembl.
DR   GO; GO:0008021; C:synaptic vesicle; IDA:MGI.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0005262; F:calcium channel activity; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IDA:MGI.
DR   GO; GO:0005516; F:calmodulin binding; IDA:MGI.
DR   GO; GO:0005261; F:cation channel activity; IGI:MGI.
DR   GO; GO:0005234; F:extracellular-glutamate-gated ion channel activity; IEA:InterPro.
DR   GO; GO:0016595; F:glutamate binding; ISO:MGI.
DR   GO; GO:0016594; F:glycine binding; IMP:UniProtKB.
DR   GO; GO:0042165; F:neurotransmitter binding; IEA:Ensembl.
DR   GO; GO:0004972; F:NMDA glutamate receptor activity; IDA:MGI.
DR   GO; GO:0005102; F:receptor binding; IPI:MGI.
DR   GO; GO:0022843; F:voltage-gated cation channel activity; IEA:Ensembl.
DR   GO; GO:0008344; P:adult locomotory behavior; IMP:MGI.
DR   GO; GO:0008306; P:associative learning; IMP:MGI.
DR   GO; GO:0055074; P:calcium ion homeostasis; IDA:MGI.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; ISO:MGI.
DR   GO; GO:0006816; P:calcium ion transport; IDA:MGI.
DR   GO; GO:0006812; P:cation transport; IGI:MGI.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IMP:MGI.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; IMP:MGI.
DR   GO; GO:0001661; P:conditioned taste aversion; IMP:MGI.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IMP:MGI.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; IDA:MGI.
DR   GO; GO:0007612; P:learning; IMP:MGI.
DR   GO; GO:0007611; P:learning or memory; IMP:MGI.
DR   GO; GO:0007616; P:long-term memory; IMP:MGI.
DR   GO; GO:0060179; P:male mating behavior; IMP:MGI.
DR   GO; GO:0007613; P:memory; IMP:MGI.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:MGI.
DR   GO; GO:0050905; P:neuromuscular process; IMP:MGI.
DR   GO; GO:0008355; P:olfactory learning; IMP:MGI.
DR   GO; GO:0021586; P:pons maturation; IMP:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IGI:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0060134; P:prepulse inhibition; IMP:MGI.
DR   GO; GO:0018964; P:propylene metabolic process; IDA:BHF-UCL.
DR   GO; GO:0051262; P:protein tetramerization; IEA:Ensembl.
DR   GO; GO:0050770; P:regulation of axonogenesis; IMP:MGI.
DR   GO; GO:0010646; P:regulation of cell communication; IMP:MGI.
DR   GO; GO:0048814; P:regulation of dendrite morphogenesis; IMP:MGI.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IMP:MGI.
DR   GO; GO:0042391; P:regulation of membrane potential; IDA:MGI.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; IMP:MGI.
DR   GO; GO:0048168; P:regulation of neuronal synaptic plasticity; IMP:MGI.
DR   GO; GO:0043576; P:regulation of respiratory gaseous exchange; IMP:MGI.
DR   GO; GO:0051963; P:regulation of synapse assembly; IMP:MGI.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; IMP:MGI.
DR   GO; GO:0007585; P:respiratory gaseous exchange; IMP:MGI.
DR   GO; GO:0001975; P:response to amphetamine; IMP:MGI.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; ISO:MGI.
DR   GO; GO:0060992; P:response to fungicide; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IMP:MGI.
DR   GO; GO:0048511; P:rhythmic process; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IMP:MGI.
DR   GO; GO:0035176; P:social behavior; IMP:MGI.
DR   GO; GO:0001964; P:startle response; IMP:MGI.
DR   GO; GO:0001967; P:suckling behavior; IMP:MGI.
DR   GO; GO:0007268; P:synaptic transmission; TAS:MGI.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IMP:MGI.
DR   GO; GO:0008542; P:visual learning; IMP:MGI.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR018882; CaM-bd_C0_NMDA_rcpt_NR1.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_rcpt_met.
DR   InterPro; IPR001320; Iontro_rcpt.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF10562; CaM_bdg_C0; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Cell junction; Cell membrane;
KW   Complete proteome; Disulfide bond; Glycoprotein; Ion channel;
KW   Ion transport; Ligand-gated ion channel; Magnesium; Membrane;
KW   Phosphoprotein; Polymorphism; Postsynaptic cell membrane; Receptor;
KW   Reference proteome; Signal; Synapse; Transmembrane;
KW   Transmembrane helix; Transport.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    938       Glutamate receptor ionotropic, NMDA 1.
FT                                /FTId=PRO_0000011588.
FT   TOPO_DOM     19    559       Extracellular. {ECO:0000255}.
FT   TRANSMEM    560    580       Helical. {ECO:0000255}.
FT   TOPO_DOM    581    636       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    637    657       Helical. {ECO:0000255}.
FT   TOPO_DOM    658    812       Extracellular. {ECO:0000255}.
FT   TRANSMEM    813    833       Helical. {ECO:0000255}.
FT   TOPO_DOM    834    938       Cytoplasmic. {ECO:0000255}.
FT   REGION      516    518       Glycine binding. {ECO:0000250}.
FT   BINDING     523    523       Glycine. {ECO:0000250}.
FT   BINDING     688    688       Glycine. {ECO:0000250}.
FT   BINDING     732    732       Glycine. {ECO:0000250}.
FT   MOD_RES     889    889       Phosphoserine; by PKC. {ECO:0000250}.
FT   MOD_RES     890    890       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35439}.
FT   MOD_RES     896    896       Phosphoserine; by PKC. {ECO:0000250}.
FT   MOD_RES     897    897       Phosphoserine; by PKC. {ECO:0000250}.
FT   CARBOHYD     61     61       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    203    203       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    239    239       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    276    276       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    300    300       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    350    350       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    368    368       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    440    440       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    471    471       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    491    491       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     79     79       Interchain. {ECO:0000250}.
FT   VAR_SEQ     864    885       DRKSGRAEPDPKKKATFRAITS -> QYHPTDITGPLNLSD
FT                                PSVSTVV (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014222.
FT   VAR_SEQ     886    938       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014223.
FT   VARIANT     936    936       R -> T.
SQ   SEQUENCE   938 AA;  105481 MW;  C610632DD3E06171 CRC64;
     MSTMHLLTFA LLFSCSFARA ACDPKIVNIG AVLSTRKHEQ MFREAVNQAN KRHGSWKIQL
     NATSVTHKPN AIQMALSVCE DLISSQVYAI LVSHPPTPND HFTPTPVSYT AGFYRIPVLG
     LTTRMSIYSD KSIHLSFLRT VPPYSHQSSV WFEMMRVYNW NHIILLVSDD HEGRAAQKRL
     ETLLEERESK AEKVLQFDPG TKNVTALLME ARDLEARVII LSASEDDAAT VYRAAAMLNM
     TGSGYVWLVG EREISGNALR YAPDGIIGLQ LINGKNESAH ISDAVGVVAQ AVHELLEKEN
     ITDPPRGCVG NTNIWKTGPL FKRVLMSSKY ADGVTGRVEF NEDGDRKFAN YSIMNLQNRK
     LVQVGIYNGT HVIPNDRKII WPGGETEKPR GYQMSTRLKI VTIHQEPFVY VKPTMSDGTC
     KEEFTVNGDP VKKVICTGPN DTSPGSPRHT VPQCCYGFCV DLLIKLARTM NFTYEVHLVA
     DGKFGTQERV NNSNKKEWNG MMGELLSGQA DMIVAPLTIN NERAQYIEFS KPFKYQGLTI
     LVKKEIPRST LDSFMQPFQS TLWLLVGLSV HVVAVMLYLL DRFSPFGRFK VNSEEEEEDA
     LTLSSAMWFS WGVLLNSGIG EGAPRSFSAR ILGMVWAGFA MIIVASYTAN LAAFLVLDRP
     EERITGINDP RLRNPSDKFI YATVKQSSVD IYFRRQVELS TMYRHMEKHN YESAAEAIQA
     VRDNKLHAFI WDSAVLEFEA SQKCDLVTTG ELFFRSGFGI GMRKDSPWKQ NVSLSILKSH
     ENGFMEDLDK TWVRYQECDS RSNAPATLTF ENMAGVFMLV AGGIVAGIFL IFIEIAYKRH
     KDARRKQMQL AFAAVNVWRK NLQDRKSGRA EPDPKKKATF RAITSTLASS FKRRRSSKDT
     STGGGRGALQ NQKDTVLPRR AIEREEGQLQ LCSRHRES
//
ID   SDF1_HUMAN              Reviewed;          93 AA.
AC   P48061; B2R4G0; E7EVL0; H7BYN8; Q2L985; Q2L986; Q2L988; Q5IT36;
AC   Q6ICW0; Q9H554;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   09-DEC-2015, entry version 170.
DE   RecName: Full=Stromal cell-derived factor 1;
DE            Short=SDF-1;
DE            Short=hSDF-1;
DE   AltName: Full=C-X-C motif chemokine 12;
DE   AltName: Full=Intercrine reduced in hepatomas;
DE            Short=IRH;
DE            Short=hIRH;
DE   AltName: Full=Pre-B cell growth-stimulating factor;
DE            Short=PBSF;
DE   Contains:
DE     RecName: Full=SDF-1-beta(3-72);
DE   Contains:
DE     RecName: Full=SDF-1-alpha(3-67);
DE   Flags: Precursor;
GN   Name=CXCL12; Synonyms=SDF1, SDF1A, SDF1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA).
RX   PubMed=7490086; DOI=10.1006/geno.1995.1180;
RA   Shirozu M., Nakano T., Inazawa J., Tashiro K., Tada H., Shinohara T.,
RA   Honjo T.;
RT   "Structure and chromosomal localization of the human stromal cell-
RT   derived factor 1 (SDF1) gene.";
RL   Genomics 28:495-500(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GAMMA; DELTA; EPSILON AND THETA),
RP   TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND ALTERNATIVE SPLICING.
RC   TISSUE=Fetal brain, Fetal heart, and Heart;
RX   PubMed=16626895; DOI=10.1016/j.gene.2006.02.001;
RA   Yu L., Cecil J., Peng S.B., Schrementi J., Kovacevic S., Paul D.,
RA   Su E.W., Wang J.;
RT   "Identification and expression of novel isoforms of human stromal
RT   cell-derived factor 1.";
RL   Gene 374:174-179(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA).
RC   TISSUE=Fibroblast;
RA   Spotila L.D.;
RL   Submitted (OCT-1994) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA).
RC   TISSUE=Liver;
RA   Begum N.A., Barnard G.F.;
RT   "Nucleotide sequence of hIRH, human intercrine reduced in hepatomas.";
RL   Submitted (JAN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GAMMA).
RA   Callebaut C., Verdin E.;
RT   "Inhibition of X4 and R5 HIV-1 by human SDF-1g, a novel chemokine that
RT   interferes with HIV transcription.";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA).
RA   Zhao X., Zhang H., Lee S., Wong K., Zheng B.;
RT   "Polymorphism study of cell-derived factor 1 (SDF1) gene and their
RT   correlation with HIV infection in a Chinese cohort.";
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS ALPHA AND BETA).
RC   TISSUE=Thymus, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7).
RX   PubMed=16344560; DOI=10.1101/gr.4039406;
RA   Kimura K., Wakamatsu A., Suzuki Y., Ota T., Nishikawa T.,
RA   Yamashita R., Yamamoto J., Sekine M., Tsuritani K., Wakaguri H.,
RA   Ishii S., Sugiyama T., Saito K., Isono Y., Irie R., Kushida N.,
RA   Yoneyama T., Otsuka R., Kanda K., Yokoi T., Kondo H., Wagatsuma M.,
RA   Murakawa K., Ishida S., Ishibashi T., Takahashi-Fujii A., Tanase T.,
RA   Nagai K., Kikuchi H., Nakai K., Isogai T., Sugano S.;
RT   "Diversification of transcriptional modulation: large-scale
RT   identification and characterization of putative alternative promoters
RT   of human genes.";
RL   Genome Res. 16:55-65(2006).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   FUNCTION.
RX   PubMed=8752281; DOI=10.1038/382833a0;
RA   Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.-L.,
RA   Arenzana-Seisdedos F., Schwartz O., Heard J.-M., Clark-Lewis I.,
RA   Legler D.F., Loetscher M., Baggiolini M., Moser B.;
RT   "The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents
RT   infection by T-cell-line-adapted HIV-1.";
RL   Nature 382:833-835(1996).
RN   [15]
RP   INTERACTION WITH CXCR4.
RX   PubMed=9427609; DOI=10.1038/nm0198-072;
RA   Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A.,
RA   Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E.,
RA   Moore J.P.;
RT   "AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-
RT   receptor.";
RL   Nat. Med. 4:72-77(1998).
RN   [16]
RP   INTERACTION WITH HEPARAN SULFATE, AND MUTAGENESIS OF 45-LYS--LYS-48.
RX   PubMed=10446158; DOI=10.1074/jbc.274.34.23916;
RA   Amara A., Lorthioir O., Valenzuela A., Magerus A., Thelen M.,
RA   Montes M., Virelizier J.L., Delepierre M., Baleux F., Lortat-Jacob H.,
RA   Arenzana-Seisdedos F.;
RT   "Stromal cell-derived factor-1alpha associates with heparan sulfates
RT   through the first beta-strand of the chemokine.";
RL   J. Biol. Chem. 274:23916-23925(1999).
RN   [17]
RP   FUNCTION.
RX   PubMed=11069075;
RX   DOI=10.1002/1521-4141(200010)30:10<2924::AID-IMMU2924>3.0.CO;2-Y;
RA   Moepps B., Braun M., Knoepfle K., Dillinger K., Knoechel W.,
RA   Gierschik P.;
RT   "Characterization of a Xenopus laevis CXC chemokine receptor 4:
RT   implications for hematopoietic cell development in the vertebrate
RT   embryo.";
RL   Eur. J. Immunol. 30:2924-2934(2000).
RN   [18]
RP   FUNCTION.
RX   PubMed=11859124; DOI=10.4049/jimmunol.168.5.2340;
RA   Braun M., Wunderlin M., Spieth K., Knoechel W., Gierschik P.,
RA   Moepps B.;
RT   "Xenopus laevis stromal cell-derived factor 1: conservation of
RT   structure and function during vertebrate development.";
RL   J. Immunol. 168:2340-2347(2002).
RN   [19]
RP   IDENTIFICATION OF SDF-1ALPHA(3-67) AND SDF-1BETA(3-72) BY MASS
RP   SPECTROMETRY, AND PROTEOLYTIC PROCESSING OF N-TERMINUS AND C-TERMINUS.
RX   PubMed=14525775; DOI=10.1182/blood-2003-08-2857;
RA   De La Luz Sierra M., Yang F., Narazaki M., Salvucci O., Davis D.,
RA   Yarchoan R., Zhang H.H., Fales H., Tosato G.;
RT   "Differential processing of stromal-derived factor-1alpha and beta
RT   explains functional diversity.";
RL   Blood 103:2452-2459(2004).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH ACKR3.
RX   PubMed=16107333; DOI=10.1074/jbc.M508234200;
RA   Balabanian K., Lagane B., Infantino S., Chow K.Y., Harriague J.,
RA   Moepps B., Arenzana-Seisdedos F., Thelen M., Bachelerie F.;
RT   "The chemokine SDF-1/CXCL12 binds to and signals through the orphan
RT   receptor RDC1 in T lymphocytes.";
RL   J. Biol. Chem. 280:35760-35766(2005).
RN   [21]
RP   DIMERIZATION, AND MUTAGENESIS OF HIS-46.
RX   PubMed=15741341; DOI=10.1110/ps.041219505;
RA   Veldkamp C.T., Peterson F.C., Pelzek A.J., Volkman B.F.;
RT   "The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL
RT   12) is altered by pH, phosphate, sulfate, and heparin.";
RL   Protein Sci. 14:1071-1081(2005).
RN   [22]
RP   DIMERIZATION, AND INTERACTION WITH CXCR4.
RX   PubMed=16725153; DOI=10.1016/j.jmb.2006.04.052;
RA   Veldkamp C.T., Seibert C., Peterson F.C., Sakmar T.P., Volkman B.F.;
RT   "Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-
RT   derived factor-1alpha (SDF-1alpha/CXCL12).";
RL   J. Mol. Biol. 359:1400-1409(2006).
RN   [23]
RP   FUNCTION.
RX   PubMed=18802065; DOI=10.4049/jimmunol.181.7.4632;
RA   Malik M., Chen Y.-Y., Kienzle M.F., Tomkowicz B.E., Collman R.G.,
RA   Ptasznik A.;
RT   "Monocyte migration and LFA-1-mediated attachment to brain
RT   microvascular endothelia is regulated by SDF-1 alpha through Lyn
RT   kinase.";
RL   J. Immunol. 181:4632-4637(2008).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH ACKR3.
RX   PubMed=19255243; DOI=10.1124/mol.108.053389;
RA   Kalatskaya I., Berchiche Y.A., Gravel S., Limberg B.J.,
RA   Rosenbaum J.S., Heveker N.;
RT   "AMD3100 is a CXCR7 ligand with allosteric agonist properties.";
RL   Mol. Pharmacol. 75:1240-1247(2009).
RN   [25]
RP   RECEPTOR INTERACTION.
RX   PubMed=22457824; DOI=10.1371/journal.pone.0034192;
RA   Canals M., Scholten D.J., de Munnik S., Han M.K., Smit M.J., Leurs R.;
RT   "Ubiquitination of CXCR7 controls receptor trafficking.";
RL   PLoS ONE 7:E34192-E34192(2012).
RN   [26]
RP   STRUCTURE BY NMR OF 22-88, DISULFIDE BONDS, AND MUTAGENESIS OF LYS-22;
RP   PRO-23; 22-LYS-PRO-23; 25-SER--SER-27; TYR-28 AND ARG-29.
RX   PubMed=9384579; DOI=10.1093/emboj/16.23.6996;
RA   Crump M.P., Gong J.H., Loetscher P., Rajarathnam K., Amara A.,
RA   Arenzana-Seisdedos F., Virelizier J.-L., Baggiolini M., Sykes B.D.,
RA   Clark-Lewis I.;
RT   "Solution structure and basis for functional activity of stromal cell-
RT   derived factor-1; dissociation of CXCR4 activation from binding and
RT   inhibition of HIV-1.";
RL   EMBO J. 16:6996-7007(1997).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 22-88 OF MUTANT ALA-54, AND
RP   DISULFIDE BONDS.
RX   PubMed=9618518; DOI=10.1073/pnas.95.12.6941;
RA   Dealwis C., Fernandez E.J., Thompson D.A., Simon R.J., Siani M.A.,
RA   Lolis E.;
RT   "Crystal structure of chemically synthesized [N33A] stromal cell-
RT   derived factor 1alpha, a potent ligand for the HIV-1 'fusin'
RT   coreceptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:6941-6946(1998).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 22-88, DISULFIDE BONDS, AND
RP   MUTAGENESIS OF ARG-33; PHE-34; PHE-35; GLU-36; SER-37; HIS-38 AND
RP   33-ARG--HIS-38.
RX   PubMed=10954912; DOI=10.1089/10799900050116390;
RA   Ohnishi Y., Senda T., Nandhagopal N., Sugimoto K., Shioda T.,
RA   Nagal Y., Mitsui Y.;
RT   "Crystal structure of recombinant native SDF-1alpha with additional
RT   mutagenesis studies: an attempt at a more comprehensive interpretation
RT   of accumulated structure-activity relationship data.";
RL   J. Interferon Cytokine Res. 20:691-700(2000).
RN   [29]
RP   STRUCTURE BY NMR OF 22-89, AND DISULFIDE BONDS.
RX   PubMed=15588815; DOI=10.1016/j.jmb.2004.11.003;
RA   Gozansky E.K., Louis J.M., Caffrey M., Clore G.M.;
RT   "Mapping the binding of the N-terminal extracellular tail of the CXCR4
RT   receptor to stromal cell-derived factor-1alpha.";
RL   J. Mol. Biol. 345:651-658(2005).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.07 ANGSTROMS) OF 22-88 IN COMPLEX WITH
RP   HEPARIN DISACCHARIDE I-S, DISULFIDE BONDS, AND MUTAGENESIS OF ARG-29;
RP   ARG-33; 34-PHE-PHE-35; 36-GLU--HIS-38; HIS-46; LYS-48; 52-THR--ALA-56;
RP   ARG-62; ARG-68 AND GLN-69.
RX   PubMed=17264079; DOI=10.1074/jbc.M608796200;
RA   Murphy J.W., Cho Y., Sachpatzidis A., Fan C., Hodsdon M.E., Lolis E.;
RT   "Structural and functional basis of CXCL12 (stromal cell-derived
RT   factor-1 alpha) binding to heparin.";
RL   J. Biol. Chem. 282:10018-10027(2007).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 22-89, DISULFIDE BONDS, AND
RP   MUTAGENESIS OF LYS-22.
RX   PubMed=17357154; DOI=10.1002/prot.21350;
RA   Ryu E.K., Kim T.G., Kwon T.H., Jung I.D., Ryu D., Park Y.M., Kim J.,
RA   Ahn K.H., Ban C.;
RT   "Crystal structure of recombinant human stromal cell-derived factor-
RT   1alpha.";
RL   Proteins 67:1193-1197(2007).
RN   [32]
RP   STRUCTURE BY NMR OF 22-89 OF MUTANT CYS-57 AND CYS-86 IN COMPLEX WITH
RP   CXCR4 FRAGMENT, SUBUNIT, DIMERIZATION, DISULFIDE BONDS, AND
RP   MUTAGENESIS OF ARG-41; HIS-46; LYS-48; VAL-60; ARG-62; ARG-68; VAL-70;
RP   GLU-81; GLU-84 AND LYS-85.
RX   PubMed=18799424; DOI=10.1126/scisignal.1160755;
RA   Veldkamp C.T., Seibert C., Peterson F.C., De la Cruz N.B.,
RA   Haugner J.C. III, Basnet H., Sakmar T.P., Volkman B.F.;
RT   "Structural basis of CXCR4 sulfotyrosine recognition by the chemokine
RT   SDF-1/CXCL12.";
RL   Sci. Signal. 1:RA4-RA4(2008).
RN   [33]
RP   STRUCTURE BY NMR OF 22-89, ASSAY ON RAT ISCHEMIA/REPERFUSION MODEL,
RP   DIMERIZATION, AND DISULFIDE BONDS.
RX   PubMed=19551879; DOI=10.1002/pro.167;
RA   Veldkamp C.T., Ziarek J.J., Su J., Basnet H., Lennertz R.,
RA   Weiner J.J., Peterson F.C., Baker J.E., Volkman B.F.;
RT   "Monomeric structure of the cardioprotective chemokine SDF-1/CXCL12.";
RL   Protein Sci. 18:1359-1369(2009).
RN   [34]
RP   STRUCTURE BY NMR OF 22-89, AND DISULFIDE BONDS.
RA   Ziarek J.J., Veldkamp C.T., Peterson F.C., Volkman B.F.;
RT   "Solution structure of human SDF1-alpha H25R.";
RL   Submitted (SEP-2009) to the PDB data bank.
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 22-88, AND DIMERIZATION.
RX   PubMed=20077567; DOI=10.1002/prot.22666;
RA   Murphy J.W., Yuan H., Kong Y., Xiong Y., Lolis E.J.;
RT   "Heterologous quaternary structure of CXCL12 and its relationship to
RT   the CC chemokine family.";
RL   Proteins 78:1331-1337(2010).
CC   -!- FUNCTION: Chemoattractant active on T-lymphocytes, monocytes, but
CC       not neutrophils. Activates the C-X-C chemokine receptor CXCR4 to
CC       induce a rapid and transient rise in the level of intracellular
CC       calcium ions and chemotaxis. Also binds to atypical chemokine
CC       receptor ACKR3, which activates the beta-arrestin pathway and acts
CC       as a scavenger receptor for SDF-1. SDF-1-beta(3-72) and SDF-1-
CC       alpha(3-67) show a reduced chemotactic activity. Binding to cell
CC       surface proteoglycans seems to inhibit formation of SDF-1-alpha(3-
CC       67) and thus to preserve activity on local sites. Acts as a
CC       positive regulator of monocyte migration and a negative regulator
CC       of monocyte adhesion via the LYN kinase. Stimulates migration of
CC       monocytes and T-lymphocytes through its receptors, CXCR4 and
CC       ACKR3, and decreases monocyte adherence to surfaces coated with
CC       ICAM-1, a ligand for beta-2 integrins. SDF1A/CXCR4 signaling axis
CC       inhibits beta-2 integrin LFA-1 mediated adhesion of monocytes to
CC       ICAM-1 through LYN kinase. Inhibits CXCR4-mediated infection by T-
CC       cell line-adapted HIV-1. Plays a protective role after myocardial
CC       infarction. Induces down-regulation and internalization of ACKR3
CC       expressed in various cells. Has several critical functions during
CC       embryonic development; required for B-cell lymphopoiesis,
CC       myelopoiesis in bone marrow and heart ventricular septum
CC       formation. {ECO:0000269|PubMed:11069075,
CC       ECO:0000269|PubMed:11859124, ECO:0000269|PubMed:16107333,
CC       ECO:0000269|PubMed:18802065, ECO:0000269|PubMed:19255243,
CC       ECO:0000269|PubMed:8752281}.
CC   -!- SUBUNIT: Monomer or homodimer; in equilibrium. Dimer formation is
CC       induced by non acidic pH and the presence of multivalent anions,
CC       and by binding to CXCR4 or heparin. Monomeric form is required for
CC       full chemotactic activity and resistance to ischemia/reperfusion
CC       injury, whereas the dimeric form acts as a partial agonist of
CC       CXCR4, stimulating Ca2+ mobilization but with no chemotactic
CC       activity and instead acts as a selective antagonist that blocks
CC       chemotaxis induced by the monomeric form. Interacts with the N-
CC       terminus of ACKR3. {ECO:0000269|PubMed:10446158,
CC       ECO:0000269|PubMed:16107333, ECO:0000269|PubMed:16725153,
CC       ECO:0000269|PubMed:17264079, ECO:0000269|PubMed:18799424,
CC       ECO:0000269|PubMed:19255243, ECO:0000269|PubMed:9427609}.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=Beta; Synonyms=SDF-1-beta(1-72), hSDF-1beta;
CC         IsoId=P48061-1; Sequence=Displayed;
CC       Name=Alpha; Synonyms=SDF-1-alpha(1-68), hSDF-1alpha;
CC         IsoId=P48061-2; Sequence=VSP_001056;
CC       Name=Gamma; Synonyms=hSDF-1gamma, SDF-1g;
CC         IsoId=P48061-3; Sequence=VSP_041209;
CC       Name=Delta; Synonyms=hSDF-1delta;
CC         IsoId=P48061-4; Sequence=VSP_042118;
CC       Name=Epsilon; Synonyms=hSDFepsilon;
CC         IsoId=P48061-5; Sequence=VSP_042119;
CC       Name=Theta; Synonyms=hSDFphi, hSDFtheta, Phi;
CC         IsoId=P48061-6; Sequence=VSP_042120;
CC       Name=7;
CC         IsoId=P48061-7; Sequence=VSP_054781;
CC         Note=Gene prediction based on EST data.;
CC   -!- TISSUE SPECIFICITY: Isoform Alpha and isoform Beta are
CC       ubiquitously expressed, with highest levels detected in liver,
CC       pancreas and spleen. Isoform Gamma is mainly expressed in heart,
CC       with weak expression detected in several other tissues. Isoform
CC       Delta, isoform Epsilon and isoform Theta have highest expression
CC       levels in pancreas, with lower levels detected in heart, kidney,
CC       liver and spleen. {ECO:0000269|PubMed:16626895}.
CC   -!- DEVELOPMENTAL STAGE: Isoform Alpha is ubiquitously expressed in
CC       fetal tissues. Isoform Beta and isoform Delta have more limited
CC       expression patterns, with highest levels detected in fetal spleen
CC       and fetal liver, respectively. Isoform Gamma and isoform Theta are
CC       weakly detected in fetal kidney. {ECO:0000269|PubMed:16626895}.
CC   -!- PTM: Processed forms SDF-1-beta(3-72) and SDF-1-alpha(3-67) are
CC       produced after secretion by proteolytic cleavage of isoforms Beta
CC       and Alpha, respectively. The N-terminal processing is probably
CC       achieved by DPP4. Isoform Alpha is first cleaved at the C-terminus
CC       to yield a SDF-1-alpha(1-67) intermediate before being processed
CC       at the N-terminus. The C-terminal processing of isoform Alpha is
CC       reduced by binding to heparin and, probably, cell surface
CC       proteoglycans. {ECO:0000269|PubMed:14525775}.
CC   -!- MASS SPECTROMETRY: Mass=7959; Method=Electrospray; Range=22-89
CC       (P48061-2); Evidence={ECO:0000269|PubMed:14525775};
CC   -!- MASS SPECTROMETRY: Mass=7606; Method=Electrospray; Range=24-88
CC       (P48061-2); Evidence={ECO:0000269|PubMed:14525775};
CC   -!- MASS SPECTROMETRY: Mass=8522; Method=Electrospray; Range=22-93
CC       (P48061-1); Evidence={ECO:0000269|PubMed:14525775};
CC   -!- MASS SPECTROMETRY: Mass=8297; Method=Electrospray; Range=24-93
CC       (P48061-1); Evidence={ECO:0000269|PubMed:14525775};
CC   -!- SIMILARITY: Belongs to the intercrine alpha (chemokine CxC)
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAC10202.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=SDF-1 entry;
CC       URL="https://en.wikipedia.org/wiki/SDF-1_%28biology%29";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/cxcl12/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L36033; AAB39332.1; -; mRNA.
DR   EMBL; L36034; AAB39333.1; -; mRNA.
DR   EMBL; DQ345517; ABC69270.1; -; mRNA.
DR   EMBL; DQ345518; ABC69271.1; -; mRNA.
DR   EMBL; DQ345519; ABC69272.1; -; mRNA.
DR   EMBL; DQ345520; ABC69273.1; -; mRNA.
DR   EMBL; U16752; AAA97434.1; -; mRNA.
DR   EMBL; U19495; AAB40516.1; -; mRNA.
DR   EMBL; AY644456; AAT76437.1; -; mRNA.
DR   EMBL; AY874118; AAW82036.1; -; mRNA.
DR   EMBL; CR450283; CAG29279.1; -; mRNA.
DR   EMBL; AK292628; BAF85317.1; -; mRNA.
DR   EMBL; AK311814; BAG34757.1; -; mRNA.
DR   EMBL; AU120056; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AY802782; AAV49999.1; -; Genomic_DNA.
DR   EMBL; AL137026; CAC10202.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL137026; CAC10203.1; -; Genomic_DNA.
DR   EMBL; CH471160; EAW86619.1; -; Genomic_DNA.
DR   EMBL; BC039893; AAH39893.1; -; mRNA.
DR   CCDS; CCDS31186.1; -. [P48061-3]
DR   CCDS; CCDS44373.1; -. [P48061-1]
DR   CCDS; CCDS53527.1; -. [P48061-4]
DR   CCDS; CCDS60518.1; -. [P48061-7]
DR   CCDS; CCDS7207.1; -. [P48061-2]
DR   PIR; G01540; G01540.
DR   RefSeq; NP_000600.1; NM_000609.6. [P48061-1]
DR   RefSeq; NP_001029058.1; NM_001033886.2. [P48061-3]
DR   RefSeq; NP_001171605.1; NM_001178134.1. [P48061-4]
DR   RefSeq; NP_001264919.1; NM_001277990.1. [P48061-7]
DR   RefSeq; NP_954637.1; NM_199168.3. [P48061-2]
DR   UniGene; Hs.522891; -.
DR   PDB; 1A15; X-ray; 2.20 A; A/B=22-88.
DR   PDB; 1QG7; X-ray; 2.00 A; A/B=22-88.
DR   PDB; 1SDF; NMR; -; A=22-88.
DR   PDB; 1VMC; NMR; -; A=22-89.
DR   PDB; 2J7Z; X-ray; 1.95 A; A/B=22-89.
DR   PDB; 2K01; NMR; -; A/C=22-89.
DR   PDB; 2K03; NMR; -; A/C=22-89.
DR   PDB; 2K04; NMR; -; A/C=22-89.
DR   PDB; 2K05; NMR; -; A/C=22-89.
DR   PDB; 2KEC; NMR; -; A=22-89.
DR   PDB; 2KED; NMR; -; A=22-89.
DR   PDB; 2KEE; NMR; -; A=22-89.
DR   PDB; 2KOL; NMR; -; A=22-89.
DR   PDB; 2NWG; X-ray; 2.07 A; A/B=22-88.
DR   PDB; 2SDF; NMR; -; A=22-88.
DR   PDB; 3GV3; X-ray; 1.60 A; A=26-88.
DR   PDB; 3HP3; X-ray; 2.20 A; A/B/C/D/E/F/G/H/I/J=22-88.
DR   PDB; 4LMQ; X-ray; 2.77 A; D/F=29-89.
DR   PDB; 4UAI; X-ray; 1.90 A; A/B=22-89.
DR   PDBsum; 1A15; -.
DR   PDBsum; 1QG7; -.
DR   PDBsum; 1SDF; -.
DR   PDBsum; 1VMC; -.
DR   PDBsum; 2J7Z; -.
DR   PDBsum; 2K01; -.
DR   PDBsum; 2K03; -.
DR   PDBsum; 2K04; -.
DR   PDBsum; 2K05; -.
DR   PDBsum; 2KEC; -.
DR   PDBsum; 2KED; -.
DR   PDBsum; 2KEE; -.
DR   PDBsum; 2KOL; -.
DR   PDBsum; 2NWG; -.
DR   PDBsum; 2SDF; -.
DR   PDBsum; 3GV3; -.
DR   PDBsum; 3HP3; -.
DR   PDBsum; 4LMQ; -.
DR   PDBsum; 4UAI; -.
DR   ProteinModelPortal; P48061; -.
DR   SMR; P48061; 22-89.
DR   BioGrid; 112288; 6.
DR   DIP; DIP-391N; -.
DR   IntAct; P48061; 3.
DR   MINT; MINT-6491347; -.
DR   STRING; 9606.ENSP00000379140; -.
DR   BindingDB; P48061; -.
DR   ChEMBL; CHEMBL3286074; -.
DR   DrugBank; DB06822; Tinzaparin.
DR   PhosphoSite; P48061; -.
DR   BioMuta; CXCL12; -.
DR   DMDM; 1352728; -.
DR   PaxDb; P48061; -.
DR   PRIDE; P48061; -.
DR   Ensembl; ENST00000343575; ENSP00000339913; ENSG00000107562. [P48061-2]
DR   Ensembl; ENST00000374426; ENSP00000363548; ENSG00000107562. [P48061-3]
DR   Ensembl; ENST00000374429; ENSP00000363551; ENSG00000107562. [P48061-1]
DR   Ensembl; ENST00000395793; ENSP00000379139; ENSG00000107562. [P48061-7]
DR   Ensembl; ENST00000395794; ENSP00000379140; ENSG00000107562. [P48061-4]
DR   Ensembl; ENST00000395795; ENSP00000379141; ENSG00000107562. [P48061-7]
DR   GeneID; 6387; -.
DR   KEGG; hsa:6387; -.
DR   UCSC; uc001jbf.4; human. [P48061-1]
DR   UCSC; uc001jbh.3; human. [P48061-3]
DR   UCSC; uc021ppm.1; human. [P48061-4]
DR   CTD; 6387; -.
DR   GeneCards; CXCL12; -.
DR   H-InvDB; HIX0008784; -.
DR   HGNC; HGNC:10672; CXCL12.
DR   HPA; CAB017564; -.
DR   MalaCards; CXCL12; -.
DR   MIM; 600835; gene.
DR   neXtProt; NX_P48061; -.
DR   PharmGKB; PA35602; -.
DR   eggNOG; ENOG410J1S5; Eukaryota.
DR   eggNOG; ENOG4112BS6; LUCA.
DR   GeneTree; ENSGT00390000014056; -.
DR   HOGENOM; HOG000220915; -.
DR   HOVERGEN; HBG107437; -.
DR   InParanoid; P48061; -.
DR   KO; K10031; -.
DR   OMA; STPNCAL; -.
DR   OrthoDB; EOG7C5MBS; -.
DR   PhylomeDB; P48061; -.
DR   TreeFam; TF353159; -.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   ChiTaRS; CXCL12; human.
DR   EvolutionaryTrace; P48061; -.
DR   GeneWiki; Stromal_cell-derived_factor-1; -.
DR   GenomeRNAi; 6387; -.
DR   NextBio; 24808; -.
DR   PMAP-CutDB; Q5IT36; -.
DR   PRO; PR:P48061; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; P48061; -.
DR   CleanEx; HS_CXCL12; -.
DR   Genevisible; P48061; HS.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IEA:UniProtKB-KW.
DR   GO; GO:0042056; F:chemoattractant activity; IBA:GO_Central.
DR   GO; GO:0008009; F:chemokine activity; IDA:UniProtKB.
DR   GO; GO:0042379; F:chemokine receptor binding; IMP:UniProtKB.
DR   GO; GO:0045236; F:CXCR chemokine receptor binding; IDA:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; TAS:ProtInc.
DR   GO; GO:0008344; P:adult locomotory behavior; IEA:Ensembl.
DR   GO; GO:0001667; P:ameboidal-type cell migration; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; TAS:ProtInc.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0006935; P:chemotaxis; TAS:UniProtKB.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007281; P:germ cell development; IEA:Ensembl.
DR   GO; GO:0008354; P:germ cell migration; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0050930; P:induction of positive chemotaxis; IBA:GO_Central.
DR   GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl.
DR   GO; GO:1902230; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage; IDA:BHF-UCL.
DR   GO; GO:2000107; P:negative regulation of leukocyte apoptotic process; IDA:BHF-UCL.
DR   GO; GO:1903237; P:negative regulation of leukocyte tethering or rolling; IDA:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0001569; P:patterning of blood vessels; IEA:Ensembl.
DR   GO; GO:0050918; P:positive chemotaxis; IBA:GOC.
DR   GO; GO:0048842; P:positive regulation of axon extension involved in axon guidance; IEA:Ensembl.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; TAS:BHF-UCL.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:MGI.
DR   GO; GO:0033603; P:positive regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:1901741; P:positive regulation of myoblast fusion; IEA:Ensembl.
DR   GO; GO:2000406; P:positive regulation of T cell migration; IDA:MGI.
DR   GO; GO:0008064; P:regulation of actin polymerization or depolymerization; TAS:ProtInc.
DR   GO; GO:0009408; P:response to heat; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   GO; GO:0009314; P:response to radiation; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0042098; P:T cell proliferation; IEA:Ensembl.
DR   GO; GO:0022029; P:telencephalon cell migration; IEA:Ensembl.
DR   InterPro; IPR001811; Chemokine_IL8-like_dom.
DR   Pfam; PF00048; IL8; 1.
DR   SMART; SM00199; SCY; 1.
DR   SUPFAM; SSF54117; SSF54117; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chemotaxis; Complete proteome;
KW   Cytokine; Disulfide bond; Growth factor; Reference proteome; Secreted;
KW   Signal.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22     93       Stromal cell-derived factor 1.
FT                                /FTId=PRO_0000005109.
FT   CHAIN        24     93       SDF-1-beta(3-72).
FT                                /FTId=PRO_0000005110.
FT   CHAIN        24     88       SDF-1-alpha(3-67).
FT                                /FTId=PRO_0000005111.
FT   REGION       29     33       Receptor and heparin binding.
FT                                {ECO:0000305}.
FT   REGION       39     41       Receptor binding.
FT   REGION       41     51       Heparin binding.
FT   REGION       48     50       Receptor binding.
FT   REGION       60     70       Receptor binding.
FT   MOTIF        22     23       Receptor activation motif.
FT   BINDING      62     62       Heparin.
FT   BINDING      69     69       Heparin.
FT   BINDING      85     85       Heparin.
FT   SITE         46     46       Important for dimer formation.
FT   DISULFID     30     55
FT   DISULFID     32     71
FT   VAR_SEQ      39     93       VARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWI
FT                                QEYLEKALNKRFKM -> YCTCLIRVSFHGATPLTQGSWVL
FT                                YSLSCAGGETGLREPGPMVSPRVESHQEGRLGVPGPVNLGK
FT                                A (in isoform 7).
FT                                {ECO:0000303|PubMed:16344560}.
FT                                /FTId=VSP_054781.
FT   VAR_SEQ      89     93       KRFKM -> NLISAAPAGKRVIAGARALHPSPPRACPTARA
FT                                LCEIRLWPPPEWSWPSPGDV (in isoform Delta).
FT                                {ECO:0000303|PubMed:16626895}.
FT                                /FTId=VSP_042118.
FT   VAR_SEQ      89     93       KRFKM -> NC (in isoform Epsilon).
FT                                {ECO:0000303|PubMed:16626895}.
FT                                /FTId=VSP_042119.
FT   VAR_SEQ      90     93       Missing (in isoform Alpha).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7490086,
FT                                ECO:0000303|Ref.4, ECO:0000303|Ref.6,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_001056.
FT   VAR_SEQ      90     93       RFKM -> GRREEKVGKKEKIGKKKRQKKRKAAQKRKN
FT                                (in isoform Gamma).
FT                                {ECO:0000303|PubMed:16626895,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_041209.
FT   VAR_SEQ      90     93       RFKM -> IWLYGNAETSR (in isoform Theta).
FT                                {ECO:0000303|PubMed:16626895}.
FT                                /FTId=VSP_042120.
FT   MUTAGEN      22     23       Missing: Abolished CXCR4 activation
FT                                ability, but only slightly impaired
FT                                binding to the receptor.
FT                                {ECO:0000269|PubMed:9384579}.
FT   MUTAGEN      22     22       K->A: Loss of chemotactic activity.
FT                                {ECO:0000269|PubMed:17357154,
FT                                ECO:0000269|PubMed:9384579}.
FT   MUTAGEN      22     22       K->R: Abolished CXCR4 activation ability,
FT                                but only slightly impaired binding to the
FT                                receptor. {ECO:0000269|PubMed:17357154,
FT                                ECO:0000269|PubMed:9384579}.
FT   MUTAGEN      22     22       Missing: Abolished CXCR4 activation
FT                                ability, but only slightly impaired
FT                                binding to the receptor.
FT                                {ECO:0000269|PubMed:17357154,
FT                                ECO:0000269|PubMed:9384579}.
FT   MUTAGEN      23     23       P->G: Abolished CXCR4 activation ability,
FT                                but only slightly impaired binding to the
FT                                receptor. {ECO:0000269|PubMed:9384579}.
FT   MUTAGEN      25     27       SLS->AQA: Significantly impaired CXCR4
FT                                activation ability, but only slightly
FT                                impaired binding to the receptor.
FT                                {ECO:0000269|PubMed:9384579}.
FT   MUTAGEN      28     28       Y->A: Impaired CXCR4 activation ability,
FT                                but only slightly impaired binding to the
FT                                receptor. {ECO:0000269|PubMed:9384579}.
FT   MUTAGEN      28     28       Y->H: No significant effect on CXCR4
FT                                binding or activation.
FT                                {ECO:0000269|PubMed:9384579}.
FT   MUTAGEN      29     29       R->K: Slightly impaired binding and
FT                                activation of CXCR4.
FT                                {ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:9384579}.
FT   MUTAGEN      29     29       R->Q: Greatly impaired chemotactic
FT                                activity and enhanced inhibition by
FT                                heparin. {ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:9384579}.
FT   MUTAGEN      33     38       RFFESH->AAAAAA: Significantly decreased
FT                                chemotactic activity.
FT                                {ECO:0000269|PubMed:10954912}.
FT   MUTAGEN      33     33       R->A: Significantly decreased anti-HIV-1
FT                                and chemotactic activities.
FT                                {ECO:0000269|PubMed:10954912,
FT                                ECO:0000269|PubMed:17264079}.
FT   MUTAGEN      33     33       R->Q: Slightly impaired chemotactic
FT                                activity and enhanced inhibition by
FT                                heparin. Greatly impaired chemotactic
FT                                activity; when associated with Q-29.
FT                                {ECO:0000269|PubMed:10954912,
FT                                ECO:0000269|PubMed:17264079}.
FT   MUTAGEN      34     34       F->A: No effect on anti-HIV-1 and
FT                                chemotactic activities. Slightly impaired
FT                                chemotactic activity and no effect on
FT                                inhibition by heparin; when associated
FT                                with A-35. {ECO:0000269|PubMed:10954912}.
FT   MUTAGEN      35     35       F->A: No effect on anti-HIV-1 and
FT                                chemotactic activities. Slightly impaired
FT                                chemotactic activity and no effect on
FT                                inhibition by heparin; when associated
FT                                with A-34. {ECO:0000269|PubMed:10954912}.
FT   MUTAGEN      36     38       ESH->QSN: Slightly impaired chemotactic
FT                                activity, no effect on inhibition by
FT                                heparin. {ECO:0000269|PubMed:17264079}.
FT   MUTAGEN      36     36       E->A: No effect on anti-HIV-1 and
FT                                chemotactic activities.
FT                                {ECO:0000269|PubMed:10954912}.
FT   MUTAGEN      37     37       S->A: No effect on anti-HIV-1 and
FT                                chemotactic activities.
FT                                {ECO:0000269|PubMed:10954912}.
FT   MUTAGEN      38     38       H->A: No effect on anti-HIV-1 and
FT                                chemotactic activities.
FT                                {ECO:0000269|PubMed:10954912}.
FT   MUTAGEN      41     41       R->A: No effect on CXCR4 activation.
FT                                {ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      45     48       KHLK->SSLS: Loss of heparin-binding
FT                                capacity. {ECO:0000269|PubMed:10446158}.
FT   MUTAGEN      46     46       H->A: Reduced dimerization in neutral pH.
FT                                Eliminates the pH dependence of
FT                                dimerization.
FT                                {ECO:0000269|PubMed:15741341,
FT                                ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      46     46       H->L: No significant effect on
FT                                dimerization in neutral pH. Eliminates
FT                                the pH dependence of dimerization.
FT                                {ECO:0000269|PubMed:15741341,
FT                                ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      46     46       H->N: Slightly impaired CXCR4 activation
FT                                and clear resistance to inhibition by
FT                                heparin; when associated with Q-48; Q-62;
FT                                Q-68 and N-69.
FT                                {ECO:0000269|PubMed:15741341,
FT                                ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      46     46       H->R: No effect on CXCR4 activation.
FT                                Impaired dimer formation, leading to
FT                                increased chemotactic activity.
FT                                Eliminates the pH dependence of
FT                                dimerization.
FT                                {ECO:0000269|PubMed:15741341,
FT                                ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      48     48       K->A: Impaired CXCR4 activation.
FT                                {ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      48     48       K->E: Impaired CXCR4 activation.
FT                                {ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      48     48       K->Q: Slightly impaired CXCR4 activation
FT                                and clear resistance to inhibition by
FT                                heparin; when associated with N-46; Q-62;
FT                                Q-68 and N-69.
FT                                {ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      52     56       TPNCA->GPGCG: Slightly impaired
FT                                chemotactic activity, no effect on
FT                                inhibition by heparin.
FT                                {ECO:0000269|PubMed:17264079}.
FT   MUTAGEN      57     57       L->C: Formation of an intermolecular
FT                                disulfide bond, leading to a locked
FT                                dimer; when associated with C-86. No
FT                                effect on CXCR4 activation, but loss of
FT                                chemotactic activity; when associated
FT                                with C-86.
FT   MUTAGEN      60     60       V->A: Impaired CXCR4 activation.
FT                                {ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      62     62       R->A: No effect on CXCR4 activation.
FT                                {ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      62     62       R->Q: Slightly impaired CXCR4 activation
FT                                and clear resistance to inhibition by
FT                                heparin; when associated with N-46; Q-48;
FT                                Q-68 and N-69.
FT                                {ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      68     68       R->A: Impaired CXCR4 activation.
FT                                {ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      68     68       R->E: Greatly impaired CXCR4 activation.
FT                                {ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      68     68       R->Q: Slightly impaired CXCR4 activation
FT                                and clear resistance to inhibition by
FT                                heparin; when associated with N-46; Q-48;
FT                                Q-62 and N-69.
FT                                {ECO:0000269|PubMed:17264079,
FT                                ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      69     69       Q->N: Slightly impaired CXCR4 activation
FT                                and clear resistance to inhibition by
FT                                heparin; when associated with N-46; Q-48;
FT                                Q-62 and Q-68.
FT                                {ECO:0000269|PubMed:17264079}.
FT   MUTAGEN      70     70       V->A: Impaired CXCR4 activation.
FT                                {ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      81     81       E->A: No effect on CXCR4 activation.
FT                                {ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      84     84       E->A: No effect on CXCR4 activation.
FT                                {ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      85     85       K->A: No effect on CXCR4 activation.
FT                                {ECO:0000269|PubMed:18799424}.
FT   MUTAGEN      86     86       A->C: Formation of an intermolecular
FT                                disulfide bond, leading to a locked
FT                                dimer; when associated with C-57. No
FT                                effect on CXCR4 activation, but loss of
FT                                chemotactic activity; when associated
FT                                with C-57.
FT   HELIX        24     26       {ECO:0000244|PDB:4UAI}.
FT   STRAND       27     29       {ECO:0000244|PDB:2K01}.
FT   STRAND       31     34       {ECO:0000244|PDB:3HP3}.
FT   STRAND       36     38       {ECO:0000244|PDB:1VMC}.
FT   HELIX        41     43       {ECO:0000244|PDB:3GV3}.
FT   STRAND       44     49       {ECO:0000244|PDB:3GV3}.
FT   TURN         53     55       {ECO:0000244|PDB:1QG7}.
FT   STRAND       59     63       {ECO:0000244|PDB:3GV3}.
FT   TURN         64     66       {ECO:0000244|PDB:3GV3}.
FT   STRAND       69     72       {ECO:0000244|PDB:3GV3}.
FT   HELIX        79     86       {ECO:0000244|PDB:3GV3}.
SQ   SEQUENCE   93 AA;  10666 MW;  505B5A29C2B44E8D CRC64;
     MNAKVVVVLV LVLTALCLSD GKPVSLSYRC PCRFFESHVA RANVKHLKIL NTPNCALQIV
     ARLKNNNRQV CIDPKLKWIQ EYLEKALNKR FKM
//
ID   BGAL_HUMAN              Reviewed;         677 AA.
AC   P16278; B2R7H8; B7Z6B0; P16279;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   17-FEB-2016, entry version 183.
DE   RecName: Full=Beta-galactosidase;
DE            EC=3.2.1.23;
DE   AltName: Full=Acid beta-galactosidase;
DE            Short=Lactase;
DE   AltName: Full=Elastin receptor 1;
DE   Flags: Precursor;
GN   Name=GLB1; Synonyms=ELNR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=3143362; DOI=10.1016/S0006-291X(88)80038-X;
RA   Oshima A., Tsuji A., Nagao Y., Sakuraba H., Suzuki Y.;
RT   "Cloning, sequencing, and expression of cDNA for human beta-
RT   galactosidase.";
RL   Biochem. Biophys. Res. Commun. 157:238-244(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PARTIAL PROTEIN
RP   SEQUENCE, AND VARIANT LEU-10.
RC   TISSUE=Testis;
RX   PubMed=2511208;
RA   Morreau H., Galjart N.J., Gillemans N., Willemsen R.,
RA   van der Horst G.T.J., D'Azzo A.;
RT   "Alternative splicing of beta-galactosidase mRNA generates the classic
RT   lysosomal enzyme and a beta-galactosidase-related protein.";
RL   J. Biol. Chem. 264:20655-20663(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LEU-10.
RX   PubMed=2111707; DOI=10.1089/dna.1990.9.119;
RA   Yamamoto Y., Hake C.A., Martin B.M., Kretz K.A., Ahern-Rindell A.J.,
RA   Naylor S.L., Mudd M., O'Brien J.S.;
RT   "Isolation, characterization, and mapping of a human acid beta-
RT   galactosidase cDNA.";
RL   DNA Cell Biol. 9:119-127(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   LEU-10.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-10.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT CYS-521.
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-10.
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   DOMAIN ELASTIN/LAMININ BINDING.
RX   PubMed=8383699; DOI=10.1172/JCI116280;
RA   Hinek A., Rabinovitch M., Keeley F., Okamura-Oho Y., Callahan J.;
RT   "The 67-kD elastin/laminin-binding protein is related to an
RT   enzymatically inactive, alternatively spliced form of beta-
RT   galactosidase.";
RL   J. Clin. Invest. 91:1198-1205(1993).
RN   [9]
RP   FUNCTION (ISOFORM 2).
RX   PubMed=8922281;
RA   Hinek A.;
RT   "Biological roles of the non-integrin elastin/laminin receptor.";
RL   Biol. Chem. 377:471-480(1996).
RN   [10]
RP   IDENTITY OF BETA-GALACTOSIDASE-RELATED PROTEIN WITH EBP.
RX   PubMed=9497360; DOI=10.1074/jbc.273.11.6319;
RA   Privitera S., Prody C.A., Callahan J.W., Hinek A.;
RT   "The 67-kDa enzymatically inactive alternatively spliced variant of
RT   beta-galactosidase is identical to the elastin/laminin-binding
RT   protein.";
RL   J. Biol. Chem. 273:6319-6326(1998).
RN   [11]
RP   REVIEW.
RX   PubMed=10571006; DOI=10.1016/S0925-4439(99)00075-7;
RA   Callahan J.W.;
RT   "Molecular basis of GM1 gangliosidosis and Morquio disease, type B.
RT   Structure-function studies of lysosomal beta-galactosidase and the
RT   non-lysosomal beta-galactosidase-like protein.";
RL   Biochim. Biophys. Acta 1455:85-103(1999).
RN   [12]
RP   ELASTIC-FIBER ASSEMBLY STUDIES.
RX   PubMed=10841810; DOI=10.1086/302968;
RA   Hinek A., Zhang S., Smith A.C., Callahan J.W.;
RT   "Impaired elastic-fiber assembly by fibroblasts from patients with
RT   either Morquio B disease or infantile GM1-gangliosidosis is linked to
RT   deficiency in the 67-kD spliced variant of beta-galactosidase.";
RL   Am. J. Hum. Genet. 67:23-36(2000).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-464.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.M500324-MCP200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-464 AND ASN-555.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   VARIANTS MPS4B LEU-273; HIS-482 AND CYS-509, AND VARIANT GM1G1
RP   CYS-494.
RX   PubMed=1928092;
RA   Oshima A., Yoshida K., Shimmoto M., Fukuhara Y., Sakuraba H.,
RA   Suzuki Y.;
RT   "Human beta-galactosidase gene mutations in morquio B disease.";
RL   Am. J. Hum. Genet. 49:1091-1093(1991).
RN   [19]
RP   VARIANT GM1G1 CYS-49, VARIANT GM1G3 THR-51, AND VARIANT GM1G2 CYS-201.
RX   PubMed=1909089;
RA   Nishimoto J., Nanba E., Inui K., Okada S., Suzuki K.;
RT   "GM1-gangliosidosis (genetic beta-galactosidase deficiency):
RT   identification of four mutations in different clinical phenotypes
RT   among Japanese patients.";
RL   Am. J. Hum. Genet. 49:566-574(1991).
RN   [20]
RP   VARIANTS GM1G3 THR-51 AND GLN-457, VARIANTS GM1G1 ARG-123 AND CYS-316,
RP   AND VARIANT GM1G2 CYS-201.
RX   PubMed=1907800;
RA   Yoshida K., Oshima A., Shimmoto M., Fukuhara Y., Sakuraba H.,
RA   Yanagisawa N., Suzuki Y.;
RT   "Human beta-galactosidase gene mutations in GM1-gangliosidosis: a
RT   common mutation among Japanese adult/chronic cases.";
RL   Am. J. Hum. Genet. 49:435-442(1991).
RN   [21]
RP   VARIANT GM1G1 HIS-482.
RX   PubMed=1487238; DOI=10.1007/BF00220071;
RA   Mosna G., Fattore S., Tubiello G., Brocca S., Trubia M., Gianazza E.,
RA   Gatti R., Danesino C., Minelli A., Piantanida M.;
RT   "A homozygous missense arginine to histidine substitution at position
RT   482 of the beta-galactosidase in an Italian infantile GM1-
RT   gangliosidosis patient.";
RL   Hum. Genet. 90:247-250(1992).
RN   [22]
RP   VARIANTS GM1G1 CYS-208 AND ARG-578, AND VARIANTS GM1G2 HIS-590 AND
RP   GLY-632.
RX   PubMed=8213816;
RA   Boustany R.-M.N., Qian W.-H., Suzuki K.;
RT   "Mutations in acid beta-galactosidase cause GM1-gangliosidosis in
RT   American patients.";
RL   Am. J. Hum. Genet. 53:881-888(1993).
RN   [23]
RP   VARIANT GM1G3 MET-82.
RX   PubMed=8198123;
RA   Chakraborty S., Rafi M.A., Wenger D.A.;
RT   "Mutations in the lysosomal beta-galactosidase gene that cause the
RT   adult form of GM1 gangliosidosis.";
RL   Am. J. Hum. Genet. 54:1004-1013(1994).
RN   [24]
RP   VARIANTS GM1G1 SER-148 AND ALA-216, VARIANT GM1G3 TYR-214, AND VARIANT
RP   GLY-532.
RA   Hilson W.L., Okamura-Oho Y., Zhang S., Clarke J.T.R., Mahuran D.,
RA   Callahan J.W.;
RT   "Novel missense mutations in beta-galactosidase that result in GM1-
RT   gangliosidosis.";
RL   Am. J. Hum. Genet. 55:A223-A223(1994).
RN   [25]
RP   VARIANTS MPS4B HIS-83 AND CYS-482.
RX   PubMed=7586649;
RA   Ishii N., Oohira T., Oshima A., Sakuraba H., Endo F., Matsuda I.,
RA   Sukegawa K., Orii T., Suzuki Y.;
RT   "Clinical and molecular analysis of a Japanese boy with Morquio B
RT   disease.";
RL   Clin. Genet. 48:103-108(1995).
RN   [26]
RP   VARIANT GM1G3 SER-263.
RA   Suzuki Y., Sakuraba H., Oshima A.;
RT   "Beta-galactosidase deficiency (beta-galactosidosis): GM1
RT   gangliosidosis and Morquio B disease.";
RL   (In) Scriver C.R., Beaudet A.L., Sly W.S., Valle D. (eds.);
RL   The metabolic and molecular bases of inherited disease, pp.2787-2823,
RL   McGraw-Hill Publishing Co., New York (1995).
RN   [27]
RP   VARIANTS GM1G1 HIS-59; ASN-591 AND CYS-591.
RA   Morrone A., Bardelli T., Donati M.A., Giorgi M., Di Rocco R.,
RA   Gatti R., Taddeucci G., Ricci R., D'Azzo A., Zammarchi E.;
RT   "Identification of new mutations in six Italian patients affected by a
RT   variant form of infantile GM1-gangliosidosis with severe
RT   cardiomyopathy.";
RL   Am. J. Hum. Genet. 61:A258-A258(1997).
RN   [28]
RP   VARIANTS SLOWLY PROGRESSIVE GM1-GANGLIOSIDOSIS HIS-201; SER-266 AND
RP   CYS-509.
RX   PubMed=9203065;
RA   Kaye E.M., Shalish C., Livermore J., Taylor H.A., Stevenson R.E.,
RA   Breakefield X.O.;
RT   "Beta-Galactosidase gene mutations in patients with slowly progressive
RT   GM1 gangliosidosis.";
RL   J. Child Neurol. 12:242-247(1997).
RN   [29]
RP   VARIANTS MPS4B GLU-438; LYS-484 AND ALA-500.
RX   PubMed=12393180; DOI=10.1016/S0925-4439(02)00172-2;
RA   Bagshaw R.D., Zhang S., Hinek A., Skomorowski M.-A., Whelan D.,
RA   Clarke J.T.R., Callahan J.W.;
RT   "Novel mutations (Asn 484 Lys, Thr 500 Ala, Gly 438 Glu) in Morquio B
RT   disease.";
RL   Biochim. Biophys. Acta 1588:247-253(2002).
RN   [30]
RP   VARIANTS GM1G1 HIS-59; SER-121; CYS-208; MET-240 AND ASN-491, AND
RP   VARIANTS LEU-10; CYS-521 AND GLY-532.
RX   PubMed=10338095;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<401::AID-HUMU9>3.0.CO;2-N;
RA   Silva C.M.D., Severini M.H., Sopelsa A., Coelho J.C., Zaha A.,
RA   d'Azzo A., Giugliani R.;
RT   "Six novel beta-galactosidase gene mutations in Brazilian patients
RT   with GM1-gangliosidosis.";
RL   Hum. Mutat. 13:401-409(1999).
RN   [31]
RP   VARIANTS GM1G1 SER-148 AND ASN-332, AND VARIANT GLY-532.
RX   PubMed=10839995; DOI=10.1042/0264-6021:3480621;
RA   Zhang S., Bagshaw R., Hilson W., Oho Y., Hinek A., Clarke J.T.R.,
RA   Hinek A., Callahan J.W.;
RT   "Characterization of beta-galactosidase mutations Asp332-->Asn and
RT   Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1
RT   gangliosidosis.";
RL   Biochem. J. 348:621-632(2000).
RN   [32]
RP   VARIANTS GM1G1 HIS-59; HIS-482; ASN-591 AND CYS-591, AND VARIANTS
RP   GM1G2 HIS-201 AND ASP-579.
RX   PubMed=10737981;
RX   DOI=10.1002/(SICI)1098-1004(200004)15:4<354::AID-HUMU8>3.0.CO;2-L;
RA   Morrone A., Bardelli T., Donati M.A., Giorgi M., Di Rocco M.,
RA   Gatti R., Parini R., Ricci R., Taddeucci G., D'Azzo A., Zammarchi E.;
RT   "Beta-galactosidase gene mutations affecting the lysosomal enzyme and
RT   the elastin-binding protein in GM1-gangliosidosis patients with
RT   cardiac involvement.";
RL   Hum. Mutat. 15:354-366(2000).
RN   [33]
RP   VARIANTS MPS4B LEU-273; PRO-408 AND ALA-500, VARIANTS GM1G3 MET-82;
RP   ASP-270 AND TYR-281, AND VARIANT LEU-10.
RX   PubMed=11511921; DOI=10.1007/s004390100570;
RA   Paschke E., Milos I., Kreimer-Erlacher H., Hoefler G., Beck M.,
RA   Hoeltzenbein M., Kleijer W., Levade T., Michelakakis H., Radeva B.;
RT   "Mutation analyses in 17 patients with deficiency in acid beta-
RT   galactosidase: three novel point mutations and high correlation of
RT   mutation W273L with Morquio disease type B.";
RL   Hum. Genet. 109:159-166(2001).
RN   [34]
RP   VARIANTS GM1G2 TRP-68 AND CYS-201, CHARACTERIZATION OF VARIANTS GM1G2
RP   TRP-68 AND CYS-201, VARIANT PHE-436, AND MODULATING ACTION OF VARIANT
RP   PHE-436.
RX   PubMed=12644936; DOI=10.1007/s00439-003-0930-8;
RA   Caciotti A., Bardelli T., Cunningham J., D'Azzo A., Zammarchi E.,
RA   Morrone A.;
RT   "Modulating action of the new polymorphism L436F detected in the GLB1
RT   gene of a type-II GM1 gangliosidosis patient.";
RL   Hum. Genet. 113:44-50(2003).
RN   [35]
RP   VARIANT GM1G1 TYR-151, AND CHARACTERIZATION OF VARIANT GM1G1 TYR-151.
RX   PubMed=15365997; DOI=10.1002/humu.9279;
RA   Georgiou T., Drousiotou A., Campos Y., Caciotti A., Sztriha L.,
RA   Gururaj A., Ozand P., Zammarchi E., Morrone A., D'Azzo A.;
RT   "Four novel mutations in patients from the Middle East with the
RT   infantile form of GM1-gangliosidosis.";
RL   Hum. Mutat. 24:352-352(2004).
RN   [36]
RP   ERRATUM.
RA   Georgiou T., Drousiotou A., Campos Y., Caciotti A., Sztriha L.,
RA   Gururaj A., Ozand P., Zammarchi E., Morrone A., D'Azzo A.;
RL   Hum. Mutat. 24:536-537(2004).
RN   [37]
RP   VARIANTS GM1G1 HIS-59; CYS-59; CYS-208; MET-239; TYR-281; HIS-482;
RP   ASP-579; ASN-591 AND CYS-591, VARIANT GM1G2 HIS-201, VARIANT CYS-521,
RP   CHARACTERIZATION OF VARIANTS GM1G1 HIS-59; CYS-59; CYS-208; MET-239;
RP   TYR-281; HIS-482; ASP-579; ASN-591 AND CYS-591, CHARACTERIZATION OF
RP   VARIANT GM1G2 HIS-201, AND CHARACTERIZATION OF VARIANT CYS-521.
RX   PubMed=15714521; DOI=10.1002/humu.20147;
RA   Caciotti A., Donati M.A., Boneh A., d'Azzo A., Federico A., Parini R.,
RA   Antuzzi D., Bardelli T., Nosi D., Kimonis V., Zammarchi E.,
RA   Morrone A.;
RT   "Role of beta-galactosidase and elastin binding protein in lysosomal
RT   and nonlysosomal complexes of patients with GM1-gangliosidosis.";
RL   Hum. Mutat. 25:285-292(2005).
RN   [38]
RP   VARIANTS GM1G1 LEU-10 AND TYR-151.
RX   PubMed=15791924;
RA   Gururaj A., Sztriha L., Hertecant J., Johansen J.G., Georgiou T.,
RA   Campos Y., Drousiotou A., d'Azzo A.;
RT   "Magnetic resonance imaging findings and novel mutations in GM1
RT   gangliosidosis.";
RL   J. Child Neurol. 20:57-60(2005).
RN   [39]
RP   VARIANTS GM1G3 HIS-49; GLU-73; CYS-148 AND GLU-438.
RX   PubMed=15986423; DOI=10.1002/mds.20593;
RA   Roze E., Paschke E., Lopez N., Eck T., Yoshida K., Maurel-Ollivier A.,
RA   Doummar D., Caillaud C., Galanaud D., Billette de Villemeur T.,
RA   Vidailhet M., Roubergue A.;
RT   "Dystonia and parkinsonism in GM1 type 3 gangliosidosis.";
RL   Mov. Disord. 20:1366-1369(2005).
RN   [40]
RP   VARIANTS GM1G1 CYS-59; HIS-59; SER-136; VAL-151; PRO-173; CYS-199;
RP   ASP-272; ASN-346; CYS-347; PRO-420; ARG-422; ASN-441 AND CYS-590,
RP   VARIANT GM1G2 SER-264, VARIANTS GM1G3 HIS-201 AND LYS-420, VARIANTS
RP   MPS4B CYS-83; CYS-444; SER-494 AND ALA-500, AND VARIANTS PHE-436;
RP   CYS-521 AND GLY-532.
RX   PubMed=16941474; DOI=10.1002/humu.9451;
RA   Santamaria R., Chabas A., Coll M.J., Miranda C.S., Vilageliu L.,
RA   Grinberg D.;
RT   "Twenty-one novel mutations in the GLB1 gene identified in a large
RT   group of GM1-gangliosidosis and Morquio B patients: possible common
RT   origin for the prevalent p.R59H mutation among Gypsies.";
RL   Hum. Mutat. 27:1060-1060(2006).
RN   [41]
RP   VARIANTS MPS4B LEU-273; HIS-482 AND CYS-509, AND VARIANTS GM1G1
RP   CYS-201; HIS-201 AND HIS-318.
RX   PubMed=16538002; DOI=10.2152/jmi.53.103;
RA   Tatano Y., Takeuchi N., Kuwahara J., Sakuraba H., Takahashi T.,
RA   Takada G., Itoh K.;
RT   "Elastogenesis in cultured dermal fibroblasts from patients with
RT   lysosomal beta-galactosidase, protective protein/cathepsin A and
RT   neuraminidase-1 deficiencies.";
RL   J. Med. Invest. 53:103-112(2006).
RN   [42]
RP   VARIANTS GM1G1 CYS-59; HIS-59; VAL-134; LEU-147 DEL; SER-162; CYS-208;
RP   ASP-272; 377-VAL--LYS-381 DEL; TYR-491; LEU-549 AND CYS-590, VARIANT
RP   GM1G2 HIS-201, VARIANT GM1G3 ARG-155, AND VARIANTS GM1-GANGLIOSIDOSIS
RP   LEU-434 AND GLU-554.
RX   PubMed=17309651; DOI=10.1111/j.1399-0004.2007.00767.x;
RA   Santamaria R., Blanco M., Chabas A., Grinberg D., Vilageliu L.;
RT   "Identification of 14 novel GLB1 mutations, including five deletions,
RT   in 19 patients with GM1 gangliosidosis from South America.";
RL   Clin. Genet. 71:273-279(2007).
RN   [43]
RP   VARIANT TRP-595, AND CHARACTERIZATION OF VARIANT TRP-595.
RX   PubMed=17661814; DOI=10.1111/j.1399-0004.2007.00843.x;
RA   Gort L., Santamaria R., Grinberg D., Vilageliu L., Chabas A.;
RT   "Identification of a novel pseudodeficiency allele in the GLB1 gene in
RT   a carrier of GM1 gangliosidosis.";
RL   Clin. Genet. 72:109-111(2007).
RN   [44]
RP   VARIANTS GM1G1 HIS-59; THR-132; ARG-184; ASP-190; CYS-201; HIS-201;
RP   MET-239; HIS-255; ILE-329; GLU-332; ASN-346; GLN-442 AND SER-597,
RP   VARIANTS GM1G2 GLN-68; ARG-155 AND HIS-333, VARIANTS GM1G3 MET-82;
RP   ASP-270 AND GLU-438, VARIANTS MPS4B PHE-149; TYR-198; LEU-273;
RP   ALA-397; PRO-408 AND ALA-500, CHARACTERIZATION OF VARIANTS GM1G1
RP   THR-132; ARG-184; ASP-190; CYS-201; HIS-201; HIS-255; ILE-329; GLU-332
RP   AND SER-597, CHARACTERIZATION OF VARIANTS GM1G2 GLN-68; ARG-155 AND
RP   HIS-333, CHARACTERIZATION OF VARIANTS GM1G3 ASP-270 AND GLU-438, AND
RP   CHARACTERIZATION OF VARIANTS MPS4B PHE-149; TYR-198; LEU-273; ALA-397;
RP   PRO-408 AND ALA-500.
RX   PubMed=19472408; DOI=10.1002/humu.21031;
RA   Hofer D., Paul K., Fantur K., Beck M., Buerger F., Caillaud C.,
RA   Fumic K., Ledvinova J., Lugowska A., Michelakakis H., Radeva B.,
RA   Ramaswami U., Plecko B., Paschke E.;
RT   "GM1 gangliosidosis and Morquio B disease: expression analysis of
RT   missense mutations affecting the catalytic site of acid beta-
RT   galactosidase.";
RL   Hum. Mutat. 30:1214-1221(2009).
RN   [45]
RP   VARIANTS GM1G2 CYS-49; ARG-134; CYS-148; GLU-262; LEU-314; PRO-337;
RP   VAL-414; ASN-493; LEU-597 AND ILE-600, CHARACTERIZATION OF VARIANTS
RP   GM1G2 CYS-49; GLU-262; LEU-314; PRO-337; VAL-414; ASN-493; LEU-597 AND
RP   ILE-600, VARIANTS GM1G1 TRP-68; ARG-123; PRO-236; CYS-331; ASN-332;
RP   PRO-337; HIS-482 AND PRO-514, CHARACTERIZATION OF VARIANTS GM1G1
RP   TRP-68; ARG-123; PRO-236; ASN-332; PRO-337; HIS-482 AND PRO-514,
RP   VARIANT GM1G3 PHE-297, CHARACTERIZATION OF VARIANT GM1G3 PHE-297, AND
RP   VARIANTS ARG-12; GLN-129 AND CYS-521.
RX   PubMed=25936995; DOI=10.1016/j.gene.2015.04.078;
RA   Bidchol A.M., Dalal A., Trivedi R., Shukla A., Nampoothiri S.,
RA   Sankar V.H., Danda S., Gupta N., Kabra M., Hebbar S.A., Bhat R.Y.,
RA   Matta D., Ekbote A.V., Puri R.D., Phadke S.R., Gowrishankar K.,
RA   Aggarwal S., Ranganath P., Sharda S., Kamate M., Datar C.A., Bhat K.,
RA   Kamath N., Shah H., Krishna S., Gopinath P.M., Verma I.C.,
RA   Nagarajaram H.A., Satyamoorthy K., Girisha K.M.;
RT   "Recurrent and novel GLB1 mutations in India.";
RL   Gene 567:173-181(2015).
CC   -!- FUNCTION: Cleaves beta-linked terminal galactosyl residues from
CC       gangliosides, glycoproteins, and glycosaminoglycans.
CC   -!- FUNCTION: Isoform 2 has no beta-galactosidase catalytic activity,
CC       but plays functional roles in the formation of extracellular
CC       elastic fibers (elastogenesis) and in the development of
CC       connective tissue. Seems to be identical to the elastin-binding
CC       protein (EBP), a major component of the non-integrin cell surface
CC       receptor expressed on fibroblasts, smooth muscle cells,
CC       chondroblasts, leukocytes, and certain cancer cell types. In
CC       elastin producing cells, associates with tropoelastin
CC       intracellularly and functions as a recycling molecular chaperone
CC       which facilitates the secretions of tropoelastin and its assembly
CC       into elastic fibers.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of terminal non-reducing beta-D-
CC       galactose residues in beta-D-galactosides.
CC   -!- INTERACTION:
CC       Q9NSA3:CTNNBIP1; NbExp=1; IntAct=EBI-989638, EBI-747082;
CC       Q99519:NEU1; NbExp=1; IntAct=EBI-989638, EBI-721517;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Lysosome.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm, perinuclear region.
CC       Note=Localized to the perinuclear area of the cytoplasm but not to
CC       lysosomes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P16278-1; Sequence=Displayed;
CC       Name=2; Synonyms=Beta-galactosidase-related protein,
CC       Beta-galactosidase-like protein, S-Gal, Elastin-binding protein,
CC       EBP;
CC         IsoId=P16278-2, P16279-1;
CC         Sequence=VSP_031241;
CC       Name=3;
CC         IsoId=P16278-3; Sequence=VSP_039974;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: GM1-gangliosidosis 1 (GM1G1) [MIM:230500]: An autosomal
CC       recessive lysosomal storage disease marked by the accumulation of
CC       GM1 gangliosides, glycoproteins and keratan sulfate primarily in
CC       neurons of the central nervous system. GM1-gangliosidosis type 1
CC       is characterized by onset within the first three months of life,
CC       central nervous system degeneration, coarse facial features,
CC       hepatosplenomegaly, skeletal dysmorphology reminiscent of Hurler
CC       syndrome, and rapidly progressive psychomotor deterioration.
CC       Urinary oligosaccharide levels are high. It leads to death usually
CC       between the first and second year of life.
CC       {ECO:0000269|PubMed:10338095, ECO:0000269|PubMed:10737981,
CC       ECO:0000269|PubMed:10839995, ECO:0000269|PubMed:1487238,
CC       ECO:0000269|PubMed:15365997, ECO:0000269|PubMed:15714521,
CC       ECO:0000269|PubMed:15791924, ECO:0000269|PubMed:16538002,
CC       ECO:0000269|PubMed:16941474, ECO:0000269|PubMed:17309651,
CC       ECO:0000269|PubMed:1907800, ECO:0000269|PubMed:1909089,
CC       ECO:0000269|PubMed:1928092, ECO:0000269|PubMed:19472408,
CC       ECO:0000269|PubMed:25936995, ECO:0000269|PubMed:8213816,
CC       ECO:0000269|Ref.24, ECO:0000269|Ref.27}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: GM1-gangliosidosis 2 (GM1G2) [MIM:230600]: A
CC       gangliosidosis characterized by onset between ages 1 and 5. The
CC       main symptom is locomotor ataxia, ultimately leading to a state of
CC       decerebration with epileptic seizures. Patients do not display the
CC       skeletal changes associated with the infantile form, but they
CC       nonetheless excrete elevated amounts of beta-linked galactose-
CC       terminal oligosaccharides. Inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:10737981, ECO:0000269|PubMed:12644936,
CC       ECO:0000269|PubMed:15714521, ECO:0000269|PubMed:16941474,
CC       ECO:0000269|PubMed:17309651, ECO:0000269|PubMed:1907800,
CC       ECO:0000269|PubMed:1909089, ECO:0000269|PubMed:19472408,
CC       ECO:0000269|PubMed:25936995, ECO:0000269|PubMed:8213816}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: GM1-gangliosidosis 3 (GM1G3) [MIM:230650]: A
CC       gangliosidosis with a variable phenotype. Patients show mild
CC       skeletal abnormalities, dysarthria, gait disturbance, dystonia and
CC       visual impairment. Visceromegaly is absent. Intellectual deficit
CC       can initially be mild or absent but progresses over time.
CC       Inheritance is autosomal recessive. {ECO:0000269|PubMed:11511921,
CC       ECO:0000269|PubMed:15986423, ECO:0000269|PubMed:16941474,
CC       ECO:0000269|PubMed:17309651, ECO:0000269|PubMed:1907800,
CC       ECO:0000269|PubMed:1909089, ECO:0000269|PubMed:19472408,
CC       ECO:0000269|PubMed:25936995, ECO:0000269|PubMed:8198123,
CC       ECO:0000269|Ref.24, ECO:0000269|Ref.26}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Mucopolysaccharidosis 4B (MPS4B) [MIM:253010]: A form of
CC       mucopolysaccharidosis type 4, an autosomal recessive lysosomal
CC       storage disease characterized by intracellular accumulation of
CC       keratan sulfate and chondroitin-6-sulfate. Key clinical features
CC       include short stature, skeletal dysplasia, dental anomalies, and
CC       corneal clouding. Intelligence is normal and there is no direct
CC       central nervous system involvement, although the skeletal changes
CC       may result in neurologic complications. There is variable
CC       severity, but patients with the severe phenotype usually do not
CC       survive past the second or third decade of life.
CC       {ECO:0000269|PubMed:11511921, ECO:0000269|PubMed:12393180,
CC       ECO:0000269|PubMed:16538002, ECO:0000269|PubMed:16941474,
CC       ECO:0000269|PubMed:1928092, ECO:0000269|PubMed:19472408,
CC       ECO:0000269|PubMed:7586649}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 35 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Beta-galactosidase entry;
CC       URL="https://en.wikipedia.org/wiki/Beta-galactosidase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22590; AAA51822.1; -; mRNA.
DR   EMBL; M27507; AAA51819.1; -; mRNA.
DR   EMBL; M27508; AAA35599.1; -; mRNA.
DR   EMBL; M34423; AAA51823.1; -; mRNA.
DR   EMBL; AK300021; BAH13196.1; -; mRNA.
DR   EMBL; AK312988; BAG35825.1; -; mRNA.
DR   EMBL; BT007147; AAP35811.1; -; mRNA.
DR   EMBL; AC112211; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC007493; AAH07493.1; -; mRNA.
DR   CCDS; CCDS43061.1; -. [P16278-1]
DR   CCDS; CCDS43062.1; -. [P16278-3]
DR   CCDS; CCDS46785.1; -. [P16278-2]
DR   PIR; A32688; A32611.
DR   PIR; B32688; B32688.
DR   RefSeq; NP_000395.2; NM_000404.3. [P16278-1]
DR   RefSeq; NP_001073279.1; NM_001079811.2. [P16278-3]
DR   RefSeq; NP_001129074.1; NM_001135602.2. [P16278-2]
DR   UniGene; Hs.443031; -.
DR   PDB; 3THC; X-ray; 1.80 A; A/B/C/D=24-677.
DR   PDB; 3THD; X-ray; 1.79 A; A/B/C/D=24-677.
DR   PDB; 3WEZ; X-ray; 2.11 A; A/B/C/D=24-677.
DR   PDB; 3WF0; X-ray; 2.20 A; A/B/C/D=24-677.
DR   PDB; 3WF1; X-ray; 2.00 A; A/B/C/D=24-677.
DR   PDB; 3WF2; X-ray; 2.30 A; A/B/C/D=24-677.
DR   PDB; 3WF3; X-ray; 2.15 A; A/B/C/D=24-677.
DR   PDB; 3WF4; X-ray; 2.30 A; A/B/C/D=24-677.
DR   PDBsum; 3THC; -.
DR   PDBsum; 3THD; -.
DR   PDBsum; 3WEZ; -.
DR   PDBsum; 3WF0; -.
DR   PDBsum; 3WF1; -.
DR   PDBsum; 3WF2; -.
DR   PDBsum; 3WF3; -.
DR   PDBsum; 3WF4; -.
DR   ProteinModelPortal; P16278; -.
DR   SMR; P16278; 29-647.
DR   BioGrid; 108984; 36.
DR   IntAct; P16278; 12.
DR   MINT; MINT-3008481; -.
DR   STRING; 9606.ENSP00000306920; -.
DR   BindingDB; P16278; -.
DR   ChEMBL; CHEMBL2522; -.
DR   CAZy; GH35; Glycoside Hydrolase Family 35.
DR   iPTMnet; P16278; -.
DR   PhosphoSite; P16278; -.
DR   SwissPalm; P16278; -.
DR   BioMuta; GLB1; -.
DR   DMDM; 215273939; -.
DR   MaxQB; P16278; -.
DR   PaxDb; P16278; -.
DR   PRIDE; P16278; -.
DR   DNASU; 2720; -.
DR   Ensembl; ENST00000307363; ENSP00000306920; ENSG00000170266.
DR   Ensembl; ENST00000399402; ENSP00000382333; ENSG00000170266.
DR   Ensembl; ENST00000445488; ENSP00000393377; ENSG00000170266.
DR   GeneID; 2720; -.
DR   KEGG; hsa:2720; -.
DR   UCSC; uc003cfh.1; human. [P16278-1]
DR   UCSC; uc003cfj.1; human. [P16278-2]
DR   CTD; 2720; -.
DR   GeneCards; GLB1; -.
DR   GeneReviews; GLB1; -.
DR   HGNC; HGNC:4298; GLB1.
DR   HPA; CAB008382; -.
DR   HPA; HPA040610; -.
DR   MalaCards; GLB1; -.
DR   MIM; 230500; phenotype.
DR   MIM; 230600; phenotype.
DR   MIM; 230650; phenotype.
DR   MIM; 253010; phenotype.
DR   MIM; 611458; gene.
DR   neXtProt; NX_P16278; -.
DR   Orphanet; 79255; GM1 gangliosidosis type 1.
DR   Orphanet; 79256; GM1 gangliosidosis type 2.
DR   Orphanet; 79257; GM1 gangliosidosis type 3.
DR   Orphanet; 309310; Mucopolysaccharidosis type 4B.
DR   PharmGKB; PA28709; -.
DR   eggNOG; KOG0496; Eukaryota.
DR   eggNOG; COG1874; LUCA.
DR   HOGENOM; HOG000221607; -.
DR   HOVERGEN; HBG004841; -.
DR   InParanoid; P16278; -.
DR   KO; K12309; -.
DR   OrthoDB; EOG7GXPCD; -.
DR   PhylomeDB; P16278; -.
DR   TreeFam; TF314816; -.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   Reactome; R-HSA-2022857; Keratan sulfate degradation.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-2206308; MPS IV - Morquio syndrome B.
DR   Reactome; R-HSA-4085001; Sialic acid metabolism.
DR   SABIO-RK; P16278; -.
DR   ChiTaRS; GLB1; human.
DR   GeneWiki; GLB1; -.
DR   GenomeRNAi; 2720; -.
DR   NextBio; 10738; -.
DR   PRO; PR:P16278; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Proteomes; UP000005640; Unplaced.
DR   Bgee; P16278; -.
DR   CleanEx; HS_GLB1; -.
DR   ExpressionAtlas; P16278; baseline and differential.
DR   Genevisible; P16278; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0004565; F:beta-galactosidase activity; IMP:UniProtKB.
DR   GO; GO:0016936; F:galactoside binding; IEA:Ensembl.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0044262; P:cellular carbohydrate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0006488; P:dolichol-linked oligosaccharide biosynthetic process; TAS:Reactome.
DR   GO; GO:0019388; P:galactose catabolic process; IEA:Ensembl.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0042340; P:keratan sulfate catabolic process; TAS:Reactome.
DR   GO; GO:0042339; P:keratan sulfate metabolic process; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0018279; P:protein N-linked glycosylation via asparagine; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0006665; P:sphingolipid metabolic process; TAS:Reactome.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 3.20.20.80; -; 1.
DR   InterPro; IPR026283; B-gal_1-like.
DR   InterPro; IPR025300; BetaGal_jelly_roll_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR031330; Gly_Hdrlase_35_cat.
DR   InterPro; IPR019801; Glyco_hydro_35_CS.
DR   InterPro; IPR013781; Glyco_hydro_catalytic_dom.
DR   InterPro; IPR001944; Glycoside_Hdrlase_35.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   PANTHER; PTHR23421; PTHR23421; 1.
DR   Pfam; PF13364; BetaGal_dom4_5; 1.
DR   Pfam; PF01301; Glyco_hydro_35; 1.
DR   PIRSF; PIRSF006336; B-gal; 1.
DR   PRINTS; PR00742; GLHYDRLASE35.
DR   SUPFAM; SSF49785; SSF49785; 2.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   PROSITE; PS01182; GLYCOSYL_HYDROL_F35; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Gangliosidosis;
KW   Glycoprotein; Glycosidase; Hydrolase; Lysosome; Mucopolysaccharidosis;
KW   Polymorphism; Reference proteome; Signal; Zymogen.
FT   SIGNAL        1     23
FT   PROPEP       24     28
FT                                /FTId=PRO_0000012185.
FT   CHAIN        29    677       Beta-galactosidase.
FT                                /FTId=PRO_0000012186.
FT   ACT_SITE    188    188       Proton donor. {ECO:0000255}.
FT   ACT_SITE    268    268       Nucleophile. {ECO:0000255}.
FT   CARBOHYD     26     26       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    247    247       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    464    464       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16263699,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    498    498       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    542    542       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    545    545       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    555    555       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   VAR_SEQ       1     30       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_039974.
FT   VAR_SEQ      83    244       YVPWNFHEPWPGQYQFSEDHDVEYFLRLAHELGLLVILRPG
FT                                PYICAEWEMGGLPAWLLEKESILLRSSDPDYLAAVDKWLGV
FT                                LLPKMKPLLYQNGGPVITVQVENEYGSYFACDFDYLRFLQK
FT                                RFRHHLGDDVVLFTTDGAHKTFLKCGALQGLYTTVDFGT
FT                                -> LPGSCGQVVGSPSAQDEASPLSEWRASYNSA (in
FT                                isoform 2). {ECO:0000303|PubMed:2511208}.
FT                                /FTId=VSP_031241.
FT   VARIANT      10     10       P -> L (in GM1G1; dbSNP:rs7637099).
FT                                {ECO:0000269|PubMed:10338095,
FT                                ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:15791924,
FT                                ECO:0000269|PubMed:2111707,
FT                                ECO:0000269|PubMed:2511208,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_008671.
FT   VARIANT      12     12       L -> R (in dbSNP:rs4302331).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074053.
FT   VARIANT      49     49       R -> C (in GM1G1 and GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:1909089,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_003329.
FT   VARIANT      49     49       R -> H (in GM1G3).
FT                                {ECO:0000269|PubMed:15986423}.
FT                                /FTId=VAR_062340.
FT   VARIANT      51     51       I -> T (in GM1G3).
FT                                {ECO:0000269|PubMed:1907800,
FT                                ECO:0000269|PubMed:1909089}.
FT                                /FTId=VAR_003330.
FT   VARIANT      59     59       R -> C (in GM1G1; loss of galactosidase
FT                                activity; severe mutation).
FT                                {ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_026129.
FT   VARIANT      59     59       R -> H (in GM1G1; with cardiac
FT                                involvement in some patients; loss of
FT                                galactosidase activity; severe mutation).
FT                                {ECO:0000269|PubMed:10338095,
FT                                ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17309651,
FT                                ECO:0000269|PubMed:19472408,
FT                                ECO:0000269|Ref.27}.
FT                                /FTId=VAR_008672.
FT   VARIANT      68     68       R -> Q (in GM1G2; 7.4% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062341.
FT   VARIANT      68     68       R -> W (in GM1G2 and GM1G1; loss of
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:12644936,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_026130.
FT   VARIANT      73     73       K -> E (in GM1G3).
FT                                {ECO:0000269|PubMed:15986423}.
FT                                /FTId=VAR_062342.
FT   VARIANT      82     82       T -> M (in GM1G3; mild phenotype).
FT                                {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:19472408,
FT                                ECO:0000269|PubMed:8198123}.
FT                                /FTId=VAR_008673.
FT   VARIANT      83     83       Y -> C (in MPS4B).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062343.
FT   VARIANT      83     83       Y -> H (in MPS4B; 2-5% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:7586649}.
FT                                /FTId=VAR_008674.
FT   VARIANT     109    109       R -> W (in dbSNP:rs35289681).
FT                                /FTId=VAR_053875.
FT   VARIANT     121    121       R -> S (in GM1G1).
FT                                {ECO:0000269|PubMed:10338095}.
FT                                /FTId=VAR_008675.
FT   VARIANT     123    123       G -> R (in GM1G1; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:1907800,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_003331.
FT   VARIANT     129    129       E -> Q. {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074054.
FT   VARIANT     132    132       M -> T (in GM1G1; 4.3% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062344.
FT   VARIANT     134    134       G -> R (in GM1G2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074055.
FT   VARIANT     134    134       G -> V (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037937.
FT   VARIANT     136    136       P -> S (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062345.
FT   VARIANT     147    147       Missing (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037938.
FT   VARIANT     148    148       R -> C (in GM1G3 and GM1G2).
FT                                {ECO:0000269|PubMed:15986423,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_062346.
FT   VARIANT     148    148       R -> S (in GM1G1).
FT                                {ECO:0000269|PubMed:10839995,
FT                                ECO:0000269|Ref.24}.
FT                                /FTId=VAR_013541.
FT   VARIANT     149    149       S -> F (in MPS4B; 2.0% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062347.
FT   VARIANT     151    151       D -> V (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062348.
FT   VARIANT     151    151       D -> Y (in GM1G1; complete lack of
FT                                protein; loss of galactosidase activity).
FT                                {ECO:0000269|PubMed:15365997,
FT                                ECO:0000269|PubMed:15791924}.
FT                                /FTId=VAR_026131.
FT   VARIANT     155    155       L -> R (in GM1G2 and GM1G3; 6.7% of wild-
FT                                type galactosidase activity).
FT                                {ECO:0000269|PubMed:17309651,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_037939.
FT   VARIANT     162    162       L -> S (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037940.
FT   VARIANT     173    173       L -> P (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062349.
FT   VARIANT     184    184       Q -> R (in GM1G1; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062350.
FT   VARIANT     190    190       G -> D (in GM1G1; 3.4% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062351.
FT   VARIANT     198    198       D -> Y (in MPS4B; 17.4% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062352.
FT   VARIANT     199    199       Y -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062353.
FT   VARIANT     201    201       R -> C (in GM1G1 and GM1G2; 8.4% of wild-
FT                                type galactosidase activity; activity
FT                                severely reduced in transfection with the
FT                                F-436 polymorphism).
FT                                {ECO:0000269|PubMed:12644936,
FT                                ECO:0000269|PubMed:16538002,
FT                                ECO:0000269|PubMed:1907800,
FT                                ECO:0000269|PubMed:1909089,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_003332.
FT   VARIANT     201    201       R -> H (in GM1G1 and GM1G2; also in a
FT                                patient with a slowly progressive GM1-
FT                                gangliosidosis form; 36.2% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:16538002,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17309651,
FT                                ECO:0000269|PubMed:19472408,
FT                                ECO:0000269|PubMed:9203065}.
FT                                /FTId=VAR_013542.
FT   VARIANT     208    208       R -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:10338095,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:17309651,
FT                                ECO:0000269|PubMed:8213816}.
FT                                /FTId=VAR_008676.
FT   VARIANT     214    214       D -> Y (in GM1G3). {ECO:0000269|Ref.24}.
FT                                /FTId=VAR_013543.
FT   VARIANT     216    216       V -> A (in GM1G1). {ECO:0000269|Ref.24}.
FT                                /FTId=VAR_013544.
FT   VARIANT     236    236       L -> P (in GM1G1; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074056.
FT   VARIANT     239    239       T -> M (in GM1G1; loss of galactosidase
FT                                activity; severe mutation; causes a rapid
FT                                degradation of the protein precursor).
FT                                {ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_026132.
FT   VARIANT     240    240       V -> M (in GM1G1).
FT                                {ECO:0000269|PubMed:10338095}.
FT                                /FTId=VAR_008677.
FT   VARIANT     255    255       Q -> H (in GM1G1; 2.4% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062354.
FT   VARIANT     262    262       G -> E (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074057.
FT   VARIANT     263    263       P -> S (in GM1G3). {ECO:0000269|Ref.26}.
FT                                /FTId=VAR_013545.
FT   VARIANT     264    264       L -> S (in GM1G2).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062355.
FT   VARIANT     266    266       N -> S (in GM1G3).
FT                                {ECO:0000269|PubMed:9203065}.
FT                                /FTId=VAR_013546.
FT   VARIANT     270    270       Y -> D (in GM1G3; originally classified
FT                                as Morquio syndrome).
FT                                {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_013547.
FT   VARIANT     272    272       G -> D (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_038346.
FT   VARIANT     273    273       W -> L (in MPS4B; decreased galactosidase
FT                                activity). {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:16538002,
FT                                ECO:0000269|PubMed:1928092,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_003333.
FT   VARIANT     281    281       H -> Y (in GM1G1 and GM1G3).
FT                                {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:15714521}.
FT                                /FTId=VAR_013548.
FT   VARIANT     297    297       L -> F (in GM1G3; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074058.
FT   VARIANT     314    314       F -> L (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074059.
FT   VARIANT     316    316       Y -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:1907800}.
FT                                /FTId=VAR_003334.
FT   VARIANT     318    318       N -> H (in GM1G1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:16538002}.
FT                                /FTId=VAR_062356.
FT   VARIANT     329    329       T -> I (in GM1G1; 5.0% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062357.
FT   VARIANT     331    331       Y -> C (in GM1G1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074060.
FT   VARIANT     332    332       D -> E (in GM1G1; 2.3% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062358.
FT   VARIANT     332    332       D -> N (in GM1G1; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:10839995,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_013549.
FT   VARIANT     333    333       Y -> H (in GM1G2; 3.0% of wild-type
FT                                galactosidase activity; the mutant
FT                                protein is localized in the lysosomal-
FT                                endosomal compartment).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062359.
FT   VARIANT     337    337       L -> P (in GM1G1 and GM1G2; loss of
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074061.
FT   VARIANT     346    346       K -> N (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062360.
FT   VARIANT     347    347       Y -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062361.
FT   VARIANT     377    381       Missing (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037941.
FT   VARIANT     397    397       P -> A (in MPS4B; 24.0% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062362.
FT   VARIANT     408    408       Q -> P (in MPS4B; 1.1% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_013550.
FT   VARIANT     414    414       G -> V (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074062.
FT   VARIANT     420    420       T -> K (in GM1G3).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062363.
FT   VARIANT     420    420       T -> P (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062364.
FT   VARIANT     422    422       L -> R (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062365.
FT   VARIANT     434    434       S -> L (in GM1-gangliosidosis;
FT                                unclassified clinical type).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037942.
FT   VARIANT     436    436       L -> F (seems to have a modulating action
FT                                in the expression of the severity of
FT                                other mutations; dbSNP:rs34421970).
FT                                {ECO:0000269|PubMed:12644936,
FT                                ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_026133.
FT   VARIANT     438    438       G -> E (in GM1G3 and MPS4B; mild form;
FT                                5.7% of wild-type galactosidase
FT                                activity). {ECO:0000269|PubMed:12393180,
FT                                ECO:0000269|PubMed:15986423,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_013551.
FT   VARIANT     441    441       D -> N (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062366.
FT   VARIANT     442    442       R -> Q (in GM1G1).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062367.
FT   VARIANT     444    444       Y -> C (in MPS4B).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062368.
FT   VARIANT     457    457       R -> Q (in GM1G3).
FT                                {ECO:0000269|PubMed:1907800}.
FT                                /FTId=VAR_003335.
FT   VARIANT     482    482       R -> C (in MPS4B; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:7586649}.
FT                                /FTId=VAR_008678.
FT   VARIANT     482    482       R -> H (in MPS4B and GM1G1; severe
FT                                decrease in galactosidase activity).
FT                                {ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:1487238,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:16538002,
FT                                ECO:0000269|PubMed:1928092,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_003336.
FT   VARIANT     484    484       N -> K (in MPS4B; mild form; fibroblasts
FT                                from MPS4B compound heterozygotes for K-
FT                                484 and A-500 have 1.9% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:12393180}.
FT                                /FTId=VAR_013552.
FT   VARIANT     491    491       D -> N (in GM1G1).
FT                                {ECO:0000269|PubMed:10338095}.
FT                                /FTId=VAR_008679.
FT   VARIANT     491    491       D -> Y (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037943.
FT   VARIANT     493    493       K -> N (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074063.
FT   VARIANT     494    494       G -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:1928092}.
FT                                /FTId=VAR_013553.
FT   VARIANT     494    494       G -> S (in MPS4B).
FT                                {ECO:0000269|PubMed:16941474}.
FT                                /FTId=VAR_062369.
FT   VARIANT     500    500       T -> A (in MPS4B; mild form; 2.1% of
FT                                wild-type galactosidase activity).
FT                                {ECO:0000269|PubMed:11511921,
FT                                ECO:0000269|PubMed:12393180,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_013554.
FT   VARIANT     509    509       W -> C (in MPS4B; also in a patient with
FT                                a slowly progressive form of GM1-
FT                                gangisidosis; loss of galactosidase
FT                                activity). {ECO:0000269|PubMed:16538002,
FT                                ECO:0000269|PubMed:1928092,
FT                                ECO:0000269|PubMed:9203065}.
FT                                /FTId=VAR_003337.
FT   VARIANT     514    514       L -> P (in GM1G1; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074064.
FT   VARIANT     521    521       R -> C (in a GM1-gangliosidosis patient;
FT                                mild phenotype; reduction of
FT                                galactosidase activity; unknown
FT                                pathological significance;
FT                                dbSNP:rs4302331).
FT                                {ECO:0000269|PubMed:10338095,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|PubMed:16641997,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_008680.
FT   VARIANT     532    532       S -> G. {ECO:0000269|PubMed:10338095,
FT                                ECO:0000269|PubMed:10839995,
FT                                ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|Ref.24}.
FT                                /FTId=VAR_008681.
FT   VARIANT     549    549       P -> L (in GM1G1).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037944.
FT   VARIANT     554    554       G -> E (in GM1-gangliosidosis;
FT                                unclassified clinical type).
FT                                {ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037945.
FT   VARIANT     578    578       K -> R (in GM1G1).
FT                                {ECO:0000269|PubMed:8213816}.
FT                                /FTId=VAR_008682.
FT   VARIANT     579    579       G -> D (in GM1G1 and GM1G2; loss of
FT                                galactosidase activity; severe mutation).
FT                                {ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:15714521}.
FT                                /FTId=VAR_013555.
FT   VARIANT     590    590       R -> C (in GM1G1).
FT                                {ECO:0000269|PubMed:16941474,
FT                                ECO:0000269|PubMed:17309651}.
FT                                /FTId=VAR_037946.
FT   VARIANT     590    590       R -> H (in GM1G2).
FT                                {ECO:0000269|PubMed:8213816}.
FT                                /FTId=VAR_008683.
FT   VARIANT     591    591       Y -> C (in GM1G1; with cardiac
FT                                involvement in some patients; loss of
FT                                galactosidase activity; severe mutation;
FT                                causes a rapid degradation of the protein
FT                                precursor). {ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|Ref.27}.
FT                                /FTId=VAR_008684.
FT   VARIANT     591    591       Y -> N (in GM1G1; with cardiac
FT                                involvement in some patients; loss of
FT                                galactosidase activity; severe mutation;
FT                                causes a rapid degradation of the protein
FT                                precursor). {ECO:0000269|PubMed:10737981,
FT                                ECO:0000269|PubMed:15714521,
FT                                ECO:0000269|Ref.27}.
FT                                /FTId=VAR_008685.
FT   VARIANT     595    595       R -> W (reduction of galactosidase
FT                                activity). {ECO:0000269|PubMed:17661814}.
FT                                /FTId=VAR_037947.
FT   VARIANT     597    597       P -> L (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074065.
FT   VARIANT     597    597       P -> S (in GM1G1; 2.1% of wild-type
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:19472408}.
FT                                /FTId=VAR_062370.
FT   VARIANT     600    600       T -> I (in GM1G2; decrease in
FT                                galactosidase activity).
FT                                {ECO:0000269|PubMed:25936995}.
FT                                /FTId=VAR_074066.
FT   VARIANT     632    632       E -> G (in GM1G2).
FT                                {ECO:0000269|PubMed:8213816}.
FT                                /FTId=VAR_008686.
FT   CONFLICT     89     89       H -> Y (in Ref. 4; BAH13196).
FT                                {ECO:0000305}.
FT   CONFLICT    201    201       R -> A (in Ref. 1; AAA51822).
FT                                {ECO:0000305}.
FT   STRAND       32     35       {ECO:0000244|PDB:3THD}.
FT   TURN         36     39       {ECO:0000244|PDB:3THD}.
FT   STRAND       40     43       {ECO:0000244|PDB:3THD}.
FT   STRAND       46     48       {ECO:0000244|PDB:3THD}.
FT   STRAND       51     54       {ECO:0000244|PDB:3THD}.
FT   HELIX        57     59       {ECO:0000244|PDB:3THD}.
FT   HELIX        62     64       {ECO:0000244|PDB:3THD}.
FT   HELIX        65     74       {ECO:0000244|PDB:3THD}.
FT   STRAND       78     83       {ECO:0000244|PDB:3THD}.
FT   HELIX        86     89       {ECO:0000244|PDB:3THD}.
FT   HELIX       100    102       {ECO:0000244|PDB:3THD}.
FT   HELIX       104    113       {ECO:0000244|PDB:3THD}.
FT   STRAND      117    121       {ECO:0000244|PDB:3THD}.
FT   HELIX       131    134       {ECO:0000244|PDB:3THD}.
FT   HELIX       137    141       {ECO:0000244|PDB:3THD}.
FT   STRAND      147    149       {ECO:0000244|PDB:3THD}.
FT   HELIX       152    169       {ECO:0000244|PDB:3THD}.
FT   HELIX       170    172       {ECO:0000244|PDB:3THD}.
FT   HELIX       174    176       {ECO:0000244|PDB:3THD}.
FT   STRAND      178    184       {ECO:0000244|PDB:3THD}.
FT   STRAND      186    188       {ECO:0000244|PDB:3WF0}.
FT   HELIX       189    191       {ECO:0000244|PDB:3THD}.
FT   HELIX       197    211       {ECO:0000244|PDB:3THD}.
FT   STRAND      213    224       {ECO:0000244|PDB:3THD}.
FT   HELIX       225    231       {ECO:0000244|PDB:3THD}.
FT   STRAND      236    241       {ECO:0000244|PDB:3THD}.
FT   HELIX       248    258       {ECO:0000244|PDB:3THD}.
FT   STRAND      260    262       {ECO:0000244|PDB:3THD}.
FT   STRAND      265    272       {ECO:0000244|PDB:3THD}.
FT   HELIX       286    298       {ECO:0000244|PDB:3THD}.
FT   STRAND      302    306       {ECO:0000244|PDB:3THD}.
FT   TURN        322    324       {ECO:0000244|PDB:3THD}.
FT   HELIX       345    354       {ECO:0000244|PDB:3THD}.
FT   TURN        355    357       {ECO:0000244|PDB:3THD}.
FT   STRAND      375    378       {ECO:0000244|PDB:3THD}.
FT   STRAND      380    384       {ECO:0000244|PDB:3THD}.
FT   TURN        385    388       {ECO:0000244|PDB:3THD}.
FT   HELIX       389    392       {ECO:0000244|PDB:3THD}.
FT   STRAND      398    402       {ECO:0000244|PDB:3THD}.
FT   HELIX       407    409       {ECO:0000244|PDB:3THD}.
FT   STRAND      413    421       {ECO:0000244|PDB:3THD}.
FT   STRAND      426    433       {ECO:0000244|PDB:3THD}.
FT   STRAND      439    447       {ECO:0000244|PDB:3THD}.
FT   STRAND      450    456       {ECO:0000244|PDB:3THD}.
FT   TURN        457    459       {ECO:0000244|PDB:3THD}.
FT   STRAND      462    467       {ECO:0000244|PDB:3THD}.
FT   STRAND      472    478       {ECO:0000244|PDB:3THD}.
FT   HELIX       487    489       {ECO:0000244|PDB:3THD}.
FT   STRAND      509    513       {ECO:0000244|PDB:3THD}.
FT   HELIX       516    521       {ECO:0000244|PDB:3THD}.
FT   TURN        522    527       {ECO:0000244|PDB:3THD}.
FT   STRAND      550    556       {ECO:0000244|PDB:3THD}.
FT   STRAND      568    572       {ECO:0000244|PDB:3THD}.
FT   STRAND      578    583       {ECO:0000244|PDB:3THD}.
FT   STRAND      586    591       {ECO:0000244|PDB:3THD}.
FT   TURN        593    595       {ECO:0000244|PDB:3THD}.
FT   STRAND      601    603       {ECO:0000244|PDB:3THD}.
FT   HELIX       605    607       {ECO:0000244|PDB:3THD}.
FT   STRAND      610    612       {ECO:0000244|PDB:3THD}.
FT   STRAND      614    622       {ECO:0000244|PDB:3THD}.
FT   STRAND      627    629       {ECO:0000244|PDB:3THD}.
FT   HELIX       631    633       {ECO:0000244|PDB:3THD}.
FT   STRAND      634    641       {ECO:0000244|PDB:3THD}.
SQ   SEQUENCE   677 AA;  76075 MW;  74421586B1BCFECA CRC64;
     MPGFLVRILP LLLVLLLLGP TRGLRNATQR MFEIDYSRDS FLKDGQPFRY ISGSIHYSRV
     PRFYWKDRLL KMKMAGLNAI QTYVPWNFHE PWPGQYQFSE DHDVEYFLRL AHELGLLVIL
     RPGPYICAEW EMGGLPAWLL EKESILLRSS DPDYLAAVDK WLGVLLPKMK PLLYQNGGPV
     ITVQVENEYG SYFACDFDYL RFLQKRFRHH LGDDVVLFTT DGAHKTFLKC GALQGLYTTV
     DFGTGSNITD AFLSQRKCEP KGPLINSEFY TGWLDHWGQP HSTIKTEAVA SSLYDILARG
     ASVNLYMFIG GTNFAYWNGA NSPYAAQPTS YDYDAPLSEA GDLTEKYFAL RNIIQKFEKV
     PEGPIPPSTP KFAYGKVTLE KLKTVGAALD ILCPSGPIKS LYPLTFIQVK QHYGFVLYRT
     TLPQDCSNPA PLSSPLNGVH DRAYVAVDGI PQGVLERNNV ITLNITGKAG ATLDLLVENM
     GRVNYGAYIN DFKGLVSNLT LSSNILTDWT IFPLDTEDAV RSHLGGWGHR DSGHHDEAWA
     HNSSNYTLPA FYMGNFSIPS GIPDLPQDTF IQFPGWTKGQ VWINGFNLGR YWPARGPQLT
     LFVPQHILMT SAPNTITVLE LEWAPCSSDD PELCAVTFVD RPVIGSSVTY DHPSKPVEKR
     LMPPPPQKNK DSWLDHV
//
ID   BRI1_ARATH              Reviewed;        1196 AA.
AC   O22476; C0LGS4;
DT   28-MAR-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   17-FEB-2016, entry version 152.
DE   RecName: Full=Protein BRASSINOSTEROID INSENSITIVE 1;
DE            Short=AtBRI1;
DE            EC=2.7.10.1;
DE            EC=2.7.11.1;
DE   AltName: Full=Brassinosteroid LRR receptor kinase;
DE   Flags: Precursor;
GN   Name=BRI1; OrderedLocusNames=At4g39400; ORFNames=F23K16.30;
OS   Arabidopsis thaliana (Mouse-ear cress).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; Gunneridae;
OC   Pentapetalae; rosids; malvids; Brassicales; Brassicaceae; Camelineae;
OC   Arabidopsis.
OX   NCBI_TaxID=3702;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], TISSUE SPECIFICITY, AND MUTANTS
RP   BRI1-101; BRI1-104; BRI1-113 AND BRI1-115.
RC   STRAIN=cv. Columbia;
RX   PubMed=9298904; DOI=10.1016/S0092-8674(00)80357-8;
RA   Li J., Chory J.;
RT   "A putative leucine-rich repeat receptor kinase involved in
RT   brassinosteroid signal transduction.";
RL   Cell 90:929-938(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, MUTANTS BRI1-5/DWF2-W41;
RP   BRI1-6/BRI1-119/DWF2-399; BRI1-7/DWF2-WM3-2; BRI1-8/DWF2-WM6-2 AND
RP   BRI1-9/DWF2-WMB19, AND DISRUPTION PHENOTYPE.
RC   STRAIN=cv. En-2, and cv. Wassilewskija-2;
RX   PubMed=10557222; DOI=10.1104/pp.121.3.743;
RA   Noguchi T., Fujioka S., Choe S., Takatsuto S., Yoshida S., Yuan H.,
RA   Feldmann K.A., Tax F.E.;
RT   "Brassinosteroid-insensitive dwarf mutants of Arabidopsis accumulate
RT   brassinosteroids.";
RL   Plant Physiol. 121:743-752(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND MUTANTS BRI1-1; BRI1-108; BRI1-117 AND
RP   BRI1-102.
RC   STRAIN=cv. Columbia;
RX   PubMed=10938344; DOI=10.1104/pp.123.4.1247;
RA   Friedrichsen D.M., Joazeiro C.A.P., Li J., Hunter T., Chory J.;
RT   "BRASSINOSTEROID-INSENSITIVE-1 is a ubiquitously expressed leucine-
RT   rich repeat receptor serine/threonine kinase.";
RL   Plant Physiol. 123:1247-1256(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=cv. Columbia;
RX   PubMed=20064227; DOI=10.1186/1471-2164-11-19;
RA   Gou X., He K., Yang H., Yuan T., Lin H., Clouse S.D., Li J.;
RT   "Genome-wide cloning and sequence analysis of leucine-rich repeat
RT   receptor-like protein kinase genes in Arabidopsis thaliana.";
RL   BMC Genomics 11:19-19(2010).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Columbia;
RX   PubMed=10617198; DOI=10.1038/47134;
RA   Mayer K.F.X., Schueller C., Wambutt R., Murphy G., Volckaert G.,
RA   Pohl T., Duesterhoeft A., Stiekema W., Entian K.-D., Terryn N.,
RA   Harris B., Ansorge W., Brandt P., Grivell L.A., Rieger M.,
RA   Weichselgartner M., de Simone V., Obermaier B., Mache R., Mueller M.,
RA   Kreis M., Delseny M., Puigdomenech P., Watson M., Schmidtheini T.,
RA   Reichert B., Portetelle D., Perez-Alonso M., Boutry M., Bancroft I.,
RA   Vos P., Hoheisel J., Zimmermann W., Wedler H., Ridley P.,
RA   Langham S.-A., McCullagh B., Bilham L., Robben J.,
RA   van der Schueren J., Grymonprez B., Chuang Y.-J., Vandenbussche F.,
RA   Braeken M., Weltjens I., Voet M., Bastiaens I., Aert R., Defoor E.,
RA   Weitzenegger T., Bothe G., Ramsperger U., Hilbert H., Braun M.,
RA   Holzer E., Brandt A., Peters S., van Staveren M., Dirkse W.,
RA   Mooijman P., Klein Lankhorst R., Rose M., Hauf J., Koetter P.,
RA   Berneiser S., Hempel S., Feldpausch M., Lamberth S., Van den Daele H.,
RA   De Keyser A., Buysshaert C., Gielen J., Villarroel R., De Clercq R.,
RA   van Montagu M., Rogers J., Cronin A., Quail M.A., Bray-Allen S.,
RA   Clark L., Doggett J., Hall S., Kay M., Lennard N., McLay K., Mayes R.,
RA   Pettett A., Rajandream M.A., Lyne M., Benes V., Rechmann S.,
RA   Borkova D., Bloecker H., Scharfe M., Grimm M., Loehnert T.-H.,
RA   Dose S., de Haan M., Maarse A.C., Schaefer M., Mueller-Auer S.,
RA   Gabel C., Fuchs M., Fartmann B., Granderath K., Dauner D., Herzl A.,
RA   Neumann S., Argiriou A., Vitale D., Liguori R., Piravandi E.,
RA   Massenet O., Quigley F., Clabauld G., Muendlein A., Felber R.,
RA   Schnabl S., Hiller R., Schmidt W., Lecharny A., Aubourg S.,
RA   Chefdor F., Cooke R., Berger C., Monfort A., Casacuberta E.,
RA   Gibbons T., Weber N., Vandenbol M., Bargues M., Terol J., Torres A.,
RA   Perez-Perez A., Purnelle B., Bent E., Johnson S., Tacon D., Jesse T.,
RA   Heijnen L., Schwarz S., Scholler P., Heber S., Francs P., Bielke C.,
RA   Frishman D., Haase D., Lemcke K., Mewes H.-W., Stocker S.,
RA   Zaccaria P., Bevan M., Wilson R.K., de la Bastide M., Habermann K.,
RA   Parnell L., Dedhia N., Gnoj L., Schutz K., Huang E., Spiegel L.,
RA   Sekhon M., Murray J., Sheet P., Cordes M., Abu-Threideh J.,
RA   Stoneking T., Kalicki J., Graves T., Harmon G., Edwards J.,
RA   Latreille P., Courtney L., Cloud J., Abbott A., Scott K., Johnson D.,
RA   Minx P., Bentley D., Fulton B., Miller N., Greco T., Kemp K.,
RA   Kramer J., Fulton L., Mardis E., Dante M., Pepin K., Hillier L.W.,
RA   Nelson J., Spieth J., Ryan E., Andrews S., Geisel C., Layman D.,
RA   Du H., Ali J., Berghoff A., Jones K., Drone K., Cotton M., Joshu C.,
RA   Antonoiu B., Zidanic M., Strong C., Sun H., Lamar B., Yordan C.,
RA   Ma P., Zhong J., Preston R., Vil D., Shekher M., Matero A., Shah R.,
RA   Swaby I.K., O'Shaughnessy A., Rodriguez M., Hoffman J., Till S.,
RA   Granat S., Shohdy N., Hasegawa A., Hameed A., Lodhi M., Johnson A.,
RA   Chen E., Marra M.A., Martienssen R., McCombie W.R.;
RT   "Sequence and analysis of chromosome 4 of the plant Arabidopsis
RT   thaliana.";
RL   Nature 402:769-777(1999).
RN   [6]
RP   GENOME REANNOTATION.
RC   STRAIN=cv. Columbia;
RG   The Arabidopsis Information Resource (TAIR);
RL   Submitted (APR-2011) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   PHOSPHORYLATION AT SER-838; THR-842; THR-846; SER-858 AND THR-872, AND
RP   MUTAGENESIS OF LYS-911.
RX   PubMed=11027724; DOI=10.1104/pp.124.2.751;
RA   Oh M.-H., Ray W.K., Huber S.C., Asara J.M., Gage D.A., Clouse S.D.;
RT   "Recombinant BRASSINOSTEROID INSENSITIVE 1 receptor-like kinase
RT   autophosphorylates on serine and threonine residues and phosphorylates
RT   a conserved peptide motif in vitro.";
RL   Plant Physiol. 124:751-766(2000).
RN   [8]
RP   STEROID-BINDING.
RX   PubMed=10875920; DOI=10.1126/science.288.5475.2360;
RA   He Z., Wang Z.-Y., Li J., Zhu Q., Lamb C., Ronald P., Chory J.;
RT   "Perception of brassinosteroids by the extracellular domain of the
RT   receptor kinase BRI1.";
RL   Science 288:2360-2363(2000).
RN   [9]
RP   SUBCELLULAR LOCATION, STEROID-BINDING, AND AUTOPHOSPHORYLATION.
RX   PubMed=11268216; DOI=10.1038/35066597;
RA   Wang Z.-Y., Seto H., Fujioka S., Yoshida S., Chory J.;
RT   "BRI1 is a critical component of a plasma-membrane receptor for plant
RT   steroids.";
RL   Nature 410:380-383(2001).
RN   [10]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH BAK1.
RX   PubMed=12150928; DOI=10.1016/S0092-8674(02)00814-0;
RA   Nam K.H., Li J.;
RT   "BRI1/BAK1, a receptor kinase pair mediating brassinosteroid
RT   signaling.";
RL   Cell 110:203-212(2002).
RN   [11]
RP   PHOSPHORYLATION, AND INTERACTION WITH BAK1.
RX   PubMed=12150929; DOI=10.1016/S0092-8674(02)00812-7;
RA   Li J., Wen J., Lease K.A., Doke J.T., Tax F.E., Walker J.C.;
RT   "BAK1, an Arabidopsis LRR receptor-like protein kinase, interacts with
RT   BRI1 and modulates brassinosteroid signaling.";
RL   Cell 110:213-222(2002).
RN   [12]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH BAK1.
RX   PubMed=15548744; DOI=10.1105/tpc.104.025387;
RA   Russinova E., Borst J.-W., Kwaaitaal M., Cano-Delgado A., Yin Y.,
RA   Chory J., de Vries S.C.;
RT   "Heterodimerization and endocytosis of Arabidopsis brassinosteroid
RT   receptors BRI1 and AtSERK3 (BAK1).";
RL   Plant Cell 16:3216-3229(2004).
RN   [13]
RP   INTERACTION WITH TTL.
RX   PubMed=15319482; DOI=10.1105/tpc.104.023903;
RA   Nam K.H., Li J.;
RT   "The Arabidopsis transthyretin-like protein is a potential substrate
RT   of BRASSINOSTEROID-INSENSITIVE 1.";
RL   Plant Cell 16:2406-2417(2004).
RN   [14]
RP   PHOSPHORYLATION AT SER-838; SER-858; THR-872; THR-880; THR-982 AND
RP   SER-1168, INTERACTION WITH BAK1, AND MUTAGENESIS OF SER-838; THR-842;
RP   THR-846; SER-858; THR-872; THR-1039; SER-1044; THR-1045; THR-1049;
RP   SER-1168; SER-1172; 1179-SER-THR-1180 AND SER-1187.
RX   PubMed=15894717; DOI=10.1105/tpc.105.031393;
RA   Wang X., Goshe M.B., Soderblom E.J., Phinney B.S., Kuchar J.A., Li J.,
RA   Asami T., Yoshida S., Huber S.C., Clouse S.D.;
RT   "Identification and functional analysis of in vivo phosphorylation
RT   sites of the Arabidopsis BRASSINOSTEROID-INSENSITIVE1 receptor
RT   kinase.";
RL   Plant Cell 17:1685-1703(2005).
RN   [15]
RP   INTERACTION WITH SERK1.
RX   PubMed=16473966; DOI=10.1105/tpc.105.039412;
RA   Karlova R., Boeren S., Russinova E., Aker J., Vervoort J.,
RA   de Vries S.C.;
RT   "The Arabidopsis SOMATIC EMBRYOGENESIS RECEPTOR-LIKE KINASE1 protein
RT   complex includes BRASSINOSTEROID-INSENSITIVE1.";
RL   Plant Cell 18:626-638(2006).
RN   [16]
RP   FUNCTION.
RX   PubMed=17138891; DOI=10.1126/science.1134040;
RA   Belkhadir Y., Chory J.;
RT   "Brassinosteroid signaling: a paradigm for steroid hormone signaling
RT   from the cell surface.";
RL   Science 314:1410-1411(2006).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17578906; DOI=10.1101/gad.1561307;
RA   Geldner N., Hyman D.L., Wang X., Schumacher K., Chory J.;
RT   "Endosomal signaling of plant steroid receptor kinase BRI1.";
RL   Genes Dev. 21:1598-1602(2007).
RN   [18]
RP   GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=17588517; DOI=10.1016/j.molcel.2007.05.015;
RA   Jin H., Yan Z., Nam K.H., Li J.;
RT   "Allele-specific suppression of a defective brassinosteroid receptor
RT   reveals a physiological role of UGGT in ER quality control.";
RL   Mol. Cell 26:821-830(2007).
RN   [19]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=17520012; DOI=10.1371/journal.pone.0000449;
RA   Kwezi L., Meier S., Mungur L., Ruzvidzo O., Irving H., Gehring C.;
RT   "The Arabidopsis thaliana brassinosteroid receptor (AtBRI1) contains a
RT   domain that functions as a guanylyl cyclase in vitro.";
RL   PLoS ONE 2:E449-E449(2007).
RN   [20]
RP   SUBUNIT.
RX   PubMed=17905839; DOI=10.1529/biophysj.107.112003;
RA   Hink M.A., Shah K., Russinova E., de Vries S.C., Visser A.J.;
RT   "Fluorescence fluctuation analysis of Arabidopsis thaliana somatic
RT   embryogenesis receptor-like kinase and brassinosteroid insensitive 1
RT   receptor oligomerization.";
RL   Biophys. J. 94:1052-1062(2008).
RN   [21]
RP   MUTAGENESIS OF GLY-989.
RX   PubMed=18332904; DOI=10.1038/cr.2008.36;
RA   Xu W., Huang J., Li B., Li J., Wang Y.;
RT   "Is kinase activity essential for biological functions of BRI1?";
RL   Cell Res. 18:472-478(2008).
RN   [22]
RP   FUNCTION, PHOSPHORYLATION AT SER-838; THR-846; SER-858; SER-1166 AND
RP   THR-1180, INTERACTION WITH BAK1, AND MUTAGENESIS OF SER-838; THR-842;
RP   THR-846; SER-858; THR-1049; SER-1166; SER-1168; SER-1172; SER-1179 AND
RP   THR-1180.
RX   PubMed=18694562; DOI=10.1016/j.devcel.2008.06.011;
RA   Wang X., Kota U., He K., Blackburn K., Li J., Goshe M.B., Huber S.C.,
RA   Clouse S.D.;
RT   "Sequential transphosphorylation of the BRI1/BAK1 receptor kinase
RT   complex impacts early events in brassinosteroid signaling.";
RL   Dev. Cell 15:220-235(2008).
RN   [23]
RP   PHOSPHORYLATION AT SER-887, AND PHOSPHORYLATION OF SERK1.
RX   PubMed=19105183; DOI=10.1002/pmic.200701059;
RA   Karlova R., Boeren S., van Dongen W., Kwaaitaal M., Aker J.,
RA   Vervoort J., de Vries S.C.;
RT   "Identification of in vitro phosphorylation sites in the Arabidopsis
RT   thaliana somatic embryogenesis receptor-like kinases.";
RL   Proteomics 9:368-379(2009).
RN   [24]
RP   FUNCTION, MUTAGENESIS OF TYR-831; TYR-898; TYR-945; TYR-956; TYR-961;
RP   TYR-1052; TYR-1057; TYR-1058; TYR-1070 AND TYR-1072,
RP   AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-831 AND TYR-956.
RX   PubMed=19124768; DOI=10.1073/pnas.0810249106;
RA   Oh M.-H., Wang X., Kota U., Goshe M.B., Clouse S.D., Huber S.C.;
RT   "Tyrosine phosphorylation of the BRI1 receptor kinase emerges as a
RT   component of brassinosteroid signaling in Arabidopsis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:658-663(2009).
RN   [25]
RP   INTERACTION WITH CDG1.
RX   PubMed=21855796; DOI=10.1016/j.molcel.2011.05.037;
RA   Kim T.W., Guan S., Burlingame A.L., Wang Z.Y.;
RT   "The CDG1 kinase mediates brassinosteroid signal transduction from
RT   BRI1 receptor kinase to BSU1 phosphatase and GSK3-like kinase BIN2.";
RL   Mol. Cell 43:561-571(2011).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 29-788 IN COMPLEX WITH
RP   BRASSINOLIDE, AND GLYCOSYLATION AT ASN-112; ASN-154; ASN-233; ASN-275;
RP   ASN-351 AND ASN-545.
RX   PubMed=21666665; DOI=10.1038/nature10153;
RA   Hothorn M., Belkhadir Y., Dreux M., Dabi T., Noel J.P., Wilson I.A.,
RA   Chory J.;
RT   "Structural basis of steroid hormone perception by the receptor kinase
RT   BRI1.";
RL   Nature 474:467-471(2011).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 23-784 IN COMPLEX WITH
RP   BRASSINOLIDE, AND GLYCOSYLATION AT ASN-112; ASN-154; ASN-233; ASN-275;
RP   ASN-351; ASN-510; ASN-545 AND ASN-573.
RX   PubMed=21666666; DOI=10.1038/nature10178;
RA   She J., Han Z., Kim T.W., Wang J., Cheng W., Chang J., Shi S.,
RA   Wang J., Yang M., Wang Z.Y., Chai J.;
RT   "Structural insight into brassinosteroid perception by BRI1.";
RL   Nature 474:472-476(2011).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 29-788 IN COMPLEX WITH
RP   BRASSINOLIDE, AND GLYCOSYLATION AT ASN-112; ASN-154; ASN-233; ASN-275;
RP   ASN-351; ASN-545 AND ASN-573.
RX   PubMed=23929946; DOI=10.1126/science.1242468;
RA   Santiago J., Henzler C., Hothorn M.;
RT   "Molecular mechanism for plant steroid receptor activation by somatic
RT   embryogenesis co-receptor kinases.";
RL   Science 341:889-892(2013).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.98 ANGSTROMS) OF 865-1160 IN COMPLEX WITH
RP   ATP, AND GLYCOSYLATION AT ASN-154; ASN-275 AND ASN-545.
RX   PubMed=24461462; DOI=10.1111/tpj.12445;
RA   Bojar D., Martinez J., Santiago J., Rybin V., Bayliss R., Hothorn M.;
RT   "Crystal structures of the phosphorylated BRI1 kinase domain and
RT   implications for brassinosteroid signal initiation.";
RL   Plant J. 78:31-43(2014).
CC   -!- FUNCTION: Receptor with a dual specificity kinase activity acting
CC       on both serine/threonine- and tyrosine-containing substrates.
CC       Regulates, in response to brassinosteroid binding, a signaling
CC       cascade involved in plant development, including expression of
CC       light- and stress-regulated genes, promotion of cell elongation,
CC       normal leaf and chloroplast senescence, and flowering. Binds
CC       brassinolide, and less effectively castasterone, but not
CC       2,3,22,23-O-tetramethylbrassinolide or ecdysone. May be involved
CC       in a feedback regulation of brassinosteroid biosynthesis.
CC       Phosphorylates BRI1-associated receptor kinase 1 (BAK1),
CC       Transthyretin-Like protein (TTL) and SERK1 on 'Ser-299' and 'Thr-
CC       462' in vitro. May have a guanylyl cyclase activity.
CC       {ECO:0000269|PubMed:10557222, ECO:0000269|PubMed:10938344,
CC       ECO:0000269|PubMed:17138891, ECO:0000269|PubMed:17520012,
CC       ECO:0000269|PubMed:18694562, ECO:0000269|PubMed:19124768}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10027}.
CC   -!- ENZYME REGULATION: Activated by Ser and Thr phosphorylation.
CC   -!- SUBUNIT: Monomer or homodimer in the plasma membrane. Heterodimer
CC       with BAK1 in the endosomes. Interacts with SERK1 and TTL in a
CC       kinase-dependent manner. Component of the SERK1 signaling complex,
CC       composed of KAPP, CDC48A, GRF6 or GRF7, SERK1, SERK2, SERK3/BAK1
CC       and BRI1. Interacts with CDG1 (PubMed:21855796).
CC       {ECO:0000269|PubMed:12150928, ECO:0000269|PubMed:12150929,
CC       ECO:0000269|PubMed:15319482, ECO:0000269|PubMed:15548744,
CC       ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:16473966,
CC       ECO:0000269|PubMed:17905839, ECO:0000269|PubMed:18694562,
CC       ECO:0000269|PubMed:21855796}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-1797828, EBI-1797828;
CC       Q944A7:At4g35230; NbExp=4; IntAct=EBI-1797828, EBI-1797846;
CC       Q94F62:BAK1; NbExp=5; IntAct=EBI-1797828, EBI-617138;
CC       O65280:F6N23.9; NbExp=2; IntAct=EBI-1797828, EBI-1797930;
CC       Q94AG2:SERK1; NbExp=5; IntAct=EBI-1797828, EBI-1555537;
CC       Q9LVM5:TTL; NbExp=3; IntAct=EBI-1797828, EBI-1803584;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endosome membrane; Single-pass type I membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously.
CC       {ECO:0000269|PubMed:10938344, ECO:0000269|PubMed:9298904}.
CC   -!- DEVELOPMENTAL STAGE: Expressed constitutively in either dark- or
CC       light-grown seedlings.
CC   -!- DOMAIN: Contains one leucine-zipper motif and two pairs of
CC       conservatively spaced Cys (Cys pair 1 and 2) involved in forming
CC       heterodimers. {ECO:0000269|PubMed:17520012}.
CC   -!- DOMAIN: A 70 amino acid island between the 21th and the 22th LRR
CC       is essential for the binding of brassinosteroids.
CC       {ECO:0000269|PubMed:21666665}.
CC   -!- DOMAIN: The JM domain (815-883) is a positive regulator of kinase
CC       activity and is required for Tyr phosphorylation.
CC       {ECO:0000269|PubMed:17520012}.
CC   -!- DOMAIN: A guanylyl cyclase domain (1021-1134) having an in vitro
CC       activity is included in the C-terminal kinase domain.
CC       {ECO:0000269|PubMed:17520012}.
CC   -!- PTM: Autophosphorylated on Tyr-831, Tyr-956 and maybe Tyr-1072.
CC       Phosphorylated on at least 12 sites, with a preference for Ser
CC       residues. Transphosphorylated on Ser-887 by SERK1 and on Ser-838,
CC       Thr-846, Ser-858 and Ser-1166 by BAK1. Phosphorylation on Ser-1166
CC       enhances the kinase activity. {ECO:0000269|PubMed:11027724,
CC       ECO:0000269|PubMed:12150928, ECO:0000269|PubMed:12150929,
CC       ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562,
CC       ECO:0000269|PubMed:19105183, ECO:0000269|PubMed:19124768}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:17588517}.
CC   -!- DISRUPTION PHENOTYPE: Dwarf phenotype and aberrant leaf shape.
CC       {ECO:0000269|PubMed:10557222}.
CC   -!- MISCELLANEOUS: Binding of brassinosteroid induces intramolecular
CC       autophosphorylation of BRI1. Interaction with BAK1 activates both
CC       receptor kinases and the full activation of either receptor kinase
CC       requires transphosphorylation by their partners. Optimum in vitro
CC       phosphorylation of the substrate requires Arg or Lys residues at
CC       P-3, P-4, and P+5 (relative to the phosphorylated amino acid at
CC       P=0). Homodimerizes in the absence of ligand and binds
CC       brassinosteroid in the absence of its coreceptor BAK1.
CC   -!- MISCELLANEOUS: The bri1-9 mutation produces a fully active protein
CC       with a subtle conformational change that is recognized for
CC       reglucosylation by UGGT, resulting in its endoplasmic reticulum
CC       retention via Glc(1)Man(9)GlcNAc(2)-calreticulin/calnexin
CC       interaction. {ECO:0000305|PubMed:17588517}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 25 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=PlantP kinase Classification PPC;
CC       URL="http://plantsp.genomics.purdue.edu/family/class.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF017056; AAC49810.1; -; Genomic_DNA.
DR   EMBL; FJ708766; ACN59359.1; -; mRNA.
DR   EMBL; AL078620; CAB44675.1; -; Genomic_DNA.
DR   EMBL; AL161595; CAB80603.1; -; Genomic_DNA.
DR   EMBL; CP002687; AEE87069.1; -; Genomic_DNA.
DR   PIR; T09356; T09356.
DR   RefSeq; NP_195650.1; NM_120100.2.
DR   UniGene; At.27898; -.
DR   UniGene; At.69020; -.
DR   PDB; 3RGX; X-ray; 2.47 A; A=23-784.
DR   PDB; 3RGZ; X-ray; 2.28 A; A=23-784.
DR   PDB; 3RIZ; X-ray; 2.52 A; A=29-788.
DR   PDB; 3RJ0; X-ray; 2.54 A; A=29-788.
DR   PDB; 4LSA; X-ray; 2.50 A; A=29-788.
DR   PDB; 4LSX; X-ray; 3.30 A; A/B=29-788.
DR   PDB; 4M7E; X-ray; 3.60 A; A/B=24-784.
DR   PDB; 4OA2; X-ray; 2.48 A; A=865-1196.
DR   PDB; 4OA6; X-ray; 2.43 A; A=865-1160.
DR   PDB; 4OA9; X-ray; 2.70 A; A=865-1160.
DR   PDB; 4OAB; X-ray; 2.30 A; A=865-1160.
DR   PDB; 4OAC; X-ray; 1.98 A; A=865-1160.
DR   PDB; 4OH4; X-ray; 2.25 A; A/B=863-1172.
DR   PDB; 4Q5J; X-ray; 2.77 A; A/B=863-1180.
DR   PDBsum; 3RGX; -.
DR   PDBsum; 3RGZ; -.
DR   PDBsum; 3RIZ; -.
DR   PDBsum; 3RJ0; -.
DR   PDBsum; 4LSA; -.
DR   PDBsum; 4LSX; -.
DR   PDBsum; 4M7E; -.
DR   PDBsum; 4OA2; -.
DR   PDBsum; 4OA6; -.
DR   PDBsum; 4OA9; -.
DR   PDBsum; 4OAB; -.
DR   PDBsum; 4OAC; -.
DR   PDBsum; 4OH4; -.
DR   PDBsum; 4Q5J; -.
DR   ProteinModelPortal; O22476; -.
DR   SMR; O22476; 30-774, 863-1160.
DR   BioGrid; 15375; 24.
DR   DIP; DIP-45997N; -.
DR   IntAct; O22476; 7.
DR   STRING; 3702.AT4G39400.1; -.
DR   iPTMnet; O22476; -.
DR   PaxDb; O22476; -.
DR   PRIDE; O22476; -.
DR   EnsemblPlants; AT4G39400.1; AT4G39400.1; AT4G39400.
DR   GeneID; 830095; -.
DR   Gramene; AT4G39400.1; AT4G39400.1; AT4G39400.
DR   KEGG; ath:AT4G39400; -.
DR   TAIR; AT4G39400; -.
DR   eggNOG; ENOG410IF0B; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   eggNOG; COG4886; LUCA.
DR   HOGENOM; HOG000116551; -.
DR   InParanoid; O22476; -.
DR   KO; K13415; -.
DR   OMA; QPTDSAD; -.
DR   PhylomeDB; O22476; -.
DR   BioCyc; ARA:AT4G39400-MONOMER; -.
DR   EvolutionaryTrace; O22476; -.
DR   PRO; PR:O22476; -.
DR   Proteomes; UP000006548; Chromosome 4.
DR   Genevisible; O22476; AT.
DR   GO; GO:0005768; C:endosome; IDA:TAIR.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IDA:TAIR.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:TAIR.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:TAIR.
DR   GO; GO:0004672; F:protein kinase activity; IDA:TAIR.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:TAIR.
DR   GO; GO:0005496; F:steroid binding; IDA:TAIR.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0048657; P:anther wall tapetum cell differentiation; IMP:TAIR.
DR   GO; GO:0010268; P:brassinosteroid homeostasis; IEP:TAIR.
DR   GO; GO:0009742; P:brassinosteroid mediated signaling pathway; IMP:TAIR.
DR   GO; GO:0009729; P:detection of brassinosteroid stimulus; IMP:TAIR.
DR   GO; GO:0048366; P:leaf development; IMP:TAIR.
DR   GO; GO:0060548; P:negative regulation of cell death; IMP:UniProtKB.
DR   GO; GO:0010584; P:pollen exine formation; IMP:TAIR.
DR   GO; GO:0009911; P:positive regulation of flower development; IGI:TAIR.
DR   GO; GO:1900140; P:regulation of seedling development; IMP:UniProtKB.
DR   GO; GO:0010224; P:response to UV-B; IGI:TAIR.
DR   Gene3D; 2.60.120.200; -; 1.
DR   Gene3D; 3.80.10.10; -; 4.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR013210; LRR_N_plant-typ.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00560; LRR_1; 2.
DR   Pfam; PF13855; LRR_8; 2.
DR   Pfam; PF08263; LRRNT_2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Brassinosteroid signaling pathway;
KW   Cell membrane; Complete proteome; Endosome; Glycoprotein; Kinase;
KW   Leucine-rich repeat; Lipid-binding; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Signal; Steroid-binding; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24   1196       Protein BRASSINOSTEROID INSENSITIVE 1.
FT                                /FTId=PRO_0000024305.
FT   TRANSMEM    793    813       Helical. {ECO:0000255}.
FT   REPEAT       71     98       LRR 1. {ECO:0000255}.
FT   REPEAT       99    121       LRR 2. {ECO:0000255}.
FT   REPEAT      122    146       LRR 3. {ECO:0000255}.
FT   REPEAT      148    169       LRR 4. {ECO:0000255}.
FT   REPEAT      172    197       LRR 5. {ECO:0000255}.
FT   REPEAT      199    221       LRR 6. {ECO:0000255}.
FT   REPEAT      222    244       LRR 7. {ECO:0000255}.
FT   REPEAT      245    268       LRR 8. {ECO:0000255}.
FT   REPEAT      269    290       LRR 9. {ECO:0000255}.
FT   REPEAT      291    314       LRR 10. {ECO:0000255}.
FT   REPEAT      316    338       LRR 11. {ECO:0000255}.
FT   REPEAT      339    363       LRR 12. {ECO:0000255}.
FT   REPEAT      364    388       LRR 13. {ECO:0000255}.
FT   REPEAT      390    413       LRR 14. {ECO:0000255}.
FT   REPEAT      415    439       LRR 15. {ECO:0000255}.
FT   REPEAT      441    463       LRR 16. {ECO:0000255}.
FT   REPEAT      464    487       LRR 17. {ECO:0000255}.
FT   REPEAT      488    511       LRR 18. {ECO:0000255}.
FT   REPEAT      513    535       LRR 19. {ECO:0000255}.
FT   REPEAT      536    559       LRR 20. {ECO:0000255}.
FT   REPEAT      561    583       LRR 21. {ECO:0000255}.
FT   REPEAT      653    677       LRR 22. {ECO:0000255}.
FT   REPEAT      678    701       LRR 23. {ECO:0000255}.
FT   REPEAT      702    725       LRR 24. {ECO:0000255}.
FT   REPEAT      727    750       LRR 25. {ECO:0000255}.
FT   DOMAIN      883   1158       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     889    897       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     957    959       ATP. {ECO:0000269|PubMed:24461462}.
FT   NP_BIND     963    966       ATP. {ECO:0000269|PubMed:24461462}.
FT   NP_BIND    1009   1014       ATP. {ECO:0000269|PubMed:24461462}.
FT   MOTIF        62     69       Cys pair 1.
FT   MOTIF       763    770       Cys pair 2.
FT   ACT_SITE   1009   1009       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     597    597       Brassinolide.
FT                                {ECO:0000269|PubMed:21666666,
FT                                ECO:0000269|PubMed:23929946}.
FT   BINDING     642    642       Brassinolide.
FT                                {ECO:0000269|PubMed:23929946}.
FT   BINDING     647    647       Brassinolide; via amide nitrogen.
FT                                {ECO:0000269|PubMed:21666665,
FT                                ECO:0000269|PubMed:21666666,
FT                                ECO:0000269|PubMed:23929946}.
FT   BINDING     705    705       Brassinolide.
FT                                {ECO:0000269|PubMed:21666666}.
FT   BINDING     911    911       ATP. {ECO:0000269|PubMed:24461462}.
FT   BINDING    1027   1027       ATP. {ECO:0000269|PubMed:24461462}.
FT   MOD_RES     831    831       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MOD_RES     838    838       Phosphoserine.
FT                                {ECO:0000269|PubMed:11027724,
FT                                ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MOD_RES     842    842       Phosphothreonine.
FT                                {ECO:0000269|PubMed:11027724}.
FT   MOD_RES     846    846       Phosphothreonine.
FT                                {ECO:0000269|PubMed:11027724,
FT                                ECO:0000269|PubMed:18694562}.
FT   MOD_RES     851    851       Phosphothreonine. {ECO:0000255}.
FT   MOD_RES     858    858       Phosphoserine.
FT                                {ECO:0000269|PubMed:11027724,
FT                                ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MOD_RES     872    872       Phosphothreonine.
FT                                {ECO:0000269|PubMed:11027724,
FT                                ECO:0000269|PubMed:15894717}.
FT   MOD_RES     880    880       Phosphothreonine.
FT                                {ECO:0000269|PubMed:15894717}.
FT   MOD_RES     887    887       Phosphoserine.
FT                                {ECO:0000269|PubMed:19105183}.
FT   MOD_RES     891    891       Phosphoserine. {ECO:0000255}.
FT   MOD_RES     956    956       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MOD_RES     981    981       Phosphoserine. {ECO:0000255}.
FT   MOD_RES     982    982       Phosphothreonine.
FT                                {ECO:0000269|PubMed:15894717}.
FT   MOD_RES    1035   1035       Phosphoserine. {ECO:0000255}.
FT   MOD_RES    1039   1039       Phosphothreonine. {ECO:0000255}.
FT   MOD_RES    1042   1042       Phosphoserine. {ECO:0000255}.
FT   MOD_RES    1044   1044       Phosphoserine. {ECO:0000255}.
FT   MOD_RES    1045   1045       Phosphothreonine. {ECO:0000255}.
FT   MOD_RES    1049   1049       Phosphothreonine. {ECO:0000255}.
FT   MOD_RES    1052   1052       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:C0LGT6}.
FT   MOD_RES    1060   1060       Phosphoserine. {ECO:0000255}.
FT   MOD_RES    1072   1072       Phosphotyrosine. {ECO:0000255}.
FT   MOD_RES    1166   1166       Phosphoserine.
FT                                {ECO:0000269|PubMed:18694562}.
FT   MOD_RES    1168   1168       Phosphoserine.
FT                                {ECO:0000269|PubMed:15894717}.
FT   MOD_RES    1169   1169       Phosphothreonine. {ECO:0000255}.
FT   MOD_RES    1172   1172       Phosphoserine. {ECO:0000255}.
FT   MOD_RES    1179   1179       Phosphoserine. {ECO:0000255}.
FT   MOD_RES    1180   1180       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18694562}.
FT   MOD_RES    1187   1187       Phosphoserine. {ECO:0000255}.
FT   CARBOHYD    112    112       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21666665,
FT                                ECO:0000269|PubMed:21666666,
FT                                ECO:0000269|PubMed:23929946}.
FT   CARBOHYD    154    154       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21666665,
FT                                ECO:0000269|PubMed:21666666,
FT                                ECO:0000269|PubMed:23929946,
FT                                ECO:0000269|PubMed:24461462}.
FT   CARBOHYD    233    233       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21666665,
FT                                ECO:0000269|PubMed:21666666,
FT                                ECO:0000269|PubMed:23929946}.
FT   CARBOHYD    275    275       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21666665,
FT                                ECO:0000269|PubMed:21666666,
FT                                ECO:0000269|PubMed:23929946,
FT                                ECO:0000269|PubMed:24461462}.
FT   CARBOHYD    351    351       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21666665,
FT                                ECO:0000269|PubMed:21666666,
FT                                ECO:0000269|PubMed:23929946}.
FT   CARBOHYD    387    387       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    401    401       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    438    438       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    510    510       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21666666}.
FT   CARBOHYD    545    545       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21666665,
FT                                ECO:0000269|PubMed:21666666,
FT                                ECO:0000269|PubMed:23929946,
FT                                ECO:0000269|PubMed:24461462}.
FT   CARBOHYD    573    573       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21666666,
FT                                ECO:0000269|PubMed:23929946}.
FT   CARBOHYD    636    636       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    653    653       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    737    737       N-linked (GlcNAc...). {ECO:0000255}.
FT   MUTAGEN      69     69       C->Y: In bri1-5; brassinosteroid-
FT                                insensitive semi-dwarf mutant.
FT   MUTAGEN     611    611       G->E: In bri1-113; brassinosteroid-
FT                                insensitive semi-dwarf mutant.
FT   MUTAGEN     613    613       G->S: In bri1-7; brassinosteroid-
FT                                insensitive semi-dwarf mutant.
FT   MUTAGEN     644    644       G->D: In bri1-6; brassinosteroid-
FT                                insensitive semi-dwarf mutant.
FT   MUTAGEN     662    662       S->F: In bri1-9; brassinosteroid-
FT                                insensitive semi-dwarf mutant.
FT   MUTAGEN     750    750       T->I: In bri1-102; brassinosteroid-
FT                                insensitive dwarf mutant.
FT   MUTAGEN     831    831       Y->D,E: No effect on kinase activity,
FT                                flowering time or leaf size, but altered
FT                                leaf shape.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN     831    831       Y->F: No effect on kinase activity but
FT                                altered flowering time and leaf size and
FT                                shape. {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN     838    838       S->A: Decreases peptide phosphorylation,
FT                                but no effect on autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN     838    838       S->D: Increased kinase activity; when
FT                                associated with D-842; D-846 and D-858.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN     842    842       T->A: Decreases peptide phosphorylation,
FT                                but no effect on autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN     842    842       T->D: Increased kinase activity; when
FT                                associated with D-838; D-846 and D-858.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN     846    846       T->A: Decreases peptide phosphorylation,
FT                                but no effect on autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN     846    846       T->D: Increased kinase activity; when
FT                                associated with D-838; D-842 and D-858.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN     858    858       S->A: Decreases peptide phosphorylation,
FT                                but no effect on autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN     858    858       S->D: Increased kinase activity; when
FT                                associated with D-838; D-842 and D-846.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN     872    872       T->A: 10-fold increase in peptide
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:15894717}.
FT   MUTAGEN     898    898       Y->F: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN     909    909       A->T: In bri1-1; brassinosteroid-
FT                                insensitive dwarf mutant.
FT   MUTAGEN     911    911       K->E: Loss of kinase activity; dwarf
FT                                mutant. {ECO:0000269|PubMed:11027724}.
FT   MUTAGEN     945    945       Y->F: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN     956    956       Y->F: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN     961    961       Y->F: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN     983    983       R->N: In bri1-8; brassinosteroid-
FT                                insensitive dwarf mutant.
FT   MUTAGEN     983    983       R->Q: In bri1-108; brassinosteroid-
FT                                insensitive dwarf mutant.
FT   MUTAGEN     989    989       G->I: In bri1-301; impaired kinase
FT                                activity and loss of autophosphorylation.
FT                                {ECO:0000269|PubMed:18332904}.
FT   MUTAGEN    1031   1031       A->W: In bri1-104; brassinosteroid-
FT                                insensitive dwarf mutant, but no effect
FT                                on interaction with TTL.
FT   MUTAGEN    1039   1039       T->A: Abolishes peptide phosphorylation,
FT                                and to a lower level autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717}.
FT   MUTAGEN    1042   1042       S->A: Abolishes peptide phosphorylation,
FT                                and to a lower level autophosphorylation.
FT   MUTAGEN    1044   1044       S->A: Abolishes peptide phosphorylation,
FT                                and autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717}.
FT   MUTAGEN    1045   1045       T->A: Abolishes peptide phosphorylation,
FT                                and autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717}.
FT   MUTAGEN    1048   1048       G->D: In bri1-115; brassinosteroid-
FT                                insensitive dwarf mutant and no
FT                                interaction with TTL.
FT   MUTAGEN    1049   1049       T->A: Abolishes peptide phosphorylation,
FT                                and autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN    1049   1049       T->D: Loss of kinase activity and
FT                                brassinosteroid signaling.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN    1052   1052       Y->F: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN    1057   1057       Y->F: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN    1058   1058       Y->F: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN    1070   1070       Y->F: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN    1072   1072       Y->F: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:19124768}.
FT   MUTAGEN    1078   1078       E->K: In bri1-101; brassinosteroid-
FT                                insensitive dwarf mutant and no
FT                                interaction with TTL.
FT   MUTAGEN    1139   1139       D->N: In bri1-117; brassinosteroid-
FT                                insensitive dwarf mutant.
FT   MUTAGEN    1166   1166       S->D: Increased kinase activity; when
FT                                associated with D-1168; D-1172; D-1179
FT                                and D-1180.
FT                                {ECO:0000269|PubMed:18694562}.
FT   MUTAGEN    1168   1168       S->A: Decreases peptide phosphorylation,
FT                                but no effect on autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN    1168   1168       S->D: Increased kinase activity; when
FT                                associated with D-1166; D-1172; D-1179
FT                                and D-1180. {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN    1172   1172       S->A: Decreases peptide phosphorylation,
FT                                but no effect on autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN    1172   1172       S->D: Increased kinase activity; when
FT                                associated with D-1166; D-1168; D-1179
FT                                and D-1180. {ECO:0000269|PubMed:15894717,
FT                                ECO:0000269|PubMed:18694562}.
FT   MUTAGEN    1179   1180       ST->A: Decreases peptide phosphorylation,
FT                                but no effect on autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717}.
FT   MUTAGEN    1179   1179       S->D: Increased kinase activity; when
FT                                associated with D-1166; D-1168; D-1172
FT                                and D-1180.
FT                                {ECO:0000269|PubMed:18694562}.
FT   MUTAGEN    1180   1180       T->D: Increased kinase activity; when
FT                                associated with D-1166; D-1168; D-1172
FT                                and D-1179.
FT                                {ECO:0000269|PubMed:18694562}.
FT   MUTAGEN    1187   1187       S->A: Decreases peptide phosphorylation,
FT                                but no effect on autophosphorylation.
FT                                {ECO:0000269|PubMed:15894717}.
FT   HELIX        32     43       {ECO:0000244|PDB:3RGZ}.
FT   HELIX        49     51       {ECO:0000244|PDB:3RIZ}.
FT   STRAND       57     59       {ECO:0000244|PDB:3RGX}.
FT   HELIX        61     63       {ECO:0000244|PDB:3RGZ}.
FT   STRAND       67     70       {ECO:0000244|PDB:3RGZ}.
FT   STRAND       73     78       {ECO:0000244|PDB:3RGZ}.
FT   HELIX        88     94       {ECO:0000244|PDB:3RGZ}.
FT   TURN         95     97       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      103    105       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      111    113       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      126    128       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      131    137       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       138    146       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      152    154       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      157    161       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      176    179       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      182    184       {ECO:0000244|PDB:3RGX}.
FT   STRAND      186    188       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       190    195       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      204    206       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      209    214       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      226    228       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      249    251       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       261    264       {ECO:0000244|PDB:3RGZ}.
FT   TURN        265    267       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      273    275       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      282    284       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      295    297       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      300    306       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       309    314       {ECO:0000244|PDB:3RGX}.
FT   TURN        315    317       {ECO:0000244|PDB:3RGX}.
FT   STRAND      319    322       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      325    330       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       334    338       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      344    346       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      349    355       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       358    361       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      369    371       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      374    379       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       385    388       {ECO:0000244|PDB:3RGZ}.
FT   TURN        389    391       {ECO:0000244|PDB:3RGX}.
FT   STRAND      393    396       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      399    405       {ECO:0000244|PDB:3RGZ}.
FT   TURN        408    411       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      413    415       {ECO:0000244|PDB:4LSA}.
FT   STRAND      420    422       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      425    431       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       434    438       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      444    446       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      449    454       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       458    462       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      468    470       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       482    486       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      492    494       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      497    500       {ECO:0000244|PDB:3RIZ}.
FT   HELIX       506    510       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      516    518       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      525    527       {ECO:0000244|PDB:3RIZ}.
FT   HELIX       530    534       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      540    542       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      549    551       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       554    558       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      564    566       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      569    575       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       578    581       {ECO:0000244|PDB:3RGZ}.
FT   TURN        582    585       {ECO:0000244|PDB:3RGZ}.
FT   TURN        591    594       {ECO:0000244|PDB:4LSA}.
FT   STRAND      596    601       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      611    617       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       623    631       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      641    645       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      651    654       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      658    660       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      663    668       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       672    676       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      682    684       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      687    693       {ECO:0000244|PDB:3RGX}.
FT   HELIX       696    700       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      706    708       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      715    717       {ECO:0000244|PDB:3RGX}.
FT   HELIX       720    724       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      729    732       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      735    741       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      744    747       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       748    750       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       753    756       {ECO:0000244|PDB:3RGZ}.
FT   STRAND      761    764       {ECO:0000244|PDB:3RGZ}.
FT   HELIX       873    879       {ECO:0000244|PDB:4OAC}.
FT   TURN        880    883       {ECO:0000244|PDB:4OAC}.
FT   HELIX       885    887       {ECO:0000244|PDB:4OAC}.
FT   STRAND      888    892       {ECO:0000244|PDB:4OAC}.
FT   STRAND      895    901       {ECO:0000244|PDB:4OAC}.
FT   STRAND      907    913       {ECO:0000244|PDB:4OAC}.
FT   TURN        916    918       {ECO:0000244|PDB:4OAC}.
FT   HELIX       919    929       {ECO:0000244|PDB:4OAC}.
FT   HELIX       931    933       {ECO:0000244|PDB:4OAC}.
FT   STRAND      942    948       {ECO:0000244|PDB:4OAC}.
FT   STRAND      951    957       {ECO:0000244|PDB:4OAC}.
FT   HELIX       964    968       {ECO:0000244|PDB:4OAC}.
FT   HELIX       971    973       {ECO:0000244|PDB:4OAC}.
FT   HELIX       980    999       {ECO:0000244|PDB:4OAC}.
FT   STRAND     1001   1006       {ECO:0000244|PDB:4OAC}.
FT   HELIX      1012   1014       {ECO:0000244|PDB:4OAC}.
FT   STRAND     1015   1017       {ECO:0000244|PDB:4OAC}.
FT   STRAND     1023   1025       {ECO:0000244|PDB:4OAC}.
FT   STRAND     1032   1034       {ECO:0000244|PDB:4OAC}.
FT   TURN       1050   1052       {ECO:0000244|PDB:4OAC}.
FT   HELIX      1055   1058       {ECO:0000244|PDB:4OAC}.
FT   STRAND     1060   1063       {ECO:0000244|PDB:4OAC}.
FT   HELIX      1065   1081       {ECO:0000244|PDB:4OAC}.
FT   TURN       1089   1093       {ECO:0000244|PDB:4OH4}.
FT   HELIX      1102   1108       {ECO:0000244|PDB:4OAC}.
FT   HELIX      1109   1111       {ECO:0000244|PDB:4OAC}.
FT   HELIX      1113   1116       {ECO:0000244|PDB:4OAC}.
FT   HELIX      1121   1123       {ECO:0000244|PDB:4OH4}.
FT   HELIX      1126   1137       {ECO:0000244|PDB:4OAC}.
FT   HELIX      1142   1144       {ECO:0000244|PDB:4OAC}.
FT   HELIX      1148   1159       {ECO:0000244|PDB:4OAC}.
SQ   SEQUENCE   1196 AA;  130543 MW;  C7FBA1C21294E600 CRC64;
     MKTFSSFFLS VTTLFFFSFF SLSFQASPSQ SLYREIHQLI SFKDVLPDKN LLPDWSSNKN
     PCTFDGVTCR DDKVTSIDLS SKPLNVGFSA VSSSLLSLTG LESLFLSNSH INGSVSGFKC
     SASLTSLDLS RNSLSGPVTT LTSLGSCSGL KFLNVSSNTL DFPGKVSGGL KLNSLEVLDL
     SANSISGANV VGWVLSDGCG ELKHLAISGN KISGDVDVSR CVNLEFLDVS SNNFSTGIPF
     LGDCSALQHL DISGNKLSGD FSRAISTCTE LKLLNISSNQ FVGPIPPLPL KSLQYLSLAE
     NKFTGEIPDF LSGACDTLTG LDLSGNHFYG AVPPFFGSCS LLESLALSSN NFSGELPMDT
     LLKMRGLKVL DLSFNEFSGE LPESLTNLSA SLLTLDLSSN NFSGPILPNL CQNPKNTLQE
     LYLQNNGFTG KIPPTLSNCS ELVSLHLSFN YLSGTIPSSL GSLSKLRDLK LWLNMLEGEI
     PQELMYVKTL ETLILDFNDL TGEIPSGLSN CTNLNWISLS NNRLTGEIPK WIGRLENLAI
     LKLSNNSFSG NIPAELGDCR SLIWLDLNTN LFNGTIPAAM FKQSGKIAAN FIAGKRYVYI
     KNDGMKKECH GAGNLLEFQG IRSEQLNRLS TRNPCNITSR VYGGHTSPTF DNNGSMMFLD
     MSYNMLSGYI PKEIGSMPYL FILNLGHNDI SGSIPDEVGD LRGLNILDLS SNKLDGRIPQ
     AMSALTMLTE IDLSNNNLSG PIPEMGQFET FPPAKFLNNP GLCGYPLPRC DPSNADGYAH
     HQRSHGRRPA SLAGSVAMGL LFSFVCIFGL ILVGREMRKR RRKKEAELEM YAEGHGNSGD
     RTANNTNWKL TGVKEALSIN LAAFEKPLRK LTFADLLQAT NGFHNDSLIG SGGFGDVYKA
     ILKDGSAVAI KKLIHVSGQG DREFMAEMET IGKIKHRNLV PLLGYCKVGD ERLLVYEFMK
     YGSLEDVLHD PKKAGVKLNW STRRKIAIGS ARGLAFLHHN CSPHIIHRDM KSSNVLLDEN
     LEARVSDFGM ARLMSAMDTH LSVSTLAGTP GYVPPEYYQS FRCSTKGDVY SYGVVLLELL
     TGKRPTDSPD FGDNNLVGWV KQHAKLRISD VFDPELMKED PALEIELLQH LKVAVACLDD
     RAWRRPTMVQ VMAMFKEIQA GSGIDSQSTI RSIEDGGFST IEMVDMSIKE VPEGKL
//
ID   PGFRB_MOUSE             Reviewed;        1098 AA.
AC   P05622;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1988, sequence version 1.
DT   20-JAN-2016, entry version 179.
DE   RecName: Full=Platelet-derived growth factor receptor beta;
DE            Short=PDGF-R-beta;
DE            Short=PDGFR-beta;
DE            EC=2.7.10.1;
DE   AltName: Full=Beta platelet-derived growth factor receptor;
DE   AltName: Full=Beta-type platelet-derived growth factor receptor;
DE   AltName: Full=CD140 antigen-like family member B;
DE   AltName: Full=Platelet-derived growth factor receptor 1;
DE            Short=PDGFR-1;
DE   AltName: CD_antigen=CD140b;
DE   Flags: Precursor;
GN   Name=Pdgfrb; Synonyms=Pdgfr, Pdgfr1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Fibroblast;
RX   PubMed=3020426; DOI=10.1038/323226a0;
RA   Yarden Y., Escobedo J.A., Kuang W.-J., Yang-Feng T.L., Daniel T.O.,
RA   Tremble P.M., Chen E.Y., Ando M.E., Harkins R.N., Francke U.,
RA   Fried V.A., Ullrich A., Williams L.T.;
RT   "Structure of the receptor for platelet-derived growth factor helps
RT   define a family of closely related growth factor receptors.";
RL   Nature 323:226-232(1986).
RN   [2]
RP   FUNCTION AS RECEPTOR FOR PDGFA AND PDGFB, SUBUNIT, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=8440729;
RA   Seifert R.A., van Koppen A., Bowen-Pope D.F.;
RT   "PDGF-AB requires PDGF receptor alpha-subunits for high-affinity, but
RT   not for low-affinity, binding and signal transduction.";
RL   J. Biol. Chem. 268:4473-4480(1993).
RN   [3]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=7958864; DOI=10.1101/gad.8.16.1888;
RA   Soriano P.;
RT   "Abnormal kidney development and hematological disorders in PDGF beta-
RT   receptor mutant mice.";
RL   Genes Dev. 8:1888-1896(1994).
RN   [4]
RP   INTERACTION WITH GRB10.
RX   PubMed=10454568;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=14514732; DOI=10.1097/01.ASN.0000089828.73014.C8;
RA   Taneda S., Hudkins K.L., Topouzis S., Gilbertson D.G.,
RA   Ophascharoensuk V., Truong L., Johnson R.J., Alpers C.E.;
RT   "Obstructive uropathy in mice and humans: potential role for PDGF-D in
RT   the progression of tubulointerstitial injury.";
RL   J. Am. Soc. Nephrol. 14:2544-2555(2003).
RN   [6]
RP   FUNCTION, AND MUTAGENESIS OF TYR-578; TYR-715; TYR-739; TYR-750;
RP   TYR-770; TYR-1008 AND TYR-1020.
RX   PubMed=14624252; DOI=10.1371/journal.pbio.0000052;
RA   Tallquist M.D., French W.J., Soriano P.;
RT   "Additive effects of PDGF receptor beta signaling pathways in vascular
RT   smooth muscle cell development.";
RL   PLoS Biol. 1:E52-E52(2003).
RN   [7]
RP   REVIEW ON FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=15207813; DOI=10.1016/j.cytogfr.2004.03.005;
RA   Betsholtz C.;
RT   "Insight into the physiological functions of PDGF through genetic
RT   studies in mice.";
RL   Cytokine Growth Factor Rev. 15:215-228(2004).
RN   [8]
RP   MUTAGENESIS OF ASP-849, CATALYTIC ACTIVITY, FUNCTION, AND INTERACTION
RP   WITH PIK3R1.
RX   PubMed=15284236; DOI=10.1074/jbc.M406051200;
RA   Chiara F., Goumans M.J., Forsberg H., Ahgren A., Rasola A.,
RA   Aspenstrom P., Wernstedt C., Hellberg C., Heldin C.H., Heuchel R.;
RT   "A gain of function mutation in the activation loop of platelet-
RT   derived growth factor beta-receptor deregulates its kinase activity.";
RL   J. Biol. Chem. 279:42516-42527(2004).
RN   [9]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2.
RX   PubMed=14966296; DOI=10.1128/MCB.24.5.2190-2201.2004;
RA   Persson C., Saevenhed C., Bourdeau A., Tremblay M.L., Markova B.,
RA   Boehmer F.D., Haj F.G., Neel B.G., Elson A., Heldin C.H.,
RA   Roennstrand L., Ostman A., Hellberg C.;
RT   "Site-selective regulation of platelet-derived growth factor beta
RT   receptor tyrosine phosphorylation by T-cell protein tyrosine
RT   phosphatase.";
RL   Mol. Cell. Biol. 24:2190-2201(2004).
RN   [10]
RP   FUNCTION, AND PHOSPHORYLATION AT TYR-685; TYR-933 AND TYR-969.
RX   PubMed=14993293; DOI=10.1128/MCB.24.6.2573-2583.2004;
RA   Plattner R., Koleske A.J., Kazlauskas A., Pendergast A.M.;
RT   "Bidirectional signaling links the Abelson kinases to the platelet-
RT   derived growth factor receptor.";
RL   Mol. Cell. Biol. 24:2573-2583(2004).
RN   [11]
RP   INTERACTION WITH CBL, AND UBIQUITINATION.
RX   PubMed=15753096; DOI=10.1074/jbc.M410265200;
RA   Takayama Y., May P., Anderson R.G., Herz J.;
RT   "Low density lipoprotein receptor-related protein 1 (LRP1) controls
RT   endocytosis and c-CBL-mediated ubiquitination of the platelet-derived
RT   growth factor receptor beta (PDGFR beta).";
RL   J. Biol. Chem. 280:18504-18510(2005).
RN   [12]
RP   INTERACTION WITH CBL AND PLCG1, AND FUNCTION.
RX   PubMed=17620338; DOI=10.1074/jbc.M701797200;
RA   Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P.,
RA   Druker B.J., Naramura M., Band V., Band H.;
RT   "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-
RT   derived growth factor receptor beta provides a dual mechanism of
RT   negative regulation.";
RL   J. Biol. Chem. 282:29336-29347(2007).
RN   [13]
RP   FUNCTION.
RX   PubMed=18948621; DOI=10.1161/CIRCRESAHA.108.176768;
RA   Mellgren A.M., Smith C.L., Olsen G.S., Eskiocak B., Zhou B.,
RA   Kazi M.N., Ruiz F.R., Pu W.T., Tallquist M.D.;
RT   "Platelet-derived growth factor receptor beta signaling is required
RT   for efficient epicardial cell migration and development of two
RT   distinct coronary vascular smooth muscle cell populations.";
RL   Circ. Res. 103:1393-1401(2008).
RN   [14]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=18213589; DOI=10.1002/dvdy.21436;
RA   Van den Akker N.M., Winkel L.C., Nisancioglu M.H., Maas S.,
RA   Wisse L.J., Armulik A., Poelmann R.E., Lie-Venema H., Betsholtz C.,
RA   Gittenberger-de Groot A.C.;
RT   "PDGF-B signaling is important for murine cardiac development: its
RT   role in developing atrioventricular valves, coronaries, and cardiac
RT   innervation.";
RL   Dev. Dyn. 237:494-503(2008).
RN   [15]
RP   FUNCTION.
RX   PubMed=19030102; DOI=10.1371/journal.pone.0003794;
RA   Wu E., Palmer N., Tian Z., Moseman A.P., Galdzicki M., Wang X.,
RA   Berger B., Zhang H., Kohane I.S.;
RT   "Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR
RT   genetically defined cells.";
RL   PLoS ONE 3:E3794-E3794(2008).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-306; ASN-312; ASN-467 AND
RP   ASN-478.
RC   TISSUE=Myoblast;
RX   PubMed=19656770; DOI=10.1074/mcp.M900195-MCP200;
RA   Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I.,
RA   Bausch-Fluck D., Elliott S.T., Boheler K.R., Van Eyk J.E.,
RA   Wollscheid B.;
RT   "The mouse C2C12 myoblast cell surface N-linked glycoproteome:
RT   identification, glycosite occupancy, and membrane orientation.";
RL   Mol. Cell. Proteomics 8:2555-2569(2009).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH PIK3R1.
RX   PubMed=19742316; DOI=10.1371/journal.pone.0006922;
RA   Zhou L., Takayama Y., Boucher P., Tallquist M.D., Herz J.;
RT   "LRP1 regulates architecture of the vascular wall by controlling
RT   PDGFRbeta-dependent phosphatidylinositol 3-kinase activation.";
RL   PLoS ONE 4:E6922-E6922(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Lung, and Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [19]
RP   FUNCTION.
RX   PubMed=21664579; DOI=10.1016/j.devcel.2011.04.019;
RA   Olson L.E., Soriano P.;
RT   "PDGFRbeta signaling regulates mural cell plasticity and inhibits fat
RT   development.";
RL   Dev. Cell 20:815-826(2011).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 1005-1015 IN COMPLEX WITH
RP   PTPN11, AND INTERACTION WITH PTPN11.
RX   PubMed=7521735; DOI=10.1016/S0969-2126(00)00044-7;
RA   Lee C.-H., Kominos D., Jacques S., Margolis B., Schlessinger J.,
RA   Shoelson S.E., Kuriyan J.;
RT   "Crystal structures of peptide complexes of the amino-terminal SH2
RT   domain of the Syp tyrosine phosphatase.";
RL   Structure 2:423-438(1994).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for homodimeric PDGFB and PDGFD and for heterodimers
CC       formed by PDGFA and PDGFB, and plays an essential role in the
CC       regulation of embryonic development, cell proliferation, survival,
CC       differentiation, chemotaxis and migration. Plays an essential role
CC       in blood vessel development by promoting proliferation, migration
CC       and recruitment of pericytes and smooth muscle cells to
CC       endothelial cells. Plays a role in the migration of vascular
CC       smooth muscle cells and the formation of neointima at vascular
CC       injury sites. Required for normal development of the
CC       cardiovascular system. Required for normal recruitment of
CC       pericytes (mesangial cells) in the kidney glomerulus, and for
CC       normal formation of a branched network of capillaries in kidney
CC       glomeruli. Promotes rearrangement of the actin cytoskeleton and
CC       the formation of membrane ruffles. Binding of its cognate ligands
CC       - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or
CC       homodimeric PDGFD -leads to the activation of several signaling
CC       cascades; the response depends on the nature of the bound ligand
CC       and is modulated by the formation of heterodimers between PDGFRA
CC       and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL,
CC       SHC1 and NCK1. Activation of PLCG1 leads to the production of the
CC       cellular signaling molecules diacylglycerol and inositol 1,4,5-
CC       trisphosphate, mobilization of cytosolic Ca(2+) and the activation
CC       of protein kinase C. Phosphorylation of PIK3R1, the regulatory
CC       subunit of phosphatidylinositol 3-kinase, leads to the activation
CC       of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the
CC       C-terminus of PTPN11, creates a binding site for GRB2, resulting
CC       in the activation of HRAS, RAF1 and down-stream MAP kinases,
CC       including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation
CC       and activation of SRC family kinases. Promotes phosphorylation of
CC       PDCD6IP/ALIX and STAM (By similarity). Receptor signaling is down-
CC       regulated by protein phosphatases that dephosphorylate the
CC       receptor and its down-stream effectors, and by rapid
CC       internalization of the activated receptor. {ECO:0000250,
CC       ECO:0000269|PubMed:14624252, ECO:0000269|PubMed:14993293,
CC       ECO:0000269|PubMed:15284236, ECO:0000269|PubMed:17620338,
CC       ECO:0000269|PubMed:18948621, ECO:0000269|PubMed:19030102,
CC       ECO:0000269|PubMed:19742316, ECO:0000269|PubMed:21664579,
CC       ECO:0000269|PubMed:8440729}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:15284236}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Binding of PDGFB and/or PDGFD leads to
CC       dimerization and activation by autophosphorylation on tyrosine
CC       residues.
CC   -!- SUBUNIT: Interacts with homodimeric PDGFB and PDGFD, and with
CC       heterodimers formed by PDGFA and PDGFB. May also interact with
CC       homodimeric PDGFC. Monomer in the absence of bound ligand.
CC       Interaction with homodimeric PDGFB, heterodimers formed by PDGFA
CC       and PDGFB or homodimeric PDGFD, leads to receptor dimerization,
CC       where both PDGFRA homodimers and heterodimers with PDGFRB are
CC       observed. Interacts with SH2B2/APS. Interacts directly (tyrosine
CC       phosphorylated) with SHB. Interacts (tyrosine phosphorylated) with
CC       PIK3R1 and RASA1. Interacts (tyrosine phosphorylated) with CBL.
CC       Interacts (tyrosine phosphorylated) with SRC and SRC family
CC       kinases. Interacts (tyrosine phosphorylated) with PIK3C2B, maybe
CC       indirectly. Interacts (tyrosine phosphorylated) with SHC1, GRB7,
CC       GRB10 and NCK1. Interaction with GRB2 is mediated by SHC1.
CC       Interacts (via C-terminus) with SLC9A3R1 (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       P39688:Fyn; NbExp=3; IntAct=EBI-1554855, EBI-524514;
CC       P18031:PTPN1 (xeno); NbExp=3; IntAct=EBI-1554855, EBI-968788;
CC       Q9JHL1:Slc9a3r2; NbExp=2; IntAct=EBI-1554855, EBI-538451;
CC       Q91YD9:Wasl; NbExp=2; IntAct=EBI-1554855, EBI-642417;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cytoplasmic vesicle {ECO:0000250}. Lysosome lumen
CC       {ECO:0000250}. Note=After ligand binding, the autophosphorylated
CC       receptor is ubiquitinated and internalized, leading to its
CC       degradation.
CC   -!- TISSUE SPECIFICITY: Weakly expressed in glomerular mesangial cells
CC       and interstitial cells. Up-regulated in areas of renal fibrosis.
CC       In mice with unilateral ureteral obstruction, increased expression
CC       in interstitial cells at day 4 and expression is markedly elevated
CC       at day 7 and is maximal at day 14. {ECO:0000269|PubMed:14514732}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-578, and to a lesser degree, Tyr-
CC       580 is important for interaction with SRC. Phosphorylation at Tyr-
CC       715 is important for interaction with GRB2. Phosphorylation at
CC       Tyr-739 and Tyr-750 is important for interaction with PIK3R1.
CC       Phosphorylation at Tyr-750 is important for interaction with NCK1.
CC       Phosphorylation at Tyr-770 and Tyr-856 is important for
CC       interaction with RASA1/GAP. Phosphorylation at Tyr-856 is
CC       important for efficient phosphorylation of PLCG1 and PTPN11,
CC       resulting in increased phosphorylation of AKT1, MAPK1/ERK2 and/or
CC       MAPK3/ERK1, PDCD6IP/ALIX and STAM, and in increased cell
CC       proliferation. Phosphorylation at Tyr-1008 is important for
CC       interaction with PTPN11. Phosphorylation at Tyr-1008 and Tyr-1020
CC       is important for interaction with PLCG1. Dephosphorylated by PTPRJ
CC       at Tyr-750, Tyr-856, Tyr-1008 and Tyr-1020 (By similarity).
CC       Dephosphorylated by PTPN2 at Tyr-578 and Tyr-1020. {ECO:0000250}.
CC   -!- PTM: N-glycosylated. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. After autophosphorylation, the receptor is
CC       polyubiquitinated, leading to its degradation.
CC       {ECO:0000269|PubMed:15753096}.
CC   -!- DISRUPTION PHENOTYPE: No apparent phenotype up to 16 dpc.
CC       Lethality late during gestation or at birth, due to widespread
CC       bleedings. This is due to a severe shortage of vascular smooth
CC       muscle cells and pericytes, especially in the central nervous
CC       system, skin, lung and heart. Mutants suffer from hemorrhages,
CC       anemia, thrombocytopenia, and show defects in the formation of
CC       kidney glomeruli, due to a lack of mesangial cells.
CC       {ECO:0000269|PubMed:15207813, ECO:0000269|PubMed:18213589,
CC       ECO:0000269|PubMed:7958864}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04367; CAA27882.1; -; mRNA.
DR   PIR; A25742; PFMSRB.
DR   RefSeq; NP_001139740.1; NM_001146268.1.
DR   RefSeq; NP_032835.2; NM_008809.2.
DR   UniGene; Mm.4146; -.
DR   PDB; 1AYA; X-ray; 2.05 A; P/Q=1005-1015.
DR   PDB; 1AYC; X-ray; 2.30 A; P=736-744.
DR   PDBsum; 1AYA; -.
DR   PDBsum; 1AYC; -.
DR   ProteinModelPortal; P05622; -.
DR   SMR; P05622; 32-311, 525-562, 575-694, 797-958.
DR   BioGrid; 202089; 5.
DR   DIP; DIP-39669N; -.
DR   IntAct; P05622; 13.
DR   MINT; MINT-2832882; -.
DR   STRING; 10090.ENSMUSP00000025522; -.
DR   BindingDB; P05622; -.
DR   ChEMBL; CHEMBL2749; -.
DR   GuidetoPHARMACOLOGY; 1804; -.
DR   iPTMnet; P05622; -.
DR   PhosphoSite; P05622; -.
DR   MaxQB; P05622; -.
DR   PaxDb; P05622; -.
DR   PRIDE; P05622; -.
DR   GeneID; 18596; -.
DR   KEGG; mmu:18596; -.
DR   UCSC; uc008fbk.2; mouse.
DR   CTD; 5159; -.
DR   MGI; MGI:97531; Pdgfrb.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P05622; -.
DR   KO; K05089; -.
DR   PhylomeDB; P05622; -.
DR   BRENDA; 2.7.10.1; 3474.
DR   EvolutionaryTrace; P05622; -.
DR   NextBio; 294486; -.
DR   PRO; PR:P05622; -.
DR   Proteomes; UP000000589; Unplaced.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0005925; C:focal adhesion; ISO:MGI.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; ISO:MGI.
DR   GO; GO:0043202; C:lysosomal lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; IMP:MGI.
DR   GO; GO:0005019; F:platelet-derived growth factor beta-receptor activity; ISS:UniProtKB.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; TAS:DFLAT.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; ISO:MGI.
DR   GO; GO:0019901; F:protein kinase binding; ISO:MGI.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; IDA:MGI.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; ISO:MGI.
DR   GO; GO:0030325; P:adrenal gland development; IGI:MGI.
DR   GO; GO:0035909; P:aorta morphogenesis; IGI:BHF-UCL.
DR   GO; GO:0001568; P:blood vessel development; IEP:UniProtKB.
DR   GO; GO:0055003; P:cardiac myofibril assembly; IGI:UniProtKB.
DR   GO; GO:0060947; P:cardiac vascular smooth muscle cell differentiation; TAS:DFLAT.
DR   GO; GO:0060326; P:cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; ISO:MGI.
DR   GO; GO:0060981; P:cell migration involved in coronary angiogenesis; IMP:UniProtKB.
DR   GO; GO:0035441; P:cell migration involved in vasculogenesis; IMP:UniProtKB.
DR   GO; GO:0048568; P:embryonic organ development; IEP:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0001822; P:kidney development; IMP:MGI.
DR   GO; GO:0072277; P:metanephric glomerular capillary formation; IGI:UniProtKB.
DR   GO; GO:0072262; P:metanephric glomerular mesangial cell proliferation involved in metanephros development; IMP:UniProtKB.
DR   GO; GO:0072223; P:metanephric glomerular mesangium development; IEP:UniProtKB.
DR   GO; GO:0006807; P:nitrogen compound metabolic process; IMP:MGI.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; ISO:MGI.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; ISO:MGI.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IMP:MGI.
DR   GO; GO:0035791; P:platelet-derived growth factor receptor-beta signaling pathway; ISO:MGI.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISO:MGI.
DR   GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; IDA:UniProtKB.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; IDA:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; ISO:MGI.
DR   GO; GO:0032516; P:positive regulation of phosphoprotein phosphatase activity; ISO:MGI.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:UniProtKB.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IGI:BHF-UCL.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IMP:MGI.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; IMP:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IDA:MGI.
DR   GO; GO:0048705; P:skeletal system morphogenesis; IMP:MGI.
DR   GO; GO:0071670; P:smooth muscle cell chemotaxis; IGI:BHF-UCL.
DR   GO; GO:0048745; P:smooth muscle tissue development; IMP:MGI.
DR   GO; GO:0001894; P:tissue homeostasis; IMP:MGI.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR027288; PGFRB.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF53; PTHR24416:SF53; 3.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF13895; Ig_2; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500948; Beta-PDGF_receptor; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 4.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Chemotaxis;
KW   Complete proteome; Cytoplasmic vesicle; Developmental protein;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Lysosome; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     31
FT   CHAIN        32   1098       Platelet-derived growth factor receptor
FT                                beta.
FT                                /FTId=PRO_0000016758.
FT   TOPO_DOM     32    531       Extracellular. {ECO:0000255}.
FT   TRANSMEM    532    552       Helical. {ECO:0000255}.
FT   TOPO_DOM    553   1098       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       33    119       Ig-like C2-type 1.
FT   DOMAIN      128    209       Ig-like C2-type 2.
FT   DOMAIN      213    308       Ig-like C2-type 3.
FT   DOMAIN      330    402       Ig-like C2-type 4.
FT   DOMAIN      415    523       Ig-like C2-type 5.
FT   DOMAIN      599    961       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     605    613       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    825    825       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     633    633       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     561    561       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     578    578       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     580    580       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     685    685       Phosphotyrosine; by ABL1 and ABL2.
FT                                {ECO:0000269|PubMed:14993293}.
FT   MOD_RES     715    715       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     739    739       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     750    750       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     762    762       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     770    770       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     774    774       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     777    777       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     856    856       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     933    933       Phosphotyrosine; by ABL1 and ABL2.
FT                                {ECO:0000269|PubMed:14993293}.
FT   MOD_RES     969    969       Phosphotyrosine; by ABL1 and ABL2.
FT                                {ECO:0000269|PubMed:14993293}.
FT   MOD_RES    1008   1008       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1020   1020       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD     44     44       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     88     88       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    214    214       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    291    291       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    306    306       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    312    312       N-linked (GlcNAc...); atypical.
FT                                {ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    353    353       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    370    370       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    444    444       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    467    467       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19656770}.
FT   CARBOHYD    478    478       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19656770}.
FT   DISULFID     53     99       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    148    189       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    234    290       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    435    507       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   MUTAGEN     578    578       Y->F: Strongly reduced levels of vascular
FT                                smooth muscle cells and pericytes in
FT                                developing blood vessels; when associated
FT                                with F-715; F-739; F-750; F-770; F-1008
FT                                and F-1020.
FT                                {ECO:0000269|PubMed:14624252}.
FT   MUTAGEN     715    715       Y->F: Strongly reduced levels of vascular
FT                                smooth muscle cells and pericytes in
FT                                developing blood vessels; when associated
FT                                with F-578; F-739; F-750; F-770; F-1008
FT                                and F-1020.
FT                                {ECO:0000269|PubMed:14624252}.
FT   MUTAGEN     739    739       Y->F: Strongly reduced levels of vascular
FT                                smooth muscle cells and pericytes in
FT                                developing blood vessels; when associated
FT                                with F-578; F-715; F-750; F-770; F-1008
FT                                and F-1020.
FT                                {ECO:0000269|PubMed:14624252}.
FT   MUTAGEN     750    750       Y->F: Strongly reduced levels of vascular
FT                                smooth muscle cells and pericytes in
FT                                developing blood vessels; when associated
FT                                with F-578; F-715; F-739; F-770; F-1008
FT                                and F-1020.
FT                                {ECO:0000269|PubMed:14624252}.
FT   MUTAGEN     770    770       Y->F: Strongly reduced levels of vascular
FT                                smooth muscle cells and pericytes in
FT                                developing blood vessels; when associated
FT                                with F-578; F-715; F-739; F-750; F-1008
FT                                and F-1020.
FT                                {ECO:0000269|PubMed:14624252}.
FT   MUTAGEN     849    849       D->N: Increased autophosphorylation in
FT                                the absence of PDGFB binding. Increased
FT                                autophosphorylation in response to PDGFB
FT                                binding. Constitutive interaction with
FT                                PIK3R1, and constitutive AKT1 activation.
FT                                {ECO:0000269|PubMed:15284236}.
FT   MUTAGEN    1008   1008       Y->F: Strongly reduced levels of vascular
FT                                smooth muscle cells and pericytes in
FT                                developing blood vessels; when associated
FT                                with F-578; F-715; F-739; F-750; F-770
FT                                and F-1020.
FT                                {ECO:0000269|PubMed:14624252}.
FT   MUTAGEN    1020   1020       Y->F: Strongly reduced levels of vascular
FT                                smooth muscle cells and pericytes in
FT                                developing blood vessels; when associated
FT                                with F-578; F-715; F-739; F-750; F-770
FT                                and F-1008.
FT                                {ECO:0000269|PubMed:14624252}.
SQ   SEQUENCE   1098 AA;  122806 MW;  8D391CAFAC3FC31D CRC64;
     MGLPGVIPAL VLRGQLLLSV LWLLGPQTSR GLVITPPGPE FVLNISSTFV LTCSGSAPVM
     WEQMSQVPWQ EAAMNQDGTF SSVLTLTNVT GGDTGEYFCV YNNSLGPELS ERKRIYIFVP
     DPTMGFLPMD SEDLFIFVTD VTETTIPCRV TDPQLEVTLH EKKVDIPLHV PYDHQRGFTG
     TFEDKTYICK TTIGDREVDS DTYYVYSLQV SSINVSVNAV QTVVRQGESI TIRCIVMGND
     VVNFQWTYPR MKSGRLVEPV TDYLFGVPSR IGSILHIPTA ELSDSGTYTC NVSVSVNDHG
     DEKAINISVI ENGYVRLLET LGDVEIAELH RSRTLRVVFE AYPMPSVLWL KDNRTLGDSG
     AGELVLSTRN MSETRYVSEL ILVRVKVSEA GYYTMRAFHE DDEVQLSFKL QVNVPVRVLE
     LSESHPANGE QTIRCRGRGM PQPNVTWSTC RDLKRCPRKL SPTPLGNSSK EESQLETNVT
     FWEEDQEYEV VSTLRLRHVD QPLSVRCMLQ NSMGGDSQEV TVVPHSLPFK VVVISAILAL
     VVLTVISLII LIMLWQKKPR YEIRWKVIES VSSDGHEYIY VDPVQLPYDS TWELPRDQLV
     LGRTLGSGAF GQVVEATAHG LSHSQATMKV AVKMLKSTAR SSEKQALMSE LKIMSHLGPH
     LNVVNLLGAC TKGGPIYIIT EYCRYGDLVD YLHRNKHTFL QRHSNKHCPP SAELYSNALP
     VGFSLPSHLN LTGESDGGYM DMSKDESIDY VPMLDMKGDI KYADIESPSY MAPYDNYVPS
     APERTYRATL INDSPVLSYT DLVGFSYQVA NGMDFLASKN CVHRDLAARN VLICEGKLVK
     ICDFGLARDI MRDSNYISKG STYLPLKWMA PESIFNSLYT TLSDVWSFGI LLWEIFTLGG
     TPYPELPMND QFYNAIKRGY RMAQPAHASD EIYEIMQKCW EEKFETRPPF SQLVLLLERL
     LGEGYKKKYQ QVDEEFLRSD HPAILRSQAR FPGIHSLRSP LDTSSVLYTA VQPNESDNDY
     IIPLPDPKPD VADEGLPEGS PSLASSTLNE VNTSSTISCD SPLELQEEPQ QAEPEAQLEQ
     PQDSGCPGPL AEAEDSFL
//